<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /scratch/yujieq/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761062Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} NDA/BLA Multi-Disciplinary Review and Evaluation</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<affiliation key="aff0">
								<orgName type="department">DMPP</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">DSAT</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="laboratory">DCARP=Division of Cardiovascular and Renal Products OPQ=Office of Pharmaceutical Quality OPDP=Office of Prescription Drug Promotion OSE= Office of Surveillance and Epidemiology DEPI= Division of Epidemiology</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761062Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} NDA/BLA Multi-Disciplinary Review and Evaluation</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<note>1</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>

		<encodingDesc>
			<appInfo>
				<application version="0.6.0-SNAPSHOT" ident="GROBID-SDO" when="2020-09-21T05:37+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid-sdo"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 5  <ref type="bibr">Studies 20060326, 20101291, 20070337, and 20110142. ............... 171</ref>    The applicant, Amgen, Inc. has submitted this Biologics License Application (BLA) under section 351 of the Public Health Services Act for romosozumab, proposed tradename Evenity, seeking an indication for the treatment of postmenopausal women with osteoporosis at high risk of fracture. The proposed dose is 210 mg once monthly for one year. Romosozumab 210 mg is administered by a healthcare provider and requires 2 separate subcutaneous injections utilizing two single-use prefilled syringes. Romosozumab, also referred to as AMG785 in the application, is an IgG2 humanized monoclonal antibody that binds and inhibits sclerostin. The pharmacologic class proposed by the applicant in labeling is "sclerostin inhibitor". Sclerostin is the protein product of the SOST gene and is secreted by the osteocyte. Sclerostin is thought to act by binding to low-density lipoprotein receptor-related proteins 4, 5, and 6 (LRP4, LRP5, and LRP6), inhibiting Wingless-related integration (Wnt) signaling and reducing osteoblast-mediated bone formation. Inhibition of sclerostin leads to a transient stimulation of bone formation and inhibition of bone resorption. Romosozumab is first in class with sclerostin inhibitors being a new therapeutic class of osteoporosis treatments. This is the second review cycle for romosozumab. Late in the first review cycle of this BLA, data from an active-controlled, phase 3 fracture study in women with postmenopausal osteoporosis at increased risk for fracture, Study 20110142 (Study 142), became available and demonstrated an imbalance in positively adjudicated serious cardiovascular events for romosozumab vs. the active control alendronate. In response to the concerning cardiovascular safety findings, FDA issued a Complete Response Letter. This submission addresses the deficiencies outlined.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions on the Substantial Evidence of Effectiveness</head><p>The applicant has provided substantial evidence of effectiveness to support approval of romosozumab for the treatment of osteoporosis in postmenopausal women at high risk of fracture. The evidence of effectiveness derives from the placebo-controlled fracture trial 20070337 (Study 337) and the active-controlled fracture trial 20110142 (Study 142). These studies evaluated whether 12 months of treatment with romosozumab followed by continued therapy with an anti-resorptive agent provided fracture risk reduction in postmenopausal women.</p><p>Study 337 (N = 7180), reviewed in the first BLA cycle, was a phase 3, randomized, double-blind, placebo-controlled, parallel-group study that assessed the efficacy and safety of romosozumab 210 mg administered subcutaneously (SC) every month (QM) for a duration of 12 months followed by denosumab 60 mg every 6 months for 12 months compared to 12 months of placebo followed by 12 months of denosumab in women with postmenopausal osteoporosis. The study demonstrated a statistically significant reduction with romosozumab compared to placebo for both co-primary endpoints, which were 1) the subject incidence of new vertebral fractures at 12 months and 2) the subject incidence of new vertebral fractures at 24 months. During the 12-month double-blind period, the subject incidence of new vertebral fracture with absolute risk reduction of 1.3 0.8, 1.8; p &lt; 0.001) and relative risk reduction ; p &lt; 0.001). At 24 months, the subject incidence of new vertebral fracture with romosozumab followed by denosumab was 0.6 2.5 followed by denosumab, with a significant absolute risk reduction of 1.9 confidence 1.3, 2.5; p &lt; 0.001). and relative risk reduction CI: 60, 84; p &lt; 0.001). Romosozumab also significantly increased bone mineral density (BMD) at all sites. At month 12, compared with placebo, romosozumab increased mean maintained the increases in BMD at all sites at month 24.</p><p>Study 142 (N = 4093) was a phase 3, randomized, double-blind, alendronate-controlled study that assessed the efficacy and safety of romosozumab 210 mg SC monthly for a duration of 12 months followed by alendronate 70 mg weekly compared with alendronate 70 mg weekly alone in women with postmenopausal osteoporosis with a history of fracture. Compared with Study 337, Study 142 enrolled a population at higher risk of osteoporosis-related fracture. The two primary endpoints were 1) time to first clinical fracture (including nonvertebral and symptomatic vertebral fracture, the applicant pre-specified this endpoint as "subject incidence of clinical fractures", which is not appropriate, see details in 8.1.1) through the primary analysis period and 2) the subject incidence of new vertebral fracture through month 24. The primary analysis period ended after clinical fracture events had been confirmed for at least 330 subjects and all subjects had completed the month 24 visit. At 24 months, the subject incidence of new vertebral fracture with romosozumab followed by alendronate with alendronate alone, with a significant and relative risk reduction of 50 ; p &lt; 0.001). Through the primary analysis period, the hazard ratio for clinical fractures was 0.73 0.61, 0.88; p &lt; 0.001) for romosozumab followed by alendronate compared to alendronate alone, based on 464 subjects with clinical fractures the the alendronate alone group) with a median follow-up of 33 months. Regarding BMD, significantly higher increases were observed with romosozumab compared to alendronate at all sites assessed. At month 12, the mean BMD treatment difference was femoral neck. Romosozumab followed by alendronate maintained the significantly higher increases in BMD at all sites at month 24.</p><p>The effect of romosozumab on the risk of vertebral fractures, clinical fractures and nonvertebral fractures in Study 337 and Study 142 is summarized in <ref type="table" target="#tab_87">Table 1</ref>.</p><p>Nonvertebral fractures were secondary endpoints in both studies. In Study 337, the risk reduction for nonvertebral fractures at 24 months observed with romosozumab followed by denosumab compared to placebo alone did not meet statistical significance when adjusted for multiplicity. In Study 142, romosozumab followed by alendronate significantly reduced the risk of nonvertebral fractures compared with alendronate alone through the primary analysis period, with a haz nonvertebral fractures with a median follow-up of 33 months.</p><p>The data suggested a potential reduction in hip fractures, however, Studies 337 and 142 were not designed adequately to demonstrate romosozumab's efficacy for reduction in hip fractures.</p><p>Additional analyses of the primary endpoints of Studies 337 and 142 (new vertebral fracture and clinical fracture in Study 142 and new vertebral fracture in Study 337) conducted in postmenopausal women did not identify differences in efficacy across subgroups defined by the following baseline characteristics: age, race, geographic region, baseline lumbar spine BMD Tscore, baseline total hip/femoral neck BMD T-score, baseline body mass index (BMI), fracture history, and Fracture Risk Assessment Tool (FRAX) score. Likewise, subgroup analyses of NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 16 percent change in BMD at the lumbar spine and total hip in Study 142 and Study 337 showed that romosozumab increased BMD over a wide range of baseline BMD T-scores and in subgroups defined by age and geographic region. The effects of romosozumab across these subgroups indicate that romosozumab can be effective in increasing BMD and reducing the risk for vertebral and nonvertebral fracture across a broad population of postmenopausal women with osteoporosis at high risk for fracture.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Benefit-Risk Assessment</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Benefit-Risk Summary and Assessment</head><p>Romosozumab, trade name Evenity, is a sclerostin inhibitor proposed for the treatment of osteoporosis in postmenopausal women at high risk of fracture. The dosing regimen is 210 mg administered by a healthcare professional once monthly for one year. The FDA has concluded that the benefits outweigh the risks and is granting approval.</p><p>Osteoporosis is a skeletal disorder characterized by low bone mass and structural deterioration of bone, which leads to bone fragility and increased fracture risk. Postmenopausal osteoporosis occurs due to the hormonal changes beginning at menopause which leads to increased bone loss. In the United States, about 8 million women aged 50 years or older have postmenopausal osteoporosis and approximately 1.5 million suffer osteoporosis-related fractures annually. The risk of fracture increases with age and a history of a prior osteoporosis-related fracture. Osteoporotic fractures can be associated with significant morbidity and mortality. Hip fractures are the most serious type of fractures and can impair the ability to walk and to live independently. Hip fractures are also associated with increased mortality.</p><p>Multiple effective treatments for postmenopausal osteoporosis are currently available. However, postmenopausal osteoporosis remains both underdiagnosed and undertreated in the United States. Approved therapies for postmenopausal osteoporosis include anti-resorptive agents (bisphosphonates, denosumab, calcitonin and raloxifene) as well as bone-forming (anabolic) agents (teriparatide and abaloparatide). These therapies with the exception of calcitonin, have been shown to reduce fracture. However, compliance, side effects, and some limitations on duration of use may be obstacles to treatment with these approved drugs.</p><p>The efficacy of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture was established in two fracture studies, Study 337 and Study 142 Study 337 (N = 7180) was a 24-month randomized, multicenter, double-blind, placebo-controlled clinical trial in postmenopausal women with osteoporosis aged 50 to 90 years (mean age of 71 years). Patients were randomized to receive one year of romosozumab 210 mg (N = 3589) or placebo (N = 3591) once monthly by subcutaneous injection administered by a healthcare professional. During the second year of the trial, all patients received denosumab 60 mg every 6 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 1 7 months. Patients also received daily supplemental calcium (500 to 1000 mg) and vitamin D (600 to 800 IU). At baseline, the mean T-score wasleast one prevalent vertebral fracture.</p><p>The co-primary endpoints of study 337 were the incidence of new vertebral fractures in patients treated with romosozumab compared to placebo at 12 months and the incidence of new vertebral fractures in patients treated with romosozumab then denosumab compared to placebo then denosumab at 24 months. During the 12-month double-blind romosozumab treatment per n p &lt; 0.001) and a p &lt; 0.001). At 24 months, the n absolute risk reduction of 1.9 1.3, 2.5; p &lt; 0.001) and a relative risk reduction Study 142 (N = 4093) was a multicenter, randomized, double-blind, alendronate-controlled clinical trial in postmenopausal women with osteoporosis and a history of a fracture aged 50 to 90 years (mean age of 74 years). Patients were randomized to receive one year of romosozumab 210 mg once monthly by subcutaneous injection administered by a healthcare professional or oral alendronate 70 mg once weekly. During the second year of the trial, all patients received oral alendronate 70 mg once weekly. Patients also received daily supplemental calcium (500 to 1000 mg) and vitamin D (600 to 800 IU). At baseline, the mean T-score was -3.0 at the lumbar spine and 96 vertebral fracture. Compared with Study 337, Study 142 enrolled a population at higher risk of osteoporosis-related fracture.</p><p>The coprimary endpoints of study 142 were the incidence of new morphometric vertebral fractures at month 24 and time to first clinical fracture (a composite of nonvertebral fracture and symptomatic vertebral fracture). The clinical fracture endpoint was event-driven and the primary analysis occurred when all subjects had reached 24 months of study participation and clinical fracture was confirmed in at least 330 subjects. At 24 months, the subject incidence of new alendronate alone, with an absolute risk reduction of 4.0 2.5, 5.6; p &lt; 0.001) and a relative risk reduction Through the primary analysis period the hazard ratio for romosozumab followed by alendronate compared to alendronate alone, based on 464 subjects with clinical fractures the the alendronate alone group) with a median follow-up of 33 months. Additionally, romosozumab followed by alendronate significantly reduced the risk of nonvertebral fractures compared with alendronate alone through the primary analysis period, with a hazard ratio of 0.81 0.66, 0.99; p &lt; 0.019), based on 395 subjects with nonvertebral fractures with a median follow-up of 33 months.</p><p>When considering the risks and benefits of romosozumab, hip fracture is associated with the highest morbidity and mortality. Hip fractures were recorded in both Studies 337 and 142. While NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">1 8</ref> the data suggest a reduction in hip fractures, neither study was adequately designed to assess romosozumab for hip fracture reduction.</p><p>Romosozumab demonstrated statistically significant gains in BMD at the lumbar spine, total hip and femoral neck. Results for BMD increases were consistent across the phase 2 and phase 3 placebo-and active-controlled studies. For both Study 142 and Study 337, the treatment effects were consistent (relative risks favored romosozumab) in all subgroups of baseline characteristics examined, including age, race, geographic region, a range of baseline BMD T-scores, and subjects with a history of prior vertebral, nonvertebral, or fragility fracture. Although only a very small percentage of patients were from the United States in both studies <ref type="bibr">(1.8</ref> in Study 142), the consistent efficacy results among all subgroups support applicability of romosozumab effects on fracture risk reduction and extrapolation of efficacy results to the US population.</p><p>The safety profile of romosozumab is mainly derived from the two fracture clinical trials (studies 337 and 142). Important adverse events that occurred in the placebo-controlled fracture trial (Study 337) included hypersensitivity reactions, injection site reactions, hypocalcemia, osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). Safety data from Study 142 confirmed the previously established risks of romosozumab. However, Study 142 also raised a new safety concern. In Study 142, there was an imbalance in serious cardiovascular events for romosozumab vs.</p><p>vs. during the 12-month double-blind period of the study.</p><p>This cardiovascular risk imbalance prompted additional analyses that focused on major adverse cardiac events (MACE), a composite endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke that is commonly used to assess cardiovascular risk or benefit. the romosozumab group experienced MACE However, when each fracture trial is considered separately, the results diverged. In the placebocontrolled Study 337, MACE:</p><p>and 30 romosozumab group experienced MACE, with a hazard ratio of contrast, in the active controlled S ts in the romosozumab group experienced MACE yielding a hazard ratio of 1.87 <ref type="bibr">( 1.11, 3.14)</ref>.</p><p>It is unclear whether romosozumab truly increases cardiovascular risk, as there are several factors that make the interpretation of the signal difficult. The fracture studies were not specifically designed to assess cardiovascular safety outcomes. Data regarding these events may not have been collected as rigorously as was necessary during the conduct of the studies to accurately capture all events. In addition, most of the analyses of the cardiovascular safety findings were conducted post-hoc after the imbalance in serious cardiovascular events in Study 142 was identified. Another limitation is the low number of MACE during the 12-month double-blind period of the fracture studies (approximately 60 events in each trial). Additionally, there is NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="formula">1 9</ref> uncertainty regarding the applicability of the cardiovascular findings to the US population. Only and population of Study 142 were from the US, raising questions about the generalizability of the cardiovascular safety findings to the US population. Lastly, we are unable to rule out a cardioprotective effect of alendronate in Study 142 or that the findings were due to chance.</p><p>A definitive mechanistic cause to explain romosozumab's effect on the cardiovascular system has not been found. An alternate explanation for the cardiovascular findings has also not been found. Therefore, given the totality of the available data, and the uncertainty surrounding these data, major adverse cardiac events are considered potential risks of romosozumab therapy.</p><p>Other important safety risks of romosozumab include the following:</p><p>1. Hypersensitivity reactions: Like other monoclonal antibodies, romosozumab is associated with hypersensitivity reactions. Clinically significant hypersensitivity reactions, including angioedema, erythema multiforme, and urticaria, occurred in romosozumab-treated subjects in the clinical studies, but the incidence was low. 2. Hypocalcemia: Inhibition of sclerostin by romosozumab leads to rapid bone mass accrual at initiation of treatment and an increased demand for bone-building substrates such as calcium. Based on the clinical study data, hypocalcemia is an important identified risk. Mild and transitory decreases in albumin-corrected calcium and a compensatory increase in intact parathyroid hormone (iPTH) were observed after initiation of romosozumab. Based on the totality of data, the risk of hypocalcemia is manageable, with adequate calcium and vitamin D intake recommended for all romosozumab-treated patients and monitoring of serum calcium in patients with stage 5 chronic kidney disease (CKD). 3. Osteonecrosis of Jaw (ONJ): ONJ is an important risk of romosozumab due to its antiresorptive activity. There was one case of ONJ during treatment with romosozumab and two cases after romosozumab-treated subjects had transitioned to antiresorptive therapy. 4. Atypical Femur Fracture (AFF): AFF is an important risk of romosozumab due to its antiresorptive activity. Three cases of AFF were reported after romosozumab-treated subjects had transitioned to alendronate therapy. 5. Injection Site Reactions: There was a higher incidence of injection site reactions during the double-blind period in the romosozumab group than in the control groups in all phase 2 and 3 studies .</p><p>When all data are considered, the benefits outweigh the risks for one year of romosozumab therapy in postmenopausal women with osteoporosis who are at high risk of fracture and who have not had a recent myocardial infarction or stroke. Romosozumab reduces the risk of vertebral and nonvertebral fracture. Although the fracture studies were not designed adequately to assess hip fracture, the outcome with the most associated morbidity and mortality, there were favorable point estimates in both studies for the romosozumab group compared to the control group, suggesting the potential for reduction in the risk of hip fractures on romosozumab. The evidence was not sufficient but the plausibility of an effect</p><p>Reference ID: 4416253 (b) <ref type="bibr" target="#b86">(4)</ref> NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 2 0 was considered in the benefit-risk assessment. Because of the different cardiovascular findings in the two large trials of romosozumab, it is not possible to exclude cardiovascular risk with romosozumab use. Given this potential risk, and the high risk of subsequent cardiac events in the year following a myocardial infarction or stroke, patients who are candidates for romosozumab therapy who have had a myocardial infarction or stroke within the prior year should not initiate romosozumab, as outlined in product labeling, including a Boxed Warning for prescribers and a Medication Guide for patients. Romosozumab's other risks are also adequately mitigated with labeling.</p><p>In addition to routine pharmacovigilance, a postmarketing study will be required to assess the impact of the boxed warning on romosozumab's prescribing patterns and potential for channeling bias. Depending on the findings of this study, a comparative safety study or trial may also be required to rule out an unacceptable increase in risk of MI, stroke, and cardiovascular death among users of romosozumab compared to users of an appropriate comparator(s).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimension Evidence and Uncertainties Conclusions and Reasons</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Condition</head><p>Postmenopausal osteoporosis is a bone disease characterized by loss of bone mass, leading to an increased risk for fractures. Postmenopausal women are the most common patient group to have osteoporosis. About postmenopausal women over age 50 will fracture bone due to osteoporosis The risk of fracture increases with age. The risk also increases with a history of a previous osteoporosis-related fracture In older patients, hip fracture is associated with increased loss of independence and increased mortality</p><p>Osteoporosis increases the risk of fracture in postmenopausal women. The risk of fracture increases with age and a history of a prior osteoporosisrelated fracture.</p><p>In older patients, fracture, predominantly hip fracture, is associated with increased morbidity and mortality.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Current Treatment Options</head><p>Current treatment options for postmenopausal osteoporosis include medications that inhibit bone loss (bisphosphonates, RANK ligand inhibitors, estrogen agonists/antagonists, and</p><p>Multiple therapies are available for the treatment of osteoporosis in postmenopausal women. Rare but serious side effects have decreased the usage of some of the currently available therapies and many patients NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 2 1</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimension Evidence and Uncertainties Conclusions and Reasons</head><p>calcitonin) and medications that stimulate bone formation (parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) analogs) Bisphosphonates are the most widely prescribed medications for osteoporosis. Rare but serious side effects with bisphosphonates (osteonecrosis of the jaw and atypical femoral fractures) have reduced the use of these medications. Denosumab is a potent antiresorptive therapy that also is associated with osteonecrosis of the jaw and atypical femoral fractures. Denosumab is also associated with an increased risk of fracture after discontinuation. Teriparatide and abaloparatide are the only approved bone anabolic therapies. Their use is limited to two years because of the potential risk of osteosarcoma, which was noted in animal studies. Raloxifene is associated with deep venous thrombosis and an increase in fatal strokes.</p><p>with osteoporosis who would benefit from therapy remain untreated.</p><p>Additional therapies in a new class such as romosozumab, will expand the treatment options.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Benefit</head><p>Vertebral Fracture: In the placebocontrolled trial, romosozumab reduced the risk of vertebral fractures with an absolute risk . Romosozumab followed by denosumab reduced the risk of vertebral fractures with an Treatment with romosozumab 210 mg monthly for one year followed by antiresorptive therapy significantly increases bone mineral density at the lumbar spine and hip with accompanying significant vertebral fracture risk reduction (as demonstrated in the placebo and active-controlled trials) and nonvertebral fracture risk reduction NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 2 2</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimension</head><p>Evidence and Uncertainties Conclusions and Reasons and a relative risk reduction of compared to placebo followed by denosumab. In the active controlled trial in postmenopausal women at high risk of fracture, romosozumab followed by alendronate was superior to alendronate alone, reducing the risk of vertebral fractures with an absolute risk reduction of 4.0 risk reduction of 50 24. Nonvertebral Fracture: In the placebo-controlled trial, romosozumab was not significantly different from placebo in reducing the risk of nonvertebral fracture. In the active controlled trial in postmenopausal women at high risk of fracture, romosozumab followed by alendronate was superior to alendronate alone in reducing the risk of nonvertebral fractures after a median follow-up of 33 months, with a hazard ratio of 0.81. Bone Mineral Density (BMD): Romosozumab demonstrated consistent and significant increases in BMD at the lumbar spine, total hip and femoral neck in the fracture studies. Compared to placebo, romosozumab increased bone mineral density at after 12 months of therapy.</p><p>(as demonstrated in the activecontrolled trial) in postmenopausal women with osteoporosis NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 2 3</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimension Evidence and Uncertainties Conclusions and Reasons</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk and Risk Management</head><p>The safety data from the two large fracture trials for romosozumab include 5621 postmenopausal women who received romosozumab 210 mg once monthly for one year. Safety concerns with romosozumab use include major adverse cardiac events, injection site reactions, hypersensitivity reactions, hypocalcemia, osteonecrosis of the jaw and atypical femoral fractures. Cardiovascular safety is an important potential concern with romosozumab use. The clinical fracture trials have discrepant results for major cardiac adverse event outcomes. Additionally, there are limited data on the role of sclerostin in the cardiovascular system. The risks associated with romosozumab use can be managed with product labeling.</p><p>Product labeling will include a boxed warning about major adverse cardiac events, recommending that romosozumab not be initiated in patients who have had a myocardial infarction of stroke within the past year, and to consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Product labeling will also include warnings and precautions for injection site reactions, hypersensitivity reactions, hypocalcemia, osteonecrosis of the jaw and atypical femoral fractures.</p><p>A medication guide will inform patients about these important risks.</p><p>A Risk Evaluation and Mitigation Strategy is not needed for this product.</p><p>Postmarketing Required Studies include: a study to assess the impact of the boxed warning on romosozumab's prescribing patterns and potential for channeling bias. Depending on the findings of the first study, a comparative safety study or trial may also be required to rule out an unacceptable increase in risk of MI, stroke, and cardiovascular death among users of romosozumab compared to users of an appropriate comparator(s). Observational survey studies designed to capture patient experience data Natural history studies Patient preference studies (e.g., submitted studies or scientific publications) Other: (Please specify) Patient experience data that was not submitted in the application, but was considered in this review.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Experience Data</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">Therapeutic Context</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Condition</head><p>Osteoporosis is a skeletal disorder characterized by low bone mass and structural deterioration of bone, which leads to bone fragility and increased fracture risk. Osteoporosis results from imbalances between resorption of bone by osteoclasts and formation of new bone by osteoblasts during bone remodeling. The World Health Organization (WHO) defines osteoporosis by bone mineral density (BMD) criteria obtained using dual-energy X-ray absorptiometry (DXA). A T-score is generated by measurements of the BMD at the lumbar NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 25 spine, total hip, and femoral neck. Osteoporosis is defined by T-ons below the mean BMD of a young, healthy cohort of adults at the same location.</p><p>Osteoporosis is a common disorder, with the worldwide prevalence estimated to be around 200 million people according to the WHO. Postmenopausal osteoporosis (PMO), the most common type, is driven primarily by the hormonal changes beginning at menopause. In the US, an estimated 8.2 million women over age 50 years have postmenopausal osteoporosis and approximately 1.5 million sustain osteoporosis-related fractures annually <ref type="bibr">(NOF, 2018)</ref>. The prevalence of PMO and hence the number of osteoporosis-related fractures are projected to increase substantially as the US population ages. Osteoporotic fractures, most notably hip fractures, are associated with decreased quality of life and increased morbidity and mortality.</p><p>Despite the morbidity and mortality associated with osteoporosis, and the availability of multiple treatments to reduce fracture risk (as discussed below), osteoporosis remains underdiagnosed and undertreated. Of postmenopausal women who have an osteoporosisundergo DXA or receive a prescription for a drug to treat osteoporosis after a fracture <ref type="bibr" target="#b64">(Balasubramanian et al, 2014;</ref><ref type="bibr">NOF, 2014)</ref>. <ref type="table" target="#tab_5">Table 3</ref> summarizes the currently approved pharmacologic therapies for PMO, which include several classes of antiresorptive therapies and two types of bone-forming (anabolic) agents that act through the PTH receptor. Bisphosphonates, the main class of antiresorptive therapy, are currently the standard of care for first-line therapy. Denosumab, a RANKL antagonist, raloxifene, an estrogen receptor agonist/antagonist, and calcitonin are the other available antiresorptive therapies. Available bone-forming agents include teriparatide, a parathyroid hormone (PTH) analog and abaloparatide, a PTH related protein (PTHrp) analog.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Current Treatment Options</head><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 2 6 Excluding the calcitonin products (which were approved based on total body calcium and/or BMD data), the pharmacologic therapies listed in the above table were approved for treatment of PMO based on reduction of morphometric vertebral fractures, consistent with 1994 FDA guidance on osteoporosis drug development. Such fractures are defined solely by radiographic criteria and may be asymptomatic. Although the clinical effects of such fractures vary, as discussed above they are associated with increased morbidity and mortality and are a strong predictor of subsequent fractures (vertebral and nonvertebral). Additionally, vertebral fractures are the most common osteoporosis-related fractures in postmenopausal women <ref type="bibr" target="#b13">(Khosla, 2003)</ref>. <ref type="table" target="#tab_6">Table 4</ref> lists the absolute and relative risk reductions (ARR and RRR, respectively) compared to placebo in new morphometric vertebral fractures (the primary endpoint) in the PMO trials of approved drugs. Risk reductions were generally apparent within 1 or 2 years and maintained through 3 years. Because the trial populations had different baseline fracture risks, ARR is highly variable between drugs and trials, while RRR is more consistent. For example, the FIT-1 trial of Fosamax enrolled a high-risk population (women with baseline vertebral fractures) whereas FIT-2 enrolled a lower risk population (no baseline fractures); fracture rates in both treatment groups were much higher in FIT-1, but relative reduction in fracture risk was nearly identical in the two studies. Nonvertebral fracture is not a required endpoint for regulatory approval. <ref type="table" target="#tab_7">Table 5</ref> lists the ARR and RRR compared to placebo in the PMO trials of approved drugs that demonstrated statistically significant reductions in nonvertebral fracture risk. Risedronate (Actonel-NA) <ref type="bibr">3</ref> 3 9</p><p>Risedronate (Actonel-MN) <ref type="bibr" target="#b87">5</ref> 3 1 ARR = Absolute Risk Reduction; RRR= Relative Risk Reduction *Forteo trial: 19 months median exposure **Tymlos trial: risks at 25 months ***Fosamax FIT-2 trial: 48-month assessment Sources: Unites States Prescribing Information</p><p>In summary, there are a number of pharmacologic therapies available for the treatment of PMO. However, there are limitations with the different treatment options as detailed in <ref type="table" target="#tab_5">Table 3</ref> above. Given that PMO is a disease that is reportedly undertreated and a disease that carries with it a risk of morbidity and mortality associated with osteoporotic fracture, additional treatment options that offer advantages over the current options are needed.</p><p>3 Regulatory Background</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>U.S. Regulatory Actions and Marketing History</head><p>Romosozumab is a new molecular entity and currently not marketed in the US or anywhere else in the world. The FDA took a Complete Response action for the original BLA submission in July 2017 as described above in Section 1.1. There are currently no other marketing applications for romosozumab under review in other divisions of the FDA.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 30</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of Presubmission/Submission Regulatory Activity</head><p>The romosozumab IND (100391) was opened in November 2006. For a detailed listing of presubmission regulatory activity, refer to the review of the original BLA submission (signed in DARRTS <ref type="bibr">May 3, 2017</ref>). An End of Phase 2 meeting was held in 2011. The applicant proposed to conduct a 12-month placebo-controlled phase 3 fracture trial. After discussion, the Division advised that the duration of the study should be a minimum of 2 years. It was acceptable that romosozumab treatment be limited to one year with all enrolled subjects (placebo and romosozumab treated subjects) receiving the same active control product for the second year. It was agreed that new vertebral fracture at 12 months and at 24 months could be coprimary efficacy endpoints.</p><p>The BLA was first submitted on July 19, 2016, with evidence of efficacy and safety from the 24month primary analysis of the phase 3 placebo-controlled fracture study in women with <ref type="bibr">PMO, Study 2007337 (Study 337)</ref>. Late in the first review cycle, data from an active-controlled, phase 3 fracture study in women with PMO at increased risk for fracture, Study 20110142 (Study 142), became available and demonstrated an imbalance in positively adjudicated serious cardiovascular events for romosozumab vs. the active control alendronate during the 12-month double-blind period of the study. Additionally, data from the recently completed 12-month placebo-controlled phase 3 BMD study in men with osteoporosis, Study 20110174 (Study 174), also indicated an imbalance in positively adjudicated serious cardiovascular events. The applicant requested a meeting with FDA to discuss these findings, which took place on May 19, 2017.</p><p>In response to the concerning cardiovascular safety findings of Study 142 and Study 174, the FDA issued a Complete Response Letter on <ref type="bibr">July 13, 2017</ref>, which outlined the following:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DEFICIENCY:</head><p>Preliminary findings from Study 20110142 show a higher incidence of cardiovascular serious adverse events with romosozumab compared to alendronate in women with postmenopausal osteoporosis. A similar signal was seen in Study 20110174, a smaller study comparing romosozumab to placebo in men with osteoporosis. These findings raise concerns that romosozumab may increase cardiovascular risk. Although Study 20070337 did not appear to have a cardiovascular safety signal, these disparate findings across studies require detailed review once the completed final analyses have been submitted. These additional data, including the efficacy data from the head-to-head comparison of romosozumab to alendronate, are needed before we can complete the benefit/risk assessment and determine whether the benefits of romosozumab outweigh its risks.</p><p>TO ADDRESS THIS DEFICIENCY: Complete analyses of Studies 20110142 and 20110174. Submit the individual clinical study reports together with an integrated assessment of cardiovascular risk that takes NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 3 1</p><p>into account the totality of the data. This should include the basis for your conclusion that the benefits of romosozumab outweigh the identified cardiovascular risks. Provide all pertinent narratives and datasets. We recommend that you request a meeting to discuss the details of your proposal for responding to the deficiency before you resubmit the application.</p><p>An End of Review meeting was held with the applicant on October 26, 2017. FDA requested an analysis of Major Adverse Cardiovascular Events (MACE), a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, as well as analyses of each of these individual components. Additionally, because of the early separation of events in the treatment groups (by Month 2), FDA recommended that the cardiovascular safety analyses include demonstration that romosozumab does not have off-target effects on platelet aggregation (e.g., via an in vitro platelet aggregation study), vasoconstriction, and systolic and diastolic blood pressure. FDA also requested an analysis of non-serious cardiac ischemic events (e.g., angina).</p><p>The BLA was resubmitted on July 9, 2018. The resubmission addressed the requirements put forth in the Complete Response letter and the recommendations communicated to the applicant at the End of Review meeting.</p><p>On January 4, 2019, the applicant submitted a clinical information amendment outlining all changes that resulted from additional data available through the end of the final analysis periods of Studies 337 and 142 (as compared to what was initially reported in the clinical study reports, which covered the primary analysis periods of the studies). This constituted a major amendment to the application. On January 7, 2019, FDA notified the applicant that the PDUFA goal date would therefore be extended by three months to allow time for a thorough review of this amendment. Site 1-678YLY, Jose Fernando Molina Restrepo, M.D., Medellin, Columbia: two investigators with the same last name in the same location appeared unusual, high enrollment (752 total between the two sites), new investigator(s). A Form 483 was issued for failure to conduct an investigation in accordance with the signed statement of investigator and the investigational plan. This site was classified as voluntary action indicated (VAI). This VAI did not impact data integrity from this site. Site 1-64PLTY, Jaime Restrepo, M.D., Medellin, Columbia: two investigators with same last name in same location appeared unusual, high enrollment (752 total between the two sites), new investigator(s). This site was classified as no action indicated (NAI). Site 1-52SFOU, Magda Dabrowska, M.D., Poland: high enrollment (264), high site efficacy effect (-2.04), relative high number of outliers, no prior inspection in the past 3 years. This site was classified as NAI. Site 1-3RA0SB (Recknor, US): US site for comparison. This site was classified as NAI.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Product Quality</head><p>The review team from the Office of Biotechnology Products recommends approval of this BLA. The supplement does not include any changes related to product quality. Please see the Office of Biotechnology Product's BLA 761062 Resubmission Executive Summary and Memorandum of Review.</p><p>Drug Substance: Romosozumab is produced from a recombinant DNA-derived Chinese Hamster Ovary (CHO) cell line using standard cell culture techniques. The master cell bank (MCB) and working cell bank <ref type="bibr">(WCB)</ref> have been adequately characterized and tested. Tables 1 and 2, pages 7 -19 of the Integrated Quality Assessment from the first review cycle outline the critical quality attributes of the romosozumab drug substance. The data provided in the BLA supports a shelf life of months for the romosozumab drug substance when stored at .</p><p>Drug Product Manufacturing: Drug product manufacturing process steps include Reference ID: 4416253 (b) (4) (b) <ref type="bibr" target="#b86">(4)</ref> (b) <ref type="bibr" target="#b86">(4)</ref> (b) <ref type="bibr" target="#b86">(4)</ref> Device considerations: During the first review cycle, the device constituent was found acceptable for approval by the General Hospital Devices Branch (GHDB)/ Office of Device Evaluation/Center for Devices and Radiological Health (CDRH). In this resubmission, the applicant includes the addition of breakloose and extrusion (BLE) testing for use in stability and lot release at the Amgen Dun Laoghaire (ADL) site. The information provided is adequate to support transfer of drug product syringe break loose and extrusion testing from Amgen Manufacturing Limited (AML) to ADL.</p><p>Labeling: Product labeling has been reviewed by the Office of Biotechnology Products and changes have been agreed upon with the applicant Postmarketing studies: During the original review cycle, a postmarketing commitment study had been discussed with the applicant. The requested data are included in the BLA resubmission, have been reviewed, and are acceptable.</p><p>Reference ID: 4416253</p><formula xml:id="formula_0">(b) (4) (b) (4) (b) (4) (b) (4) (b)<label>(4)</label></formula><p>(b) <ref type="bibr" target="#b86">(4)</ref> NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 34</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Microbiology</head><p>Romosozumab is not an antimicrobial agent. Clinical microbiology studies are not applicable to this BLA. The microbiology product quality of the romosozumab drug substance and combination drug/device product were reviewed by the Product Quality team.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Devices and Companion Diagnostic Issues</head><p>Drug product manufacturing processes were modified to manufacture prefilled syringes (PFS) in three presentations: 70 mg/mL and 120 mg/mL in 1 mL Long glass syringes, and 90 mg/mL in 1 mL syringes. Only the 90 mg/mL syringe presentation is intended for commercial registration and production. Refer to the Center for Devices and Radiological Health (CDRH) review for details.</p><p>Reference ID: 4416253</p><formula xml:id="formula_1">(b)<label>(4)</label></formula><p>(b) <ref type="bibr" target="#b86">(4)</ref> NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 35 5 Nonclinical Pharmacology/Toxicology</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Executive Summary</head><p>The Applicant carried out a comprehensive nonclinical program for the original BLA submission that included pharmacology, pharmacokinetics/ADME and toxicology studies.</p><p>Prompted by the adverse cardiovascular findings in Study 142, the sponsor conducted five additional nonclinical studies to examine the potential risk of sclerostin inhibition for acute ischemic cardiovascular events. A study to assess the risk for osteonecrosis of the jaw (ONJ) was also conducted.</p><p>The new studies showed (A) in an in vitro study: no activation of human platelets by romosozumab; (B) in the ovariectomized (OVX) ApoE knockout (KO) mouse atherosclerosis model: no effects of sclerostin antibody on systemic markers of inflammation or endothelial activation, no meaningful qualitative or quantitative effects of sclerostin antibody treatment on aortic atherosclerotic lesions except for a decrease in plaque volume at end of study, and no effects of sclerostin antibody on gene transcription that would be consistent with an atherogenic effect; (C) in human artery atherosclerotic plaques: no expression of sclerostin in vulnerable plaque areas, and generally no association between sclerostin expression and plaque features or cardiovascular events observed in the plaque donors; (D) in a genome-wide association study (GWAS) database: no genetic association between risk of osteoporosis or fracture and risk of MI or stroke; and (E) in human coronary artery rings: no vasoconstrictive effect of romosozumab or human sclerostin. An additional nonclinical study showed lack of induction of ONJ-like lesions by sclerostin antibody in OVX rats with experimental periodontitis.</p><p>The Applicant discussed the concerns about cardiovascular safety, particularly the potential for ischemic events, from a nonclinical perspective based on the available nonclinical data and current literature. The concerns included potential roles of sclerostin in vascular calcification and atherosclerosis-associated pathology. The data from previously conducted nonclinical studies suggested that sclerostin inhibition does not induce or exacerbate vascular calcification. The data from the newly conducted study in the mouse atherosclerosis model showing lack of an effect of sclerostin antibody on mineralized plaque volume appeared to confirm this conclusion. Additionally, the fact that the inverse relationship between sclerostin expression and dystrophic calcification in human carotid arterial plaques was unlikely to reflect a direct relationship also strengthened this conclusion.</p><p>The atherosclerosis study in the ApoE KO mice was the most elaborate new nonclinical study conducted. The results of this 16-week study did not suggest exacerbation of atherosclerosis or significant transcriptional changes in aortic plaques as a result of antibody-mediated sclerostin inhibition. Accordingly, the reduced expression of sclerostin in human and mouse atherosclerotic plaques does not appear to be causally related to atherosclerosis or its</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>The resubmission included five new nonclinical studies to further investigate the effects of sclerostin antibody on cardiovascular endpoints and identify a potential biological mechanism for the adverse cardiovascular effects.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of previous studies</head><p>Sclerostin is an extracellular inhibitor of the canonical Wnt signaling pathway and is produced mainly by the osteocyte. A comprehensive nonclinical study program was conducted to support the original BLA submission.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 3 7</p><p>Romosozumab blocks the interaction of sclerostin with low density lipoprotein receptor-related protein (LRP)5 and LRP6, two co-receptors involved in Wnt signaling, thereby activating the Wnt pathway in osteoblastic cells.</p><p>In humans, romosozumab transiently stimulates bone formation and inhibits bone resorption, based on evaluation of bone turnover markers. In 12-month bone quality studies in ovariectomized (OVX) rats and monkeys, at doses equivalent to <ref type="bibr">1-19x and 1-22x</ref> the human AUC(0-y subcutaneous dose of 210 mg, respectively, romosozumab increased bone mass and strength of the lumbar spine, tibia, femur, and radius in a dose-and time-dependent manner. Bone formation and resorption markers were rapidly and transiently increased. The bone changes consisted of increases in trabecular thickness in vertebrae and long bone metaphyses and increases in cortical thickness in long bone metaphyses and diaphyses. These effects were due to stimulation of bone formation concomitant with suppression of bone resorption, mostly at trabecular and endosteal bone surfaces, as observed by histomorphometry. An improvement in bone quality was observed in the vertebrae of rats and monkeys at 19-22x human exposure multiples. Bone quality was maintained at all other evaluated sites.</p><p>Toxicity studies of up to 6-month duration were conducted in rats and monkeys. The main findings were related to the pharmacologic effect of romosozumab and included red blood cell, white blood cell and platelet decreases, serum calcium and phosphorus decreases, and extramedullary hematopoiesis. The effects were associated with hyperostosis and increases in bone formation and densitometric parameters. Exposure multiples in the 6-month studies ranged from 1-38x and 1-93x human exposure, in rats and monkeys, respectively. Assessments of local tolerance did not reveal significant concerns.</p><p>A carcinogenicity study was conducted in Sprague Dawley rats. The rats were dosed for up to 98 weeks with 0, 3, 10, 50 mg/kg/week, equivalent to 1-19x human exposure. Romosozumab did not affect mortality and caused a dose-dependent increase in bone mass with trabecular and cortical bone thickening at all doses. Romosozumab did not cause significant increases in tumor incidences in males or females. A low incidence of osteosarcoma (2/54) was observed in high dose males at 19x human exposure. However, the lack of statistical significance of this finding and the large exposure multiple suggests that romosozumab is unlikely to increase the human risk of osteosarcoma.</p><p>Reproductive toxicity was evaluated in rat fertility and early embryonic development (FEED), embryofetal development (EFD) and pre-and postnatal development (PPND) studies. Findings in the definitive FEED and EFD studies included reduced ventral processes of the 6 th cervical vertebrae at doses of 100 and 300 mg/kg (17-56x human exposure). However, this anatomical structure is not present in humans and the finding is not considered clinically relevant. Fetal poly-and syndactyly were observed in the definitive EFD study at 32x human exposure, consistent with the syndactyly that has been observed in sclerosteosis patients and SOST knockout mice. Although it may have been treatment-related, the finding is considered of low NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 38 clinical relevance based on the exposure multiple and the timing of digit formation in the first trimester in humans when placental transfer of immunoglobulins is limited. In the PPND study, there were small decreases in femoral bone density and/or thickness in the F1 offspring at 1.5-56x human exposure of unclear biological significance. None of these findings are considered relevant for the postmenopausal indication.</p><p>In the original BLA submission, the sponsor evaluated multiple potential safety concerns based on the weight of evidence from nonclinical studies, clinical studies and published literature. There was no indication that romosozumab would increase the risks for vascular calcification, but potential effects on processes underlying cardiovascular ischemic events were not considered at the time. Increased risks for osteoarthritis, altered longitudinal bone growth, hyperostosis, hypercementosis, altered hematopoiesis or glucose metabolism, sarcopenia, and -mediated inflammation were also considered unlikely. The risk of vascular calcification is further discussed in the general discussion of concerns about cardiovascular effects of sclerostin at the end of this section.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nonclinical Evaluation of Sclerostin and Cardiovascular Disease</head><p>To further address the imbalance in serious cardiovascular (CV) events observed in clinical studies and to assess the plausibility of a treatment related effect, the sponsor conducted five new non-GLP nonclinical pharmacology studies with romosozumab or a rat surrogate sclerostinantibody (r13C7), which is romosozumab engineered with rat Fc. A study of the effects of r13C7 in a rodent model of ONJ was also conducted ( <ref type="table" target="#tab_92">Table 6</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>The objective of this study was to evaluate the potential effects of sclerostin antibody r13C7 on potential transcriptional and morphologic changes in atherosclerotic plaques in aortas from high fat diet-fed ovariectomized (OVX) Apolipoprotein E (ApoE) knockout (KO) mice (ApoE KO-OVX mice) compared with high fat diet-fed OVX Wild Type (WT) mice (WT-OVX mice). The effects of alendronate for 16 weeks were also evaluated.</p><p>The ApoE KO mouse model is a well-known model of atherogenesis. ApoE plays a key protective role in atherosclerosis. First, plasma ApoE maintains plasma cholesterol homeostasis by facilitating hepatic uptake of lipoprotein remnants. Second, in atherosclerotic lesions ApoE together with ApoA-I facilitates cholesterol efflux from macrophage foam cells within the affected intimal layer. ApoE present in the atherosclerotic lesion also modifies macrophageand T lymphocyte-mediated immune responses that contribute to this chronic inflammatory disease.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>Female WT or ApoE KO mice (C57Bl/6) were placed on a high--6 weeks of age. After 2 weeks, the mice were ovariectomized (OVX). Two weeks after ovariectomy, at age 9-10 weeks, mice were dosed by subcutaneous injection once weekly with 10 mg/kg of the rat sclerostin antibody r13C7 for <ref type="bibr">3, 8, or 16</ref> weeks, or twice weekly with alendronate (ALN) (0.02 mg/kg) for 16 weeks. Control mice were treated with reference item A or B (placebo solution or saline), respectively <ref type="table" target="#tab_9">(Table 7)</ref>. Evaluations included clinical signs, body weight, r13C7 serum concentrations, clinical chemistry, serum lipids, bone turnover markers, serum cytokine and chemokines, aorta histopathology, aorta gene (RNA) expression profiles, and aorta plaque volume and mineralization (measured by microCT). A defined region of the aortic arch was used for RNA sequencing.</p><p>Anticipated exposure (AUC) to sclerostin-antibody r13C7 (10 mg/kg) was approximately 4-fold greater than clinical exposure to romosozumab 210 mg monthly based on AUC comparison. It is unclear how this exposure was calculated but it may have been based on data from a 1-year rat bone quality study (107899), in which the 10 mg/kg dose yielded a 4.3-fold animal vs. human AUC exposure multiple, the bone formation marker osteocalcin was increased by approximately , The 0.02 mg/kg alendronate dose was 4-fold greater than the human equivalent oral weekly dose of 70 mg were not described or discussed in the main section of the report.</p><p>Reference ID: 4416253 (b) <ref type="bibr" target="#b86">(4)</ref> (b) <ref type="bibr" target="#b86">(4)</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical signs and body weight;</head><p>Mortality, clinical observations and body weight were not affected by r13C7 or alendronate treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bioanalysis (TK)</head><p>In general, all animals dosed with r13C7 had detectable r13C7 serum levels on Days 22, 57 and 113, confirming exposure. However, levels were quite variable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical chemistry</head><p>Lipids: ApoE KO-OVX mice showed the expected increases in serum cholesterol, HDL, LDL, cholesterol/HDL ratio, and triglycerides as compared to WT-OVX mice. Treatment with r13C7 or ALN did not have an effect on clinical chemistry parameters in either WT-OVX or ApoE KO-OVX mice.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">4 2</ref> Bone turnover markers <ref type="bibr">(PINP,</ref><ref type="bibr">OPG,</ref><ref type="bibr">TRACP 5b)</ref>: Levels of PINP (bone formation marker) were similar in WT-OVX and ApoE KO-OVX control mice. R13C7 significantly increased PINP in both WT-OVX and ApoE KO-OVX mice at all time points, indicating the expected bone formation effect. The increase in PINP was variable and averaged approximately ALN for 16 weeks led to a significant reduction in serum PINP in ApoE KO OVX mice, as expected for an antiresorptive drug.</p><p>Levels of OPG (osteoprotegerin) (inhibitor of osteoclast formation/maturation and also a known Wnt target gene and negative regulator of vascular calcification) were lower in ApoE KO-OVX mice than in WT mice on Days 57 and 113. OPG levels were not affected by either r13C7 or alendronate treatment for either genotype at any time point.</p><p>Levels of TRACP 5b (osteoclast marker) decreased over time in ApoE KO-OVX mice and were significantly lower than in WT mice on D113. TRACP 5b levels were not affected by either r13C7 or ALN in either genotype.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic markers of inflammation or endothelial activation Markers evaluated included:</head><p>Chemokines that attract and/or recruit activated blood immune cells to sites of inflammation (MCP1, RANTES, IL-16, MIP--CD40L and biomarkers released by endothelial cells in response to vascular injury (Endocan-1, Follistatin, ICAM1, P-selectin and E-selectin) Major pro-inflammatory cytokines (IL--6 and TNF-Biomarkers of vascular calcification (OPN) and cell proliferation (TIMP1 and M-CSF) Small increases in only a couple of markers (OPN and TIMP1) were observed in ApoE KO vs. WT mice on Day 22. There were also a few transient changes, usually decreases on Day 57 only, in a couple of markers in r13C7-treated but not vehicle-treated WT or ApoE KO animals, e.g. a decrease in E-Selectin in r13C7-treated ApoE KO mice. However, in general, r13C7 did not significantly alter these markers in either WT or ApoE KO OVX mice. Based on the lack of an effect of r13C7 on P-selectin and CD40L in both genotypes, sclerostin inhibition had no effect on platelet activation.</p><p>In WT-OVX mice, a limited number of Wnt target genes, or genes known to be regulated by sclerostin antibody related to ossification and bone mineralization, were differentially expressed in the aorta of r13C7-treated animals at Week 3 (only), and an acute response pre-Week 3 cannot be excluded. Some genes involved in ECM organization were also differentially expressed at Week 3 in r13C7 vs. vehicle treated WT mice.</p><p>In ApoE KO-OVX mice, r13C7 treatment led to a significant gene expression change in 3 pathways at Week 8, but the enrichment of these pathways was driven by only a small number of genes. The pathways did not intersect with the atherosclerosis-related pathways identified by genotype (ApoE KO-OVX vs. WT-OVX) comparison and are therefore unlikely to play a role in atherosclerosis progression. Two of these pathways were related to triglyceride synthesis and vascular calcification, respectively, possibly playing a role in arterial disease. However, this is weak evidence for a significant vascular effect of sclerostin antibody. At week 16, only 4 genes changed expression, and no pathways were significantly enriched.</p><p>In the ApoE KO-OVX mice, no Wnt target genes or sclerostin antibody responsive bone genes significantly changed expression due to r13C7 treatment at any time point. However, Dkk2, a known Wnt antagonist, was upregulated (about 2-fold) with r13C7 treatment at week 3. In ApoE KO-OVX mice, there was no clear evidence of upregulation by r13C7 of genes involved in ECM structure, bone mineralization, and cell cycle. Sclerostin antibody had no effect on prostaglandin signaling genes in ApoE KO-OVX mice, suggesting a lack of related prothrombotic effects.</p><p>Thus, RNA sequencing did not identify a typical gene expression signature attributable to r13C7 treatment that would be associated with the development or progression of atherosclerosis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SOST and Dkk1</head><p>In bone, expression of Wnt antagonists Dkk1 and SOST is upregulated in response to sclerostin antibody treatment, possibly explaining the attenuation of the bone effect over time. In the current study, the Dkk1 gene was not expressed in mouse aorta in any of the conditions NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">4 5</ref> examined. SOST expression was downregulated in ApoE KO-OVX vs. WT-OVX mouse aortas at Weeks 8 and 16, suggesting atherosclerosis might be associated with Wnt pathway inhibition and feedback SOST decrease. However, the lack of changes in Wnt pathway genes in ApoE KO-OVX vs. WT-OVX mice, described above, contradicts this hypothesis. SOST expression was not affected by r13C7 treatment in either WT-OVX or ApoE KO-OVX mice at any time point, which is different from the increase in SOST expression in bone upon sclerostin antibody treatment and osteoblastic Wnt activation.</p><p>To understand the SOST downregulation in ApoE KO-OVX mouse aorta, an analysis was performed on relevant genes differentially expressed in ApoE KO-OVX vs. WT-OVX mice. The data showed that upstream regulators compatible with both upregulation and downregulation of SOST expression were enriched in ApoE KO-OVX vs. WT-OVX mouse aorta. However, it is unclear which of these regulators is a major modulator of SOST expression in the vasculature.</p><p>While systemic markers of inflammation or endothelial activation were not affected by r13C7 (above), several genes related to inflammation, e.g. MCP-1, IL-6, and ICAM1, were locally upregulated in the aorta of ApoE KO-OVX mice, consistent with the local upregulation of inflammation signaling pathways. The expression of these genes was not affected by r13C7 in either genotype. There was no evidence of in vivo platelet activation in WT or ApoE KO-OVX mice by sclerostin antibody, since P-selectin and CD40L were unaltered.</p><p>Thus, the data indicate that Scl-Ab r13C7 does not affect atherosclerosis-related gene expression in aortic arch tissue.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Micro-CT evaluation of atherosclerotic plaques</head><p>In the ApoE KO-OVX mice, atherosclerotic total plaque volume (mm 3 ) (absolute and relative to aorta volume) increased over time, as expected, and consistent with the histology data. Treatment with r13C7 led to a statistically significant decrease in plaque volume of approximately e sponsor's report as not biologically relevant. The relatively small mineralized plaque volume was increased in ApoE KO-OVX mice vs. WT-OVX plaque volume was not affected by r13C7. The increase in mineralized plaque volume in untreated ApoE KO-OVX vs. WT-OVX mice was consistent with the observed decrease in serum OPG, which has been reported to be a negative regulator of vascular calcification.</p><p>Alendronate caused a slight decrease in total plaque volume but had no effect on mineralized plaque volume at Week 16.</p><p>In a published study by <ref type="bibr" target="#b16">Krishna et al (2017)</ref> conducted in ApoE KO male mice on high fat diet and dosed with Angiotensin II (Ang II) for 28 days, a model in which atherosclerosis and aortic aneurysm develop, excess systemic levels of sclerostin reduced several measures of atherosclerosis, aneurysm, and markers of inflammation. Atherosclerotic plaque area (Sudan IV NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">4 6</ref> imately contrasting results of this study and the sponsor's study are discussed further in Section 5.4.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p>The action of sclerostin antibody r13C7 was investigated in the high fat diet-fed ApoE KO-OVX mouse, an established mouse model for atherosclerosis, following ovariectomy. Administration of r13C7 by subcutaneous injection once weekly at a dose of 10 mg/kg (predicted to be 4-fold greater than the clinical exposure of romosozumab of 210 mg once monthly) for <ref type="bibr">3, 8, or 16</ref> weeks was well tolerated in ovariectomized (OVX) ApoE KO and WT mice. There was no genotype effect on the levels of systemic markers of inflammation or endothelial/platelet activation (cytokines/chemokines). Sclerostin inhibition by r13C7 also had no significant effects on these markers in either WT-OVX or ApoE KO-OVX mice. Sclerostin antibody had no meaningful effects on the incidence of atherosclerotic plaques in ApoE KO-OVX mice. There was an increase in the incidence of plaques with necrosis at Week 16, but no effect on plaque fibrocartilaginous metaplasia at any time point in ApoE KO-OVX mice. The increase in plaque necrosis may signal a concern about increased plaque instability. Sclerostin antibody decreased aortic total plaque volume at Week 16, but the significance of this finding is unclear in the context of the other study results. Sclerostin antibody had no effect on the mineralized plaque volume in ApoE KO-OVX mice. Sclerostin antibody did not result in gene transcriptional changes in aorta tissue that would be expected to affect the development or progression of atherosclerosis. Sclerostin (SOST) gene expression decreased with the progression of atherosclerosis in ApoE KO-OVX mice but was unaffected by r13C7 administration in both genotypes. Alendronate for 16 weeks did not alter total or mineralized plaque volume or plaque histologic features in ApoE KO-OVX mice. The findings generally support the concept that inhibition of sclerostin by r13C7 does not promote atheroprogression in the OVX ApoE KO mouse model. However, the data on plaque necrosis suggest a potential concern about increased plaque instability.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>The expression pattern of sclerostin was examined using immunohistochemistry in sections of human atherosclerotic plaques classified as stable or unstable based on morphological features (i.e. fibrotic vs. classical atheromatous plaques) derived from the carotid and femoral arteries of patients undergoing an endarterectomy procedure. The association between sclerostin expression and factors known to predispose to plaque rupture, i.e., lipid content, macrophage content, smooth muscle cell content, collagen content, calcification, and intraplaque hemorrhage was also determined.</p><p>Reference ID: 4416253 (b) <ref type="bibr" target="#b86">(4)</ref> (b) <ref type="bibr" target="#b86">(4)</ref> NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 47 Methods A retrospective analysis was performed on 94 carotid artery plaques and 50 femoral/iliac artery plaques collected from women. Samples were accessed from the AtheroExpress biobank of embedded atherosclerotic plaque samples that had been collected during surgical endarterectomy. Serial sections were stained for expression of alpha-smooth muscle actin (aSMA) and human sclerostin, and a third section was stained with hematoxylin and eosin (H&amp;E). Sections were scored to reflect the extent and location of sclerostin staining and the results were combined with pre-existing AtheroExpress data pertaining to the plaques selected and the clinical characteristics of the patients. Two control formalin fixed paraffin embedded (FFPE) aorta specimens were also stained for sclerostin. The types of plaques assessed in this study were considered representative of those found in post-menopausal women.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>The aorta consists of three layers, the Tunica Adventitia (T.adventitia), Tunica media (T.media), and Tunica intima (T.intima) ( <ref type="figure" target="#fig_0">Figure 1</ref>). Sclerostin staining revealed generally low expression in the T.media of the arterial plaques examined, with the majority no expression. Strong staining was observed in the vessel wall of a limited number of early atherosclerotic plaque samples with only minimal to slight expansion of the T. intima, as well as in control FFPE aorta. Staining was already decreased in intensity in the region immediately deep to the intimal expansion, indicating sclerostin expression decreases early in plaque formation. Advanced lesions typically showed low or absent staining. Where present, sclerostin expression was restricted to deeper parts of the plaque/vessel wall, i.e., the T. media and adjacent sub-intimal region, where it was of decreased intensity compared to control aorta. Expression of sclerostin was never seen in the superficial plaque region closest to the vessel lumen (fibrous cap and endothelium) which are relevant to plaque stability. Absence of sclerostin expression was not associated with age at endarterectomy, history of artery disease or cardiac outcomes during the patient follow up period of at least 3 years. Absence of sclerostin was also not associated with plaque pro-inflammatory cytokine expression (MCP1, IL6, and osteopontin), and was not associated with most of the plaque features assessed including lipid content, macrophage content, collagen content, and hemorrhage.</p><p>Absence of sclerostin expression was associated with two plaque features. One feature was moderate/heavy dystrophic calcification in the T. intima and T. media of the carotid (not femoral) artery, which is a feature of advanced plaques. The report's authors concluded that given the common absence of sclerostin from plaques in the study and given that downregulation of sclerostin appears to occur during plaque progression, the absence of sclerostin expression in plaques with dystrophic calcification most likely reflects the advanced nature of the atherosclerosis in these plaques rather than a direct association with calcification per se. There was also an association between the absence of sclerostin and moderate/heavy smooth muscle cell (SMC) content in the T. intima but not the T. media in the femoral (not carotid) artery, but this was not further discussed.</p><p>Elevated sclerostin has been shown to reduce circulating levels of the pro-inflammatory However, the current study showed no relationship between sclerostin expression and the presence of any of these cytokines in atherosclerotic plaques.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>According to published literature, common single nucleotide polymorphisms (SNPs) near SOST are associated with levels of SOST RNA expression and BMD. None of these SNPs have so far been reported to be significantly associated with risk of stroke or MI by genome-wide association studies (GWAS). Public databases of GWAS results from the UK Biobank were examined to test for an association of these SNPs with stroke or myocardial infarction.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>In a search using the Global Biobank Engine three BMD-associated SNPs from the GWAS literature were found in the UK Biobank dataset. The SNP rs2741856 was selected for this study, because it has been genotyped in UK Biobank participants, and is strongly linked to the most significant BMD association at the SOST locus reported in the literature. Values reported are from the Global Biobank Engine (Stanford).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>Both alleles of rs2741856, C and G, are common in the UK Biobank participants of European descent, and the frequency of the minor allele G is approximately Portal.org database, the major allele C is associated with lower expression of SOST, with the most statistically significant effect in tibial artery (p = 4.5 x 10 -6 ; normalized expression score -0.29; n = 388). A statistically significant effect was also observed in aorta (p = 4.9 x 10 -4 ; normalized expression score -0.30; n = 267), and in coronary artery, thyroid, brain and nerve-tibial (p&lt;0.05 for all). The level of expression in these tissues varied also between -0.2 and -0.32.</p><p>Among the 337,208 participants of European descent, there is an imbalance in osteoporosis and fracture risk between the carriers of the 2 alleles. The major allele C with lower SOST expression is associated with a decreased risk of osteoporosis (p = 1.32 x 10 -9 ; odds ratio (OR) = 0.84 , a decreased occurrence of fracture in the past 5 years (p = 3.88 x 10 -7 ; OR = 0.93</p><p>It is likely that this allele mirrors the pharmacologic effects of romosozumab 210 mg once monthly (a non-saturating Introduction Coronary circulation (vasoconstriction) is a factor affecting risk of acute ischemia (MI/stroke). Thus, a potential effect of romosozumab on vascular tone could be an underlying factor in the observed MI/stroke imbalance. Therefore, the sponsor conducted an in vitro vasoconstriction assay.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>Human coronary artery rings were prepared from healthy human donors and mounted on an isometric test apparatus to allow for direct measurement of contraction or relaxation of the coronary rings in myograph baths containing physiological saline solution. The effects of romosozumab <ref type="bibr">(1, 3, 10, 30, 10, 300 ug/mL)</ref> and human recombinant sclerostin (MW 21498 Da) <ref type="bibr">(1,</ref><ref type="bibr">3,</ref><ref type="bibr" target="#b48">10,</ref><ref type="bibr">30,</ref><ref type="bibr">100</ref>, 300 pmol/L) (stock solutions prepared in a vehicle of sodium acetate buffer) on vascular tone were evaluated. Sumatriptan was used as a positive control.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>Romosozumab did not induce vasoconstriction at concentrations up to 300 ug/mL, which is equivalent to approximately 10-fold the human Cmax with 210 mg once monthly Recombinant human sclerostin also did not induce vasoconstriction at concentrations up to 300 pmol/L, a concentration approximately 10-fold the reported serum values in postmenopausal women. The responses to both sclerostin-antibody and sclerostin were similar to those of the vehicle control. The positive control, sumatriptan, caused the expected concentration dependent constriction of the isolated human coronary artery rings.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Since romosozumab is an inhibitor of bone resorption, it may be associated with a rare side effect, osteonecrosis of the jaw (ONJ). Therefore, this study was conducted in aged OVX rats with ligature-induced experimental periodontitis to examine the potential for sclerostin inhibition to increase the risk for ONJ.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>Female Sprague Dawley rats were ovariectomized at 6 months of age followed by a 2-month bone depletion period. Rats were then administered either weekly intraperitoneal injections of sclerostin antibody (r13C7). The dose of sclerostin antibody was predicted to provide a similar systemic exposure as the 210 mg once monthly clinical dose of romosozumab, based on AUC. After 12 weeks of treatment, periodontitis was induced with a ligature around the left maxillary second molar. Animals were necropsied after an additional 10-week treatment period. Study endpoints included evaluation of serum bone formation marker PINP at pre-dose, weeks 6, 12, and 22, ex-vivo micro-CT of dissected maxillae and vertebrae, histopathologic evaluation of the maxillae, and histomorphometry of vertebral cancellous bone.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>Sclerostin antibody r13C7 transiently increased serum PINP and increased mineralizing surface (MS/BS) and bone volume in vertebral cancellous bone, consistent with the expected stimulation of bone formation by sclerostin inhibition. In vertebral bone, ZA decreased bone formation (MS/BS), and sclerostin antibody suppressed bone resorption (ES/BS). Vehicletreated animals showed extensive alveolar bone loss and inflammatory infiltrate in areas of experimental periodontitis. By contrast, ZA-treated animals showed minimal alveolar bone loss and a reduced number of osteoclasts. In sclerostin antibody treated rats, bone loss was also markedly reduced compared to vehicle controls, but osteoclastic bone resorption did not appear suppressed. ZA-treated but not sclerostin antibody treated rats developed radiographic and histologic features of ONJ, evidenced by a marked increase in the relative area of osteonecrotic bone containing empty osteocytic lacunae and by increased bone exposure. Features of ONJ were not observed in sclerostin antibody treated animals. The alveolar bone of sclerostin antibody and vehicle treated animals had a similar appearance, with minimal Reference ID: 4416253 (b) <ref type="bibr" target="#b86">(4)</ref> (b) <ref type="bibr" target="#b86">(4)</ref> NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 52 osteonecrosis (relative area approximately histologic evidence of active bone resorption.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>In OVX rats with experimental periodontitis, sclerostin antibody enhanced bone formation and prevented alveolar bone loss, but did not induce ONJ-like lesions in contrast to the bisphosphonate ZA.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion of concerns (nonclinical perspective)</head><p>In the attempt to clarify the observed imbalance in serious CV events observed in the alendronate-controlled Study 142 and in Study 174, the sponsor discussed the concerns regarding potential cardiovascular effects of sclerostin inhibition based on nonclinical studies and published literature. The issues addressed included: (1) medial vascular calcification, <ref type="bibr" target="#b84">(2)</ref> potential effects on pathophysiological mechanisms underlying thrombotic/ischemic events such as MI and stroke (plaque rupture, plaque erosion, and vasospasm), and (3) potential association between genetic variability in sclerostin expression and MI or stroke based on human genetics data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Vascular calcification</head><p>Sclerostin is expressed in the aorta of several species (mouse, monkey, human). Since there have been reports of upregulation of sclerostin in foci of vascular calcification in mice, rats and humans, and sclerostin has been shown to inhibit mineralization by bone cells, it has been suggested that sclerostin may function as a negative regulator of vascular calcification However, conflicting data showing low expression of sclerostin in normal or calcified human vasculature indicate that the role of sclerostin in the aorta is unclear and its presence may simply be a marker of the calcification process. Data from previously conducted nonclinical studies did not show evidence of adverse effects of sclerostin inhibition on the vasculature in the absence of vascular mineralization. There were no vascular effects in a 6-month repeatdose monkey toxicity study conducted with romosozumab at up to 93-fold clinical exposure based on AUC (Study 107426), and no vascular mineralization in aged OVX monkeys dosed for 1 year with romosozumab at 22-fold clinical AUC exposure (Study 107903). Vascular lesions were also not observed in a 6-month rat study with romosozumab at up to 39-fold clinical AUC exposure.</p><p>Although sclerostin expression is absent or low in rat aorta (Study 119937), aortic medial calcification has been observed in rats secondary to experimental chronic kidney disease (CKD), and sclerostin expression is upregulated in foci of vascular calcification. However, aortic calcification is not exacerbated when these rats are treated with sclerostin antibody and is not promoted in the total absence of sclerostin in SOST KO mice with CKD. In addition, romosozumab had no effect on the incidence or severity of spontaneous age-related arterial pathology characterized by focal medial vascular calcification or ectopic ossification in normal rats dosed for up to 98 weeks at up to 19-fold the clinical AUC exposure (Study 107895).</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">5 3</ref> Thus, sclerostin inhibition does not appear to cause initiation of vascular calcification or exacerbation of pre-existing medial calcification in animals.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mechanisms underlying MI and stroke</head><p>Atherosclerosis is a chronic inflammatory disease and most commonly underlies thrombotic/ischemic events such as MI and stroke. Specific mechanisms that can lead to these events include plaque rupture, plaque erosion and vasospasm.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Atherosclerosis</head><p>In Amgen Study #2 (124609) in the ApoE KO OVX mouse atherosclerosis model, it was shown that treatment with sclerostin antibody r13C7 had no significant effects on systemic inflammation markers or on atherosclerosis or aortic transcriptional changes.</p><p>The results were in apparent contrast with those obtained by <ref type="bibr" target="#b16">Krishna et al. (2017)</ref> in the ApoE KO male mouse treated with Angiotensin-II (Ang II) for 28 days, a model for atherosclerosis and aortic aneurysm (AA). Ang II plays a critical role in the induction of atherosclerosis and may accelerate the progression of atherosclerotic lesions to infarction. In that study, excess SOST (in SOST-transgenic ApoE KO mouse, or in ApoE KO mice injected with SOST) inhibited Ang IIinduced aortic aneurysm and atherosclerosis, and was associated with reductions in circulating proinflammatory cytokines (MCP-1, IL-6 and TNFdegradation and macrophage infiltration. The sponsor commented that the contrasting findings between the two studies suggest that the consequence of overexpression of SOST or excess sclerostin does not predict the effects of inhibition of sclerostin with sclerostin antibody administered at 'non-saturating' doses.</p><p>The differences between the studies may be due to the different animal models used. The administration of Ang II in the mouse model used in the published study <ref type="bibr" target="#b16">(Krishna et al., 2017)</ref> may specifically contribute to atherosclerosis and/or aneurysm through activation of sclerostinsensitive Wnt signaling. In fact, the study showed that Wnt signaling was activated in Ang IItreated ApoE KO mice that developed aortic aneurysms vs. those that did not, and that SOST expression in human aortic aneurysm samples was decreased possibly through epigenetic silencing. In the sponsor's study in ApoE KO mice not treated with Ang II, there was no difference in Wnt target gene expression between control and ApoE KO mice. Therefore, atherosclerosis in this model appears to be Wnt-independent, which may explain the lack of effect of sclerostin antibody. It is unlikely that the sclerostin antibody dose selection was inadequate.</p><p>The role of Wnt signaling in cardiac and vascular disease has recently been reviewed <ref type="bibr">(Foulqier et al., 2018)</ref>. Interestingly, the article highlights the crosstalk between WNT, TGF-and Angiotensin II signaling. The authors concluded that, despite conflicting experimental data, a general picture is emerging that excessive stimulation of WNT signaling adversely affects cardiovascular pathology.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">5 4</ref> A study in the ApoE KO mouse similar to the study by <ref type="bibr" target="#b16">Krishna et al. (2017)</ref> could be done to test for a potential reduction in atherosclerosis by SOST addition or use of the SOST-Tg genotype. Conversely, an evaluation of the effect of sclerostin antibody in the Ang II-treated mouse could be conducted to identify a potentially atherosclerosis-enhancing effect.</p><p>Regardless, a positive result in any model would not negate the lack of an imbalance on serious cardiovascular events observed in clinical Study 337. Similarly, the negative result of the completed study in the ApoE KO OVX mouse does not refute the cardiovascular safety signal in clinical Studies 142 and 174. Ultimately the role of sclerostin and its inhibition in these cardiovascular events remains unclear.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Plaque rupture</head><p>Plaque rupture can be induced by inflammation and altered immunity via a reduction in extracellular matrix, particularly the plaque's fibrous cap. However, the study in the ApoE KO-OVX mice (Study 124609) did not show an effect of sclerostin antibody r13C7 on inflammatory markers or on the transcription of genes that play a role in inflammation, adaptive immunity, or ECM homeostasis, even though the latter genes were differentially regulated in ApoE KO-OVX vs. WT mice. In this context, the relevance of the slight decrease in plaque volume in the r13C7treated ApoE KO-OVX mice at Week 16, e.g. for plaque rupture, is unclear. Plaque rupture can also be caused by mechanical instability due to calcification or hemorrhage. However, romosozumab did not promote vascular calcification in the previously conducted rat and monkey toxicity studies, and sclerostin inhibition did not cause aortic calcification in CKD rodents. Also, sclerostin antibody r13C7 did not affect mineralized plaque volume in Study 124609, and sclerostin was not expressed in human atherosclerotic plaques' fibrous caps, a location that is important for the plaque's stability <ref type="bibr">(Study 150498)</ref>. In addition, plaque hemorrhage was not observed in ApoE KO-OVX mice (Study 124609) and sclerostin expression was not correlated with human arterial plaque hemorrhage. Plaque necrosis is an additional feature potentially associated with increased plaque instability. The increase in the incidence of plaques with necrosis upon dosing of ApoE KO-OVX mice with sclerostin antibody may suggest a possible role for sclerostin in plaque rupture.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Plaque erosion</head><p>Plaque erosion due to endothelial apoptosis/dysfunction in combination with platelet adhesion and activation, neutrophil activation, and local oxidative stress is believed to enhance thrombogenesis and precipitate cardiovascular ischemic events. In ApoE KO-OVX mice, transcriptional pathways related to apoptosis, innate immunity, neutrophil recruitment/signaling and oxidative stress were upregulated, but these pathways were not affected by sclerostin antibody administration. Furthermore, sclerostin antibody treatment did not affect circulating markers of endothelial activation and their aortic mRNA expression <ref type="bibr">(Study 124609)</ref>. In addition, based on the lack of sclerostin expression in the T. intima and endothelium in human atherosclerotic plaques, sclerostin inhibition seems to be an unlikely factor in plaque erosion.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">5 5</ref> Both plaque rupture and erosion can be complicated by enhanced thrombogenesis triggered by an imbalance in vasodilators (e.g. the prostanoids prostacyclin, PGl2) and vasoconstrictors (e.g. platelet thromboxane A2, TXA2). However, in the aorta of ApoE KO-OVX mice, gene transcription related to the prostanoid pathway, while differentially regulated than in WT mice, was not affected by sclerostin antibody. Circulating markers of endothelial/platelet activation were also not changed by sclerostin antibody treatment (Study 124609). In addition, romosozumab did not enhance in vitro platelet activation at up to 10-fold the clinical Cmax achieved with 210 mg once monthly <ref type="bibr">(Study 125269)</ref>. Moreover, in rat and monkey repeat dose toxicity studies, intrinsic and extrinsic coagulation was not affected by romosozumab, altogether suggesting a lack of effect of sclerostin inhibition on thrombogenesis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Vasospasm</head><p>Vasospasm may cause acute ischemia both in the presence and absence of atherosclerosis. It may be precipitated by hyperreactivity of vascular smooth muscle cells or by endothelial dysfunction in response to blood flow changes that can reduce nitric oxide, which has a regulatory function in vasodilation. Neither romosozumab at up to 10-fold human Cmax with 210 mg once monthly, nor human recombinant sclerostin at up to 10-fold the serum concentration in postmenopausal women induced vasoconstriction (a key mediator of vasospasm) in an in vitro assay using isolated healthy human coronary artery rings <ref type="bibr">(Study 150483)</ref>.</p><p>Romosozumab is unlikely to cause acute changes in blood flow through effects on blood pressure since blood pressure and electrocardiograms were unaffected in instrumented monkeys following single intravenous dose of romosozumab at approximately 32-and 21-fold clinical exposure with 210 mg once monthly based on AUC and Cmax, respectively, or in 1month and 6-month repeat dose toxicity study in monkeys. Additionally, although nitric oxide signaling pathways were differentially regulated in the ApoE KO-OVX mouse, these pathways were unchanged in response to sclerostin antibody treatment <ref type="bibr">(Study 124609)</ref>. Also, no clinically important effects on blood pressure or electrocardiograms have been observed in clinical trials with romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human genetics</head><p>In sclerosteosis subjects, clinical or radiographic evidence of involvement of the central or peripheral cardiovascular system has not been reported in the literature. However, the size of this population is small. Using public databases of GWAS, a statistically more robust analysis of common SNPs at the SOST locus showed that genetically reduced SOST expression in aorta and tibial artery by a common SNP in the European population has a significant effect on BMD, osteoporosis and bone fracture, but no detectable effect on risk of myocardial infarction or stroke (Study 150655).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Intrinsic factors and specific populations</head><p>Romosozumab exposure is higher in subjects with lower body weight, in subjects with severe renal impairment, and in male subjects; however, no dose adjustment is needed based on body weight, renal function or sex. Population PK analysis indicated that other factors including age, race, disease state (low bone mass or osteoporosis), or prior exposure to alendronate do not have meaningful influence on the PK of romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impact of immunogenicity on PK</head><p>Among 5914 postmenopausal women treated with the romosozumab 210 mg SC monthly dosage regimen, antibodies that were classified as neutralizing. Development of anti-drug antibodies (ADA) was associated with reduced serum romosozumab concentrations. Among the 77 romosozumab-treated subjects who had MACE in <ref type="bibr">Studies 20070337, 20110142 and 20110174, 8</ref> subjects had PK data available. The patient profiles for these 8 subjects are summarized in <ref type="table" target="#tab_11">Table 8</ref>. The romosozumab concentrations in these 8 subjects and in the overall study population are shown in <ref type="figure">Figure .</ref> The PK data show that the romosozumab concentrations in subjects who had MACE were generally within the range of the overall observed concentrations in Phase 3 trials. The limited data did not demonstrate a correlation between systemic romosozumab exposure and MACE. It should be noted that samples for assessment of plasma concentrations were collected at various times post-dose in all subjects and are not necessarily reflective of concentrations at the time of MACE.  <ref type="bibr" target="#b88">(6)</ref> NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 5 9   <ref type="table" target="#tab_13">Table 9</ref> lists the studies that are relevant to the review of the BLA resubmission. For a listing of all clinical studies performed in the romosozumab development program, refer to the clinical review of the original submission. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Objectives</head><p>The primary objective of this study was to assess the effect of romosozumab treatment for 12 months followed by alendronate (ALN) treatment compared with ALN treatment alone on the subject incidence of the following during the primary analysis period:</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">6 2</ref> clinical fracture (nonvertebral fracture and symptomatic vertebral fracture) in postmenopausal women with osteoporosis; and new vertebral fracture in postmenopausal women with osteoporosis</p><p>The secondary objectives of the study included the following: to assess the effect of romosozumab treatment for 12 months followed by ALN treatment compared with ALN treatment alone on the following during the primary analysis period: wo vertebral fracture, and clinical vertebral fracture); and Percent changes in DXA BMD at the lumbar spine, total hip, and femoral neck. to assess the effect of romosozumab treatment for 12 months compared with ALN treatment on the following during the 12-month double-blind ALN-controlled study period:</p><p>fracture and fracture and new or worsening vertebral fracture, hip fracture, clinical vertebral forearm, humerus, Percent changes in DXA BMD at the lumbar spine, total hip and femoral neck to assess the effect of romosozumab treatment for 12 months followed by ALN treatment compared with ALN treatment alone on subject incidence of hip fracture, ring the overall study period.</p><p>The term "clinical" vertebral fracture refers to those vertebral fractures that are symptomatic. Many vertebral fractures are asymptomatic and are detected incidentally on radiographic imaging.</p><p>The use of an active control in Study 142 enabled a direct comparison of romosozumab efficacy to a currently approved therapy. The active control, alendronate, an oral bisphosphonate that reduces fracture risk by decreasing bone resorption and subsequently increasing bone density, represented a different mechanism of action from the bone-forming agent teriparatide that was used in Study 289, the other active-controlled study in the romosozumab clinical program (discussed in review of the original BLA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methodology</head><p>Study 142 was a phase 3, multicenter, international, randomized, double-blind, double-dummy, alendronate-controlled study of romosozumab in postmenopausal women with osteoporosis.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">6 3</ref> The study was designed to evaluate whether romosozumab treatment for 12 months followed by alendronate, compared with alendronate treatment alone, is effective in reducing the incidence of clinical fracture and new vertebral fracture.</p><p>Subjects were randomized in a 1:1 ratio (stratified by a receive either romosozumab 210 mg subcutaneously (SC) every month (QM) or alendronate 70 mg orally every week (QW) in a blinded fashion for the duration of the 12-month double-blind alendronate-controlled study period. All subjects also received matched placebo for either alendronate or romosozumab. After the initial 12-month study period, subjects received alendronate for the remainder of the study while remaining blinded to their initial treatment assignment (romosozumab or alendronate).</p><p>The primary analyses were to be performed at the end of the primary analysis period, which was defined as when clinical fracture events were confirmed for at least 330 subjects and all subjects completed the month 24 study visit. Upon completion of the primary analysis period, the study was to continue until at least 440 subjects experienced a nonvertebral fracture (unless the superiority of romosozumab was already proven for nonvertebral fractures at the primary analysis).</p><p>Approximately 200 subjects at participating centers were also enrolled in an Imaging and pharmacokinetic/bone turnover marker (PK/BTM)/Biomarker substudy. Within this substudy, a subset of approximately 100 subjects were planned to participate in the imaging (DXA, QCT) portion of the substudy.</p><p>The study schema is presented in <ref type="figure">Figure .</ref>   </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key Enrollment Criteria</head><p>Subjects included ambulatory postmenopausal women age 55 to 90 years with at least 1 of the following BMD and fracture criteria:</p><p>BMD T-score at the total hip or femoral neck of -2.50 and EITHER: -at least 1 moderate (SQ2) or severe (SQ3) vertebral fracture OR -at least 2 mild (SQ1) vertebral fractures OR BMD T-score at the total hip or femoral neck of -2.00 and EITHER: -at least 2 moderate (SQ2) or severe (SQ3) vertebral fractures OR -a fracture of the proximal femur that occurred within 3 to 24 months prior to randomization.</p><p>In addition, at least 1 hip must have been evaluable by DXA. Key exclusion criteria included a history of metabolic or bone diseases, severe and significant lab abnormalities, organ or bone marrow transplants, or possible diagnosis of multiple myeloma or related lymphoproliferative disorder. The use of agents affecting bone metabolism was also exclusionary; however, for selected therapies permissible off-treatment periods prior to randomization were allowed as outlined in Section 4.2 of the study protocol. Detailed inclusion and exclusion criteria for the main study are provided in Section 4 of the study protocol.</p><p>Subjects participating in the imaging component of the Imaging and PK/BTM/Biomarker Substudy were to be excluded if they had the following: a non-evaluable vertebra in the region of interest for spine QCT scans as assessed by the central imaging vendor at the time of screening, based on lateral spine x-rays; a nonvertebral fracture or clinical vertebral fracture within 6 months prior to enrollment; or were unavailable for protocol-required substudy procedures.</p><p>The eligibility criteria were appropriate to ensure that the population only included subjects at high risk for fracture (which is acceptable for an active-controlled trial) and were adequate to ensure reliable interpretation of efficacy results. The participants in Study 142 were at higher risk for subsequent fracture than the participants in the placebo-controlled Study 337. Study 337 had exclusionary criteria based on severity of prior fracture (including hip fracture) and low BMD T-scores.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods for Treatment Assignment and Blinding</head><p>Treatment assignments were obtained through an interactive voice response system (IVRS). Eligible subjects were randomized in a 1:1 ratio in a double-blind manner to either the romosozumab or the alendronate treatment group. Randomization was stratified by age (&lt; 75 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="formula">6 5</ref> years).</p><p>Following the end of the primary analysis period, subjects and site personnel remained blinded to a subject's original treatment assignment.</p><p>These randomization and blinding methods are acceptable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Investigational Products, Dose and Mode of Administration</head><p>Romosozumab was supplied as a single-use 1 mL prefilled syringe (PFS) containing 70 mg of romosozumab per mL. During the 12-month double-blind alendronate-controlled study period, subjects received 3 SC prefilled syringe injections of romosozumab (i.e., 210 mg) or matched placebo at each dosing visit (i.e., day 1 study visit, and monthly study visits thereafter to month 11). Injections were administered by a healthcare professional into different sites on the subject's anterior abdominal wall, upper thigh, or upper arm.</p><p>The study protocol and the clinical study report specified that the active control alendronate was considered an investigational product; neither document specified whether the alendronate used in the study was US-approved. Blinded and open-label alendronate was "commercially manufactured and labeled." Therefore, specific alendronate dosing instructions (as detailed in marketed labeling) were to be provided to all subjects. Although the protocol and clinical study report (CSR) did not describe the specific alendronate dosing instructions, both the protocol and CSR did specifically state that alendronate labeling was to be followed when alendronate was dispensed. Placebo to alendronate was presented in identical containers. During the 12-month double-blind study period, subjects were dispensed a 2-month supply of alendronate or matched placebo on day 1 of the month 2, 4, 6, 8, and 10 visits. One 70 mg tablet was self-administered orally by the subjects once each week. Following the 12month double-blind study period, subjects were dispensed a 6-month supply at the month 12 visit and every 6 months thereafter through the end of study. Subjects were asked to bring in all used and unused packages to study visits to assess compliance. The investigational site staff counted the number of returned tablets and captured this information on drug accountability forms and in the eCRF.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose Adjustments and Modifications</head><p>No dosing adjustments for romosozumab/placebo were permitted. Romosozumab/placebo could be administered +/-2 weeks of the target visit date; if the dose could not be administered +/-2 weeks of the target visit date, the dose was considered missed.</p><p>No dosing adjustments for alendronate/placebo or alendronate were permitted. If a subject missed a scheduled dose of the investigational product, the dose was to be taken as soon as possible as long as it was before the next scheduled dose. Dosing was to be resumed at the same dose (70 mg QW). Double or extra doses were not permitted.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">6 6</ref> Other Protocol-required Therapies:</p><p>From screening to end-of-study, subjects were to receive daily calcium and vitamin D supplementation at a minimum of 500 to 1,000 mg elemental calcium and 600 to 800 IU vitamin D. In addition, subjects with a serum 25-hydroxy ( ng/mL and 40 ng/mL at screening received an initial loading dose of 50,000 to 60,000 IU vitamin D after randomization. Subjects with a serum 25 (OH) vitamin D level of &gt; 40 ng/mL at screening may have received the vitamin D loading dose at the principal investigator's discretion.</p><p>If a subject developed hypercalcemia or hypocalcemia during the study, the calcium and/or vitamin D supplementation could be adjusted to maintain serum calcium concentration within the normal range.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Concomitant Therapy</head><p>Investigators were permitted to prescribe any concomitant medications or treatments deemed necessary to provide adequate care, except for those listed as excluded concomitant medications in the protocol (which included all medications known or suspected to affect bone metabolism). If a subject received any IV bisphosphonate therapy or oral bisphosphonate therapy equivalent to &gt; 1 month of therapy (except alendronate as study medication) while onstudy, investigational product was discontinued.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Assessments</head><p>Following the initial screening visit and the Day 1 visit, study visits occurred monthly during the 12-month double-blind period of the study. For the remainder of the study, visits occurred at Month 15, Month 18 and Month 24, and every 6 months thereafter (for subjects who were in the study for more than 24 months); phone contacts were performed during the months with no study visits (for continuous monthly monitoring of adverse events and concomitant medications).</p><p>Lateral spine X-rays were performed at screening, Month 12, Month 24 and at the end of study. DXA of the lumbar spine was performed on Day 1, Month 12, Month 24 and at the end of study. Serum laboratory assessments (including serum chemistry and hematology and antiromosozumab antibodies) were performed at most study visits. The detailed schedule of assessments is provided in the CSR <ref type="table" target="#tab_5">(Table 8-3)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fracture Analysis and Definitions</head><p>At baseline/screening, a single, central imaging center radiologist determined prevalent vertebral fractures on lateral-spine X-rays using the following Genant visual semiquantitative grading (SQ) scale: SQ grade 0 (SQ0) = no fracture SQ grade 1 (SQ1) = mild fract NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 6 7 middle, or posterior) For assessment of incident vertebral fracture, x-rays were scored at the central imaging center blinded to treatment and using the SQ scale. Investigators were alerted by the central imaging vendor when a new or worsening vertebral fracture was identified.</p><p>If a subject presented with acute back pain at a time point other than when a scheduled lateral spine x-ray was obtained during the primary analysis period, unscheduled lateral spinal x-rays were obtained for submission to the central imaging facility for evaluation. The central imaging vendor informed the sites if a new or worsening vertebral fracture was identified. Worsening was defined as an increase of at least 1 grade on the SQ scale.</p><p>For incident fractures, the following listing defines each fracture type:</p><p>New vertebral fractures previous grade of 0 in any vertebra from T4 to L4 on the Genant SQ Scoring scale. A primary reader reviewed radiographs as received. If a new vertebral fracture was identified, the second reader assessed the results blinded to the first reader's findings. A third reader adjudicated if the primary and secondary readers disagreed.</p><p>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. A single, central imaging center radiologist confirmed clinical fractures from either local radiology reports or from local radiographs sent to the central imaging center.</p><p>Nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of a reported fracture, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</p><p>Major nonvertebral fracture was a subset of nonvertebral fractures limited to pelvis, distal femur (i.e., femur excluding hip), proximal tibia (i.e., tibia excluding ankle), ribs, proximal humerus (i.e., humerus excluding elbow), forearm, and hip.</p><p>Hip fracture was a subset of nonvertebral fractures limited to femur neck, femur intertrochanter, and femur subtrochanter.</p><p>Major osteoporotic fractures included hip, forearm or humerus fractures that were not NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">6 8</ref> associated with a pathologic fracture regardless of trauma severity, and clinical vertebral fractures.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Endpoints</head><p>The co-primary endpoints were the following:</p><p>Time to first clinical fracture through the primary analysis period Subject incidence of new vertebral fracture through Month 24</p><p>For time to first clinical fracture through the primary analysis period, with differing follow-up time for subjects, the pre-defined statistical analysis method was a Cox proportional hazards model. Therefore, the Applicant's description of the clinical fracture endpoint as "subject incidence of clinical fracture through the primary analysis period" does not appear to be consistent with the analysis method, which describes the relation between the time to first clinical fracture incidence and treatment (adjusting for other potential covariates), with varying follow-up time as opposed to fixed follow-up time across subjects. Results for the clinical fracture endpoint will be described in labeling as risk reduction based on a time to event analysis for the above endpoint.</p><p>The secondary endpoints controlled for overall type I error were the following:</p><p>Percent change from baseline in BMD at the lumbar spine, total hip and femoral neck at month 12 and month 24 Nonvertebral fracture through the primary analysis period Additional secondary endpoints that were not controlled for type I error were the following:</p><p>During The primary and key secondary endpoints were appropriate as clinically relevant endpoints. Currently the most widely used endpoint in clinical trials for new osteoporosis drugs is new morphometric (radiographically identified) vertebral fracture (which may or may not be symptomatic), which is the most common osteoporosis-related fracture in postmenopausal women <ref type="bibr" target="#b13">(Khosla, 2003)</ref>. Clinical fractures, which encompass all symptomatic fractures (i.e., nonvertebral fractures and vertebral fractures that are symptomatic and come to clinical attention), account for most of the morbidity and mortality associated with osteoporosis. Of note, for the clinical fracture endpoint, symptomatic vertebral fractures were included regardless of trauma severity or pathologic fractures. Historically, high-trauma fractures and pathologic fractures have been excluded in the assessment of fracture endpoints.</p><p>As discussed above in Section 2.1, nonvertebral fractures (the key secondary endpoint in this study) at virtually any site increase the risk of subsequent fracture and are associated with increased mortality.</p><p>There were multiple exploratory endpoints, including the following measuring PRO (patientreported outcomes) and ClinRO (clinician-reported outcomes):</p><p>PRO and ClinRO measures (Osteoporosis Assessment Questionnaire Short Version OPAQ SV , EQ-5D-5L EuroQoL-5 Dimensions-5 Levels Health Survey , Limited Activity LAD , and Brief Pain Inventory BPI worst pain) at months <ref type="bibr">6,12, 18, 24, 30, and 36</ref> Change from baseline in PRO and ClinRO measures (OPAQ SV, EQ-5D-5L, LAD, and BPI worst pain) at months <ref type="bibr">6, 12, 18, 24, 30, and 36</ref> Safety endpoints included the following (assessed during the 12-month double-blind alendronate-controlled study period and the primary analysis period):</p><p>Subject incidence of adverse events by system organ class and preferred term Changes from baseline in laboratory assessments (serum chemistry and hematology) and the shifts from baseline to the worst value Changes from baseline in vital signs Subject incidence of antiromosozumab antibodies NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 7 0</p><p>These safety endpoints were adequate to assess general safety and the previously identified risks of romosozumab. However, as discussed in Section 8.2.5, safety measures were not adequate for a comprehensive assessment of cardiovascular risk (e.g., electrocardiograms and serum lipid values were not performed).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis Plan</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample size considerations</head><p>The study planned to enroll 4000 subjects (2000:2000 equally allocated between the treatment groups) based on the anticipated number of clinical fracture and new vertebral fracture endpoints using a simulation study. The dropout rate was assumed 10 for the first year and 8 per year thereafter. Endpoints were to be tested 2-sided with alpha level at 0.05. The assumptions and the corresponding study power with 2000 subjects per group are presented in the table below based on simulation results.  <ref type="table" target="#tab_87">Table 1</ref> and <ref type="table" target="#tab_4">Table 2</ref> in the SAP Source: study 20110142 SAP.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Time Intervals</head><p>The Applicant pre-specified different analysis time intervals as follows.</p><p>On-Study Period: The time period from the randomization date to the end of study date, inclusive. Overall Study Period: If the study will continue to the final analysis, the overall study period is defined as the time period from the randomization date to the end of final analysis period date, inclusive.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Double-blind</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis Populations</head><p>The Applicant pre-defined the following analysis sets. In all efficacy analysis sets, subjects were analyzed according to their randomized treatment assignment, regardless of treatment received. In the safety analysis set, subjects were analyzed according to their actual received treatment.</p><p>Full Analysis Set: All randomized subjects. Used as the primary analysis set for the following endpoints: nonvertebral fracture, clinical fracture, clinical vertebral fracture, all fracture, major nonvertebral fracture, major osteoporotic fracture, and hip fracture. These fractures were identified from adverse event reporting.</p><p>Primary Efficacy Analysis Set For Vertebral Fractures: All randomized subjects who had a baseline and at least 1 post-baseline evaluation of vertebral fracture by lateral spine X-ray (as planned in the study's schedule of assesments), at or before the time point under consideration. Subjects who had vertebrae with missing Genant semiquantitative scores at baseline and whose first post-baseline spinal radiograph showed no fracture on the same vertebrae were also included in this analysis set. This analysis set was used as the primary analysis set for new, new or worsening, and multiple new or worsening vertebral fractures.</p><p>Primary Efficacy Analysis Set for BMD Endpoints for the Double-blind ALN-controlled Study Period and Primary Analysis Period: All randomized subjects who had a baseline and at least 1 post-baseline evaluation at or before the time point under consideration. Note that this subset could potentially be different from endpoint to endpoint due to missing data. Safety Analysis Set: All randomized subjects who received at least 1 active dose of investigational product in the 12-month double-blind ALN-controlled study period. Used to analyze safety data for the double-blind study period, primary analysis period, and overall study period.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Handling of Missing Data</head><p>For vertebral fracture assessment, any missing post-baseline vertebral fracture status due to missing spinal x-ray assessment was imputed using the status from the last nonmissing postbaseline visit (i.e.</p><p>For other type of fractures, no imputation was used unless specified.</p><p>For endpoints evaluated by DXA or QCT at any anatomical site, missing post-baseline values were imputed using LOCF approach (by carrying forward the last nonmissing post-baseline </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Handling of Multiplicity</head><p>If both the co-primary endpoints were significant at the 0.05 level <ref type="bibr">(2-sided)</ref>, each of the following secondary DXA BMD endpoints were tested hierarchically at 0.05 <ref type="bibr">(2-sided)</ref> according to the following sequence: 1) percent change from baseline in BMD at lumbar spine at Month 24 2) percent change from baseline in BMD at total hip at Month 24 3) percent change from baseline in BMD at femoral neck at Month 24 4) percent change from baseline in BMD at lumbar spine at Month <ref type="formula">12  5</ref>) percent change from baseline in BMD at total hip at Month <ref type="formula">12  6</ref>) percent change from baseline in BMD at femoral neck at Month 12.</p><p>If all preceding endpoints were significant, 7) the nonvertebral fracture endpoint would be tested using a group sequential approach at the primary analysis and the final analysis based on a 1-sided test (alpha=0.025). The Lan-DeMets alpha spending function <ref type="bibr">(Lan and DeMets,1983</ref>) that approximates a Pocock boundary <ref type="bibr">(Pocock, 1977)</ref>, (0.025*LN(1+(EXP(1) -1)*information fraction)), was to be used to determine the significance level at the time of the primary analysis. Based on the number of subjects with nonvertebral fractures at the time of the primary analysis out of the total 440 planned, which represents the information fraction in the alpha spending function, the significance level would be calculated at the time of analysis, the significance level is 0.0216.</p><p>If the significance of nonvertebral fracture is not demonstrated at the time of the primary analysis, the nonvertebral fracture endpoint will be tested again using a 1-sided test at the time of the final analysis. Based on the alpha level spent at the primary analysis, the significance level at final will be determined.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Co-Primary Efficacy Endpoints</head><p>The number and percentage of subjects with at least 1 new vertebral fracture through Month 24 were summarized by randomized treatment group. Point estimates of absolute risk reduction (difference in proportions, control -treatment) and the relative risk reduction (100*(1-risk ratio)) (risk ratio was the ratio of proportions, treatment over control) as well as -Haenszel method, adjusting for age strata, baseline total hip BMD T-score strata -2.5, &gt; -2.5) and presence or absence of vertebral fracture at baseline. The subject incidence of new vertebral NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 7 3</p><p>fractures through Month 24 was tested using a logistic regression model and the primary efficacy analysis set for vertebral fractures. The model included the treatment as the main effect, age strata, baseline total hip BMD T-score, and presence or absence of severe vertebral fracture at baseline as covariates.</p><p>Time to first clinical fracture through the primary analysis period was analyzed using a stratified Cox proportional hazards model controlling for age strata with presence or absence of severe vertebral fracture at baseline, baseline total hip BMD T-score, and treatment as the independent variable based on the full analysis set. The estimated hazard ratio, corresponding -value from the model were provided. The cumulative incidence of fractures was summarized using the Kaplan-Meier estimates.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Secondary Efficacy Endpoints</head><p>The primary efficacy subset for BMD was used for analysis of percent change from baseline in BMD at the lumbar spine, total hip, and femoral neck at months 12, 24 and 36.</p><p>The treatment comparisons of the BMD in lumbar spine, total hip and femoral neck at months 12 and 24 were analyzed using the ANCOVA LOCF model including treatment, age (stratification factor), presence or absence of severe vertebral fracture at baseline, machine type, machine type-by-baseline value interaction and baseline value of the endpoint. The least-squares mean of the treatment difference (treatmentinterval were summarized by time points of interest, where each time point was estimated using a separate ANCOVA model.</p><p>The primary efficacy analysis set for vertebral fracture was used for analysis of subject incidence of new vertebral fracture through Month 12.</p><p>The full analysis set was used for analysis of the following endpoints:</p><p>Subject incidence of nonvertebral fracture through Month 12, through Month 24, and through the primary analysis period; Subject incidence of hip fracture through Month 12 and through Month 24.</p><p>The cumulative incidence of each type of fracture was summarized using the Kaplan-Meier estimates at the time point(s) of interest. The point estimate of the adjusted risk difference (difference in Kaplan-Meier estimates at the time point of interest, control arm -treatment arm) and the corresponding 95 confidence interval were provided using the inverse varianceweighted method. Stratified Cox proportional hazards model controlling for age strata with presence or absence of severe vertebral fracture at baseline, baseline total hip BMD T-score, and treatment as the independent variable was also used. The significance of the treatment effect between treatment arm and control arm (for the secondary endpoints in the testing sequence) was assessed based on the Cox proportional hazards model. The estimated hazard ratio and corresponding 95 confidence interval from the model were also provided.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 7 4</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subgroup analysis</head><p>The co-primary efficacy endpoints (incidence of new vertebral fractures through Month 24 and clinical fractures through the primary analysis period), and nonvertebral fractures through the primary analysis period, were also evaluated by subgroups defined below.</p><p>years) Presence or absence of severe vertebral fracture at baseline (based on most severe Genant semiquantitative grade at baseline on screening spinal radiograph) Number of prevalent vertebral fractures at baseline (0-1, 2, 3; based on screening spinal radiograph) Race (White and non-White) Geographic region Western Europe and New Zealand/Australia Central and Eastern Europe and Middle East Asia Pacific and South Africa North America Central/Latin America Central/Latin America and all regions excluding Central/Latin America Baseline lumbar spine BMD T--3, &gt; --2.5, &gt; -2.5) Baseline total hip or femoral neck BMD T--3 vs. both total hip and femoral BMD T-score &gt; -3 Baseline body mass index (BMI; tertiles) Fracture Risk Assessment tool (FRAX) score for major osteoporotic fracture <ref type="bibr">(tertiles)</ref> no)</p><p>The percent changes from baseline in lumbar spine BMD and total hip BMD at Month 12 and Month 24 were analyzed for the following subgroups: years) Geographic region Baseline lumbar spine BMD T--3, &gt; --2.5, &gt; -2.5; for lumbar spine BMD analysis only) Baseline total hip BMD T--3, &gt; --2.5, &gt; -2.5; for total hip BMD analysis only)</p><p>For each category of a subgroup, these endpoints were summarized and analyzed using the same approach as the primary analysis described above. The treatment-by-subgroup interaction was tested using the same statistical model (i.e. logistic regression for new vertebral fractures, Cox proportional hazard model for clinical fractures, and nonvertebral fractures and ANCOVA-LOCF model for percent change in BMD endpoints) including individual subgroup and treatment-by-subgroup interaction. If the p-value of the interaction was &gt; 0.05, the treatmentby-subgroup interaction was considered not significant. Otherwise, a 2-sided Gail and Simon test was used to test whether there was qualitative interaction.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 7 5</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol Amendments</head><p>The original protocol for this study was approved on December 15, 2011 and was amended 5 times. All amendments occurred before unblinding. Major changes to the study protocol in these 5 amendments are summarized as follows: <ref type="bibr">Amendment 1 (April 27, 2012)</ref>:</p><p>Subjects with a reported history of hearing loss associated with cranial nerve VIII compression due to excessive bone growth were excluded from study participation. A physician was to be available during administration of investigational product, and all subjects were closely observed for approximately 30 minutes after dosing. The investigator was to be alerted if a subject experienced a BM study and was required to discuss implications for individual fracture risk, alternative treatment options, and options for continuing in the study with the subject. <ref type="bibr">Amendment 2 (November 14, 2012)</ref>:</p><p>Amended exclusion criteria to ensure that pre-existing disorders and/or the administration of medications did not confound the benefit/risk assessment for romosozumab. Amended proscribed treatments during the study to ensure those did not confound the benefit/risk assessment for romosozumab. Provided more detail on the adjudication of possible events of osteonecrosis of the jaw, atypical femoral fractures, and cardiovascular events. Clarified that worsening vertebral fractures were considered for endpoints evaluating the incidence of all fractures. For endpoints evaluating the incidence of major osteoporotic fractures, corrected the definition to include forearm instead of wrist fractures. Baseline total hip BMD T-score was aligned with the Statistical Analysis Plan as an adjustment factor for the evaluation of new vertebral fracture incidence. Specified that serious adverse events must be reported within 24 hours after the investigator's knowledge of the event and clarified the point of reference for evaluation of expectedness of serious adverse events (i.e., clarified the appropriate reference safety information per local regulatory reporting requirements). Clarified the day 1 lumbar spine DXA scan may have been taken together with the screening proximal femur DXA scan for subject convenience. Replaced the Month 21 clinic visit with a telephone call. For subjects participating in the Imaging and PK/BTM /Biomarker Substudy, the spine QCT assessments at Month 36 and the end-of-study visits were eliminated. <ref type="bibr">Amendment 3 (June 21, 2013)</ref> Lowered the minimum age from 60 to 55 years and allowed 3 additional qualifying BMD and fracture history combinations. The protocol-mandated off-treatment times for exclusionary medications were revised. Rescreening was allowed for subjects who previously failed screening if in the opinion of the investigator the reason for the initial screen failure has resolved or was no longer applicable. Assessments for formation of antiromosozumab antibodies were added at the Month 1 and Month 3 study visits to allow a more comprehensive characterization of the antibody response. Retesting of serum calcium would be permitted within the screening window if the initial test indicated an elevated level of serum calcium within 1.1 x the upper limit of normal. <ref type="bibr">Amendment 4 (July 8, 2015)</ref> Upon completion of the primary analysis period, subjects were followed for nonvertebral fractures. Subjects and site personnel remained blinded to initial treatment assignments and the study proceeded in an event-driven manner. The final analysis (end-of-study) occurred when nonvertebral fracture events were confirmed for at least 440 subjects, or earlier if the primary analysis demonstrated superiority of romosozumab treatment for nonvertebral fracture risk reduction. The duration of participation for subjects was changed from 25 to 59 months if study completion was achieved at primary analysis, or from 37 to 71 months if study completion was achieved when 440 subjects experienced a nonvertebral fracture. Approximately 200 subjects were planned to be enrolled in the Imaging and PK/BTM/Biomarker Substudy, with a subset of approximately 100 subjects participating in the imaging (DXA, QCT) portion of the substudy. The exclusion criteria for hyper-/hypothyroidism and hyper-/hypoparathyroidism were clarified. The Month 15 study visit was eliminated for all but the substudy participants, and sampling for antibody testing was added to the Month 18 visit. The end of primary analysis and end-of-study visits were replaced by telephone contact. <ref type="bibr">Amendment 5 (September 14, 2016)</ref> Moved the following Month-12 exploratory endpoints to secondary endpoints: nonvertebral fracture, hip fracture, major osteoporotic fracture <ref type="bibr">(hip, forearm, humerus, and clinical vertebral</ref> The majority of these changes were made in response to FDA requests. All of these changes were acceptable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data Quality and Integrity</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Monitoring</head><p>The study centers were monitored by the applicant. Monitors were responsible for reviewing adherence to the protocol, compliance with Good Clinical Practices, and the completeness, accuracy, and consistency of the data.</p><p>The applicant used multiple Contract Research Organizations (CROs) for this study. The CROs used and their respective roles are listed in <ref type="table" target="#tab_87">Table 11</ref>. <ref type="table" target="#tab_87">Table 11</ref> Contract Research Organizations and Responsibilities *Source: <ref type="table" target="#tab_11">Table 8</ref>-1 of CSR From study start until primary analysis, an external, independent Data Monitoring Committee (DMC) monitored the unblinded safety data and considered efficacy data to assess the benefit/risk profile of romosozumab. The DMC members had access to individual treatment assignments if knowledge of this was necessary to evaluate safety. To minimize the potential for bias, the DMC members did not have direct contact with study site personnel or subjects.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Standardization of Laboratory and Radiographic Procedures</head><p>Central laboratories were used to analyze all screening and on-study samples for serum chemistry, hematology, biomarker and BTMs (P1NP, osteocalcin -specific --resistant acid and antiromosozumab antibodies as well as X-rays, DXA data, and High Resolution peripheral QCT (HR-pQCT) data. Regarding local laboratories, study monitors evaluated their internal and external quality control, quality assurance, and accreditation schemes.</p><p>The central laboratories used in this study and their respective responsibilities are listed in <ref type="table" target="#tab_4">Table 12</ref>. Lateral spine X-rays, DXA images, and HR-pQCT images were acquired according to specific instructions provided by the central imaging vendor and all images were analyzed by the central imaging center, Bioclinica Inc. Adequate quality control measures were in place as detailed in the charter for the central imaging vendor.</p><p>In summary, it appears that adequate measures were in place to ensure data quality and integrity.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20110142: Efficacy Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Compliance with Good Clinical Practices</head><p>The applicant attested that the study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) and applicable FDA or local regulations/guidelines.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subject Enrollment and Disposition</head><p>Subject disposition during the full analysis period is presented in <ref type="table" target="#tab_5">Table 133</ref>. A total of 4093 subjects were randomized; 2046 subjects were randomized to the romosozumab 210 mg QM treatment group and 2047 subjects were randomized to the alendronate 70 mg QW treatment group. Subjects were stratified by age; 48 years.</p><p>Eighty nine percent of enrolled subjects completed the 12-month double-blind period period (romosozumab/alendronate: 77</p><p>During the 12month double blind period, withdrawn consent, death and adverse events were the most frequently reported reasons for discontinuation from stu and 1 and 1 , respectively, in the alendronate group). Throughout the primary analysis period, withdrawn consent and death were the most frequently reported reasons for discontinuation from study in both treatment groups ( , respectively, in the romosozumab/alendronate group and 12 5 , respectively, in the alendronate/alendronate group).) NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 8 0 The study had a somewhat high overall discontinuation rate through the end of primary this rate was the same in each treatment group, and reasons for discontinuation were also generally balanced between the treatment groups. Disposition results are similar to Study 337, with the exception that the overall discontinuation rate was lower in S .</p><p>In the 12-month double-blind period, 85 ional product (romosozumab: 86 : 85 group never received investigational product, all due to withdrawn consent after NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 8 1 product, 4 due to withdrawn consent, 2 due to ineligibility, and 1 subject was mistakenly randomized. Forty-nine <ref type="bibr">(1 -</ref> <ref type="table">blind investigational product, but  never received open-label alendronate (romosozumab:</ref> .</p><p>Overall for the primary analysis period, 70 administration (romosozumab/alendronate: 70 ; alendronate/alendronate, 70 primary analysis period, the most frequently reported reasons for discontinuation of investigational product were withdrawn consent (romosozumab/alendronate: 7</p><p>Overall the study had an acceptable level of investigational product completion, and rates of investigational product discontinuation were balanced between treatment groups for both the double-blind and overall primary analysis period. Results are similar to Study 337.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol Deviations</head><p>Important protocol deviation (IPD) categories were defined prior to the first subject visit and updated during the IPD reviews throughout the study prior to database lock.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>12-Month Double-blind Period</head><p>A total of 227 (6 -blind period <ref type="table" target="#tab_6">(Table 14)</ref>. The most frequently reported IPDs pertained to weekly alendronate or matching placebo tablets (2 alendronate group) and those who missed more than 3 scheduled monthly injections of romosozumab or matching placebo during the double-blind period (1 2 respectively).</p><p>During the double-blind treatment period, 6 subjects who were randomized to alendronate received either romosozumab or matching placebo to romosozumab. Two of these subjects received active doses of romosozumab. These 2 subjects were included in the alendronate group for efficacy analyses, but in the romosozumab group for safety analyses, as described in SAP. The other 4 subjects received all SC placebo injections and active alendronate tablets as planned in the double-blind period.</p><p>Similarly, during the double-blind period, 2 subjects who were randomized to romosozumab received alendronate or matching placebo tablets. One of these subjects received and took 4 active alendronate tablets. Both of these subjects were included in the romosozumab group for efficacy and safety analyses.</p><p>Other important protocol deviations during the 12-month double-blind treatment period included the following: entered study even though entry criteria were not satisfied <ref type="table" target="#tab_5">(53 subjects,  1</ref> received an excluded concomitant medication (7 su <ref type="bibr">(2 su</ref> . The number of protocol deviations was low and overall balanced between treatment groups. Based on their nature and low, balanced incidences, the important deviations identified in this study were unlikely to have affected the interpretation of the study results.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Demographic Characteristics</head><p>Demographic and disease characteristics were generally balanced between the 2 treatment groups <ref type="table" target="#tab_7">(Table 155)</ref>. As required by the inclusion criteria, all enrolled subjects were women. The mean age of all subjects was 74.3 years (range: 55 to 90 years), and 52 were 75 -Hispanic/Latino. Body composition of the subjects included mean (SD) weight of 59 <ref type="formula" target="#formula_34">(11)</ref>   </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other Baseline Characteristics</head><p>Baseline disease characteristics were generally balanced between the treatment groups (Error! Reference source not found.) after age 45. The mean baseline lumbar spine, total hip, and femoral neck BMD T-scores were -2.96, -2.80, and -2.90, respectively. Baseline spine radiographs evaluated by the central baseline.</p><p>Baseline clinical risk factors relevant to determination of the 10-year probability of a major osteoporotic fracture, according to the FRAX, were similar between treatment groups. The mean 10-year probabilities of major osteoporotic fractures calculated with femoral neck BMD were 20 for the romosozumab group and 20 r the alendronate group. For the subset of osteoporotic hip fractures, corresponding probabilities were subjects in each treatment group, 28 , and 79 in each treatment group reported a cardiovascular risk factor including history of hypercholesterolemia, hypertension, diabetes, or clinical cardiovascular disease. Of note, fasting serum lipid values were not assessed.</p><p>The use of prior osteoporosis medications was reported for 9 in each treatment group; oral bisphosphonates were the most frequently reported prior osteoporosis medication (6 in each treatment group), followed by PTH or PTH derivatives and calcitriol (both 1 in each treatment group).</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">8 6</ref> Nearly all subjects (98 in each treatment group) reported use of calcium and vitamin D at baseline. Based on screening values for 25(OH) vitamin D, 3032 (74 d an initial loading dose of 50000 to 60000 IU vitamin D within 1 week of randomization .</p><p>In summary, as intended, the study enrolled a population of subjects at high risk for fracture, with 96 38 subjects with a history of nonvertebral fracture at or after age 45. This is in contrast to Study 337, with 18 baseline and 22 Baseline characteristics other than BMD and previous fracture history that contribute to the FRAX determination of fracture risk (e.g., BMI, smoking history, glucocorticoid use) were generally consistent with Study 337.</p><p>Baseline medical characteristics were similar to Study 337, with the exception of a higher Within each study, however, cardiovascular medical history and baseline cardiovascular risk factors were balanced between treatment groups.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment Compliance, Concomitant Medications</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment Compliance During 12-Month Double-blind Period</head><p>Eighty-six percent of subjects randomized to romosozumab continued investigational product throughout the double-blind treatment period. Of these subjects .</p><p>Eighty-five percent of subjects randomized to alendronate continued investigational product throughout the double-blind treatment period. Of these subjects, The rates of treatment compliance and use of prohibited concomitant medications were acceptable and well-balanced between treatment groups.   <ref type="table" target="#tab_16">Table 10</ref>-1 in study 20110142 report. CI = confidence interval; N = Number of subjects randomized; N1 = Number of subjects in the primary analysis set for vertebral fractures; QM = every month; QW = weekly; RRR = relative risk reduction ALN/ALN is Alendronate 70 mg QW/Alendronate 70 mg QW a Based on the Mantel-Haenszel method adjusted for age strata, baseline total hip BMD T-score <ref type="bibr">( -2.5, &gt; -2.5)</ref>, and presence of severe vertebral fracture at baseline b Calculated from risk ratio as 100 x <ref type="bibr">(1 -risk ratio)</ref> c Based on logistic regression model adjusted for age strata, baseline total hip BMD T-score and presence of severe vertebral fracture at baseline; p-value based on score test NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 8 8</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy Results -Co-Primary Endpoints</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>New vertebral fractures through Month 24</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical fractures through primary analysis period</head><p>The study protocol pre-defined the clinical fractures as non-vertebral fractures and clinical (i.e. symptomatic) vertebral fractures. The primary analysis was event-driven based on the number of observed clinical fractures and occurred after a median follow-up time of 33 months. At the time of the primary analysis, 464 subjects had experienced a clinical fracture and all subjects had completed the 24-month visit. Clinical fracture occurred in 9.7 of subjects in the romosozumab group compared to 13.0 of subjects in the alendronate group through the primary analysis period. Romosozumab significantly reduced the risk of clinical fractures compared to alendronate alone with a hazard ratio of 0.73 -0.88, p-value: &lt;0.001). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy Results -Secondary endpoints controlled for type I error</head><p>The secondary efficacy endpoints that were controlled for type I error are presented in the order of testing sequence followed by other endpoints that were not included in the testing sequence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMD endpoints</head><p>With multiplicity adjustment, at Month 12, romosozumab significantly increased mean BMD by compared with alendronate at the lumbar spine, total hip and femoral neck respectively (p&lt; 0.001 for all 3 sites). At Month 24, romosozumab for 12 months followed by alendronate for 12 months, significantly increased BMD with treatment differences of compared with alendronate alone at the lumbar spine, total hip, and femoral neck (p &lt; 0.001 for all 3 sites). Romosozumab followed by alendronate maintained increases in BMD at the lumbar spine, total hip, and femoral neck at all 3 sites at Month 36.   <ref type="table" target="#tab_16">Table 10</ref>-5 in study 20110142 study report. N=Number of subjects with values at baseline and at least one post-baseline visit at or before month 36 LOCF=last-observation-carried-forward a BMD endpoint at Month 36 was not under multiplicity control Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction. Missing values are imputed by carrying forward the last non-missing post-baseline value prior to the missing value and within the treatment period.   <ref type="table" target="#tab_16">Table 10</ref>-5 in study 20110142 study report. N=Number of subjects with values at baseline and at least one post-baseline visit at or before month 36. LOCF=last-observation-carried-forward a BMD endpoint at Month 36 was not under multiplicity control. Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction. Missing values are imputed by carrying forward the last non-missing post-baseline value prior to the missing value and within the treatment period. Source: <ref type="table" target="#tab_16">Table 10</ref>-5 in study 20110142 study report.</p><p>The positive gains in BMD were consistent with what was shown in Study 337 study, demonstrating that romosozumab is effective across populations at high risk for fracture.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nonvertebral Fracture through Primary Analysis Period</head><p>Through the primary analysis period, a total of 395 subjects experienced nonvertebral fractures, 217 subjects in the romosozumab then alendronate group and 178 subjects in the alendronate alone group. Romosozumab followed by alendronate significantly reduced the risk of nonvertebral fracture (hazard ratio=0.81, 1-sided P-value=0.019, which was below the alpha level of 0.0233).</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 9 1     KM=Kaplan-Meier a Absolute risk difference is based on inverse--2.5, &gt; -2.5), and presence of severe vertebral fracture at baseline. b The hazard ratio estimate is based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD Tscore, and presence of severe vertebral fracture at baseline. Source: <ref type="table" target="#tab_6">Table 14</ref> <ref type="bibr">-4.4.7</ref> in study 20110142 report.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy Results -Subgroup analyses</head><p>Romosozumab demonstrated a consistent treatment effect across the subgroups defined in section 8.1.1, as evident by estimates that favored romosozumab/alendronate over alendronate/alendronate in most of the subgroups of baseline characteristics examined with respect to new vertebral fractures, clinical fractures and non-vertebral fractures. In a few subgroups with small sample sizes, very minor numerical treatment effect estimates favoring alendronate/alendronate over romosozumab/alendronate were observed instead, but the confidence intervals for the treatment effect differences were wide. In summary, there was largely consistency of romosozumab's treatment effect on fracture risk reduction across subgroups (see forest plots presented in <ref type="figure">Figure to</ref>  At Month 12 and Month 24, romosozumab/alendronate appears to have a greater BMD increase at the lumbar spine, total hip and femoral neck compared to alendronate/alendronate in all subgroups.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effect of Antiromosozumab Antibodies on Efficacy</head><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} <ref type="bibr">9 5</ref> Among subjects who received romosozumab, the overall incidence of antiromosozumab antibodies at any study visit through Month 18 was 16 neutralizing antibodies. The antibody status through Month 18 was selected for evaluation of efficacy and safety by antibody status, as the 6-month follow-up period after completion of the 12-month romosozumab treatment phase allowed for washout of romosozumab from serum and enabled the most accurate neutralizing antibody detection.</p><p>The presence of antiromosozumab binding and neutralizing antibodies did not affect the efficacy of romosozumab as assessed by BMD. For subjects who received romosozumab, the percent change from baseline in BMD at the lumbar spine, total hip, and femoral neck at Month 12 and Month 24 was compared among subjects who developed binding or neutralizing antiromosozumab antibodies through Month 18 vs. those who were negative for antiromosozumab antibodies through Month 18. These results are summarized in <ref type="table" target="#tab_4">Table 24</ref>. Baseline values for BTMs were similar between the romosozumab and alendronate groups. The bone formation marker P1NP showed a rapid increase in the romosozumab group that peaked at Month 1 (time point of first assessment), returning to baseline by Month 6. As expected, during double-blind treatment, alendronate reduced P1NP through Month 12. The median percent change from baseline in P1NP was greater in the romosozumab group than in the alendronate group at all time points evaluated during double-blind treatment, and the difference between the romosozumab and alendronate groups was nominally statistically significant at each time point (nominal p &lt; 0.001 at months <ref type="bibr">1, 3, 6, 9, and 12</ref> The bone resorption marker sCTX showed a decrease in the romosozumab group at Month 1 (time point of first assessment) and remained reduced but above the levels in the alendronate group through Month 12. After Month 12 (i.e., when all subjects received open-label alendronate), the median sCTX value in the romosozumab/alendronate group decreased at Months 15, 18, and 24 to levels that were similar to those in the alendronate/alendronate NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 97 group. At Month 36, the median sCTX value in the romosozumab/alendronate group increased but remained below baseline (nominal p = 0.042 vs. alendronate/alendronate group).</p><p>In summary, the results of the BTM measures support the dual effect on bone and are consistent with those observed in the romosozumab group in the placebo-controlled studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient-reported and Clinician-reported Outcomes</head><p>PRO/ClinROs were evaluated as exploratory endpoints in Study 142 to describe subjects' experience of pain and its impact on subjects' activities and health-related quality of life at 6month intervals for the overall 24-month study period and at 1-month intervals for the first 3 months post fracture using the OPAQ SV, EQ-5D-5L, LAD survey questionnaires, and 1 item extracted from the BPI assessing the worst pain experienced in the past 24</p><p>No consistent or clinically meaningful differences in PRO/ClinRO endpoints (OPAQ SV, EQ-5D-5L, LAD, or BPI worst pain score) were identified between the romosozumab and alendronate groups during the 12-month double-blind period or between the romosozumab/alendronate and alendronate/alendronate groups during the primary analysis period. A summary of results for these endpoints is provided in <ref type="table" target="#tab_87">Table 11</ref>-1 of the CSR.</p><p>Post fracture data were obtained at months 1, 2, and 3 for subjects who had a clinical fracture on study using the prefracture baseline for comparison. No consistent or clinically meaningful differences in PRO/ClinRO endpoints (OPAQ SV, EQ-5D-5L, LAD, or BPI worst pain score) were identified between the romosozumab and alendronate groups 1, 2, or 3 months postfracture. A summary of results for these endpoints is provided in <ref type="table" target="#tab_87">Table 11</ref>-2 of the CSR.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20110174</head><p>This section summarizes the key design elements of Study 174. Although the clinical study report was submitted with this BLA, this review does not include a review of efficacy and general safety results of Study 174, as the study population is not one for which an indication is currently sought with this BLA. Cardiovascular safety data from Study 174, however, are included in the review of this BLA (and are discussed alongside those of Study 337 and Study 142 in Section 8.2.5, Analysis of Cardiovascular Safety).</p><p>Study 174 was a 15-month randomized, double-blind, placebo-controlled study evaluating the effect of 12 months of romosozumab treatment on lumbar spine BMD in men with osteoporosis. Subjects were randomized 2:1 to receive either romosozumab 210 mg (3 injections of 70 mg each) or matching placebo for 12 months and were followed for an additional 3 months to assess immunogenicity.</p><p>The population included men 55 to 90 years old with osteoporosis, defined as a T--2.5 at the lumbar spine, total hip or femoral neck, or a T--1.5 with a history of a NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 98 fragility nonvertebral or vertebral fracture. Subjects were excluded from the study if T-score was &lt;-3.5 at the hip or they had a history of a hip fracture.</p><p>The mean age of the enrolled population was 72 years. Approximately 74 white. The geographic distribution of enrolled subjects was Europe , Safety analyses included assessments of treatment-emergent adverse events, clinical laboratory assessments, vital signs, and anti-romosozumab antibodies. Specific adverse event adjudication committees were established for osteonecrosis of the jaw, atypical femoral fractures, and cardiovascular events.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20070337: Design</head><p>This section summarizes the key design elements of Study 337, which was previously reviewed during the first review cycle.</p><p>Study 337 was a 24-month, multicenter, double-blind, randomized, placebo-controlled study in postmenopausal women with osteoporosis age 55 to 90 years study evaluating romosozumab 210 mg monthly (given SC by healthcare providers as three 1 mL prefilled syringes containing 70 mg/mL) for the treatment of postmenopausal osteoporosis. Osteoporosis was defined as a BMD T--2.5. Subjects with a BMD T--3.5 at the total hip or femoral neck, history of hip fracture, severe vertebral fracture, or more than 2 moderate vertebral fractures were excluded from the study. Subjects with metabolic bone disease, significant laboratory abnormalities, or use of drugs known to affect bone were also excluded. Prior use of osteoporosis therapies was allowed with appropriate washout periods.</p><p>Subjects were randomized 1:1 to receive either romosozumab 210 mg or matching placebo by subcutaneous (SC) injection every month for the first 12 months of the study. After the 12month double-blind treatment period, all subjects received denosumab 60 mg SC every 6 months in an open-label fashion while still remaining blinded to their initial treatment assignment. Subjects were to receive daily calcium (500 to 1000 mg) and vitamin D (600 to 800 prevalent vertebral fracture (yes, no), as determined by site staff at randomization based on local reading of the spine X-ray.</p><p>The coprimary endpoints of the study were incidence of new vertebral fractures at 12 and 24 months. Secondary endpoints included clinical fracture and nonvertebral fracture. To control the overall type I error, the primary and secondary efficacy endpoints were tested sequentially at the 2-follows: Multiple substudies were included in this trial: a PK substudy; a BTM and biomarker substudy; an imaging substudy I (forearm DXA, total body DXA, high resolution peripheral quantitative computed tomography (HR-pQCT)); an imaging substudy II (lumbar spine, proximal femur DXA substudy); a bone biopsy substudy; a calcium substudy; an audiology substudy; an osteoarthritis substudy; a pharmacogenetics substudy; and mineral substudy (serum intact parathyroid hormone (iPTH) and urinary calcium).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20070337: Efficacy Results</head><p>Study population: The study enrolled 7180 subjects. The mean age of the enrolled population   Subgroup analyses demonstrated consistent results for the coprimary endpoints in all subgroups of baseline characteristics examined, including age, race, geographic region, a range of baseline BMD T-scores, and subjects with a history of prior vertebral, nonvertebral, or fragility fracture. Similar estimates of treatment effect were obtained in sensitivity analyses based on stratification variables, the full analysis set, and per protocol analysis set. After controlling for baseline covariates individually and simultaneously in the primary analysis model, romosozumab (Month 12) and romosozumab/denosumab (Month 24) continued to demonstrate a treatment effect compared with placebo (Month 12) and placebo/denosumab (Month 24) for the coprimary endpoint at Month 12 and Month 24.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20060326</head><p>This section summarizes the key features of supportive Study 326, the dose-finding study reviewed with the original BLA.</p><p>Study 326 was a multiple dose study in 419 postmenopausal women with low BMD that primarily evaluated the effect of romosozumab versus placebo on lumbar spine BMD. During the 24-month romosozumab treatment phase of the study, subjects were randomized to 1 of 5 double-blind dosing regimens of romosozumab (70 mg monthly, 140 mg every 3 months, 210 mg every 3 months or 210 mg monthly), placebo, open-label alendronate or teriparatide for the first 12 months. During the second 12 months of the treatment phase of the study, the romosozumab and placebo groups continued their assigned treatment. The primary endpoint was percent change from baseline in lumbar spine BMD at Month 12.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 102 Treatment with romosozumab demonstrated a dose-related increase in BMD with a waning of BMD increases after the first year of therapy. At Month 12, the mean percent chance in lumbar monthly, compared with -was chosen for further development in the Phase 3 studies.</p><p>All subjects in the placebo and romosozumab dose groups continued on their blinded therapy for the second year of the study. BMD in the romosozumab arms did continue to increase in the second year of therapy although the increases were not as robust as those achieved in the first year of therapy. <ref type="figure" target="#fig_6">Figure 6</ref> below depicts the BMD response for the 210 mg dose group and shows waning BMD increases after 12 months of therapy. <ref type="figure" target="#fig_6">Figure 6</ref> also shows the BMD response once romosozumab is discontinued and patients are transitioned to no therapy (placebo). BMD approaches baseline within one year off therapy.</p><p>Based on the results of this trial, the applicant chose to limit the duration of exposure to 12 months of romosozumab the fracture trials. These data therefore support limiting the duration of romosozumab therapy to 12 months. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Integrated Assessment of Efficacy</head><p>The evidence of effectiveness of romosozumab for the treatment of PMO derives from Study 142, the phase 3 study covered in this review, as well as phase 3 Study 337 and four additional supportive studies <ref type="bibr">(326, 291, 156, and 289)</ref>, which were all reviewed with the original BLA. <ref type="table" target="#tab_4">Multi-disciplinary Review and Evaluation {BLA 761062}  {Evenity, romosozumab}   103   This section focuses on the efficacy results from the primary analyses of Study 142 and Study  337</ref>, which together comprise the majority of the efficacy data and are the only studies with fracture endpoints. Efficacy data from these studies are presented side by side and are not integrated with each other due to the differences in the control group (placebo in 337 versus active control in 142) and patient populations (i.e., higher fracture risk in Study 142).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NDA/BLA</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fracture Efficacy Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>New Vertebral Fracture</head><p>Morphometric vertebral fracture was a primary endpoint for both Study 337 (at 12 months and 24 months) and Study 142 (at 24 months).</p><p>In the placebo-controlled Study 337, the subject incidence of morphometric vertebral fracture at <ref type="bibr">Month 12 ,</ref><ref type="bibr">yielding an 53,</ref><ref type="bibr">84)</ref>. At Month 24 during treatment with denosumab, the subject incidence of morphometric vertebral fracture was 2.5 /denosumab group and 0.6 romosozumab/denosumab group with an absolute risk reduction of 1.</p><p>1.3, 2.5) and a relative risk reduction of 60, 84).</p><p>In the active-controlled Study 142, the subject incidence of morphometric vertebral fracture at Month 24 alone followed by alendronate group, relative risk</p><p>The higher fracture incidence in Study 142 was expected given the high fracture risk of the enrolled population.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Fracture</head><p>Clinical fracture incidence at Month 12 was the first secondary endpoint in the testing sequence in Study 337 and time to first clinical fracture through the primary analysis period was a coprimary endpoint in Study 142. Clinical fracture is a composite endpoint including symptomatic vertebral fractures and nonvertebral fractures.</p><p>In Study 337, romosozumab significantly reduced the risk of clinical fracture through Month 12, with an absolute fractures at 24 months did not reach statistical significance when adjusted for multiplicity.</p><p>In Study 142, a significant reduction in clinical fracture risk for subjects who received 12 months of romosozumab followed by alendronate was seen when compared with subjects who received alendronate alone for the duration of the primary analysis period. The hazard ratio for romosozumab followed by alendronate was 0.73 compared to </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nonvertebral Fracture</head><p>Nonvertebral fracture was a secondary endpoint included in the testing hierarchy for both Study 337 and Study 142.</p><p>In Study 337, nonvertebral fracture risk reduction with romosozumab was not statistically significant. The applicant attributes this finding to a lower than expected nonvertebral fracture incidence in the placebo group in Central/Latin America in the first 12 months of ( incidence in the romosozumab group. Central/Latin America was the highest enrolling region, accounting study population. Overall baseline characteristics were similar across all of the geographic regions. However, the applicant notes that a lower prevalence of historical nonvertebral fracture and a lower FRAX 10-year probability of major osteoporotic and hip fracture was observed for subjects in the Central/Latin America region relative to most other regions.</p><p>In Study 142, nonvertebral fracture assessed through the primary analysis period was a secondary endpoint included in the sequential testing procedure. Through the primary analysis period, there was an estimated hazard ratio of 0.81 0.66, 0.99; p &lt; 0.019) for romosozumab followed by alendronate compared to alendronate alone, based on 395 subjects with nonvertebral fractures and a median follow-up of 33 months. The multiplicity adjusted 1sided p-value (adjusting for the fixed sequence and the group sequential testing) was significant (p = 0.019) for this endpoint, indicating a significant benefit with romosozumab followed by alendronate compared with alendronate alone.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hip Fracture</head><p>Hip fracture outcomes were not included in the hierarchal testing procedures for Studies 337 and 142. Additionally, neither study was designed to demonstrate a difference in hip fractures. In Study 337 a statistically significant reduction in hip fractures compared to placebo was not demonstrated although a trend in reduction at both 12 and 24 months was seen.</p><p>In Study 142, through the primary analysis period, romosozumab followed by alendronate showed a reduced risk of hip fracture compared with alendronate alone, with a hazard ratio of , 0.92), based on 107 subjects with hip fractures. However, this endpoint was not part of the planned statistical testing sequence and was not adjusted for multiplicity.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 105</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of Fracture Endpoint Results with Follow-on Therapy</head><p>Both Study 337 and Study 142 demonstrated that romosozumab provides ongoing vertebral and nonvertebral fracture risk reduction with follow-on antiresorptive therapy after the end of the 12-month treatment period.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMD Results</head><p>Romosozumab demonstrated significantly higher BMD increases at the lumbar spine, total hip and femoral neck, compared to both placebo and alendronate.</p><p>BMD percent change from baseline at Month 12 in Study 337 and Study 142 is summarized in <ref type="table" target="#tab_4">Table 298</ref> below.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 29. Bone Mineral Density Percent Change From Baseline at Month 12 in the Pivotal Fracture Studies (ANCOVA Model) (Primary Efficacy Analysis Set for BMD, LOCF)</head><p>LOCF=last-observation-carried-forward *Source: <ref type="table" target="#tab_7">Table 15</ref> of SCE In both studies, subgroup analyses showed consistent percent BMD increases from baseline for romosozumab compared to control at the lumbar spine and total hip when analyzed by age, NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 106 geographic region, and baseline BMD T-score. Of note, the percent change in BMD at the lumbar spine and total hip was similar between North America and all other regions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bone Turnover Markers Results</head><p>BTMs were assessed in Study 337, Study 142 and the supportive placebo-controlled studies. BTM results showed a similar pattern of increase in bone formation markers (P1NP, BSAP, and osteocalcin) and decrease in the bone resorption marker, sCTX. Bone formation markers peaked and returned to baseline by approximately month 6 to 9, while the bone resorption marker decreased within a month after the first dose and generally remained below levels seen with placebo at Month 12 (and slightly above levels seen with alendronate in Study 142). Across the studies, the maximum P1NP increase was observed at the Month 1 time point in all romosozumab groups and the maximum decrease in sCTX occurred at Month 1.</p><p>Although the BTM responses were reduced over subsequent doses, there remained a response after each dose, suggesting continued smaller effects of romosozumab after each dose over 12 months.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional Efficacy Considerations: Considerations on Benefit in the US Postmarket Setting</head><p>Only a very small number of subjects in Study 337</p><p>Study 142 (57/4093, studies demonstrated that there were no treatment-by-region interactions for the co-primary endpoints. Additionally, the lumbar spine and total hip BMD changes were consistent across all geographic areas. Given these consistent findings across all geographic regions, the fracture and BMD results can be considered applicable to the U.S. population and U.S. medical practice. Additionally, since the population of Study 174 is one for which an indication is not currently sought (i.e., men with osteoporosis), the general safety results of this study are not included in this section.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of Safety</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Review Approach</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the Safety Database</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overall Exposure</head><p>This BLA resubmission provides additional safety data from 4054 postmenopausal women with osteoporosis and a history of fracture in Study 142 as well as cardiovascular safety data from 244 men with osteoporosis in Study 174. The safety review during the first review cycle of this original BLA submission included data from 8274 postmenopausal women in the phase 2 and phase 3 studies, including 7157 women with osteoporosis in the placebo-controlled fracture study (Study 337), 218 subjects with osteoporosis who were transitioning from bisphosphonate therapy (Study 289), 353 subjects with low bone mass in the dose-finding study (Study 326), 252 Japanese subjects with osteoporosis in a dedicated study in Japan (Study 291), and 294 subjects with osteoporosis enrolled in a non-inferiority BMD study <ref type="bibr">(Study 156)</ref>.</p><p>With the additional data in this submission, the romosozumab safety database includes approximately 14000 subjects in 18 romosozumab clinical studies, of which 7518 subjects received at least 1 dose of romosozumab with 6180 women receiving romosozumab for at least 6 months and 5712 women receiving romosozumab for at least 12 months.</p><p>In addition, cardiovascular data from 244 men with osteoporosis who received romosozumab (n = 163) or placebo (n = 81) for 12 months (Study 174) are included in Section 8.2.5 (Analysis of Cardiovascular Safety) to provide an evaluation of cardiovascular safety across the pivotal phase 3 studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Relevant characteristics of the safety population</head><p>The study population in Study 142 was sufficiently diverse to represent the expected target population. Refer to the discussion in the demographic section of Section 8.1.2.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adequacy of the safety database</head><p>The safety database for Study 142 was adequate in terms of size, duration, subject demographics, and disease characteristics. Refer to the demographics and baseline characteristics sections of Section 8.1.2.</p><p>Because of the large numbers of patients needed to show fracture risk reduction, the safety database for romosozumab also greatly exceeds ICH E1 guidelines, which recommend a minimum of 100 patients exposed for a minimum of one-year from prospective studies appropriately designed to provide at least one year exposure at dosage levels intended for clinical use (ICH Guideline: The Extent of Population Exposure to Assess Clinical Safety for Drugs NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 108 Intended for Long-Term Treatment of <ref type="bibr">Non-life-threatening Conditions, 1994)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adequacy of Applicant's Clinical Safety Assessments</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Issues Regarding Data Integrity and Submission Quality</head><p>Submission quality is adequate regarding overall organization, ease of finding information, proper location of information and data. There were no data quality or integrity issues identified.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Categorization of Adverse Events</head><p>The applicant's approach to the definition and categorization of adverse events was appropriate. Adverse event analyses were categorized using Medical Dictionary for Regulatory Activities (MedDRA) version 19.1.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Routine Clinical Tests</head><p>The methodology and frequency of routine clinical testing (as described in Section 8.1.1) was adequate to monitor for known and potential safety risks of romosozumab in the study population.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Results: Study 20110142</head><p>Results included in this section are based on the primary analyses of Studies 142 and 337, which are the analyses presented in the Clinical Study Reports (CSRs) of these studies. Of note, the Integrated Summary of Safety (ISS) includes results from the final analyses of both studies (which occurred after database lock). This led to small differences between the data in the study 337 study report from the first review cycle and the study 337 data submitted with integrated summary of safety in this resubmission. As requested in an IR during the review cycle, the applicant provided a detailed listing of every change that occurred when safety data were updated in the final analyses.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exposure:</head><p>In Study 142, the safety analyses included 2040 subjects in the romosozumab/alendronate group and 2014 subjects in the alendronate/alendronate group who received at least 1 dose of active investigational product. Of the 2046 subjects randomized to romosozumab in Study 142, 8 subjects did not receive investigational product during the 12month double blind period and were therefore not included in the safety analysis group, and 2 subjects were added to the romosozumab safety analysis set group (subjects who were randomized to alendronate but mistakenly received active doses of romosozumab). Of the 2047 subjects randomized to alendronate in Study 142, 33 did not qualify for the safety analysis set. Seven subjects did not receive the subcutaneous placebo injection and oral alendronate was not dispensed, while 3 subjects received subcutaneous placebo but were not dispensed oral alendronate. The 2 subjects who mistakenly received at least one active dose of romosozumab NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 109 were moved to the romosozumab treatment group for safety outcomes. The remaining 21 subjects who did not qualify for inclusion in the safety analysis set received at least one dose of subcutaneous placebo given in the clinic, however, boxes for the dispensed drug were never returned, and therefore reconciliation was unable to confirm exposure.</p><p>During the 12-month double-blind period, the median number of double-blind SC injections of romosozumab or matching placebo received was 12 (range: 1 to 12) in both groups. In the treatment group, the median cumulative romosozumab exposure was 2520 mg (range: 70 mg to 2520 mg).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>All Adverse Events</head><p>A summary of all adverse events is provided in <ref type="table" target="#tab_4">Table 29</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Deaths</head><p>The incidence of fatal adverse events by system/organ/class (SOC) is provided in <ref type="table" target="#tab_4">Table 29</ref>. Regarding the fatal adverse events that were termed "death," review of the subject narratives revealed that one death was likely due to pulmonary sepsis (in the alendronate group), and the remaining deaths all had undetermined causes. Importantly, the incidence of death with an undetermined cause was similar in both treatment groups during both study periods (with a slightly higher incidence in the alendronate group).  Fatal adverse events were slightly more a result of the older population enrolled in Study 142.</p><p>Of note, an imbalance in events of fatal malignant lung neoplasm was observed in Study 337 (4 subjects in the romosozumab group and 0 subjects in the placebo group). All subjects who had fatal malignant lung neoplasm events in Study 337 were current or former smokers, and all had a short time to diagnosis. In addition, the overall incidence of fatal and nonfatal lung neoplasm events was balanced between treatment groups. No imbalance in such events was observed in Study 142. Therefore, based on the totality of the data, there is no convincing safety concern for lung neoplasms. Malignant tumors are discussed further in the "Adverse Events of Interest" section below.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serious Adverse Events</head><p>The subject incidence rate of serious adverse events was similar between treatment groups in the double-blind period and the primary analysis period.</p><p>in <ref type="table" target="#tab_5">Table 31</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>12-Month Double-blind Period</head><p>During the 12-month double-blind period, serious adverse events were reported for 262 <ref type="formula" target="#formula_34">(</ref>  In general, the incidence of serious adverse events was fairly balanced between treatment groups. Of note, fractures occurred less commonly in the romosozumab arm, consistent with the superior fracture efficacy of romosozumab compared to alendronate. Myocardial infarction in the double-blind period occurred in 2 subjects in the alendronate arm and 8 subjects in the romosozumab arm.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjudicated Cardiovascular Serious Adverse Events</head><p>All deaths, as well as all serious adverse events deemed by the investigator to be of potential cardiovascular etiology were submitted to an independent committee for adjudication (the Duke Clinical Research Institute, or DCRI). In addition, all serious adverse events with terms mapping to a predefined preferred term list potentially indicative of cardiovascular etiology were also adjudicated. The positively adjudicated cardiovascular serious adverse events (CV SAEs) were summarized according to event classifications in the DCRI charters as follows: death, cardiac ischemic events (myocardial infarction, angina requiring hospitalization, coronary revascularization), cerebrovascular events (stroke, TIA ), noncoronary revascularization, hospitalization for heart failure, and peripheral vascular event not requiring revascularization. Positively-adjudicated cardiovascular death included cardiovascular death and death of undetermined cause.</p><p>The subject incidence rate of all adjudicated positive CV SAEs romosozumab NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 115 group (50 subjects) (38 subjects) during the 12-month double-blind treatment period. This imbalance was driven by events of myocardial infarction, which occurred in 16 subjects ) in the romosozumab group and 5 subjects ) in the alendronate group, and stroke, which occurred in 13 subjects ) in the romosozumab group and 7 subjects ) in the alendronate group.</p><p>The following subject incidences were reported for various groupings of CV SAEs during the 12month double-blind period: hospitalization for heart fa -coronary ischemic events not requiring During the primary analysis period, the overall subject incidence of positively adjudicated CV SAEs was alendronate/alendronate group. Positively adjudicated cardiac ischemic events were reported respectively. Positively adjudicated of subjects in the romosozumab/ group. Although there were small imbalances in certain CV SAEs during the primary analysis period, the imbalances were driven by events during the first 12 months of the study (that is, CV SAEs were balanced from Month 13 through the end of the study).</p><p>Refer to section 8.2.5 for discussion of the imbalance in CV SAEs observed in Study 142 as well as an overall analysis of cardiovascular safety.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dropouts and/or Discontinuations Due to Adverse Effects</head><p>Withdrawal of Investigational Product (12-Month Double-blind Period) The subject incidence rates of adverse events resulting in discontinuation of investigational product were similar between treatment groups in the double-blind period.</p><p>Adverse events led to discontinuation of investigational product for 70 (3 the romosozumab group and 64 (3</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Withdrawal of Investigational Product (Primary Analysis Period)</head><p>The subject incidence rates of adverse events resulting in discontinuation of investigational product were similar between treatment groups in the primary analysis period as well.</p><p>Adverse events led to withdrawal of investigational product for 133 (7 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 116 received romosozumab/alendronate and 146 (7 alendronate during the primary analysis period. Adverse events (preferred terms) that led to upper Withdrawal From the Study  The subject incidence rates of adverse events resulting in withdrawal from study were similar between treatment groups in the double-blind period. Adverse events led to withdrawal from the study for 30 (2 received romosozumab and 27 (1 alendronate during the 12-month double-blind period. All adverse events (preferred terms) leading to withdrawal from the study were repo group.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Withdrawal From the Study (Primary Analysis Period)</head><p>The subject incidence rates of adverse events resulting in withdrawal from study were similar between treatment groups in the primary analysis period also.</p><p>Adverse events led to withdrawal from the study for 47 (2 romosozumab/alendronate and 43 (2 the primary analysis period. All adverse events (preferred terms) leading to withdrawal from In summary, the rates of discontinuations due to adverse events were acceptable. There was no substantial difference between the two treatment groups. Results for Study 142 were similar to those of Study 337 for adverse events leading to withdrawal.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse Events of Interest</head><p>Events of interest for this study included hypocalcemia, injection site reactions, adverse events potentially related to hypersensitivity, malignant or unspecified tumor, hyperostosis, and osteoarthritis, as well as positively adjudicated atypical femoral fractures (AFF) and positively adjudicated osteonecrosis of the jaw (ONJ). These events represent those causally (i.e., hypocalcemia), potentially (i.e., hyperostosis), or theoretically (i.e., osteoarthritis, malignancy) associated with sclerostin inhibition; adverse events associated with injectable monoclonal antibodies (i.e., hypersensitivity events and injection site reactions); and positively adjudicated adverse events associated with antiresorptive therapies (osteonecrosis of A summary of adverse events of interest is provided in <ref type="table" target="#tab_4">Table 32</ref>. Subject incidences of these events in the romosozumab group were similar to the alendronate group, with the exception of injection site reactions. Search strategies using MedDRA SMQ-defined search terms to identify events associated with injection site reactions showed a slightly higher incidence of injection site reactions during the double-blind period in the romosozumab group than in the Hypocalcemia has been reported with osteoporosis therapies that inhibit bone resorption. Based on earlier studies, the nadir in serum calcium appears to occur between 2 weeks and 1 month following romosozumab injection. In this study, serum calcium was assessed at Month 1 and therefore, hypocalcemia defined by low laboratory values may have been missed.</p><p>Adverse Events of Hypocalcemia: During the 12-month doubleevent of hypocalcemia (preferred term) was reported in each treatment group. No hypocalcemia event was serious. Both adverse events of hypocalcemia were grade 1 (&lt;lower LLN to 8.0 mg/dL) or grade 2 (&lt;8.0 -7.0 mg/dL) in severity and neither resulted in discontinuation of investigational product or discontinuation from the study. alendronate/alendronate group. No hypocalcemia event was serious. All adverse events of hypocalcemia were grade 1 or grade 2 in severity and did not result in discontinuation of investigational product or discontinuation from the study</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse Events Potentially Related to Hypersensitivity</head><p>The applicant used a narrow standardized MedDRA query (SMQ) for hypersensitivity reactions. During the 12-month double-blind period, adverse events potentially related to hypersensitivity were reported for 122 <ref type="bibr" target="#b88">(6</ref> romosozumab group and 118 (6 alendronate group. Adverse events potentially related to subjects in either treatment group were rash eczema . Serious adverse events potentially related to hypersensitivity were reported for 3 p. Adverse events potentially related to hypersensitivity led to discontinuation from respectively, in the romosozumab group and 3 (0. alendronate group. Adverse events potentially related to investigational product subjects with injection site rash, 1 with mouth swelling) and no subject in the alendronate group. Adverse events potentially related to hypersensitivity that occurred days after administration of investigational product were reported for romosozumab group (1 event each of dermatitis allergic, eye allergy, pruritus allergic, rash, rash maculopapular, and rash pruritic) and no subject in the alendronate group. alendronate group reported concomitant (i.e. f hypersensitivity event on the same investigational product administration date with overlapping start and resolution dates) or recurrent (i.e. hypersensitivity event at 2 or more different investigational product administration dates) NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 119 adverse events potentially related to hypersensitivity. No concomitant event(s) was reported for more than 1 subject in either treatment group. Recurrent events reported for more than 1 subject in the romosozumab and alendronate groups, respectively, were rash (2 subjects, 3 subjects); eczema <ref type="bibr" target="#b84">(2,</ref><ref type="bibr">1)</ref>; dermatitis allergic <ref type="bibr" target="#b84">(2,</ref><ref type="bibr">0)</ref>; and injection site rash <ref type="bibr" target="#b84">(2,</ref><ref type="bibr">0)</ref>.</p><p>For the overall primary analysis period, 205 (10 group and 185 (9 alendronate/alendronate group had adverse events respectively, had serious adverse events.</p><p>The potential hypersensitivity reactions reported in study 142 occurred using a drug product concentration of 70 mg/mL where patients required 3 injections of 1mL each to reach the 210 mg dose. The to-be-marketed formulation of romosozumab will be the 90 mg/mL concentration, where patients will need two injections of 1.17 mL each. Study 20120156 was a 6-month trial that compared bone density changes of the romosozumab 70 mg/mL formulation and the romosozumab 90 mg/mL formulation. Potential hypersensitivity reactions occurred in 3 romosozumab group and The potential for hypersensitivity reactions may be more pronounced with the higher concentration of romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse Events of Injection Site Reactions</head><p>During the 12-month double-blind period, adverse events of injection site reactions were reported for 90 (4 romosozumab group and 53 (3 alendronate group; none were considered serious. The most frequently reported injection site reactions ( of subjects in either treatment group) were injection site pain (romosozumab:</p><p>Injection site reactions reported in Study 142 occurred using a drug product concentration of 70 mg/mL where patients required 3 injections of 1 mL each to reach the 210 mg dose. In trial 20120156 comparing the 70 mg/mL and the 90 mg/mL formulations, injection site reactions jects in the 70 mg/mL romosozumab , the to-be-marketed formulation. The potential for injection site reactions may be more pronounced with the higher concentration of romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse Events of Malignant or Unspecified Tumors</head><p>The Wnt-beta-catenin pathway plays a role in both sclerostin signaling and some tumor suppressor signaling. Therefore, the applicant evaluated romosozumab's potential to cause malignant tumors using a narrow standardized MedDRA query (SMQ) for malignancies and unspecified tumors.</p><p>During the 12-month double-and 28 of malignancies NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 120 or unspecified tumors. The most frequently reported adverse event (preferred terms) in the romosozumab and alendronate groups, respectively, was basal cell . All subjects in either treatment group. Serious adverse events of 20 .</p><p>During the 24-month study period, 84 (4 alendronate group and 85 (4 he alendronate/alendronate group were reported to have adverse events of malignancies or unspecified tumors. The most frequently reported adverse events (preferred terms) in the romosozumab/alendronate and alendronate/alendronate groups, respectively, were subjects in either treatment group. Serious malignancy events were reported for 61 (3 ab/alendronate group and 59 (3 subjects in the alendronate/alendronate group over the 24-month study period.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inflammatory Conditions</head><p>Some literature suggests that sclerostin inhibition promotes tumor necrosis factor (TNF)mediated inflammatory joint disease. The applicant constructed a MedDRA search strategy to identify events related to TNF mediated inflammation.</p><p>During the 12-month double-blind treatment period, TNF-mediated inflammatory events were alendronate group. The most frequently reported event (preferred term) was rheumatoid arthritis (romosozumab:</p><p>TNF-mediated inflammatory events was similar between treatment groups for subjects with a prior history of these events (romosozumab:</p><p>For subjects with a prior history of rheumatoid arthritis, the incidence of TNF-mediated inflammatory events was also similar between treatment of these events had a preferred term of rheumatoid arthritis.</p><p>For the overall primary analysis period, TNF-mediated inflammatory events were reported for alendronate/alendronate group. The most frequently reported events (preferred terms) were ronate/alendronate: -14). The incidence of TNF-mediated inflammatory events for romosozumab/alendronate group group, and with no prior history. For subjects with a prior history of osteoarthritis, the incidence of TNFmediated inflammatory events was similar between treatment groups (romosozumab/alendronate alendronate/alendronate of these events had a preferred term of rheumatoid arthritis. Over the entire primary analysis period, serious hyperostosis events were reported for alendronate/alendronate group. In addition to the 2 serious adverse events that occurred during the 12-month double-blind treatment period described above, during the open-label treatment period, 1 subject in the romosozumab/alendronate group had spinal column stenosis (grade 2, assessed by the investigator as not related), for which the subject was hospitalized, treated with medication and received surgical intervention 16 months later. Also during the open-label treatment period, 1 subject in the alendronate/alendronate group had extraskeletal ossification (ossification of maxillary sinus; grade 3, assessed by the investigator as related) in the setting of the serious adverse event of sinusitis, for which the subject was hospitalized and treated with medication. All 4 serious adverse events resolved, and none resulted in discontinuation from investigational product or from the study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse Events of Osteoarthritis</head><p>Sclerostin is expressed in articular cartilage, which raised the concern that sclerostin inhibition may negatively affect articular cartilage.</p><p>During the 12-month double-blind period, 138 (7 group and in the alendronate group were reported to have adverse events of osteoarthritis. The most frequently reported adverse events (preferred terms) in the NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 122 romosozumab and alendronate groups, respectively, were osteoarthritis <ref type="bibr">(6 osteoarthritis (1.</ref> were reported for &lt; treatment group. Serious osteoarthritis events were reported for 8 he alendronate group.</p><p>During the primary analysis period, 247 (12 alendronate group and 268 (13 ndronate/alendronate group were reported to have adverse events of osteoarthritis. The most frequently reported adverse events (preferred terms) in the romosozumab/alendronate and alendronate/alendronate groups, respectively, were osteoarthritis <ref type="bibr">(10 , 3</ref> Serious primary analysis period. Based on review of the subject narratives for these serious osteoarthritis events, these events are unlikely to be related to romosozumab therapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjudicated Events of Atypical Femoral Fracture</head><p>Atypical femoral fracture is a rare adverse reaction associated with potent anti-resorptive medications. The Applicant defined atypical femoral fracture as an event of interest and all potential events of femoral fracture identified through a predefined search of MedDRA terms were submitted to an independent external adjudication committee for review and adjudication. No positively adjudicated adverse events of AFF were reported during the 12month double-blind period.</p><p>Positively adjudicated atypical femoral fracture cases were identified during the open-label alendronate treatment period for a total of 3 subjects in the romosozumab/alendronate group and 4 subjects in the alendronate/alendronate group during the primary analysis period. All were considered serious adverse events.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjudicated Events of Osteonecrosis of the Jaw</head><p>Osteonecrosis of the jaw (ONJ) is a rare adverse reaction associated with potent anti-resorptive medications. The applicant defined ONJ as an event of interest and all potential events of ONJ identified through a predefined search of MedDRA terms were submitted to an independent external adjudication committee for review and adjudication. No positively adjudicated adverse events of ONJ occurred during the 12-month double-blind treatment period.</p><p>During the open-label alendronate treatment period, 1 adjudicated event of ONJ occurred in each treatment group, for a total of 2 adjudicated events of ONJ in the 24-month study period.</p><p>In summary, as was observed in Study 337, injection site reactions in Study 142 occurred at a higher incidence in the romosozumab group than in the control group. All other adverse events of interest occurred at a similar incidence in the romosozumab and control groups in each study. The conclusions regarding the adverse events of interest have not changed since the NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 123 original BLA. Review of adverse events in these prespecified categories of interest did not reveal any clinically relevant findings in the two studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment Emergent Adverse Events and Adverse Reactions</head><p>Treatment-emergent adverse events (TEAEs) occurred at a similar incidence in both treatment summarized in <ref type="table" target="#tab_5">Table 33</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>12-Month Double-blind period</head><p>During the 12-month double-blind period, TEAEs occurred at a similar incidence in subjects who received romosozumab (76 s who received alendronate (79 The system organ classes with the highest subject incidences of adverse events in both treatment groups were Infections and usculoskeletal and Conn</p><p>The most frequently reported TEAEs during the 12-month double-blind period in the romosozumab or alendronate groups, respectively, No TEAEs the romosozumab group than in the alendronate group.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary Analysis Period</head><p>During the primary analysis period, the percentages of subjects reporting TEAEs were similar between the romosozumab/alendronate group <ref type="formula" target="#formula_34">(</ref>  Based on the integrated data for TEAEs from Study 142 and Study 337, the following are in at least one study) adverse reactions to romosozumab: arthralgia, headache and muscle spasms. All of these events occurred more commonly in romosozumab-treated subjects compared to placebo-treated subjects.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Laboratory Findings</head><p>Assessment of serum chemistry and hematology laboratories was performed at baseline, Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24, and then every 6 months through the end of the study (for those subjects who participated beyond 24 months).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Evaluation of abnormal serum laboratory values was conducted using Common Terminology</head><p>Criteria for Adverse Events version 3 (CTCAE v3.0) grading.</p><p>During the 12-month double-blind period, the subject incidence of laboratory test results CTCAE romosozumab group and 470 (23 the alendronate group. Four subjects in the romosozumab group had CTCAE grade 4 laboratory results, including 2 subjects with below-normal sodium (&lt;120 mmol/L); 1 subject with belownormal bicarbonate (&lt;8 mmol/L); 2 subjects with below-normal hemoglobin (&lt; 6.5 g/dL); and 1 subject with below-normal platelet count (&lt; 25,000/mm 3 ). In the alendronate group, subjects with CTCAE grade 4 laboratory results included 1 subject with above-normal glucose (&gt; 500 mg/dL) and 1 subject with below-normal neutrophil count (&lt; 500/mm 3 ).</p><p>Over the primary analysis period, the subject incidence of laboratory test results with CTCAE /alendronate group and 636 (32 subjects in the alendronate/alendronate group. Six subjects in the romosozumab/alendronate group had CTCAE grade 4 laboratory results including 3 subjects with below-normal sodium; 1 subject with below-normal potassium (&lt; 2.5 mmol/L); 1 subject with below-normal bicarbonate; 1 subject with above-normal glucose; 2 subjects with below-normal hemoglobin; 2 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 126 subjects with below-normal platelet count, and 4 subjects with below-normal neutrophil count. In the alendronate/alendronate group, subjects with CTCAE grade 4 laboratory results included 2 subjects with below-normal sodium; 1 subject with above-normal glucose; 3 subjects with below-normal platelet count, and 1 subject with below-normal neutrophil count.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serum Calcium</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Changes From Baseline in Serum Calcium</head><p>Mild and transitory decreases in serum albumin-corrected calcium were observed in both the romosozumab and alendronate treatment groups. At baseline, the mean albumin-corrected serum calcium levels for the romosozumab and alendronate groups, respectively, were 9.8 mg/dL (2.44 mmol/L) and 9.8 mg/dL (2.44 mmol/L). Based on earlier studies, the nadir in serum calcium appears to occur between 2 weeks and 1 month following romosozumab injection. However, in Studies 337 and 142 serum calcium was not assessed prior to Month 1. Therefore, it is possible that the nadir may have occurred prior to Month 1. At Month 1, the median percent change from baseline was -3 received romosozumab and -2 subjects who received alendronate. Serum calcium levels trended towards baseline over time, such that at month 12, the median percent change from baseline was -1 remained stable for the remainder of the primary analysis period.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Low Serum Calcium</head><p>The table below lists the CTCAE grades associated with abnormal albumin-corrected serum calcium values . </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>High Serum Calcium</head><p>During the 12-month double-blind period, no subject in either group had an above-normal corrected calcium result of CTCAE grade 4 (&gt; 13.5 mg/dL) romoso corrected serum calcium from normal at baseline to CTCAE grade 2 (&gt; 11.5 -12.5 mg/dL) and 1 subject in the romosozumab group had an increase in corrected serum calcium from normal at baseline to CTCAE grade 3 (&gt; 12.5 -13.5 mg/dL).</p><p>Over the primary analysis period, no subject in either group had an above-normal corrected calcium result of grade 4 n the romosozumab/alendronate group and 4 in the alendronate/alendronate group had an increase in corrected serum calcium from normal at baseline to grade 2 romosozumab/alendronate group had an increase from normal at baseline to grade 3.</p><p>Calcium increases are not expected given the mechanism of action of romosozumab or alendronate. The increase in calcium is likely to be due to the required calcium and vitamin D supplementation. A patient's potential underlying pathophysiology of calcium metabolism, such as hyperparathyroidism could also be unmasked due to treatment with calcium and vitamin D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serum Phosphorus</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Changes from Baseline in Serum Phosphorus</head><p>Mild decreases in serum phosphorus in both treatment groups were also observed in both the romosozumab and alendronate treatment groups. At baseline, the mean serum phosphorus levels for the romosozumab and alendronate groups was 3.7 mg/dL. There was a decrease in serum phosphorus levels at month 1; the median percent change from baseline was -5 subjects who received romosozumab and -5 Phosphorus levels remained below baseline for the remainder of the study. At month 12, the median percent change from baseline was -5 r the romosozumab group and -5 alendronate group, and at month 24 was -6 dronate group andfor the alendronate/alendronate group.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Low Serum Phosphorus</head><p>The following table lists the CTCAE grades associated with abnormal low phosphorus values.  <ref type="formula">3</ref> 1.0 mg/dL -&lt; 2.0 mg/dL Grade 4 &lt; 1.0 mg/dL * LLN = lower limit of normal; ULN = upper limit of normal During the 12-month double-and 5 below-normal phosphorus result of CTCAE grade 3 (&lt; 2.0 -1.0 mg/dL); no CTCAE grade 4 (&lt; 1.0 mg/dL) subjects in the a decrease in phosphorus from normal at baseline to CTCAE grade 2 (&lt; 2.5 -2.0 mg/dL) and 5 respectively, had decreases to grade 3 from normal at baseline. romosozumab/alendronate group alendronate/alendronate group had a grade 3 below-normal romosozumab/alendronate group and had a decrease from normal at baseline to grade 2 respectively, had decreases to grade 3 from normal at baseline.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serum Alkaline Phosphatase</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Changes from Baseline in Alkaline Phosphatase</head><p>At baseline, the mean ALP levels for the romosozumab and alendronate groups, respectively, were 85 U/L and 84 U/L. There was an increase in alkaline phosphatase levels at month 1 in the romosozumab group corresponding with an increase in the bone formation marker BSAP; the median percent change from baseline was 22 ho received romosozumab and -3 subjects who received alendronate. By month 12 (1 month after the last dose of romosozumab), median alkaline phosphatase levels were below baseline for the romosozumab group and below baseline for the alendronate group. At month 24, median percent changes from baseline were -21 in the romosozumab/alendronate group and -21 the alendronate/alendronate group.</p><p>During the 12-month double-blind period, no subject in either treatment group had an abovenormal alkaline phosphatase (ALP) result of CTCAE grade 3 (&gt;5 -20x ULN) or grade 4 (&gt; 20 x ULN) alendronate group had increases in ALP from normal at baseline to CTCAE grade 2 (&gt; 2.5 -5 x ULN)).</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 129 and no subjects in the alendronate/alendronate group had a grade 3 above-normal ALP result; no grade 4 results were reported. Six romosozumab/alendronate group alendronate/alendronate group had increases in ALP from normal at baseline to grade 2 . One subject in the romosozumab/alendronate group had an increase in ALP from normal at baseline to grade 3. In summary, the observed trends in calcium, phosphorus and alkaline phosphatase were as expected and consistent with the previously established safety profile of romosozumab (in the original BLA) and with the known safety profile of alendronate.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Potential Hy's Law Cases</head><p>Potential drug-induced liver injury was assessed by evaluating subjects' alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, and ALP test results to identify cases that may have met Hy's Law laboratory criteria. No subject met the Hy's Law criterion of ALT or AST &gt; 3 x the ULN and total bilirubin &gt; 2 x ULN and ALP &lt; 2 x ULN at baseline or at any time during the primary analysis period.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other Laboratory Parameters</head><p>No apparent trends were noted in other serum chemistry or in hematology parameters. There were no clinically meaningful changes from baseline in potassium, bicarbonate, blood urea nitrogen, creatinine, total bilirubin, albumin, total protein, red blood cell count, hemoglobin, reticulocyte count, platelet count, white blood cell count, neutrophil count, eosinophil count, basophil count, lymphocyte count, or monocyte count in either treatment group.</p><p>Laboratory data for Study 142 were consistent with the laboratory profile previously reported in the original BLA for the phase 2 and 3 romosozumab studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Vital Signs</head><p>No notable differences between treatment groups were observed for blood pressure, pulse, body temperature, body weight, BMI, or height.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Electrocardiograms (ECGs)</head><p>ECGs were not assessed in Study 142.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>QT Interval</head><p>Since romosozumab is a monoclonal antibody and therefore a large protein product, it is unlikely to interact with cardiac cell ion channels. As described in the review of the original BLA submission, no patterns of QT abnormalities (or any other ECG abnormalities) were identified on ECGs in phase 1 and 2 romosozumab studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunogenicity (Antiromosozumab Antibodies)</head><p>Since romosozumab is a large humanized monoclonal antibody that could trigger an immune response, the applicant developed and validated two assays to detect the presence of antiromosozumab antibodies in human serum: an electrochemiluminescence (ECL)-based bridging immunoassay to detect binding antibodies to romosozumab and an ECL-based competitive binding assay to determine the neutralizing potential of anti-drug antibodies (ADA). The applicant used signal to noise values to evaluate the magnitude of the antibody response.</p><p>The antibody status through Month 18 was selected for evaluation of efficacy and safety by antibody status, as the 6-month follow-up period after completion of the 12-month romosozumab treatment phase allowed for washout of romosozumab from serum and enabled the most accurate neutralizing antibody detection. Subjects who received placebo or alendronate were not tested for antiromosozumab antibodies.</p><p>-existing binding antibodies at baseline; none had pre-existing neutralizing antibodies. For subjects with postbaseline results during the 12-month double blind treatment period and through Month 18 (n = 1955), 310 (15 .</p><p>The incidence of the development of antiromosozumab binding antibodies was similar for the Month 18, as was the incidence of the development of The antiromosozumab antibodies did not affect the safety of romosozumab. The subject incidence of overall adverse events, adverse events of autoimmune disorders, adverse events potentially related to hypersensitivity and adverse events of injection site reactions during the 12-month double-blind period and overall study period was similar for subjects who had or did not have antiromosozumab antibody development through Month 18. These results for the 12month double-blind period are summarized in the table below. Note that there are too few subjects with neutralizing antibodies to determine the impact of neutralizing antibodies on safety. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Cardiovascular Safety</head><p>This section discusses the concern regarding romosozumab's cardiovascular safety, a concern that was initially raised by the safety findings in Study 142. As mentioned in the previous section, the subject incidence rate of adjudicated positive cardiovascular serious adverse events (CV SAEs) in Study 142 alendronate group (38 subjects) during the 12-month double-blind period of the study. This alendronate group. An imbalance in DCRI positively-adjudicated CV SAEs was also observed in the small BMD study in men with osteoporosis (Study 174), with a higher incidence in romosozumab-treated subjects vs. placebo, with the imbalance also driven by events of myocardial infarction and stroke, although these event rates were very low limiting conclusions. An imbalance in positively-adjudicated CV SAEs was not observed between romosozumab and NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 132 placebo in the placebo-controlled study in postmenopausal women with osteoporosis (Study 337).</p><p>Given the differences in cardiovascular safety results between the trials, it is unclear if the cardiovascular safety signal reflects a true increase in cardiovascular risk with romosozumab therapy. The three key studies were not specifically designed to assess cardiovascular safety outcomes. While there was a prespecified adjudication process for all serious cardiovascular adverse events, neither study assessed key measures associated with cardiovascular risk, such as fasting serum lipids, C-reactive protein levels and electrocardiograms. Therefore, it was not possible to assign a well-validated complete cardiovascular risk score (e.g., Framingham risk score) to study subjects, which would have enabled a more reliable characterization and interpretation of the pattern of events. Additionally, since cardiovascular events were not an expected outcome or a clear adverse event of interest, data regarding these events may not have been collected as rigorously as was necessary during the conduct of the studies to accurately capture all events. Rather, much of the analysis of cardiovascular safety data was done post-hoc after the imbalance in events in Study 142 was identified. Therefore, the reliability of the cardiovascular safety data may be limited. Another limitation of the studies is the uncertainty regarding the applicability of the cardiovascular findings to the US population and US medical practice. S study population of Study 337 was from the US, there is concern regarding the generalizability of the cardiovascular safety findings to the US population. Another limitation in the ability to interpret the observed imbalance in myocardial infarction and stroke events and assess romosozumab's cardiovascular risk derives from the overall low number of events of myocardial infarction and stroke observed in the studies. While the pivotal fracture studies were powered to assess fracture outcomes, they were not adequately powered to assess cardiovascular outcomes. Finally, the rate of study treatment group during the 12-month doublethe overall primary analysis period) raises additional uncertainty, as there may have been additional uncaptured cardiovascular events. Compared to Study 142, Study 337 had a similar discontinuation rate for the 12-month double-ach treatment group), and a lower rate for the overall 24-To further explore the cardiovascular safety signal and the divergent results in the subject incidence of myocardial infarction and stroke in the first year among the pivotal studies, the applicant performed a comprehensive evaluation of cardiovascular safety that included a second adjudication of the adverse events reported in the pivotal phase 3 studies (337, 142 and 174). Cardiovascular adverse events were evaluated with the following 3 methods:</p><p>1. Prespecified adjudication of potential CV SAEs in Studies 337, 142, and 174 by DCRI. This adjudication was added to the study protocols before the studies were initiated. This adjudication included all deaths, serious adverse events meeting prespecified "trigger" preferred terms, and additional serious adverse events identified by DCRI during review of triggered events. Investigators also had the option to flag potential CV SAEs for and 174 by the Thrombolysis in Myocardial Infarction (TIMI) Study Group to identify potential cardiovascular adverse events (full TIMI adjudication). Also performed was a readjudication by TIMI of all deaths and other serious adverse events previously adjudicated by DCRI, blinded to treatment and initial DCRI adjudication result. The triggering events and the requisite supporting documentation were the same as for the DRCI adjudication. 3. Analyses based on treatment-emergent adverse event reporting (to assure that the level of cardiovascular risk was not underestimated by the adjudication process). For adverse events reported on the eCRF that coded to standardized categories pertaining to cardiovascular and cerebrovascular events (i.e., treatment-emergent adverse event reporting), the subject incidence of adverse events was summarized using cardiovascular-related system organ class (SOC) and high level group term (HLGT) categories. As a more focused approach, narrow scope standardized MedDRA query (SMQ) and Amgen MedDRA query (AMQ) search strategies were used to summarize relevant event categories (e.g., myocardial infarction and stroke).</p><p>The applicant also performed additional nonclinical studies to evaluate biological plausibility that romosozumab might influence the rate of cardiovascular events.</p><p>The following sections provide an integrated summary of findings from the 3 pivotal studies that are relevant to the assessment of cardiovascular safety. These results are based on the final analyses of Studies 142, 337, and 174, which were the analyses presented in the Comprehensive Cardiovascular Report (CCR).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Baseline Characteristics</head><p>Although enrollment criteria allowed for populations of the same age in all 3 studies (55 to 90 years), the mean age of subjects in Study 142 was 3.5 years older than subjects in Study 337 and 2 years older than subjects in Study 174. Mean age was balanced between treatment groups within each study.</p><p>With respect to cardiovascular risk factors (e.g., diabetes, hypercholesterolemia, and hypertension), which are not necessarily indicative of a history of cardiovascular disease, the prevalences of hypercholesterolemia and diabetes were evenly distributed across studies and treatment groups. In line with the older mean age, the prevalence of hypertension was somewhat higher in 142 compared with the other 2 studies but was balanced between treatment groups. The prevalences of medical history specific to atherosclerotic cardiovascular disease (identified using MedDRA search strategies) were comparable between treatment groups in each of the pivotal phase 3 studies. In Studies 337 and 142, the use of cardiovascularrelated baseline medications (i.e., started on or before study day 1 and continued during the NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 134 study) was similar between treatment groups within each study as well as among subjects with cardiovascular-related medical history.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cardiovascular Serious Adverse Events (Adjudication by DCRI)</head><p>CV SAEs were initially adjudicated by DCRI in Studies 337, 142, and 174. The CV SAEs were summarized according to event classifications in the DCRI charters as follows: death, cardiac ischemic events (myocardial infarction, angina requiring hospitalization, coronary revascularization), cerebrovascular events (stroke, TIA ), noncoronary revascularization, hospitalization for heart failure, and peripheral vascular event not requiring revascularization. Positively-adjudicated cardiovascular death included cardiovascular death and death of undetermined cause. The CV SAEs were summarized for the 12-month doubleblind period and the overall study period for each study. In addition, a meta-analysis of the 3 pivotal, phase 3 studies was performed.</p><p>As discussed above, in Study 142 a higher subject incidence of CV SAEs was observed in the romosozumab group compared with the alendronate group during the double-blind treatment period, specifically for events of serious myocardial infarction and stroke <ref type="table" target="#tab_5">(Table 35</ref>). An imbalance in the subject incidence of positively adjudicated CV SAEs was also observed in Study 174 but event rates were very low, limiting conclusions. There was no imbalance observed in Study 337 during the double-blind treatment period.  For the meta-analysis of all 3 studies, the subject incidence of positively-adjudicated CV SAEs during the 12-month double-blind treatment period was slightly higher in the romosozumab group compared to  Although the prespecified endpoint for the DCRI adjudication was the subject incidence of positively-adjudicated CV SAEs, it is important to understand the risk in terms of the impact on the Major Adverse Cardiac Event (MACE) composite endpoint (comprised of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke), an endpoint that is commonly used to evaluate cardiovascular benefit or harm.</p><p>A post-hoc analysis of MACE was performed for the double-blind period and the overall study period for Studies 337, 142, and 174 individually. Additionally, a meta-analysis of integrated data from the 3 studies was performed for both time periods. This analysis showed an imbalance in the subject incidence of MACE in Study 142 and Study 174 during the double-blind period that was not present in Study 337.</p><p>Results for the MACE composite endpoint in the meta-analysis of the 3 studies are discussed below and listed in <ref type="table" target="#tab_6">Table 40</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overall Study Period</head><p>Study 142 showed no imbalance between treatment groups in the incidence of MACE in the alendronate/ alendronate; hazard ratio 1.15 <ref type="bibr">8, 1.50)</ref>.</p><p>Study 337 showed no imbalance between treatment groups in the incidence of MACE in the 0.83, 1.49).</p><p>For the meta-analysis of all 3 studies, the incidence of MACE in the overall study period was -on therapy (denosumab or alendronate) group vs. the control (placebo or alendronate)/follow-on therapy (denosumab or alendronate) group; hazard ratio Examination of the time to first MACE during the follow-on therapy period from month 12 onward in Studies 337 and 142 showed no apparent separation between treatment groups, suggesting that the imbalance in rates of cardiovascular events in Study 142 that occurred during the first 12 months of exposure was not sustained during long-term follow up after drug exposure. However, a definitive conclusion regarding persistent risk following cessation of NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 141 therapy cannot be made since the number of subjects at risk varied as the study progressed beyond Month 12 (due to the variability in follow-up duration for this event-driven trial).</p><p>Regarding the annual incidence rates of MACE in Study 142, the alendronate group had a low rate of cardiovascular events in the first year, with an increase in the rate of these events in subsequent years. The annual rates of events in subjects on open-label alendronate in years 2 and 3 were similar regardless of initial treatment group, and higher than what was observed in subjects on alendronate in year 1. During years 2 and 3 (i.e., during the open-label alendronate period), the annual incidences of MACE, regardless of treatment in the first year, ranged between the alendronate group in the first year was ( <ref type="figure" target="#fig_6">Figure 6</ref>). Of note, the annual incidence of MACE in the romosozumab group during the first year of the study was between the incidences observed for alendronate during years 2 and 3 in both study arms.</p><p>The reason for this pattern of MACE incidence rates by year is unclear. It may reflect chance findings, a higher risk with romosozumab or that alendronate may have had a short-term protective effect for cardiovascular outcomes. The FDA's exploratory network meta-analysis estimating the hazard ratio of alendronate vs. placebo was consistent with the possibility of the latter. The plausibility of such an effect is addressed below (under "Nonclinical and Human Genetic Data, Possible Explanations of Observed Imbalance, Epidemiology Reviews"). However, ultimately it is not possible to know the reason for these findings and we are left with the uncertainty that romosozumab may increase cardiovascular risk. Subgroup analyses in the individual studies and based on a meta-analysis of all 3 studies did not identify a population at consistently increased relative risk of a MACE with administration of romosozumab, including no difference in relative risk among subjects with and without a history of prior cardiovascular disease before randomization. Specific demographic characteristics, including age, geographic region, smoking history and history of risk factors for cardiovascular disease, such as hypercholesterolemia, hypertension, and diabetes, were evaluated to determine if one or more specific subgroups of study subjects were at increased risk for developing an on-study MACE.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 143 Point estimates for hazard ratios for subgroups based on geographic region were consistent with the hazard ratios of the overall population.</p><p>As expected, there was a consistently higher absolute risk of MACE for subjects with a history of cardiovascular risk factors in both Study 142 and Study 337. However, for subgroups of subjects with cardiovascular risk factors, including history of ischemic heart disease and cerebrovascular disorders as well as history of a cardiovascular or cerebrovascular event, the point estimates of the hazard ratios (romosozumab vs. alendronate) for the MACE composite endpoint through Month 12 within each of the subgroups were consistent with the hazard ratio of the overall population within each study, independent of whether the subgroup represented a higher or lower risk population.</p><p>Subgroup analysis was also performed by total cardiovascular risk score using a modified Raloxifene Use for the Heart (RUTH) criteria. Modified RUTH criteria are listed in <ref type="table" target="#tab_5">Table 38</ref>. Modified RUTH scores ranged from 0 (indicating no cardiovascular risk) to 13 (indicating the highest cardiovascular risk). As expected, the absolute risk of MACE increased with increasing modified RUTH score. However, hazard ratios during the double-blind treatment period indicated that the relative risk of MACE was consistent over a range of modified RUTH scores NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 144 ( <ref type="figure" target="#fig_7">Figure 7)</ref>, and that there was no pattern of increasing hazard ratio with increasing modified RUTH score.  <ref type="figure" target="#fig_0">Figure 15</ref> of CCR Additionally, in response to an information request during the review cycle, the applicant performed another post-hoc evaluation of cardiovascular risk via a modified Framingham Risk Score (FRS). The FRS required modification because the age of the enrolled romosozumab pivotal study population was higher (maximum age enrolled = 90 years) than the age range in which the FRS was validated, and fasting lipid levels were not collected in the pivotal studies of romosozumab. Assumptions for total cholesterol and HDL cholesterol, and extrapolation of the score for age were based on average values for age categories in the National Health and Nutrition Examination Survey (NHANES) database for years 2007-2010. These data were supplemented with medical history and baseline medication data collected in the studies. If subjects reported events in their medical history indicative of hypercholesterolemia based on the narrow search of the hyperlipidemia SMQ or were taking a statin at baseline they were given the score for the higher category.</p><p>Analyses based on modified FRS scores were performed for the <ref type="bibr">12-month</ref>  Study 337 population. As expected, the subject incidence of MACE was higher in patients with higher modified FRS in both treatment groups in Studies 337, 142, and 174. However, there was no consistent modified FRS subgroup that demonstrated a higher relative risk for MACE on romosozumab. As with the modified RUTH score, there was no pattern of increasing hazard ratio with increasing modified FRS. The hazard ratio was actually lower for the modified FRS subgroup with highest risk (&gt; 2 risk) in Study 337 and 142.</p><p>The consistent hazard ratios for MACE across all geographic regions suggests that the findings are widely applicable throughout the world, and somewhat allays the concern that the cardiovascular safety findings may not be applicable to the US population (which had a very small representation in the studies as discussed previously).</p><p>Regarding the method for assigning cardiovascular risk, the applicant's use of the modified RUTH score was limited. It was not possible to estimate risk via the more widely utilized FRS, TIMI Risk Score, the Reynolds Score, or the ACC/AHA ASCVD Risk Estimator, as these require fasting lipid values, C-reactive protein (CRP) values and/or electrocardiograms, which were not performed in Studies 337 or 142. The modified RUTH score, although previously used in osteoporosis and breast cancer clinical trials to estimate cardiovascular risk, is not a widely utilized assessment of cardiovascular risk. Since the applicant imputed the hypercholesterolemia category as described above (rather than using actual measurement of serum lipid levels at baseline) to determine both the modified RUTH score and FRS scores, cardiovascular risk assessments with these scores may not be adequately predictive. However, the consistency of results for cardiovascular risk assessment and subgroup analysis using either the modified FRS or the modified RUTH score indicates that these scores likely still have some predictive value.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sensitivity Analysis -TIMI Study Group</head><p>Results for adjudication by the TIMI Study Group were consistent with the results of the adjudication by DCRI. An increase was observed in the subcategory of positively-adjudicated TIAs (n = 11 across studies in the double-blind period for the TIMI Study Group vs. n = 6 for DCRI), but the overall number of subjects with positively-adjudicated cerebrovascular events in the first year was the same for the TIMI Study Group and DCRI (n = 48).</p><p>As listed below, from the meta-analysis of the three trials, the subject incidence of MACE and associated hazard ratios for romosozumab in the 12-month double-blind period was consistent between the modes of adjudication.</p><p>. 0. CI 0.99-1.99) TIMI Readjudication (TIMI adjudication of events previously adjudicated by DCRI):</p><p>. 0 CI 1.02-2.13) . CI 1.00-2.08) The hazard ratio results for all modes of adjudication were driven by events of myocardial infarction and stroke.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serious Adverse Events Considered Negatively Adjudicated Due to Insufficient Source Documentation</head><p>Except for cases of death, serious adverse events that lacked sufficient source documentation for definitive adjudication were considered negatively adjudicated by DCRI. At the applicant's request, DCRI retrospectively identified these events and the supporting documentation that was not available. Overall, adjudicated serious adverse events in Study 142, and no events in Study 174 were negatively adjudicated due to insufficient documentation. A sensitivity analysis was performed in which subjects with events that were negatively adjudicated due to insufficient documentation were considered positively adjudicated in the analyses. The number of subjects with CV SAEs that were negatively-adjudicated for insufficient documentation was generally balanced between treatment groups within each study through Month 12 and the overall study period. Therefore, considering these subjects as having positively-adjudicated CV SAEs in the analysis had no overall impact on hazard ratios <ref type="table" target="#tab_5">(Table 39</ref>).  <ref type="table" target="#tab_6">Table 40</ref> shows the outcomes of treatment-emergent adverse event reporting side-by-side with the adjudication results for DCRI and the TIMI Study Group. This comparison includes an endpoint of all-cause death because potential cardiovascular etiology could not be determined for fatal treatment-emergent adverse events without making assumptions relating to SMQs and AMQs that could bias the results. Myocardial infarction and stroke were identified by narrow search SMQ and AMQ, respectively, for treatment-emergent adverse event reporting, and by positively-adjudicated events for DCRI (based on serious adverse events) and the TIMI Study Group (based on all adverse events). The subject incidences of treatment-emergent adverse events of myocardial infarction and stroke were generally comparable to those of the adjudications. This provides assurance regarding the comprehensiveness of the adjudication process. committees (DCRI and TIMI). Interpretation and conclusions from Studies 337 and 174 remained unchanged following the TIMI adjudication process. In addition, incidences of CV SAEs were consistent between analyses based on treatment-emergent adverse event reporting and the adjudicated cardiovascular adverse events, providing further assurance regarding comprehensiveness and reliability of the adjudication process.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DCRP Consultation</head><p>The Division of Bone, Reproductive and Urologic Products consulted the Division of Cardiovascular and Renal Products (DCRP) to request their assistance in reviewing the cardiovascular safety signal from the meta-analysis of the 3 pivotal studies, as well the adjudication process from the DRCI and the readjudication from the TIMI group. DCRP determined that both the DRCI and TIMI adjudication processes were adequate, and the required documentation was sufficient to render an adequate adjudication. DCRP also confirmed that the DCRI and TIMI adjudications yielded similar results. DCRP concluded that the overall hazard ratio for cardiovascular events from the meta-analysis was low but with an overall marginally significant hazard ratio for romosozumab vs. comparator. Refer to their written consult for further details regarding their analysis of the applicant's comprehensive cardiovascular safety assessment.</p><p>Nonclinical and Human Genetic Data, Possible Explanations of Observed Imbalance, Epidemiology Reviews</p><p>As discussed in the nonclinical section of this memorandum, the nonclinical data suggest that there is limited biological plausibility for a causal link between sclerostin inhibition and cardiovascular risk. Sclerostin is expressed in the aorta and in vascular and valvular calcification. However, its function in these sites is not known. Expression of sclerostin in vascular smooth muscle cells in foci of vascular mineralization in animals would be unlikely to explain the early imbalance in positively-adjudicated CV SAEs observed in Study 142. The timing of the observed events, with early separation between the alendronate and romosozumab arms within the first 3 months of treatment, is not consistent with a process involving vascular calcification. In addition, sclerostin inhibition did not appear to result in the initiation of vascular calcification or exacerbation of pre-existing medial calcification associated with aging or chronic kidney disease in animals, as shown by chronic toxicology evaluation in monkeys, a species that constitutively expresses sclerostin in the aorta, and in a lifetime study in rats, a species in which sclerostin is expressed in mineralizing foci.</p><p>In response to the cardiovascular safety findings observed in Study 142, the applicant performed additional nonclinical studies to explore plausible mechanisms that could account for an increased cardiovascular risk with romosozumab, including an in vitro human platelet activation study, an in vitro vasoconstriction study, a study that assessed sclerostin expression in atherosclerotic plaques, a study in the ApoE -/-mouse model of atherogenesis and a genome NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 149 wide association study. For further details and discussion regarding these studies, refer to Section 5 of this review.</p><p>In patients with sclerosteosis or van Buchem disease, in whom sclerostin expression is absent or reduced due to a genetic mutation, there is no evidence of early onset vascular calcification or increased cardiovascular risk in the literature or through written communications with a scientific expert on the disease <ref type="bibr">(Beighton, 2011c;</ref><ref type="bibr">Beighton, 2011d)</ref>. The applicant included these communications in the BLA submission. Of note, these data are limited given the rarity of the disease and would not necessarily be able to detect a modest increase in cardiovascular risk if present.</p><p>Overall, the available nonclinical data do not definitively identify a mechanism to support biological plausibility for a causal relationship of romosozumab treatment with myocardial infarction or stroke. However, the finding of an increased incidence of necrotic aortic plaques in ApoE-/-mice (in Study 124609 as described in the nonclinical section of this memorandum) may be relevant, as recently available clinical data demonstrate that necrotic coronary plaques are at high risk of rupture, potentially leading to myocardial infarction <ref type="bibr" target="#b24">(Williams et al., 2019)</ref>. Relevant nonclinical data, however, are still limited, and the role of sclerostin in the cardiovascular system is currently not well understood.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alendronate Cardioprotection</head><p>One possible explanation for the imbalance of serious cardiovascular events in Study 142 (other than a true increased risk with romosozumab) is that alendronate may have had an early cardioprotective effect on subjects in the alendronate treatment group. The FDA's exploratory network meta-analysis indirectly estimating the hazard ratio of MACE for alendronate vs. placebo (discussed above) was consistent with this as a possibility. There is also biologic plausibility to this theory, as bisphosphonates and statins (drugs used to treat hyperlipidemia and reduce the risk of ischemic cardiovascular events) both inhibit the mevalonate pathway (however, bisphosphonates have high specificity to bone and osteoclasts). To date, studies evaluating this theory of a cardioprotective effect of alendronate (and other bisphosphonates) have yielded mixed results. The alendronate controlled clinical fracture trials did not demonstrate a cardioprotective benefit.</p><p>A recent retrospective cohort study using a population-wide database managed by the Hong Kong Hospital Authority investigated the risk of cardiovascular events with and without alendronate in hip fracture patients <ref type="bibr" target="#b20">(Sing CW et al., 2018)</ref>. A total of 4594 patients treated with osteoporosis therapy were matched with 13,568 nontreated patients. Alendronate was associated with a significantly lower risk of 1-year cardiovascular mortality (hazard ratio 0.33; cident myocardial infarction (hazard ratio 0.89), and a marginally significant reduction in risk of stroke at 5 years and 10 years (hazard ratio consistent in multiple sensitivity analyses. In contrast, a meta-analysis <ref type="bibr" target="#b14">(Kim DH et al., 2015)</ref> that estimated the risks of cardiovascular events (including total cardiovascular events, atrial fibrillation, myocardial infarction, stroke and cardiovascular death) in 58 randomized controlled trials of bisphosphonates in adults with low bone mass found that bisphosphonates do not appear to have beneficial or harmful effects on atherosclerotic cardiovascular events. Another meta-analysis <ref type="bibr">(Kranenberg G et al., 2016)</ref> reviewed 61 randomized controlled studies that reported the effects of bisphosphonates on arterial wall disease, cardiovascular events, cardiovascular mortality or all-cause mortality. There was no restriction for the type of population used in the studies. This meta-analysis found that bisphosphonates have no effect on arterial stiffness (based on 2 trials) or on cardiovascular events (based on 20 trials), but they did reduce arterial wall calcification (based on 2 trials), reduce the risk of cardiovascular mortality (based on 10 trials) and reduce all-cause mortality (based on 48 trials) in various patient groups, including osteoporosis and cancer patients.</p><p>Although a cardioprotective effect of alendronate is a possibility, we cannot assume that the observed imbalance in cardiovascular events was due to this, as such a protective effect of bisphosphonates has not been established, and the available relevant data are not conclusive.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background Rates of Myocardial infarction and Stroke</head><p>Another possible explanation for the imbalance observed in the two treatment arms is that the rates of observed events in each treatment group of Study 142 are within the expected variation range for cardiovascular events in the study population. To explore this possibility, the applicant conducted a targeted PubMed search for background rates of serious cardiovascular outcomes reported in population-based epidemiology studies of women and men aged 55-90 years. The applicant reviewed 10 population-based epidemiology studies (5 in osteoporosis patient populations, 5 in non-osteoporosis populations). The studies identified a background incidence rate estimate for myocardial infarction as 2-10 per 1,000 person-years (PYs) in the general population and 3-13 PYs in osteoporosis population, and for stroke 1-47 and 16-38 per 1,000 PYs, respectively. For comparison, in the 3 pivotal studies, the incidence rate of positively adjudicated myocardial infarction ranged from 3 to 8 per 1,000 PYs and the incidence rate of positively-adjudicated stroke ranged from 2 to 19 per 1,000 PYs in the romosozumab arm. In the alendronate arm, the corresponding rates were 3 and 4 per 1,000 PYs, respectively. In contrast, the incidence rates in the placebo group ranged from 0-2 and 3-13 per 1,000 PYs for MI and stroke, respectively.</p><p>Based on these findings, the applicant believes that the incidence rates of positively adjudicated myocardial infarction and stroke reported among subjects in the three phase 3 studies, including subjects receiving romosozumab, are within the ranges reported in population-based studies for similarly aged cohorts of women. Based on their literature review, DEPI concluded that 1) the background incidence rates of stroke and myocardial infarction vary substantially in the published literature. These substantially varied incidence rate estimates may be due to: 1) lack of validation for the case ascertainment algorithms used to identify CV SAE outcomes in administrative claims-based databases; 2) the selection of a high-risk study population (patients with a prior diagnosis of osteoporotic fracture) to derive the expected background rates; or 3) other confounding factors such as race, geographic locations, and baseline CV risk profiles which were inconsistent with the trial population. This heterogeneity may explain the wide range of the background rate estimates.</p><p>Despite the wider range of estimates derived from their literature search, DEPI, like the applicant, concluded that the incidence rates of myocardial infarction and stroke reported in the different treatment groups in Study 337 and Study 142 all fall within the expected background incidence rates in similarly aged osteoporosis populations. For full details regarding DEPI's literature search, results and analysis, refer to the consult entered in .</p><p>Given that the range of incidence rates of myocardial infarction and stroke reported in the literature is very wide, it is not surprising that the rates observed in the pivotal romosozumab studies fall within this range. Therefore, although it is somewhat reassuring that the rates observed in Study 142 do fall within the reported background ranges, we cannot conclude that this explains the observed imbalance of events, as we do not have a precise, established estimate of this range. Currently there is no definitive evidence to account for a mechanism by which romosozumab could lead to an increased risk of cardiac ischemic and cerebrovascular events. The only signal that may suggest potential biologic plausibility is the nonclinical finding of an increased incidence of necrotic aortic plaques in a mouse model of atherogenesis that was exposed to romosozumab (see the nonclinical section of this memorandum for details). Relevant nonclinical data, however, are still limited, and the role of sclerostin in the cardiovascular system is currently not well understood.</p><p>Although there currently is no definitive evidence to explain a mechanism by which romosozumab could increase the risk of cardiac ischemic and cerebrovascular events, there is also currently no evidence of an alternative cause or explanation for the observed imbalance in these events in Study 142. Therefore, we must consider that the imbalance in events of myocardial infarction and stroke observed in Study 142 and Study 174 may represent an increased risk of these events with romosozumab therapy and factor this potential risk into our benefit-risk assessment.</p><p>For all the reasons discussed above, it is not possible to definitively determine whether romosozumab increases cardiovascular risk, whether this is a chance finding or whether the findings reflect a cardioprotective effect of alendronate. Without definitive data resolving this uncertainty, we conclude at this time that romosozumab may increase cardiovascular risk. To ensure benefits outweigh the risks, romosozumab should be avoided in patients at high cardiovascular risk (e.g., those who have had a myocardial infarction or stroke within the preceding year).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Outcome Assessment (COA) Analyses Informing Safety/Tolerability</head><p>Not applicable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Analyses by Demographic Subgroups</head><p>Adverse events were analyzed separately by ). There were no notable differences in the incidence rates of adverse events between the two subgroups. Cardiovascular adverse events were analyzed by multiple different subgroups as described in Section 8.2.5.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Specific Safety Studies/Clinical Trials</head><p>The applicant studied patients who transitioned from bisphosphonate therapy in two studies, Study 289 and Study 223, to understand safety and efficacy parameters in this population. As NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 153 discussed in the review of the original BLA, results from these studies do not raise any safety concerns for patients who transition to romosozumab from long-term (&gt;3 years) bisphosphonate therapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional Safety Explorations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human Carcinogenicity or Tumor Development</head><p>Although the Wnt-beta-catenin pathway has a known role in both sclerostin signaling and some tumor suppressor signaling, there are no data to suggest a cancer risk associated with romosozumab. Nonclinical rat studies included a rat lifetime pharmacology (carcinogenicity) study at doses up to 50 mg/kg QW and results did not raise concern for carcinogenicity. In addition, the totality of the data from the romosozumab clinical program do not support a risk for cancer, although conclusions may be limited because the duration of romosozumab treatment was limited to only 1 year.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human Reproduction and Pregnancy</head><p>No studies of romosozumab have been conducted in pregnant or breastfeeding women, and all studies have specifically excluded pregnant or breastfeeding women.</p><p>Romosozumab is not recommended for use in pregnant or premenopausal women.</p><p>No pregnancies were reported with exposure to romosozumab during any of the clinical studies of romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pediatrics and Assessment of Effects on Growth</head><p>Romosozumab has not been studied in children and adolescents. This drug is indicated for postmenopausal women and is not expected to be used for a pediatric indication. A full pediatric waiver was previously obtained.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overdose, Drug Abuse Potential, Withdrawal, and Rebound</head><p>Reference ID: 4416253 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 154 Neither the effects of overdose of romosozumab nor an antidote to overdose are known. Data from completed phase 1 clinical studies demonstrate that romosozumab has an acceptable safety profile up to the highest dose tested (doses up to 10 mg/kg SC and 5 mg/kg IV).</p><p>There is no evidence that use of romosozumab could lead to drug abuse or dependence.</p><p>Regarding potential withdrawal or rebound, Study 326, a multi-dose study in women with low BMD that primarily evaluated the effect of different doses of romosozumab on lumbar spine BMD at Month 12, also evaluated romosozumab off-treatment effects. In this study, 5 dose levels of romosozumab were evaluated against placebo. Lumbar spine BMD at Month 12 was the primary endpoint. Subjects continued to receive romosozumab for an additional 12 months and then were randomized again within their initial treatment groups to receive placebo or denosumab for 12 months (study months 24-36). As depicted in <ref type="figure" target="#fig_8">Figure 8</ref>, for subjects who received placebo after romosozumab 210 mg monthly (n=20), mean percent change from at month 36. For subjects who received denosumab after romosozumab 210 mg monthly (n=20), lumbar spine BMD continued to increase through month 36. Study 326 also studied retreatment after subjects had been off-treatment. In this study, the retreatment phase was from months 36 to 48, during which time all participating subjects received romosozumab 210 mg QM regardless of their initial treatment. Although BMD gains and BTM levels demonstrate that retreatment with romosozumab achieve similar changes when compared to initial 12 months of romosozumab therapy, the small number of patients studied (19 subjects who received placebo from month 24-36 group and 16 subjects who received denosumab from months 24-36) limits extrapolation of results into a larger patient NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 155 population. The safety of romosozumab in the retreatment phase (month 36 to 48) was consistent with results seen up to 24 months of romosozumab treatment and in line with expectations based on previous clinical study findings, but these findings are similarly limited by the small number of patients.</p><p>In addition, the 16 subjects in Study 326 who received active treatment for the first 48 months (romosozumab from months 0 to 24, denosumab for months 24 to 36 and romosozumab from month 36 to 48) were followed from months 48 to 72. These subjects had no indication of rebound or withdrawal effects in clinical laboratory values:</p><p>Median </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety in the Postmarket Setting</head><p>There are little postmarketing safety data for romosozumab. Romosozumab was recently approved for use in Japan and postmarketing safety data are not available. The safety profile of romosozumab in the postmarket setting is expected to resemble the safety profile established in clinical trials. However, there is an increased concern for hypocalcemia in patients with severe renal failure who were excluded from clinical trials. These patients should be monitored for hypocalcemia during therapy. This concern will be communicated in the label.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Integrated Assessment of Safety</head><p>The safety profile of romosozumab in Study 142 with respect to the overall subject incidences of adverse events, serious adverse events, fatal adverse events, and adverse events leading to withdrawal of investigational product or withdrawal from the study is consistent with the adverse event profile presented in the original BLA. Results for adverse events of interest based on prespecified adverse event categories, positively adjudicated ONJ, and positively adjudicated AFF were also consistent with the data presented in the original BLA, with injection site reactions being the only adverse event of interest that was higher in romosozumab group than in the control group. The imbalance in positively adjudicated CV SAEs in Study 142 based on the prespecified DC driven by events of .</p><p>. subjects), is a new safety finding compared with the safety data presented in the original BLA. This BLA resubmission included an integrated safety analysis composed of pivotal PMO phase 3 Studies 337 and 142, as well as an integrated safety analysis from all phase 2 and 3 studies in PMO (including the supportive studies 326, 291, 156 and 289). All subjects who received romosozumab were pooled to form the total romosozumab group and all subjects who received placebo or active comparator were pooled to form the total control group. Per our request, Study 174 was excluded from all pooled safety analysis sets and only cardiovascular safety data from that study were addressed in our review of the resubmission.</p><p>New analyses integrating Study 142 into the existing populations with Study 337 and with all other phase 2 and 3 studies were provided in Module 2.7.4 of the submission. Our review of these pooled analyses did not identify any additional safety signals, other than the cardiovascular safety signal mentioned above and discussed in detail in section <ref type="bibr">8.2.5</ref>. In addition to the risk of serious cardiovascular events of myocardial infarction and stroke, the totality of the safety data demonstrates the following key risks of romosozumab that are consistent with those identified in the original BLA: hypersensitivity reactions, injection site reactions, hypocalcemia, ONJ and AFF.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SUMMARY AND CONCLUSIONS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Issues</head><p>One potential statistical issue related to the co-primary endpoint of time to first clinical fractures in Study 142 was described in section 8.1.1. For time to first clinical fracture through the primary analysis period, with varied follow-up time for subjects, the pre-defined statistical analysis method was a Cox-proportional hazard model. Therefore, the Applicant's description of the clinical fracture endpoint as "subject incidence of clinical fracture through the primary analysis period", did not appear to be consistent with the analysis method. Hazard model analysis describes the relation between the fracture incidence and other potential covariates with varying follow-up time as opposed to fixed follow-up time and were appropriately labeled as risk reduction based on time to event analysis for the above endpoint. This statistical terminology issue does not impact the statistical analysis methods and results for the clinical fracture endpoint.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions and Recommendations</head><p>The safety and efficacy of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture was evaluated in two large fracture efficacy trials, a placebo-controlled fracture trial 20070337 (study 337) and the active-controlled fracture trial 20110142 (study 142). These studies evaluated whether 12 months of treatment with romosozumab followed by continued therapy with an anti-resorptive agent provided fracture risk reduction in postmenopausal women.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 157 Study 337 (N = 7180), reviewed in the first BLA cycle, was a phase 3, randomized, double-blind, placebo-controlled, parallel-group study that assessed the efficacy and safety of romosozumab 210 mg administered subcutaneously (SC) every month (QM) for a duration of 12 months followed by denosumab 60 mg every 6 months for 12 months compared to 12 months of placebo followed by 12 months of denosumab in women with postmenopausal osteoporosis. The study demonstrated a statistically significant reduction with romosozumab compared to placebo for both co-primary endpoints, which were 1) the subject incidence of new vertebral fractures at 12 months and 2) the subject incidence of new vertebral fractures at 24 months. During the 12-month double-blind period, the subject incidence of new vertebral fracture with te risk cebo followed by CI: 1.3, 2.5). and relative risk Clinical fracture (a composite of nonvertebral and clinical vertebral fractures) and nonvertebral fracture were secondary endpoints in study 337. At 12 reduction se clinical fractures were nonvertebral fractures and the risk reduction of nonvertebral fractures when considered alone did not meet statistical significance when adjusted for multiplicity. Study 337 was not adequately designed to assess romosozumab's efficacy for reduction in hip fractures.</p><p>Romosozumab also significantly increased BMD at all sites. At month 12, compared with and BMD at all sites at Month 24.</p><p>Study 142 (N = 4093) was a phase 3, randomized, double-blind, alendronate-controlled study that assessed the efficacy and safety of romosozumab 210 mg SC monthly for a duration of 12 months followed by alendronate 70 mg weekly compared with alendronate 70 mg weekly alone in women with postmenopausal osteoporosis with a history of fracture. Compared with Study 337, Study 142 enrolled a population at higher risk of osteoporosis-related fracture. The coprimary endpoints were 1) the subject incidence of clinical fracture (nonvertebral and clinical vertebral fracture) through the primary analysis period and 2) the subject incidence of new vertebral fracture through Month 24. The primary analysis occurred after clinical fracture events had been confirmed for at least 330 subjects and all subjects had completed the Month 24 visit. At 24 months, the subject incidence of new vertebral fracture with romosozumab 62). At the end of the primary analysis period, the subject incidence of clinical fracture with with a median follow-up of 33 months. Romosozumab followed by alendronate significantly The safety of romosozumab is documented with approximately 5621 subjects exposed to romosozumab for one year in the two phase 3 fracture trials. In these two trials, a total of 105 deaths occurred during the double-blind 12-month study periods. The events were generally well balanced between the treatment groups with two exceptions. In trial 20070337, an group and 8 (0.2) subjects in the romosozumab group. This imbalance in deaths was predominantly due to malignant lung neoplasm, which occurred in no subjects in the placebo group and 4 subjects in the romosozumab group. All affected subjects were current or former smokers, the time to onset was short (47-132 days after first treatment of romosozumab), and the overall incidence of fatal and nonfatal lung neoplasms was balanced between treatment groups. In trial 20110142, an imbalance in deaths was noted for fatal cardiac disorders, which occurred in 3 --treated subjects. This cardiovascular safety finding along with the imbalance in adjudicated serious adverse cardiac events in study 142 is the predominant safety concern for romosozumab.</p><p>The outcomes of interest to evaluate cardiovascular risk were major adverse cardiovascular events (MACE) that occurred during the double-blind period of each trial. MACE was defined as a composite endpoint of cardiovascular death, nonfatal myocardial infarction (MI) or nonfatal stroke, Cardiovascular death included deaths of undetermined cause. Across the two fracture experienced a major cardiac adverse event, yielding However, when each fracture trial is considered separately, the results diverge. In the placebocontrolled control group, 30 (0.8</p><p>Further evaluation of potential differences between the two fracture trials did not reveal an explanation for the differences in MACE outcomes. The participants in study 142 (74 years) were slightly older than those in study 337 (71 years) with slightly higher baseline positive the small number of events in both fracture trials, subgroup analyses based on demographic characteristics and osteoporosis characteristics were not informative. Because of the early separation of events between romosozumab and alendronate groups in the Kaplan Meier NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 159 curve, further evaluation of romosozumab's effect on platelet aggregation, vasoconstriction, and blood pressure were assessed but did not reveal concerning findings in the limited data available. It is recognized that the sclerostin gene SOST mRNA is expressed in the heart, aorta, liver, and kidney. However, nonclinical and in vitro evaluations have not provided conclusive evidence regarding an association between sclerostin inhibition and adverse cardiovascular structural or functional effects. Therefore, cardiovascular adverse events remain a potential risk with romosozumab therapy.</p><p>Other safety risks for romosozumab identified in the clinical fracture trials include the following:</p><p>Injection Site Reactions: Across both fracture women in the romosozumab romosozumab group; 70 romosozumab group and control group). Injection site reactions resulted in discontinuation of treatment in 7 (0. group.</p><p>In the first review cycle, injection site reactions were evaluated based on antidrug antibody romosozumab treated subjects. When evaluated in terms of neutralizing antibody status, treated subjects.</p><p>The injection site reactions reported in the fracture trials occurred using a drug product concentration of 70 mg/mL where patients required 3 injections of 1mL each to reach the 210 mg dose. The to-be-marketed formulation of romosozumab will be the 90 mg/mL concentration, where patients will need two injections of 1.17mL each. In trial 20120156 comparing the 70 mg/mL and the 90 mg/mL formulations, injection site reactions occurred in mg/mL romosozumab group.</p><p>The potential for injection site reactions may be more pronounced with the higher concentration of romosozumab or in patients who develop binding antibodies to romosozumab.</p><p>Hypersensitivity: Like other monoclonal antibodies, romosozumab may be associated with hypersensitivity reactions. In study 337, hypersensitivity reactions were noted double-blind 12-month study period. In study 142, potential hypersensitivity reactions were NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 160 romosozumab group during the 12-month double-blind period. Clinically significant hypersensitivity reactions included angioedema, erythema multiforme, and urticaria. The potential for hypersensitivity reactions in the fracture trials are reported with use of romosozumab 70 mg/mL formulation. The to-be-marketed formulation of romosozumab will be the 90 mg/mL concentration, where patients will need two injections of 1.17mL each. Trial 20120156 was a 6-month trial that compared bone density changes of the romosozumab 70 mg/mL formulation and the romosozumab 90 mg/mL formulation. Potential hypersensitivity reactions occurred in 3</p><p>The potential for hypersensitivity reactions may be more pronounced with the higher concentration of romosozumab.</p><p>Hypocalcemia: Hypocalcemia has been reported with osteoporosis therapies that inhibit bone resorption. Romosozumab predominantly functions as a bone anabolic agent but also has some function as an antiresorptive agent. One proposed mechanism for the hypocalcemia is through the rapid bone mass accrual at initiation of treatment and an increased demand for bonemineralization substrates such as calcium. Based on earlier studies, the nadir in serum calcium appears to occur between 2 weeks and 1 month following romosozumab injection. However, in Studies 337 and 142 serum calcium was not assessed prior to Month 1. Therefore, it is possible that the nadir may have occurred prior to Month 1. In study 337, no serious adverse events of hypocalcemia were reported during the first year. One adverse event of Grade 2 hypocalcemia (albumin-corrected serum calcium 7.0 to 8.0 mg/dL) was reported in a romosozumab-treated subject. In study group. No hypocalcemia event was reported as serious. Mild and transitory decreases in albumin-corrected calcium and a compensatory increase in iPTH were observed after initiation of romosozumab. Based on the totality of data, the risk of hypocalcemia is manageable in all romosozumab-treated patients, with an additional safeguard of monitoring serum calcium in patients with stage 5 chronic kidney disease (CKD) who are at higher risk for hypocalcemia.</p><p>Osteonecrosis of Jaw (ONJ): Osteonecrosis of the jaw (ONJ) is a rare adverse reaction associated with potent antiresorptive medications. The applicant defined ONJ as an event of interest and all potential events of ONJ were submitted to an independent external adjudication committee for review and adjudication. In study 337, no placebo subjects and one romosozumab subject had a positively adjudicated case of ONJ during the 12-month double-blind period. One additional subject who had received romosozumab had positively adjudicated ONJ while undergoing denosumab therapy in the second year of the study. In study 142, no cases of ONJ occurred in the 12-month double-blind treatment period. In the second year of the trial when all subjects were on alendronate, two cases of ONJ occurred. One subject was in the alendronate alone group and the other subject was in the romosozumab then alendronate group.</p><p>While ONJ has been reported with potent antiresorptive agents such as denosumab and alendronate, the occurrence of ONJ with romosozumab therapy was not anticipated, given the NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 161 predominant anabolic action of the product. The mechanism is unclear at this time and ONJ will continue to be followed closely.</p><p>Atypical Femur Fracture (AFF): Atypical femoral fracture is a rare adverse reaction associated with potent antiresorptive medications. The applicant defined atypical femoral fracture as an event of interest and all potential events of femoral fracture were submitted to an independent external adjudication committee. In study 337, no placebo subjects and one romosozumab subject had a positively adjudicated case of atypical femoral fracture. In study 142, no cases of atypical femoral fracture occurred in the 12-month double-blind treatment period. In the second year of the trial when all subjects were on alendronate, 6 cases of atypical femoral fracture were positively adjudicated (four in the alendronate alone group and 2 in the romosozumab then alendronate group). An additional subject from the romosozumab then alendronate group experienced an atypical femoral fracture after withdrawing from the study. She had received romosozumab for 12 months and alendronate for 2.5 years.</p><p>Similar to ONJ, the occurrence of atypical femoral fracture with romosozumab therapy was not anticipated. The mechanism is unclear at this time and atypical femoral fracture will continue to be followed closely.</p><p>Osteoporosis is a skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone leading to an increase in fragility and fracture. The goal of osteoporosis therapy is to reduce the risk of fracture. The risk of fracture increases with age and a history of a prior osteoporosis-related fracture. In older patients, fracture, predominantly hip fracture, is associated with increased morbidity and mortality. Approximately 300,000 hip fractures occur each year in the US. Mortality in the year following hip fracture ranges from 10published reports and increases with age. While the romosozumab fracture studies were not designed adequately to assess hip fracture, a positive trend in hip fracture risk reduction was seen. Similarly, the occurrence of a cardiac ischemic event in postmenopausal women also confers the risk of considerable morbidity and mortality (with 1-year mortality estimates ranging from approximately 5--Cardiovascular disease is the leading cause of death in women and cardiovascular risk increases after menopause.</p><p>When all data are considered, the benefits outweigh the risks for one year of romosozumab therapy in postmenopausal women with osteoporosis who are at high risk of fracture. Romosozumab reduces the risk of vertebral and nonvertebral fracture. Although the fracture studies were not designed adequately to assess hip fracture, the outcome with the most associated morbidity and mortality, these studies did suggest a positive trend in risk reduction for hip fractures. Because of the different cardiovascular findings in the two large trials of romosozumab, the cardiovascular risk is considered a potential risk rather than a definitive risk. Given this potential risk, and the high risk of subsequent cardiac events in the year following a myocardial infarction or stroke, patients who are candidates for romosozumab therapy who have had a myocardial infarction or stroke within the prior year should not have romosozumab initiated, as outlined in product labeling. The review team recommends APPROVAL for romosozumab for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Product labeling should include a boxed warning about the cardiovascular risk including the recommendation that patients with a history of stroke or myocardial infarction within the preceding year not receive romosozumab. Additionally, the review team recommends further evaluation of the cardiovascular signal post-approval as outlined below.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9">Advisory Committee Meeting and Other External Consultations</head><p>An Advisory Committee meeting was held on January 16, 2019 to discuss the cardiovascular safety findings from the romosozumab fracture trials. The committee was asked to consider if the cardiovascular safety of romosozumab was adequately characterized or if additional safety data were needed.</p><p>The questions posed to the committee with a brief overview of the committee responses are outlined below:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion Question 1:</head><p>Discuss whether the cardiovascular safety of romosozumab has been adequately characterized. If additional safety data are needed, discuss the type(s) of data that are needed and whether these data should be obtained pre-approval or post-approval.</p><p>Committee Discussion: The committee members agreed that the cardiovascular safety profile of romosozumab was not adequately characterized. Committee members noted that it is unclear whether there is any increased cardiovascular risk with romosozumab, given the differences between the two trials (337 and 142). All members agreed that additional data are necessary to better characterize the potential cardiovascular risk. Most members agreed that a traditional observational study would not provide reliable data to draw conclusions regarding romosozumab's cardiovascular safety. This concern was based on the likely channeling of the use of the drug to patients with low cardiovascular risk given the Boxed Warning. Some members recommended a dedicated cardiovascular outcomes trial (CVOT) to better characterize the risk. Most members recognized that a dedicated CVOT would provide the most reliable data, although some thought it would not be feasible because it would likely require many thousands of patients and take several years to complete. Some suggested that enriching the population with patients at higher cardiovascular risk would help to overcome this limitation. Proponents of a CVOT agreed that it would need to be active-controlled rather than placebo-controlled to ensure clinical equipoise in a population at high risk of fracture. Regarding the timing of an additional study examining cardiovascular safety, all but one member agreed that the study could be conducted post-approval.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 163</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion Question 2:</head><p>Amgen is seeking an indication for the treatment of osteoporosis in postmenopausal women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.</p><p>Discuss whether the benefit/risk profile of romosozumab could be improved by further narrowing the indicated population to patients at low cardiovascular risk, and if so, how to define the narrowed population.</p><p>Committee Discussion: The committee members agreed that romosozumab treatment provides significant benefit in preventing the morbidity and mortality associated with osteoporosis. However, because of the uncertainties surrounding the cardiovascular risk of romosozumab, some members stated that it may be challenging for physicians and patients to weigh the benefits and risks on an individual basis. Additionally, the panel members noted that withholding the drug from anyone with a single cardiovascular disease risk factor may deny them a greatly needed benefit (e.g., prevention of potential morbidity and mortality associated with severe osteoporosis). Several committee members cited data showing that the risk of MACE is highest for patients who have had a myocardial infarction or stroke within the past year. Most members agreed that the best approach would be to warn against romosozumab use in this population.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Voting Question:</head><p>Is the overall benefit/risk profile of romosozumab acceptable to support approval?</p><p>A. Yes, for Amgen's proposed indication (treatment of osteoporosis in postmenopausal women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy) B. Yes, but for a different indication C. No Provide a rationale for your vote. If you voted for (b), describe the patient population in whom the benefits outweigh the risks. Committee Vote: A: 15 B: 3 C: 1 Committee Discussion: Most committee members voted "A" in support of approval of Amgen's proposed indication for romosozumab. These panel members agreed that romosozumab is clearly effective for treating severe osteoporosis, for which therapeutic options are limited, and that these benefits outweigh the identified and potential risks. However, members recommended that an additional study be conducted post-approval to better characterize romosozumab's potential cardiovascular risk. Additionally, there was wide support among members for including a boxed warning in the label against use in patients at highest risk for MACE (at least until more is known regarding romosozumab's cardiovascular risk). One of the members who voted "B" in support of a different indication had concerns about the potential safety signal and had suggested the need for a REMS or additional pre-approval data. The other member who voted "B" stated that the phrase "intolerant to other available osteoporosis therapy" was too vague. The one member who voted "C" stated that there is not enough evidence to determine whether or not the benefits outweigh the risks.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="10">Pediatrics</head><p>The applicant submitted an agreed initial Pediatric Study Plan iPSP on 1/12/2016 requesting a full waiver of the requirement to conduct pediatric studies, given that postmenopausal osteoporosis does not exist in the pediatric population. The iPSP was reviewed by the Pediatric Review Committee (PeRC) and PeRC concurred with the Applicant's plan for a full waiver.</p><p>During the first review cycle of this application, the applicant requested a full waiver from pediatric studies because the studies would be impossible given the lack of postmenopausal osteoporosis in the pediatric population. The request was reviewed by PeRC <ref type="bibr">March 1, 2017</ref> and PeRC agreed the request was appropriate and acceptable. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="11">Labeling Recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="12">Risk Evaluation and Mitigation Strategies (REMS)</head><p>The Applicant did not propose a REMS for the marketing of romosozumab.</p><p>A REMS is not necessary to ensure the benefits outweigh the risks of romosozumab. Serious cardiovascular events of MI and stroke are an important potential risk; however, in the Agency's experience, REMS programs have minimal impact in mitigating the risk of MACE unless the REMS is designed specifically to limit who might receive the product. Such a REMS may not have the intended impact and is likely to require elements that would be burdensome to healthcare providers and patients. Therefore, as this product is efficacious and will be indicated for use in a higher risk population, a REMS is not necessary. Risk minimization will include communication of important risks for romosozumab through labeling including a boxed warning, limitations of use, and warning and precaution statements and a Medication Guide that alerts patients to the important risks.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13">Postmarketing Requirements and Commitment</head><p>The predominant safety concern for romosozumab is the cardiovascular safety signal seen in one of the fracture studies in postmenopausal women. The applicant proposes</p><p>As discussed at the Advisory Committee meeting, it is unlikely that an observational study will adequately answer the question of cardiovascular safety with romosozumab use. Other options considered include either a randomized, active controlled cardiovascular outcomes study or a large simple trial where patients are randomized and with observational outcome followup. The applicant believes that neither of the randomized options are feasible because the proposed boxed warning language would limit the enrolled population to one of lower cardiovascular risk.</p><p>In conjunction with the Division of Epidemiology, we developed the following required postmarketing study:</p><formula xml:id="formula_2">Reference ID: 4416253 (b) (4) (b) (4) (b) (4)</formula><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 167 Study 2: The applicant will conduct a comparative safety study or trial The applicant will conduct a comparative safety study or trial adequately designed and powered to rule out an unacceptable increase in risk of MI, stroke, and cardiovascular death among users of romosozumab compared to users of an appropriate comparator(s). The need, feasibility, design and milestones for this study or trial will be contingent upon the findings from study 1.</p><p>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 170</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Financial Disclosure</head><p>A Financial Disclosure form (3454) states that there was no arrangement by which compensation of the investigators or sub-investigators of the studies could be affected by the outcomes of these studies. The applicant has adequately disclosed financial interests/arrangements with clinical investigators.</p><p>A total of 10 investigators participating in Study 20110142 had disclosable financial arrangements. The sites of these investigators were in Australia, Germany, Hong Kong, and the U.S. Locations. All of these sites enrolled 3 or fewer subjects, with the exception of the one in Hong Kong, which enrolled 201 subjects. Compensation to the investigator for conducting the study where the value could be influenced by the outcome of the study: 0 Significant payments of other sorts: 9</p><p>Proprietary interest in the product tested held by investigator: 0 Significant equity interest held by investigator in Sponsor of covered study: 1</p><p>Is an attachment provided with details of the disclosable financial interests/arrangements:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes</head><p>No (Request details from Applicant) Is a description of the steps taken to minimize potential bias provided:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes</head><p>No (Request information from Applicant)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Number of investigators with certification of due diligence (Form FDA 3454, box 3)</head><p>Is an attachment provided with the reason:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes</head><p>No (Request explanation from Applicant) NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 171 OCP Appendices</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="14.3.1.">Immunogenicity</head><p>This section provides integrated immunogenicity results from all clinical studies in postmenopausal women (including newly submitted data from Study 20110142). Note that the immunogenicity results in the Office of Clinical Pharmacology Review (DARRTS Reference ID 4076576) for the original BLA submission do not include immunogenicity results from Study 20110142.</p><p>A total of romosozumab treatment in the phase 2 and phase 3 studies developed anti-drug antibodies subjects. For subjects who received the recommended 210 mg romosozumab monthly dosing Of the subjects who developed antibodies to romosozumab, approximately 4.7 (50/1072) had antibodies that were classified as neutralizing.</p><p>The impact of immunogenicity on PK was evaluated in subjects who received romosozumab 210 mg in <ref type="bibr">Studies 20060326, 20070337, 20101291, and 20110142</ref>. The presence of ADA resulted in reduced mean serum trough romosozumab concentrations by up different time-points from Month 3 to Month 12. NAb resulted in a greater reduction in serum romosozumab concentrations based on the limited number of subjects <ref type="table" target="#tab_6">(Table 44</ref>). baseline at the lumbar spine, total hip, and femoral neck showed comparable results between ADA negative and ADA positive subjects. Data for lumbar spine BMD are shown in <ref type="table" target="#tab_6">Table 45</ref>. The impact of immunogenicity on fracture was assessed based on results from Studies 20070337 and 20110142. In study 20070337 had a new vertebral fracture through Month 24 tested positive for ADA and none of them were positive for NAb. In Study 20110142, in subjects who had a new vertebral fracture through Month 24 (n = 75) the ADA and NAb incidences were , respectively. In general, subjects who experienced a new vertebral fracture through Month 24 had similar immunogenicity incidences for ADA and NAb compared to the overall population exposed to romosozumab.</p><p>The Office of Clinical Pharmacology Review (DARRTS Reference ID 4076576) for the original BLA submission determined that the development of anti-romosozumab binding and neutralizing antibodies did not appear to have an impact on the incidence of injection site reactions, hypersensitivity or autoimmune disorders. This finding was further supported by the results from Study 20110142 <ref type="table" target="#tab_6">(Table 46</ref>). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="14.3.2.">Individual Study Summary: Study 20110142</head><p>Blood samples for measurement of serum romosozumab concentrations were collected predose at baseline and at <ref type="bibr">Months 1,</ref><ref type="bibr">3,</ref><ref type="bibr" target="#b88">6,</ref><ref type="bibr" target="#b47">9,</ref><ref type="bibr" target="#b52">and 12</ref> in a PK subgroup. The serum romosozumab concentrations are summarized in <ref type="table" target="#tab_6">Table 477</ref>. Blood samples for immunogenicity assessment were collected at baseline, and at <ref type="bibr">Months 1,</ref><ref type="bibr">3,</ref><ref type="bibr" target="#b88">6,</ref><ref type="bibr" target="#b52">12,</ref><ref type="bibr">18</ref> and 24. Among 1955 subjects treated with romosozumab who had at least one postbaseline result through Month 18, of subjects developed ADA. Among the ADA positive subjects had neutralizing antibodies.</p><p>The impact of immunogenicity on PK was assessed by the subject ADA status through Month 12 <ref type="table" target="#tab_6">(Table 488</ref>). The PK results overall showed lower mean serum romosozumab concentrations in ADA positive subjects compared to ADA negative subjects; however the difference was within 2 across all the PK time-points. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="14.3.3.">Population PK</head><p>The Applicant submitted two updated population PK analysis reports: Addendum 1 and Addendum 3. Compared with the original population PK report 119384A, PK results from two additional studies were included in the analysis dataset resulting in 304 additional subjects with 1257 additional serum concentrations in the latest updated population PK analysis report Addendum 3 <ref type="table" target="#tab_6">(Table 49</ref>).</p><p>The PK parameters of the updated models (Addendum 1 and Addendum 3) are very similar to the original model. The originally identified significant covariates for clearance (body weight, eGFR, Japanese Race, and Manufacturing process) remain to be significant. Sex was additionally identified as a covariate to have significant effect on clearance and exposure. The population PK model predicted that a reference male subject has approximately CI: higher exposure based on steady state AUC than a female subject.</p><p>No dose adjustment is necessary based on these significant covariates identified by the population PK model. Severe renal impairment and ESRD patients are predicted to have AUCss the typical reference;. Exposure-response analysis indicated that the exposure increase is not expected to have an effect on efficacy or safety, however, hypocalcemia remains a concern in ESRD patients. Other covariates are predicted to result in the change in Cmax and steady state AUC to be within 80-12 a typical reference subject ( <ref type="figure">Figure )</ref>. Refer to Office of Clinical Pharmacology Review (DARRTS <ref type="bibr">Reference ID 4076576)</ref> in the original BLA submission for additional information.  <ref type="bibr">20060220, 20060221, 20060223, 20090378, 20101180, 20120277, 20110227, and 20110253</ref>         Source: <ref type="figure" target="#fig_0">Figure 12</ref> in rtq-12oct2018.pdf, submitted on 10/19/2018, eseq0061 --------------------------------------------------------------------------------------------This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record. This memo responds to your consult to us requesting our assistance in reviewing the cardiovascular safety signal from a meta-analysis of three clinical trials conducted by Amgen (i.e., Applicant), as well as the adjudication process from the Duke University Clinical Research Institute (DCRI) and the re-adjudication process from the Thrombolysis in Myocardial Infarction group (TIMI) for romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>--------------------------------------------------------------------------------------------</head><formula xml:id="formula_3">/s/ -----------------------------------------------------------</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DCRP Summary and Assessment</head><p>The Applicant evaluated romosozumab for the treatment of osteoporosis in three clinical trials: 1) placebo controlled trial in osteoporotic women (study 20070337, N= 7157, 1:1 randomization); 2) alendronate-controlled trial in osteoporotic women (study 20110142, N=4054, 1:1 randomization); and 3) placebo-controlled trial in osteoporotic men (study 20110174, N= 244, 163 on romosozumab, and 81 on placebo). Each trial had a 12-month double blind period followed by an extension period. Study 20070337 had an extension of 12 additional months where subjects were treated with open label denosumab. Study 20110142 had a median extension of 24 months (median duration of study 36 months) where subjects were treated with open label alendronate until the requisite number of endpoints was achieved in this event-driven trial. Study 20110174 had an extension of an additional 3 months where the subjects were observed but not treated.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2</head><p>The distribution of subject baseline characteristics (i.e., demographics, cardiovascular medical history, modified-RUTH cardiovascular risk score, cardiovascular medications) was similar between the romosozumab and controls arms for each study and between each study.</p><p>Cardiovascular adverse events were adjudicated by DCRI and by the TIMI group. The triggering events and the requisite supporting documentation were the same for both adjudication entities.</p><p>From a meta-analysis of the three trials, the incidence of events leading to death, myocardial infarction, or stroke in the 12-month double-blind period was low but with a marginally statistically significant hazard ratio (HR) against romosozumab that was consistent between the modes of adjudication: DCRI Adjudication: Incidence 1.3% vs 0.9%, HR 1.40 (95%CI 0.99-1.99); DCRI-matched TIMI Adjudication (TIMI adjudication of events previously adjudicated by DCRI): Incidence 1.2% vs 0.8%, HR 1.47 (95%CI 1.02-2.13); Full TIMI Adjudication: Incidence 1.2% vs 0.8%, HR 1.44 (95%CI 1.00-2.08). The results were driven by study 20110142. There was no imbalance in cardiovascular events in study 20070337. The HR results were driven by cardiac ischemic events (i.e., composite of myocardial infarction, angina requiring hospitalization, and coronary revascularization-either percutaneous coronary intervention or coronary artery bypass surgery), myocardial infarction, and cerebrovascular events (stroke / TIA) during the 12-month double blind study period.</p><p>There was no imbalance of events in the overall study period, most likely due to termination of romosozumab after 12 months. One exception to the results in the overall study period was a marginally statistically significant HR for stroke both by DCRI and TIMI adjudications.</p><p>The results were not impacted by baseline cardiovascular risk as measured by the modified RUTH score.</p><p>In conclusion, DCRI and TIMI adjudications yielded similar results. Meta-analysis of cardiovascular events from the three osteoporosis trials showed a low incidence but an overall marginally significant HR for romosozumab vs comparator driven by one study. Assuming a positive benefit / risk evaluation of romosozumab, the cardiovascular risk based on these low numbers of events and marginally significant HRs can be described in the label.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p>Romosozumab (trade name Evenity) is a humanized monoclonal antibody against sclerostin and was developed for the treatment of osteoporosis in postmenopausal women. The therapeutic dosing regimen is 210 mg SC administered by a healthcare professional once each month. Sclerostin is a glycoprotein that inhibits osteoblast-mediated bone formation. By inhibiting sclerostin, romosozumab increases bone formation and decreases bone resorption.</p><p>The sclerostin gene mRNA is expressed in the heart, aorta, liver and kidney. In early development, the Applicant was concerned that inhibition of sclerostin may promote or exacerbate vascular calcification. The Applicant therefore convened an independent clinical endpoint committee (DCRI) to adjudicate reported cardiovascular serious adverse events 3 (SAEs) from the single pivotal trial (20070337) that supported the BLA for the treatment of postmenopausal women with osteoporosis.</p><p>Study 20070337 (FRAME) was a double-blind, placebo-controlled trial (N= 7157). Study drug (romosozumab 210 mg SC q month or placebo) was administered for 12 months followed by open-label denosumab 60 mg SC q 6 months for an additional12-month period. The co-primary efficacy endpoints were the incidence of new vertebral fracture through month 12, and through month 24. This trial met the statutory requirements for substantial evidence of effectiveness and did not show a cardiovascular safety signal. The incidence of DCRI-positively adjudicated cardiovascular SAEs was similar between the treatment groups during the 12-month and the 24-month time periods <ref type="table" target="#tab_87">(Table 1</ref>). mg SC q month (n=163) or placebo (n=81) for 12 months and were followed for an additional 3 months after completion of the double-blind period for evaluation of safety and immunogenicity. The primary efficacy endpoint was percent change from baseline in dual-energy x-ray absorptiometry (DXA) bone marrow density (BMD) at the lumbar spine at month 12. There was no follow-on therapy. First-patient-enrolled was 16 June 2014; the cut-off date was 27 January 2016. The study report was finalized on 21 July 2016.</p><p>The results of studies 20110142 and 20110174 demonstrated statistically significant effectiveness of romosozumab for each study's primary efficacy endpoint. However, there was a higher incidence of the DCRI-positively adjudicated cardiovascular SAEs during the first year in the romosozumab arm over the alendronate arm in study 20110142 and in the romosozumab arm over the placebo arm in study 20110174, although the latter study was too small to draw a credible conclusion <ref type="table" target="#tab_4">(Table 2</ref>). DBRUP consulted DCRP on 21 September 2017 to attend post-CR meetings with the Applicant pursuant to reconciliation strategies regarding the cardiovascular safety signal. The Applicant met with DBRUP and consulting staff from DCRP on 26 October 2017 to discuss plans to evaluate cardiovascular SAEs. Plans to re-engage DCRI and simultaneously hire the TIMI group were discussed as stated in the Meeting Minutes dated 22 Nov 2017. Advice from DCRP that were documented in the Minutes included: 1) submission of adjudication packages; 2) incorporation of atrial fibrillation/atrial flutter as a baseline risk factor; 3) evaluation of the percentage of events originally adjudicated as negative because of missing data; 4) itemization of cardiovascular events by individual study; 5) specification of particular documentation missing; 6) compilation of a list of cases adjudicated as negative because of missing data; 7) disclosure of adjudication decisions by each reviewer from the TIMI committee; and 8) prespecification of the standardized MedDRA queries and trigger terms used by TIMI to identify additional events.</p><p>Based on the original DCRI adjudication process, an event in which insufficient information was provided yielded a negative adjudication (i.e., the event was not a cardiovascular SAE). The 6 original DCRI adjudication process also focused on SAEs. DCRI was requested to perform a retrospective re-review of all negatively adjudicated events in the three studies to determine if the original negative adjudication result was due to a site reported event with adequate source documentation not meeting the endpoint definition, or if the original negative adjudication result was due to a lack of recommended source documentation, and if so, what specific missing documentation resulted in the negative decision. Based on the DCRI adjudication charter, final adjudication decisions undergoing re-review would not be modified as there would be no changes to adjudication results. The re-review effort would be considered a source documentation adequacy review.</p><p>The TIMI study group was also requested to perform a posthoc adjudication of the cardiovascular adverse events in the three studies to assure that 1) relevant events had not been missed and that 2) the focus on SAEs in the prespecified adjudication by DCRI was not overly narrow.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjudication Processes</head><p>DCRI and TIMI adjudicated major adverse cardiac events (MACE) defined as cardiovascular adverse events leading to death, positively adjudicated myocardial infarction, and positively adjudicated stroke. The analysis of MACE was performed for the double-blind period and overall study period for studies 20070337 (12-month double blind, 24 months overall study period), 20110142 (12 months double blind, median 36 months overall study period), and 20110174 (12 months double blind, 15 months overall study period).</p><p>TIMI did not submit a written adjudication report because, as explained by the Applicant, TIMI's role was to confirm the DCRI adjudication results. The TIMI adjudication process and results, as well as those from DCRI, were reported by the Applicant in their Comprehensive Cardiovascular Report that included the DCRI and TIMI charters.</p><p>DCRI and TIMI independent adjudication processes are illustrated in <ref type="figure" target="#fig_0">Figure 1</ref>. The key distinctions between the adjudication processes were: 1) The TIMI group adjudicated all adverse events (serious and non-serious) meeting the triggers for adjudication; and 2) The TIMI group adjudicated an event as either positive, negative, or suspected (i.e., insufficient information was not categorically assigned a negative adjudication).</p><p>Events triggering adjudication for both the DCRI and TIMI processes are summarized in <ref type="table" target="#tab_5">Table  3</ref>. The specific triggers included death (all events), cerebrovascular events, cardiac ischemic events, heart failure, non-coronary revascularization, and peripheral vascular events not needing revascularization. These triggers were the same for both adjudication processes. However, the DCRI trigger for heart failure required hospitalization whereas hospitalization was not explicitly stated as a requirement for heart failure adjudication in the TIMI process. The required source documentation to support the adjudications for each trigger was similar for both adjudication processes <ref type="table" target="#tab_6">(Table 4</ref>).</p><p>Reviewer Assessment: The adjudication processes were adequate, and the required documentation was sufficient to render an adequate adjudication.   </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjudication Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Baseline Characteristics</head><p>The baseline characteristics were generally similar between the arms of each trial and between each trial ( <ref type="table" target="#tab_7">Table 5</ref>). The mean ages ranged from 71 to 74 years. Approximately 26%-29% of the subjects in the two large trials in osteoporotic women (20070337 and 20110142) were smokers (current or former), and 50-63% of the subjects in the small trial of osteoporotic men (20110174) were current/former smokers. Most of the subjects in all three trials had an estimated glomerular filtration Incidence between 60-90 mL/min/1.73m 2 .</p><p>Approximately 75% of the subjects in the romosozumab program had a cardiovascular-related disease. The cardiovascular medical histories were generally similar between the arms of each trial and between each trial, including cardiac risk as determined by the modified RUTH score ( <ref type="table" target="#tab_92">Table 6</ref>).</p><p>The modified RUTH score was used by the Applicant in this analysis <ref type="table" target="#tab_9">(Table 7)</ref> and was developed to assess cardiovascular risk in women enrolled in the Raloxifene Use for The Heart (RUTH) study <ref type="bibr" target="#b28">(Mosca, 2001)</ref>. Women with &gt; 4 risk points were at increased risk for cardiovascular events. Women with &lt; 4 risk points were of low cardiovascular risk as assessed in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial as shown in <ref type="figure" target="#fig_18">Figure 2</ref>  <ref type="bibr" target="#b27">(Keech, 2005)</ref>. The MORE dataset (N = 5133) showed an approximate overall 2% incidence of coronary events and an approximate overall 2% incidence of cerebrovascular events in the placebo arm (n=2576); and an approximate overall 2% incidence of coronary events and approximate overall 1% incidence of cerebrovascular events in the Raloxifene arm (n=2557). Those subjects classified as low risk (n=4457, mean risk score 1.6 + 1.0) had an approximate 1% incidence of coronary events and an approximate 1% incidence of cerebrovascular events in both the placebo arm (n=2259) and in the Raloxifene arm (n=2198), respectively. Those subjects classified as high risk (n=676, mean risk score 5.0 + 1.7) had an approximate 7% incidence of coronary events and an approximate 6% incidence of cerebrovascular events in the placebo arm (n=317); and an approximate 5% incidence of coronary events and an approximate 3% incidence of cerebrovascular events in the Raloxifene arm (n=359).</p><p>Approximately 60% of the subjects in the intention-to-treat population of the romosozumab program were taking at least one cardiovascular-related medication (e.g., aspirin, antiplatelet, beta-blocker, anticoagulant, angiotensin-II receptor blocker, ACE-inhibitors, statins). Approximately 20-38% of the subjects were on a specific medication ( <ref type="table" target="#tab_11">Table 8</ref>). In subjects who had a cardiovascular related condition at baseline, the prevalence of baseline cardiovascular medications was higher: approximately 75% were on at least one cardiovascular medication with 22-50% taking specific medications ( <ref type="table" target="#tab_13">Table 9</ref>). The use of cardiovascular-related baseline concomitant medications was generally evenly distributed between the arms of each trial as well as between each trial.      </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjudicated Event Analysis</head><p>DCRI: In the overall study period for the three studies, there were 5070 reported SAEs of which 1150 were adjudicated ( <ref type="figure" target="#fig_2">Figure 3</ref>). Of these, 697 were adjudicated positively (criteria for cardiovascular event satisfied) and 453 were adjudicated negatively (criteria not met). Of the negatively adjudicated events, 400 had sufficient information but did not meet the criteria for an event, and 53 were adjudicated as negative due to insufficient information. The missing information was associated with cardiac ischemic, heart failure, peripheral vascular and cerebrovascular events and was mostly discharge summaries, medical records, hospital records, imaging, ECGs, and additional information not provided due to subject withdrawal of consent .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TIMI:</head><p>In the overall study period for the three studies, there were 80,214 adverse events of which 1329 were adjudicated ( <ref type="figure" target="#fig_3">Figure 4</ref>). Of these, 690 were adjudicated positively, 39 were adjudicated as suspected events, 23 events were assessed as duplicate, and 577 were adjudicated negatively.</p><p>A sensitivity analysis was performed by the Applicant to ascertain whether a negative adjudication by DCRI due to insufficient information impacted the overall assessment of a potential cardiovascular safety signal. The Applicant assumed that all negatively adjudicated events due to insufficient information were positive. The results for the 12-month double-blind period and the overall study period respectively showed no difference in the HR comparing romosozumab and control between DCRI-positively adjudicated events and DCRI-positively adjudicated events + negatively adjudicated events due to insufficient documentation assumed positive for the sensitivity analysis <ref type="table" target="#tab_16">(Table 10)</ref>.</p><p>A side-by-side comparison of DCRI and TIMI adjudications from reported treatment-emergent adverse events for all-cause death, myocardial infarction, and stroke for the 12-month doubleblind period in each study is presented in <ref type="table" target="#tab_87">Table 11</ref>. The incidence of positively adjudicated allcause deaths, myocardial infarction, and stroke endpoints was low (i.e., 1.3%-2.6% in the romosozumab arm; 1.2%-1.9% in the placebo arm) and similar between the DCRI and TIMI adjudications for all the studies. These numbers were similar to the overall incidence of coronary events and cerebrovascular events in the MORE trial.</p><p>The incidence of positively adjudicated endpoints between the placebo and romosozumab arms in study 20070337 was virtually identical to each other.</p><p>In both the DCRI and TIMI adjudications, there was a small numerical increase in the incidence of all the endpoints in study 20110142 for the romosozumab arm vs the alendronate arm: In study 20110174, the number of positive adjudications was too small to render an inference.</p><p>Meta-analyses of adjudicated events from studies 20070337, 20110142, 20110174 displayed by Forrest Plots are found in the Appendix.</p><p>The HR for positively adjudicated events leading to death, myocardial infarction, and stroke for romosozumab vs control based on DCRI, DCRI-matched TIMI, and full TIMI adjudications through the double-blind 12-month period are shown in <ref type="figure" target="#fig_5">Figure 5</ref> for all three studies, <ref type="figure" target="#fig_6">Figure 6</ref> for study 20110142, and <ref type="figure" target="#fig_7">Figure 7</ref> for study 20070337. Analogous results for the overall study periods are respectively shown in <ref type="figure" target="#fig_8">Figure 8</ref> for all three studies, <ref type="figure" target="#fig_38">Figure 9</ref> for study 20110142, and <ref type="figure" target="#fig_0">Figure 10</ref> for study 20070337. The HR comparing romosozumab to control in the doubleblind 12-month period were marginally significant and consistent between the modes of adjudication: DCRI Adjudication: Incidence 1.3% vs 0.9%, HR 1.40 (95%CI 0.99-1.99); DCRImatched TIMI Adjudication: Incidence 1.2% vs 0.8%, HR 1.47 (95%CI 1.02-2.13); Full TIMI Adjudication: Incidence 1.2% vs 0.8%, HR 1.44 (95%CI 1.00-2.08).</p><p>These results were driven only by study 20110142 (DCRI Adjudication: Incidence 2.0% vs 1.1%, HR 1.87, 95%CI 1.11-3.14; DCRI-matched TIMI Adjudication: Incidence 1.9% vs 1.0%, HR 1.96, 95%CI 1.14-3.36; and Full-TIMI Adjudication: Incidence 1.9% vs 1.0%, HR 1.96, 95%CI 1.14-3.36) during the 12-month double blind period. Despite statistical significance in this trial, the incidences were low.</p><p>Study 20070337 showed no cardiovascular safety signal with any mode of adjudication during the 12-month period.</p><p>The HR values regressed to neutrality for the overall study period by all adjudication modalities in all three studies.</p><p>A meta-analysis of the time to first occurrence of positively adjudicated cardiovascular adverse events leading to death, myocardial infarction or stroke through the double-blind 12-month period for the three trials is shown in <ref type="figure" target="#fig_0">Figure 11</ref> for DCRI and <ref type="figure" target="#fig_0">Figure 12</ref> for TIMI. Analogous results for the overall study periods are shown in <ref type="figure" target="#fig_0">Figure 13</ref> for DCRI and <ref type="figure" target="#fig_0">Figure 14</ref> for TIMI. The data showed a low incidence of events and a marginally significant HR for romosozumab vs comparator (DCRI: Incidence 1.3% vs 0.9%, HR 1.40, 95%CI 0.99-1.99; TIMI: Incidence 1.2% vs 0.8%, HR 1.44, 95%CI 1.00-2.08) for the 12-month period. This was driven by study 20110142 comparing romosozumab to alendronate showing a low rate of events but statistically significant HRs (DCRI: Incidence 2.0% vs 1.1%, HR 1.87, 95%CI 1.11-3.14; TIMI: Incidence 1.9% vs 1.0%, HR 1.96, 95%CI 1.14-3.36). The HR regressed towards neutrality when incorporating data from the overall study period.</p><p>A meta-analysis of the time to first occurrence of positively adjudicated cardiovascular adverse events leading to death, myocardial infarction, or stroke through the double-blind 12-month period stratified by modified RUTH score is shown in <ref type="figure" target="#fig_0">Figure 15</ref> for DCRI and <ref type="figure" target="#fig_0">Figure 16</ref> for TIMI.</p><p>Analogous results for the overall study periods are shown in <ref type="figure" target="#fig_0">Figure 17</ref> for DCRI and <ref type="figure" target="#fig_0">Figure 18</ref> for TIMI. There was a trend towards a cardiovascular safety signal for romosozumab vs comparator for all subgroups of the modified RUTH score (i.e., &lt; 4, &gt; 4, &lt;6, &gt;6, &lt;8, &gt;8) as adjudicated by DCRI and TIMI for the 12-month period. The trend was attenuated for all modified-RUTH subgroups in the overall study period, more pronounced in the TIMI adjudication.</p><p>A series of meta-analyses was conducted to evaluate the HR of romosozumab vs comparator for components of the composite of death, myocardial infarction, and stroke.</p><p>The time to first occurrence of positively adjudicated cardiovascular adverse events leading to death through month 12 is shown in <ref type="figure" target="#fig_0">Figure 19</ref> for DCRI and <ref type="figure" target="#fig_18">Figure 20</ref> for TIMI. Analogous results for the overall study period are shown in <ref type="figure" target="#fig_0">Figure 21</ref> for DCRI and <ref type="figure" target="#fig_18">Figure 22</ref> for TIMI. The results showed no trend towards a mortality safety signal.</p><p>A meta-analysis of the time to first occurrence of positively adjudicated cardiovascular adverse events leading to myocardial infarction through month 12 is shown in <ref type="figure" target="#fig_2">Figure 23</ref> for DCRI and <ref type="figure" target="#fig_3">Figure 24</ref> for TIMI. Analogous results for the overall study period are shown in <ref type="figure" target="#fig_5">Figure 25</ref> for DCRI and <ref type="figure" target="#fig_6">Figure 26</ref> for TIMI. The results showed a low incidence of events, a statistically significant HR for myocardial infarction by DCRI adjudication (Incidence 0.4% vs 0.2%, HR 1.97, 95%CI 1.01-3.84) and a non-statistically significant HR by TIMI adjudication (Incidence 0.4% vs 0.2%, HR 1.69, 95%CI 0.87-3.27) for the 12-month period. These results were driven by study 20110142 showing statistically significant results with both adjudication processes (DCRI: Incidence 0.8% vs 0.2%, HR 3.21, ; TIMI: Incidence 0.8% vs 0.3%, HR 2.67, 95%CI 1.05-6.83). The HR regressed to neutrality for the overall study periods.</p><p>A meta-analysis of the time to first occurrence of positively adjudicated cerebrovascular adverse events (stroke + TIA) through month 12 is shown in <ref type="figure" target="#fig_7">Figure 27</ref> for DCRI and <ref type="figure" target="#fig_8">Figure 28</ref> for TIMI.</p><p>Analogous results for the overall study period are shown in <ref type="figure" target="#fig_18">Figure 29</ref> for DCRI and <ref type="figure" target="#fig_2">Figure 30</ref> for TIMI. The results showed a low incidence of events. There was a non-statistically significant HR for cerebrovascular events by DCRI adjudication for the 12-month period (Incidence 0.5% vs 0.3%, HR 1.45, 95%CI 0.81-2.60) but a statistically significant HR by TIMI adjudication (Incidence 0.6% vs 0.2%, HR 2.32, . This was driven by study 20110142 (DCRI: Incidence 0.8% vs 0.3%, HR 2.29, 95%CI 0.94-5.58; TIMI: Incidence 0.9% vs 0.2%, HR 3.61, 95%CI 1.34-9.74). The HR for cerebrovascular events was statistically significant for the overall study period by DCRI adjudication (Incidence 1.6% vs 1.1%, HR 1.44, 95%CI 1.05-1.98) and by TIMI adjudication (Incidence 1.7% vs 1.2%, HR 1.42, 95%CI 1.04-1.94). These results were also driven by study 20110142.</p><p>The incidence of positively-adjudicated stroke as a component of cerebrovascular events was low with a non-significant HR in the 12-month period by DCRI and TIMI adjudication ( <ref type="figure" target="#fig_0">Figure 31</ref>, <ref type="figure" target="#fig_2">Figure 32</ref>): (DCRI: Incidence 0.4% vs 0.3%, HR 1.26, 95%CI 0.68-2.32; TIMI: Incidence 0.4% vs 0.2%, HR 1.61, 95%CI 0.83-3.12). However, the results were marginally significant for positively adjudicated stroke for the overall study period <ref type="figure" target="#fig_2">(Figure 33</ref>, <ref type="figure" target="#fig_2">Figure 34)</ref>  A triggering event for both DCRI and TIMI adjudication was cardiac ischemic event that consisted of myocardial infarction, angina requiring hospitalization, and coronary revascularization by either percutaneous coronary intervention or coronary artery bypass surgery. A meta-analysis of the time to first occurrence of positively adjudicated cardiac ischemic events through month 12 is shown in <ref type="figure" target="#fig_2">Figure 35</ref> for DCRI and <ref type="figure" target="#fig_2">Figure 36</ref> for TIMI.</p><p>Analogous results for the overall study period are shown in <ref type="figure" target="#fig_2">Figure 37</ref> for DCRI and <ref type="figure" target="#fig_2">Figure 38</ref> for TIMI. The results showed a low incidence of events. Through the 12-month double-blind period, the DCRI adjudication showed a non-significant HR (Incidence 0.6% vs 0.4%, HR 1.54, 95%CI 0.90-2.63) for the three studies but a statistically significant result in study 20110142 (Incidence 0.8% vs 0.3%, HR 2.68, 95%CI 1.05-6.84). TIMI adjudication showed the same results (Incidence 0.5% s 0.4%, HR 1.48, 95%CI 0.84-2.61) driven by study 20110142 (Incidence 0.8% vs 0.3%, HR 2.84, . These signals were attenuated for the overall study periods.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 3: DCRI Adjudication of SAEs in the Overall Study Period</head><p>Source: Comprehensive Cardiovascular Report-Appendix 4 and Table 14-1.1</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 4: TIMI Adjudication of AEs in the Overall Study Period</head><p>Source: Comprehensive Cardiovascular Report-Appendix 3 and    </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 8: Hazard Ratio of Positively Adjudicated Cardiovascular Adverse Events leading to Death, Myocardial Infarction, or Stroke based on DCRI, DCRI-matched TIMI, and Full TIMI for Overall Study Period: all 3 studies</head><p>Source: Comprehensive Cardiovascular Report (14-6.16.1.4)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 9: Hazard Ratio of Positively Adjudicated Cardiovascular Adverse Events leading to Death, Myocardial Infarction, or Stroke based on DCRI, DCRI-matched TIMI, and Full TIMI for Overall Study Period: study 20110142</head><p>Source: Comprehensive Cardiovascular Report (14-6.16.1.5)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 10: Hazard Ratio of Positively Adjudicated Cardiovascular Adverse Events leading to Death, Myocardial Infarction, or Stroke based on DCRI, DCRI-matched TIMI, and Full TIMI for Overall Study Period: study 20070337</head><p>Source: Comprehensive Cardiovascular Report (14-6.16.1.6) --------------------------------------------------------------------------------------------This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record. </p><formula xml:id="formula_4">-------------------------------------------------------------------------------------------- /s/ ------------------------------------------------------------ FORTUNATO F</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Benefit-Risk Assessment</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Benefit-Risk Summary and Assessment</head><p>Romosozumab (proposed trade name Evenity) is a first-in-class sclerostin inhibitor proposed as a one-year treatment for postmenopausal osteoporosis to reduce the risk of fracture. The dosing regimen is 210 mg administered subcutaneously once monthly in the arm, abdominal wall or thigh by a health care provider. Two back-to-back injections are needed to administer the full dose.</p><p>Osteoporosis is a skeletal disorder characterized by low bone mass, compromised bone strength, and an increased risk of fracture. While osteoporosis can occur in both men and women, studies in postmenopausal women provide most of the data defining the disease and its sequelae. The goal of treatment is to reduce the risk of fracture.</p><p>The efficacy of romosozumab was evaluated in a clinical trial of postmenopausal women with osteoporosis who were receiving calcium and vitamin D supplementation. Fracture outcomes were assessed after patients received one year of treatment with romosozumab or placebo, and again after patients had subsequently received a year of treatment with denosumab.</p><p> One year of treatment with romosozumab significantly reduced the risk of new vertebral fractures compared to placebo. The incidence of new vertebral fractures was 0.5% with romosozumab and 1.8% with placebo (p&lt;0.001). The absolute risk reduction was 1.3% (95% confidence interval 0.8%-1.8%) and the relative risk reduction was 73% (95% confidence interval 53%-84%). Based on the bounds of the 95% confidence interval for the absolute risk reduction, the number needed to treat to prevent one new vertebral fracture is 56-125.</p><p> One year of romosozumab followed by one year of denosumab significantly reduced the risk of new vertebral fractures compared to one year of placebo followed by one year of denosumab. The incidence of new vertebral fractures was 0.6% with romosozumab then denosumab and 2.5% with placebo then denosumab (p&lt;0.001). The absolute risk reduction was 1.9% (95% confidence interval 1.3%-2.5%) and the relative risk reduction was 75% (95% confidence interval 60%-84%).</p><p>The robust and statistically persuasive findings (p&lt;0.001) from this single fracture outcomes trial together with supportive bone mineral density data from two dose-finding trials meet the requirement for substantial evidence of effectiveness.</p><p>Romosozumab did not significantly reduce the risk of nonvertebral fractures, likely because the trial was underpowered for these events.</p><p>Based on the observation that patients previously treated with romosozumab experienced large losses of their accrued bone mineral density</p><p>Reference ID: 4124009 after switching to placebo for one year, the beneficial effect of romosozumab on vertebral fractures is expected to wane within one year after stopping romosozumab if another osteoporosis therapy is not initiated. The application provides evidence of fracture risk reduction beyond the one year of treatment with romosozumab only for patients who subsequently received one year of treatment with denosumab.</p><p>Only 3% of the pivotal Phase 3 trial population was from North America. There were too few patients to statistically analyze fracture outcomes in this subgroup. However, the bone mineral density increases among North Americans were consistent with those for the overall trial population. These data support generalizability of the foreign data to patients in the United States.</p><p>Treatment with romosozumab for one year did not appear to have adverse cardiovascular effects compared to placebo. In contrast, topline results from an ongoing trial that became available late in the review cycle showed adverse cardiovascular effects with romosozumab compared to alendronate (an approved osteoporosis therapy). Adverse cardiovascular effects were also seen in a recently completed, small male osteoporosis trial. Reasons for the discrepant results are unclear. The hazard ratios for Major Adverse Cardiovascular Events (MACE), a composite endpoint of adjudicated serious adverse events of myocardial infarction and stroke, and cardiovascular death were:  1.03 (95% confidence interval 0.62, 1.72) in the pivotal Phase 3 trial included in the application  1.87 (95% confidence interval <ref type="bibr">1.11, 3.14)</ref> in the alendronate trial  1.55 (95% confidence interval 0.31, 7.69) in the male osteoporosis trial Romosozumab's remaining safety concerns are generally infrequent and have been seen with other therapeutic biologics or with some of the other approved osteoporosis therapies. These safety concerns include:  Hypersensitivity reactions, which were reported as serious in 0.2% of patients  Injection site reactions (e.g., pain and erythema), which were reported in 5-10% of patients, but rarely led to treatment discontinuation  Hypocalcemia, which was reported in less than 0.5% of patients. Those with renal impairment, particularly end-stage renal disease, appear to be particularly susceptible to hypocalcemia with romosozumab.  Osteonecrosis of the jaw, which was reported in three patients, one currently and two previously treated with romosozumab  Atypical femoral fracture, which was reported in two patients, one currently and one previously treated with romosozumab About 19% of patients treated with the 210 mg romosozumab dose developed binding antibodies. About 4% of those with binding antibodies tested positive for neutralizing antibodies. The incidence of injection site reactions was slightly higher among patients with antibodies. There were no other apparent effects of antibodies on safety. Antibodies decreased romosozumab exposures by up to 25%. However, romosozumab concentrations among patients with binding antibodies were all within the range of concentrations observed in patients without binding antibodies. In general, the presence of antibodies had no apparent effect on efficacy, although it is possible that some patients may have reduced efficacy as evidenced by a romosozumab-treated patient who developed neutralizing antibodies then had persistently undetectable romosozumab concentrations despite continued dosing.</p><p>The new data showing potential cardiovascular risk are preliminary. A full report of these data and the fracture outcomes data from the head-tohead comparison of romosozumab to alendronate are needed to determine whether there is a population for whom the benefits of romosozumab outweigh its risks, and whether risk minimization strategies beyond labeling are needed to ensure the benefits outweigh the risks. The remaining safety concerns can be adequately mitigated by labeling, including a Medication Guide.</p><p>In summary, the Division cannot determine whether the benefits of romosozumab outweigh the identified risks and uncertainties until we have completed a thorough review of the cardiovascular safety of romosozumab and its comparative efficacy from the alendronate-controlled trial. These data should be included in the resubmission.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimension Evidence and Uncertainties Conclusions and Reasons</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Condition</head><p> Osteoporosis is characterized by low bone mass and compromised bone strength. Osteoporosis increases the risk of fracture.  Osteoporosis is underdiagnosed. About 50% of postmenopausal women over 50 years of age will have an osteoporotic fracture.  Vertebral fractures are the most common site of osteoporotic fracture and can cause kyphosis, back pain, height loss, and impaired lung function.  In older patients, hip fracture is associated with loss of independence and increased mortality.</p><p>Osteoporosis increases the risk of fracture.</p><p>Underdiagnosis of osteoporosis is a major public health issue.</p><p>Vertebral fractures are the most common site of osteoporotic fracture.</p><p>Fractures can cause morbidity. Hip fracture is associated with increased mortality in older patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Current Treatment Options</head><p> The goal of treatment is to reduce the risk of fracture. Approved treatments include two drugs that stimulate bone formation (teriparatide, abaloparatide) and several drugs that inhibit bone loss (bisphosphonates, denosumab, estrogen agonists/antagonists, and calcitonin).  All approved treatments for postmenopausal osteoporosis except for calcitonin have been definitively shown to reduce the risk of fracture.  Bisphosphonates are the most widely prescribed osteoporosis medications, but use has declined because of fears related to the serious, but rare side Multiple therapies are available for the treatment of postmenopausal osteoporosis. The goal of treatment is to reduce the risk of fracture.</p><p>Many patients with osteoporosis who would benefit from therapy remain untreated.</p><p>Additional therapies, such as romosozumab</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimension Evidence and Uncertainties Conclusions and Reasons</head><p>effects of osteonecrosis of the jaw and atypical femoral fractures.  Teriparatide and abaloparatide cause osteosarcoma in rats. Because human relevance cannot be excluded, these drugs are indicated for patients at high risk of fracture and lifetime use beyond two years is not recommended.</p><p>will expand the treatment options for osteoporosis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Benefit</head><p> In a clinical trial of postmenopausal women with osteoporosis who were receiving calcium and vitamin D supplementation, one year of treatment with romosozumab significantly reduced the risk of new vertebral fractures compared to placebo.</p><p>o The incidence of new vertebral fractures was 0.5% with romosozumab and 1.8% with placebo (p&lt;0.001). The absolute risk reduction was 1.3% (95% confidence interval 0.8%-1.8%) and the relative risk reduction was 73% (95% confidence interval 53%-84%).</p><p>o Based on the lower and upper bounds of the 95% confidence interval for the absolute risk reduction, the number needed to treat to prevent one new vertebral fracture is 56-125.  The statistically persuasive findings (p&lt;0.001) from this single fracture outcomes trial together with the supportive bone mineral density data from two dose-finding trials provide convincing evidence of efficacy.  In the same clinical trial, one year of romosozumab followed by one year of denosumab significantly reduced the risk of new vertebral fractures compared to one year of placebo followed by one year of denosumab.</p><p>o The incidence of new vertebral fractures was 0.6% with romosozumab then denosumab and 2.5% with placebo then denosumab (p&lt;0.001). The absolute risk reduction was 1.9% (95% confidence interval 1.3%-2.5%) and the relative risk reduction was 75% (95% confidence interval 60%-84%).</p><p>The Applicant has provided substantial evidence of effectiveness for romosozumab when used as a one-year treatment for postmenopausal osteoporosis.</p><p>Based on the bone mineral density data, the beneficial effect of romosozumab on vertebral fractures is expected to wane within one year after stopping romosozumab if another osteoporosis therapy is not initiated.</p><p>Evidence of fracture risk reduction beyond the one year of treatment with romosozumab is available only for patients who subsequently received one year of treatment with denosumab.</p><p>The number needed to treat to prevent one vertebral fracture after one year of treatment with romosozumab is 56-125.</p><p>Romosozumab has not been shown to reduce the risk of nonvertebral fractures, likely because the trial was underpowered for this endpoint.</p><p>The Phase 3 trial enrolled too few patients from the United States to statistically evaluate 6</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimension Evidence and Uncertainties Conclusions and Reasons</head><p> Romosozumab did not significantly reduce the risk of nonvertebral fractures, a composite of fractures from sites such as ribs, forearm, and hip.  Romosozumab's effects on bone mineral density provide strong support for initiating another osteoporosis therapy after the one-year treatment course.</p><p>o After one year, the mean percent increase in bone mineral density with romosozumab compared to placebo was 12.7% (95% confidence interval 12.4%, 12.9%) at the lumbar spine, 5.8% (95% confidence interval 5.6%, 6.0%) at the total hip and 5.2% (95% confidence interval 4.9%, 5.4%) at the femoral neck. o Patients had considerable loss of these bone mineral density gains within one year of stopping romosozumab. o Patients who transitioned to one year of denosumab after completing one year of romosozumab maintained their bone mineral density gains from romosozumab after the combined two years of therapy.  Only 3% of the pivotal Phase 3 trial population was from North America.</p><p>There were too few patients to statistically analyze fracture outcomes in this subgroup. However, the bone mineral density changes among North Americans were consistent with those for the overall trial population, and support generalizability of the foreign data to patients in the United States. efficacy in this subgroup. However, based on the totality of data, it is reasonable to conclude that the foreign data are applicable to the United States population.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk</head><p> Treatment with romosozumab for one year did not appear to have adverse cardiovascular effects compared to placebo. In contrast, topline results from an ongoing trial that became available late in the review cycle showed adverse cardiovascular effects with romosozumab compared to alendronate (an approved osteoporosis therapy). Adverse cardiovascular effects were also seen in a recently completed, small male osteoporosis trial. Reasons for the discrepant results are unclear. The hazard ratios for Major Adverse Cardiovascular Events (MACE), a composite endpoint of adjudicated serious adverse events of myocardial infarction and stroke, and</p><p>Romosozumab may increase the risk of major adverse cardiovascular events. There was no apparent effect when romosozumab was compared with placebo, but preliminary data from two other trials -including a large trial comparing romosozumab to alendronateshow increased risk. Reasons for the discrepant results are unclear.</p><p>The other safety concerns are generally o Hypersensitivity reactions (reported as serious in 0.2% of patients) o Injection site reactions, such as pain and erythema (reported in 5-10% of patients, and rarely led to treatment discontinuation) o Hypocalcemia (reported in less than 0.5% of patients). Those with renal impairment, particularly end-stage renal disease, appear to be particularly susceptible to hypocalcemia with romosozumab. o Osteonecrosis of the jaw (rare -three cases in patients currently or previously treated with romosozumab) o Atypical femoral fractures (rare -two cases in patients currently or previously treated with romosozumab)  About 19% of patients treated with the 210 mg dose developed binding antibodies. About 4% of those with binding antibodies tested positive for neutralizing antibodies. The incidence of injection site reactions was slightly higher among patients with antibodies. There were no other apparent effects of antibodies on safety.</p><p>infrequent and have been seen with other therapeutic biologics or with some of the other approved osteoporosis therapies.</p><p>Binding and neutralizing antibodies to romosozumab may slightly increase the risk of injection site reactions but do not appear to have other notable effects on safety.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk Management</head><p> The new data showing cardiovascular risk are preliminary. A full report of these data and the fracture outcomes data from the head-to-head comparison of romosozumab to alendronate are needed to determine whether there is a population for whom the benefits of romosozumab outweigh its risks, and whether risk minimization strategies beyond labeling are needed to ensure the benefits outweigh the risks.  If romosozumab can otherwise be approved, the remaining safety concerns can be adequately mitigated by labeling, including a Medication Guide.</p><p>A full report of the cardiovascular effects and the head-to-head comparison to alendronate is needed before we can assess whether the benefits of romosozumab outweigh its risks.</p><p>Labeling, including a Medication Guide for patients, will be adequate to mitigate all of the other currently identified safety concerns with romosozumab. 8</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Background</head><p>Amgen submitted this Biologics License Application (BLA) for romosozumab (trade name Evenity), a first-in-class sclerostin inhibitor proposed for the treatment of postmenopausal osteoporosis. Romosozumab is not approved in any country. The proposed dosing regimen is 210 mg (given as two back-to-back injections of 105 mg) administered subcutaneously by a healthcare provider in the patient's arm, abdominal wall or thigh once monthly for 12 months.</p><p>Sclerostin, a glycoprotein produced by osteocytes, inhibits the Wingless-related integration site (Wnt) signaling pathway, leading to reduced bone formation and increased bone resorption.</p><p>Patients with the rare bone disorder, sclerosteosis, have an inactivating mutation in the sclerostin gene that leads to a lack of sclerostin, and have dense bones that are resistant to fracture. Patients with Van Buchem disease lack a regulatory element of the sclerostin gene, leading to reduced sclerostin concentrations and a resistance to fractures. Based on these effects, the Applicant developed romosozumab, a humanized immunoglobulin G2 (IgG2) monoclonal antibody, that binds and inhibits sclerostin to reduce the risk of fractures in patients with osteoporosis.</p><p>This BLA was reviewed under the Prescription Drug User Fee Act (PDUFA) V "Program" because it contains a new molecular entity and was received after October 1, 2012. This document summarizes the Division's recommendations on the application.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Product Quality</head><p>The Office of Pharmaceutical Quality and the Center for Devices and Radiological Health recommend approval. See their reviews for details.</p><p>Evenity is a drug-device combination product containing romosozumab in a sterile, preservativefree solution within a single-use syringe. The syringe includes a needle. Each syringe delivers a volume of 1.17 mL containing 105 mg of romosozumab in a concentration of 90 mg/mL. Inactive ingredients include calcium, acetate, sucrose, polysorbate 20, sodium hydroxide and Water for Injection -none of which are novel. A syringe delivers one-half of the required dose; therefore, two back-to-back injections using two separate syringes are needed to deliver the full dose.</p><p>Romosozumab is produced from a recombinant DNA-derived Chinese Hamster Ovary (CHO) cell line using standard cell culture techniques. The Applicant provided adequate data to ensure that the product is pure and potent, and has acceptable manufacturing processes. All required pre-licensing manufacturing inspections were acceptable.</p><p>If romosozumab can be approved, the Chemistry reviewers recommend a postmarketing commitment 9</p><p>The Office of Pharmaceutical Quality also assessed the Applicant's assays for detecting binding and neutralizing antibodies to romosozumab. The reviewers found the assays to be adequate. Of note, the presence of romosozumab can interfere with the neutralizing assay, preventing detection of low concentrations of neutralizing antibodies. The Applicant handled this issue by including an assessment of neutralizing antibodies four months after the last dose of romosozumab in the Phase 2 and 3 trials.</p><p>The stability data support a shelf-life of 36 months for the drug product when stored at 2-8 degrees Celsius.</p><p>The Center for Devices and Radiological Health reviewed the syringe component and concluded that it is suitable for the intended use.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Nonclinical Pharmacology/Toxicology</head><p>The Nonclinical Pharmacology/Toxicology reviewers recommend approval. See their review for details.</p><p>Romosozumab binds with similar affinity to human, rat and monkey sclerostin. Anti-drug antibodies developed in some rats and monkeys, lowering exposures. These animals were removed from the longer-term nonclinical studies or removed from data analyses involving pharmacokinetic evaluations. Romosozumab was highly immunogenic in rabbits so this species was not used for toxicity assessments.</p><p>The drug substance formulation used in the nonclinical studies was either identical to that used for the Phase 3 trial or adequately bridged to the Phase 3 formulation via a monkey pharmacokinetic study.</p><p>In ovariectomized rats and monkeys (animal models of postmenopausal osteoporosis), romosozumab increased bone mass and bone strength without negatively affecting bone quality.</p><p>The Applicant conducted toxicology studies up to six months duration in rats and monkeys. The reviewers attribute the main findings in these studies to the pharmacologic effect of romosozumab. For example, decreases in red blood cells, leukocytes, and platelets, and extramedullary hematopoiesis were associated with hyperostosis (excessive bone growth), and attributed to the narrowing of the hematopoietic bone marrow space. There were also decreases in serum calcium and phosphorus (attributed to use of these minerals for new bone formation). Multiples of human exposure ranged from 1 to 38-fold in rats and 1 to 93-fold in monkeys.</p><p>As discussed in the Safety Section and Benefit/Risk Assessment, the Applicant has identified a cardiovascular safety signal in an ongoing active-controlled Phase 3 trial and in a small trial in men, which was not observed in the Phase 3 trial included in the BLA. The sclerostin gene or protein is expressed in portions of the vasculature (the aorta, pulmonary artery, and calcified vascular smooth muscle cells). However, there were no adverse findings from the nonclinical program that lend support to the cardiovascular findings observed in the clinical trials. Specifically, there were no electrocardiographic effects in the one-month and six-month monkey 10 toxicity studies, no cardiac or vascular histopathologic findings in rats or monkeys, no radiographic evidence of vascular calcification in a 12-month monkey bone study, and no effect on the incidence of vascular calcification in a two-year rat study.</p><p>The Applicant did not assess mutagenicity because monoclonal antibodies are not expected to alter DNA or chromosomes. We recommended a rodent carcinogenicity study because of the potential for romosozumab to activate Wnt signaling, because this pathway may be involved in tumorigenesis. The 98-week carcinogenicity study in rats did not show any drug-related tumors. Two cases of osteosarcoma were seen in males in the high-dose group (19-times human exposure) that were not statistically different to control. The reviewers concluded that romosozumab is unlikely to increase the human risk of osteosarcoma.</p><p>Findings from the reproductive toxicity studies in rats included:</p><p> No effects on fertility in rats given romosozumab at 1.5 to 56-times human exposure.</p><p> Reduced ventral processes of the sixth cervical vertebra at 17 to 56-times human exposure. This finding represents a developmental delay but the reviewers do not consider it to be relevant because this anatomical structure is not present in humans.</p><p> Poly-and syndactyly at 32-times human exposure. This finding is consistent with the syndactyly seen in humans who have homozygous sclerosteosis, and in mice that have a knockout of the sclerostin gene. The reviewers consider this finding to have low clinical relevance based on the exposure multiple, and timing of digit formation in the first trimester in humans when placental transfer of immunoglobulins is limited.</p><p> Mild decreases in bone mass and size in the offspring of female rats that had been given romosozumab doses at 1.5 to 56-times human exposure.</p><p>Note that the Applicant is seeking approval in postmenopausal women, a population that is no longer of reproductive potential.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Clinical Pharmacology</head><p>The Clinical Pharmacology and Pharmacometrics reviewers recommend approval. See their review for details. Key findings are summarized below.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Selected pharmacokinetic parameters:</head><p>Romosozumab has nonlinear pharmacokinetics, with a greater than dose-proportional increase in exposure. For example, there is a 550-fold increase in mean area under the concentration-time curve (AUC inf ) with a 100-fold increase in subcutaneous dosing from 0.1 mg/kg to 10 mg/kg (the proposed dose of 210 mg corresponds to 3 mg/kg for a 70 kg women).</p><p>After a single 210 mg dose to healthy subjects, the median time to maximal concentrations (Tmax) was five days (range 2-7 days) with a Cmax of 22 mcg/mL. In the pivotal Phase 3 trial, steady state was achieved by Month 3 following once monthly dosing. At steady state, trough serum concentrations of romosozumab ranged from 8-10 mcg/mL in pre-dose samples, and the effective half-life was about 13 days.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Intrinsic and extrinsic factors:</head><p>The Applicant tested a single romosozumab dose in the pivotal Phase 3 trial. The Clinical Pharmacology reviewers are not recommending dose adjustments based on intrinsic factors (e.g., age, body weight, renal impairment) or extrinsic factors (e.g., drug interactions), as summarized below.</p><p> In a single-dose pharmacokinetic study, patients with severe renal impairment had a 29% mean increase in romosozumab Cmax and a 44% mean increase in romosozumab AUC compared to healthy subjects (smaller increases are expected in patients with mild or moderate renal impairment). These modest pharmacokinetic differences do not necessitate dosage adjustment. In contrast, mean romosozumab exposures were similar between patients with end-stage renal disease on hemodialysis and healthy subjects. The reason for the discrepancy between those with severe renal impairment and end-stage renal disease is unclear.</p><p> Population pharmacokinetic modeling did not identify an impact of age on romosozumab exposures but noted an increase in romosozumab exposures among patients with lower body weight. Romosozumab AUC among patients in the lowest quartile of body weight was about 50% higher than in the highest quartile of body weight. These data are consistent with the bone mineral density changes seen with romosozumab in the pivotal Phase 3 trial, where percent increases at the lumbar spine were progressively smaller with increasing quartile of body weight. For example, the median increase at one year was 14.8% in the lowest quartile of body weight compared to 10.8% in the highest quartile. However, the highest quartile still had large increases in bone mineral density and had a numerically lower incidence of new vertebral fractures compared to the lowest quartile. There was also no statistical interaction between treatment and body mass index with respect to new vertebral fractures. In totality, based on these data from the pivotal Phase 3 trial, which administered the same dose to all patients regardless of body weight, there is no need for dosage adjustment based on body weight.</p><p> The Applicant did not assess romosozumab exposures in patients with hepatic impairment, characterize the metabolic pathway of romosozumab, or conduct drug-drug interaction studies. This is reasonable because, unlike small molecule drugs which are often metabolized by hepatic enzymes, large therapeutic antibodies are typically degraded into amino acids by ubiquitous proteases.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose-finding:</head><p>The Phase 2 dose-finding trial (20060326) in postmenopausal women with low bone mineral density included two active-comparator arms, and an extension and retreatment phase. For dose-selection for Phase 3, the Applicant focused on the initial two year treatment period and comparisons between placebo and the five tested subcutaneous romosozumab doses (70 mg monthly, 140 mg monthly, 210 mg monthly, 140 mg every three months, 210 mg every three months). There were dose-dependent increases in bone mineral density during the first year of treatment, with more gradual increases during the second year.</p><p>During the first year of treatment with romosozumab, bone turnover markers showed an increase in bone formation and a reduction in bone resorption. During the second year, the bone turnover markers showed persistent effects on bone resorption but not on bone formation.</p><p>Based on the bone mineral density data and bone turnover markers, the Applicant proposed to treat patients with romosozumab for only one year. They chose the 210 mg monthly dose for Phase 3 testing because this dose had the greatest effect on bone mineral density and bone formation markers during one year of treatment.</p><p>After the two year treatment period, patients were re-randomized to one year of denosumab or placebo. After treatment with placebo for one year, patients previously treated with romosozumab had experienced large losses of their accrued bone mineral density. These data provide an opportunity to assess what happens to bone mineral density when romosozumab is stopped without initiation of other osteoporosis therapy, and support the need for continued osteoporosis therapy after romosozumab is stopped.</p><p>Another dose-finding Phase 2 trial (20101291) was conducted in postmenopausal Japanese women with osteoporosis. This one year trial compared three romosozumab doses (70 mg, 140 mg, or 210 mg once monthly) to placebo. Findings were consistent with the other dose-finding trial, with the greatest bone mineral density gains at the lumbar spine with the 210 mg monthly dose.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bone turnover markers:</head><p>In the pivotal Phase 3 trial, the bone formation marker, type 1 Nterminal procollagen (P1NP), peaked two weeks after starting romosozumab but declined to concentrations seen with placebo at Month 9 and further declined to concentrations about 15% below placebo at Month 12. The bone resorption marker collagen type 1 C-telopeptide (CTX), nadired two weeks after starting romosozumab and remained about 25% below placebo at Month 12. These data like those from the Phase 2 dose-finding trial, support two mechanisms of action -increased bone formation (that is transient, lasting less than a year) and reduced bone resorption (that persists after one year of treatment).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Formulation changes:</head><p>In the dose-finding Phase 2 trial (20060326) and the pivotal Phase 3 trial <ref type="formula" target="#formula_34">(20070337)</ref>, investigators administered the 70 mg/mL formulation of romosozumab. The full 210 mg dose was given as three back-to-back 1.0 mL injections. In contrast, the to-be-marketed product uses single-use prefilled syringes containing 90 mg/mL of romosozumab. Health care providers will administer the 210 mg dose as two 1.17 mL injections, with each injection providing 105 mg of romosozumab. The Applicant adequately bridged the differences between the Phase 3 and to-be-marketed products with the following approach:</p><p> A clinical pharmacology study and a separate six-month bone mineral density non-inferiority trial compared the 210 mg romosozumab dose given in the 70 mg/mL formulation to the 90 mg/mL formulation. Both formulations in these bridging trials used the Phase 3 drug substance manufacturing site. We had recommended the non-inferiority trial because formulation changes of complex protein products, such as romosozumab, could potentially</p><formula xml:id="formula_5">Reference ID: 4124009 (b) (4)</formula><p>impact immunogenicity, which could in turn affect the efficacy or safety profile. This noninferiority trial is discussed in more detail in the Efficacy and Safety sections.</p><p> Another clinical pharmacology study compared the pharmacokinetic profile of the 210 mg romosozumab dose given in the 90 mg/mL formulation produced at the Phase 3 drug substance manufacturing site to the 90 mg/mL formulation produced at the to-be-marketed drug substance manufacturing site.</p><p> Lastly, the Office of Pharmaceutical Quality determined that comparative analytical data, including lot release testing, additional characterization, and stability studies were sufficient to bridge the change in the commercial manufacturing site for the drug product.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunogenicity:</head><p>One subject in the first-in-human study developed neutralizing antibodies to romosozumab following a 10 mg/kg dose. In this subject, the romosozumab concentration became undetectable on Day 7 and remained undetectable through Day 168 despite continued dosing with 1 mg/kg subcutaneously every two weeks.</p><p>About 19% of patients treated with the 210 mg dose developed binding antibodies. About 4% of those with binding antibodies tested positive for neutralizing antibodies. The 90 mg/mL formulation did not have a higher incidence of binding or neutralizing antibodies than the 70 mg/mL formulation in the head-to-head six month non-inferiority trial.</p><p>In the pivotal Phase 3 trial, romosozumab exposures were reduced by up to 25% among patients with binding antibodies compared to those who were antibody negative, with greater reductions among those with neutralizing antibodies. However, romosozumab concentrations among patients with binding antibodies were all within the range of concentrations observed in patients without binding antibodies. In addition, patients with binding antibodies had similar percent increases in bone mineral density compared to those without antibodies. Based on these data, it appears that most patients with antibodies to romosozumab should not have a reduction in efficacy, although it is possible that some patients may have reduced efficacy, as evidenced by the patient with neutralizing antibodies in the first-in-human trial who had undetectable romosozumab concentrations despite continued dosing. As discussed in the Safety section, patients with antibodies to romosozumab appear to have a slightly higher incidence of injection site reactions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.">Clinical Microbiology</head><p>Not applicable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">Clinical/Statistical-Efficacy</head><p>This section summarizes the design and key efficacy results for the two Phase 3 trials. See the clinical and statistical reviews and Cross-Discipline Team Leader memorandum for details.</p><p>Study 20070337: This is the multinational, randomized, double-blind, placebo-controlled, pivotal Phase 3 trial designed to establish the efficacy of romosozumab for the treatment of postmenopausal osteoporosis. Postmenopausal women 55-90 years of age at increased risk of fracture were randomized to 12 months of blinded treatment with romosozumab 210 mg given in the 70 mg/mL formulation (n=3589) or placebo (n=3591), each administered as three subcutaneous back-to-back injections once monthly in the arm, abdominal wall, or thigh. After this 12-month treatment period, all patients were switched to open-label denosumab, an antiresorptive agent, administered at the approved dose of 60 mg subcutaneously every six months for an additional 12 months. There is an ongoing open-label extension during which patients are continuing to receive denosumab for a second year -results from this extension are not included in the application. All injections were administered by study personnel. Patients also received daily calcium and vitamin D supplementation.</p><p>Post-treatment x-rays of the spine and bone mineral density assessments were performed at months 12, 24 and 36. Spine x-rays and bone mineral density images were read blindly at a central facility.</p><p>The co-primary efficacy endpoints were:  Percentage of patients with a new morphometric (radiographically defined) vertebral fracture through Month 12  Percentage of patients with a new morphometric vertebral fracture through Month 24</p><p>New morphometric vertebral fracture is the standard efficacy endpoint for drugs intended to treat postmenopausal osteoporosis.</p><p>The Applicant controlled type I error for the following secondary endpoints using sequential testing:</p><p> The Applicant also included secondary endpoints for percent change from baseline to Month 12 and Month 24 in lumbar spine, total hip and femoral neck bone mineral density. These endpoints were not controlled for type 1 error.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>15</head><p>The primary analysis set for vertebral fractures and bone mineral density changes included all randomized patients who had a baseline and at least one post-baseline evaluation of the endpoint of interest at or before the time point under consideration. For bone mineral density changes, missing data were imputed using last-observation-carried-forward. All randomized patients were used for the other fracture endpoints that did not include vertebral fractures.</p><p>Results: This trial randomized 3589 patients to romosozumab and 3591 patients to placebo. About 89% of patients in both treatment groups completed the 12-month double-blind period, and about 84% of the original randomized population also completed 12 months of open-label denosumab. All patients were postmenopausal women. The age range was 55-90 years (mean 71 years), and about 31% were at least 75 years old. Approximately 57% of the patients were Caucasian and 40% were Hispanic or Latino. The mean body mass index was 24.7 kg/m 2 (range 10.0-53.8 kg/m 2 ). Most patients were from Central/Latin America (43%) and Central/Eastern Europe (29%). Only 3% of patients were from North America. A total of 132 patients (1.8%) were from the United States. About 18% of patients had at least one verified vertebral fracture at baseline. Baseline mean T-scores were about -2.7 at the lumbar spine (about 40% of patients had a lumbar spine T-score of -3.0), -2.7 at the femoral neck, and -2.5 at the total hip.</p><p>The extent to which injections occurred at the three allowed sites (arm, abdominal wall, or thigh) is unclear. The application is receiving a Complete Response letter for unrelated reasons (see the Safety and Benefit/Risk sections) so we will ask the Applicant to include injection site data in the resubmission to ensure that all proposed injection sites were reasonably represented in the trial. <ref type="table" target="#tab_87">Table 1</ref>, the incidence of new vertebral fracture through Month 12 was significantly (p&lt;0.001) lower with romosozumab compared to placebo (0.5% vs. 1.8%). Through Month 24, the incidence of new vertebral fracture was 0.6% in the romosozumab then denosumab group compared to 2.5% in the placebo then romosozumab group (p&lt;0.001). The relative risk reductions were 73% (95% confidence interval 53%, 84%) through Month 12 and 75% (95% confidence interval 60%, 84%) through Month 24. Based on the upper and lower bounds of the 95% confidence interval for the absolute risk reduction, the number needed to treat to prevent one new vertebral fracture is 56-125. The statistically persuasive findings from this single fracture outcomes trial (p&lt;0.001) together with the supportive bone mineral density data from the other trials provide convincing evidence of efficacy.  <ref type="bibr">1</ref> 1.3% (0.8%, 1.8%) 1.9% (1.3%, 2.5%) Relative risk reduction 1 73% (53%, 84%) 75% (60%, 84%) N=number randomized; N1=number in primary analysis set for vertebral fractures 1 95% confidence interval in parentheses Secondary efficacy endpoints: The incidence of clinical fracture through Month 12, the first hierarchical secondary endpoint, was 1.6% with romosozumab compared to 2.5% with placebo (p&lt;0.01), with a corresponding relative risk reduction of 36% (95% confidence interval 11%, 54%).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Co-primary endpoint: As shown in</head><p>The romosozumab group had about 25% fewer nonvertebral fractures at months 12 and 24, but was not statistically superior to the placebo group at Month 12 (p=0.10, tested at the 0.05 alpha level) or to the placebo then denosumab group at Month 24 (p=0.029, tested at the 0.025 alpha level). The Applicant attributed this lack of statistical significance to reduced power. The power calculations had assumed a nonvertebral fracture incidence of 3.5% in the placebo group at 12 months and a treatment effect of at least 40%, but the observed incidence was only 2.1% and the relative risk reduction was only 25%. Because of the failed significance on nonvertebral fractures, statistical testing of the remaining hierarchical secondary endpoints should not proceed. <ref type="table" target="#tab_4">Table 2</ref>, romosozumab increased bone mineral density compared to placebo at the lumbar spine, total hip, and femoral neck at Month 12, with the largest treatment effects seen at the lumbar spine. From Month 12-24, the percent increases in bone mineral density were slightly smaller in the romosozumab then denosumab group compared to the placebo then denosumab group, which resulted in slightly smaller treatment effects at Month 24 compared to Month 12. The percent increases compared to placebo at Month 12 and Month 24 had associated p-values of less than 0.001, although these p-values are nominal because this testing was not controlled for type I error.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bone mineral density changes: As shown in</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subgroup analyses:</head><p>As discussed in the statistical review, analyses of the co-primary efficacy endpoints were consistent across tested subgroups based on age, race (Caucasian vs. non-Caucasian) and region, with no relevant treatment-by-subgroup interactions. Through Month 24, new vertebral fracture in the North American region occurred in none of 97 patients treated with romosozumab then denosumab and five of 87 patients treated with placebo then denosumab. These are too few events to reliably assess subgroup results in this geographic region. However, mean percent changes in bone mineral density among North Americans were consistent with the Reference ID: 4124009 (b) <ref type="bibr" target="#b86">(4)</ref> overall results at the lumbar spine, total hip, and femoral neck, supporting the applicability of the foreign data to the population in the United States. Study 20120156: This was a multicenter, randomized, Phase 3 trial to evaluate the noninferiority of the to-be-marketed 90 mg/mL romosozumab concentration to the 70 mg/mL formulation used in the pivotal Phase 3 trial. There were four treatment groups randomized in a 22:5:22:5 ratio to six months of treatment with:</p><p> Romosozumab 90 mg/mL-two back-to-back injections for a total dose of 210 mg  Placebo 90 mg/mL -two back-to-back injections  Romosozumab 70 mg/mL-three back-to-back injections for a total dose of 210 mg  Placebo 70 mg/mL -three back-to-back injections</p><p>The placebo groups were included to allow for double-blinding within concentrations.</p><p>The primary efficacy endpoint was the percent change from baseline in bone mineral density at the lumbar spine. Romosozumab 90 mg/mL would be declared non-inferior to the 70 mg/mL formulation if the lower bound of the one-sided 97.5% confidence interval for the treatment difference (90 mg/mL minus 70 mg/mL) was greater than the prespecified non-inferiority margin of -2%. This margin was calculated based on the treatment effect at six months on lumbar spine bone mineral density with the 210 mg monthly dose in the dose-finding Phase 2 trial (which tested the 70 mg/mL formulation). That treatment effect was 8.0% (95% confidence interval 6.6%, 9.3%). The non-inferiority margin allows at most a 30% loss, which is our standard noninferiority margin for bone mineral density, and is acceptable.</p><p>Results: In this trial, 118 patients were randomized to romosozumab 70 mg/mL, 123 patients were randomized to romosozumab 90 mg/mL and 53 patients were randomized to placebo. Completion rates were 89% for placebo, 93% for romosozumab 70 mg/mL, and 95% for romosozumab 90 mg/mL. At baseline, lumbar spine bone mineral density was 0.8% across the two romosozumab arms and the placebo group. Compared to placebo, romosozumab 70 mg/mL increased lumbar spine mineral density by 8.8% and romosozumab 90 mg/mL increased lumbar spine bone mineral density by 8.4%. The LS mean treatment difference (90 mg/mL vs. 70 mg/mL formulation) was -0.4% (95% confidence interval -1.5%, 0.7%). The to-be-marketed concentration was declared non-inferior to the Phase 3 concentration because the lower bound of -1.5% is greater than the pre-specified non-inferiority margin of -2.0%. Consistent findings were seen for bone mineral density changes at the total hip and femoral neck.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.">Safety</head><p>Most of the safety data come from the pivotal Phase 3 trial, which was much larger than the other trials. The one-year placebo-controlled data from this trial were pooled with the one-year placebo-controlled data from the two dose-finding Phase 2 trials. These pooled data (hereafter referred to as the "pooled dataset") serve as the main dataset for safety analyses. Safety findings from the Phase 3 non-inferiority trial that used the to-be-marketed drug substance concentration of 90 mg/mL are of interest as well. This formulation had a similar safety profile to the 70 mg/mL formulation, except where noted below. See the Clinical review and Cross-Discipline Team Leader memorandum for a detailed discussion of safety.</p><p>Exposures: A total of 5478 patients received at least one dose of romosozumab, 3879 of whom were treated for at least one year. These exposures are adequate, and meet the International Conference on Harmonization E1A guideline recommendations for drugs that treat chronic, nonlife-threatening conditions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Deaths:</head><p>In the pooled dataset, 0.8% of the romosozumab-treated patients and 0.7% of the placebo-treated patients died. There were no notable imbalances in the cause of death between treatment groups except for death due to lung cancer, which was reported in four romosozumabtreated patients and none receiving placebo. As discussed by the clinical reviewer, all four of these deaths occurred in current or former smokers, all cases of lung cancer (i.e., fatal plus nonfatal cases) were balanced between treatment groups (five cases each), and there was no overall imbalance in malignant/unspecified tumors between treatment groups (1.7% with romosozumab vs. 1.9% with placebo). These data on deaths do not raise any safety concerns.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serious Adverse Events:</head><p>In the pooled dataset, 9.5% of the romosozumab-treated patients and 8.8% of the placebo-treated patients reported at least one serious adverse event. As shown in the Clinical Review, for each of the preferred terms, there were generally very small imbalances between treatment groups (differences of less than 0.2%), sometimes favoring romosozumab and sometimes favoring placebo, none of which raise any safety concerns.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discontinuations due to Adverse Events:</head><p>In the pooled dataset, adverse events leading to discontinuation were reported in 1.2% of the romosozumab-treated patients and 1.4% of the placebo-treated patients. The only adverse events leading to discontinuation in more than one romosozumab-treated patient were arthralgia, musculoskeletal pain, and extremity pain (each reported in three patients) and abdominal pain, back pain, and nausea (each reported in two patients). These data do not raise any safety concerns.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Common Adverse Events:</head><p>In the pooled dataset, 78% of the romosozumab-treated patients and 80% of the placebo-treated patients reported at least one adverse event. The most commonly reported adverse events (with incidence above 2%) that also occurred at an incidence of at least 0.5% higher with romosozumab than placebo included nasopharyngitis (13.2% vs. 12.3%), arthralgia (12.7% vs. 11.8%), headache (6.5% vs. 5.8%), muscle spasm (4.5% vs. 3.8%), and neck pain (2.2% vs. 1.5%). These data can be labeled and do not raise major safety concerns.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse Events of Interest:</head><p>Adverse events of interest based on animal findings or the mechanism of action include:</p><p>Atypical Femoral Fractures and Osteonecrosis of the Jaw: Atypical femoral fractures and osteonecrosis of the jaw are associated with antiresorptive agents, and could potentially be seen with romosozumab, which has antiresorptive activity.</p><p>In the 12-month pooled dataset, there was one adjudicated case (0.03%) of atypical femoral fracture, which occurred in the pivotal Phase 3 trial in a patient treated with romosozumab for about 3.5 months, who fell from a standing height. This patient was not exposed to other products associated with atypical femoral fractures and reported prodromal pain in the affected region prior to study start. To date, four additional adjudicated cases of atypical femoral fracture have been identified in an ongoing alendronate-controlled, Phase 3 trial. One of these cases occurred in a patient who had received alendronate for 21 months after one year of romosozumab. The remaining three cases occurred in patients randomized to alendronate with treatment durations of 16, 17, and 28 months.</p><p>In the pivotal Phase 3 trial, there were two adjudicated cases of osteonecrosis of the jaw. One case occurred after nearly one year of treatment with romosozumab and the other occurred about three months after starting denosumab in a patient who was previously treated with romosozumab. In the ongoing alendronate-controlled, Phase 3 trial, there were two additional cases -one in a patient who had received alendronate for about 16 months after one year of romosozumab and one in a patient randomized to alendronate after 21 months of treatment.</p><p>The risks of atypical femoral fracture and osteonecrosis of the jaw appear rare, are well known with antiresorptive therapies, and can be handled with labeling.</p><p>Hypocalcemia: Romosozumab can cause hypocalcemia as a result of calcium influx into bone (during bone formation) and reduced calcium release from bone into the blood stream (because of decreased bone resorption). Romosozumab lowered serum calcium throughout the 12-month placebo-controlled period in the pivotal Phase 3 trial, with average reductions from baseline of about 0.1-0.2 mg/dL. There were no reported serious adverse events of hypocalcemia. To assess the extent of outliers, the Applicant reported the incidence of worst albumin-corrected serum calcium using the Common Terminology Criteria for Adverse Events version 3.0 grading system. In the pooled dataset, seven romosozumab-treated patients (0.2%) and three placebotreated patients (&lt;0.1%) developed grade 1 hypocalcemia (below the lower limit of normal but no lower than 8.0 mg/dL), seven romosozumab-treated patients (0.2%) and one placebo-treated patient (&lt;0.1%) developed grade 2 hypocalcemia (7.0-7.9 mg/dL), and no romosozumab-treated patients developed more severe hypocalcemia.</p><p>Although hypocalcemia was rare, it is important to note that the pivotal Phase 3 trial included calcium and vitamin D supplementation. In addition, patients with a screening 25-hydroxyvitamin D concentration of 20-40 ng/mL received a loading dose of 50,000-60,000 international units of vitamin D after randomization. Those with a screening 25-hydroxy-vitamin D concentration below 20 ng/mL were excluded and those with a concentration above 40 ng/mL could still receive the vitamin D loading dose at the investigator's discretion. About three-fourths of randomized patients received the starting dose. Therefore, the risk of hypocalcemia without these interventions is unknown.</p><p>Patients with renal impairment may be at particular risk for hypocalcemia with romosozumab. In the renal impairment pharmacokinetic study, which included calcium and vitamin D supplementation, hypocalcemia was reported in none of the healthy subjects, in one of the patients with severe renal impairment, and in four of those with end-stage renal disease. This risk is not related to increased romosozumab exposures, which were comparable in those with endstage renal disease and healthy volunteers.</p><p>The risk of hypocalcemia can be adequately managed with labeling that includes statements about the need for adequate calcium and vitamin D supplementation prior to, and during, treatment with romosozumab, as well as monitoring of serum calcium in patients at increased risk of hypocalcemia.</p><p>Hypophosphatemia: Romosozumab can cause hypophosphatemia based on the same mechanisms that can cause hypocalcemia. Sixteen romosozumab-treated patients (0.4%) and four placebotreated patients (0.1%) developed serum phosphate in the range of 2.0-2.4 mg/dL. This risk, which appears infrequent, can be handled with labeling.</p><p>Parathyroid Hormone: The pivotal Phase 3 trial included a substudy involving 656 patients to assess the effects of romosozumab on serum parathyroid hormone. Serum parathyroid hormone increased above baseline throughout the 12-month placebo-controlled treatment period, with 38% of the romosozumab-treated patients and 15% of the placebo-treated patients having at least one parathyroid hormone measurement above the upper limit of the reference range. Most of the outliers had parathyroid hormone concentrations that were up to twice the upper limit of the reference range, although 1.7% of the romosozumab-treated patients had elevations above three times the upper limit of normal. The highest measured serum parathyroid hormone in the romosozumab-treated group was about 300 pg/mL. These findings likely reflect a compensatory increase in parathyroid hormone because of calcium sequestration in bone. In the renal impairment clinical pharmacology study, there were greater increases in serum parathyroid hormone among romosozumab-treated patients with severe renal impairment and even further increases in those with end-stage renal disease. These findings should be labeled.</p><p>Hyperostosis: Hyperostosis (excessive bone growth) with neurological consequences is seen with sclerosteosis and van Buchem disease. In the pooled dataset, the incidence of hyperostosis was not increased with romosozumab (0.5%) compared to placebo (0.8%), nor was there an increase in adverse events related to neurological compression. A potential neurological consequence of hyperostosis is hearing loss. An audiology substudy in 498 patients did not detect a higher incidence of hearing loss with romosozumab compared to placebo.</p><p>Cardiovascular safety: The Applicant adjudicated cardiovascular events in the pivotal Phase 3 trial. During the 12-month placebo-controlled period, the romosozumab and placebo groups were balanced with regard to the incidence of adjudicated cardiovascular serious adverse events (1.3% in both arms) as well as adjudicated serious cardiac ischemic events (0.4% in both arms) and cerebrovascular events (0.3% in both arms).</p><p>However, two months prior to the action goal date, the Applicant informed us of unanticipated cardiovascular findings in an ongoing <ref type="bibr">Phase 3 trial (20110142)</ref>. This 4000-patient trial randomized women with postmenopausal osteoporosis to romosozumab or alendronate then had all patients take only alendronate after one year.</p><p>. Topline results showed a 50% mean reduction in the incidence of new vertebral fractures and a 19% mean reduction in the incidence of nonvertebral fractures with romosozumab followed by alendronate compared to alendronate alone. However, using the same adjudication process as that used in the pivotal Phase 3 trial, this trial found an imbalance during the 12-month double-blind period in adjudicated cardiovascular serious adverse events (2.5% romosozumab vs. 1.9% alendronate) as well as adjudicated serious cardiac ischemic events (0.8% romosozumab vs. 0.3% alendronate) and cerebrovascular events (0.8% romosozumab vs. 0.3% alendronate). Similar imbalances were also seen in a recently completed, small (n=244) male osteoporosis trial.</p><p>Corresponding hazard ratios through Month 12 for Major Adverse Cardiovascular Events (MACE), a composite endpoint assessing cardiovascular risk comprised of adjudicated serious adverse events of myocardial infarction and stroke as well as cardiovascular death were 1.03 (95% confidence interval 0.62, 1.72) for the pivotal Phase 3 trial, 1.87 (95% confidence interval <ref type="bibr">1.11, 3.14)</ref> for the ongoing alendronate-controlled trial, and 1.55 (95% confidence interval 0.31, 7.69) for the male osteoporosis trial.</p><p>Reasons for the discrepant trial results are unclear. We informed the Applicant that we would not be able to take a favorable action on this review cycle because we need to first conduct a thorough review of the cardiovascular issue before we can determine whether the benefits of romosozumab outweigh its risks. We stated this would not be possible in the remaining review cycle, even with a Major Amendment, because the Applicant still needs to complete their analyses of the data and put together a detailed submission of the findings. We also stated that an advisory committee meeting would likely be needed when those data are submitted.</p><p>Immunogenicity: In the pivotal Phase 3 trial, the incidence of hypersensitivity reactions, assessed using Standardized MedDRA queries, was similar among romosozumab-and placebo-treated patients, and was not increased further among those who had binding antibodies. This search strategy identified seven romosozumab-treated patients (0.2%) and no placebo-treated patients with hypersensitivity serious adverse events. Some of these cases suggest that romosozumab has the potential to cause significant hypersensitivity reactions. For example, one of the patients developed cough, dyspnea and wheezing about 24 hours after her first romosozumab dose, followed by a rash on the back two days later. Another case involved facial edema and generalized rash about three weeks after the fifth dose, treated with a glucocorticoid and antihistamine. Another patient developed a macular truncal rash three days after the first dose and exfoliative dermatitis and angioedema on Day 28.</p><p>In the trial comparing the 90 mg/mL and 70 mg/mL formulations, there were no reports of serious adverse events of hypersensitivity, although the overall incidence of hypersensitivity reactions was numerically higher with the 90 mg/mL formulation (11.4% vs. 2.5%).</p><p>Hypersensitivity can be handled with labeling.</p><p>Injection Site Reactions: In the pivotal Phase 3 trial, injection site reactions were more common with romosozumab (5.2%) than placebo (2.9%), with a higher incidence among romosozumabtreated patients who were antibody positive (6.8%) compared to those who were antibody negative (5.0%). Similar patterns were seen according to the neutralizing antibody status but the small numbers of patients with neutralizing antibodies limit conclusions.</p><p>None of the reported injection site reactions were categorized as serious. In the pivotal Phase 3 trial, these reactions were most commonly injection site pain (1.7% with romosozumab vs. 1.3% with placebo), erythema (1.5% vs. 0.1%), and pruritis (0.7% vs. 0.2%).</p><p>In the clinical trial comparing the 90 mg/mL and 70 mg/mL formulations, the overall incidence of injection site reactions was 10.6% with the 90 mg/mL formulation and 9.2% with the 70 mg/mL formulation. The 90 mg/mL formulation had numerically higher incidences of injection site erythema (5.7% vs. 1.7% with the 70 mg/mL formulation) and injection site swelling (2.4% vs. 0% with the 70 mg/mL formulation) whereas the 70 mg/mL formulation had a numerically higher incidence of injection site pain (5.9% vs. 2.4% with the 90 mg/mL formulation).</p><p>Injection site reactions can be handled with labeling.</p><p>Bone Histomorphometry: In the pivotal Phase 3 trial, the Applicant obtained quadruple-labeled iliac bone biopsies in 34 patients at Month 2, 73 patients at Month 12, and 47 patients at Month 24. These biopsies did not identify any safety concerns.</p><p>Other Laboratory Data and Vital Signs: The clinical reviewer identified no notable effects of romosozumab on other laboratory data or on vital signs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.">Advisory Committee Meeting</head><p>This application was not taken to advisory committee. We did not identify efficacy or safety issues requiring input from an advisory panel at the time of filing. However, the unexpected cardiovascular findings that came to light towards the end of this review cycle will likely be discussed at an advisory committee meeting during the next review cycle.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="10.">Pediatrics</head><p>This Application triggers the Pediatric Research Equity Act (PREA) because of the new active ingredient. The Pediatric Review Committee agreed with a full waiver. Pediatric studies would be impossible because postmenopausal osteoporosis does not occur in children.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="11.">Other Relevant Regulatory Issues</head><p>Trade Name / Proper Name: The Division of Medication Error Prevention and Analysis (DMEPA) has concluded that the proposed trade name "Evenity" is acceptable. However, the proper name (romosozumab), as proposed, does not include a four-digit distinguishing suffix, in accordance with the final guidance "Nonproprietary Naming of Biological Products" that issued in January 2017. DMEPA planned to address the suffix issue after approval when it appeared that the application would be approved on this review cycle. See their reviews for details. Because we are issuing a Complete Response letter, the trade name will need to be revisited during the next review cycle. We will also inform the Applicant in the Complete Response letter that we intend to assign a suffix to the proper name if/when FDA approves the application.</p><p>Financial Disclosures: Four sub-investigators from three Columbian sites that enrolled about 13% of patients in the pivotal Phase 3 trial did not return signed financial disclosures. As discussed in the clinical review, a sensitivity analysis of the co-primary efficacy endpoints excluding these four sites did not meaningfully change the results.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inspections:</head><p>The Office of Study Integrity and Surveillance (OSIS) conducted clinical and bioanalytical inspections of the key clinical pharmacology studies. The only noteworthy findings involved the bioanalytical inspection of the clinical pharmacology study used to help bridge the to-be-marketed 90 mg/mL formulation to the 70 mg/mL formulation used in the pivotal Phase 3 trial. The inspectors issued a Form 483, citing potential concerns . After obtaining additional information from the Applicant, OSIS determined that the bioanalytical data from this study are acceptable. The Office of Pharmaceutical Quality reviewed the confirmatory antibody assay and found it to be adequate.</p><p>The Office of Scientific Investigations (OSI) inspected four of the 222 clinical sites involved in the conduct of the pivotal Phase 3 trial. These four sites contributed 1054 (15%) of the 7180 enrolled patients in the trial. Three of the sites were classified as NAI (no deviation from regulations). The fourth site was issued an FDA Form 483 and classified as VAI (deviations from regulations). At this site, 147 patients (44%) were randomized outside of the protocolspecified screening windows. This was attributed to delayed access to investigational product from the Applicant and backlogged randomization. There were a few other minor deviations at this site (e.g., enrollment of eight patients who should have been excluded based on their baseline serum calcium concentrations). OSI concluded that the data generated from these four sites appear acceptable to support the proposed indication but recommended that the review team further assess the delay in time to randomization.</p><p>The protocol for the pivotal Phase 3 trial specified that the screening visit can last up to 35 days and allowed for an additional 35 day rescreening window if patients needed vitamin D supplementation. After learning about the delay at the site above, we asked the Applicant to assess the extent to which such delays occurred across the pivotal Phase 3 trial. The Applicant responded that 6.7% of the randomized population had a screening duration beyond 35 days and that 1.3% had a screening duration beyond 70 days (with most of these outliers coming from two Columbian sites, one of which was inspected). The baseline spine x-rays and some of the bone mineral density images were obtained during screening. Therefore, a long delay between these baseline images and randomization could potentially allow for interval changes (e.g., new fractures) during screening that would not be captured prior to randomization. However, given that only about 1% of patients had a screening duration beyond 70 days, and that bone mineral density changes occur very slowly, it is unlikely that this delay would have meaningfully affected the overall bone mineral density results. In addition, the Applicant compared the presence or absence of fractures on screening x-rays with those seen on the first post-treatment x-ray and noted full concordance, supporting that there was no interval development of vertebral fractures between the baseline images and randomization among the patients who had a screening duration beyond 70 days.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human Factors:</head><p>The Applicant submitted Human Factors validation data from brodalumab, one of their other products to provide support that labeling will adequately communicate that two syringes are needed with romosozumab to administer one complete dose. DMEPA concluded that there were no critical differences in the use of romosozumab and brodalumab, and that the brodalumab Human Factors validation data do not show label comprehension difficulties, use task deviations, or dosing errors involving the use of two prefilled syringes to administer a complete dose. In addition, DMEPA reviewed results from the romosozumab labeling comprehension study, which evaluated the romosozumab Instructions for Use and found these results acceptable. No additional Human Factors data are needed. The Instructions for Use will be incorporated in Section 2 of the Prescribing Information if romosozumab can be approved.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="12.">Labeling</head><p>All labeling is deferred because the application cannot be approved on this review cycle.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.">Postmarketing</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head> Postmarketing Risk Evaluation and Mitigation Strategies</head><p>None presently, but we will reassess the need for risk minimization strategies beyond labeling during the next review cycle if romosozumab can otherwise be approved.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head> Other Postmarketing Requirements and Commitments</head><p>When romosozumab can be approved, the Chemistry reviewers recommend a postmarketing commitment .</p><p>Reference ID: 4124009</p><formula xml:id="formula_6">(b) (4) (b) (4) ---------------------------------------------------------------------------------------------------------</formula><p>This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. </p><formula xml:id="formula_7">--------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Benefit-Risk Assessment</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Benefit-Risk Summary and Assessment</head><p>Romosozumab, trade name Evenity, is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women. The dosing regimen is 210mg administered by a healthcare professional once monthly for one year. It is this reviewer's recommendation that romosozumab cannot be approved for this indication at this time.</p><p>Osteoporosis is a skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone leading to an increase in fragility and fracture. While osteoporosis can occur in both men and women, studies in postmenopausal women represent the majority of the data defining the disease and its sequelae. The risk of fracture increases with age and a history of a prior osteoporosis-related fracture. In older patients, fracture, predominantly hip fracture, is associated with increased morbidity and mortality.</p><p>The efficacy of romosozumab for the treatment of postmenopausal osteoporosis was evaluated in a 24-month, randomized, multicenter, double blind, placebo-controlled clinical trial in postmenopausal women aged 50 to 90 years (mean age of 71). Patients were randomized to receive one year of romosozumab 210mg (N = 3589) or placebo (N = 3591) once monthly by subcutaneous injection administered by a healthcare professional. During the second year of the trial, all patients received denosumab 60mg every 6 months. Patients also received daily supplemental calcium (500 to 1000 mg) and vitamin D (600 to 800 IU). 57% of patients were Caucasian, 12% were Asian, and 2% were Black; 40% were Hispanic. At baseline, the mean T-score was -2.7 at the lumbar spine and 18% of patients had at least one prevalent vertebral fracture.</p><p>The co-primary endpoints were the incidence of new vertebral fractures in patients treated with romosozumab compared to placebo at 12 months and the incidence of new vertebral fractures in patients treated with romosozumab/denosumab compared to placebo/denosumab at 24 months. Romosozumab resulted in a significant reduction in the incidence of new vertebral fractures compared to placebo at 12 months (0.5% romosozumab compared to 1.8% placebo, p &lt;0.001). The absolute risk reduction in new vertebral fracture was 1.3% at 12 months and the relative risk reduction was 73% for romosozumab compared to placebo. The incidence of new vertebral fractures at 24 months was 0.6% in patients treated with romosozumab then denosumab compared to 2.5% in patients treated with placebo then denosumab (p &lt;0.001). The relative risk reduction in new vertebral fracture at 24 months was 75% for patients treated with romosozumab/denosumab compared to patients treated with placebo/denosumab and the absolute risk reduction was 1.9%. Romosozumab significantly increased bone mineral density at all sites with a treatment difference of 13% at the lumbar spine, 6% at the total hip and 5% at the femoral neck after 12 months of therapy.</p><p>Adverse events that occurred during treatment with romosozumab, a sclerostin inhibitor, include hypocalcemia, injection site reactions, and hypersensitivity reactions. Osteonecrosis of the jaw and atypical femoral fractures also occurred.</p><p>There is a concern that inhibition of sclerostin by romosozumab may promote or exacerbate vascular calcification. In the postmenopausal osteoporosis safety population, there was no signal suggesting concern regarding cardiovascular safety with romosozumab use. However, in newly completed trials not submitted in the application, preliminary data suggest a cardiovascular safety concern for romosozumab use in both postmenopausal women and men. These data, once available, will require in depth review prior to reaching a conclusion on cardiovascular safety with romosozumab use. Therefore, a Complete Response action is recommended for this review cycle.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimension Evidence and Uncertainties Conclusions and Reasons</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Condition</head><p> Osteoporosis is a bone disease characterized by low bone mass and deterioration of bone tissue leading to an increased risk of fracture.</p><p>Osteoporosis is a silent disease until a fracture occurs  Postmenopausal women are the most common patient group to have osteoporosis. 50% of postmenopausal women over age 50 will break a bone due to osteoporosis  The risk of fracture increases with age. The risk also increases with a history of a previous osteoporosis-related fracture  In older patients, hip fracture is associated with increased loss of independence and increased mortality</p><p>Osteoporosis increases the risk of fracture in postmenopausal women. The risk of fracture increases with age and a history of a prior osteoporosis-related fracture.</p><p>In older patients, fracture, predominantly hip fracture, is associated with increased morbidity and mortality</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Current Treatment Options</head><p> Current treatment options for postmenopausal osteoporosis include medications that inhibit bone loss (bisphosphonates, RANKL inhibitors, estrogen agonists/antagonists, and calcitonin) and medications that stimulate bone formation (PTH and PTHrP analogs)  Therapy can reduce the risk of vertebral fracture by up to 70%  Bisphosphonates are the most widely prescribed medications. Rare but serious side effects with bisphosphonates (osteonecrosis of the jaw and atypical femoral fractures) have influenced the use of these medications.  Densoumab also is associated with osteonecrosis of the jaw and atypical femoral fractures, which likely limits the use of the medication.  Teriparatide and abaloparatide are associated with the potential risk of osteosarcoma, which was noted in animal studies.</p><p>Multiple therapies are available for treatment of osteoporosis in postmenopausal women. Rare but serious side effects have decreased the usage of currently available therapies and many patients with osteoporosis who would benefit from therapy remain untreated.</p><p>Additional therapies in a new class such as romosozumab, will expand the treatment options and potentially enhance treatment for those in need.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimension Evidence and Uncertainties Conclusions and Reasons</head><p>Benefit  Romosozumab was evaluated in a single 24 month randomized phase 3 trial of 7180 women with postmenopausal osteoporosis. Patients received romosozumab 210mg or matching placebo by subcutaneous injection administered by a healthcare provider once a month for 12 months. After 12 months, all patients received open-label denosumab 60mg by subcutaneous injection administered by a healthcare provider every 6 months for 2 doses.  The co-primary endpoints were incidence of morphometric (seen on xray) vertebral fracture at 12 months and 24 months. Morphometric vertebral fracture is the accepted primary endpoint for fracture trials supporting an osteoporosis indication. Secondary endpoints include incidence of clinical fracture and incidence of nonvertebral fracture and change in bone mineral density  Romosozumab reduced the risk of vertebral fractures with an absolute risk reduction of 1.3% and a relative risk reduction of 73% at month 12 and an absolute risk reduction of 1.9% and a relative risk reduction of 75% at month 24  Romosozumab reduced the risk of clinical fractures with an absolute risk reduction of 1.2% and a relative risk reduction of 36% at month 12. However, clinical fracture is a composite endpoint of symptomatic vertebral fractures and nonvertebral fractures. In the fracture trial, 88% of clinical fractures were nonvertebral fractures. Romosozumab did not have significant reductions in nonvertebral fracture at 12 or 24 months.  Romosozumab increased bone mineral density after 12 months of therapy at the lumbar spine 13%, total hip 6% and femoral neck 5%.</p><p>Treatment with romosozumab 210mg monthly for one year significantly increases bone mineral density at the lumbar spine and hip with accompanying significant vertebral fracture risk reduction in postmenopausal women with osteoporosis Treatment with denosumab 60mg every 6 months for one year following romosozumab therapy maintained the bone mineral density increases and vertebral fracture benefit Risk  The safety data for romosozumab include 7384 patients, of which 3695 received romosozumab 210mg once monthly for one year.  Hypocalcemia, injection site reactions, and hypersensitivity reactions are safety concerns with romosozumab use  Osteonecrosis of the jaw and atypical femoral fractures also occurred in the romosozumab trials, usually associated with additional antiresorptive medication use.</p><p>Romosozumab was associated with hypocalcemia, injection site reactions, and hypersensitivity reactions. Osteonecrosis of the jaw and atypical femoral fractures also occurred.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antibody formation occurs in 20% of patients</head><p>Reference ID: 4123729</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cross Discipline Team Leader Review</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimension Evidence and Uncertainties Conclusions and Reasons</head><p> Antibody formation against romosozumab occurred in 20% of patients on romosozumab, neutralizing capability occurred in 5% of patients with binding antibodies. The presence of antibodies can reduce romosozumab exposure but do not appear to affect the effectiveness of romosozumab.  There was no signal for cardiovascular safety in the safety population for this initial application. However, additional preliminary safety data from other romosozumab trials suggest a concern regarding the cardiovascular safety of romosozumab in both postmenopausal women and men but generally does not appear to affect efficacy.</p><p>There remains a concern regarding the cardiovascular safety of romosozumab. While no signal was seen in the placebo-controlled trials reviewed, new preliminary data from additional trials do show a safety signal. Therefore, these newly completed trials need to be submitted and reviewed in depth prior to reaching a conclusion on cardiovascular safety with romosozumab use.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk Management</head><p> For the known risks of hypocalcemia, injection site reactions, hypersensitivity reactions, osteonecrosis of the jaw and atypical femoral fractures, prescribing information and a Medication Guide for patients are sufficient to mitigate the risk of romosozumab.  However, further analysis of the data regarding cardiovascular safety with romosozumab use is needed prior to decisions regarding romosozumab approval for treatment of osteoporosis in postmenopausal women and the need for any risk management plan.</p><p>The concerns regarding cardiovascular safety with romosozumab use must be resolved before romosozumab can be approved and a risk management plan developed, if needed.</p><p>This will require in depth review of the safety signals in the full reports of the newly completed trials once they are submitted.</p><p>Reference ID: 4123729</p><p>Cross Discipline Team Leader Review 6</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Background</head><p>The Applicant, Amgen, Inc. has submitted this Biologics License Application (BLA) under section 351 of the Public Health Services Act for romosozumab seeking an indication for the treatment of postmenopausal women with osteoporosis at increased risk of fracture. The proposed dose is 210 mg romosozumab once monthly. Romosozumab 210 mg is administered by a healthcare provider as 2 separate subcutaneous injections utilizing two single-use prefilled syringes. Romosozumab, also referred to as AMG785 in the application, is an IgG2 humanized monoclonal antibody that binds and inhibits sclerostin. The pharmacologic class proposed by the Applicant in labeling is "sclerostin inhibitor". Sclerostin is the protein product of the SOST gene, and is secreted by the osteocyte. Sclerostin is thought to act by binding to low-density lipoprotein receptor-related proteins 4, 5, and 6 (LRP4, LRP5, and LRP6), inhibiting Wnt signaling and reducing osteoblast-mediated bone formation. Inhibition of sclerostin leads to a transient stimulation of bone formation and inhibition of bone resorption. Romosozumab is first in class with sclerostin inhibitors being a new therapeutic class of osteoporosis therapies.</p><p>Osteoporosis is a systemic skeletal disease characterized by low bone mass and structural deterioration of bone tissue leading to bone fragility and increased risk of fracture. The goal of therapy is to reduce the risk of fracture. Currently, there are nine different molecular entities, many with multiple formulations and regimens, approved for the treatment of postmenopausal osteoporosis (see <ref type="table" target="#tab_87">Table 1</ref>, page 24 of the primary clinical review).</p><p>The romosozumab IND (100391) was opened in November 2006. An End-of Phase 2 meeting was held in 2011. The Applicant proposed to conduct a 12-month placebo-controlled phase 3 fracture trial. After discussion, the Division advised that the duration of the study should be a minimum of 2 years. It was acceptable that romosozumab treatment be limited to one year. However, in that case all subjects (placebo and romosozumab treated subjects) should receive the same active control product for the second year. The endpoints could be coprimary -new vertebral fracture at 12 months and at 24 months.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Product Quality</head><p>The review team from the Office of Biotechnology Products recommends approval of Evenity (romosozumab). Romosozumab is a humanized IgG2 monoclonal antibody that binds to and inhibits sclerostin. </p><formula xml:id="formula_8">(b) (4) (b) (4) (b) (4) 7</formula><p>Assessment outline the critical quality attributes of the romosozumab drug substance. The data provided in the BLA supports a shelf life of months for the romosozumab drug substance when stored at .</p><p>Drug Product Manufacturing: Drug product manufacturing process steps . <ref type="table" target="#tab_5">Table 3</ref> and 2, pages 23 -26 of the Integrated Quality Assessment outlines the critical quality attributes of the romosozumab drug product.</p><p>Drug Product: Evenity (romosozumab) is a combination product with the drug product presented in single-use prefilled syringes with a romosozumab concentration of 90 mg/mL. Each prefilled syringe contains 105 mg romosozumab in 1.17 mL volume. Other excipients in the 1.17 mL volume include calcium (0.61 mg), acetate (3.8 mg), sucrose (70 mg), polysorbate 20 (0.07 mg), sodium hydroxide and Water for Injection. Evenity is a sterile, preservative-free, clear to opalescent, colorless to light yellow solution for subcutaneous injection. The pH of the solution is 5.2. The container closure system consists of a 1 mL syringe with an needle covered with an needle shield and a plunger-stopper .</p><p>The dose of romosozumab, 210 mg, requires injection of two prefilled syringes. Evenity is packaged as a carton containing two single use prefilled syringes. The stability data in the BLA support a shelf life of 36 months for Evenity when stored at the recommended storage condition of 2 -8C.</p><p>Microbiology: Both the drug substance and drug product quality microbiology parts of this BLA are recommended for approval. Please see Dr. Bo Chi's drug substance quality microbiology review and Dr. Lakshmi Rani Narasimhan's drug product quality microbiology review for complete details.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Facilities:</head><p>This site manufactures the drug substance and preforms drug product lot release and stability testing. A pre-license inspection was conducted by reviewers from OBP and DIA and covered the manufacturing operations for romosozumab DS including quality assessment procedures, manufacturing process, facilities and equipment, material management, data entry, contamination prevention, laboratory controls, and training programs. Assessment was made in accordance with ICH Q7A. A three-item 483 with respect to equipment performance qualification, laboratory record documentation, and document review, was issued. This site is recommended for approval from a facilities assessment standpoint. This site is a multiproduct facility responsible for drug product manufacture, drug product in-process and lot release testing, and inspection. The most recent inspection was conducted on and resulted in VAI with final compliance decision of approve. CGMP coverage was provided for profiles during the inspection, and found acceptable. Based on the firm's compliance history and current acceptable GMP status, and the fact that the facility, similar processes, and most of the equipment proposed for romosozumab manufacture are currently approved , the pre-license inspection of facility was waived for this BLA. This site is recommended for approval from a facilities assessment standpoint.</p><p>Amgen, Inc <ref type="bibr">(Amgen Thousand Oaks, ATO, FEI 2026154)</ref>: This site is responsible for the DS master cell bank and working cell bank storage, and working cell bank production. The most recent inspection was a limited GMP inspection conducted in in response to two Risk Evaluation and Mitigation Strategies. The inspection was NAI. This site is recommended for approval from a facilities assessment standpoint.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Amgen Manufacturing Limited (AML, Juncos, PR, FEI 1000110364):</head><p>This site is responsible for drug substance and drug product lot release and stability testing as well as drug product packaging and labeling. The most recent inspection was and resulted in VAI with final compliance decision of approve. This site is recommended for approval from a facilities assessment standpoint.</p><p>This site is responsible for drug substance unprocessed bulk mycoplasma and adventitious viral testing; and drug product container closure integrity for stability testing. The most recent inspection was conducted on and resulted in NAI. This site is recommended for approval from a facilities assessment standpoint.</p><p>Amgen Technology Ireland (Amgen Dun Laoghaire, ADL, FEI 3002808497): This site is responsible for drug substance lot release and stability testing; and drug product lot release and stability testing. The most recent inspection was conducted on and resulted in VAI with final compliance decision of approve. This site is recommended for approval from a facilities assessment standpoint.</p><p>Environmental Assessment: A claim for a categorical exclusion is being made under 21 CFR 25.31 (c). This application is for marketing approval of a biologic product comprised of substances that occur naturally in the environment and approval of this action would not alter significantly the concentration or distribution of the substance, its metabolites, or degradation products in the environment. To the sponsor's knowledge, no extraordinary circumstances, as described in 21 CFR 25.21, exist that would result in significant impact to the environment from the discharge of this substance. This waiver request is acceptable. <ref type="bibr" target="#b47">9</ref> Device considerations: A consultation for review of the device components of the romosozumab drug product was obtained from the General Hospital Devices Branch (GHDB)/ Office of Device Evaluation/Center for Devices and Radiological Health (CDRH). The recommendation is that the device constituent parts of the combination product can be approved. Please see the consult completed by Sarah Mollo for complete details.</p><p>Labeling: The primary and secondary container closure labeling review have been conducted and changes recommended to the Applicant. Further labeling negotiations will be deferred until the next review cycle.</p><p>Postmarketing Commitments: The OBP review team recommends the following postmarketing commitment:</p><p>After further discussion regarding the updated action plan for this BLA, OBP recommends that this PMC remain under consideration for the next review cycle as the Applicant would have insufficient time to address the PMC prior to the anticipated application resubmission.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Nonclinical Pharmacology/Toxicology</head><p>The nonclinical pharmacology/toxicology team is recommending that this BLA can be approved. The Applicant has conducted a complete pharmacology/toxicology program, which has been reviewed by the pharmacology/toxicology team. Please see the reviews from Dr. Gemma Kuijpers, Dr. Andrea Benedict, Dr. Laurie McLeod-Flynn, and Dr. Miyun Tsai-Turton for complete details.</p><p>Romosozumab is a humanized IgG2 monoclonal antibody that binds to and inhibits sclerostin. Sclerostin has an inhibitory effect on bone formation. Sclerostin is produced by the osteocyte and can bind to low density lipoprotein receptor related protein (LRP) 4, LRP5, or LRP6 receptors. Sclerostin interaction with LRP5/6 leads to inhibition of the Wnt/beta-catenin signaling pathway and ultimately decreased bone formation and increased bone resorption. Romosozumab binds to sclerostin and inhibits the interaction of sclerostin and LRP5/6, allowing increased bone formation.</p><p>Pharmacology: The Applicant conducted in vitro and in vivo pharmacology studies with sclerostin-antibodies. In vitro studies showed high affinity binding of romosozumab to sclerostin, which led to blockade of the sclerostin-mediated inhibition of bone matrix mineralization in a mouse calvarial cell line.</p><p>Bone quality studies of up to 12 months in duration were conducted in ovariectomized rats and monkeys. The doses used were up to 19x human exposure in rats and 22x human exposure in monkeys, based on AUC. Romosozumab increased bone mass and strength of lumbar spine,</p><formula xml:id="formula_9">Reference ID: 4123729 (b) (4)</formula><p>Cross Discipline Team Leader Review 10 tibia, femur, and radius in a dose-and time-dependent manner. The bone changes consisted of increases in trabecular thickness in vertebrae and long bone metaphyses, as well as increases in cortical thickness in long bones. The noted effects were due to stimulation of bone formation concomitant with suppression of bone resorption mostly at trabecular and endosteal bone surfaces. In monkeys, both formation and resorption responses were transient and peaked at 10 weeks. Based on bone mass vs. strength correlations, bone quality was maintained at all evaluated sites.</p><p>Toxicology: Toxicity studies of up to 6-month duration were conducted in rats and monkeys. The main findings were related to the pharmacologic effect of romosozumab, specifically increasing bone formation and bone density with evidence of hyperostosis affecting the bone marrow. Findings included decreases in calcium and phosphorus levels and decreases in RBC, WBC and platelets with evidence of extramedullary hematopoiesis. Exposure multiples in the 6-month studies ranged from 1-38x and 1-93x human exposure, in rats and monkeys, respectively.</p><p>Because of rapidly accumulating knowledge of the role of sclerostin, LRP 5/6, and Wnt betacatenin signaling, the Applicant included evaluation of multiple potential clinical safety concerns in the clinical trials. This approach was based on the weight of evidence from nonclinical studies, clinical studies and published literature. As outlined in Dr. Kuijper's review, there is no nonclinical evidence suggesting romosozumab would increase the risk for osteoarthritis, vascular calcification, increased longitudinal bone growth, hyperostosis, altered hematopoiesis, sarcopenia, altered glucose metabolism, or exacerbation of TNF-mediated inflammation. Additionally, the nonclinical data do not support a concern about tumor induction or promotion due to activation of Wnt signaling.</p><p>With specific regard for vascular calcification, aged OVX monkeys treated for up to 12 months with doses equivalent to 1 and 22 times human exposure at 210 mg monthly did not result in aortic calcification.</p><p>Qualification of impurities: This drug product contains no novel excipients. Other product related impurities have been adequately qualified.</p><p>Genotoxicity: The genotoxicity potential of romosozumab was not evaluated. Romosozumab is a protein product and lacks non-protein or linkage material and therefore is unlikely to react with DNA or chromosomal material.</p><p>Carcinogenicity: Osteosarcoma has previously been observed with the bone anabolic agents. In rats treated for 2 years with parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) analogues, osteosarcoma and other bone tumors developed at low human exposure multiples. For romosozumab, a carcinogenicity study was conducted in Sprague Dawley rats. The rats were dosed for up to 98 weeks with 0, 3, 10, 50 mg/kg/week of romosozumab, equivalent to 1-19x human exposure. The study did not show any significant increases in tumor incidences. A low incidence of osteosarcoma (2/54) was observed in high dose males at 19x romosozumab human exposure. The large exposure multiple suggests that romosozumab is unlikely to increase the human risk of osteosarcoma.</p><p>Reproductive toxicology: Romosozumab's reproductive toxicity was evaluated in rat fertility and early embryonic development, embryofetal development and pre-and postnatal development (PPND) studies. Findings in the embryonic studies included reduced ventral processes of the 6th cervical vertebrae at doses of 100 and 300 mg/kg (17-56x human exposure). This finding is not considered clinically relevant due to lack of the anatomical structure in humans. Fetal poly-and syndactyly were observed in the embryofetal study at 32x human exposure. This finding is consistent with the syndactyly observed in sclerostosis patients and in SOST knockout mice. The finding is of low clinical relevance based on the exposure multiple, and the timing of digit formation in the first trimester in humans, when placental transfer of immunoglobulins is limited. In the PPND study, there were small decreases in bone mass and size in the F1 offspring at 1.5-56x human exposure of unclear biological significance. None of these findings are considered relevant for the postmenopausal indication.</p><p>Labeling: In the first two rounds of label negotiations, the nonclinical team made changes to the proposed product labeling including <ref type="bibr">Sections 8,</ref><ref type="bibr">12.1,</ref><ref type="bibr">13.1,</ref><ref type="bibr">and 13.2</ref>. Further label negotiations have been deferred at this time because the application will be receiving a Complete Response letter.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Clinical Pharmacology</head><p>The clinical pharmacology team is recommending that this BLA can be approved; please see Dr. Lin Zhou's review for complete details.</p><p>General clinical pharmacology: Romosozumab is administered as a subcutaneous injection once monthly for 12 months. The 210 mg dose requires 2 syringes of 105 mg each with injection of the second syringe occurring immediately after the first syringe. The estimated bioavailability of a romosozumab 210 mg was 81%. The median time to maximum romosozumab concentration (Tmax) was 5 days (range: 2 to 7 days) following subcutaneous administration. The mean (SD) maximum serum concentration (Cmax) was 22.2 (5.8) mcg/mL and the mean area under the concentration-time curve (AUC) was 389 (127) mcg*day/mL. Steady-state concentration was reached by month 3.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Intrinsic factors:</head><p>Renal Impairment: Mineral metabolism is impaired in patients with renal disease. A renal impairment study was conducted with romosozumab because of the potential for effects related to mineral metabolism, a pharmacodynamic effect of romosozumab. The population pharmacokinetic analysis indicated an increase in romosozumab exposure with increasing severity of renal impairment.</p><p>A clinical study of subjects with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis was conducted with the proposed romosozumab 210 mg dose. In subjects with severe renal impairment, mean C max and AUC were 29% and 44% higher compared to healthy subjects. However most subjects with severe renal impairment had C max and AUC values that overlapped with the exposure range seen in healthy subjects. In subjects with ESRD on hemodialysis, mean romosozumab exposure was similar to healthy subjects. The number of subjects with hypocalcemia was 0/8 healthy subjects, 1/8 subjects with severe renal impairment, and 4/8 in subjects with ESRD requiring hemodialysis. There was no increased exposure to romosozumab in hemodialysis subjects, so the hypocalcemia is likely due to combination of underlying alterations in mineral metabolism associated with renal disease itself and romosozumab effects.</p><p>Drug-Drug interactions: No formal drug-drug interaction studies have been performed. Romosozumab is a humanized monoclonal antibody, is not metabolized by CYP enzymes, and therefore, has a very low risk of drug-drug interactions.</p><p>Bisphosphonate: The pharmacokinetics of romosozumab was similar in patients transitioning from alendronate therapy.</p><p>Demographic interactions: Based on a population pharmacokinetic analysis, no notable difference in pharmacokinetics with age (20-89 years), gender, or race were noted.</p><p>Formulation bridging: The Phase 3 fracture trial in postmenopausal women with osteoporosis used romosozumab 70 mg/mL in a glass prefilled syringe (PFS) presentation containing drug substance and drug product manufactured at Amgen Thousand Oaks (ATO). The planned commercial drug substance process was transferred from ATO to (Amgen Rhode Island, [ARI]). The commercial 90 mg/mL PFS drug product manufacturing process was transferred from ATO to .</p><p>The Applicant conducted a single-dose, randomized pharmacokinetic equivalence study to demonstrate the comparative bioavailability of the clinical trial 70 mg/ml formulation and the 90 mg/mL formulation (study 20120277). In addition, a clinical study was conducted comparing bone mineral density changes achieved with romosozumab 210 mg delivered as three 1.0 mL PFS injections of the 70 mg/mL concentration and romosozumab 210 mg delivered as two 1.17-mL PFS injections of the 90 mg/mL concentration (study 20120156).</p><p>Both study 20120277 and 20120156 utilized drug substance and drug product manufactured at ATO. To support the new drug substance manufacturing site, the Applicant conducted a single-dose, randomized pharmacokinetic bioequivalence study to demonstrate the comparative bioavailability between the 90 mg/ml formulation manufactured at ATO and ARI. While the drug substance manufacturing sites were different, both the ATO and the ARI drug product were manufactured at ATO. To support drug product manufactured at the Applicant is relying upon analytic comparability.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20120277</head><p>is an open label, single dose, parallel group study in healthy subjects that compared the pharmacokinetic profile of a single dose of romosozumab 210 mg delivered as three 1.0 mL PFS injections of the 70 mg/mL concentration (Process 2 at ATO) with two 1.17-mL PFS injections of the 90 mg/mL concentration (Process 2 at ATO). A total of 172 subjects were randomized (87 received the 70 mg/mL formulation, 85 received the 90 mg/mL formulation). Of the randomized subjects, the Applicant included 166 subjects in the PK analysis (82 in the 70 mg/mL group, 84 in the 90 mg/mL group). The geometric mean ratio (90% CI) of test (90 mg/mL) to reference (70 mg/mL) for C max was 0.992 (0.909 , 1.082), AUC last 0.897 (0.814 , 0.989), and AUC inf 0.896 (0.813 , 0.987). However, as outlined in the clinical pharmacology primary review, on FDA analysis when 2 subjects were excluded, the CI for C max and AUC last remained in the range demonstrating bioequivalence (0.8 -1.25) but the lower bound of the 90% CI for AUC inf fell to 0.799. The clinical pharmacology team accepts that comparability has been established because AUC inf is based on extrapolated data and the extrapolation method may not be the most appropriate method due to romosozumab's drug disposition. Additionally, the small difference in AUC inf would not be expected to have clinical implications. This reviewer agrees with the clinical pharmacology rationale.</p><p>The Office of Study Integrity and Surveillance (OSIS) conducted an inspection of the bioanalytical site for study 20120277. Concerns were raised regarding drug stability during the freeze-thaw stability for method validation. These concerns were conveyed to the Applicant and the Applicant reevaluated the freeze-thaw stability and provided additional data. Upon review of the data, the data from the bioanalytical portion of study 20120277 are reliable.</p><p>Study 20120156 is a 6 month, randomized, placebo controlled study evaluating the BMD changes of romosozumab 210 mg delivered using three 1.0 mL PFS injections of the 70 mg/mL concentration and romosozumab 210 mg delivered using two 1.17-mL PFS injections of the 90 mg/mL concentration in postmenopausal women with osteoporosis. Please see the primary statistical review and the primary clinical review, pages 86-90 for complete details.</p><p>Subjects were randomized 22:5:22:5 to romosozumab 210 mg as two injections of 90 mg/mL in 1.17 mL PFS; placebo as two 1.17 mL PFS injections; romosozumab 210 mg as three injections of 70 mg/mL in 1mL PFS; placebo as three 1 mL PFS injections. Subjects also received calcium (500 -1000mg daily) and vitamin D (600 -800 IU daily) supplementation. The primary endpoint was change in lumbar spine BMD at month 6. The noninferiority margin was set based on data from the Phase 2 trial 20060326. In this trial, the treatment difference for romosozumab 210 mg (3 injections of 70 mg/mL) at 6 months was 8% (95% CI : <ref type="bibr">6.6 , 9.3)</ref>. Therefore, 30% of the lower bound of the CI yields a NI margin of 2%.</p><p>A total of 294 subjects were enrolled into the trial (118 received 70 mg/mL, 123 received 90 mg/mL, 53 received placebo) and 273 (93%) subjects were included in the primary analysis data set (110 (93%) 70 mg/mL, 117 (95%) 90 mg/mL, 44 (83%) placebo). The change from baseline to month 6 in BMD was 9.6% for 70 mg/mL, 9.2% for 90 mg/mL, and 0.8% for placebo. The difference between the 70 mg/mL concentration and the 90 mg/mL concentration is 0.4% (95% CI: -1.5 , 0.7). Therefore, BMD increases achieved with treatment of romosozumab 210 mg delivered using the 90 mg/mL formulation are not inferior to romosozumab 210 mg delivered using the 70 mg/mL formulation at 6 months.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20150197</head><p>is an open label, single dose, parallel group study in healthy subjects that compared the pharmacokinetic profile of a single dose of romosozumab 210 mg using two 1.17-mL PFS injections of the 90 mg/mL concentration using drug substance manufactured at ATO (Process 2, scale) versus drug substance manufactured at ARI (Process 2, scale). A total of 188 subjects were randomized (96 ATO, 92 ARI). Of the randomized Reference ID: 4123729 <ref type="formula" target="#formula_0">(4)</ref> subjects, 186 were included in the PK analysis (96 ATO, 90 ARI). The geometric mean ratio (90% CI) of test (ARI) to reference (ATO) for C max was 0.92 (0.86 , 0.98), AUC last 0.91 (0.84 , 0.99), and AUC inf 0.90 (0.83 , 0.98). The FDA analysis confirmed the applicant's analysis and comparability between ATO and ARI was demonstrated.</p><formula xml:id="formula_10">(b) (4) (b)</formula><p>The Office of Study Integrity and Surveillance (OSIS) conducted an inspection of the clinical site for study 20120197 and recommends accepting the clinical data.</p><p>Comparable bioavailability and/or clinical data are not required to support the switch in DP manufacturing from ATO to . The Applicant adequately demonstrated that the ATO and drug products are analytically comparable. Because there are no significant process changes that could impact safety or potency, analytical comparability is sufficient to support the DP manufacturing.</p><p>TQT study: Because romosozumab is a large protein product that is unlikely to interact with cardiac cell ion channels, a thorough QT study was not required or performed.</p><p>Immunogenicity: Romosozumab is a large humanized monoclonal antibody that could trigger an immune response. The Applicant developed and validated two assays to detect the presence of anti-romosozumab antibodies in human serum: an electrochemiluminescence (ECL)-based bridging immunoassay to detect binding antibodies to romosozumab and an ECL-based competitive binding assay to determine the neutralizing potential of anti-drug antibodies (ADA). Data on antibody titer is not available. The Applicant used signal to noise values to evaluate the magnitude of the antibody response.</p><p>Romosozumab's immunogenicity potential was assessed in all clinical studies of healthy volunteers and postmenopausal women. In Phase 1 studies 66/832 (8%) subjects developed binding antibodies to romosozumab after at least a single dose of drug product. Neutralizing antibodies developed in 18 subjects (27% of subjects with binding antibodies, 2% of all Phase 1 subjects).</p><p>In the Phase 2 and 3 studies, 20% of subjects developed binding antibodies and 5% with binding antibodies developed neutralizing antibodies. In some cases, the antibodies were transient and the antibody assays were negative by the last time point tested. A transient romosozumab response was seen in approximately 50% of subjects with positive binding antibodies. A transient response occurred in 24% of subjects of subjects with positive neutralizing antibodies.</p><p>The 24 month dose finding study was extended to include one year off of romosozumab followed by a one year retreatment phase. In the initial treatment period, 60/ 255 (24%) subjects exposed to romosozumab developed binding antibodies and 8 (13%) of those subjects developed neutralizing antibodies. There was not an apparent dose-related trend in antibody formation. During months 24 to 36, 45 of 179 (25%) subjects exposed to romosozumab had positive binding antibodies at month 36. Six (13%) subjects with binding antibodies were positive for neutralizing antibodies. During repeat exposure to romosozumab (month 36 to 48), 22 (16%) subjects who were antibody positive prior to retreatment were negative for <ref type="bibr" target="#b86">(4)</ref> binding antibodies in the retreatment phase, 11 (8%) subjects who were positive prior to retreatment remained positive during the retreatment phase and 2 (1%) subjects developed new binding antibodies to romosozumab. No subjects developed new neutralizing antibody to romosozumab during retreatment.</p><formula xml:id="formula_11">Reference ID: 4123729 (b) (4) (b) (4) (b)</formula><p>Effects of anti-drug antibody development on romosozumab pharmacokinetics: The development of antibodies to romosozumab resulted in reduced serum concentrations of romosozumab. In phase 1 studies, one subject enrolled in a single dose study who developed neutralizing antibodies to romosozumab was inadvertently then enrolled in a multi-dose study.</p><p>In the second study (second exposure to romosozumab), the subject received a dose of 1mg/kg of romosozumab. Romosozumab serum concentration rose to 2010 ng/ml on Day 5, dropped below the lower limit of quantification (BQL = 50 ng/mL) on Day 7 and remained BQL through the PK sampling window up to 168 days, despite continued dosing once every two weeks.</p><p>In the Phase 3 studies of 6 months duration or longer, the presence of binding antibodies appeared to decrease romosozumab exposure up to 25% at months 3, 6, and 9. At month 12, exposures were approximately 10% decreased in antibody positive subjects compared to antibody negative subjects.</p><p>Effects of anti-drug antibody development on efficacy parameters: Exploratory analyses were conducted to evaluate the effect on romosozumab antibody on BMD. In the fracture efficacy trial 20070337, the month 15 antibody status was used for evaluation. As outlined in the table below, at months 12 and 24, subjects who developed antibodies experienced similar BMD increases to subjects without antibodies to romosozumab. Additionally, the assay S/N ratio did not appear to affect the BMD results. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effects of anti-drug antibody development on safety parameters:</head><p>When evaluated based on antibody status, there were no differences in overall adverse event reporting in antibody positive subjects compared to antibody negative subjects. Specific evaluations were performed for hypersensitivity reactions, injection site reactions, and autoimmune disorders. There were no differences in potential hypersensitivity reaction and autoimmune disorder adverse event reporting in antibody positive subjects compared to antibody negative subjects. Injection site reaction adverse events were reported in 3% of placebo subjects, 5% of romosozumab antibody negative subjects, and 7% of romosozumab antibody positive subjects.</p><p>Labeling: The Office of Clinical Pharmacology recommends edits to the Special Populations and Clinical Pharmacology sections of the proposed product labeling. Further labeling discussions with the Applicant are deferred at this time.</p><p>Postmarketing Studies: No postmarketing studies are recommended by the clinical pharmacology review team.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.">Clinical Microbiology</head><p>Romosozumab is not an antimicrobial agent. Clinical microbiology studies are not applicable to this BLA. The microbiology product quality of the romosozumab drug substance and combination drug/device product is discussed in Section 3 of this review.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">Clinical/Statistical-Efficacy</head><p>The Applicant is seeking an indication for treatment of postmenopausal osteoporosis. This is the first osteoporosis indication for this product and fracture efficacy data are required to support approval. The Division has generally accepted a robust result (p value &lt;0.01) from a single phase 3 fracture trial with supportive bone mineral density data from the dose finding study for approval of an initial osteoporosis indication. The Applicant conducted one key fracture efficacy trial (20070337) with supportive evidence from the dose-finding trial 20060326.</p><p>Because there is a large single fracture efficacy trial, an integrated summary of efficacy will not be the focus of this review. The dose-finding trial 20060326 is presented and discussed, followed by the efficacy findings of trial 20070337.</p><p>Trial 20060326: Please refer to the clinical review, pages 65 -82 for complete details. Trial 20060326 is a randomized, placebo and active-controlled 24-month dose finding study that evaluated 5 different doses of romosozumab. The study has been extended several times. The first extension (months 24 to 36) is for a 12 month phase where subjects were randomized to either placebo or denosumab 60 mg SC every 6 months. The second extension (months 36 to 48) is for a retreatment phase with romosozumab. The third extension remains ongoing and includes 24 months of zoledronic acid 5 mg once yearly or no treatment. All subjects also were to take at least 1000 mg calcium and at least 800 IU Vitamin D daily. During the romosozumab retreatment phase, subjects were to receive a 50,000 IU oral vitamin D loading dose.</p><p>For the initial 24 months study, postmenopausal women with low bone mass were randomized to receive placebo or romosozumab as follows:</p><p> romosozumab 70 mg (50 subjects) or placebo (10 subjects) SC monthly  romosozumab 140 mg (50 subjects) or placebo (10 subjects) SC monthly  romosozumab 210 mg (50 subjects) or placebo (10 subjects) SC monthly  romosozumab 140 mg (50 subjects) or placebo (10 subjects) SC every 3 months  romosozumab 210 mg (50 subjects) or placebo (10 subjects) SC every 3 months Two additional arms were open label:</p><p> alendronate 70 mg po weekly for the first 12 months. Subjects were then switched to romosozumab 140 mg monthly for months 12 -24.  teriparatide 20mcg SC daily for the first 12 months. Subjects were discontinued after 12 months.</p><p>Subjects and study personnel were blinded to treatment (romosozumab or placebo) and dose (70mg/140mg/210mg) but not to dose frequency.</p><p>For the first 24 months of the study, romosozumab was provided in single-use 5 mL vials containing approximately 1 mL of study medication (70 mg/mL romosozumab). Placebo presentation was identical. For the month 36 -48 romosozumab retreatment phase, romosozumab was presented in a single-use 1 mL prefilled syringe containing the 70 mg/mL formulation.</p><p>The primary endpoint is change in lumbar spine BMD at month 12. Secondary endpoints included change in lumbar spine, femoral neck and total hip BMD at month 6; change in femoral neck, total hip, and distal 1/3 radius BMD at month 12; change in bone turnover markers (P1NP, CTX, OC, BSAP) at months <ref type="bibr">1, 2, 3, 6, 9, and 12.</ref> All active control analyses are exploratory. For all endpoints, the placebo group was pooled. Additionally, the study included a bone biopsy substudy, which included 32 subjects, and a quantitative CT (QCT) substudy, which enrolled 172 subjects.</p><p>Study Population: The enrolled postmenopausal population included women age 55 -85 years, with low bone mass. Subjects with a positive osteoporotic fracture history were excluded from enrollment. The mean age of the enrolled population was 67 years, 86% of the population was white, and the mean lumbar spine T score was -2.3. As outlined in the table below, 92% of subjects completed the initial 12 months of the study and 87% completed the study to month 24.For the open label alendronate arm, after the first year, subjects in the alendronate arm were transitioned to romosozumab 140mg monthly. Overall, 51 subjects were enrolled, 49 subjects completed the first 12 months of the study and 45 subjects completed through month 24. Subjects in the teriparatide arm only participated in the first 12 months of the study, 55 subjects were randomized and 46 subjects completed through month 12. For months 24 to 36, subjects who chose to continue in the study were re-randomized to receive placebo or denosumab 60 mg SC every 6 months. The teriparatide group was discontinued, the romosozumab groups were pooled and randomized while the placebo and alendronate/romosozumab 140mg qmonth groups were randomized separately. As outlined in the table below, 260 subjects chose to continue into the denosumab extension, with 131 receiving placebo and 129 receiving denosumab. For months 36 to 48, subjects who were initially in the alendronate arm were discontinued from the trial. All subjects from the original placebo or romosozumab arms who continued in the trial received romosozumab 210 mg monthly. Overall, 167 subjects enrolled in the romosozumab retreatment phase and 155 subjects completed 48 months. Results: Lumbar spine BMD: In the first 24 months of the study, bone mineral density of the spine was evaluated at baseline, and months 3, 6, 12, 18, and 24.The primary endpoint is percent change in lumbar spine BMD at month 12. As outlined in the table below, treatment with all doses of romosozumab resulted in significant increases in BMD. More robust results were achieved with monthly romosozumab dosing. Treatment with alendronate 70 mg weekly resulted in a 4.1% increase in lumbar spine BMD at month 12. Treatment with daily teriparatide 20 mcg resulted in a 7.1% increase in lumbar spine BMD at month 12. Romosozumab 210 mg qmonth resulted in BMD increases that were significantly greater then both active controls (p&lt;0.0001 after Hochberg adjustment). Other BMD Endpoints: As outlined in the primary clinical review, romosozumab increased BMD of the hip with larger increases achieved with the monthly dosing groups. The treatment difference compared to placebo with romosozumab 210 mg monthly was 4.9% at the total hip and 4.8% at the femoral neck. At the mid third radius, a site of predominantly cortical bone, small decreases in BMD were seen in all romosozumab dose groups, similar to placebo. The treatment difference compared to placebo with romosozumab 210 mg monthly was -0.3%. The finding of no change or loss in cortical BMD of the radius is consistent with other anabolic agents.</p><p>BMD at Month 24: All subjects in the placebo and romosozumab dose groups continued on their blinded therapy for the second year of the study. Subjects in the teriparatide arm were discontinued after 12 months and subjects in the alendronate arm were transitioned to romosozumab 140 mg monthly. As shown in figure 10-8 below, BMD in the romosozumab arms did continue to increase in the second year of therapy although the increases are not as robust as those achieved in the first year of therapy. Bone Turnover Markers: Both markers of bone formation (P1NP, osteocalcin, and BSAP) and markers of bone resorption (CTX) were evaluated during the first 24 months of the study.</p><p>As shown in the figure below, P1NP, a marker of bone formation increased in all romosozumab groups and were greatest at month 1. The increases in bone formation were not maintained and levels returned to baseline by month 9. Levels remained above baseline the longest for the 210 mg monthly group (yellow). Bone formation with alendronate therapy (gray) in the first 12 months is suppressed, which is expected. In the second year, with romosozumab 140 mg monthly treatment following the alendronate therapy, bone formation does increase in a similar pattern to other romosozumab groups. The teriparatide group is not</p><formula xml:id="formula_12">Reference ID: 4123729</formula><p>Cross Discipline Team Leader Review 20 displayed below because subjects were discontinued at 12 months. During the 12 months of teriparatide treatment, P1NP increased, reaching a plateau at month 6 and remained elevated through month 12. Therefore, stimulation of bone formation seen with romosozumab is different from the other anabolic agents available. <ref type="bibr">Source: CSR 20060326, Figure 14q-4.4.3, page 2407</ref> For bone resorption, serum CTX is suppressed with romosozumab therapy. As shown in the figure below, the greatest decreases are seen at month 1. Monthly dosing groups romosozumab 140 mg (red) and 210 mg (yellow) remained suppressed through month12. The largest decreases in serum CTX were seen with alendronate therapy (gray). Alendronate is an antiresorptive agent, so the sustained decrease in CTX is expected. In the second year of the study during treatment with romosozumab 140 mg monthly, serum CTX trended up toward baseline. <ref type="bibr">Source: CSR 20060326, Figure 14q-4.5.1, page 2409</ref> Denosumab Extension: During months 24 to 36, subjects who chose to participate in the denosumab extension were randomized to receive either denosumab or placebo. As displayed in the figure below, treatment with denosumab resulted in increases in BMD. Cessation of osteoporosis therapy and treatment with placebo resulted in BMD returning to baseline 12 months after romosozumab is discontinued. Similar results were seen for total hip and femoral neck BMD. Romosozumab Retreatment: Subjects who completed months 36 of the denosumab extension could elect to participate in the romosozumab retreatment. All subjects who participated in the month 36 to 48 extension received romosozumab 210 mg monthly. As displayed in the figure below, following placebo, retreatment with romosozumab had a similar pattern of BMD increase as was seen with initial romosozumab treatment. Following the antiresorptive medication denosumab, there appears to be a 6 month lag before BMD with romosozumab retreatment begins to increase. Conclusions: The data from trial 20060326 demonstrate dose-related increases in bone mineral density with romosozumab therapy. Bone mineral density increases are more robust with monthly dosing as compared to every 3 month dosing. At the End-of Phase 2 meeting, the Applicant proposed the 210 mg monthly dose for further development. This is the only dose that was statistically better then both alendronate and teriparatide. The Division recommended that both the 140 mg monthly dose and the 210 mg monthly dose be taken into Phase 3 as the BMD responses were similar. The Applicant chose to take 210 mg monthly for evaluation in the fracture efficacy trial. Therefore, it is unknown as to whether a lesser dose of the medication would achieve fracture efficacy results. The Applicant also proposed limiting romosozumab therapy to one year of treatment. The Division agreed that the data support limiting dosing to one year of therapy.</p><p>Trial 20101291 is a randomized, placebo-controlled, dose-finding study is Japanese women with osteoporosis. Please see the primary clinical review, pages 82-86 for complete details. BMD changes with romosozumab are consistent with the findings from trial 20060326.</p><p>Trial 20080289 is a randomized, open-label study to evaluate the effect of romosozumab compared to teriparatide in patients previously treated with bisphosphonates. While this study is not sufficient to support any comparative claims, it does offer some information on BMD response to romosozumab in subjects previously treated with bisphosphonates. Enrolled subjects were required to have been taking a bisphosphonate for at least 3 years prior to screening and to have been treated in the last year and immediately prior to screening with alendronate 70mg weekly, or equivalent. As outlined in the figure below, there is no apparent lag in BMD increases achieved with romosozumab therapy in subjects previously treated with bisphosphonates. <ref type="bibr">Source: CSR 20080289, page 213</ref> Trial 20070337: Trial 20070337 is a 24-month, multicenter, double-blind, randomized, placebo-controlled study evaluating healthcare provider administered monthly subcutaneous romosozumab 210 mg for the treatment of postmenopausal osteoporosis (PMO). The coprimary endpoints of the study are incidence of new morphometric (radiographic) vertebral fractures at month 12 and 24 months. Because of the waning bone effect of romosozumab after 1 year, the Applicant chose to limit the duration of romosozumab exposure to one year. Therefore, this 24 month study is designed as double blind in the first year, and then all subjects will receive healthcare provider administered open label denosumab 60 mg every 6 month in the second year. Multiple substudies were included in this trial: a pharmacokinetic (PK) substudy; a bone turnover marker (BTM) and biomarker substudy; an imaging substudy I (forearm DXA, total body DXA, high resolution peripheral quantitative computed tomography (HR-pQCT)); an imaging substudy II (lumbar spine, proximal femur DXA substudy); a bone biopsy substudy; a calcium substudy; an audiology substudy; an osteoarthritis substudy; a pharmacogenetics substudy; and mineral substudy (serum intact parathyroid hormone (iPTH) and urinary calcium).</p><p>Study population: Trial 20070337 enrolled postmenopausal women with osteoporosis age 50 to 90 years. Osteoporosis was defined as a BMD T-score at the total hip or femoral neck of  -2.5. Subjects with a history of hip fracture, severe vertebral fracture, or more than 2 moderate vertebral fractures were excluded from the study. Subjects with metabolic bone disease, laboratory abnormalities, or use of drugs known to affect bone were also excluded. Prior use of osteoporosis therapies was allowed with appropriate wash out. The original study enrollment was targeting 6000 subjects. The sample size was increased to 6600 subjects after blinded review of the pooled nonvertebral fracture incidence was 12.5% lower than the original assumptions.</p><p>Study treatments: Subjects were randomized 1:1 to receive either romosozumab 210 mg or matching placebo by subcutaneous (SC) injection every month for the first 12 months of the trial. Injections were administered by a healthcare provider. The dose of 210 mg required three 1 mL syringes of 70 mg/mL romosozumab. Randomization was stratified by age (&lt; 75 years,  75 years) and prevalent vertebral fracture (yes, no), as determined by site staff at randomization based on local reading of the spine X-ray. After the 12-month double-blind placebo-controlled treatment period, all subjects entered the 12-month open-label denosumab treatment period where they received denosumab 60 mg SC every 6 months in an open-label fashion while still remaining blinded to their initial treatment assignment (romosozumab or placebo). Denosumab injections were also administered by a healthcare provider. Subjects were to receive daily calcium (500 to 1000 mg) and vitamin D (600 to 800 IU) supplementation.</p><p>Efficacy measures: The coprimary endpoints of trial 20070337 are subject incidence of new morphometric vertebral fracture at month 12 and month 24. Spine radiographs were obtained at screening, month 6, month 12, and month 24. Morphometric vertebral fractures were determined using the semiquantitative method of Genant. Nonvertebral fractures were confirmed by the central read facility using radiographs, CT, or MRI. If these were not available, a medical report was acceptable. Bone mineral density of the hip and lumbar spine by DXA was obtained at baseline, month 12 and month 24.</p><p>A central radiologic facility, was used for fracture assessment, DXA and quantitative CT readings. The central read facility managed DXA readings and DXA quality control including cross calibration with a central phantom and longitudinal quality control conducted by the study sites and reviewed by the central facility.</p><p>To control the overall type I error, the primary and secondary efficacy endpoints were tested sequentially at the 2-sided 5% significance level, as listed:</p><p>1. Subject incidence of new vertebral fracture through months 12 and 24 2. Subject incidence of clinical fracture through month 12 3. Subject incidence of non-vertebral fracture through months 12 and 24 (testing for months 12 and 24 were controlled by Hochberg procedure at 0.05 level within the step) 4. Subject incidence of clinical fracture through month 24 5. Subject incidence of major non-vertebral fracture through months 12 and 24 (testing for months 12 and 24 were controlled by Hochberg procedure at 0.05 level within the step) 6. Subject incidence of new or worsening vertebral fracture through months <ref type="bibr">12 and 24</ref> (testing for months 12 and 24 were controlled by Hochberg procedure at 0.05 level within the step) 7. Subject incidence of hip fracture through months 12 and 24 (testing for months 12 and 24 were controlled by Hochberg procedure at 0.05 levels within the step)</p><p>The Applicant defined several analysis dataset populations. The primary analysis population for vertebral fractures included all randomized subjects who had a baseline and at least one post-baseline evaluation for vertebral fracture at or before the specific timepoint under consideration. The full analysis population for all other fracture assessments (nonvertebral fracture, clinical fracture, major nonvertebral fracture, major osteoporotic fracture, hip fracture) included all randomized subjects. The primary efficacy analysis population for BMD and patient reported endpoints included all randomized subjects who had a baseline and at least one post baseline evaluation of the endpoint of interest at or before the specific timepoint under consideration.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results:</head><p>Disposition: As outlined in the table below, 7180 (3589 romosozumab, 3591 placebo) subjects were randomized into the trial. As outlined in the table below, approximately 84% of subjects completed the two years of the trial. The most common reason for discontinuation was withdrawal of consent. Subjects could complete the trial after discontinuing study drug. For the 24-month study period, approximately 83% of subjects completed study drug dosing.  <ref type="formula" target="#formula_34">(2)</ref> 47 <ref type="formula" target="#formula_34">(1)</ref> 100 <ref type="formula" target="#formula_34">(1)</ref> Lost to follow-up 42 <ref type="formula" target="#formula_34">(1)</ref> 49 <ref type="formula" target="#formula_34">(1)</ref> 91 <ref type="formula" target="#formula_34">(1)</ref> Required alternative therapy 2 (&lt;0.1) 4 (0.1) 6 (&lt;0.1) Other* 104 <ref type="formula" target="#formula_34">(3)</ref> 100 <ref type="formula" target="#formula_34">(3)</ref> 204 <ref type="formula" target="#formula_34">(</ref>  <ref type="formula" target="#formula_34">(12)</ref> 425 <ref type="formula" target="#formula_34">(12)</ref> 866 <ref type="formula" target="#formula_34">(12)</ref> Black or African American 74 <ref type="formula" target="#formula_34">(2)</ref> 77 <ref type="formula" target="#formula_34">(2)</ref> 151 <ref type="formula" target="#formula_34">(2)</ref> American Indian/ Alaskan Native 63 <ref type="formula" target="#formula_34">(2)</ref> 64 <ref type="formula" target="#formula_34">(2)</ref> 127 <ref type="formula" target="#formula_34">(2)</ref> Hawaiian/Pacific Islander 1 (&lt;0.1) 0 1 (&lt;0.1) Multiple 59 <ref type="formula" target="#formula_34">(2)</ref> 60 <ref type="formula" target="#formula_34">(2)</ref> 119 <ref type="formula" target="#formula_34">(2)</ref>   <ref type="formula" target="#formula_34">(11)</ref> 58 <ref type="formula" target="#formula_34">(11)</ref> 58 <ref type="formula" target="#formula_34">(11)</ref>  Reviewer comment: It is unusual to see the analysis population increase at month 24, compared to month 12. However, it is possible given the construct of the primary analysis population. If a subject had a baseline radiograph and then only had spine radiograph at month 24, they could be included in the month 24 analysis population and excluded from the month 12 population.</p><p>Subgroup analyses were conducted based on age (&lt; 65 years,  65 years, &lt; 75 years,  75 years), race, geographic region, prevalent vertebral fracture status, history of fragility fracture, history of nonvertebral fracture after age 55 years, baseline lumbar spine BMD T-score, baseline hip or femoral neck BMD T-score, baseline body mass index, and baseline World Health Organization Fracture Risk Assessment (FRAX) score for major osteoporotic fracture. As displayed in the primary statistical review Appendix A2, the reduction in new vertebral fracture risk showed similar trends in all subgroups evaluated.</p><p>Clinical and Nonvertebral Fracture: In the statistical hierarchy of fracture assessments, clinical fracture at month 12 is the first secondary endpoint. Nonvertebral fracture at month 12 and 24 is the next endpoint in the statistical hierarchy, followed by clinical fracture at month The Applicant attributes the lack of significance of the nonvertebral fracture reduction to a regional subgroup interaction in Central/Latin America where a lower than expected nonvertebral fracture rate in the placebo group was observed (assumed 3.5%, observed 1.2%). The observed nonvertebral fracture rate was also lower than expected in the small enrolled population in North America (assumed 3.5%, observed 1.1%). In the original 24 month sample size calculation, the Applicant assumed a nonvertebral fracture rate of 4% during the first 12 months of the trial and with a sample size of 6000 subjects the study had a power of 93% to detect a 40% decrease in nonvertebral fractures after 12 months of romosozumab compared with placebo. During the study, the pooled nonvertebral fracture rate was monitored and the Applicant observed that the rate was lower than expected. Therefore, the sample size was increased in protocol amendment number 4 using a 3.5% nonvertebral fracture rate, increasing the sample size to 6600. The total sample size of 6600 subjects was anticipated to provide 91% power to detect a 40% decrease in the risk of nonvertebral fracture after romosozumab treatment for 12 months.</p><p>Other Fracture Endpoints: Other fracture endpoints included in the hierarchal testing were subject incidence of major nonvertebral fracture through months 12 and 24; subject incidence of new or worsening vertebral fracture through months 12 and 24; and subject incidence of hip fracture through months 12 and 24. For all of these endpoints, the Applicant reports adjusted p-values but based on the statistical plan, hierarchal testing should have stopped after lack of significance of nonvertebral fractures. The Applicant also conducted analyses of numerous exploratory fracture endpoints, which are not discussed in this review.</p><p>Bone Mineral Density: Bone mineral density was not included in the hierarchal statistical testing. Bone mineral density of the hip and lumbar spine DXA was measured at baseline, month 12 and month 24. Analyses used an ANCOVA model adjusting for treatment, age and prevalent vertebral fracture stratification variables, baseline value, machine type, and baseline value-by-machine type interaction, without adjustment for multiplicity.</p><p>As outlined in the table below, treatment with romosozumab resulted in significant increases in both lumbar spine and hip bone mineral density. At month 12, the treatment difference is 12.7% at the lumbar spine, 5.8% at the total hip, and 5.2% at the femoral neck. From month <ref type="bibr">12 -24</ref>, treatment with open-label denosumab resulted in increases in bone mineral density in all groups. Despite the increase in BMD in the placebo group, the treatment difference remained similar (11.1% at the lumbar spine, 5.3% at the total hip, and 4.9% at the femoral neck).</p><p>Reference ID: 4123729 When subgroups including age, race, and geographic region were evaluated, changes in BMD were consistent.</p><formula xml:id="formula_13">(b) (4) (b) (4)</formula><p>Reviewer Comment: The BMD endpoints were not included in the hierarchal statistical testing. Based on this, it would be reasonable not to include the BMD findings in product labeling. However, change in BMD with therapy is an important endpoint for prescribers and given the robust findings, the statistical significance would likely remain after multiplicity adjustment. Therefore, inclusion of the BMD findings in product labeling will be considered.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Applicability of Efficacy Findings to U.S. Patients and U.S. Medical Practice:</head><p>Of the 7180 subjects enrolled in the fracture efficacy trial for romosozumab, 195 (2.7%) were from North America. Only a small number of fractures occurred in the North American population. Given the very small population enrolled, the Applicant was asked to justify the applicability of the study findings to the U.S. population and U.S. medical practice. As outlined in <ref type="figure" target="#fig_0">figure  18</ref>, there was no treatment by region interaction for new vertebral fractures at month 12 (source: BLA 761062, 2.7.3 Summary of Clinical Efficacy, page 126). When lumbar spine BMD was evaluated, the BMD changes were consistent across all regions (figure 19, source: BLA 761062, 2.7.3 Summary of Clinical Efficacy, page 127). Given the consistent findings across all geographic regions, the results from study 20070337 can be considered applicable to the U.S. population and U.S. medical practice.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions on the Substantial Evidence of Effectiveness:</head><p>The Applicant has provided substantial evidence to support one year of romosozumab therapy for treatment of osteoporosis in postmenopausal women. Fracture risk reduction with romosozumab 210 mg SC administered by a healthcare provider once a month, is demonstrated in trial 20070337. Demonstration of fracture risk reduction is required for a treatment of osteoporosis indication. Morphometric vertebral fracture at month 12 and month 24 are the coprimary endpoints for trial 20070337. Morphometric vertebral fracture, an asymptomatic fracture diagnosed by radiograph, is an acceptable endpoint that has been used for most approved osteoporosis therapies. At 12 months, the new morphometric vertebral fracture absolute risk reduction was 1.3% and the relative risk reduction was 73% (p&lt;0.001) with romosozumab compared to placebo. Romosozumab was given for one year, for the second year of the trial all subjects received denosumab. At 24 months, the new morphometric vertebral fracture absolute risk reduction was 1.9% and the relative risk reduction was 75% (p&lt;0.001) with romosozumab/denosumab compared to placebo/denosumab. A significant reduction in clinical fracture was demonstrated at month 12. The clinical fracture absolute risk reduction was 1.2% and the relative risk reduction was 36% (p=0.008) with romosozumab compared to placebo. However, clinical fracture is a composite of nonvertebral and symptomatic vertebral fractures. Nonvertebral fractures make up 88% of the fractures in this composite endpoint and a significant reduction in nonvertebral fracture was not demonstrated with romosozumab therapy.</p><p>Supportive evidence is provided by the bone mineral density increases from trials <ref type="bibr">20070337, 20060326 and 20120156.</ref> In the clinical fracture trial 20070337, the treatment difference in lumbar spine BMD at month 12 was 12.7% with romosozumab. This is comparable to the lumbar spine BMD treatment difference of 11.5% observed in trial 20060326. Increases in hip BMD were also consistently observed with romosozumab therapy. In trial 20070337, the 12 month BMD romosozumab treatment difference compared to placebo was 5.8% at the total hip and 5.2% at the femoral neck. In trial 20060326, the treatment difference at 12 months was 4.9% at the total hip and 4.8% at the femoral neck.</p><p>Only 2.7% (195/7180 subjects) of the enrolled population for the fracture trial 20070337 was from North America. Therefore, a question of the applicability of the predominantly non-U.S. results to the U.S. population was raised. Evaluation of by-region treatment effect demonstrated no differences in the BMD response to romosozumab. Therefore, the results from trial 20070337 can be considered applicable to the U.S. population and U.S. medical practice.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.">Safety</head><p>This integrated review of safety primarily focuses on trial 20070337, the fracture efficacy trial in which 7157 subjects were enrolled and received treatment. In addition, 12 month placebo controlled safety data is available from studies 20060326 (N=419), the phase 2 dose-finding study and 20101291 (N=252), the phase 2 dose finding study in Japanese women.</p><p>Exposure: The pooled safety population is comprised of postmenopausal women with osteoporosis or low bone mass who were enrolled in placebo-controlled trials at least 12 months in duration. This includes 7384 subjects (3689 placebo, 3695 romosozumab 210mg). Of those, 7184 subjects received at least 12 months of study drug (3305 placebo, 3879 romosozumab). This safety database exceeds the population exposure recommended in the ICH E1A guideline. Specific Safety Assessments: Special safety studies for romosozumab include assessment of immunogenicity (discussed in the clinical pharmacology/immunogenicity section of this review) and local tolerance evaluations for injection site reactions. Specific substudies of trial 20070337 included evaluation of bone histomorphometry, calcium and mineral metabolism, audiology, and osteoarthritis. Specific adverse event adjudication committees were set up for osteonecrosis of the jaw, atypical femoral fractures, and cardiovascular events. Deaths: A total of 53 (24 (0.7%) placebo, 29 (0.8%) romosozumab) deaths occurred in the pooled safety population. As outlined in table 28, page 110 of the primary clinical review, the most common reason stated is death not otherwise specified occurring in 5 subjects in each group. An imbalance was noted in death due to malignant lung neoplasm, which occurred in 4 subjects in the romosozumab group and no subjects in the placebo group. Dr. Chang conducted a thorough review. All affected subjects were current or former smokers, the time to onset was short (47-132 days after first treatment of romosozumab), and the overall incidence of lung neoplasm was balanced between treatment groups. I agree with Dr. Chang that the findings should be outlined in the product label.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serious Adverse Events:</head><p>In the pooled safety population, 323 (9%) subjects in the placebo group and 352 (10%) subjects in the romosozumab group experienced a serious adverse event.</p><p>The most common occurrences in the romosozumab treatment group were pneumonia (10 (0.3%) placebo, 19 (0.5%) romosozumab); hypertension (5 (0.1%) placebo, 8 (0.2%) romosozumab); unstable angina (3 (&lt;0.1%) placebo, 7 (0.2%) romosozumab); cardiac failure congestive (4 (0.1%) placebo, 7 (0.2%) romosozumab); and chronic obstructive pulmonary disease (15 (0.4%) placebo, 7 (0.2%) romosozumab).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse Events leading to Study Withdrawal:</head><p>In the pooled safety population, 50 (1%) subjects in the placebo group and 45 (1%) subjects in the romosozumab group discontinued from the study due to an adverse event. The most common adverse events leading to study withdrawal were arthralgia (1 placebo, 3 romosozumab); musculoskeletal pain (2 placebo, 3 romosozumab); pain in extremity (0 placebo, 3 romosozumab); abdominal pain (0 placebo, 2 romosozumab); back pain (2 placebo, 2 romosozumab); and nausea (0 placebo, 2 romosozumab).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse Events leading to Study Drug Discontinuation:</head><p>In the pooled safety population, 96 (3%) subjects in the placebo group and 106 (3%) subjects in the romosozumab group discontinued study drug due to an adverse event. The most common reasons for study drug discontinuation were pain in extremity <ref type="bibr">(1 placebo, 8 romosozumab)</ref>; arthralgia (5 placebo, 5 romosozumab); nausea (0 placebo, 4 romosozumab); bone pain (1 placebo, 3 romosozumab); allergic dermatitis (1 placebo, 3 romosozumab); dizziness (5 placebo, 3 romosozumab); fatigue (3 placebo, 3 romosozumab); and musculoskeletal pain (7 placebo, 3 romosozumab).  <ref type="formula" target="#formula_34">(12)</ref> 459 <ref type="formula" target="#formula_34">(13)  Nasopharyngitis</ref> 438 <ref type="formula" target="#formula_34">(12)</ref> 459 <ref type="formula" target="#formula_34">(13)</ref> Back pain 378 <ref type="formula" target="#formula_34">(11)</ref> 375 <ref type="formula" target="#formula_34">(11)</ref> Pain in Extremity 302 <ref type="formula" target="#formula_34">(8)</ref> 279 <ref type="formula" target="#formula_34">(8)  Fall</ref> 318 <ref type="formula" target="#formula_34">(9)</ref> 254 <ref type="formula" target="#formula_34">(7)</ref> Headache 205 <ref type="formula" target="#formula_34">(6)</ref> 233 <ref type="formula" target="#formula_34">(7)</ref> Hypertension 259 <ref type="formula" target="#formula_34">(7)</ref> 225 <ref type="formula" target="#formula_34">(6)</ref> Upper respiratory tract infection, viral 227 <ref type="formula" target="#formula_34">(6)</ref> 206 <ref type="formula" target="#formula_34">(6)</ref> Osteoarthritis 220 <ref type="formula" target="#formula_34">(6)</ref> 186 <ref type="formula" target="#formula_34">(5)  Influenza</ref> 182 <ref type="formula" target="#formula_34">(5)</ref> 169 <ref type="formula" target="#formula_34">(5)</ref> Source: CSR20070337, table 14-6.4.1</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse Events of Interest:</head><p>Hypocalcemia: Hypocalcemia has been reported with osteoporosis therapies that inhibit bone resorption. This discussion will focus on the first year of trial 20070337 when romosozumab or placebo was given. As discussed under laboratories below, the nadir in serum calcium appears to be 1 month following romosozumab injection. In trial 20070337, no serious adverse events of hypocalcemia were reported during the first year. One adverse event of Grade 2 hypocalcemia (corrected calcium 7.0 to 8.0 mg/dL, 1.75 to 2.0 mmol/L) was reported in a romosozumab treated subject.</p><p>Patients with renal failure have altered mineral metabolism because of the underlying renal disease and the role the kidney plays for maintaining calcium and phosphorus levels. Study 34 20110227 evaluated the effect of romosozumab therapy on patients with Stage 4 (eGFR 15 -29) renal insufficiency (N=8) and subjects with end stage renal disease on hemodialysis (N=8) compared to healthy subjects (N=8). All subjects received an oral loading dose of 50,000IU vitamin D and were required to take supplemental calcium and vitamin D (amount based on the subject's baseline laboratories). No healthy subjects developed hypocalcemia. One subject in the stage 4 renal insufficiency groups developed Grade 1 hypocalcemia (corrected calcium 8.0mg/dL to LLN, or 2.0 mmol/L to LLN). Four subjects in the end stage renal disease group developed hypocalcemia, 1 subject with Grade 1 hypocalcemia, 2 subjects with Grade 2 hypocalcemia and 1 subject with Grade 3 hypocalcemia ( corrected calcium 6 -7 mg/dL; 1.5 -1.75 mmol/L).</p><p>Reviewer Comment: I agree with Dr. Chang that the issues of hypocalcemia and the need to monitor calcium levels in renal failure patients should be described in product labeling.</p><p>Hypersensitivity: The Applicant used a narrow standardized MedDRA query (SMQ) for hypersensitivity reactions. In the pooled safety population, potential hypersensitivity reactions occurred in 253 (7%) subjects in the placebo group and 249 (7%) subjects in the romosozumab group. The most common preferred terms were rash, dermatitis allergic, and eczema. When the search was narrowed to events occurring within 2 days of study drug administration, events were reported in 32 (1%) placebo subjects and 48 (1%) romosozumab subjects. The most common preferred terms were injection site rash and rash. One fatality due to circulatory collapse occurred on study day 345, 9 days after romosozumab administration. The investigator did not think this event was related to study drug as there were no reports of flushing, pruritus, or urticaria preceding the event. Serious adverse events related to hypersensitivity reactions occurred in 1 (&lt;0.1%) subjects in the placebo group and 7 (0.2) subjects in the romosozumab group. Discontinuation from the trial due to hypersensitivity reactions occurred in 2 subjects in each treatment group. Discontinuation of study drug due to potential hypersensitivity reactions occurred in 6 (0.2%) subjects in the placebo group and 11 (0.3%) in the romosozumab group.</p><p>In the pooled safety population, hypersensitivity reactions were evaluated based on antidrug antibody status. Potential hypersensitivity reactions occurred in 7% of placebo treated subjects, 7% of binding antibody negative romosozumab treated subjects and 7% binding antibody positive romosozumab treated subjects. When evaluated in term os neutralizing antibody status, potential hypersensitivity reactions occurred in 7% of placebo treated subjects, 7% of neutralizing antibody negative romosozumab treated subjects and 4% neutralizing antibody positive romosozumab treated subjects.</p><p>The potential hypersensitivity reactions reported in the pooled safety population occurred using a drug product concentration of 70 mg/mL where patients required 3 injections of 1mL each to reach the 210 mg dose. The to-be-marketed formulation of romosozumab will be the 90 mg/mL concentration, where patients will need two injections of 1.17mL each. Trial 20120156 was a 6-month trial that compared bone density changes of the romosozumab 70 mg/mL formulation and the romosozumab 90 mg/mL formulation. Potential hypersensitivity reactions occurred in 3 (6%) subjects in the placebo group, 3 (3%) subjects in the 70 mg/mL romosozumab group and 14 (11%) subjects in the 90 mg/mL romosozumab group.</p><p>Reviewer Comment: The potential for hypersensitivity reactions may be more pronounced with the higher concentration of romosozumab. Injection Site Reactions: In the pooled safety population, injection site reactions occurred in 107 (3%) subjects in the placebo group and 192 (5%) subjects in the romosozumab group. There were no serious adverse events related to injection site reactions. Discontinuation from the trial due to injection site reactions occurred in 2 subjects in each treatment group. Discontinuation of study drug due to injection site reactions occurred in 2 (&lt;0.1%) subjects in the placebo group and 5 (0.1%) in the romosozumab group.</p><p>In the pooled safety population, injection site reactions were evaluated based on antidrug antibody status. Injection site reactions occurred in 3% of placebo treated subjects, 5% of binding antibody negative romosozumab treated subjects and 7% binding antibody positive romosozumab treated subjects. When evaluated in terms of neutralizing antibody status, injection site reactions occurred in 3% of placebo treated subjects, 7% of neutralizing antibody negative romosozumab treated subjects and 7% neutralizing antibody positive romosozumab treated subjects.</p><p>The injection site reactions reported in the pooled safety population occurred using a drug product concentration of 70 mg/mL where patients required 3 injections of 1mL each to reach the 210 mg dose. In trial 20120156 comparing the 70 mg/mL and the 90 mg/mL formulations, injection site reactions occurred in no subjects in the placebo group, 11 (9%) subjects in the 70 mg/mL romosozumab group and 13 (11%) subjects in the 90 mg/mL romosozumab group.</p><p>Reviewer Comment: The potential for injection site reactions may be more pronounced with the higher concentration of romosozumab or in patients who develop binding antibodies to romosozumab.</p><p>Malignant or unspecified tumors: The Wnt-beta-catenin pathway plays a role in sclerostin signaling. Wnt-beta catenin is also thought to play a role in some tumor suppressor signals. Therefore, the Applicant evaluated the sclerostin inhibitor romosozumab's potential for malignant tumors. In the pooled safety population, adverse events of malignant or unspecified tumors were reported in 71 (2%) subjects in the placebo group and 61 (2%) subjects in the romosozumab group. Serious adverse events of malignant or unspecified tumors were reported in 44 (1%) subjects in the placebo group and 39 (1%) subjects in the romosozumab group.</p><p>Inflammatory Conditions: Some literature suggests that sclerostin inhibition promotes tumor necrosis factor (TNF)-mediated inflammatory joint disease. The Applicant constructed a MedDRA search strategy to identify events related to TNF mediated inflammation. In the pooled safety population, in subjects with a prior history of TNF mediated inflammatory disease, TNF mediated inflammatory adverse events occurred in 8 (13%) subjects in the placebo group and 5 (8%) subjects in the romosozumab group. In subjects without a prior history, TNF mediated inflammatory adverse events occurred in 6 (0.2%) subjects in the placebo group and 2 (&lt;0.1%) subjects in the romosozumab group.</p><p>Osteoarthritis: Sclerostin is expressed in articular cartilage, raising concerns that sclerostin inhibition may negatively affect articular cartilage. In the pooled safety population, adverse events of osteoarthritis were reported in 320 (9%) subjects in the placebo group and 291 (8%) subjects in the romosozumab group. Serious adverse events of osteoarthritis were reported in 17 (1%) subjects in the placebo group and 7 (0.2%) subjects in the romosozumab group.</p><p>The Applicant also conducted an osteoarthritis substudy in trial 20070337. This substudy enrolled 343 (175 placebo, 168 romosozumab) subjects. During the 12-month study, 38 subjects (25 (14%) placebo, 13 (8%) romosozumab) discontinued the study. The endpoint was change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score with ANCOVA using treatment, baseline WOMAC score, baseline BMI, and baseline age as independent variables. The baseline WOMAC total score was 36.68 in the placebo group and 39.38 in the romosozumab group. The LS mean change in total WOMAC score was -1.3 in the placebo group and -2.2 in the romosozumab group. Progressive worsening of knee osteoarthritis was reported in 25 (21%) placebo subjects and 21 (17%) romosozumab subjects. Osteoarthritis adverse events were reported in 12% of placebo subjects and 8% of romosozumab subjects.</p><p>Hyperostosis: Hyperostosis with adverse neurologic consequences is a feature of diseases of sclerostin overexpression (sclerosteosis and van Buchem disease). The Applicant constructed a MedDRA search strategy to identify events related to hyperostosis. In the pooled safety database, adverse events of hyperostosis were reported in 29 (1%) subjects in the placebo group and 19 (1%) subjects in the romosozumab group. Most preferred terms were related to spinal stenosis. Serious adverse events of hyperostosis were reported in 5 (1%) subjects in the placebo group and 1 (&lt;0.1%) subject in the romosozumab group.</p><p>One potential neurologic consequence of hyperostosis is hearing loss. The Applicant conducted an audiology substudy of trial 20070337 that enrolled 498 (243 placebo, 255 romosozumab) subjects. During the 12 month study, 34 subjects (18 (7%) placebo, 16 (6%) romosozumab) discontinued the study. The protocol defined hearing changes using American Speech-Language-Hearing Association (ASHA) criteria. Hearing loss is defined as increase hearing threshold  20 dB at any single frequency, or loss of  10 dB at any 2 adjacent frequencies, or loss of response at 3 consecutive frequencies where responses were previously obtained. Hearing gain is defined as decrease hearing threshold  20 dB at any single frequency, or gain of  10 dB at any 2 adjacent frequencies, or loss of response at baseline but a response is obtained post-baseline at 3 consecutive frequencies. Through month 12, protocol-defined hearing loss was reported in 43/184 (23%) subjects in the placebo group and 54/209 (26%) subjects in the romosozumab group. Protocol-defined hearing gain was reported in 24/184 (19%) subjects in the placebo group and 40/209 (19%) subjects in the romosozumab group. The LS mean change in air conduction was 0.3 in the placebo group and 1.0 in the romosozumab group.</p><p>Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ) is a rare adverse reaction associated with potent anti-resorptive medications. The Applicant defined ONJ as an event of interest and all potential events of ONJ identified through a predefined search of MedDRA terms were submitted to an independent external adjudication committee for review and adjudication. In the pooled safety population, no placebo subjects and one romosozumab subject had a positively adjudicated case of ONJ. In Trial 20070337, one additional subject who had received romosozumab had a positively adjudicated ONJ while undergoing denosumab therapy.</p><p>Additional adjudicated cases of ONJ were reported from ongoing trials, specifically Trial 20110142, a 24-month, randomized, active controlled fracture study evaluating treatment with romosozumab compared to alendronate. In the first 12 months of the study, subjects are randomized to romosozumab or alendronate. In the second year of the trial, all subjects receive alendronate. Both cases of ONJ occurred during the second year alendronate treatment period. One subject was on romosozumab then alendronate, the other subject was on alendronate then continued on alendronate.</p><p>Reviewer Comment: I agree with Dr. Chang that the product labeling should contain information about ONJ.</p><p>Atypical femoral fractures: Atypical femoral fracture is a rare adverse reaction associated with potent anti-resorptive medications. The Applicant defined atypical femoral fracture as an event of interest and all potential events of femoral fracture identified through a predefined search of MedDRA terms were submitted to an independent external adjudication committee for review and adjudication. In the pooled safety population, no placebo subjects and one romosozumab subject had a positively adjudicated case of atypical femoral fracture.</p><p>Additional adjudicated cases of atypical femoral fracture were reported from ongoing trials, specifically Trial 20110142. In trial 20110142, there were 5 femoral fractures sent for adjudication, four of which were positively adjudicated as atypical femoral fractures. All cases occurred in the second year alendronate treatment period. One subject was on romosozumab then alendronate; the other three subjects were on alendronate then continued on alendronate.</p><p>Reviewer Comment: I agree with Dr. Chang that the product labeling should contain information about atypical femoral fractures.</p><p>Cardiovascular Safety: Sclerostin gene SOST mRNA is expressed in the heart, aorta, liver, and kidney. Therefore, there is a concern that inhibition of sclerostin by romosozumab may promote or exacerbate vascular calcification. The Applicant has identified cardiovascular adverse events as an event of interest and all deaths and potential cardiovascular-related serious adverse events from Trial 20070337 were submitted for adjudication to an external independent committee comprised of physicians with expertise in cardiology, osteoporosis, internal medicine, or neurology. Adjudicated cardiovascular events of death (including those classified as cardiovascular and those deemed of indeterminate cause and thus included among cardiovascular deaths), cardiac ischemic event, cerebrovascular event, noncoronary revascularization, heart failure, and peripheral vascular events not requiring revascularization are summarized.</p><p>As outlined in the table below, the incidence of positively adjudicated cardiovascular serious adverse events was similar between treatment groups during the first year of the trial. Laboratories:</p><p>Calcium: Calcium levels were evaluated in the main 20070337 study as well as several substudies. The calcium substudy enrolled 1687 (854 placebo, 833 romosozumab) subjects. Approximately 9% of subjects discontinued the study. The demographic make-up of the substudy population was similar to the main study. Hypocalcemia was defined as a calcium&lt;7.5 mg/dL. At study day 14, no subjects had a calcium less than 7.5 mg/dL. Calcium corrected by albumin was also collected in the bone turnover marker substudy. As outlined in the figure below, the nadir in serum calcium seems to occur at day 14 through month 1. Calcium then returns toward baseline. The calcium decreases with denosumab in the second year of the trial are expected given the antiresorptive action of denosumab. In trial 20070337, serum calcium was evaluated at baseline and months <ref type="bibr">1 , 3, 6, 9, 11, and 12</ref> in the first year of the study. The baseline mean calcium level in both groups was 9.7 mg/dL. At month 1, the percent change was 0% in the placebo group and -2.2% in the romosozumab group.</p><p>Phosphorus: In trial 20070337, the baseline mean serum phosphorus level was 3.8 mg/dL in both treatment groups. At month 1, the percent change was 0% in the placebo group and -5.1% in the romosozumab group. Phosphorus levels remained below baseline for the remainder of romosozumab treatment, although the absolute values were in the normal range.</p><p>Parathyroid hormone: The serum iPTH and urinary calcium substudy enrolled 656 (346 placebo, 310 romosozumab) subjects. Approximately 3% of subjects discontinued the study. The demographic make-up of the substudy population was similar to the main study. The baseline median iPTH was 4.2 pmol/L in the placebo group and 4.4 pmol/L in the romosozumab group. At month 6, the median percent change in iPTH was 4% in the placebo group and 29% in the romosozumab group (nominal p-value &lt;0.001 from Wilcoxon rank-sum test without multiplicity adjustment). This increase in iPTH was maintained with the month 12 median percent change of 8% in the placebo group and 27% in the romosozumab group (nominal p-value &lt;0.001).</p><p>Liver Transaminases: The Applicant evaluated the pooled safety database for potential Hy's law cases, defined as ALT or AST &gt;3x ULN, total bilirubin &gt;2x ULN, and no other explanation for the increases. Subjects were not excluded from the studies with elevated transaminase levels. At baseline, in the pooled safety database, 6/3689 placebo subjects and 3/3695 romosozumab treated subjects had AST levels &gt;3x ULN and 10/3689 placebo subjects and 2/3694 romosozumab treated subjects had ALT levels &gt;3x ULN. On study, 29 /3612 placebo subjects and 9/3608 romosozumab subjects developed AST &gt;3x ULN and 31/3613 placebo subjects and 16/3608 romosozumab treated subjects had ALT levels &gt;3x ULN. As outlined in the clinical review pages 135 -138, Dr. Chang has carefully reviewed the data from the most concerning potential Hy's law cases and none of the cases support a liver signal with romosozumab therapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Special Studies:</head><p>Bone Histomorphometry: Bone biopsies using fluorochrome labeling were obtained from 139 subjects (68 placebo/denosumab, 71 romosozumab/denosumab). A total of 154 biopsies were obtained at different timepoints during the trial. Month 2 biopsies were obtained in 34 subjects (18 placebo, 16 romosozumab); month 12 biopsies were obtained from 73 subjects <ref type="bibr">(33 placebo, 40 romosozumab)</ref>; and month 24 biopsies were obtained from 47 subjects (23 placebo/ denosumab, 24 romosozumab/denosumab). Some subjects had sequential biopsies -15 subjects had biopsies at month 12 and 24 (6 placebo/denosumab, 9 romosozumab/denosumab). Qualitatively, there was no evidence or marrow fibrosis or osteomalacia. One subject who received romosozumab then denosumab had woven bone at the iliac crest. The Applicant believes this is evidence of a microcallus and a nonpathologic process.</p><p>Histomorphometry: The month 2 cohort received quadruple fluorochrome labeling which is a fairly new technique. Subjects received double label at baseline, and then again at month 2. This technique is supposed to allow evaluation of baseline dynamic parameters (the first set of label) and then evaluation after 2 months of therapy (the second set of labels). Within-subject comparisons between baseline and month 2 showed evidence of osteoblast stimulation and osteoclast inhibition with increased bone formation rate and decreased eroded surface. The mineralizing capability of the bone did not appear compromised. The month 12 cohort received the standard double tetracycline labeling. Increased bone volume was observed in the romosozumab group compared to placebo but the dynamic bone formation parameters seen at month 2 had markedly decreased.</p><p>Cardiovascular safety, revisited: Sclerostin gene SOST mRNA is expressed in the heart, aorta, liver, and kidney. Therefore, there is a concern that inhibition of sclerostin by romosozumab may promote or exacerbate vascular calcification. The Applicant identified cardiovascular adverse events as an event of interest and is adjudicating all deaths and cardiovascular serious adverse events in their trials. The large phase 3 fracture trial did not show a cardiovascular safety signal. However, another large trial (20110142) that was not part of the initial marketing application was recently completed and did suggest a cardiovascular safety signal.</p><p>The Division met with the Applicant on May 19, 2017 to discuss the new safety data. Trial 20110142 is a 24 month, randomized, active control fracture study evaluating treatment with romosozumab versus alendronate. The trial enrolled 4054 postmenopausal women with osteoporosis. Preliminary analysis of safety findings revealed a clear imbalance in positively adjudicated serious cardiovascular adverse events, as displayed in the figure below (source: company presentation from May 19 th ).</p><p>Reference ID: 4123729 (b) <ref type="bibr" target="#b86">(4)</ref> Reviewer Comment: The preliminary data presented at the May 19 th meeting call into question the cardiovascular safety of romosozumab in the intended population. The Applicant will need to complete their review of the available data from the completed trials not submitted with this marketing application. Therefore, a Complete Response action is the only course available. After the Applicant has completed their review, the data should be submitted for review.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.">Advisory Committee Meeting</head><p>An Advisory Committee meeting was not held for romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="10.">Pediatrics</head><p>The Applicant submitted an agreed initial Pediatric Study Plan iPSP on 1/12/2016 requesting a full waiver of the requirement to conduct pediatric studies, given that postmenopausal osteoporosis does not exist in the pediatric population. The iPSP was reviewed by the Pediatric Review Committee (PeRC) and PeRC concurred with the Applicant's plan for a full waiver.</p><p>In this application, the Applicant requested a full waiver from pediatric studies because the studies would be impossible given the lack of postmenopausal osteoporosis in the pediatric population. The request was reviewed by PeRC <ref type="bibr">March 1, 2017</ref> and PeRC agreed the request was appropriate and acceptable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="11.">Other Relevant Regulatory Issues</head><p>Financial disclosures: The Applicant has provided financial disclosure information for studies <ref type="bibr">20060326, 20070337, 20080289, 20101291, and 20120156</ref>. Dr. Chang has reviewed the provided financial disclosure information and found that there were three sites in Columbia where four co-investigators did not submit financial disclosure information. These sites accounted for 13% of the primary analysis population for vertebral fractures. A sensitivity analysis removing these three sites was performed. As outlined in table 13, page 54 of the primary clinical review, there was no change in the new vertebral fracture coprimary endpoints.</p><p>Office of Scientific Investigations (OSI) audits: Four clinical sites participating in study 20070337 were inspected by the Office of Scientific Investigations.</p><p>Site 1-678YLY, Jose Fernando Molina Restrepo, M.D., Medellin, Columbia . This site was selected because two investigators with the same last name, in the same geographic location, and with high subject enrollment numbers (752 total between the two sites) were outliers and these clinical investigators had not been inspected previously. There were no discrepancies between source documents and FDA data listing regarding the reasons for study discontinuation for the 25 subject records inspected. A FDA Form 483, Inspectional Observations, was issued at the conclusion of the inspection for failure to conduct an investigation in accordance with the signed statement of investigator and the investigational plan. This site was classified as VAI.</p><p>Site 1-64PLTY, Jaime Restrepo, M.D., Medellin, Columbia. This site was selected because two investigators with the same last name, in the same geographic location, and with high subject enrollment numbers (752 total between the two sites) were outliers and these clinical investigators had not been inspected previously. A total of 23 subject records were selected and reviewed for initial informed consent and data verification. Records review of the 23 subjects did not identify any subjects who did not meet the protocol inclusion/exclusion criteria. The site obtained the x-rays and DXA scans in a timely fashion. All informed consent documents reviewed were signed appropriately. No unreported adverse events were found. This site was classified as NAI.  <ref type="formula" target="#formula_0">(264)</ref>, high site efficacy effect size and no prior inspection in the past 3 years. Records of 40 out of 62 subjects who discontinued the study were reviewed, and there were no discrepancies between source documents and FDA data listings regarding the reasons for study discontinuation. This site was classified as NAI.</p><p>Site 1-3RA0SB, Chris Recknor, M.D., US: This site in the US was selected for comparison. A comprehensive case review was conducted for 19 randomized subjects. Records review included, but was not limited to, financial disclosure, training, informed consent documents, monitoring, and IRB communications, adverse events, primary efficacy, lab results, and test article control. This site was classified as NAI.</p><p>Human Factors: Romosozumab is intended to be a healthcare provider administered medication. The total dose requires two prefilled syringes, each containing 105mg romosozumab. The two PFS will be supplied in a single carton. The Applicant did not conduct a label comprehension study and instead is relying upon the human factors validation study from another product, brodalumab. The Division of Medication Error, Prevention and Analysis reviewed the materials provided (brodalumab labeling, brodalumab HF validation results) and did not identify any critical differences in the use of Evenity (romosozumab) PFS and brodalumab PFS. The human factors validation study results for brodalumab do not show label comprehension difficulties, use task deviations, or dosing errors concerning the need to use two prefilled syringes to administer a complete dose. Thus, the brodalumab PFS study results support the labeling comprehension of Evenity (romosozumab) PFS.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="12.">Labeling</head><p>Prescribing Information: The review team has made significant edits to the prescribing information. At this time, further work on the prescribing information has been deferred to the next review cycle.</p><p>Significant issues under discussion include whether clinical fracture data are appropriate for the clinical studies section of the product label and whether clinical fractures should be mentioned in the fracture efficacy sentence that is part of the indication.</p><p>Other Labeling: Other labeling has been deferred to the next review cycle.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.">Postmarketing Recommendations</head><p>Risk Evaluation and Management Strategies (REMS): In this review cycle, the Applicant has not proposed a REMS and the review team did not believe that one was necessary for the safe use of romosozumab. However, the new cardiovascular safety concerns will necessitate that the review team revisit the need for a REMS during the review of the new safety data if appropriate.</p><p>Postmarketing <ref type="bibr">Requirements (PMRs)</ref> and Commitments (PMCs): In this review cycle, the Applicant did not propose clinical postmarketing studies and the review team did not find that a study was needed to further define the safety risks of romosozumab. However, the new cardiovascular safety concerns will necessitate that the review team revisit the need for a postmarketing safety study during the review of the new safety data if appropriate.</p><p>The OBP team is proposing a postmarketing commitment</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="14.">Recommended Comments to the Applicant</head><p>Deficiency:</p><p>The new safety findings from Studies 20110142 and 20110174 which identify an imbalance of incidences of cardiovascular serious adverse events with higher incidences in the romosozumab group when compared to active control alendronate or placebo raise concern regarding the cardiovascular safety of romosozumab. Although, Study 20070337 did not demonstrate a cardiovascular safety signal, these different and disparate findings between studies require detailed review once the completed final analyses of these additional studies have been submitted.</p><p>To address this deficiency:</p><p>We advise you to complete analysis of both Studies 20110142 and 20110174 and to submit these additional studies along with narratives and datasets to the Division for review.</p><formula xml:id="formula_14">Reference ID: 4123729 (b) (4) (b) (4)</formula><p>Cross Discipline Team Leader Review <ref type="bibr" target="#b94">44</ref> Other Comments to the Applicant:</p><p>On January 13, 2017, FDA issued a final guidance entitled Nonproprietary Naming of Biological Products, which states that FDA intends to designate a proper name that includes a four-letter distinguishing suffix that is devoid of meaning for certain biological products. Your 351(a) BLA is within the scope of this guidance. FDA intends to assign a four-letter suffix for inclusion in the proper name designated in the license at such time as FDA approves the BLA.</p><p>Please note this guidance contains information collection provisions that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act (PRA) of 1995. These provisions of the guidance describe the submission of proposed suffixes to FDA and a sponsor's related analysis of proposed suffixes, which are considered, under the PRA, as information collection. FDA is not currently implementing information collection provisions of the guidance.</p><p>However, provisions of the final guidance that do not describe the information collection provisions should be considered final and represent FDA's current thinking on the nonproprietary naming of biological products. These include, generally, the description of the naming convention (including its format for originator, related, and biosimilar biological products) and the considerations that support the convention.</p><p>---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. </p><formula xml:id="formula_15">--------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommended Indication(s)/Population</head><p>Treatment of osteoporosis in postmenopausal women.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>I. Background/ Summary:</head><p>Amgen notified the Division on May 15, 2017 that it had found unanticipated results after completing preliminary high-level analysis of Study 20110142, the phase 3 randomized, double-blind, activecomparator study of romosozumab followed by alendronate compared to alendronate alone. As this phase of Study 20110142 only ended in April 2017, it had not been submitted as part of this BLA 761062 submission . However, the study is part of IND 100391 for romosozumab for the treatment of osteoporosis.</p><p>Amgen met with the FDA on May 19, 2017 to share and discuss the unexpected results of higher incidences of cardiovascular (CV) SAEs in Study 20110142 in the romosozumab-exposed group (2.5% romosozumab versus 1.8% alendronate alone) and in a recently completed small men's study, Study 20110174 (4.9% romosozumab versus 2.5% placebo), both of which potentially impact the ongoing BLA 761062 review. The meeting minutes are available under IND 100391 Memorandum to File (FRM-ADMIN-01) from June 8, 2017.</p><p>Reference ID: 4110866</p><formula xml:id="formula_16">(b) (4) (b) (4) (b) (4) Debuene Chang MD</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary/ Conclusion:</head><p>These new unexpected safety findings from Study 20110142 and Study 20110174 identify an imbalance of incidences of CV SAEs with higher incidences in the romosozumab group when compared to placebo. In contrast, the BLA Study 20070337 demonstrated balanced incidence rates of CV SAEs between study groups (1.3% romosozumab versus 1.3% placebo). Preliminary efficacy analysis of Study 20110142 continue to support efficacy for romosozumab but these different and disparate safety findings between studies will have to be reviewed in detail once the Sponsor has completed final analyses of these additional studies.</p><p>The Division advised the Sponsor at the May 19, 2017 meeting to complete analysis of both Studies 20110142 and 20110174 and to submit these additional studies along with narratives and datasets to the Division for review. The Sponsor was further advised that an Advisory Committee may be needed to review the different results of the three studies. Specifically, the Division stated the following in the meeting minutes from May 19, 2017, filed with IND 100391:</p><p>"With regards to the ongoing review of BLA 761062, given these findings, the FDA explained we would not be able to take a favorable action on this review cycle. Before we can consider whether the benefits of romosozumab outweigh its risks, we will need to conduct a thorough review of the cardiovascular issue, and this would not be possible in the remaining two months of the review clock Amgen still needs to complete its analyses of the data and put together a detailed submission of the findings. The FDA also mentioned that an advisory committee meeting would likely now be needed."</p><p>In light of this new information from Study 20110142 and 20110174 which impacts this BLA and the additional information from these studies needed to complete review of this product, I recommend that a complete response (CR) be sent to the Sponsor for this review cycle.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Updated Recommendation: CR-Not Approvable</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>II. Cardiovascular (CV) SAE Findings:</head><p>A. Unexpected Results from Study 20110142: Amgen presented the key preliminary results of Study 20110142. During the 12-month period of romosozumab vs. alendronate, adjudicated serious adverse cardiovascular events were reported in 2.5% of romosozumab-treated patients vs. 1.9% of alendronate-treated patients. This imbalance was driven by cardiac ischemic events (myocardial infarction 0.8% vs. 0.2%) and stroke (0.6% vs. 0.3%). The key cardiovascular (CV) findings for Study 20110142 are in the table below: Debuene Chang MD </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>III. Comparison Studies 20110142, 20070337, and 20110197:</head><p>A. Subject Incidences of Adjudicated Positive CV SAEs Between Studies: Study 20070337, the phase 3 study for the BLA with &gt; 7000 subjects, showed balance between the study groups for CV SAEs whereas Study 20110142, alendronate-controlled study with &gt; 4000 subjects, showed imbalance between the two groups with higher incidences in the romosozumab group (2.5% versus 1.8%). The small men's study (N=244 subjects) Study 20110174 also showed imbalance of CV incidences with higher rates in the romosozumab group (4.9% romo versus 2.5% for placebo). The following table 2 compares the three studies (20110174 men only study, 20070337 BLA phase 3 study, 20110142 alendronate-controlled study):</p><p>Reference ID: 4110866 </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>B. Differences Between Two Studies, 20110142 and 20070337:</head><p>1) Inclusion and Exclusion Criteria Differences: There were differences in the criteria for inclusion/exclusion between the two patient populations which resulted in different patient populations. The following table 3 compares the differences:</p><p>Reference ID: 4110866 Debuene Chang MD </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2) Baseline CV Risk Factors:</head><p>Preliminary comparisons of the three studies for baseline CV risk factors found that age was a difference between the patients in Study 20070337 and 20110142 with the subjects in 20110142 averaging 4 years older than in Study 20070337.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IV. Primary Efficacy Results from 20110142:</head><p>Primary Endpoints were consistent with 20070337 results of fracture reduction. Specifically, the preliminary results found 50% reduction in the incidence of new vertebral fracture through month 24 with romosozumab for 12 months followed by alendronate for 12 months compared to alendronate alone (relative risk = 0.50; odds ratio = 0.48; adjusted p &lt; 0.001). In addition, there was a 27% reduction in the incidence of clinical fracture (clinical vertebral and nonvertebral) was demonstrated through the primary analysis with romosozumab for 12 months followed by alendronate compared to alendronate alone (adjusted p &lt; 0.001, based on 464 subjects with clinical fractures.</p><p>---------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.        Romosozumab is a humanized immunoglobulin G2 (IgG2) monoclonal antibody which binds and inhibits sclerostin. This new molecular entity is a bone-forming agent with a dual effect on bone, increasing bone formatin and decreasing bone resorption. The Sponsor seeks to market romosozumab for the treatment of osteoporosis in postmenopausal women.</p><formula xml:id="formula_17">--------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- T D</formula><p>Postmenopausal women with osteoporosis have increase risks of bone fracture due to decreased bone mass and impaired bone structure. Sclerostin, secreted by osteocytes inhibits the canonical Wingless-related integration site (Wnt) signaling pathway in bone and decreases osteoblast-mediated bone formation as well promotes osteoclast function and bone resorption. Patients with rare disorders lacking sclerostin inform our current knowledge of sclerostin function on bone. Sclerosteosis, a rare bone disorder resulting from a mutation of the sclerostin gene (SOST) leading to a lack of sclerostin, is characterized by thick bones with normal lamellar quality but denser quality which are resistant to fracture. Patients with Van Buchem disease who lack a regulatory element of the SOST gene have reduced sclerostin and are resistant to fracture.</p><p>The proposed proprietary name, EVENITY, was submitted to IND100391 (November 25, 2015, Serial Number 0401) and the Division of Medication Error Prevention and Analysis (DMEPA) found that the name, EVENITY was conditionally acceptable <ref type="bibr">(March 24, 2016</ref>. Thus, the Sponsor submitted the proposed proprietary name to this BLA on July 29, 2016 but the DMEPA review team initially denied the proposed name because it was vulnerable to confusion with a pending proposed named product, UNAMITY and not acceptable from a safety perspective. The DEMPA review team stated the following in their initial denial of the name (DMEPA review <ref type="bibr">October 5, 2016)</ref>: </p><formula xml:id="formula_18">"</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions on the Substantial Evidence of Effectiveness 1.2.</head><p>The Sponsor demonstrated that romosozumab was effective in the treatment of osteoporosis in postmenopausal women with a single study <ref type="formula" target="#formula_34">(2007337)</ref> which provided the primary evidence to support effectiveness.</p><p>Study 2007337 was a 24 month long, placebo-controlled, parallel-group study in 222 centers worldwide to assess efficacy and safety of 12 months of romosozumab treatment followed by 12 months of denosumab treatment, a currently approved FDA treatment (12 months romosozumab/12 months denosumab) compared to placebo followed by 12 months of denosumab (12 months placebo/12 months denosumab) in postmenopausal women with osteoporosis. The co-primary endpoints were new vertebral fractures at 12 months and 24 months.</p><p>Because the Sponsor relied on only one study, the FDA required that the Sponsor meet a persuasive efficacy level of &lt;0.01 or less and that other non-pivotal studies support the results. The study demonstrated that 210 mg SQ QM romosozumab significantly reduced new vertebral fractures compared to placebo at 12 months and the effect persisted into month 24 when all subjects transitioned to denosumab. Specifically, romosozumab significantly reduced the risk of new vertebral fracture compared with placebo during the 12-month double-blind period (odds ratio = 0.27; p &lt; 0.001), with a relative risk reduction of 73% (95% CI: 53, 84). At 24 months, the relative risk reduction persisted for subjects initially randomized to romosozumab with a relative risk reduction of 75% (95% CI: 60, 84; odds ratio = 0.24, p &lt; 0.001).</p><p>Study 20070337 was the only study with fracture as a primary endpoint but three placebocontrolled studies, 20060326, 20101291, and 20120156, supported the efficacy of romosozumab with primary or secondary endpoints for bone mineral density (BMD). These studies demonstrated significant BMD percentages increased when compared to placebo at the lumbar spine, total hip and femoral neck. Bone formation markers P1NP, osteocalcin, and BSAP and bone absorption marker, sCTX, supported the romosozumab dual functions of bone formation and suppression of bone absorption.</p><p>One caveat is that in the study 20070337, patient demographics did not reflect the US population which comprised only 2.5% of the study population. Hispanic or Latino subjects encompassed 43% of the subjects in the study. But when compared by race, ethnicity, and individual geographical, each of the groups still show significant efficacy for reducing fractures and increasing BMD at the lumbar spine, hip, and femoral neck when romosozumab is compared to placebo at 12 months and 24 months. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Benefit-Risk Assessment</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Benefit-Risk Summary and Assessment</head><p>Osteoporosis is characterized by bone loss, disruption of bone architecture, compromised strength and increase in fractures. About 10 million Americans have osteoporosis, and several times as many are at risk because of low bone density. Post-menopausal osteoporosis (PMO), the most common type, is driven primarily by the hormonal changes beginning at menopause. Caucasian women are at highest risk; about half will experience an osteoporotic fracture in their lifetime. PMO causes no symptoms until fractures, usually with minimal trauma, develop in the later stages. Fractures of the vertebrae, the most common type, weaken the spine and lead to additional fractures, with potential irreversible loss of height and function. Hip fractures frequently impair the ability to walk and to live independently. Both vertebral and hip fractures are associated with increased mortality. A variety of effective treatments is available, such that many fractures are now preventable. However, PMO remains seriously under-diagnosed and under-treated in the US, and additional treatment options are needed.</p><p>Romosozumab (EVENITY), a humanized immunoglobulin G2 (IgG2) monoclonal antibody that binds and inhibits sclerostin, a regulatory factor in bone metabolism and is indicated for the treatment of osteoporosis in postmenopausal women. Since sclerostin inhibits bone formation and stimulates bone resorption, romosozumab has a dual effect on bone by increasing bone formation and decreasing bone resorption. Adequate intake of calcium and vitamin D is also important for all postmenopausal women, especially those with osteoporosis</p><p>In a large phase 3 study of postmenopausal women with osteoporosis, romosozumab significantly reduced the risk of new vertebral fracture by 73% through month 12 compared with placebo with absolute risk reduction of 1.3. The risk reduction at month 12 persisted through month 24, with a 75% risk reduction after both treatment groups transitioned to antiresorptive therapy (denosumab) with absolute risk reduction of 1.9. Fewer new vertebral fractures occurred during follow-on treatment in subjects who had received romosozumab (5 fractures) compared with subjects who had received placebo (25 fractures) in the first year of study. The relative risk reductions for new vertebral fracture compare favorably with those of existing antiresorptive and bone-forming therapies. For new vertebral fracture, the treatment effects were consistent (relative risks favored romosozumab over placebo and romosozumab/denosumab over placebo/denosumab) in all subgroups of baseline characteristics examined, including age, race, geographic region, a range of baseline BMD T-scores, and subjects with a history of prior vertebral, nonvertebral, or fragility fracture. Results for bone mineral density (BMD) values were consistent across the phase 2 and phase 3 placebo-controlled studies. Romosozumab 210 mg every month (QM) demonstrated significant increases in BMD at the lumbar spine, total hip and femoral neck.</p><p>Although only 2.5% of patients were recruited in the large phase 3 study from patients in the US, the consistent results for vertebral fractures reduction and increased BMD among all subgroups when compared to placebo support wide applicability of romosozumab effects on new vertebral fracture reduction and extrapolation of efficacy results to the US population.</p><p>The most important safety risks identified during studies include the following: a) Atypical Femur Fracture (AFF): Since romosozumab has antiresorptive activity, as demonstrated by bone turnover markers (BTM) profiles and histomorphometry data from bone biopsies, AFF is an important potential risk for romosozumab. Atypical low-energy or low trauma fractures of the femoral shaft have been reported in patients receiving romosozumab. b) Osteonecrosis of Jaw (ONJ): Since romosozumab has antiresorptive activity, as demonstrated by BTM profiles and histomorphometry data from bone biopsies, ONJ is an important potential risk for romosozumab. Osteonecrosis of the jaw, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients receiving romosozumab. c) Hypersensitivity: Like other monoclonal antibodies, romosozumab could be associated with hypersensitivity reactions. Based on medical review of the integrated safety data, hypersensitivity is considered an important identified risk with romosozumab. Clinically significant hypersensitivity reactions, including angioedema, erythema multiforme, and urticaria, occurred in the romosozumab group. d) Hypocalcemia: Inhibition of sclerostin by romosozumab leads to rapid bone mass accrual at initiation of treatment and an increased demand for bone-building substrates such as calcium. Based on the clinical trial data, hypocalcemia is considered an important identified risk. Mild and transitory decreases in albumin-corrected calcium and a compensatory increase in iPTH were observed after initiation of romosozumab Based on the totality of data, the risk of hypocalcemia is manageable with appropriate monitoring recommended for patients with stage 5 chronic kidney disease (CKD).</p><p>In clinical studies, romosozumab was well tolerated except for increased injection site reactions, hypersensitivity, and hypocalcemia seen in patients with renal disease. AFF and ONJ were rare but seen in the large clinical trial in romosozumab patients.</p><p>Romosozumab reduces the risk for vertebral fractures within one year of treatment which continues once patients transition to an antiabsorptive osteoporotic drug is both a bone forming and antiabsorptive agent increases BMD at lumbar spine, total hip, and femoral neck. The data supports effectiveness of romosozumab for both reduction of new vertebral fractures and BMD gains at the lumbar spine, total hip, and femoral neck when compared to placebo across many subgroups and will likely have wide applicability in women with PMO. From the clinical trial data, the risks for romosozumab include AFF, ONJ, hypersensitivity, and hypocalcemia. These risks were either very rare (AFF or ONJ) or were present in few patients (hypersensitivity and hypocalcemia). These risks can be managed with labeling warnings if this drug is In summary, romosozumab is effective to reduce the risk of vertebral fractures in postmenopausal women and has qualities of bone formation and antiabsorption of bone with tolerable safety risks. The benefits to reduce new vertebral fractures in PMO outweigh the safety risks. This drug has a place in the armamentarium of treatments against osteoporosis in post-menopausal women if approved.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimension Evidence and Uncertainties Conclusions and Reasons</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Condition</head><p> Osteoporosis, a skeletal disorder of loss of bone mass and architecture which leads to an increased risk for fractures.</p><p> Fractures significantly impact individual quality of life, morbidity, mortality and place an economic burden on society. As an example, in hip fractures patients, only 40% of patients will regain full mobility while 40% will be transferred to nursing care and 20% of patients will die within the first year.</p><p>Osteoporosis in post-menopausal women leads to increased lifetime risk for fractures.</p><p>Osteoporotic fractures cause significant morbidity and mortality.  For new vertebral fracture, the treatment effects were consistent (relative risks favored romosozumab over placebo and romosozumab/denosumab over placebo/denosumab) in all subgroups of baseline characteristics examined, including age, race, geographic region, a range of baseline BMD T-scores, and subjects with a history of prior vertebral, nonvertebral, or fragility fracture.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Current</head><p> Results for bone mineral density (BMD) values were consistent across the phase 2 and phase 3 placebo-controlled studies <ref type="bibr">(20070337, 20101291, 20060326, and 20120156)</ref>. Romosozumab 210 mg every month (QM) demonstrated significant increases in BMD at the lumbar spine, total hip and femoral neck, and the effect was seen</p><p>The large clinical study demonstrated that romosozumab is effective in reducing the risk of vertebral fractures at 12 months and at 24 months (after patients transition into antiabsorptive therapy at 12 months).</p><p>Because new vertebral fracture efficacy was found across all subgroups, it is likely romosozumab will have wide applicability for reducing new vertebral fractures in women with PMO.</p><p>BMD gains at lumbar spine, total hip and femoral neck support efficacy of romosozumab across multiple studies which was maintained through transition to an antiresorptive therapy. . BMD gains were maintained or augmented further in studies that included a transition to antiresorptive therapy (denosumab) after completion of romosozumab.</p><p> Romosozumab consistently increased BMD at the lumbar spine and total hip regardless of baseline BMD T-scores, age, and geographic region. When analyzed by region, the percent change in BMD at the lumbar spine and total hip was similar between North America and all other regions, and romosozumab demonstrated statistically significant increases in BMD in all regions.</p><p> Retreatment with romosozumab after a treatment-free interval of 12 months showed comparable effects on BMD as those observed after initial exposure to romosozumab but the data is limited by small numbers of patients in each study group (i.e. N&lt;20 in each group).</p><p>Because of the consistent BMD gains found across multiple subgroups, romosozumab effects on reducing fractures will likely to have widespread applicability for women with PMO.</p><p>Retreatment with romosozumab appears effective on BMD gains; however, a conclusion cannot be made based on the few number of patients studied with re-treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk</head><p> Atypical Femur Fracture (AFF): Since romosozumab has antiresorptive activity, as demonstrated by bone turnover markers (BTM) profiles and histomorphometry data from bone biopsies, AFF is an important potential risk for romosozumab. Atypical low-energy or low trauma fractures of the femoral shaft have been reported in patients receiving romosozumab.</p><p> Osteonecrosis of Jaw (ONJ): Since romosozumab has antiresorptive AFF is a risk with romosozumab as it was reported in the clinical trials but it is rare.</p><p>ONJ is a risk with romosozumab as it was reported in the clinical trials but it is rare.  Hypersensitivity: Like other monoclonal antibodies, romosozumab could be associated with hypersensitivity reactions. Based on medical review of the integrated safety data, hypersensitivity is considered an important identified risk with romosozumab. Clinically significant hypersensitivity reactions, including angioedema, erythema multiforme, and urticaria, occurred in the romosozumab group. No anaphylaxis was reported in the clinical trials.</p><p> Hypocalcemia: Inhibition of sclerostin by romosozumab leads to rapid bone mass accrual at initiation of treatment and an increased demand for bone-building substrates such as calcium. Based on the clinical trial data, hypocalcemia is considered an important identified risk. Mild and transitory decreases in albumin-corrected calcium and a compensatory increase in iPTH were observed after initiation of romosozumab. Based on the totality of data, the risk of hypocalcemia is manageable with appropriate monitoring recommended for patients with stage 5 CKD.</p><p>Hypersensitivity is a risk as it was reported in the clinical trials but it was relatively rare.</p><p>Hypocalcemia is a risk as it was seen in the clinical trials, mostly in renal failure patients. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dimension Evidence and Uncertainties Conclusions and Reasons</head><p> Hyperostosis: The intended pharmacologic effect of romosozumab is an increase in BMD and bone strength; however, hyperostosis (excessive bone growth) may be a potential risk with romosozumab administration. The current data, including the audiology substudy, do not support a safety risk of hyperostosis with romosozumab use; however, given the mechanism of action for romosozumab, it is considered a potential risk. The data does not support a safety risk for hyperostosis with romosozumab.</p><p>Hyperostosis is a theoretical risk but the clinical trials did not support this risk.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk Management</head><p> AFF, ONJ, hypersensitivity and hypocalcemia risks can be managed by labeling  REMS level risks were not identified during the review.</p><p>The risks for AFF and ONJ can be managed with labeling as the numbers of cases were rare and all were confounded. Hypersensitivity rates are consistent with other immunoglobulin therapies and can be managed with labeling.</p><p>Hypocalcemia risks are manageable with labeling. Osteoporosis is a skeletal disorder of loss of bone mass and architecture which leads to an increased risk for fractures. It currently affects 15-38% of women over 50 years of age in the US and other regions of the world. <ref type="bibr" target="#b71">(Wade et al, 2014;</ref><ref type="bibr" target="#b74">Wright et al, 2014;</ref><ref type="bibr">Hernlund et al, 2013)</ref>. The World Health Organization (WHO) provides criteria using dual-energy X-ray absorptiometry (DXA) to define osteoporosis by bone mineral density (BMD). A T-score is generated by measurements of the BMD at the lumbar spine, total hip, and femoral neck. Osteoporosis is defined by T-score  2.5 standard deviations from the mean BMD of a young, healthy cohort of women at the same location.</p><p>Annually, an estimated 10% (4.5 million of 44 million women) of postmenopausal osteoporosis (PMO) women across the US, Europe, Canada, Australia, and Japan will have osteoporotic fractures <ref type="bibr" target="#b71">(Wade et al, 2014;</ref><ref type="bibr" target="#b74">Wright et al, 2014;</ref><ref type="bibr">Hernlund et al, 2013;</ref><ref type="bibr" target="#b72">Wade et al, 2012;</ref><ref type="bibr">Burge et al, 2007)</ref>. These women have increased risk of multiple types of fractures such as hip, vertebral, extremity, etc. that can significantly impact individual quality of life, morbidity, mortality and place an economic burden on society <ref type="bibr">(NOF, 2014;</ref><ref type="bibr">WHO, 2007;</ref><ref type="bibr">OSG, 2004)</ref>. For example, in hip fractures patients, 20% of patients will die within the first year. An additional 20% of patients will be transferred to nursing care and only 40% will regain full mobility.</p><p>Osteoporotic fractures are a significant risk for subsequent fractures within a near time proximity. Vertebral fractures increase subsequent additional vertebral risk by five times as well as increase for other fractures by two to three times. Hip fractures increase subsequent risk of other fractures by 2.5 times <ref type="bibr">(NOF, 2014;</ref><ref type="bibr">van Helden et al, 2006;</ref>. Lindsey et al, 2001 found that new vertebral fracture within one year after a previous fracture was 19%.</p><p>Van Geel et al, 2009 found that subsequent fractures occurred the most frequently within one to two years (23%) and five years (54%) after non-vertebral fractures and symptomatic fractures in PMO women, doubling the risk of an initial first fracture. The following <ref type="figure" target="#fig_0">figure 1</ref> illustrates the risk of subsequent fractures in women after an initial nonvertebral or symptomatic fracture.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Osteoporosis, a skeletal disorder of loss of bone mass and architecture leads to an increased risk for fractures which significantly impact individual quality of life, morbidity, mortality and place an economic burden on society. As an example, in hip fractures patients, only 40% of patients will regain full mobility while 40% will be transferred to nursing care and 20% of patients will die within the first year. The risk of subsequent fractures doubles after a first fracture with second fractures most frequently within two years following the first fracture.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Current Treatment Options 2.2.</head><p>Pharmacologic therapies for osteoporosis and the prevention of osteoporotic fractures consist of 1 class of bone-forming agents and several types of antiresorptive therapies, including bisphosphonates. Bisphosphonates are currently the standard of care in many countries; in 2011 in the US, bisphosphonates were used by 83% of women who were using any pharmacologic osteoporosis therapy <ref type="bibr">(Sarpong, 2014)</ref>.</p><p>Despite the availability of cost-effective and well-tolerated treatments to reduce fracture risk, postmenopausal women who have an osteoporosis-related fracture are underdiagnosed and undertreated; only about 20% receive either a BMD test or a prescription for a drug to treat osteoporosis after a fracture <ref type="bibr" target="#b64">(Balasubramanian et al, 2014;</ref><ref type="bibr">NOF, 2014;</ref><ref type="bibr">Diez-Perez et al, 2011;</ref><ref type="bibr">WHO, 2007;</ref><ref type="bibr">OSG, 2004)</ref>.</p><p>In their respective phase 3 clinical studies, 3 antiresorptive therapies for osteoporosis (risedronate, denosumab, and zoledronic acid) demonstrated significant reductions of 60% to 65% in the risk of vertebral fractures within 1 year (see approved product labeling). For other therapies, it took between 19 months (for teriparatide) to 3 years or longer (for alendronate, ibandronate, and other therapies) to demonstrate a significant reduction in the risk of vertebral, nonvertebral, or clinical fracture.</p><p>Bone-forming therapies can provide larger improvements in bone structure and strength compared with antiresorptives; however, only 1 is available -teriparatide, a parathyroid hormone [PTH] analog. Teriparatide has some limitations, such as the need for daily injections, a relatively small BMD increase at the hip (2.6% total hip in 19 months) <ref type="bibr">(Neer et al, 2001)</ref>, a boxed warning of potential risk of osteosarcoma, and a treatment duration limited to a lifetime 2 year maximum. In addition, the time to onset of effect with teriparatide may leave patients relatively unprotected early in treatment. According to 1 study, about 12% of patients had a fracture in the 2 years following initiation of teriparatide use, even in persistent users, and most (64%) of those fractures occurred during the first year on therapy <ref type="bibr" target="#b65">(Bonafede et al, 2015)</ref>. Furthermore, transitioning patients from a bisphosphonate to teriparatide, which is more common than use of teriparatide as first-line treatment, can lead to reduced or delayed gains in BMD over the first year of treatment relative to treatment-nave subjects <ref type="bibr">(Miller et al, 2008;</ref><ref type="bibr">Obermayer-Pietsch et al, 2008;</ref><ref type="bibr">Ettinger et al, 2004)</ref>.</p><p>In summary, by inhibiting sclerostin, romosozumab demonstrates a dual effect on bone, increasing bone formation and decreasing bone resorption, leading to rapid and substantial gains in BMD and improved bone strength. Romosozumab is administered once monthly (QM) and has a rapid onset of effect, thus offering an important additional treatment option for osteoporosis in postmenopausal women at increased risk for fracture. These patients will benefit from rapid fracture risk reduction, significant BMD gains, and improved underlying skeletal strength for ongoing fracture risk reduction with follow-on antiresorptive therapy. The following table 1 summarizes the major pharmacologic treatments for osteoporosis. The following table 2 lists the absolute and relative risk reductions (ARR, RRR) in new morphometric vertebral fractures (the primary endpoint) in the PMO trials of approved drugs. Risk reductions were generally apparent within 1 or 2 years and maintained through 3 years (the Forteo trial was stopped at ~19 months for safety concerns -see below). Because the trial populations differed in baseline fracture risk, ARR is highly variable between drugs/trials while RRR is more consistent. For example, the FIT-1 trial of Fosamax enrolled a high risk population (women with baseline vertebral fractures) and FIT-2 a lower risk population (no baseline fractures); fracture rates in both treatment groups were much higher in FIT-1, but relative reduction in fracture risk was nearly identical in the two studies.   for initial rollout (NME/original BLA reviews) ARR = Absolute Risk Reduction; RRR= Relative Risk Reduction *Forteo trial = 19 months' median exposure **Fosamax FIT-2 trial = 48 month assessment Sources: Prescribing information <ref type="figure">(Forteo, RIS, ZOL, DEN, RAL)</ref>; <ref type="bibr">Lancet 1996</ref><ref type="bibr">,348:1535</ref><ref type="bibr">JBMR 2004</ref><ref type="bibr">, 19:1241</ref> Reviewer <ref type="figure" target="#fig_0">Comments: There are a number of drugs available for osteoporosis treatment. The  most commonly used drugs, the bisphosphonates, have only antiabsorptive function on bone.  One class of drug, teriparatide, builds bone but takes up to 19 months to reduce the risk of  fractures. It carries a boxed warning on the label for the risk of osteosarcoma and</ref>  Romosozumab is a new molecular entity and currently not marketed in the US or anywhere else in the world. There are no other marketing applications or review in other divisions of the FDA but the Sponsor is developing the drug for other indications including osteoporosis in men.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of Presubmission/Submission Regulatory Activity 3.2.</head><p>The following key DBRUP interactions occurred during clinical development with the Sponsor. Detail listing is in Appendix 13.5.</p><p> DBRUP recommended that the Sponsor conduct a 2-year rodent bioassay to evaluate the carcinogenic potential of romosozumab. The Carcinogenicity Assessment Committee (CAC) returned recommendations and confirmed acceptability of the proposed Carcinogenicity Special Protocol Assessment (SPA) request for a rat lifetime pharmacology study.</p><p>DBRUP met with the Sponsor, December 12, 2012 (type C meeting), to support a new drug product concentration for romosozumab. In the clinical fracture study, a 70 mg/ mL concentration required 3 injections to reach the 210 mg dose. The Sponsor proposed to market a 90 mg/ mL concentration which would then require 2 injections to achieve the 210 mg dose. Agreement was reached regarding the analytical comparability and clinical studies need to support the new concentration.</p><p> DBRUP gave feedback (end of phase 2 [EOP2] meeting and July 2015 Type C meeting)</p><p>regarding the selection of a single dose (210 mg QM) for phase 3 study(ies), and studying effects on patients off romosozumab treatment and with retreatment.  Safety assessments include appropriate adjudication of cardiovascular events and inclusion of osteoarthritis, bone biopsy, calcium, and serum intact parathyroid hormone (iPTH) and urinary calcium substudies in the phase 3 study.</p><p> DBRUP confirmed at the May 18, 2016 prefiling meeting that Study 20070337 is adequate to support Biologics Licensing Application (BLA) market application and recommended that the Sponsor provide in-depth justification around the applicability of the global study data to the intended US population and US medical practice.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Foreign Regulatory Actions and Marketing History 3.3.</head><p>Romosozumab is currently not marketed in any country in the world.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety</head><p>Office of Scientific Investigations (OSI) 4.1.</p><p>The Office of Scientific Investigations (OSI) was requested to audit four sites, Sites 1-52SFOU, 1-678YLY, 1-64PLTY, and 1-3RA0SB. The rationales for selection of these sites are listed below:</p><p> Sites At the time of this writing, site inspections have been completed and one site (Restrepo, Site # 1-678YLY) has been issued a preliminary voluntary action indicated (VAI) due to major issue of delayed randomization while the remaining 3 sites have been issued preliminary no action indicated (NAI). Final audit results are pending.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Product Quality 4.2.</head><p>The commercial product will be presented in a single-use prefilled syringe (PFS) containing 1.17 mL of a 90 mg/mL solution; thus, 2 injections will be required to achieve the 210 mg dose. The drug substance for the commercial product will be manufactured at Amgen Rhode Island (ARI) using the commercial process that is referred to as Process 2 ARI.</p><p>Romosozumab drug substance was initially manufactured at Amgen Thousand Oaks (ATO) using a manufacturing process referred to as Process 1 ATO. The results of the romosozumab clinical biopharmaceutics program support the comparability of the romosozumab drug substances manufactured with Process 1 ATO, Process 2 ATO (the process used in the pivotal phase 3 Study 20070337), and Process 2 ARI (the process that will be used for commercial manufacturing).</p><p>Romosozumab drug product developed for initial clinical studies was supplied in a glass vial containing 70 mg/mL romosozumab (containing Process 1 ATO). The pivotal phase 3 clinical studies in postmenopausal osteoporosis <ref type="bibr">(20070337 and 20080289)</ref> used 70 mg/mL glass PFS presentations (containing Process 2 ATO). The planned commercial product will be a PFS with 90 mg/mL romosozumab containing Process 2 ARI drug substance. The vial and glass PFS presentations are not currently planned for commercialization.</p><p>To confirm that changes in the manufacturing process, production site, formulation, and product presentation (vial to PFS and glass PFS to PFS) did not impact product quality, several comparability assessments were conducted. The results of the clinical biopharmaceutics program demonstrate that romosozumab drug substance and drug product planned for commercial use are bioequivalent to those used in the pivotal phase 3 studies.</p><p>See CMC reviews for product quality details.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Microbiology 4.3.</head><p>There are no clinical microbiology issues with this product.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nonclinical Pharmacology/Toxicology 4.4.</head><p>Conclusions from the nonclinical review are outlined here. Refer to the nonclinical review by Dr. Gemma Kuijpers, DBRUP for details.  The submitted nonclinical information is adequate and supports the safety of the proposed treatment with once-monthly subcutaneous doses of 210 mg in the intended treatment population.</p><p> AMG785 was generally well tolerated by animals at doses equivalent to large human exposure multiples, and apart from indirect effects related to the pharmacological activity, little toxicity was observed.</p><p> Information available from humans with sclerostin deficiency disorders or SOST knockout mice is also generally reassuring regarding bone safety, general toxicity and carcinogenicity. embryo fetal digit anomalies observed with AMG785 treatment replicate similar observations in humans and mice with sclerostin deficiencies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Pharmacology 4.5.</head><p>Key findings from clinical pharmacology are outlined here; for details see Clinical Pharmacology review by Dr. Lin Zhou.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mechanism of Action 4.5.1.</head><p>Romosozumab (formerly known as AMG 785) is a humanized immunoglobulin G2 (IgG2) monoclonal antibody that binds and inhibits sclerostin. Romosozumab increases bone formation due to the activation of bone lining cells, increased bone matrix production by osteoblasts, and recruitment of osteoprogenitor cells. The following figure 2 illustrates the mechanism of action for romosozumab in bone.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 2: Graphic Representation of Mechanism of Action for Romosozumab</head><p>Source: Clinical Overview <ref type="figure" target="#fig_18">Figure 2</ref> with reviewer edits.</p><p>Additionally, romosozumab results in changes to expression of osteoclast mediators, thereby decreasing bone resorption. Together, this dual-effect of increasing bone formation and decreasing bone resorption results in rapid increases in trabecular and cortical bone mass, improvements in bone structure and strength, and fracture risk reduction.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacodynamics</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>4.5.2.</head><p>The dose-BMD response model described the romosozumab dose-dependent BMD gains at both lumbar spine and total hip for all data including 210-mg SC QM dose of romosozumab in postmenopausal osteoporosis subjects.</p><p>The dose-BMD model demonstrated a significant relationship between romosozumab dose and frequency with BMD gains at lumbar spine and total hip. For a given dose, QM administration provided significantly greater BMD gains at lumbar spine and total hip than every 3 months (Q3M) administration, while BMD gains were similar for QM and Q3M dosing of the same cumulative dose (eg, 70 mg QM versus 210 mg Q3M). Model predicted time courses for the QM dose regimens indicated that the 210 mg dose provided the most rapid and extensive gains in BMD over the course of 12-month treatment.</p><p>The concentration-response model adequately described the relationship between romosozumab concentration, bone turnover markers (P1NP and sCTX), and BMD gains at the lumbar spine. Out of the dosing regimens studied, the highest BMD gains at 12 months were observed for 210 mg SC QM. The greatest increase in the bone formation marker P1NP, and the longest duration of P1NP increase above baseline were also obtained with the 210 mg SC QM dosing regimen.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The Sponsor selected 210 mg QM, the highest dose, based on PD studies which demonstrated that romosozumab 210 mgs QM provided greater BMD gains at the lumbar spine and total hip than Q3M (i.e. 210 mg QM had greater BMD gains compared to 210 mg Q3M) and bone formation marker, P1NP, had the greatest increase and longest sustained increase above baseline at this dose.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunogenicity</head><p>In the phase 2 and phase 3 clinical studies of osteoporosis in postmenopausal women, the incidence of binding and neutralizing antidrug antibodies (ADAs) was 19.9% (852 of 4289) and 1.1% (46 of 4289), respectively. The incidence of binding and neutralizing ADAs in women dosed with 210 mg QM was similar to the overall studies at 19.1% (758 of 3959) and 0.8% (31 of 3959), respectively. The presence of binding ADAs appeared to decrease romosozumab exposure up to 25% at months 3, 6, and 9. The exposures became comparable at month 12 (difference in mean values was approximately 10%) between ADA positive and ADA negative subjects. The concentration values were within the range of subjects in whom no ADAs were detected. Additionally, population PK analysis showed that the presence of ADAs did not impact on the PK of romosozumab. For subjects who received romosozumab, the percent change from baseline in BMD at the lumbar spine, total hip, and femoral neck at month 12 and month 24 was compared among subjects who developed binding or neutralizing antiromosozumab antibodies through month 15 versus those who were negative for antiromosozumab antibodies through month 15.</p><p>At month 12, the mean percent changes in BMD at the lumbar spine were 13.1% (negative antibody status), 13.1% (positive binding antiromosozumab antibody), and 11.6% (positive neutralizing antiromosozumab antibody). Corresponding values at month 24 were 16.7%, 16.7%, and 15.1%, respectively. Percent change from baseline at the total hip and femoral neck also showed consistent results The following table 3 summarizes BMD at lumbar spine, total hip and femoral neck at month 12 and month 24 by ADA status at month 15 for patients in study 20070337.  When administered to healthy subjects at single SC doses ranging from 0.1 mg/kg to 10 mg/kg, romosozumab exhibited nonlinear PK. At low doses, mean apparent clearance (CL/F) was approximately 4-fold higher at a dose of 0.1 mg/kg than at 3 mg/kg. At higher doses, between 3 mg/kg and 10 mg/kg, the PK appeared to be linear, based on relatively similar clearance and dose-normalized maximum serum concentration (Cmax) and area under the curve from time 0 to infinity (AUCinf). Generally, Cmax was observed within the first week after administration. Serum romosozumab concentrations declined with a mean half-life (t1/2) of approximately 11 to 18 days during the beta (plateau) phase and 6-7 days during the gamma (terminal) phase. The bioavailability of romosozumab was estimated to be 50% to 70% after SC administration of 1 to 5 mg/kg.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacokinetics in Healthy Subjects</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacokinetics in Patients-Post Menopausal Women</head><p>Following administration of SC doses every 4 weeks (Q4W) at 3 mg/kg for 3 months, accumulation based on mean Cmax and AUC values following 3 doses was approximately 20% to 36% more than exposure after the first dose. The mean effective t1/2 was 12.8 days after 3 doses of 3 mg/kg. Approximately linear PK was observed when comparing Cmax and AUC values following 2 mg/kg and 3 mg/kg Q4W. When multiple SC doses of romosozumab 70 mg, 140 mg, or 210 mg QM were administered to postmenopausal women with osteoporosis or low BMD, steady state was generally reached by month 3 with minimal accumulation (&lt; 2 fold) following multiple doses and maintained at a similar level throughout the rest of the study. Ctrough was approximately dose proportional from 140 mg to 210 mg, however a more than dose-proportional increase in Ctrough was observed from 70 mg to 140 mg.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacokinetics in Patients With Renal Impairment</head><p>Because of the large molecular weight of romosozumab, renal clearance was not expected to play a role in the total clearance of romosozumab. However, chronic kidney disease (CKD) has been implicated with disturbances of the Wnt pathway with an elevated level of serum sclerostin reported in CKD subjects. A phase 1 study (Study 20110227) was conducted in healthy subjects and subjects with stage 4 renal impairment or stage 5 CKD requiring hemodialysis, to investigate the PK, PD, and safety of romosozumab in subjects with renal impairment where subjects received a single dose of 210 mg SC Results from Study 20110227 showed the exposure of romosozumab for subjects with stage 4 renal impairment was 44% higher than for subjects with normal renal function.</p><p>The population PK analysis indicated an increase in romosozumab AUC with increasing severity of renal impairment with about a 50% increase in predicted median AUC in subjects with endstage renal disease (assuming no hemodialysis during romosozumab treatment). The predicted upper bound (95%) AUC was approximately 50% lower than the maximum exposure obtained with a 10 mg/kg single dose, which was demonstrated to be tolerated in clinical studies. The administration of romosozumab was well tolerated, with no deaths or adverse events leading to withdrawal from the study.  <ref type="figure" target="#fig_0">(stage 4 and ESRD) compared with healthy patients and found that  although renal failure increase exposure of romosozumab, the increases are predicted to be  less than the maximum tolerated exposure in single dosing clinical studies of up to 10 mg/ kg,  a dose well tolerated by patients. Specifically, this renal failure study demonstrated there was  a 50% increase in predicted median AUC, but the upper limits (95%) was still 50% below the  maximum exposure found in single-dose phase 1 studies of 10 mg/kg. Patients had higher  rates of elevated iPTH and hypocalcemia and AEs related to hypocalcemia when compared to  the general population. See section 8.3.8 laboratories for details.</ref> The increased rates of hypocalcemia and AEs related to hypocalcemia in this renal failure patient population should be addressed in the labeling.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacokinetics in Patients With Hepatic Impairment</head><p>Because romosozumab is a monoclonal antibody and is not eliminated via hepatic metabolic mechanisms (eg, by cytochrome P450 [CYP] enzymes), hepatic impairment and drug interaction studies (eg, with CYP inhibitors) were not considered necessary and have therefore not been conducted.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Because romosozumab, a monoclonal antibody, is not eliminated by the hepatic metabolic mechanisms, it is acceptable for the Sponsor not to conduct hepatic impairment studies.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Population Pharmacokinetics</head><p>Population PK and PK/PD analyses in healthy subjects and postmenopausal women with low BMD or osteoporosis were performed using non-linear mixed effects modeling method and characterized absorption, distribution, and elimination of romosozumab. The key findings from the population PK analyses were the following:</p><p> After SC administration of 210 mg romosozumab, bioavailability was high (81%) and absorption was complete in approximately 14 days. Bioavailability is nonlinear at lower doses but at higher doses such as 210 mg, it is linear. The rate of absorption was similar across the range of doses evaluated.</p><p> Romosozumab is eliminated through a slow nonspecific elimination pathway mediated by the hepatic reticuloendothelial system (ie, linear clearance [CL]), and a rapid saturable elimination pathway (ie, target-mediated nonlinear clearance) mediated by degradation of romosozumab-sclerostin complex in the peripheral compartments, which results in a concentration dependent clearance of romosozumab.</p><p> Sclerostin is &gt; 95% bound for the entire dosing interval for a 210-mg SC QM regimen which suggests full target-engagement has been achieved.</p><p> There were no differences in romosozumab PK between healthy subjects or postmenopausal women with low BMD or osteoporosis. Prior alendronate or postmenopausal osteoporosis treatment, presence of antiromosozumab antibodies (antidrug antibodies [ADAs]), and baseline sclerostin had no impact on PK.  Body weight, age, gender, race (Japanese versus non-Japanese), and estimated glomerular filtration rate (eGFR), were identified as having an impact on PK. The effect of body weight (on both clearance and volume) and eGFR (on clearance) had the greatest impact, with decreasing body weight or decreasing eGFR resulting in increasing romosozumab exposure. However PK/PD modeling demonstrated body weight and eGFR had minimal impact on BMD gain at 12 months, with gains in BMD over a weight range of 43 to 86 kg or across stages of renal impairment comparable (15%) to a typical subject. Additionally, predicted exposures (95% upper bound) after 210 mg QM dosing in the lowest body weight subjects included in the analysis (&lt; 43 kg) or subjects with end-stage renal disease (eGFR &lt; 15 mL/min) were approximately 60% and 50% lower respectively than the exposure obtained with a 10 mg/kg dose, which was demonstrated to be tolerated in clinical studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The Sponsor used PK/ PD modeling to determine that dose adjustment is not necessary for patient baseline characteristics which have impact on PK. Although low body weight and low eGFR had the greatest impact on increasing romosozumab exposure, PK/PD modeling demonstrated that these factors had minimal impact on BMD gain at 12</head><p>months and that the maximum exposure will still be less than the maximum tolerable dose (10 mg/ kg).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Devices and Companion Diagnostic Issues 4.6.</head><p>Drug product manufacturing processes were modified to manufacture prefilled syringes (PFS) in three presentations: 70 mg/mL and 120 mg/mL in 1 mL Long glass syringes, and 90 mg/mL in 1 mL syringes. Only the 90 mg/mL syringe presentation is intended for commercial registration and production. See section 4.2 product quality for additional information on the syringe.</p><p>Refer to the Center for Device and Radiological Health (CDRH) review for details.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consumer Study Reviews 4.7.</head><p>Not applicable as this product is for injection by health care practitioners.  <ref type="bibr">20060326, 20101291, 20120156, and 20080289)</ref>. Clinical efficacy and safety was based on the one trial, study 20070337 and the four supportive studies. All clinical studies including phase 1 studies completed in support of romosozumab is listed in Appendix 13.2. Results of the applicant's analyses will be presented with the reviewer's commentary and edits. In certain cases of question, the statistics reviewer will be consulted to confirm or supplement the Applicants' analyses. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">Sources of Clinical Data and Review Strategy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Trial Design</head><p>This was a multicenter, international, randomized, double-blind, placebo-controlled, parallelgroup study in postmenopausal women with osteoporosis, defined as low BMD at the total hip or femoral neck. Subjects were randomized 1:1 (stratified by age group [&lt; 75 years, 75 years] and prevalent vertebral fracture) to receive romosozumab 210 mg subcutaneously (SC) every month (QM) or matched placebo SC QM for 12 months, after which both groups received openlabel denosumab 60 mg every 6 months (Q6M) for an additional 12 months, blinded to initial treatment assignment. This 24-month primary analysis period (12 months of double-blind romosozumab or placebo followed by 12 months of open-label denosumab) was followed by a 12-month open-label extension period through month 36 (currently ongoing) in which eligible subjects continued to receive denosumab 60 mg Q6M. The current marketing application contains information for only the 24-month primary analysis period and does not contain information for the extension period through month 36.</p><p>The study included 10 substudies: Three substudies which include bone turnover markers (BTM) &amp; biomarker substudy and two imaging substudies are discussed in section 6. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Number of Subjects Planned: Approximately 6600</head><p>Diagnosis and Main Criteria for Eligibility: Subjects included postmenopausal women age 55 to 90 years with a BMD T-score at the total hip or femoral neck of -2.50. Key exclusion criteria included a BMD T-score of  -3.50 at the total hip or femoral neck, a hip fracture at any time, any severe or more than 2 moderate vertebral fractures, severe metabolic or bone diseases, and significant laboratory abnormalities. There were no prevalent fracture inclusion criteria and no adjustment to higher BMD inclusion criteria for prevalent fractures.</p><p>The use of agents affecting bone metabolism was also exclusionary; however, for selected therapies permissible off-treatment periods were allowed before randomization. For example, prior oral bisphosphonate therapy was allowed with the following limits:</p><p> any dose received within 3 months prior to randomization  more than 1 month of cumulative use between 3 and 12 months prior to randomization  more than 3 years of cumulative use, unless last dose received  5 years prior to randomization For IV bisphosphonates, the limits included:</p><p> Zoledronic acid: -any dose received within 3 years prior to randomization -more than 1 dose received within 5 years prior to randomization  IV ibandronate or IV pamidronate: -any dose received within 12 months prior to randomization -more than 3 years of cumulative use, unless last dose received  5 years prior to randomization</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Investigational Products, Dose and Mode of Administration</head><p>Investigational Product: Romosozumab 210 mg SC QM or matched placebo SC QM followed by denosumab 60 mg SC Q6M.</p><p>Other Therapy: Daily calcium and vitamin D supplementation, that at a minimum was to be in the range of 500 to 1000 mg elemental calcium and 600 to 800 IU vitamin D. An initial loading dose of 50 000 to 60 000 IU vitamin D within 1 week after randomization was also administered, based on serum 25 hydroxy (OH) vitamin D concentration at screening for subjects with the following process: subjects with a serum 25 (OH) vitamin D level of  20 ng/mL and  40 ng/mL at screening received an initial loading dose of 50,000 to 60,000 IU vitamin D after randomization. Subjects with a serum 25 (OH) vitamin D level of &gt; 40 ng/mL at screening may also receive the vitamin D loading dose at the principal investigator's discretion. Subjects with serum 25(OH) vitamin D levels &lt; 20 ng/ mL were excluded. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Duration of Treatment:</head><p>The primary analysis period included a 24-month study period that consisted of 12 months of double-blind treatment with romosozumab or placebo, followed by 12 months of open-label treatment with denosumab. After the 24-month study period, eligible subjects who entered the extension period received an additional 12 months of openlabel treatment with denosumab, for a total treatment period of 36 months. This application only contained information to the end of the 24 month study period and does not contain information for the extension from month 24 to month 36.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fracture Analysis and Definitions:</head><p>At baseline/ screening, a single, central imaging center radiologist determined prevalent vertebral fractures on lateral-spine X-rays using the following Genant visual semiquantitative grading (SQ) scale:</p><p> SQ grade 0 (SQ0) = no fracture  SQ grade 1 (SQ1) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior)  SQ grade 2 (SQ2) = moderate fracture, 25 to 40% reduction in height  SQ grade 3 (SQ3) = severe fracture, greater than 40% reduction in height</p><p>For incident fractures, the following listing defines each fracture type:  New vertebral fractures occurred when there was  1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 on the Genant SQ Scoring scale. All readers will be from the central imaging center. A primary reader will review radiographs as received. If a new vertebral fracture is identified, the second reader will assess the results blinded to the first reader's findings. activity restrictions during the study and after nonvertebral or clinical vertebral fractures.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis Plan</head><p>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05. If the testing sequence was stopped at a particular step, the remaining endpoints in the testing sequence were not formally tested for statistical significance, and the corresponding p-values were considered descriptive. The following figure 3 graphs this pre-specified fixed-sequence testing for fracture endpoints (see definitions of fractures in the section above). The p-values for the analyses of other secondary, exploratory, and substudy endpoints were nominal without adjusting for multiplicity. All p-values were 2-sided.</p><p>Coprimary Endpoints: The primary analysis set for vertebral fractures was used for analyses of subject incidence of new vertebral fracture through month 12 and through month 24. The number and percentage of subjects with new vertebral fracture was summarized by treatment group. The significance of the treatment effect between romosozumab and placebo (month 12) and romosozumab/denosumab and placebo/denosumab (month 24) was assessed using a logistic regression model with treatment as the main effect and age and prevalent vertebral fracture strata as covariates. The odds ratio, corresponding 95% confidence interval, and pvalue of the score test were provided. Statistical significance for the coprimary endpoints was declared if the p-values for testing the treatment effects through month 12 and month 24 were both &lt; 0.05. Point estimates of absolute risk reduction (difference in proportions, controltreatment), risk ratio (ratio of proportions, treatment over control), and the corresponding 95% confidence intervals were also calculated using the Mantel-Haenszel method adjusting for age and prevalent vertebral fracture strata.</p><p>Secondary Fracture Endpoints: Analyses of new or worsening vertebral fractures and multiple new or worsening vertebral fractures were performed on the primary analysis set using the logistic regression analysis described for the coprimary endpoints. For other fracture endpoints, a time-to-event analysis was used on the full analysis set. In this analysis, the cumulative incidence of fractures was summarized using Kaplan-Meier estimates.</p><p>The significance of the treatment effect between romosozumab and placebo (month 12) or romosozumab/denosumab and placebo/denosumab (month 24) was assessed using a stratified Cox proportional hazards model that controlled for age and prevalent vertebral fracture strata and had treatment as the independent variable. The estimated hazard ratio, corresponding 95% confidence interval, and the p-value of the score test were provided. Point estimate of the adjusted risk difference (difference in Kaplan-Meier estimates, control arm -treatment arm) and the corresponding 95% confidence interval were also provided using the inverse varianceweighted method. Adjusted p-values based on the testing sequence for secondary fracture endpoints were provided in addition to the nominal p-values from the statistical tests.</p><p>Subgroup Analyses: Subgroups analyses were performed for new vertebral fracture, clinical fracture, and nonvertebral fracture at months 12 and 24 using subgroup categories of age &lt; 65 and  65 years, age &lt; 75 and  75 years, prevalent vertebral fracture status (yes, no), history of fragility fracture (yes, no), history of nonvertebral fracture at age  55 years (yes, no), race (white, non-white), geographic region (Western Europe and Australia/New Zealand, Central and Eastern Europe; Asia Pacific; North America; and Central/Latin America), baseline lumbar spine BMD T-score ( -3, &gt; -3 and -2.5, &gt; -2.5), baseline total hip or femoral neck BMD T-score -3 vs both total hip and femoral neck BMD T-score &gt; -3, baseline body mass index (BMI) (tertiles), and World Health Organization Fracture Risk Assessment tool (FRAX) score for major osteoporotic fracture (tertiles). The treatment-by-subgroup interaction was tested quantitatively. If the p-value for the quantitative interaction was  0.05, qualitative interaction testing was performed.</p><p>Bone Mineral Density Endpoints: The primary efficacy analysis set for BMD (month 12 and month 24) was used for analyses of percent change from baseline in BMD. The treatment comparisons of the BMD in lumbar spine, total hip and femoral neck at months 12 and 24 were analyzed using an analysis of covariance (ANCOVA) model with last observation carried forward (LOCF) imputation as the primary analysis. The ANCOVA model included treatment, age and prevalent vertebral fracture strata, and baseline value of the endpoint. Additional covariates of machine type and machine type-by-baseline value interaction were also included. Least squares mean of the treatment difference (treatment -control), the corresponding 95% confidence interval, and p-value were used to compare treatments at each time point.</p><p>The following <ref type="table" target="#tab_7">Table 5</ref> summarizes statistical methods for the fracture endpoints of study 20070337: Safety Endpoints: The safety analysis set was used for the safety analyses. Subject incidence of all treatment-emergent adverse events (hereafter referred to as adverse events) was tabulated by system organ class and preferred term according to the treatment actually received. Adjudicated events of osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) were summarized by number of events and subject incidence. Adjudicated cardiovascular events were summarized as subject incidence.</p><p>Laboratory tests were also summarized over time by actual value and change from baseline for all tests, and also by percent change from baseline for select laboratory tests. Laboratory tests were summarized using Common Terminology Criteria for Adverse Events (CTCAE) shift tables of the baseline to the worst post baseline grade. The numbers and percentages of subjects exhibiting antiromosozumab antibodies (baseline and months <ref type="bibr">1, 3, 6, 12, 15, and 24)</ref> and antidenosumab antibodies (months 12 and 24) were tabulated.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol Amendments</head><p>The following table 6 summarizes important changes to study design 20070337 during development. A coprimary objective was added to assess the effect of romosozumab treatment for 12 months followed by denosumab treatment for 12 months compared with placebo followed by denosumab treatment on the subject incidence of new vertebral fracture. This change was made following discussions with the Agency after the 19 August 2011 EOP2 Meeting (Amgen Response to Questions submitted 07 February 2012, SN 0139), The eligibility criteria were modified to allow participation of a wider range of patients. Specifically, the minimum age was lowered from 60 to 55 years.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Changes in inclusion and/or exclusion criteria</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample size modification</head><p>20070337 Protocol Amendment 1</p><p>(30 August 2012)</p><p>The number of subjects enrolled was increased from 5,600 to 6,000 to ensure enough power to assess the effect of treatment regimens on reduction in non-vertebral fractures at the end of 24 months. The sample size was modified based on the new assumption that the incidence rate of new vertebral and nonvertebral fracture in the placebo group was 12.5% lower than the original assumptions. Using the revised assumption of in the placebo group, the sample size for the study was increased to 6600 subjects. The sample size was increased twice to insure enough patients to achieve enough power with the addition of the co-primary endpoint at 24 months and because the rate of non-vertebral fractures was 12.5% lower than the original assumptions. Age limit was lowered from age 60 to 55 in order to allow more patients into the study. Together these changes allowed the study to recruit enough subjects to complete the study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Changes in study duration</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data Quality and Integrity: Sponsor's Assurance</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Monitoring</head><p>The study centers were monitored by the Sponsor. Monitors were responsible for reviewing adherence to the protocol; compliance with GCP; and the completeness, accuracy, and consistency of the data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Investigator Meetings and Staff Training</head><p>The sponsor organized investigator and clinical research associate meetings before study start and during the study to provide information on the investigational product, the study rationale and design, responsibilities under FDA GCP, and training on the detailed study requirements.   for initial rollout (NME/original BLA reviews) (HR-pQCT) data. Where local laboratories were used, their participation in internal and external quality control, quality assurance, and accreditation schemes was evaluated by the study monitors.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Standardization of Laboratory Procedures</head><p>Lateral spine X-rays, DXA images, and HR-pQCT images were acquired according to specific instructions provided by the central imaging vendor and all images were analyzed by the central imaging center.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>6.1.2.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Compliance with Good Clinical Practices</head><p>The independent ethics committee (IEC) or institutional review board (IRB) reviewed and approved the study protocol and informed consent. This study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) and applicable Food and Drug Administration (FDA) or local regulations/guidelines.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Financial Disclosure</head><p>See Appendix 13.2 for financial disclosure. Although a number of investigators did not return their disclosure forms, 4 sub-investigators in Columbia who were involved in a significant number of subjects (955 subjects -13% of subjects) did not return their signed financial disclosures. The following table 7 lists these sites and investigators along with reasons from the Sponsor on attempts to obtain the signed financial disclosure: Reviewer Comments: These four sub-investigators who did not return signed financial disclosure forms are noteworthy because they were involved in a significant number of <ref type="bibr">Reference</ref>   <ref type="figure" target="#fig_0">955 patients -13% of the study)</ref>. The statistics reviewer performed a sensitivity analysis on the co-primary endpoints with these sites removed and the results did not differ from the study results. See section data quality and data integrity for discussion.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Disposition</head><p>The study was conducted globally at 222 centers in 25 countries: 31 centers in Central/Latin America (43% of randomized subjects), 51 centers in Central and Eastern Europe (29 % of randomized subjects), 52 centers in Western Europe and Australia/New Zealand (14 % of randomized subjects), 62 centers in Asia Pacific (12 % of randomized subjects) and 26 centers in North America (3% of randomized subjects). Countries that randomized more than 10% of subjects included Colombia (25 %), Poland (17 %), and Brazil <ref type="bibr">(11 %)</ref>.</p><p>A total of 16,716 subjects were screened for the study and 7180 were randomized to the romosozumab 210 mg (3589 subjects) and placebo (3591 subjects) groups. The following two tables 8 and 9 summarize subject disposition in study 20070337 for the double blind period through month 12 (table 8) and through the extension period where all patients were treated with denosumab to month 24 (table 9).  Eighty-nine percent of enrolled subjects completed the 12-month double-blind period (romosozumab, 89%; placebo, 89%) and 84 % of subjects completed the 24-month study period (romosozumab/denosumab, 83 %; placebo/denosumab, 84 %). Throughout the study, withdrawn consent was the most frequently reported reason for withdrawal from study in both treatment groups (romosozumab, 7 %; placebo, 7 % during 12-month double-blind period and romosozumab/denosumab, 10 %; placebo/denosumab, 9 % during the 24-month study period).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protocol Violations/Deviations</head><p>A total of 254 (4 %) subjects had at least 1 important protocol deviation (including eligibility criteria deviations that were considered important) during the 24-month study period. The most frequently reported important protocol deviations pertained to subjects who missed &gt; 3 doses of romosozumab or placebo during the double-blind period (1 % of subjects in the romosozumab group and 2 % of subjects in the placebo group). Of the 34 (0.5%) subjects who received an incorrect box for romosozumab or placebo during double-blind treatment, 14 (0.2%) received investigational product that did not match the subject's randomized treatment group. Six of these subjects were randomized to placebo and received a dose of romosozumab in error during the double-blind period. Therefore, these 6 subjects were included in the placebo group (ie, as randomized) for efficacy analyses, but in the romosozumab group (ie, as treated) for safety analyses. During review, the Office of Scientific Investigator (OSI) noted that one of the sites, Dr. Jose FM Restrepo (Site # 1-678YLY/68007) in Columbia had a major issue of delayed randomization. The Sponsor was asked to report randomization times for study 20070337. The Sponsor reported that a total of 7% (481 patients) of the subjects enrolled in Study 20070337 had a screening duration &gt; 35 days and 1.3% (95 patients) exceeded 70 days in total screening duration. Of the subjects with a screening period longer than 70 days, the majority were between 71 and 79 days, with few subjects exceeding 90 days. The longer screening duration was predominantly observed in the Latin American region, specifically at 2 sites in Columbia.</p><p>Although required by the protocol, most subjects with a long screening period did not have repeat testing performed prior to randomization. The Sponsor examined these subjects' screening, and as applicable, baseline or on-study spinal X-rays, calcium, and vitamin D values as a surrogate for prior-to-randomization values to ensure that subjects did not have a severe fracture (or more than 2 moderate fractures), hypo-or hypercalcemia, or excessively low vitamin D levels that would have deemed them ineligible to participate. Subject listings confirm that all subjects met X-ray and vitamin D eligibility criteria and only 1 did not meet calcium eligibility criteria-with grade 1 hypercalcemia at screening and baseline.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Although there was 7% screening delay &gt; 35 days and the majority of the patients with &gt; 70 days screening delayed were not rescreened, patient eligibility did not appear to have been affected by the delays.</head><p>Other important protocol deviations (entered study even though entry criteria were not satisfied, missed month 12 or end of treatment lateral spine X-ray, had a calcium level below the lower limit of normal at month 11 or month 11 + 14 days and was not withdrawn, received an excluded concomitant medication) were each reported for &lt; 1.0% of subjects in either treatment group.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The low incidences and balanced protocol deviations between treatment groups do not raise concern about protocol</head><p>deviations affecting interpretation of the study results.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table of Demographic Characteristics and Other Baseline Characteristics</head><p>Demographic characteristics were generally balanced between the 2 treatment groups. All enrolled subjects were women as required by the inclusion criteria. Overall, 57 % of randomized subjects were white and 40 % were Hispanic or Latino. The mean age of study subjects was 70.9 years (range: 55 to 90 years), and 31 % of subjects were  75 years of age at enrollment. Body composition of the study subjects included mean (SD) weight of 57.94 (10.96) kg, mean (SD) height of 153.2 (7.3) cm, and mean (SD) BMI of 24.70 (4.36) kg/m2. <ref type="table" target="#tab_16">Table  10</ref> summarizes the demographic characteristics in Study 20070337. Baseline laboratory parameters were balanced between the 2 treatment groups including mean baseline albumin-adjusted calcium, phosphorus, and creatinine. Glomerular filtration rate was  60 mL/min/1.73 m2 for the majority of subjects (81 %). 99.7% of subjects had baseline serum concentrations of 25 (OH) vitamin D  20 ng/mL. A minority of subjects (7 %) had used osteoporosis medications with oral bisphosphonates the most frequently reported prior osteoporosis medication (5 % of subjects). 99% of subjects reported baseline concomitant medication of calcium and vitamin D concomitant use was reported for concomitant medication. 77 % (5550 subjects) of subjects started with an initial loading dose of 50,000 to 60,000 IU vitamin D at baseline.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Baseline demographics between the two treatment groups were similar at baseline for age, vital signs, and medical histories.</head><p>Spine radiographs showed that 18 % of subjects had at least 1 verified prevalent vertebral fracture at baseline and 22 % subjects had a history of nonvertebral fracture at or after age 45. The study had excluded patients with any prevalent severe vertebral fractures or more than 2 moderate vertebral fractures. The following table 11 summarizes prevalent fracture history of subjects. The mean baseline lumbar spine, total hip, and femoral neck BMD T-scores were -2.72, -2.47, and -2.75, respectively. Baseline characteristics relevant to determination of the 10-year probability of a major osteoporotic fracture, according to the WHO Fracture Risk Assessment tool (FRAX), were similar between treatment groups. The mean 10-year probabilities of major osteoporotic fractures and of hip fractures calculated with femoral neck BMD were 13.4 % (range: 2.7% to 69.7%) and 5.9% (range: 0.3% to 57.9%), respectively. Baseline cardiovascular risk factors (age, smoking history, and history of hypercholesterolemia, hypertension, diabetes, or cardiovascular disease) were also similar between the 2 treatment groups. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The demographics was well balanced between groups in both major characteristics and laboratory parameters which is reflective of the quality of randomization but there were demographic differences which are significant weaknesses of the trial when extrapolating the results to the US population.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>This study was conducted mostly out of the US and the race demographics differ significantly from the US population. 43% of the subjects were enrolled from Latin America and 29% were from Eastern/Central Europe while only 3 % of the subjects were enrolled from the US. There is higher enrollment of Hispanics and lower enrollment of Blacks when comparing the study demographics to the US population.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>There is evidence that the predominance of South American/ Hispanic subjects enrolled in this trial affected the sample size as there were fewer new vertebral fractures found in this population than predicted. Under a protocol amendment, the sample size was increased in order to reach statistical power for the primary endpoints because this predominant population had fewer fractures than anticipated. However, the baseline prevalent vertebral fracture history is well balanced between the treatment and placebo groups (19% romosozumab versus 18% placebo patients) which support extrapolation of the study results to the US population.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment Compliance, Concomitant Medications, and Rescue Medication Use</head><p>The investigational product (romosozumab or matched placebo PFS and denosumab PFS) was not dispensed to the subjects; all romosozumab, placebo, and denosumab injections were administered by authorized healthcare professionals at the study centers, and were documented on the eCRF.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Concomitant medications included calcium and vitamin D supplementation for all subjects.</head><p>Rescue medication -No rescue medications for osteoporosis were planned for the study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Of note, on a search of the database for concomitant medications during the double-blinded period, 15 patients on romosozumab and 12 patients in the placebo group started on a variety of osteoporotic medications, mostly bisphosphonates. 2 patients started on strontium renelate (1 in romosozumab, 1 in placebo) and 2 patients in the romosozumab group each started on a SERM or teriparatide.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy Results -Primary Endpoint</head><p>In Study 20070337, the pivotal phase 3 study, romosozumab significantly reduced the incidence of new vertebral fractures compared with placebo through month 12 (p &lt; 0.001), with a relative risk reduction of 73% (95% CI: 53%, 84%) and absolute risk reduction by % of 1.30 (95% CI: 0.79, 1.80). In addition, in subjects who received romosozumab during the first year, reduction in fracture risk persisted through the second year in subjects who transitioned from romosozumab to denosumab compared with those who transitioned from placebo to denosumab (p &lt; 0.001), with a relative risk reduction of 75% (95% CI: 60%, 84%) and absolute risk reductions by % of 1.89 (95% CI: 1.30, 2.49) at month 24.</p><p>Fewer new vertebral fractures occurred during follow-on treatment in subjects who had received romosozumab compared with subjects who had received placebo in the first year of study (5 versus 25 fractures in the second year, respectively) even though both arms were receiving denosumab during the second year. The following <ref type="table" target="#tab_4">Table 12</ref> summarizes the coprimary endpoints with accompanying relative risk ratios and p-values, both p-values &lt; 0.001. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: New vertebral fractures results through month 12 and month 24 met statistical significance (p &lt; 0.001) for absolute risk reductions and relative risk reductions at both month 12 and month 24 which fulfilled the more persuasive requirements (p &lt; 0.01) for a single pivotal study, a presubmission agreement.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subgroup analysis for co-primary endpoints:</head><p>A consistent treatment effect was found across all subgroups for the coprimary endpoints of vertebral fracture at 12 and 24 months. No significant quantitative interactions were detected through month 12 or through month 24 for any subgroup of baseline characteristics examined (age, prevalent vertebral fracture status, race, geographic region, baseline lumbar spine BMD Tscore, baseline total hip/femoral neck BMD T-score, baseline BMI, FRAX score, history of nonvertebral fracture at or after age 55, and history of fragility fracture). All p-values on tests of quantitative interactions were &gt; 0.05; therefore, no relevant treatment-by-subgroup interactions (quantitative or qualitative) were identified through month 12 or through month 24 for any subgroup. Efficacy was evaluated by combining all results from all centers. No centers were removed from the analysis because of potential fraudulent data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data Quality and Integrity -Reviewers' Assessment</head><p>Three sites in Columbia where 4 co-investigators did not submit financial disclosures were analyzed to confirm that these site results did not alter the study results. This sensitivity analysis of the co-primary endpoints, removing these 3 sites (sites 68001, 68002, 68006) demonstrated that the results of the co-primary endpoints are unchanged and that both endpoints remain statistically significant. The following table 13 summarizes the co-primary endpoints, new vertebral fractures at 12 and 24 months, with these sites removed. Source: Statistics reviewer analysis with reviewer edits.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments:</head><p>As the analysis demonstrated that both the co-primary endpoints are statistically significant (p&lt;0.001), and consistent with the findings from the pivotal study, the missing financial disclosures at these sites did not affect co-primary efficacy outcomes in the study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy Results -Secondary and other relevant endpoints</head><p>Analysis of results from secondary fracture endpoints followed the pre-specified fixed-sequence procedure for multiplicity adjustment of the endpoints to maintain the overall significance level at 0.05, discussed with types of fracture definitions in section 6.1.1.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head></head><p>Step 1: Co-primary new vertebral fracture endpoints.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head></head><p>Step 2: Clinical fractures, defined as nonvertebral fractures plus symptomatic (clinical) vertebral fractures, at 12 months was the next step in the analysis which showed that romosozumab significantly reduced the incidence of clinical fractures by 36% (95% CI: 11%, 54%) compared with placebo through month 12 (p = 0.008). The following table 14 summarizes clinical fractures results through 12 months, step 2 of the fixed-sequence procedure for multiplicity adjustment.  Step 3: Nonvertebral fractures: The third step of the pre-specified fixed-sequence testing was to analyze nonvertebral fractures incidences at two time points, through month 12 and month 24. The relative risk reduction with romosozumab for nonvertebral fracture through month 12 (25% [95% CI: -5%, 47%]) was not statistically significant (p = 0.096). For the relative risk reduction with romosozumab for nonvertebral fracture through month 24 (25% [95% CI: 3%, 43%]), the p-value was nominally significant (p = 0.029), but did not meet statistical significance after adjusting for multiple comparisons (p = 0.057). The following table 14 summarizes nonvertebral fractures through 12 months and 24 months.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Clinical fractures through 24 months did NOT meet clinical significance when adjusted for multiplicity as expected. The Sponsor performed subgroup analysis on clinical and nonvertebral fractures, discussed below.</head><p>Clinical Fracture Subgroup Analysis: The subgroup analyses of clinical fracture and nonvertebral fracture through month 12 showed a significant quantitative interaction by geographical region (p = 0.029 and p = 0.042, respectively). The nonvertebral component of clinical fractures (defined as nonvertebral fractures plus symptomatic vertebral fractures) accounted for more than 85% of clinical fractures. Nonvertebral subgroup analysis through 12 months by region showed that the Central/Latin American fracture rates were lower than expected (3.5%) with observed rates in placebo (1.2%) and no reduction in the romosozumab group (1.5%). Central/ Latin America accounted for 43% of the randomized population.</p><p>The Sponsor performed a post hoc subgroup analysis to examined Central/Latin America separately from all other regions combined (ie, rest-of-world). Through 12 months, the nonvertebral fracture rate was 2.7% in the placebo group (closer to the expected rate of 3.5%) and 1.6% in the romosozumab group (relative risk reduction 42% [95% CI <ref type="bibr">: 11, 63]</ref>, nominal p = 0.012 post hoc). Through month 24, the rest-of-world nonvertebral fracture rate was 4.3% in the placebo group and 2.9% in the romosozumab group (relative risk reduction 33% [95% CI: 7, 52], p = 0.016.</p><p>Baseline characteristic by region showed a lower height, lower prevalence of historical nonvertebral fractures, and lower World Health Organization Fracture Risk Assessment tool (FRAX) 10-year probabilities of major osteoporotic/ hip fractures in the Central/ Latin American population. Physical characteristics and baseline BMD T-scores at the hip and femoral neck were similar across all regions of the study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The large proportion of the study population from Central/ Latin</head><p>America (43%) had regional differences with lower rates of fractures than expected when compared to the rest of the world for nonvertebral fractures. These regional differences influenced the overall fracture endpoints for nonvertebral fractures through 12 months, 24 months and clinical fractures at 24 months such that none of these fracture endpoints were statistically significant when adjusted for multiplicity. The study appears to be underpowered for these fracture endpoints since the actual fracture rate of the study subjects was less than expected.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reduction of clinical fractures is not an appropriate endpoint for this study for the following reasons:</head><p>1) The term, clinical fracture, does not have clinical meaningfulness among healthcare professionals and can be subject to different interpretation in the labeling.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2) Clinical fractures at 24 months were not statistically significant when adjusted for multiplicity. 3) Clinical fracture rates in this study are combined from nonvertebral fractures (85%)</head><p>and clinical vertebral fractures (15%). As nonvertebral fracture endpoints were not statistically significant, the incidence rate differences for clinical fractures in the The following table 17 summarizes the other secondary fracture endpoints through month 12 and through month 24 by incidence, risk reduction, nominal p-values, and adjusted p-values.  <ref type="figure" target="#fig_0">2 of the pre-specified fixed-sequence procedure had an adjusted p-value &lt; 0.05. See section  6.1.1 for fracture definitions. These endpoints included major nonvertebral, new or worsening  vertebral and hip fractures at both 12 and 24 months.   Additional fracture endpoints of major osteoporotic fractures (hip, forearm, or humerus  fractures not associated with a pathologic fracture regardless of trauma severity and clinical  vertebral fractures) and multiple new/ worsening vertebral fractures were not in the testing  sequence and each had p-values &lt; 0.05 at both month 12 and 24</ref> which are statistically significant. The sponsor is not seeking claims for these types of fractures in this application.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: As noted in above comments, none of the fracture endpoints after step</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMD endpoint:</head><p>Romosozumab significantly increased BMD at the lumbar spine, total hip, and femoral neck compared with placebo at both month 12 and month 24.</p><p>Romosozumab had consistent effect on BMD regardless of baseline age, baseline BMD, and geographic region at the lumbar spine and total hip. The following table 18 summarizes these BMD percentile changes from baseline at both month 12 and 24 for lumbar spine, total hip and femoral neck sites where the p-value &lt; 0.001 for all comparisons. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>error, these findings support the primary endpoint for fracture reduction at both 12 months and 24 months in this patient population and should be included in the labeling.</head><p>Exploratory Endpoints: New vertebra fractures at Month 6: Through month 6, 14 (0.4%) subjects in the romosozumab group and 26 (0.8%) subjects in the placebo group had a new vertebral fracture; the relative risk reduction for romosozumab compared with placebo was 46% (95% CI: -3, 72; odds ratio = 0.54; nominal p = 0.056)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Exploratory endpoint of new vertebral fractures at 6 months had a pvalue = 0.056, was not statistically significant.</head><p>Substudy Results: Bone Turnover Marker and Biomarker Substudy During the first 12 months of study 20070337, in subjects randomized to romosozumab, procollagen Type 1 N-telopeptide (P1NP) showed a rapid increase that peaked at day 14 and returned to baseline by month 9. Similar to P1NP, serum concentrations of bone specific alkaline phosphatase (BSAP) and osteocalcin peaked at day 14 and declined thereafter, returning to baseline by month 12. Changes in P1NP were assessed through month 24 after the end of double-blind treatment. In both treatment groups, denosumab caused similar reductions in P1NP from months 12 to 24, although the median percent change from baseline in P1NP was significantly lower in the romosozumab/denosumab group than in the placebo/denosumab group at month 13. A rapid initial decrease in serum type 1 collagen C-telopeptide (sCTX) and TRAP5b was observed in subjects randomized to romosozumab (sCTX nadir at day 14, TRAP 5b nadir at 1 month) and levels of both bone resorption markers remained below baseline through month 12. After transition to denosumab, both arms of the study showed the expected decrease in bone resorption markers. The following figures 4 graphs P1NP percent changes from baseline by visit and study group.  The following figure 5 graphs sCTX percent changes from baseline by study visit. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Bone turnover markers (BTM) are consistent with dual actions of romosozumab with bone formation and anti-absorption. Action appears to be rapid in onset within the first two weeks of initial drug application, reaching maximal effects by 2 weeks and then tapering off. In both P1NP and sCTX, there is a dose response just after each dose which tapers off by month 9. The BTM patterns support limiting use of romosozumab to one year as BTM levels demonstrate reduced response to romosozumab over time.</head><p>Imaging Substudies In the overall study, romosozumab significantly increased DXA BMD at the lumbar spine, total hip, and femoral neck compared with placebo at month 12. When subjects were transitioned to denosumab, BMD continued to increase. Subjects in the Lumbar Spine and Proximal Femur DXA substudy underwent DXA assessments every six months. In these subjects, romosozumab resulted in progressive increases from baseline in BMD at these 3 sites compared with placebo beginning at month 6 (p &lt; 0.001 at each site).</p><p>The following <ref type="figure" target="#fig_6">figure 6</ref> demonstrates BMD percent change from baseline by visit with 95% CIs from analysis of covariance model (ANCOVA) Model for lumbar spine, total hip, and femoral neck in the imaging substudies.   <ref type="figure">at LS, TH, and FN which is sustained after all patients are transitioned</ref>  Bone Biopsy Substudy Changes in bone architecture, resorption, and formation were evaluated by bone histology, quantitative histomorphometry and micro-CT in the Bone Biopsy substudy (139 subjects who provided 154 biopsies). Bone quality is discussed in section 8.3.6 and bone biopsy and labeling procedures is in section 13.6.4.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Imaging substudies support romosozumab's effects by increasing BMD</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histology:</head><p>A total of 34 subjects were evaluated at month 2, 73 at month 12, and 47 at month 24 (15 of whom underwent sequential biopsy evaluation at months 12 and 24). Quadruple-labeled iliac crest bone biopsies labeled at baseline and after 2 months of treatment, (with 100% labeling compliance) covered a period of potential robust bone formation. These, as well as bone biopsies obtained at month 12, compared the effect of romosozumab with placebo. Biopsies obtained at month 24 provided a cross-sectional comparison of romosozumab for 12 months followed by denosumab for 12 months with placebo followed by denosumab. All but one subject complied with the tetracycline labeling procedure at months 12 and 24. All biopsies evaluable for histology at months 2, 12 and 24 showed normal lamellar bone, normal mineralization, and osteoid. There was no evidence of osteomalacia, marrow fibrosis, or clinically significant marrow abnormality. The month 24 bone biopsy for one subject who received romosozumab followed by denosumab showed woven bone at the top of the iliac crest suggesting microcallus formation, consistent with a nonpathologic process. No other biopsies showed woven bone.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histomorphometry:</head><p>Month 2: Twenty-nine subjects (15 romosozumab, 14 placebo) with quadruple fluorochrome labeling (double fluorochrome labeling at baseline and before month 2) were evaluated for histomorphometry at month 2. Within-subject comparisons between baseline and month 2 showed significant increases in single-label, double-label, and mineralizing surfaces and surfacebased bone formation rates (BFR/BS) in the romosozumab group but not in the placebo group which suggests stimulation of bone formation indices in the cancellous, endocortical and intracortical compartments. Mineral apposition rate did not change significantly in the romosozumab group during that time period and no significant changes in histomorphometry parameters were noted in either romosozumab or placebo group (or between groups) in the periosteal compartment at month 2.</p><p>Median cancellous mineralizing surface percentages were similar at baseline but at month 2 the median percent change in mineralizing surface was 325% in the romosozumab group and 67% in the placebo groups. Similarly, median percent change in BFR/BS at month 2 was approximately 328% in the romosozumab group versus 80% in the placebo group. Consistent with increased osteoblastic activity, increased tetracycline labeling at trabecular, periosteal, and endocortical sites, as well as increased osteoid thickness and volume, and bone formation rates were seen only in subjects in the romosozumab group at month 2. Evidence of decreased osteoclast activity in the romosozumab group was also seen, including lower eroded surface in the cancellous and endocortical compartments and a significantly lower median osteoclast surface in the cancellous compartment. There were no significant differences between treatment groups in cortical thickness or porosity.</p><p>Month 12: Histomorphometry evaluations were performed using bone biopsies from 73 subjects (40 romosozumab, 33 placebo) at month 12. In contrast to the increase in bone formation parameters observed at month 2, dynamic and static formation parameters at month 12 demonstrated a decrease in bone formation. Similar to month 2, eroded surface and osteoclast surface were significantly lower in the romosozumab group than in the placebo group, indicating sustained inhibition of bone resorption.</p><p>Month 24: Histomorphometry evaluations were performed using bone biopsies 47 subjects (24 romosozumab/denosumab, 23 placebo/denosumab) at month 24. After both groups had received 12 months of denosumab, evaluation of histomorphometry parameters did not reveal any significant differences between the romosozumab/denosumab and placebo/denosumab groups.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MicroCT analyses Month 12:</head><p>MicroCT analysis was performed using bone biopsies from 73 subjects (40 romosozumab, 33 placebo) at month 12. Although there were no significant differences between treatment groups for cortical parameters, significant increases in trabecular BMD and trabecular bone volume, primarily due to increased trabecular thickness were seen at month 12 in the romosozumab compared with placebo group. The thicker trabeculae in the romosozumab group were associated with a significantly lower trabecular bone pattern factor and trabecular bone surface to bone volume compared with the placebo group at month 12. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Taken together, there is evidence that romosozumab supports increased trabecular bone formation but may have less or no effect on cortical bone. The histologic and histomorphometric results support significant increased bone formation indices, cancellous bone mineralization, and active osteoblastic activity with decreased osteoclastic activity at month 2 but cortical thickness or porosity did not change by morphometric measurements. The bone is normal by histology. By month 12, the data supports decreased bone formation by histomorphologic parameters and significant increased trabecular bone thickness and volume but no change in cortical parameters by micro CT analysis.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>By month 24 after both groups transition to 12 months of denosumab treatment, there is no difference in histomorphometric parameters. It is unclear if the woven bone found in the one patient treated with romosozumab/ denosumab at month 24 is related to romosozumab exposure as woven bone has not been found with other treatments for osteoporosis.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose/Dose Response</head><p>To be discussed in section 7.1.4</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Durability of Response</head><p>Romosozumab reduced vertebral fracture risk at 12 months and the risk was sustained into month 24 when all patients transitioned to denosumab in this study. BMD increased at the lumbar spine, total hip, and femoral neck compared with placebo beginning at month 6, with progressive gains through month 12. These gains were sustained into month 24 after all patients transitioned to denosumab at month 12. Bone formation markers increased and bone resorption markers decreased during the romosozumab treatment period, reflecting the dual effect of the drug with maximal changes during the initial weeks of treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Persistence of Effect</head><p>To be discussed in section 7.1.5 <ref type="figure" target="#fig_0">Studies (20060326, 20101291,</ref>  To determine the effect of treatment with AMG 785 versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low bone density. <ref type="figure" target="#fig_0">For the 24-month AMG 785 treatment phase (study day 1 to month 24)</ref> To study the effects of up to 12 months of treatment with AMG 785 versus placebo on the percent change from baseline  in BMD at lumbar spine (at month 6), total hip and femoral neck (at months 6 and 12), and distal radius (at month 12), and  in bone turnover markers (BTMs)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supportive Placebo-Controlled</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary Objectives:</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exploratory Objectives: For the 24-month AMG 785 treatment phase (study day 1 to month 24)</head><p> To describe the effect of up to 12 months of treatment with AMG 785 versus alendronate (ALN) or teriparatide (TPTD) on the percent change from baseline in BMD (at the lumbar spine, total hip, femoral neck, and distal radius) and BTMs  To investigate the effect of up to 24 months of treatment with AMG 785 versus placebo on the percent change from baseline in BMD (at the lumbar spine, total hip, femoral neck, and distal radius) and BTMs  To investigate the effect of transitioning from 12 months of treatment with ALN to 12 months of treatment with AMG 785 on the percent change from month 12 in BMD (at the lumbar spine, total hip, femoral neck, and distal radius) and BTMs  To describe the effect of 12 months of treatment with AMG 785 versus placebo or teriparatide on the percent change from baseline in quantitative computed tomography (QCT) BMD at the lumbar spine and proximal femur</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Although unusual for a 24 month study to have few 24 month endpoints, there is one 24-month AMG 785 (romosozumab) exploratory study endpoint comparing BMD at the lumbar spine, total hip, femoral neck, and distal radius) as well as BTMs.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For the 12-month denosumab extension phase (month 24 to month 36)</head><p> To describe the effect of transitioning from up to 24 months of treatment with AMG 785 to 12 months of treatment with denosumab on the percent change from month 24 in BMD (at the lumbar spine, total hip, femoral neck, and distal radius) and BTMs  To describe the effect of transitioning from up to 24 months of treatment with AMG 785 to 12 months of placebo on the percent change from month 24 in BMD (at the lumbar spine, total hip, femoral neck, and distal radius) and BTMs For the 12-month AMG 785 retreatment phase (month 36 to month 48) <ref type="bibr">Reference</ref>   To describe the effect of transitioning from 24 months of treatment with AMG 785 followed by 12 months of treatment with denosumab to 12 months of treatment with AMG 785 on the percent change from month 36 in BMD (at the lumbar spine, total hip, femoral neck, and distal radius) and BTMs  To describe the effect of transitioning from 24 months of treatment with AMG 785 followed by 12 months of placebo to 12 months of treatment with AMG 785 on the percent change from month 36 in BMD (at the lumbar spine, total hip, femoral neck, and distal radius) and BTMs</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For the 24-month follow-on phase (month 48 to month 72)</head><p> To describe the effect of transitioning from 48 months of treatment with active investigational product (IP) to 24 months without IP treatment on the percent change from month 48 in BMD (at the lumbar spine, total hip and femoral neck) and BTMs Note: 48 months of treatment with active IP is defined as assignment to the AMG 785  denosumab  AMG 785 treatment arms during the initial 48 months of the study.</p><p> To describe the effect of transitioning from 12, 24, or 36 months of treatment with active IP to 24 months of treatment with zoledronic acid (ZOL) on the percent change from month 48 in BMD (at the lumbar spine, total hip and femoral neck) and BTMs Note: 12, 24, or 36 months of treatment with active IP is defined as assignment to one of the following treatment arms during the initial 48 months of the study: i. placebo  placebo AMG 785 ii. placebo  denosumab AMG 785 iii.</p><p>AMG 785 placebo AMG 785</p><p>For the overall 72-month study phase (study day 1 to month 72)  To investigate the utility of novel circulating biomarkers in the postmenopausal osteoporosis setting</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Objectives: For the 24-month AMG 785 treatment phase (study day 1 to month 24)</head><p> To characterize the safety and tolerability of AMG 785 vs. placebo as determined by a review of reported adverse events, vital signs, bone histology and histomorphometry, laboratory data, ECG parameters, and formation of anti-AMG 785 antibodies</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For the 12-month denosumab extension phase (month 24 to month 36)</head><p> To characterize the safety and tolerability of transitioning from up to 24 months of treatment with AMG 785 or placebo to 12 months of treatment with denosumab or placebo as determined by a review of reported adverse events, laboratory data, and formation of anti-denosumab antibodies </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For the 12-month AMG 785 retreatment phase (month 36 to month 48)</head><p> To characterize the safety and tolerability of transitioning from 24 months of treatment with AMG 785 or placebo followed by 12 months of treatment with denosumab or placebo to 12 months of treatment with AMG 785 as determined by a review of reported adverse events, laboratory data, and formation of anti-AMG 785 antibodies</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For the 24-month follow-on phase (month 48 to month 72)</head><p> To characterize the safety and tolerability of transitioning from 12 months of retreatment with AMG 785 to 24 months of treatment with ZOL as determined by a review of reported adverse events and laboratory data  To characterize the safety and tolerability of transitioning from 12 months of retreatment with AMG 785 to 24 months without IP treatment as determined by a review of reported adverse events and laboratory data events and laboratory data</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacokinetics Objectives: For the 24-month AMG 785 treatment phase (study day 1 to month 24)</head><p> To characterize the serum concentration of AMG 785 in subjects randomized to an AMG 785 treatment regimen  To characterize the serum concentration of AMG 785 in subjects that transition from ALN to AMG 785</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For the 12-month AMG 785 retreatment phase (month 36 to month 48)</head><p> To characterize the serum concentration of AMG 785 in subjects being retreated with AMG 785 following 12 months of treatment with denosumab or placebo Study Design: Study 20060326 was a randomized, placebo-controlled, parallel-group study in postmenopausal women with low BMD at the lumbar spine, total hip or femoral neck. The study was conducted at 29 centers in Europe, North America, and Argentina. This study included a 24-month treatment phase, during which subjects received 1 of 5 doses of romosozumab, placebo, or active control (alendronate or teriparatide). This was followed by 1:1 randomization within their original treatment group to receive either denosumab or placebo in a 12-month extension phase, followed by a 12-month retreatment phase with romosozumab, followed by a 24-month follow-on phase with a single dose of zoledronic acid or no intervention. The following <ref type="figure" target="#fig_8">figure 8</ref> is a schematic of the study design which includes randomization during the first 24 months with 12 months of denosumab/ placebo randomization phase and 12 months retreatment phase.  At the beginning of the study, subjects will be randomized (1:1:1:1:1:1:1:1) to one of five dosing regimens of AMG 785, placebo, open label ALN or open label TPTD for the first 12 months of the study. The placebo group will be further randomized and evenly distributed across the five dosing regimens defined for the AMG 785 groups. Subjects, sites and study personnel will be blinded to treatment (AMG 785/ placebo) and dose (70 mg/140 mg/210 mg AMG 785), but not to dosing frequency. Upon completion of the first 12 months of the study, subjects in the AMG 785 and placebo groups will continue their assigned treatment for an additional 12 months; subjects in the TPTD group will end study participation, and subjects in the ALN group will be transitioned to receive AMG 785 140 mg SC every month (QM) for an additional 12 months.</p><p>At the end of the 24-month AMG 785 treatment phase, eligible subjects will enter a 12-month denosumab extension phase. Subjects will be randomized 1:1 within their original treatment group to receive either 60 mg denosumab or placebo every 6 months (Q6M). Subjects not participating in the 12-month denosumab extension phase will be followed for an additional three months to month 27.</p><p>At the end of the 12-month denosumab extension phase, eligible subjects will enter a 12-month AMG 785 retreatment phase. All subjects participating in the 12-month AMG 785 retreatment phase will receive 210 mg of AMG 785 QM for 12 months. Subjects not participating in the 12-month AMG 785 retreatment phase will complete the study at month 36.</p><p>At the end of the 12-month AMG 785 retreatment phase, subjects will enter a 24-month followon phase. Based on the outcome of the eligibility assessment, subjects will either receive one dose of 5 mg ZOL intravenously or no intervention. Subjects not participating in the 24-month follow-on phase will be followed for an additional 3-month observational period to month 51. The primary analysis will be performed at month 12, and exploratory analyses will be performed at month 15, month 18, month 24, month 30, month 36, month 42, month 48, month 60, and month 72. <ref type="figure" target="#fig_0">For the 24-month AMG 785 treatment phase (study day 1 to month 24)</ref> The primary endpoint is the percent change from baseline at month 12 in BMD at the lumbar spine for the individual AMG 785 groups and pooled placebo arms.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary Endpoint:</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary Endpoints: For the 24-month AMG 785 treatment phase (study day 1 to month 24)</head><p>The secondary endpoints to be evaluated for the individual AMG 785 groups and pooled placebo arms are:  Percent change from baseline at month 6 in BMD at the lumbar spine, total hip and femoral neck  Percent change from baseline at month 12 in BMD at the total hip, femoral neck, and distal radius  Percent change from baseline at months <ref type="bibr">1,</ref><ref type="bibr">3,</ref><ref type="bibr" target="#b88">6,</ref><ref type="bibr">9 and 12 in BTMs (procollagen</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exploratory Endpoints: For the 24-month AMG 785 treatment phase (study day 1 to month 24)</head><p>The following exploratory endpoints are to be evaluated for AMG 785 and the ALN and TPTD groups during the first year of the study:  Percent change from baseline at month 6 in BMD at the lumbar spine, total hip and femoral neck  Percent change from baseline at month 12 in BMD at the lumbar spine, total hip, femoral neck, and distal radius  Percent change from baseline at months <ref type="bibr">1, 3, 6, 9, and 12</ref> in BTMs (P1NP, CTX, OC, BSAP)</p><p>The following exploratory endpoints are to be evaluated for the individual AMG 785 groups and pooled placebo arms during the second year of the study:  Percent change from baseline at month 18 in BMD at the lumbar spine, total hip and femoral neck  Percent change from baseline at month 24 in BMD at the lumbar spine, total hip, femoral neck, and distal radius  Percent change from baseline at months 15, 18, 21, and 24 in BTMs (P1NP, CTX, OC, BSAP) The following exploratory endpoints are to be evaluated for AMG 785 treated subjects following the transition from ALN during the second year of the study:  Percent change from month 12 at month 18 in BMD at the lumbar spine, total hip and femoral neck  Percent change from month 12 at month 24 in BMD at the lumbar spine, total hip, femoral neck, and distal radius  Percent change from month 12 at months <ref type="bibr">13, 15, 18, 21, and 24</ref> in BTMs (P1NP, CTX, OC, and BSAP)</p><p>The following exploratory endpoints are to be evaluated for AMG 785 versus placebo or teriparatide during the first year of the study (for a subset of subjects only):</p><p> Percent change from baseline at month 12 in QCT BMD at the lumbar spine and proximal femur  Percent change from baseline at month 12 in QCT variables including trabecular volumetric density at the lumbar spine  Percent change from baseline at month 12 in QCT variables including total, cortical, and trabecular volumetric density and cortical thickness at the proximal femur</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For the 12-month denosumab extension phase (month 24 to month 36)</head><p>The following exploratory endpoints are to be evaluated following the transition to denosumab or to placebo during the 12-month denosumab extension phase of the study (month 24 to month 36):</p><p> Percent change from month 24 to month 30 in BMD at the lumbar spine, total hip and femoral neck  Percent change from month 24 to month 36 in BMD at the lumbar spine, total hip, femoral neck, and distal radius  Percent change from month 24 to months 27, 30, and 36 in BTMs (P1NP, CTX, OC, and BSAP)  Percent change from baseline to month 30 in BMD at the lumbar spine, total hip and femoral neck  Percent change from baseline to month 36 in BMD at the lumbar spine, total hip, femoral neck, and distal radius  Percent change from baseline to months 27, 30, and 36 in BTMs (P1NP, CTX, OC, and BSAP)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For the 12-month AMG 785 retreatment phase (month 36 to month 48)</head><p>The following exploratory endpoints are to be evaluated following the transition to AMG 785 during the 12-month AMG 785 retreatment phase of the study (month 36 to month 48):</p><p> Percent change from month 36 to months 39, 42, and 48 in BMD at the lumbar spine, total hip, and femoral neck  Percent change from month 36 to month 48 in BMD at the distal radius  Percent change from month 36 to months 37, 39, <ref type="bibr">42, 45, and 48</ref>   Percent change from baseline to months 39, 42, and 48 in BMD at the lumbar spine, total hip, and femoral neck  Percent change from baseline to month 48 in BMD at the distal radius  Percent change from baseline to months 37, 39, <ref type="bibr">42, 45, and 48</ref> in BTMs (P1NP, CTX, OC, BSAP)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For the 24-month follow-on phase (month 48 to month 72)</head><p>The following exploratory endpoints are to be evaluated following the transition to ZOL or no intervention during the follow-on phase of the study (month 48 to month 72):</p><p> Percent change from month 48 to months 54, 60, 66, and 72 in BMD at the lumbar spine, total hip, and femoral neck  Percent change from month 48 to months 51, 54, 60, 66, and 72 in BTMs (P1NP, CTX, OC, BSAP)  Percent change from baseline to months 54, 60, 66, and 72 in BMD at the lumbar spine, total hip, and femoral neck  Percent change from baseline to months 54, 60, 66, and 72 in BTMs (P1NP, CTX, OC, BSAP)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For the overall 72-month study phase (study day 1 to month 72)</head><p>Correlation between novel biomarkers and changes in BMD and/or BTMs as well as treatment group will be summarized.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Endpoints:</head><p>The following safety endpoints are to be evaluated during the 24-month AMG 785 treatment phase of the study: Nature, frequency, and severity of adverse events and their relationship to treatment; Changes from baseline in vital signs, laboratory assessments and ECG parameters; Bone histologic and histomorphometric parameters; Subject incidence of the formation of anti-AMG 785 antibodies.</p><p>The following safety endpoints are to be evaluated during the 12-month denosumab extension phase of the study: Nature, frequency, and severity of adverse events and their relationship to treatment; Laboratory assessments; Subject incidence of the formation of anti-denosumab antibodies.</p><p>The following safety endpoints are to be evaluated during the 12-month AMG 785 retreatment phase of the study: Nature, frequency, and severity of adverse events and their relationship to treatment; Laboratory assessments; Subject incidence of the formation of anti-AMG 785 antibodies. The following safety endpoints are to be evaluated during the 24-month follow-on phase of the study: Nature, frequency, and severity of adverse events; Laboratory assessments. Pharmacokinetic Endpoints: AMG 785 serum concentrations by visit For assignment to the no intervention group:  Incidence of a clinical vertebral fracture or fragility fracture of the wrist, humerus, hip, or pelvis between the month 24 and the month 48 visit  BMD T-score of  -2.5 at the lumbar spine, total hip or femoral neck, based on local read of the DXA scans at month 48</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Investigational Product Dosage and Administration:</head><p>During the 24-month AMG 785 treatment phase, there will be the following five AMG 785 treatment groups: During the 12-month denosumab extension phase (month 24 to month 36), there will be the following treatment group:  Denosumab 60 mg SC administration every 6 months (Q6M) During the 12-month AMG 785 retreatment phase (month 36 to month 48), there will be the following treatment group:</p><p> AMG 785 210 mg SC administration QM During the 24-month follow-on phase (month 48 to month 72), there will be the following treatment group:  ZOL 5 mg intravenous administration at the 'month 48 plus 14 days' visit</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Control Group:</head><p>During the 24-month AMG 785 treatment phase, there will be five placebo groups, which will be dosed at the corresponding schedules for AMG 785. In addition, there will be two active comparators groups of open label TPTD [20 g SC every day (QD)] and ALN [70 mg by mouth (PO) every week (QW)]. During the 12-month denosumab extension phase (month 24 to month 36), there will be a placebo group which will be dosed Q6M, corresponding to the dosing schedule for denosumab. During the 12-month AMG 785 retreatment phase (month 36 to month 48) there will not be a control group. During the 24-month follow-on phase (month 48 to month 72) there will be a no intervention group. Additionally, all subjects will be required to take at least 1000 mg of elemental calcium and 800 IU of vitamin D daily from screening through the end of study.</p><p>Procedures: Study Schedule Procedures in Appendix 13.4</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Considerations:</head><p>The sample size is based on the comparison of AMG 785 to the pooled placebo and ALN groups, on the percent change from baseline in BMD at the lumbar spine and hip at month 12. The mean percent change in lumbar spine BMD and standard deviation are assumed to be 0 (3.6) and <ref type="bibr">5 (3.6)</ref> for the placebo and AMG 785 groups respectively. The mean percent change in hip BMD and standard deviation are assumed to be 0 (2.6) and 2 (2.6) for the placebo and AMG 785 groups respectively. Allowing for 15% drop out in the first 12 months, two-sided type I error of groups respectively. Allowing for 15% drop out in the first 12 months, two-sided type I error of 5%, a sample size of 50 per group yields over 90% power on the lumbar spine and hip BMD endpoints using the two sample t-test. The total sample size is 400 subjects. If one of the AMG 785 groups is superior to the other 4 AMG 785 groups by 1 (or 0.5) point on mean percent change in lumbar spine BMD, the probability that the superior group will be numerically largest on mean percent change in lumbar spine is 74% (or 46%). The primary analysis of percent change in lumbar spine BMD will use a linear mixed effects model with 4 contrasts estimating the 4 pairwise differences between the 2 AMG 785 dose schedules (QM, Q3M) and the pooled placebo group and the 2 AMG 785 dose levels (140 mg, 210 mg) and the pooled placebo group, at month 12. The Hochberg procedure will be used to control for multiple comparisons.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subject Demographics and Disposition Up to month 24</head><p>In total, 419 subjects were enrolled and randomized: 261 received romosozumab (51 to 54 subjects per dose group), 52 received placebo, 51 received alendronate, and 55 received teriparatide. A total of 383 subjects (91%) completed 12 months of study and 315 subjects (87%) completed the first 24 months.</p><p>Subjects randomized to the teriparatide arm ended the study at month 12 (55 randomized, 46 completed). Subjects randomized to the alendronate arm were transitioned to romosozumab 140 mg QM treatment at month 12. The baseline demographic and key characteristics were comparable across the 8 arms: all subjects were women, mean age was 66.8 years, 86.4% of subjects were white, and the mean baseline lumbar spine and total hip BMD T-scores were -2.29 and -1.53, respectively.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Months 24 to 36</head><p>A total of 260 subjects were then randomized in the denosumab extension phase of the study, 129 received denosumab 60 mg Q6M group and 131 received placebo. A total of 248 subjects (95%) completed the extension phase.</p><p>Subject demographics and baseline characteristics were recorded on entering the study and were summarized to assess potential for bias within the subset of subjects rerandomized in the denosumab extension phase. Characteristics were generally well balanced between the denosumab and placebo groups.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Months 36 to 48</head><p>A total of 167 subjects were enrolled in the romosozumab retreatment phase of the study; of these, 155 subjects (93%) completed this phase. Demographic and baseline characteristics were generally comparable between the total group of 167 subjects in the retreatment phase and the total group of 419 subjects in the 12-month primary analysis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Months 48-72</head><p>A total of 141 subjects continued into the follow-on phase at month 48, including 51 who were assigned to the no-intervention group and 90 subjects assigned to receive zoledronic acid. Subjects who had previously received the treatment sequence romosozumab/ denosumab/ romosozumab were assigned to receive no intervention and subjects who had previously received any other sequences were assigned to the zoledronic acid group, although 8 subjects who received romosozumab/denosumab/ romosozumab subsequently received zoledronic acid. A total of 50 (98.0%) subjects assigned to no intervention and 88 (97.8%) who received zoledronic acid completed the follow-on phase; 1 (2.0%) subject in the no intervention group and 2 (3.4%) subjects in the zoledronic acid group discontinued the study. Demographic and baseline characteristics were generally comparable between groups, although subjects assigned to no intervention were slightly older (mean age 67.2 years versus 65.8 years for the zoledronic acid group), with a slightly higher percentage of white subjects (84.3% versus 77.8%), and higher mean time since menopause (19.6 years versus 18.1 years). Differences were noted between treatment groups in percentage of subjects in each age group category; however, overall there were similar percentages &lt; 75 years of age in each group (no intervention: 90.2%; zoledronic acid: 92.2%).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy Results</head><p>Primary endpoint At month 12, the mean percent change in lumbar spine BMD in the romosozumab groups ranged from 5.4% for 70 mg QM to 11.3% for 210 mg QM, compared with-0.1% in the placebo group. Increases for each of the romosozumab groups were significantly greater (p &lt; 0.0001) than for the placebo group after adjusting for multiplicity. In addition, all 4 comparisons included in the confirmatory testing (QM, Q3M, 140 mg, and 210 mg) significantly favored romosozumab over placebo. The following table 19 summarizes the lumbar spine DXA BMD percent changes from baseline at 12 months in the different groups of the study. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary Endpoints</head><p>Increases in BMD from baseline were seen at the lumbar spine at month 3 and month 6, with the greatest increases occurring in the 140 mg QM and 210 mg QM groups. All increases compared with placebo were statistically significant (p &lt; 0.0001).</p><p>Increases from baseline in BMD at the total hip and femoral neck were seen in some romosozumab dose groups compared with placebo at month 3, and all romosozumab dose groups at months 6 and 12, with the greatest increases occurring in the 140 mg QM and 210 mg QM groups (p &lt; 0.0001). The following table 20 summarizes BMD percent changes from baseline at the total hip and femoral neck at 12 months.  The bone formation markers P1NP, osteocalcin, and BSAP showed dose-related increases with a peak at month 1 in the romosozumab groups versus no increases in the placebo group. The marker levels decreased thereafter with pre-dose levels near baseline levels by 9 months and remaining there with continued dosing. For sCTX, following an initial decrease from baseline (largest at month 1), levels remained below baseline at month 12 in groups that received QM doses of romosozumab (70 mg QM, 140 mg QM, and 210 mg QM).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exploratory Endpoints</head><p>At months 6 and 12, statistically significant increases in BMD at the total hip and femoral neck were observed in the romosozumab 140 mg QM and 210 mg QM groups versus alendronate and teriparatide. At month 12, subjects in the romosozumab 210 mg QM group demonstrated statistically significant increases in the ultradistal radius BMD compared with subjects who received placebo or teriparatide, although the difference from alendronate was not statistically significant.</p><p>From months 12 to 24, all QM romosozumab dose regimens continued to show increases in BMD at the lumbar spine, total hip, and femoral neck; however, increases in BMD occurred more quickly during the first 12 months of treatment. During months 12 to 24, bone formation markers remained at or below baseline. For the romosozumab QM dose regimens, sCTX remained near or below baseline. The following three figures (figure <ref type="bibr" target="#b41">8,</ref><ref type="bibr" target="#b47">9,</ref><ref type="bibr" target="#b48">10)</ref> graph BMD changes for the different study groups up to month 24 for the lumbar spine, total hip and femoral neck respectively by DXA scans.   Source: CSR20060326 <ref type="figure" target="#fig_0">Figure 10-9</ref> with reviewer edits.  Source: CSR20060326 <ref type="figure" target="#fig_0">Figure 10</ref>-10 with reviewer edits.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The data supports limiting romosozumab use to 12 months as it demonstrates a tapering of BMD increases after month 12 through to month 24 at LS, TH, and FN which is consistent with decreased efficacy.</head><p>Retreatment with romosozumab during months 36 to 48 following placebo from months 24 to 36 resulted in BMD increases at the spine and hip comparable to those seen in the group that received initial treatment with romosozumab 210 mg QM during the first 12 months.</p><p>Retreatment with romosozumab in those transitioning from denosumab yielded a more modest increase in BMD at the spine and femoral neck and maintenance of BMD at the total hip and an expectedly different shift in BTMs.</p><p>From months 48 to 72, subjects who had received continuous active treatment through month 48, and then transitioned to no intervention demonstrated a decrease in BMD at the lumbar spine, total hip and femoral neck. However, when evaluated from baseline, mean percent change in BMD remained positive at the lumbar spine at month 72. In subjects who transitioned to the zoledronic acid group at month 48, the BMD gains achieved by month 48 were overall maintained by at month 72, (-0.8% change from month 48 BMD). Overall, the mean percent change in BMD at the lumbar spine remained positive from baseline at month 72 (+12.8% for subjects of treatment sequences combined), regardless of initial romosozumab dose received.</p><p>For subjects who transitioned from active treatment to either no intervention or zoledronic acid at month 48, the levels of the bone formation marker P1NP decreased through month 72. Levels of the bone formation markers osteocalcin and BSAP followed similar trends as P1NP. For subjects who had received romo (any dose)/dmab/rom and transitioned to no intervention at month 48, the levels of the bone resorption marker CTX were near baseline at month 48, increased at month 51, then decreased at month 72. For subjects transitioning to zoledronic acid at month 48, CTX declined to below baseline values, reached a nadir at month 51, then increased toward baseline.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Further discussion of retreatment and durability will be in section 7.1.5. Onset, Duration, and Durability of Efficacy Effects.</head><p>BMD by QCT substudy results: Assessment of BMD by QCT was an exploratory endpoint in a QCT substudy which demonstrated that the romosozumab 210 mg QM was associated with statistically significant increases from baseline at month 12 for lumbar spine and proximal femur in BMD, BMC, and trabecular BMD compared with placebo. Romosozumab was associated with a statistically significant increase in lumbar spine cortical BMD, cortical BMC and cortical thickness compared with placebo The following table 22 summarizes QCT percent changes from baseline at the lumbar spine for BMD, BMC, and cortical thickness at month 12 in the different groups. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary Objective:</head><p>To assess the effect of romosozumab treatment for 12 months compared with placebo on the percent change from baseline at Month 12 in bone mineral density (BMD) at the lumbar spine in Japanese women with PMO</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary Objectives:</head><p>To assess the effects of romosozumab treatment for up to 12 months compared with placebo on: </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exploratory Objective:</head><p>To characterize the pharmacokinetics of romosozumab in subjects randomized to a romosozumab treatment regimen</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Objectives:</head><p>To characterize the safety and tolerability of romosozumab compared with placebo as determined by a review of reported adverse events, laboratory data, vital signs, and formation of anti-romosozumab antibodies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary Endpoint:</head><p>The primary endpoint is the percent change from baseline in BMD at the lumbar spine at Month 12.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary Endpoint(s):</head><p> Percent change from baseline in BMD at the lumbar spine at Month 6 </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Endpoint(s):</head><p>The following safety endpoints are to be evaluated for the Day 1 to Month 12 period (treatment period):</p><p> Subject incidence of adverse events  Changes from baseline in laboratory assessments  Changes from baseline in vital signs  Subject incidence of the formation of anti-romosozumab antibodies</p><p>The following safety endpoints are to be evaluated for the Month 12 to Month 15 period (antibody follow-up study period):</p><p> Subject incidence of adverse events  Subject incidence of the formation of anti-romosozumab antibodies Study Design: This is a multi-center, randomized; double-blind, placebo-controlled, parallel-group study in Japanese women with PMO defined as low BMD at the lumbar spine, total hip or femoral neck. The study is designed to evaluate if romosozumab treatment for 12 months, compared with placebo, is effective in increasing the BMD at the lumbar spine, total hip and femoral neck. Approximately 220 subjects will be randomized 1:1:1:1 to receive either 70 mg, 140 mg or 210 mg romosozumab subcutaneous (SC) every month (QM) or matched placebo SC QM in a double-blind fashion for the duration of the 12-month treatment study period. Upon completion of the 12-month treatment study period, subjects will be followed for another 3 months for assessment of anti-romosozumab antibody formation.</p><p>From screening to end of study, subjects will receive daily supplementation with calcium and vitamin D. The minimum doses should be 500 mg elemental calcium and 600 IU vitamin D. The primary analysis will be performed after all subjects have had the opportunity to complete the Month 12 study visit. The final analysis will be performed after all subjects have had the opportunity to complete the Month 15 end of study visit. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample Size: Approximately 220 subjects</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of Subject Eligibility Criteria:</head><p>Subjects must be postmenopausal women age 55 to 85 years with a BMD T-score at the lumbar spine, total hip or femoral neck of less than or equal to -2.50. Subjects with a BMD T-score of less than or equal to -4.00 at the lumbar spine or with a BMD T-score of less than or equal to -3.50 at the total hip or femoral neck are not eligible to participate. Also excluded are subjects with a history of a vertebral fracture or hip fracture. Subjects with metabolic or bone diseases (other than osteoporosis) or significant lab abnormalities are not eligible for participation. The use of agents affecting bone metabolism is also exclusionary, however, for selected therapies permissible off-treatment periods prior to randomization are acceptable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Product Dosage and Administration:</head><p>Three romosozumab treatment groups:</p><p> 70 mg SC QM  140 mg SC QM  210 mg SC QM</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Concomitant Medications:</head><p>From screening to end of study, all subjects will be required to take daily calcium (minimal dose 500 mg) and vitamin D (minimal dose 600 IU).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Control Group:</head><p>The control group will receive matched placebo SC QM in a blinded fashion.</p><p>Procedures: Study Schedule Procedures in Appendix 13.4</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Considerations:</head><p>For the primary efficacy endpoint, comparisons of the romosozumab dose groups versus the placebo group and a test for a monotonic increasing trend in the romosozumab dose groups will be performed. These assessments will be adjusted for multiplicity using a combination of a sequential test procedure and Hochberg's method to control Type 1 error for the primary endpoint. Additionally, all pairwise comparisons of the romosozumab dose groups will be presented without correction for multiplicity. An evaluation of the dose-response relationship will also be evaluated by considering several candidate non-linear dose-response profiles from both Emax and logistic models. All pairwise comparisons will be presented for other BMD endpoints and BTM endpoints.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subject Demographics and Disposition</head><p>A total of 252 subjects were randomized equally to the 4 different treatment groups. All randomized subjects received at least 1 dose of assigned investigational product. A total of 234 (92.9%) subjects completed 12 months of treatment. Of the 18 (7.1%) subjects who Clinical Review Debuene Chang MD BLA 761062 Evenity (Proposed) -romosozumab CDER Clinical Review Template 2015 Edition 85 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews) discontinued investigational product, there was no dose-related trend. All subjects were Japanese women and the mean (SD) age was 67.7 (6.4) years.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy Results</head><p>Primary Endpoint After 12 months of treatment, romosozumab administration resulted in a dose-dependent increase in lumbar spine BMD compared with placebo, with the largest increase in the romosozumab 210 mg group. The mean differences between each of the romosozumab groups versus placebo and within the romosozumab groups were also statistically significant (p &lt; 0.0001) The following table 23 summarizes the primary endpoint of BMD percent changes from baseline at month 12 at the lumbar spine.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 23: Lumbar Spine BMD Percent Change From Baseline at Month 12</head><p>Source: CSR20101291 <ref type="table" target="#tab_16">Table 10</ref>-1 with reviewer edits.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary Endpoints</head><p>At month 6, statistically significant differences were observed between the percent change in lumbar spine BMD between the placebo and the romosozumab dose groups, and within the romosozumab dose groups (p &lt; 0.001).</p><p>Romosozumab administration resulted in a dose-dependent increase in total hip and femoral neck BMD compared with placebo, with all dosing groups showing an increase compared with placebo at month 12. The largest increase was observed in the romosozumab 210 mg group. The 1-sided p-values for BMD changes versus placebo at months 6 and 12 were &lt; 0.001 for the 2 highest doses.</p><p>Bone formation markers (P1NP, osteocalcin, and BSAP) in the romosozumab groups showed a rapid, transient, dose-dependent increase that peaked by month 1 compared with placebo. The values subsequently returned towards baseline, with levels in the romosozumab groups at or below placebo at month 12. The values of sCTX in the romosozumab groups decreased compared with placebo early in treatment (maximum at day 1 plus 1 week) and were still lower than placebo at month 12.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: This study supports romosozumab dose-dependent efficacy on increases of BMD at the lumbar spine, total hip and femoral neck for each of the 3 romosozumab dosing groups with the largest gains in the 210 mg dose group. Bone formation markers were dose-dependent and peaked by 1 month also supports romosozumab effects on BMD. AE rates were comparable among dosing groups without dose-related trends. See section 7.1 for integrated efficacy results.</head><p>Study <ref type="formula">2012156</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Investigators and Study Centers:</head><p>This study was conducted at 11 centers: 7 in Poland, 2 in the Czech Republic, and 2 in the United States.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Objectives: Primary</head><p>To evaluate the noninferiority of a 6-month treatment with romosozumab 210 mg administered every month (QM) using a 90 mg/mL concentration compared with romosozumab 210 mg QM using a 70 mg/mL concentration on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy X-ray absorptiometry (DXA) in postmenopausal women with osteoporosis</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary</head><p>To evaluate the effect of 6-month treatment with romosozumab 210 mg QM using romosozumab 90 mg/mL and 70 mg/mL on  percent changes in DXA BMD at the total hip and femoral neck  percent changes in bone turnover markers (BTM): bone formation marker procollagen type 1-N-telopeptide (P1NP) and bone resorption marker serum type 1 collagen Ctelopeptide (CTX)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exploratory</head><p>To characterize subjects taking placebo with regard to  percent changes in DXA BMD at the lumbar spine, total hip, and femoral neck  percent changes in BTMs P1NP and CTX To evaluate the safety and tolerability of 6-month treatment with romosozumab 210 mg QM using romosozumab 90 mg/mL or 70 mg/mL and compare with the respective placebo by assessing reported adverse events, laboratory data, vital signs, and the formation of antiromosozumab antibodies over the 6-month treatment and the 3-month follow-up study periods.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Design</head><p>Study 20120156 was a phase 3 randomized, multiple-dose noninferiority study of romosozumab in postmenopausal women with osteoporosis designed to evaluate the noninferiority of a romosozumab 210 mg QM using a 90 mg/mL concentration (2 x 1.17mL SC) compared with romosozumab 210 mg QM using a 70 mg/mL concentration (3 x 1mL SC) over a 6 month treatment period. Subjects then entered a 3-month follow-up period with end of study at month 9.</p><p>After confirmation of eligibility, subjects were randomized in a 22:5:22:5 ratio to the following treatment groups: romosozumab 90 mg/mL, placebo 90 mg/mL, romosozumab 70 mg/mL, or placebo 70 mg/mL. Randomization was double blinded within the concentrations From screening to EOS, subjects received daily calcium supplementation (500 to 1000 mg elemental calcium) and vitamin D supplementation (600 to 800 international units).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Number of Subjects Planned: 272</head><p>Diagnosis and Main Criteria for Eligibility: Subjects were ambulatory postmenopausal women  55 to  90 years of age at high risk for fracture. Subjects had a DXA BMD T-score of  -2.50 at the lumbar spine, total hip or femoral neck. Subjects had a history of fragility fracture or met at least 2 clinical risk factors for fracture.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Investigational Products, Dose and Mode of Administration, Manufacturing Batch Number:</head><p> Romosozumab 210 mg QM (90 mg/mL concentration) or matched placebo administered as 2 SC injections in a 1.17 mL PFS.  Romosozumab 210 mg QM (70 mg/mL concentration) or matched placebo administered as 3 SC injections in a 1.0 mL glass PFS.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Duration of Treatment: Six months of treatment followed by 3-month follow-up period</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Endpoints: Primary</head><p> percent change from baseline in DXA BMD at the lumbar spine (noninferiority)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary</head><p>Reference ID: 4093382  percent change from baseline in DXA BMD at the total hip  percent change from baseline in DXA BMD at the femoral neck  percent change from baseline in BTMs P1NP and CTX</p><formula xml:id="formula_19">(b) (4) Clinical</formula><note type="other">Review Debuene Chang MD</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p>For the 6-month treatment period of the study:</p><p> subject incidence of adverse events  change from baseline in vital signs  change from baseline in laboratory assessments  subject incidence of the formation of antiromosozumab antibodies</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For the 3-month follow-up period of the study:</head><p> subject incidence of adverse events  subject incidence of the formation of antiromosozumab antibodies</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For the overall study period (6-month treatment period followed by the 3-month follow-up period):</head><p> subject incidence of adverse events  subject incidence of the formation of antiromosozumab antibodies</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Methods:</head><p>The primary analysis to assess the treatment difference for romosozumab treatment groups (romosozumab 90 mg/mL -romosozumab 70 mg/mL) in the percent change from baseline in lumbar spine BMD at month 6 employed an analysis of covariance model. The model had main effects for randomized treatment and baseline lumbar spine BMD T-score. The lower bound of the 1-sided 97.5% confidence interval (CI) of the between-treatment group difference was compared with the noninferiority margin of -2.0% for assessing noninferiority. The primary analysis included all randomized subjects who had a baseline and at least 1 post baseline BMD measurement. Subjects were analyzed according to their randomized treatment assignment, regardless of treatment received. To assess the robustness of the primary analysis for the primary endpoint, a sensitivity analysis was performed using the per-protocol analysis subset. Except for the primary noninferiority hypothesis, all inferential statistics were considered exploratory in nature. Continuous variables were summarized descriptively using mean, median, standard deviation (SD), minimum, maximum, and the number of non-missing observations. Frequencies and percentages were presented for nominal categorical variables.</p><p>The subject incidence of treatment-emergent adverse events and laboratory values over time were summarized by actual treatment received. Laboratory shift tables were provided and compared baseline laboratory values with most extreme post baseline values. Subject incidence of antiromosozumab antibodies formation was tabulated. These safety summaries used the safety analysis subset, which included all randomized subjects who received at least 1 dose of </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subject Demographics and Disposition</head><p>A total of 294 subjects were randomized to 3 treatment groups: 53 subjects to the placebo group, 118 subjects to the romosozumab 70 mg/mL group, and 123 subjects to the romosozumab 90 mg/mL group. All randomized subjects received at least 1 dose of either romosozumab or placebo. Twenty-three (7.8%) subjects discontinued the investigational product during the 6-month treatment period: 6 (11.3%) subjects in the placebo group, 9 (7.6%) subjects in the romosozumab 70 mg/mL group, and 8 (6.5%) subjects in the romosozumab 90 mg/mL group. All subjects were female, 99% were white, and the mean age was 67.7 years.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy Results</head><p>Primary Endpoint After 6 months of treatment, mean (95% CI) lumbar spine BMD increased 0.8% (-0.4%, 2.1%) in the placebo group, 9.6% (8.8%, 10.4%) in the romosozumab 70 mg/mL group, and 9.2% (8.4%, 10.0%) in the romosozumab 90 mg/mL group. The mean difference between the two romosozumab groups was -1.5% which was within than the prespecified limit of -2.0. The following table 24 summarizes the two dose concentrations, 70mg/mL and 90 mg/mL by BMD on the lumbar spine at 6 months with ANCOVA model.  <ref type="figure" target="#fig_0">noninferiority criteria with mean difference of 1.5% ((117-110)/46 = 1.5%)</ref> which is more than the prespecified limit of -2%.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The two romosozumab concentrations (70 and 90 mg/ mL) both significantly increase BMD (p&lt; 0.0001) at the LS at 6 months compared to placebo and meet</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary Endpoints</head><p>Statistically significant differences between both romosozumab groups and the placebo group were seen in percent change from baseline in BMD at the total hip and femoral neck (1-sided pvalues for BMD changes from placebo at month 6 were &lt; 0.0001).</p><p>The maximum P1NP increase from baseline was observed at the month 1 time point in both the romosozumab groups, and sCTX decreases were observed at months 1 and 6. Safety results are discussed under section 8 with the integrated safety review.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: This study bridged two different concentration levels for romosozumab by demonstrating that 210 mg SC QM for 6 months administered in the 90 mg/ mL concentration was noninferior to the 70 mg/ mL concentration. Additionally, SAEs were comparable between the placebo and romosozumab groups and AEs were as expected for the population. AE potentially related to hypersensitivity were found more in the romosozumab group but overall AE and SAE rates were balanced between placebo and romosozumab groups.</head><p>Study 20080289 Active-Comparator Controlled-Teriparatide 6.2.4.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Title of Study: An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment With Romosozumab in Postmenopausal Women With Osteoporosis Previously Treated With Bisphosphonate Therapy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Study 20080289 was a 12 month study comparing 12 months of treatment with romosozumab to 12 months treatment with teriparatide in PMO patients, previously treated with bisphosphonates. The primary endpoint, total hip BMD, was not sufficient for direct (head-to-head) efficacy comparisons as fracture data is required. Although the BMD data for romosozumab were comparable to studies previously reviewed, this study will not be reviewed in depth because of the insufficient endpoints for comparison.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7">Integrated Review of Effectiveness</head><p>Assessment of Efficacy Across Trials 7.1. Fracture was assessed as an endpoint in the pivotal Study 20070337. No other supportive studies assessed fractures as endpoints. The coprimary efficacy endpoints were subject incidence of new vertebral fracture through month 12 and month 24. Romosozumab significantly reduced the risk of new vertebral fractures compared with placebo through month 12 (odds ratio = 0.27, p &lt; 0.001), with a relative risk reduction of 73% ([95% CI: 0.16, 0.47]). Vertebral fracture risk reduction persisted over the 24-month study period for subjects initially randomized to romosozumab, as romosozumab for 12 months followed by denosumab for 12 months significantly reduced the risk of new vertebral fractures compared with placebo for 12 months followed by denosumab for 12 months (odds ratio = 0.24, p &lt; 0.001), with a relative risk reduction of 75% (risk ratio = 0.25 [95% CI: 0.16, 0.40]).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary Endpoints</head><p>Sensitivity analyses demonstrated consistent and robust results for the coprimary endpoints. Similar estimates of treatment effect were obtained in sensitivity analyses based on verified stratification variables, the full analysis set, and per protocol analysis set. After controlling for baseline covariates individually and simultaneously in the primary analysis model, romosozumab (month 12) and romosozumab/denosumab (month 24) continued to demonstrate a treatment effect compared with placebo (month 12) and placebo/denosumab (month 24) for the coprimary endpoint at month 12 and month 24.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: New vertebral fracture results were statistically significant and robust at both the 12 month and 24 month endpoints. Fracture endpoints are important as one of the primary clinical benefit of any osteoporotic drug is to reduce morbidity of fractures in this patient population and romosozumab demonstrates efficacy which is sustained once all patients transition to denosumab.</head><p>Secondary and Other Endpoints 7.1.2.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary Fracture Endpoint: Clinical Vertebral Fractures</head><p>Clinical fractures was only studied in the pivotal study 20070337 and discussed in Section 6.1. Through month 12, 3 (&lt; 0.1%) subjects in the romosozumab group and 17 (0.5%) subjects in the placebo group had a clinical vertebral fracture. The total number of subjects with a clinical vertebral fracture during the 24-month study period was 4 (0.1%) in the romosozumab/ denosumab group and 24 (0.7%) in the placebo/denosumab group. Romosozumab (month 12) and romosozumab/denosumab (month 24) demonstrated a relative risk reduction in clinical vertebral fractures of 83% (95% CI: 42, 95) compared with placebo through month 12 and of 83% (95% CI: 51, 94) compared with placebo/denosumab through month 24. The nominal pvalues for the treatment comparisons through month 12 and month 24 were 0.001 and &lt; 0.001, respectively but when adjusted for multiplicity, the p-values were 0.008 and 0.096. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: As discussed in section 7.1, clinical fractures does not have clinical</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>meaningfulness as it is not a standard clinical term as defined in this study, clinical fractures at 24 months did not reach statistical significance when adjusted for multiplicity, and a primary component of clinical fractures, clinical vertebral fractures, is already accounted for in the co-primary efficacy endpoints.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMD Endpoints</head><p>Percent change from baseline in BMD by DXA at the lumbar spine, total hip, and femoral neck were secondary and substudy endpoints in Study 20070337 and primary and secondary endpoints in supportive studies. Assessments of BMD by QCT were secondary or substudy endpoints in <ref type="bibr">Studies 20070337, 20060326 and 20080289</ref>. Across the clinical program, the data demonstrate that romosozumab treatment leads to an increase in both trabecular and cortical BMD.</p><p>The percent change from baseline in DXA BMD at month 6 and month 18 were evaluated as part of a pre-defined substudy dedicated to evaluating the time course of BMD changes (Lumbar Spine and Proximal Femur DXA Substudy [Imaging substudy II] n = 128; 66 romosozumab and 62 placebo). The data showed that romosozumab resulted in significant and progressive increases from baseline in BMD compared with placebo beginning at month 6 (p &lt; 0.001 at spine, total hip and femoral neck. These BMD data allow comparisons between Study 20070337 and the supportive placebo-controlled studies. The significant increases in BMD at the lumbar spine as well as at the proximal femur imply an impact of romosozumab on bone that is predominantly trabecular, as well as bone that is mixed trabecular and cortical (corroborated by the histology substudy in Study 20070337 and QCT data from Study 20060326 and 20080289.) The following table 25 summarizes the BMD percent changes from baseline at the lumbar spine by visit across the placebo-controlled studies.  <ref type="figure" target="#fig_0">, total hip,  and femoral neck at 12 months which carried forward into 24 months. Each measurement  was made every 6 months and were statistically significant for BMD gains at the LS, total hip,  and femoral neck with p &lt; 0.001 at each timepoint.</ref> Bone Turnover Markers: Bone turnover markers were discussed in section 6.2 for study 20070337. The BTM data from samples collected prior to a QM dose were similar across the placebo-controlled supportive studies showing a rapid and acute increase in P1NP (median P1NP returning to baseline levels at approximately 9 months) and a rapid decrease in sCTX that remained reduced over the romosozumab dosing period. Across the studies, the maximum P1NP increase was observed at the month 1 time point in all romosozumab groups. The maximum decrease in sCTX occurred at month 1 and sCTX levels remained below placebo at month 12. These results are similar to the pivotal study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewers Comments: Integrated BMD from the pivotal studies and supportive placebo controlled studies demonstrate robust effects of romosozumab on BMD at the LS</head><p>In all studies among bisphosphonate-nave and bisphosphonate pretreated subjects, BTM levels during romosozumab treatment showed a generally similar pattern, reflecting the dual effect of romosozumab, with an increase in bone formation and a decrease in bone resorption. Across the studies, bone formation markers peaked and returned to baseline by approximately month 6 to 9 while bone resorption markers decreased within a month after the first dose and generally remained below placebo at month 12. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: BTM demonstrated consistent patterns across all the studies with rapid increase in P1NP and concurrent rapid decrease of sCTX which remained reduced over the romosozumab dosing period, consistent with romosozumab's dual functions of bone formation and anti-absorption which tapers over 12 months. Although the BTM responses are reduced over subsequent doses, there remains a smaller response after each dose and is reflective of continued smaller effects of romosozumab after each dose.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subpopulations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>7.1.3.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key Fracture Subgroup Analyses</head><p>Sensitivity subgroup analyses of key fracture endpoints including vertebral fractures, clinical fractures and nonvertebral fractures are reviewed in section 6.2 for the pivotal study 20070337 as that was the only study with fracture endpoints. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMD Subgroup Analyses</head><p>In subgroup analyses of percent change from baseline in BMD at the lumbar spine and total hip, romosozumab through month 12 and romosozumab/denosumab through month 24 increased BMD at the lumbar spine and total hip over a range of baseline BMD T-scores. This included subjects with baseline lumbar spine or total hip BMD T-scores  -3 where the LS mean treatment differences were 14.6% and 12.6% through months 12 and 24, respectively, for the lumbar spine and 6.8% and 6.4% through months 12 and 24, respectively, for the total hip. In the analyses through month 12, treatment differences across demographic subgroups (ie, age and geographic region) ranged from 12.0% to 14.4% for the lumbar spine and from 4.7% to 6.6% for the total hip and were consistent with the treatment differences observed for the overall population (12.7% for lumbar spine and 5.8% for total hip at month 12. The BMD response among those who received 50,000 IU 25, OH vitamin D during the first week of the study as compared to those who did not was not statistically different.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Subgroup analyses for BMD percent change from baseline showed consistent BMD increases at LS and TH among groups when analyzed for age, geographic regions, baseline BMD T-scores including subjects with low BMD (BMD  -3.0). BMD response were not statistically different between subjects who had vitamin D bolus supplementation and who did not have supplementation.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Study 20070337 Population and Efficacy by Region Baseline Disease by Region</head><p>Overall the baseline characteristics of the patients across the regions were similar. Although only 2.7% of the Study 20070337 population was enrolled from North America, age, and baseline BMD T-scores at the hip and femoral neck were similar between North America and other regions in the study, as were most physical characteristics. The BMI was somewhat lower in Asia Pacific, and a lower height, prevalence of historical nonvertebral fracture and FRAX 10year probability of major osteoporotic and hip fracture was observed for subjects in the Central/Latin America region relative to most other regions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Only 2.7% of the subjects in the pivotal study were from North America.</head><p>As discussed in section 6.2, regional differences in Central/ Latin America affected the fracture outcome where these patients had fewer fractures than expected.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Selected Efficacy Endpoints by Region</head><p>New vertebral fracture risk reduction and BMD changes at the spine and the hip were consistent between North America and all other regions evaluated. For fracture endpoints, the small sample number of patients recruited in North America affected the interpretation of the primary endpoint data of the North American population was affected but the overall number of new vertebral fractures was very low, 5 vertebral fractures, (3.5%) in the placebo arm and no vertebral fractures (0.0%) in the romosozumab arm at month 12. The data for BMD percent change from baseline consistently showed statistically significant increases in BMD at the hip and lumbar spine at month 12 compared to placebo, ranging from 12.2 to 14.4 in the lumbar spine, and 4.7 to 6.6 in the total hip. Romosozumab exposure (as assessed by Cmax and Ctrough) was comparable across subjects enrolled in North America and other regions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Although North American recruitment was minor, the new vertebral fracture results (0 romosozumab, 5 placebo) support romosozumab effects on vertebral fracture reduction, similar to the rest of the regions. BMD results were robust and consistently increased compared to placebo across all regions of the world such that there does not</head><p>appear to be any regional differences. Romosozumab exposure was comparable and supports no regional differences to exposure.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of Subpopulation Analyses</head><p>Subgroup analyses of the co-primary endpoints indicated that the efficacy of romosozumab was consistent regardless of baseline characteristics examined. Likewise, subgroup analyses of percent change in BMD at the lumbar spine and total hip showed romosozumab increased BMD over a range of baseline BMD T-scores and other baseline characteristics. The effects of romosozumab across these subgroups indicate that it can be effective in increasing BMD and preventing vertebral fracture across a broad population of postmenopausal women with osteoporosis. When analyzed by region, the percent change in BMD at the lumbar spine and total hip was similar between North America and all other regions, and romosozumab demonstrated statistically significant increases in BMD in all regions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Subgroup analyses showed romosozumab had consistent vertebral fracture reduction and statistically increased BMD across regions and there were no differences by baseline characteristics for these results. However, regional differences in Latin/South America affected other fracture endpoints of nonvertebral and clinical fractures as discussed in section 6.2.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose and Dose-Response 7.1.4.</head><p>Romosozumab 210 mg QM for 12 months (the chosen dose, frequency and duration of treatment) was shown to be efficacious both in subjects who are treatment-nave and in those who have previously received alendronate, and was not associated with increased adverse events compared with other dosing regimens.</p><p>The proposed dosing recommendation for submission, 210 mg SC QM, is supported by the efficacy and safety data from two supportive studies, Studies 20060326 and 20101291 in combination with PK/PD-based exposure-response analyses. The supportive studies evaluated a range of doses <ref type="bibr">(Study 20060326</ref>  20060326) to allow identification of the most efficacious dosing regimen (dose, interval, and duration) without incurring additional adverse events. These results demonstrate that romosozumab exhibits robust dose-exposure-response relationships and support the 210 mg QM dose regimen tested in the pivotal study.</p><p>Integrated analyses of BMD data for the QM dose groups in Studies 20060326 and 20101291 demonstrated that the 210-mg QM dosing regimen resulted in the greatest increase in BMD (month 12) at the lumbar spine, total hip, and femoral neck compared with the other romosozumab dosing regimens tested (70 and 140 mg QM). Furthermore, 210 mg QM and 140 mg QM consistently increased BMD at the lumbar spine, total hip, and femoral neck at months 6 and 12 (p &lt; 0.001); whereas, results for the romosozumab 70 mg QM group were less robust, in particular early in treatment when the percent change from baseline in BMD was similar to placebo at month 6 for the total hip and femoral neck. The 210 mg QM dose was also associated with greater increases in BMD at the lumbar spine and total hip than the 2 active controls, alendronate (Study 20060326) and teriparatide <ref type="bibr">(Study 20060326 and Study 20080289)</ref>. The 210 mg SC QM dosing regimen produced the largest and most prolonged increase in markers of bone formation, with median P1NP, BSAP and osteocalcin levels remaining above baseline for 6 to 12 months compared to 3 to 6 months for 140 mg SC QM). In contrast to the bone formation markers which exhibit increases in a dose dependent manner, the reduction in markers of bone resorption appeared to be less dose-dependent. This suggests that compared with 140 mg QM, the 210 mg QM dose of romosozumab has a greater impact on promoting bone formation without a corresponding further reduction of bone resorption. Efficacy, as measured by BMD and BTM, was significantly lower when romosozumab was given in 3-month intervals for both of the Q3M doses tested. For example, at month 12, the 210 mg Q3M BMD efficacy was closer to the BMD efficacy achieved with 70 mg QM dosing in Study 20060326. A dose-ranging study in subjects previously treated with bisphosphonates has not been conducted, however BMD gains at the lumbar spine, total hip, and femoral neck appeared to be greater for bisphosphonate-treated subjects who transitioned to romosozumab 210 mg QM in Study 20080289 than for subjects in Study 20060326 who transitioned from alendronate to romosozumab 140 mg QM. Also, the romosozumab 210 mg QM dose does not appear to have a different safety or immunogenicity profile compared with the other regimens tested in the dose-ranging studies.</p><p>The Sponsor's PK/PD modeling and simulations support the choice of the 210-mg QM dosing which demonstrated that a romosozumab dose of 210 mg SC QM provided greater BMD gains at month 12 compared to the other dosing regimens tested. The following <ref type="figure" target="#fig_0">figure 11</ref> illustrates the Sponsor's modeling and simulation of dose-BMD response as a function of romosozumab concentration model.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Source: Summary Clinical Pharmacology with reviewer edits. Reviewer Comments: Supportive studies 20060326 and 20101291 demonstrated significant BMD increases and increased BTMs at two romosozumab doses, 140 mg QM and 210 mg QM, while safety and immunogenicity profiles were similar among doses. The Sponsor chose the higher dose, 210 mg QM, for greater increases of BMD and bone formation markers levels which were dose-dependent. Interestingly, bone absorption marker, sCTX was not dosedependent which implies that romosozumab's dual actions of bone formation and anti-bone resorption react independently to dose so that the balance between bone formation and bone resorption is not the same at different doses.</head><p>Onset, Duration, and Durability of Efficacy Effects 7.1.5.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dosing Duration</head><p>The treatment duration in the initial phase 2 Study 20060326 was 24 months. In this study, the rate and magnitude of BMD increases and the degree of bone formation marker elevation indicated that the greatest efficacy occurred during the first 12 months of treatment. In addition, the levels of bone formation markers collected prior to a QM administration of romosozumab returned to baseline values or fell below baseline values between months 2 and 9 (depending on the dose and the marker) and remained there with continued dosing, whereas the bone resorption marker sCTX remained below the original baseline at month 12. Therefore, the duration of treatment chosen for the subsequent phase 2 and phase 3 studies and for the retreatment phase of Study 20060326 was 12 months. The pivotal study limited use of romosozumab to 12 months of treatment. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The data from BMD increases and elevation of bone formation markers demonstrates that romosozumab effects taper off during treatment so that the choice of limiting romosozumab treatment to 12 months is appropriate.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Persistence of Efficacy</head><p>The pivotal study 20070337 and supportive study 20060326 studied romosozumab efficacy in the follow-on period with antiresorptive therapy after romosozumab therapy ended.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fracture Risk Reduction with Follow-on Therapy</head><p>The pivotal study 20070337 assessed fracture risk reduction through 24 months (romosozumab or placebo treatment for 12 months followed by denosumab treatment for 12 months). Results demonstrated that fewer fractures occurred during follow-on treatment in subjects who had received romosozumab compared to those who had received placebo in the first year of study (5 versus 25 fractures in the second year, respectively) even though both groups received denosumab during the second year, risk ratio = 0.25 [95% CI: 0.16, 0.40], p&lt;0.001.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMD with Follow-on Therapy</head><p>In the pivotal study 20070337 follow-on therapy period, the initial romosozumab group (followed by denosumab) continued BMD increases at the lumbar spine, total hip, and femoral neck through month 24 when compared to the initial placebo group. Mean differences in percent change from baseline to month 24 in BMD were significantly greater for subjects in the romosozumab/denosumab group compared with the placebo/denosumab group (p &lt; 0.001 at each site), 11.1% at the lumbar spine, 5.3% at the total hip, and 4.9% at the femoral neck. These data demonstrate continued BMD increases in the romosozumab group after transitioning to denosumab. The BMD increases in the romosozumab/denosumab group, after both groups transitioned to denosumab, are of the same order of magnitude as those in the control placebo/denosumab group, maintaining the substantial BMD difference that was achieved during the first 12 months of the study. BMD gains continued in the follow-on therapy groups of the supportive study 20060326 which was consistent with the pivotal study. In this supportive study, two groups of follow-on patients maintained or continued BMD gains at the lumbar spine, total hip, and femoral neck after romosozumab therapy, one group with denosumab follow-on therapy (months 24-36) and another group with zoledronic acid follow-on therapy (months 48-72).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BTMs with Follow-on Therapy</head><p>During follow-on anti-resorptive treatment after romosozumab, markers of bone turnover were markedly reduced, as would have been expected from subjects on denosumab or zoledronic acid therapy. In the Bone Turnover Marker and Biomarker substudy of Study 20070337, median percent change in P1NP and sCTX decreased with denosumab treatment during months 12 to 24. In Study 20060326, median percent change in P1NP and sCTX decreased with denosumab treatment during months 24 to 36, regardless of initial treatment, consistent with the known effects of denosumab. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Romosozumab's effects on fracture reduction, BMD gains or BTM levels continue in follow-on anti-resorptive therapy from initial romosozumab therapy when compared to initial placebo therapy.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Resolution of Effect of Romosozumab During Off-treatment Periods</head><p>Supportive study 20060326 was the only study to include patient groups off treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMD in Off-treatment Periods</head><p>All patients randomized to initial romosozumab followed by placebo for follow-on therapy, decreased lumbar spine, total hip, and femoral neck BMD gains after discontinuation of active treatment. Subjects randomized to initial therapy with 140 or 210 mg QM doses of romosozumab decreased BMD gains at the lumbar spine, total hip, and femoral neck after romosozumab treatment was discontinued, but remained above baseline for the following 12 months during the placebo phase. In these subjects, percent change from baseline BMD (start of study) at the end of this placebo phase were as follows: 4.3 % (140 mg) and 4.8% (210 mg) at the lumbar spine; 1.3 % (140 mg) and 1.1% (210 mg) at the total hip; and 1.3% (140 mg) and 2.3% (210 mg) at the femoral neck, respectively. For the subjects initially randomized to 70 mg QM, 140 mg Q3M, and 210 mg Q3M doses of romosozumab who received placebo during months 24 to 36, BMD at lumbar spine, total hip and femoral neck were at or near baseline levels by month 36.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BTMs in Off-treatment Periods</head><p>P1NP levels in subjects randomized to romosozumab followed by placebo were below baseline at the end of romosozumab therapy which increased towards baseline during off-treatment (placebo). Subjects, randomized to 210 mg QM romosozumab followed by placebo had sCTX values near baseline at the end of romosozumab therapy which increased to above baseline during off-treatment (placebo) and then returned to baseline by 12 months off-treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Both BMD gains and BTMs in the off-treatment periods after romosozumab show return towards baseline, indicating reversibility of romosozumab's effects on bone. Higher doses of romosozumab (140 mg QM and 210 mg QM) have slower BMD gains return to baseline, likely because the changes were greater at the higher doses during romosozumab therapy. Of note, sCTX is not affected by dose differences and returned to baseline by 12 months off-treatment.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Romosozumab Efficacy During Retreatment Periods</head><p>Study 20060326 was the only study to assess re-treatment with romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMD During Retreatment Periods</head><p>Subjects received romosozumab retreatment from months 36 to 48 after having received either placebo or denosumab from months 24 to 36. After 12 months of placebo (romosozumab/ Clinical Review Debuene Chang MD BLA 761062 Evenity (Proposed) -romosozumab CDER Clinical Review Template 2015 Edition 100 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews) placebo/ romosozumab or placebo/ placebo/ romosozumab), retreatment with romosozumab showed similar increases in BMD as were seen in response to initial romosozumab treatment. After 12 months of denosumab lumbar spine BMD increased in response to romosozumab between months 36 and 48, but the gains were smaller and increases were seen regardless of whether the initial treatment was placebo or romosozumab (sequence of romosozumab/ denosumab/ romosozumab or placebo/denosumab/romosozumab).</p><p>Although the increase in BMD over the months 36 to 48 romosozumab retreatment period was highest in subjects transitioning from placebo, the overall increase in BMD from baseline was higher for subjects who had received an active agent throughout the first 48 months The following table 26 summarizes mean percent increase in lumbar spine BMD retreatment with romosozumab and compares subjects transitioning from placebo or denosumab in the 12 month period before romosozumab retreatment. The following figure 12 illustrates BMD percent changes (95% CI) from baseline at lumbar spine with romosozumab retreatment in patients transitioning from placebo or denosumab treatment in the preceding 12 months. For the all romo/placebo/romo 210 group, the mean percent increase in lumbar spine BMD from months 36 to 48 was 13.1% (total increase from baseline 15.9%). For the romo 210/placebo/romo 210 group, the mean percent increase from months 36 to 48 was 12.7% (total increase from baseline 17.6%). For the all romo/dmab/ romo 210 group, the mean percent increase in lumbar spine BMD from months 36 to 48 was 2.9% (total increase from baseline 17.3%). For the romo 210/dmab/romo 210 group, the mean percent increase from months 36 to 48 was 2.8% (total increase from baseline 22.1%).  The same pattern of changes in BMD was seen for total hip and femoral neck during the retreatment period. While the numbers of subjects were small, the mean percent changes from baseline in BMD for the lumbar spine, total hip, and femoral neck at month 48 were comparable for subjects with or without on-study positive antiromosozumab antibodies in most treatment groups.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Review</head><note type="other">Debuene Chang MD</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BTMs During Retreatment Periods</head><p>Bone formation markers increased in response to romosozumab retreatment (months 36 to 48) in all groups. For subjects who entered the retreatment phase from a placebo group, the increase in P1NP and decrease in sCTX was rapid and the levels continued to follow a similar profile as seen on initial exposure to romosozumab. For subjects who entered the retreatment phase after denosumab, P1NP and sCTX levels had been diminished during the denosumab treatment period; both P1NP and sCTX gradually increased during the retreatment period, reaching baseline levels by month 42. In these subjects, levels continued to increase above baseline through month 48 (P1NP) or remained at or slightly above baseline at month 48 (sCTX).</p><p>Results for other bone formation markers (osteocalcin and BSAP) showed results similar to those for P1NP.  <ref type="figure" target="#fig_0">into a larger patient population. In these small groups, retreatment after an antiabsorptive,  denosumab, showed smaller rate of BMD gains but the overall BMD was higher at the end of  12 months of romosozumab retreatment when compared to placebo. This higher overall gain  is due to denosomab's known effects on BMD when compared to placebo during the 12  months transition period before retreatment. The small number of patients studied (n = 19)</ref> is inadequate to conclude that romosozumab is effective for retreatment .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Although BMD gains and BTM levels demonstrate that retreatment with romosozumab achieve similar changes when compared to initial 12 months of</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>romosozumab therapy, the small number of patients studied (i.e. for romo 210 mg: N=19 for placebo M24-36 group and N=16 for denosumab M24-36 group) limits extrapolation of results</head><p>Additional Efficacy Considerations 7.2.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Considerations on Benefit in the Postmarket Setting 7.2.1.</head><p>The patient population in the pivotal study and supportive studies is representative of the postmenopausal osteoporotic patient in terms of baseline characteristics and entry criteria. The same procedure for drug administration in the healthcare setting by a healthcare provider will be expected for patients prescribed this drug. Healthcare providers will administer the drug to patients in the postmarketing setting which is the same procedure in the clinical studies.</p><p>Efficacy was based largely on a foreign population (&gt; 97%) but subgroup analyses did not demonstrate any regional differences for co-primary efficacy endpoints of reduction of vertebral fractures, gains in BMD or changes in BTMs. It is reasonable to expect that efficacy results will be the same in the US postmarket setting.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other Relevant Benefits 7.2.2.</head><p>Drug dosing schedule will be 210 mg romosozumab SC QM, given by a healthcare provider. This is a relative benefit as it does not require daily medications and can be given to patients who do not wish to take daily medications such as daily SQ injections (teriparatide), daily medications (some of the bisphosphates), or daily nasal spray (calcitonin).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Integrated Assessment of Effectiveness 7.3.</head><p>Romosozumab reduced the risk of vertebral fractures and increased BMD in postmenopausal women at an increased risk for fractures based on the totality of the clinical data package which included well-designed, adequately powered, placebo-controlled, and active comparator controlled studies in an appropriate population. The data from the phase 2 and 3 studies in the clinical development program are consistent and can be generalized to the target patient population of postmenopausal women with osteoporosis at increased risk of fracture.</p><p>The data support the following key efficacy conclusions for romosozumab:  Results for BMD were consistent across the phase 2 and phase 3 placebo-controlled studies <ref type="bibr">(20070337, 20101291, 20060326, and 20120156)</ref>. Romosozumab 210 mg QM demonstrated significant increases in BMD at the lumbar spine, total hip and femoral neck, and the effect was seen early with romosozumab treatment (as early as 3 months in Study 20060326). BMD gains were maintained or augmented further in studies that included a transition to antiresorptive therapy after completion of romosozumab. See section 7.1.2 Integrated Secondary Endpoints.</p><p> Romosozumab consistently increased BMD at the lumbar spine and total hip regardless of baseline BMD T-scores, age, and geographic region. When analyzed by region, the percent change in BMD at the lumbar spine and total hip was similar between North America and all other regions, and romosozumab demonstrated statistically significant increases in BMD in all regions. See section 7.1.3 Integrated Subpopulations.</p><p> In subjects who were previously treated with bisphosphonates, BMD gains and strength at the hip as measured by FEA were significantly greater for romosozumab 210 mg QM than for teriparatide at months 6 and 12. See section 6.2.4 Study 20080289 results.</p><p> Retreatment with romosozumab after a treatment-free interval of 12 months showed comparable effects on BMD as those observed after initial exposure to romosozumab, but the results are greatly limited by very small study groups (N&lt;20). See section 7.1.5 Onset, Duration, Durability. This safety review addresses adverse reactions with the following pre-specified categories, listed with their reasons for concern: 1) events causally associated with sclerostin inhibition  Hypocalcemia 2) events potentially associated with sclerostin inhibition  Hyperostosis   <ref type="bibr">20060220, 20060221, 20090153, 20090378; romosozumab includes studies 20060220, 20060221, 20060223, 20090153, 20090378, 20090418, 20101180, 20110227, 20110253, 20120274, 20120277, and 20150197.</ref>  This safety review is primarily based on the 12 month placebo controlled safety analysis set which is based on data from the pivotal study with 3 supportive placebo controlled studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>12-month placebo-controlled postmenopausal osteoporosis (PMO) safety analysis set (also referred to as the 12-month placebo-controlled population):</head><p>This population included subjects who were randomized and received at least 1 dose of romosozumab 210 mg QM or placebo in three phase 2 and phase 3 studies <ref type="bibr">(20060326, 20101291, and 20070337)</ref>.</p><p>Of note, two studies, studies 20080289 and 20120156, are not included in the pooling as these studies involve a different patient population or duration (alendronate pretreatment and only 6 months duration, respectively) but will be considered separately. Submission quality is adequate regarding overall organization, ease of finding information, proper location of information and data. There were no data quality and integrity issues identified.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adequacy of the safety database: 8.2.3.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer's comments: Total size and adequacy of the database appears appropriate for the dose of 210 mg monthly with 1 year use as 3879 subjects were exposed at this dose and time period.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>However, a significant number of subjects were outside the US and these demographic differences may affect the adequacy of the safety database. The disease of postmenopausal osteoporosis has world-wide prevalence but may have different rates based on many variables such as differences in diet, lifestyles, sun exposure, and access to Vitamin D, etc. The main pivotal trial studied only 2.7% US subjects but included 43% Central/ Latin American subjects and 25% Eastern European subjects. The Sponsor did make an attempt to reduce variability between demographic regions by inclusion/ exclusion criteria including minimal baseline BMD ratios at the hip, spine, and pelvis, limited vertebral spinal fracture history, and minimal baseline Vitamin D (Vit D) levels. Baseline Vit D bolus was required in some patients along with daily Vit D and calcium supplementation was required for all patients during the pivotal study in order to decrease variability of Vitamin D access. Together, these measures decreased variability in the different patient demographic populations in the studies.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adequacy of Applicant's Clinical Safety Assessments 8.3.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Review</head><note type="other">Debuene Chang MD</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Categorization of Adverse Events 8.3.2.</head><p>Adverse events coded to previous Medical Dictionary for Regulatory Activities (MedDRA) versions were recoded to MedDRA version 18.1. Only treatment-emergent adverse events were included in the safety analyses.</p><p>The Sponsor performed additional safety evaluations, listed in section 8.1, based on the mechanism of action, the pharmacologic profile of romosozumab, potential class effects of bone-forming agents, observations made during the nonclinical and clinical program, and the Division's feedback from the 19 August 2011 EOP2 meeting (14 September 2011 FDA Meeting Minutes). These additional safety analysis and search terms used are the following:</p><p> o All deaths and serious adverse events deemed by the investigator to be of potential cardiovascular origin or etiology were submitted to an independent committee for adjudication which was blinded to treatment assignment. o Classification of each death as cardiovascular-related or non-cardiovascularrelated based on predefined criteria in the Clinical Events Classification Charter. o Undetermined classification for deaths not classified into either cardiovascular-related or non-cardiovascular related and presumed to be all cardiovascular-related for completeness. o Serious adverse events with terms mapping to a predefined preferred term list potentially indicative of cardiovascular etiology were also adjudicated by the cardiovascular adjudication committee.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comment: The Sponsor's selections of these specific additional safety evaluations are appropriate and the approach for each category is reasonable.</head><p>Key additional data from individual studies were also included for evaluation below:</p><p> Safety with longer-term exposure and retreatment for the extension phases of the </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Routine Clinical Tests</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Routine Clinical Laboratory Data Analysis:</head><p>The Sponsor performed analyses of routine clinical laboratory data using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE; version 3.0) in the following categories: 1) CTCAE severity grade  2 using the 12-month placebo-controlled population.</p><p>2) Laboratory value shifts from baseline by  2 CTCAE severity grades using the 12month placebo-controlled population. 3) Study discontinuation, dose change, or addition of concomitant therapy resulting from shift tables, marked laboratory value abnormality tables for clinically significant findings that are not serious adverse events, and laboratory value changes in the 12-  o Subject incidence of binding and neutralizing ADA is reported for the 12-month placebo-controlled population. o Potential effects of ADA on safety parameters (eg, hypersensitivity, injection site reactions, or autoimmune disorder) from individual studies</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comment: The selected categories of analysis for routine laboratory values are reasonable and appropriate based on preclinical studies and the molecular basis of romosozumab. The selected population for safety analysis and time for analysis at month 12 are appropriate, given that romosozumab was given to patients for a maximum of 12 months.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Vital signs, Physical Findings and Other Observations:</head><p>The Sponsor analyzed important other observations in the following categories: 1) Vital signs and electrocardiogram (ECG) -absolute values and changes from baseline o (ECG) data, when collected, were summarized by study with no integration of data.   For romosozumab, 29 deaths (0.8% of subjects) were reported; fatal AEs reported for 2 or more subjects in the romosozumab group included lung neoplasm malignant (4 subjects), myocardial infarction (2 subjects), and death not otherwise specified <ref type="bibr">(5 subjects)</ref>. 24 deaths (0.7% of subjects) were reported among placebo subjects; fatal adverse events reported for 2 or more subjects included myocardial infarction, angina pectoris, and cerebrovascular accident (2 subjects each) and death not otherwise specified <ref type="bibr">(5 subjects)</ref>. The following table 28 shows the top fatal adverse events in the Safety population: Malignant lung neoplasm with fatal outcome was reported for 4 romosozumab subjects dosed at 210 mg QM; all were current or former smokers, 1 subject had a history of basal cell carcinoma, and 1 subject reported a family history of unspecified cancer. The onset ranged from study day 47 to 132 with 2 of the events reported as squamous cell carcinoma stage III at diagnosis, one as stage IV histology not provided, and the fourth unknown stage histology not provided.</p><p>Detailed look at all lung neoplasms and not just fatalities demonstrate that the treatment emergent adverse event (TEAE) for lung neoplasm is balanced with 0.2% in romosozumab group and 0.2% in placebo patients. The following table 29 shows the total malignancies and lung neoplasms in the controlled trials. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comment: Fatalities due to lung neoplasms during the study have a significant imbalanced of subjects in the romosozumab group (4) versus placebo group (0). All 4 patients had risk for lung neoplasm with smoking history. The days to onset was relatively short from 47-132 days after first treatment of romosozumab. On a detailed look at all lung neoplasms, the groups are well balanced at 0.2% in both the romosozumab and placebo group. Interestingly the deaths from lung neoplasms were detected early in the study.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A literature search found a paper (Hernandez et al.) which localized sclerostin in nonskeletal tissues including lung. The following quote was from the abstract: "Sclerostin was secreted by bone explants as high molecular weight forms that were reducible to the dimeric form. This dimeric form was detected in sera and in non-skeletal soft tissues specifically kidney, liver, heart and lung." Further literature searches did not reveal any reports of TNF associated diseases or lung cancers with sclerostin.</head><p>Reference ID: 4093382 (b) <ref type="bibr" target="#b88">(6)</ref> Clinical Review Debuene Chang MD BLA 761062 Evenity (Proposed) -romosozumab CDER Clinical Review Template 2015 Edition 112 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The current natural course of lung carcinoma can be rapidly fatal and death within the year would not be unexpected in this patient population once a diagnosis is made. There are insufficient cases to determine if the finding of early fatality can be attributed to the drug causing a more rapidly fatal outcome of lung neoplasm but this information would be informative in labeling.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serious Adverse Events 8.3.4.</head><p>In the 12-month placebo-controlled population at least 1 serious adverse event was reported for 9.5% of subjects in romosozumab group and 8.8% of subjects in the placebo group. The only serious adverse event occurring in  0.5% of subjects in the total romosozumab or placebo groups was pneumonia (0.5% romosozumab, 0.3% placebo). Chronic kidney disease (0.0% romosozumab, &lt; 0.1% placebo) was the only preferred term reported for &gt; 1 subject in total romosozumab or placebo treatment groups. The following table 30 summarizes the most frequently reported SAEs in the placebo-controlled safety population.  <ref type="figure" target="#fig_0">5% (19) romosozumab, 0.3% (10)</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>placebo) favoring romosozumab in both safety populations but the overall rate of pneumonia in both groups is consistent with what is expected in this patient population.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dropouts and/or Discontinuations Due to Adverse Effects 8.3.5.</head><p>In the 12-month placebo-controlled population, adverse events leading to discontinuation from study participation were reported for 1.2% (45) of subjects in romosozumab group and 1.4% (50) of subjects in the placebo group. All individual preferred terms were reported for &lt; 0.1% of subjects in total romosozumab and placebo treatment. <ref type="table" target="#tab_5">Table 31</ref> summarizes AEs leading to discontinuation from the study in the placebo-controlled safety population for &gt; 1 subject report by preferred term.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 31: AEs Leading to Discontinuation of Study</head><p>Source: ISS 14-6.2.6 with reviewer modifications. <ref type="figure" target="#fig_0">: Arthralgia (&lt;0.1% (3) romosozumab, &lt; 0.1% (1) placebo) and  musculoskeletal pain (&lt; 0.1% (3) romosozumab, &lt; 0.1% (2)</ref> placebo were the most frequently reported but the reports are minimal in both groups with no inbalance noted.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comment</head><p>Significant Adverse Events 8.3.6. Atypical Femur Fractures (AFF) has been observed with the use of antiresorptive agents. Because inhibition of bone resorption is a component of the dual effect of romosozumab, there is a potential concern for increased risk of AFF. Nonclinical data did not suggest a plausible mechanism for romosozumab to cause AFF. Aged ovariectomized and adolescent cynomolgus monkey data demonstrate the positive effect of romosozumab on cortical bone by enhancing cortical geometry, increasing mass and strength, and maintaining bone quality. The collective data across studies in ovariectomized monkeys support that romosozumab causes transient increases in intracortical remodeling effecting slight transient reductions in cortical BMD only in the radius. The weight of evidence supports that romosozumab's mode of action on cortical bone would be expected to decrease rather than increase the risk of cortical fractures.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjudicated Positive Atypical Femur Fracture</head><p>In the 12-month placebo-controlled population (excluding Study 20101291, for which events were not adjudicated [no femur fracture adverse event was reported in Study 20101291]), 1 subject in the romosozumab group and no placebo subject had a positively adjudicated event of AFF.</p><p>The following <ref type="table" target="#tab_4">Table 32</ref> summarizes the incidence of adjucated AFF by treatment group in the placebo controlled studies. The following is a summary narrative for the positive AFF patient who was treated with romosozumab in the pivotal study 20070337: Subject was a 69-year-old Dominican woman with a history of osteoporosis, femur pain, hypertension, and partial hysterectomy. The subject had no prior history of cancer, hip surgery to the affected side, or localized pain to the contralateral proximal lateral femur region. She had no prior use of proton pump inhibitors, bisphosphonates, denosumab, teriparatide, or corticosteroids. Screening X-rays showed 3 spinal fractures (T7, T8, and L4); vitamin D was 19.2 ng/mL (normal range:  20 ng/mL). BMD T-scores were 3.1 at the hip and 2.8 at the femoral neck. Approximately 3.5 months later on day 101 (after 4 doses of romosozumab 210 mg SC QM), she fell from a standing height and sustained a right femoral Reference ID: 4093382 (b) <ref type="bibr" target="#b88">(6)</ref> Clinical Review Debuene Chang MD BLA 761062 Evenity (Proposed) -romosozumab CDER Clinical Review Template 2015 Edition 115 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews) diaphysis fracture. A radiograph indicated the fracture occurred in the sub trochanteric or diaphyseal region of the femur and was a non-comminuted simple transverse or short oblique (&lt; 30 degrees) fracture. Prodromal pain in the affected hip with weight bearing was reported prior to study participation. The subject was hospitalized and underwent osteosynthesis with fixed intramedullary screws. Blinded romosozumab was continued, and the subject continued on to receive open-label denosumab. A follow-up X-ray 3 months after fracture fixation showed intact fracture fixation hardware. The outcome of the event was reported as resolved.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: This case is concerning for romosozumab actions in the early period of treatment on bone fractures with this positive AFF on day 101. She did have a prodromal pain in the region but the presence of prodromal pain does not alleviate the concern for a romosozumab link to her AFF. The early timing for her fracture after only 4 doses raises concerns for rapid onset of romosozumab effects on bone strength and quality as well as the disparity of balance between bone building and anti-absorption properties of romosozumab in the early treatment period. She had no prior exposure to known products linked to AFF such as bisphosphonate or denosumab therapy. This stand-out case remains concerning for romosozumab effects on bone for AFF. Further discussion of other cases continue in the following section.</head><p>Labeling should reflect the concern that romosozumab may be linked to AFF as a warning to practitioners and patients.</p><p>To date in all ongoing and completed studies, there were an additional 5 cases of femur fractures of which 4 cases were adjudicated positive for AFF and was adjudicated as not AFF. All 5 additional cases occurred in the blinded alendronate-controlled Study 20110142 during the open-label phase of follow-on alendronate administration with a time to onset of 502 to 1020 days after initiation of double-blind investigational product. Although the study was blinded at the time of submission for this application, the Division requested unblinded information for the patients in the study who developed AFF. Of the four patients adjudicated for AFF, one subject had been randomized to romosozumab-alendronate roll-over arm and 3 subjects had been randomized to the alendronate-alendronate roll-over arm. The one subject who developed a femur fracture which was NOT adjudicated for an AFF had been randomized to the romosozumab-alendronate roll over arm.</p><p>The following are the unblinded abbreviated summary narratives from this study <ref type="bibr">(Study 20110142</ref> upper left leg middle shaft fracture in caused by "lower" force treated by osteosynthesis. She had no prior history of cancer, localized pain to the contralateral proximal femur region, or hip surgery to the affected side. She had no prior use of corticosteroids, bisphosphonates, teriparatide, proton pump inhibitors, or denosumab. Screening spine X-ray showed fractures at L1 and L4, vitamin D was 21.6 ng/mL, and BMD T-scores were 3.80 at the hip and 3.26 at the femoral neck. The subject received romosozumab for 1 year then rolled over to receive open-label alendronate. One year and 9 months after initiating open label alendronate (Month 33), the subject experienced a right femur shaft fracture while walking. She was admitted to the hospital and underwent osteosynthesis with intramedullary nail. The investigator assessed the event as not related to blinded therapy or open-label alendronate. A follow up X-ray showed that the fracture was resolved.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2) Alendronate-Alendronate Roll-Over Arm: 3 Patients</head><p>Subject was in the alendronate-alendronate roll over arm: 72-year-old female with a history of osteoporosis, left femur fracture due to a traffic accident treated with osteosynthesis, pain in right thigh following left femur fracture (started 2004), back osteoarthritis, ex-smoker, stomatitis, polyuria, right upper limb pain, right lower limb pain, varicose veins, and measles. The subject had no prior use of corticosteroids, bisphosphonates, teriparatide, or denosumab. Screening spine X-rays showed fractures at T4 and L2, vitamin D was 23 ng/mL and BMD T-scores were 3.90 at the hip and 3.21 at the femoral neck. The subject received 1 year of alendronate followed by open label alendronate. During study Month 5, the prodromal pain in right thigh that was present before study initiation intensified following a non-serious event of ankle joint injury. During study Month 16, she fell and sustained a right femur shaft fracture. She was admitted to the hospital and femoral fracture osteosynthesis was performed. The investigator assessed the event as related to blinded therapy and open-label alendronate. The event was reported as resolved; the subject was walking with a cane and undergoing ongoing physical therapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subject</head><p>was in the alendronate-alendronate roll over arm. 58-year-old female with a history of lower leg (not knee or ankle) fracture and forearm fracture after a fall from her own height. Her last date of menstrual cycle was in 1999. She had no known history of cancer, hip surgery to the affected side, or localized pain to the contralateral proximal lateral femur region. She had no prior use of corticosteroids, bisphosphonates, teriparatide, proton pump inhibitors, or denosumab. Screening spine X-rays showed fractures at T5 and T10, vitamin D was 18.2 ng/mL and BMD T-scores  <ref type="formula">17)</ref>, she tripped over a separator on the street and sustained a left femur sub trochanteric fracture. She was admitted to the hospital, and sub trochanteric fracture osteosynthesis with intramedullary nail was performed. The investigator assessed the event as not related to blinded therapy or open-label alendronate. The event was reported to be resolved, and the subject was walking without assistance.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subject</head><p>was in the alendronate-alendronate roll over arm. 78-year-old female with a history of osteoporosis, varicose veins, and osteoarthritis. She had no prior history of corticosteroid use, hip surgery to affected area, or localized pain in the contralateral femur region; prodromal pain over the fracture site was reported during weight bearing. Screening x-rays showed a Grade 3 vertebral fracture at T7, vitamin D was 25.9 ng/mL, and BMD T-scores were 4.33 at the hip and 3.85 at the femoral neck. The subject received alendronate for 1 year then rolled over to receive open-label alendronate. One year and 4 months after rolling over to the open label alendronate (Month 28), the subject stumbled while walking on unstable ground, fell from her own height, and experienced a femur shaft fracture. She was admitted to the hospital and underwent osteosynthesis surgery. The investigator assessed the event as not related to blinded therapy or open-label alendronate. The event was reported as resolved and the subject was walking without assistance.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>B) Femur Fracture Adjudicated as NOT AFF: One patient</head><p>Subject was in the romosozumab-alendronate roll over arm.  72-year-old female with a history of osteoporosis, acid peptic disease, hysterectomy, thrombocytopenia, cystopexy, club foot correction, hypertension, dyslipidemia, chronic obstructive pulmonary disease, asthma, allergic rhinitis, and chronic back pain. The subject did not have a history of cancer or hip surgery to the affected side. She had no prior use of corticosteroids and no prodromal symptoms over the fracture site. Screening spine X-ray showed a fracture at T5, vitamin D was 17.9 ng/mL, and BMD Tscores were 2.78 at the hip and 2.36 at the femoral neck. Two weeks after initiating romosozumab, the subject underwent unspecified foot surgery. wearing shoes bigger than her size. She sustained a right femur fracture and was admitted to the hospital. She was treated with skeletal traction, analgesics, sedation, and internal fixation of the fracture. A postoperative X-ray showed adequate reduction of the right femur shaft fracture and a new right intertrochanteric femur fracture with a cephalomedullary pin in place. The subject was reported as not having had a fall, injury, or prodromal symptoms that may have led to the right intertrochanteric femur fracture. The event of intertrochanteric femur fracture was adjudicated and did not meet criteria for atypical femur fracture. The investigator assessed the events of femur shaft fracture and intertrochanteric femur fracture as not related to blinded therapy but related to open-label alendronate. The event of femur shaft fracture was reported as resolved with sequelae and the event of femur intertrochanteric fracture was ongoing. The subject was ambulating with a cane and receiving ongoing physical therapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Summary of these additional case narratives from unblinded data from the alendronate-controlled trial:  1 case: on Romo-alendronate, AFF at month 33 (after 21 months on alendronate)  1 case: on Romo-alendronate, femur fx NOT adjudicated as AFF at month 28 (after 16 months on alendronate)  3 cases: on alendronate-alendronate arm, AFF after 16, 17, and 28 months on alendronate Of note is that the baseline BMD for all subjects who developed AFF in this study exceeded the exclusion criteria in the pivotal study 20070337 of -3.5 SD BMD at either hip of femoral neck. The exception was the one case of femur fracture not adjudicated as an AFF who had higher baseline BMD (-2.78 SD hip and -2.38 SD femoral neck).</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The presence of AFF or femur fractures in this clinical study does not alleviate concerns that romosozumab is linked to these fractures although these AFF cases are confounded by alendronate treatment as all subjects presented during alendronate treatment which is known to increase risks of AFF but usually after extensive long-term treatment (3 years or more). These subjects were at baseline at high risk for fractures; given their baseline BMD values exceeded -3.50 SD.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bone Quality: Bone Biopsy Substudy in Pivotal Study 20070337:</head><p>The Sponsor submitted results of the bone biopsy substudy in the original application and then submitted additional information under Module 1.11.3 on February 14, 2017.</p><p>As described in the Bone Biopsy Substudy submitted in the original BLA twenty-nine subjects (15 romosozumab, 14 placebo) with quadruple fluorochrome labeling (double fluorochrome labeling at baseline and before month 2) were evaluated for histomorphometry at month 2. Within-subject comparisons showed significant stimulation of bone formation in the romosozumab group between baseline and month 2 in the cancellous and endocortical compartments, as demonstrated by significant increases in single-labelled, double-labelled, and mineralizing surfaces and surface-based bone formation rates (BFR/BS) in the romosozumab group. No significant changes were seen in mineral apposition rates (MAR) in the romosozumab group. In the placebo group, no significant changes were noted for any of these histomorphometry parameters in the within-subject comparisons.</p><p>At month 2, romosozumab significantly increased osteoid thickness and osteoid volume compared with placebo. As a consequence of the increased cancellous bone formation rate, the calculated parameter activation frequency (derived from BFR/BS) was also significantly increased. Consistent with the dual effect of romosozumab, a reduction in bone resorption was also evident at month 2, as indicated by significantly lower median eroded surface in the cancellous (romosozumab, 1.810%; placebo, 3.370%) and endocortical compartments (romosozumab, 1.580%; placebo, 6.270%) and a significantly lower median osteoclast surface in the cancellous compartment (romosozumab, 0%; placebo, 0.095%) in the romosozumab group. In contrast to the increase in bone formation parameters observed at month 2, dynamic and static formation parameters at month 12 demonstrated a decrease in bone formation secondary to the decrease in the rate of bone remodeling in the cancellous compartment, consistent with self-regulation of bone formation. The MAR, adjusted apposition rate, singlelabelled, double-labelled, and mineralizing surfaces, surface-and volume-based bone formation rates, activation frequency, and osteoid volume were significantly lower and mineralization lag time and formation period were significantly greater in the romosozumab group compared with the placebo group. Similar to month 2, eroded surface and osteoclast surface on both cancellous and endocortical surfaces were significantly lower in the romosozumab group, indicating sustained inhibition of bone resorption.</p><p>The following figures <ref type="figure" target="#fig_0">(Figures 13 and 14</ref>) graphs endocortical ( <ref type="figure" target="#fig_0">Figure 13</ref>) and cancellous ( <ref type="figure" target="#fig_0">Figure  14</ref>) eroded surface percentiles comparing the two groups of romosozumab treated and placebo patients at month 2 and month 12.  The following figures <ref type="figure" target="#fig_0">(Figure 15</ref> and 16) graph endocortical ( <ref type="figure" target="#fig_0">Figure 15</ref>) and cancellous ( <ref type="figure" target="#fig_0">Figure  16</ref>) bone formation rates comparing romosozumab-treated group to placebo at months 2, 12, and 24 (for cancellous bone only). Source:  Source:  As discussed in section 6.1.2, all biopsies evaluable for histology at months 2, 12, and 24 showed normal lamellar bone, normal mineralization, and osteoid.</p><p>In contrast to an increase in bone formation parameters observed at month 2, dynamic and static formation parameters at month 12 demonstrated a decrease in bone formation secondary to the decrease in the rate of bone remodeling in the cancellous compartment. Similar to month 2, eroded surface and osteoclast surface were significantly lower in the romosozumab group than in the placebo group, indicating sustained inhibition of bone resorption.</p><p>These findings were consistent with those seen in the two other bone biopsy substudies <ref type="bibr">(Study 20060326 [months 6 and 12, n = 32] and 20080289 [month 12, n = 4]</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The Sponsor postulates that the bone biopsy data decrease the biological plausibility of a potential relationship of the antiresorptive properties of romosozumab to AFF. While the bone biopsy results may support this postulate at the end of treatment at month 12, the disparate rate of bone formation compared to bone erosion is most prominent early in treatment at month 2. Early in treatment may be the time range where romosozumab's antiabsorptive mechanism increases risks of AFF. Bone formation</head><p>Clinical  <ref type="figure" target="#fig_0">fracture is supported by the only case in the pivotal trial where the patient sustained her AFF  on day 101.</ref> Taken in totality, the clinical data supports concern for romosozumab as a risk for AFF in this patient population. This concern should be included in the labeling as a warning.</p><note type="other">Review Debuene Chang MD</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>marker, N1P1, and absorption marker, sCTX, support rapid action by romosozumab within 2 weeks of the first dose and they both taper towards baseline by month 12. Early risk for</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjudicated Positive Osteonecrosis of the Jaw</head><p>Osteonecrosis of the Jaw (ONJ) has been observed with the use of antiresorptive agents. Nonclinical data findings suggest that dental disease and inflammation in rats with a lifetime exposure to romosozumab is not associated with ONJ-like findings such as exposed necrotic bone. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis. In fracture repair models, local osteoclastic activity in response to injury is better maintained with sclerostin antibody treatment when contrasted with bisphosphonates and RANKL inhibitors.</p><p>In the 12-month placebo-controlled population (excluding Study 20101291, for which events were not adjudicated), 1 subject in the romosozumab group and no placebo subject had a positively adjudicated case of ONJ. This case was confounded by continuous use of a maladaptive fitting denture. The following <ref type="table" target="#tab_5">Table 33</ref> summarizes ONJ incidence in the placebo controlled portion of the study: One additional positively adjudicated case of ONJ was identified in the romosozumab group of Study 20070337 after the double-blind period (subject was taking denosumab at the time). This case occurred after the administration of 1 dose of denosumab in a subject who had a prior non-serious adverse event of periodontitis. No initial placebo patients developed ONJ in the studies.</p><p>The following are abbreviated summary narratives for these two patients from Study 2007003: A) ONJ during placebo-controlled period Subject : 67-year-old woman (randomized to romosozumab) with osteoporosis and dentures who had a nonserious, unrelated, grade 1 adverse event of tooth fracture on day 109. The subject had no prior bisphosphonate use, no cancer history, no chemotherapy, and no radiation. The fracture of 2 teeth was without significant trauma, and required placement of a new removable partial maxillary denture at month 7, as well as extraction of 4 teeth at month 8. Approximately 13 months after the initial dose of investigational product (day 363), a grade 1, serious adverse event of delay of gum healing was reported as a not-related event The subject had exposed bone of the hard palate at the right maxilla, medial jaw at an extraction site different from the 4 extracted teeth mentioned above. The case was adjudicated positive for ONJ. Follow-up information revealed that the denture was not fitted properly and it was in contact with the exposed bone; however the subject continued to wear dentures during the adverse event of delayed gum healing. The case was readjudicated and remained positive for ONJ. The subject underwent gum cauterization and the event resolved on day 435. B) ONJ during denosumab follow-on period after 12 months romosozumab Subject 65-year-old woman with osteoporosis, diabetes mellitus, and dentures, who completed a year of romosozumab 210 mg SC QM and received 1 dose of denosumab 60 mg SC. The subject had no prior bisphosphonate use, no cancer history, no chemotherapy, and no radiation. On day 393, approximately 1 month after the first denosumab dose, the subject had nonserious; grade 2 acute apical periodontitis of the right maxillary canine tooth with subsequent need for multiple root canals and tooth extraction a few weeks later. She then developed delayed healing of the tooth socket and exposed bone which was noted at month 15 for 15 days and then again at approximately month 17. The case was adjudicated positive for ONJ. At month 22, the subject had resolution of the apical periodontitis. The magnetic resonance imaging report of the head and neck showed low intensity area and high intensity area in T1-weighted images and short time inversion recovery, respectively, and was suspicious for osteomyelitis. The subject subsequently developed the serious, grade 2 adverse event of right maxillary jawbone necrosis on day 435. Readjudication following the additional information maintained the positive adjudication classification. As of the cutoff date for this study, the event was ongoing.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: These two cases during the pivotal trial are concerning for a risk of ONJ with romosozumab, one during the placebo controlled portion and one just after a first dose of denosumab. Both cases were adjudicated positively for ONJ. No cases were identified in the placebo group either during the placebo controlled portion of the trial or during denosumab extension.</head><p>Given these findings, there is a concern for ONJ development with romosozumab, especially with maladaptive dentures. This concern should be placed in the labelling as a warning and in the med guide. <ref type="bibr">Reference</ref>  To date in all ongoing and completed studies, there were 2 additional cases of positively adjudicated ONJ. Both additional cases were found in the blinded alendronate-controlled Study 20110142, where the positively-adjudicated ONJ occurred at months 22 and 28 during the open-label phase of alendronate administration. Although the study was blinded at the time of submission for this application, the Division requested unblinded information for the patients in the study who developed ONJ along with information for AFF. The following are abbreviated summary narratives from these two patients, one was randomized to romosozumab and then rolled-over to alendronate while the other one was randomized to alendronate and rolled-over to the same alendronate:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20110142: Positively Adjudicated ONJ:</head><p>A) Randomized to romosozumab for 12 months and rolled-over to alendronate: Subject 70-year-old female from Norway with a past medical history of cardiac arrhythmia who had no prior treatment with glucocorticoids, immunosuppressants, or IV bisphosphonate, and who was a current smoker (200 pack-years). The subject was reported to have a history of dental abscess, osteomyelitis, root canal in the affected area; and dental treatment 4-6 months prior to the onset of the oral lesion. She completed 1 year of romosozumab and was then rolled over to open-label alendronate. She developed an oral infection in Month 27. In Month 28, the subject had a non-serious adverse event of ONJ, which was adjudicated as positive for ONJ. The subject wore upper dentures, and the area of lesion was at or near the contact point. B) Randomized to alendronate for 12 months and rolled-over to alendronate: Subject 84-year-old Asian female from Hong Kong with a past medical history of osteoporosis, spine fracture, and hypertension. The subject had no prior treatment with denosumab, bisphosphonate, steroids, or immunosuppressants. She completed 1 year of alendronate and was rolled over to open-label alendronate. She developed a non-serious event of osteonecrosis of the jaw in Month 21. The non-serious event of ONJ was adjudicated as negative for ONJ. Despite local debridement and treatment with antibiotics, nasopharyngolaryngosocopy suggested a non-healing wound with granulation tissue, and an imaging study with a CT suggested ONJ. The event was upgraded to serious by the investigator. Due to persistent symptoms leading to hospitalization for treatment of the event, the case was sent for readjudication, and was re-adjudicated as positive. The event of ONJ was reported as ongoing. These two cases were found in the alendronate controlled trial and unblinded at FDA request. Both cases occurred during the alendronate roll-over period but one case of each for a patient randomized to initial romosozumab treatment and placebo treatment. Alendronate treatment confounds the results as the antiabsorptive properties of the bisphosphonates are linked to both ONJ and AFF. The concern that romosozumab increases the risk of ONJ is supported by the fact that one of the patients positive ONJ patients had received romosozumab for one year prior to roll-over to alendronate.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comment: For ONJ, 2 cases (1 randomized to Romo-alendronate and 1 to alendronate-alendronate), both also appearing over 1 year after</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In totality, given the results from the pivotal trial and this alendronate-controlled trial, there is data to support that romosozumab can be linked to ONJ in this patient population, especially those with maladaptive dentures during treatment. The labeling and med guide should provide this information to providers and patients as a warning.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment Emergent Adverse Events and Adverse Reactions 8.3.7.</head><p>In the 12-month placebo-controlled population, 78.4% of subjects in the romosozumab group and 79.6% of subjects in the placebo group had adverse events.</p><p>The most frequent adverse events ( 10%) in total romosozumab or placebo treatment groups were nasopharyngitis (13.2% romosozumab, 12.3% placebo), arthralgia (12.7%, 11.8%), and back pain (10.3%, 10.5%). In general, the frequency of adverse events was similar between treatment groups; no adverse event preferred term was reported at a  2% higher incidence in the romosozumab group compared with the placebo group. <ref type="table" target="#tab_5">Table 34</ref> summarizes the rate of AEs (below):  <ref type="figure" target="#fig_0">were nasopharyngitis (13 % romosozumab, 12 % placebo), arthralgia (13 %, 12  %), and back pain (10 %, 11 %)</ref> and these items should be included in the label.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comment: The AEs were well balanced between romosozumab and placebo and no dose related trends were observed in the exposure-adjusted rate of AEs. There were no categories of AEs  2% of difference between romosozumab and placebo. The most frequent emergent AEs</head><p>AEs of special interest will be discussed in Section 8.4 and include the following:</p><p> Injection site reactions (based on the narrow search term strategy for injection site reactions),  Hypersensitivity (based on the narrow search term strategy for hypersensitivity)  Hypocalcemia (defined as albumin adjusted serum calcium that was below the lower limit of normal)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Laboratory Findings 8.3.8.</head><p>Laboratory data analyses used the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE; version 3.0). The number of subject incidences for  Grade 3 CTCAE findings are listed in Appendix 13.7 and discussed in the following section.</p><p>In general, clinical laboratory evaluations (eg, serum chemistry, hematology) demonstrated no clinically significant effect of romosozumab.</p><p>For the 12-month placebo-controlled population, the subject incidence of laboratory test results with CTCAE grade  2 was 19 % in the romosozumab group and 19 % in the placebo group. No clinically important trends were noted. Specific laboratory findings for calcium, magnesium, phosphorus, and creatinine are shown in the following table 35. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Calcium: Hypocalcemia</head><p>The mechanism of action of romosozumab suggests that administration of romosozumab may be associated with decreases in serum calcium as a result of increased bone formation and increased demands for calcium for matrix mineralization.</p><p>The subject incidence of CTCAE grade 2 decreases in serum calcium was 0.2% in the romosozumab group and &lt; 0.1% in the placebo group (see <ref type="table" target="#tab_5">Table 35</ref>). No subject in the romosozumab group had a grade 3 or 4 decrease in serum calcium although 1 subject in the placebo group had a grade 4 decrease in serum calcium. No subject with a CTCAE 1 grade decrease from baseline also had a hypocalcemia adverse event.</p><p>Adverse events of hypocalcemia were reported for &lt; 0.1% (1) of subjects in the romosozumab treatment group and no subject in the placebo group in the placebo-controlled safety population; no serious adverse events of hypocalcemia were reported.</p><p>Corrected serum calcium levels decreased the most at month 1, the median percent change from baseline was -2.2% for subjects who received romosozumab and 0.0% for subjects who received placebo. Calcium levels normalized over time as demonstrated in the following <ref type="figure" target="#fig_0">Figure  17</ref>, such that at month 12, the median percent change from baseline was -1.0% for the romosozumab group and 0.0% for the placebo group, and was 0.0% for both groups at month 24.   <ref type="figure" target="#fig_0">SAEs for hypocalcemia was found in the safety population and only  1 patient (&lt; 0.1%) had an AE related to hypocalcemia. As expected, calcium levels decreased  with the first dose of romosozumab but normalized over time, to within 1% of baseline at  month 12 and to baseline by month 24 on denosumab. Of note, all patient were  supplemented with calcium and</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer's Comments: No</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>vitamin D during the studies and some patients were bolused with vitamin D for low baseline vitamin D.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Calcium in Renal Failure:</head><p>In study 20110227, patients with renal failure were compared to healthy patients when exposed to romosozumab. All patients were supplemented with calcium and vitamin D in the study. The study found that only patients with stage 4 renal insufficiency (RI) or stage 5, end stage renal disease (ESRD) developed AEs of hypocalcemia while no healthy subjects developed hypocalcemia. No subject in the study developed a SAE or fatal hypocalcemia. Stage 5, ESRD patients had more incidences (total AEs =4) and more severe grades (total AEs = 4: grade 1= 1, grade 2 = 2, and grade 3 =1) of hypocalcemia than stage 4, RI patients (total AEs =1: grade 1 = 1). The following table 36 summarizes the number of renal insufficiency (RI) or chronic kidney disease (CKD) patients who presented with hypocalcemia by grade of presentation.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: This study demonstrates that patients with more severe renal failure had higher incidences and greater severity of hypocalcemia compared to stage 4 RI patients where only 1 AE for hypocalcemia was reported and healthy patients where none developed hypocalcemia. These findings support the use of romosozumab in renal failure patients but calcium serum calcium and vitamin D status should be monitored closely during therapy, especially in patients with ESRD which should be included in the labeling.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Phosphorus:</head><p>Because romosozumab increases bone formation, there is an increased demand for phosphorus, in addition to calcium, to support bone matrix mineralization. For the 12-month placebo-controlled population, mild decreases in phosphorus with romosozumab were observed. The subject incidence of CTCAE grade 2 decreases in phosphorus was 0.4% in the romosozumab group and 0.1% in the placebo group (grade 3: 0.2%, 0.1%) see <ref type="table" target="#tab_5">Table 36</ref> above. There were no AEs reported for hypophosphatemia.</p><p>Median percent change from baseline at month 12 was -5.4% in the romosozumab group and -2.3% in the placebo group.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: As expected, phosphorus decreased during romosozumab treatment. There were slightly higher rates of CTCAE grade 2 in phosphorus levels in the romosozumab group compared to placebo (0.4% in the romosozumab group and 0.1% in the placebo group) but CTCAE grade 3 changes were relatively balanced. Overall, phosphorus rates decreased as expected for romosozumab and the rate of severe decreases was minimal and acceptable for the mechanism of action for romosozumab. No safety issue identified.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Magnesium:</head><p>Because romosozumab increases bone formation, there may be an increased demand for magnesium, in addition to calcium and phosphorus, to support bone matrix mineralization and for its role in the calciotropic hormone axis.</p><p>For the 12-month placebo-controlled population, no change in magnesium was observed in either group. The subject incidence of CTCAE grade 2 decreases in magnesium was 0.2% in both the romosozumab and placebo groups; no grade 3 or 4 changes were reported. See table 36. There were no reported AEs associated with hypomagnesia.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Changes in magnesium were balanced for CTCAE grade 2 decreases between romosozumab and placebo groups and there were no severe grade changes of 3 or 4. Given these findings, magnesium changes are expected for this patient population and no safety issues have been identified.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fasting glucose</head><p>Several studies in rodents indicate a potential role of bone in regulation of glucose metabolism, although a clinically meaningful translation of this effect in humans is unclear. In Study 20070337, romosozumab treatment did not demonstrate an effect on fasting glucose. <ref type="table" target="#tab_5">Table 37</ref> below shows glucose abnormalities  2 CTCAE in the placebo controlled studies. Patients with diabetes were not excluded from the studies.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Glucose values are similar between groups and glucose changes from CTCAE levels are relatively balanced between romosozumab and placebo groups. Despite preclinical concerns, glucose does not appear to be a safety issue for romosozumab.</head><p>iPTH Because romosozumab increases bone formation, there may be compensatory responses in iPTH as a result of bone matrix mineralization. Study 20070337 included an iPTH and urinary calcium substudy comprising 656 subjects to characterize serum iPTH concentration and urinary calcium excretion through month 12. AEs related to iPTH elevations such as hypocalcemia were balanced between romosozumab and placebo groups.</p><p>The median percentage change from baseline in iPTH was 29% in the romosozumab group and 4% in the placebo group at month 6 and 27% in the romosozumab group and 8% in the placebo group at month 12. Differences between romosozumab and placebo were statistically significant at both timepoints (nominal p-value &lt; 0.001 from Wilcoxon rank-sum test without multiplicity adjustment). <ref type="figure" target="#fig_0">Figure 18</ref> below graphs the mean increases in iPTH compared to placebo in this iPTH substudy of 20070337. Patients are randomized to romosozumab or placebo for 12 months (in blue) and all patients follows with denosumab treatment for 12 additional months (in red).  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Review</head><note type="other">Debuene Chang MD</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: iPTH rose in response to romosozumab as expected and although levels fell over time; it was still statistically elevated compared to levels in placebo patients. The rise in iPTH levels on romosozumab may be due to the anti-absorptive mechanism, similar to denosumab. iPTH levels all elevated and were balanced between the treatment groups once all patients were on denosumab in the follow-on period by month 24.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The rise in iPTH levels in romosozumab patients support the importance of calcium and vitamin D supplementation.</head><p>iPTH in renal failure: In Phase 1 Study 20110227, the administration of romosozumab resulted in a greater increase in iPTH in subjects with stage 4 RI and stage 5 CKD requiring hemodialysis than in healthy subjects.</p><p>In this study, at baseline, the mean (SD) iPTH levels were higher for subjects with end stage renal disease (ESRD) <ref type="bibr">(11.77 [12.</ref>0] pmol/L] compared with subjects with stage 4 RI (5.01 <ref type="bibr">[1.6]</ref> pmol/L) and healthy subjects (4.68 <ref type="bibr">[3.4]</ref> pmol/L). After the administration of the single SC dose of romosozumab on day 1, serum iPTH levels increased among all treatment groups. The observed mean (SD) iPTH values and the mean (SE) percent increase from baseline in iPTH were greater for subjects with ESRD and subjects with stage 4 RI than for healthy subjects.</p><p>At day 29, mean percent increases from baseline in iPTH were 150% in subjects with stage 4 RI, 287% in subjects with ESRD, and 94% in healthy subjects. After this time point, iPTH levels returned towards baseline levels.</p><p>As additional sensitivity analyses to support the endpoint of estimated 24-hour urine calcium excretion, percent changes in estimated 24-hour urine calcium and urine calcium to creatinine ratio were further analyzed in subjects having 24-hour urine volume between 500 mL or 3500 mL or having 100% increase in their estimated 24-hour urine calcium excretion from baseline at month 6 or 12. In subjects with a 24-hour urine volume between 500 mL and 3500 mL, results were similar to those obtained for all subjects who participated in the substudy, with statistically significant differences between groups at month 6, but not at month 12. For subjects with a  100% increase in urinary calcium at months 6 and 12, no statistically significant differences between romosozumab and placebo groups were observed for estimated 24-hour urinary calcium percentage change from baseline. No AEs were identified related to hypouricalcemia or hyperurocalcemia. The changes from baseline in urinary calcium in the romosozumab group compared to placebo at 6 months and 12 months in the study 20070337 substudy for urinary calcium is summarized in <ref type="table" target="#tab_5">Table 38</ref> below:  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Urinary calcium results demonstrate greater conservation of calcium during the early months (up to month 6) and statistically significant decreases in urinary calcium loss when comparing the romosozumab treated group to placebo which is consistent with romosozumab's mechanism of action and increased demand for bone mineralization</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>early. By month 12, the differences in urinary calcium normalizes which support limited treatment with romosozumab.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Potential Hy's Law cases:</head><p>Hy's Law is used to detect drugs that can cause serious liver injury. Briefly, Hy's Law cases have the following three components: 1. &gt; 3 X ULN of ALT or AST than placebo 2. Total bilirubin &gt;2X ULN, without initial findings of cholestasis (defined as elevated serum alkaline phosphatase) 3. No other reason can be found to explain the combination of increased ALT or AST and TBL, such as viral hepatitis A, B, or C; preexisting or acute liver disease; or another drug capable of causing the observed injury At baseline: The subject incidence of elevated baseline ALT and elevated baseline AST of &gt; 3 x ULN and &gt; 5 x ULN was lower in the romosozumab group than the placebo group, and similar between treatment groups for elevations &gt; 10 x ULN and &gt; 20 x ULN. Overall, the subject incidence of elevated baseline AST and ALT &gt; 3 x ULN was lower in the romosozumab group than the placebo group <ref type="formula" target="#formula_34">(</ref> Two tables below <ref type="table" target="#tab_5">(Table 39 and Table 40</ref>) summarizes the incidence of baseline and on study AST <ref type="table" target="#tab_5">(Table 39</ref>) and ALT (    Patient level review of the elevated AST and ALT data: Of the romosozumab subjects with elevated transaminases &gt; 3 x ULN, over half had elevated transaminases at baseline (16 of 28 subjects), and the majority had confounding factors. The confounders included past medical history, such as alcoholic liver damage, hepatic steatosis, cholelithiasis, and use of concomitant medications known to cause increases in transaminases such as acetaminophen, statins, antihypertensives, and methotrexate. The transaminases trended to normal or baseline for the majority of subjects (18 of 29 [64%]). The one romosozumab subject without confounding factors had an increase of ALT (170 U/L) on study day 28 to &gt; 3 x to  5 x ULN with an AST (84 U/L) of &gt; 1 x to  3 x ULN. This subject completed a year of romosozumab, and the transaminases trended down to &gt; 1 x to  3 x ULN by study day 365 (ALT 42 U/L, AST 34 U/L).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The subject incidences for elevated AST and ALT &gt; 3X and &gt; 5X ULN were lower in the romosozumab than in the placebo group at both baseline and in study. During the study, the AST elevations &gt; 10X ULN was balanced with 2 subjects (&lt;0.1%) in each group while ALT &gt; 10X ULN remained lower for romosozumab subjects than for placebo (2 [&lt;0.1%], 4 [0.1%]). No subjects had AST or ALT elevations &gt; 20 X ULN during the studies. Overall, from this summary data, romosozumab does not appear to increase AST or ALT levels greater than in placebo patients.</head><p>Two subjects in the romosozumab arm had on-study elevations of AST and ALT &gt; 10 x ULN. One subject , with a history of transaminase elevation following use of Augmentin, had elevations of transaminase following treatment of bronchiectasis during study with Augmentin; she completed a year of romosozumab, and LFTs normalized by the end of year one. The other subject developed elevated transaminases in the setting of suspected type A viral hepatitis; romosozumab was discontinued, and LFTs trended down by the time of drug withdrawal.</p><p>In the first-in-human phase 1 Study 20060220, 1 subject in the single-dose romosozumab 10 mg/kg SC group with normal baseline liver function tests developed nausea, vomiting, and diarrhea following a meal on the evening that the study drug was administered. AST and ALT increased to &gt; 5 x ULN on study day 4 while bilirubin levels remained normal. Over the next several days, the subject's liver function tests normalized without any treatment. The following <ref type="table" target="#tab_6">Table 41</ref> summarizes the subject demographics and treatment (romosozumab) group. Baseline AST (day -1) was 22 U/L, ALT 22 U/L, alkaline phosphatase 75 U/L, and bilirubin normal.</p><p>The subject received the single dose of blinded investigational product on study day 1. On the evening of study drug administration, the subject developed nausea and vomiting after the meal and 1 episode of watery diarrhea. On study day 2, the subject vomited after lunch. The AST was 47 U/L, ALT 52 U/L, alkaline phosphatase 66 U/L, and bilirubin normal. On study 3, the subject experienced nausea after breakfast and lunch; dinner was tolerated well. On study day 4 no gastrointestinal symptoms were observed; AST was 216 U/L, ALT 530 U/L, alkaline phosphatase 188 U/L, and bilirubin normal. On study day 5, gastrointestinal symptoms resolved; no intervention was required. Study day 6: AST was 88 U/L, ALT 314 U/L, alkaline phosphatase 195 U/L, and bilirubin 0.4 mg/dL. During the next 3 days, study days 7-10, AST decreased from 93 to 38 U/L, ALT decreased from 261 to 136 U/L, alkaline phosphatase ranged between 155 and 171 U/L, and bilirubin remained normal. Hepatitis panels were nonreactive, and abdominal ultrasound was unremarkable. On (study day 26), AST and ALT were 20 and 23 U/L, respectively, and alkaline phosphatase was 121 U/L; the adverse event was considered resolved. By study day 108, AST and ALT were 17 and 20 U/L, respectively, alkaline phosphatase 71 U/L, and bilirubin normal.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comment: The symptoms and laboratory findings are consistent with hepatitis and timely related to study drug day 1 but this subject did not meet Hy's law as bilirubin was not elevated despite elevations of both AST and ALT. Her symptoms resolved by day 4 of the study with concurrent decreases towards normal of her LFTS. No subjects in phase 1 studies met Hy's Law criteria.</head><p>The following <ref type="table" target="#tab_4">Table 42</ref> provides the subject incidence of potential Hy's law cases (ie, cases that met the Hy's law laboratory criteria) for the 12-month placebo-controlled population.) The number of subjects meeting the criterion of ALT or AST &gt; 3 x ULN and total bilirubin &gt; 2 x ULN and alkaline phosphatase &lt; 2 x ULN was 1 (&lt; 0.1%) subject in the romosozumab group and 1 (&lt; 0.1%) subject in the placebo group. Of note, the sponsor noted that one patient had an error in total bilirubin levels entered into the database which made that patient meet Hy's Law criteria. Once that error was corrected, the patient no longer met Hy's Law criteria. The sponsor stated the following:</p><p>" an After the database snapshot, but prior to the investigator unblinding, the total bilirubin level that met Hy's Law criteria for Subject was reassessed and amended as total bilirubin was erroneously entered as elevated by the site. Following this correction, the subject no longer met the criteria for Hy's law. Therefore, only 1 subject met the criteria for Hy's law in the romosozumab group." </p><formula xml:id="formula_20">Reference ID: 4093382 (b) (6) (b) (6) (b) (6)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comment: The correction of the error in total bilirubin dropped the number of cases of potential Hy's Law cases to 1 in the romosozumab group and 1 in the placebo group.</head><p>Details for these potential cases are discussed in detail below. Two cases met Hy's Law criteria, one placebo and one romosozumab treated group. A further review of the cases showed alternate medical etiology for the laboratory abnormalities.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subject</head><p>was in the romosozumab arm: A 71-year-old subject ) received 210 mg romosozumab on days 1, 36, 67, 98, and 133. Following day 36 administration of romosozumab (the second dose), she had a serious adverse event of grade 1 "diffuse liver fatty deposit." Laboratory results that day were ALT: 103 U/L (3 x ULN), AST: 102 U/L (3 x ULN), and total bilirubin: 70.11 mol/L (normal range: 3 to 21 mol/L; 3 x ULN). On day 42, AST was 55 U/L, ALT was 46 U/L, and total bilirubin was 14 mol/L. Concomitant adverse events were non-serious cholelithiasis (grade 2) on day 44, nonserious diabetes mellitus (grade 1) on day 49, non-serious bile duct stone (grade 2) on day 358, and serious gastric adenocarcinoma on day 127 which led to death on day 545.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subject</head><p>was randomized to the placebo arm. An 88-year-old subject with a medical history of cholecystectomy, dyslipidemia, hypertension, osteoarthritis, diabetes mellitus, and elevated liver function tests received placebo. On day 279, the subject had a grade 3, serious adverse event of transaminases increased. Previous laboratory results at month 9 were AST: 109 U/L (3 x ULN); ALT: 11 x ULN, and total bilirubin: 1.3 mol/L (ULN: 1.2 mol/L). Laboratory results all normalized in the same month. The event resolved without treatment on day 290. Concomitant medications were lovastatin and glucosamine at the time of the event.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: There is no data to support Hy's Law cases with the use of romosozumab in these clinical studies. The only subject in the romosozumab arm who met Hy's law criteria had confounding reasons for elevated AST, ALT. and total bilirubin including cholelithiasis temporarily related to her elevated AST, ALT, and total bilirubin just 7 days after her elevated LFTs were noted at her second dose on study day 36. Furthermore, her case is confounded by her gastricarcinoma diagnosis on day 145 which lead to her death on study day 545. The second case is in a placebo patient and also confounded by her history of cholelithiasis/ cholecystectomy.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Vital Signs 8.3.9.</head><p>Analysis of vital signs (systolic and diastolic blood pressures, pulse rate, body temperature, body weight, and BMI) and electrocardiograms in individual studies demonstrated no clinically important effect of romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Romosozumab would not be expected to cause changes in these vital signs and there is no data to support any changes.</head><p>Electrocardiograms (ECGs) 8.3.10.</p><p>EKG data are provided in individual clinical study reports and were not pooled for integrated analyses. Analysis of EKGs in individual studies demonstrated no clinically important effect of romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Because of its large physical size and low potential for interfering with cardiac channel repolarization, romosozumab would not be expected to affect ECG changes. The studies did not identify ECG changes to support a safety concern.</head><p>QT 8.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.11.</head><p>There is a low likelihood for delayed cardiac repolarization due to hERG channel blockade with romosozumab, primarily based on its physical size of approximately 150 kD and the low potential for large protein therapeutics (especially monoclonal antibodies) to interfere with cardiac ion channels in vivo, including hERG-mediated current.</p><p>In pre-clinical studies in conscious telemetry-instrumented cynomolgus monkeys following single IV doses up to 300 mg/kg followed by 14 days of monitoring, there was no evidence for romosozumab -related EKG change. AUC and Cmax exposure margins achieved were up to 32fold and 210-fold, respectively, to clinical exposures at 210 mg QM. Additionally, there were no romosozumab-related electrocardiographic or blood pressure changes in the 1-month and 6month repeat-dose toxicology studies in monkeys at doses up to 300 mg/kg IV.</p><p>In the first-in-human study <ref type="bibr">(Study 20060220)</ref>, single SC doses of romosozumab (0.1 to 10 mg/kg) or placebo or single IV doses of romosozumab (1 to 5 mg/kg) or placebo were administered to healthy men (N = 16) and postmenopausal women (N = 56). A total of 54 subjects received romosozumab, and 18 subjects received placebo. Electrocardiogram evaluations included assessments for all 72 subjects. No patterns or trends in ECGs occurred that were considered to be clinically relevant.</p><p>In the phase 1b, multiple-dose study <ref type="bibr">(Study 20060221)</ref>, SC administration of 6 doses of 1 mg/kg romosozumab every 2 weeks (Q2W), or 3 doses of 3 mg/kg romosozumab every 4 weeks (Q4W) were evaluated in healthy men or postmenopausal women with low bone mass, and 3 doses of 2 mg/kg romosozumab Q4W or 6 doses of 2 mg/kg romosozumab Q2W were evaluated in healthy postmenopausal women with low bone mass. A total of 36 subjects received romosozumab, and 12 subjects received placebo. EKG evaluations included assessments for all 48 subjects. No subject had a maximum post dose Fridericia's corrected QTc (QTcF) or Bazett's corrected QTc (QTcB) value &gt; 480 msec or a maximum change in QTcF or QTcB (compared to baseline) that was &gt; 60 msec. Maximum QTcF and QTcB changes from baseline of &gt; 30 to 60 msec were observed for 7 of 36 subjects (19%) and 7 of 36 subjects (19%), respectively, who received romosozumab and 2 of 12 subjects (17%) and 1 of 12 subjects (8%), respectively, who received placebo. No patterns or trends in ECGs occurred that were considered to be clinically relevant.</p><p>In the phase 1b Study 20060223, postmenopausal women with low bone mass who had been receiving alendronate (70 mg QW) for at least 1 year were randomized to continue receiving alendronate (group A, n = 10) or discontinue alendronate and receive a single 3 mg/kg SC dose of romosozumab (group B, n = 24). In addition, a group of treatment-nave subjects received a single 3 mg/kg SC dose of romosozumab (group C, n = 6). No subject had a maximum post dose QTcF or QTcB value &gt; 480 msec. Maximum QTcF and QTcB changes from baseline of &gt; 60 msec were observed for no subjects and 1 of 10 subjects (10%), respectively, in group A; 1 of 24 subjects (4%) and 1 of 24 subjects (4%), respectively, in group B; and 1 of 6 subjects (17%) and 1 of 6 subjects (17%), respectively, in group C. Maximum QTcF and QTcB changes from baseline of &gt; 30 to 60 msec were observed for 3 of 10 subjects (30%) and 4 of 10 subjects (40%), respectively, in group A; 4 of 24 subjects (17%) and 7 of 24 subjects (29%), respectively, in group B; and 1 of 6 subjects (17%) and 1 of 6 subjects (17%), respectively, in group C. No patterns or trends in ECGs occurred that were considered to be clinically relevant. In the phase 1b Study 20090153, SC administration of 3 doses of 3 mg/kg romosozumab or placebo Q4W was evaluated in 24 healthy postmenopausal women with low bone mass. A total of 12 subjects received romosozumab and 12 subjects received placebo. Electrocardiogram evaluations included assessments for all 24 subjects. No subject had a maximum post dose QTcF or QTcB value &gt; 480 msec or a maximum QTcF or QTcB change from baseline of &gt; 30 msec. No patterns or trends in ECGs occurred that were considered to be clinically relevant.</p><p>In the phase 1 Study 20090378, SC administration of single doses of 1, 3, and 5 mg/kg romosozumab or placebo were evaluated in healthy postmenopausal Japanese and non-Japanese women. A total of 22 subjects received romosozumab, and 8 subjects received placebo. Electrocardiogram evaluations included assessments for all 30 subjects. No subject had a maximum post dose QTcF or QTcB value &gt; 480 msec or maximum QTcF or QTcB changes from baseline of &gt; 30 msec. No patterns or trends in ECGs occurred that were considered to be clinically relevant.</p><p>The phase 2a Study 20060326 evaluated the safety and efficacy of multiple doses and frequencies of romosozumab monotherapy for postmenopausal osteoporosis (data from the 12-month primary analysis). A total of 255 subjects were treated with romosozumab in this study. No subject had a QTcF &gt; 500 msec. Three subjects in the romosozumab groups (1 subject in the 210 mg QM group and 2 subjects in the 70 mg QM group) had QTcB &gt; 500 msec. None of these subjects had adverse events of cardiac arrhythmia, hypocalcemia, hypokalemia, or hypomagnesia, and all of these subjects had a cardiac history that could potentially account for these findings.</p><p>One subject in the 210 mg QM group had a QTcB of 509 msec at month 9. This subject had a screening QTcB of 491 msec; day 1 QTc of 478 msec, 463 msec, and 363 msec; month 1 QTc of 468 msec; month 3 QTc of 485 msec; and month 12 QTc of 479 msec. Month 9 QTcB and QTcF changes from baseline were &gt; 60 msec (74 msec and 64 msec, respectively) and decreased at month 12 <ref type="bibr">(44 msec and 46 msec, respectively)</ref>. The subject's medical history included hypertension and asthma, and no on-study cardiac adverse events were reported. One subject in the 70 mg QM group had a QTcB at month 12 of 506 msec. This subject had a screening QTc of 422 msec; day 1 QTc of 436 msec, 441 msec, and 460 msec; month 1 QTc of 413 msec; month 3 QTc of 445 msec; and month 9 QTc of 486 msec. Month 12 QTcB was 60 msec above baseline, and QTcF was 47 msec above baseline. The subject had a medical history of cardiac discomfort and had adverse events of aortic stenosis and hypercholesterolemia on study day 49 and hypertension on study day 268. One subject in the 70 mg QM group had a QTcB of 504 msec at month 12. This subject had a day concomitant medications that could be associated with QT prolongation included fluoxetine (started prior to study entry in 2004) and azithromycin (study days 51 to 55 for an adverse event of bronchitis, study days 331 to 335 for and adverse event of upper respiratory tract infection).</p><p>Changes from baseline in QTcB and QTcF &gt; 60 msec occurred in 4 subjects in the romosozumab groups: 3 subjects in the 210 mg QM group and 1 subject in the 210 mg Q3M group. One subject in the 210 mg QM group had 2 ECGs done at month 1 that showed different QTc changes from baseline. One ECG for this subject showed changes from baseline in QTcB and QTcF of &lt; 60 msec (31 msec for each), and the other ECG showed changes from baseline in QTcB and QTcF of &gt; 60 msec (68 msec and 67 msec, respectively). Except for the subject in the 210 mg QM group described above who had a month 9 ECG with QTc &gt; 500 msec and a change from baseline QTc &gt; 60 msec, all other subjects did not have corresponding changes in QTc intervals &gt; 500 msec. No associated cardiac events were reported. <ref type="figure" target="#fig_0">&gt; 60 msec (74 msec and 64  msec, respectively) and decreased at month 12 (44 msec and 46 msec, respectively)</ref></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: In phase 1 and 2 romosozumab studies, no EKG change patterns could be identified. In the small number of patients who had QT abnormalities, their clinical course was confounded by concurrent medications which are known to prolong QT or past medical history with baseline high QT.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The one subject in phase 2a Study 20060326 who had month 9 QTC &gt; 500 and change from baseline QTc&gt; 60 msec had a high screening QTcB of 491 msec day 1 QTc of 478 msec, 463 msec, and 363 msec; month 1 QTc of 468 msec; month 3 QTc of 485 msec; and month 12 QTc of 479 msec. Month 9 QTcB and QTcF changes from baseline were</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>. Her past medical history included asthma and hypertension which could have contributed to her high baseline QTc values. She had no on-study cardiac event.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>No on-study cardiac changes could be attributed to romosozumab use. These studies support that romosozumab does not induce EKG changes.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunogenicity</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>8.3.12.</head><p>The pharmacokinetic exposure, safety (eg, hypersensitivity, injection site reactions, or autoimmune disorder), and efficacy (changes in BMD) profiles of the subjects who tested positive for binding ADA were found to be consistent with the profiles of ADA negative Subjects. In the phase 2 and phase 3 studies included in this marketing application, the incidence of ADA was approximately 20% (852 of 4289), and the incidence of neutralizing antibodies was 1.1% <ref type="bibr">(46 of 4289)</ref>. The earliest onset of ADA was 3 months after first dose of romosozumab. ADA appears to have an effect on pharmacokinetics with a moderate decrease in exposure (up to 25% in mean values) observed during months 3 and 9 in subjects with binding ADA and a larger decrease for subjects with neutralizing ADA. The exposures were For the 12-month placebo-controlled population, 17.8% (656 of 3689) of subjects in the romosozumab group were positive at any time for binding ADA, and 0.2% (6 of 3689) were positive at any time for neutralizing ADA. The following table 43 shows the number and percentages of subjects who had binding and/or neutralizing antibodies at baseline and at any time during each placebo-controlled study.  <ref type="figure" target="#fig_2">8% (656 of 3689) of subjects in the romosozumab group were  positive at any time for binding ADA, and 0.2% (6 of 3689)</ref> were positive at any time for neutralizing ADA <ref type="figure" target="#fig_2">. Although subjects were romosozumab nave upon entrance to the pivotal  study 20070337, the assay identified 22 (0.6%)</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>patients with pre-existing antibody positive at baseline. This assay positive identification is dependent on the cut-point of the assay and this low level of positive assay at baseline is acceptable.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacokinetics values decreased by approximately 25% for subjects who turned positive for ADA in-study. There are no safety concerns for this decrease in exposure for patients who turn ADA positive. Only 6 (0.2%) of patients developed neutralizing antibodies and this low percentage of patients developing neutralizing antibodies is not a safety concern.</head><p>Binding and neutralizing antibody status was assessed in relationship to hypersensitivity, injection site reactions, and autoimmune disorders. Adverse events potentially related to hypersensitivity and autoimmune disorders were generally similar for subjects who received romosozumab, regardless of binding or neutralizing ADA status, as well as for subjects who received placebo. Injection site reaction adverse events were reported more frequently in the romosozumab group, regardless of ADA status, than in the placebo group. The following two tables <ref type="table" target="#tab_6">(Table 44 and Table 45</ref>) show the incidences of injection site reactions, hypersensitivity and autoimmune disorders by ADA status <ref type="table" target="#tab_6">(Table 44</ref> -binding antibody status, <ref type="table" target="#tab_6">Table 45</ref>-neutralizing antibody status) through month 15 for subjects treated with romosozumab 210 mg QM or placebo. The collections of search terms used to identify adverse events potentially related to hypersensitivity were based on standardized MedDRA queries (SMQs).    <ref type="figure" target="#fig_7">does not appear to affect hypersensitivity or autoimmune disorders. Injection site reactions  are higher (7%) in romosozumab treated patients regardless of ADA status but maybe more  reflective of the specific drug product and application procedure, using two syringes per dose.</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewers Comments: For patients who develop AEs, the rates for hypersensitivity and autoimmune disorders is balanced between patients who develop either binding ADA or neutralizing ADA when compared to placebo patients who do not develop antibodies.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Injection site reaction is higher for patients on romosozumab regardless of ADA status when compared to placebo patients (7% romosozumab versus 3% placebo patients). ADA status</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BMD gains and BTMs were not affected by binding or neutralizing ADA status as discussed in section 4.5, Clinical Pharmacology.</head><p>ADA Status During Re-treatment: Study 20060326 evaluated ADA status during romosozumab re-treatment. During the 12-month romosozumab retreatment period (months 36 to 48) of, 2 of 139 subjects (1.4%) developed positive binding ADA during the retreatment phase having been previously ADA negative. Eight subjects were binding ADA positive at their month 36 visit, of which 5 were positive during retreatment. Two subjects were neutralizing ADA positive at month 36, of whom 1 remained positive during retreatment. No subject developed positive neutralizing ADA during the retreatment phase having been previously antibody negative. The frequency of overall adverse events by antibody status was comparable between antibody positive and antibody negative subjects (73.7% and 84.8%, respectively). <ref type="figure" target="#fig_0">(1.4%)</ref> than the initial exposure. Importantly, no patient develop neutralizing ADA who were previously antibody negative. Furthermore, of the two subjects who had developed neutralizing ADA, one lost her neutralizing ADA status. <ref type="figure" target="#fig_3">Pharm review, section 4.4.2)</ref>:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewers Comments: In totality, this data supports the safety of re-treatment in this patient population but there is evidence that neutralizing ADA patients can have rapid declines of romosozumab levels to immeasurable levels on re-treatment. Study 20060326 demonstrated that ADA status can convert to a positive status upon re-treatment but at much lower rates</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In reviewing the antibody data, one patient who developed neutralizing ADAs on first exposure was found to have inadvertently been re-dosed and developed immeasurable levels of romosozumab. The case was as follows (from Clin</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>"one of the neutralizing antibody positive subjects (Subject ) from Phase 1 study 20060220 was inadvertently enrolled and dosed in a subsequent ascending multi-dose pharmacology/pharmacodynamic study 20060221. A rapid decline in romosozumab serum concentrations was observed in this subject after the first dose in study 20060221, and serum concentrations were not measurable after day 6, despite continued dosing once every two weeks. unexpected case provides evidence that neutralizing ADA positive patients can have much reduced concentrations of romosozumab on re-exposure. "</head><p>Reference ID: 4093382 (b) <ref type="bibr" target="#b88">(6)</ref>  All monoclonal antibodies could potentially be associated with hypersensitivity reactions. In the 12-month placebo-controlled population, adverse events potentially related to hypersensitivity based on the standardized MedDRA queries (SMQs) search strategy, were reported for 6.7% of subjects in the romosozumab treatment group and 6.9% of subjects in the placebo group; serious adverse events were reported for 0.2% (all in Study 20070337). The following <ref type="table" target="#tab_6">Table 46</ref> summarizes the numbers and percentages of AEs and SAEs potentially related to hypersensitivity in the placebo-controlled trials. The following are summary narratives of these SAEs all from the pivotal study 20070337 potentially related to hypersensitivity with romosozumab: 1) Subject had a fatal event of circulatory collapse on study day 365. This 78-year-old subject with a medical history of tobacco use developed unspecified cardiovascular disease and was hospitalized on study day 345, 8 days after receiving her twelfth dose of romosozumab. She was hospitalized in the ICU and died from cardiovascular collapse on day 365. The patient had negative antibody status (ADA negative) and negative neutralizing ADA status during the study. 2) subject had dyspnea, cough, and wheezing approximately 24 hours after receiving the first dose of romosozumab. This 74-year-old with a relevant medical history of allergic respiratory disease, allergies to Rulide (roxithromycin) and codeine, aspergillosis, asthma, bronchiectasis, gastroesophageal reflux disease, hypercholesterolemia, osteoporosis, and nephrolithiasis (all of which were ongoing at baseline) had dyspnea, cough, and wheezing approximately 24 hours after receiving the first dose of romosozumab. Two days later (day 3), she presented to the general practitioner with a rash on her chest and back. A serious, grade 4 adverse event of acute allergic reaction with unknown etiology (on chest and back) was reported. The rash resolved after treatment with hydrocortisone, and the subject was sent home with prednisolone. The event was reported as resolved on day 7. The investigator was unaware of exposure to any other antigens, and investigational product was withdrawn. The patient subsequently tested positive for antibodies (ADA positive) for months 3, 6, and 12 after the first dose but tested negative at month 15 after the first dose. Neutralizing antibody status remained negative.</p><p>3) Subject with SAE dermatitis. A 64-year-old with a medical history of COPD and eczema had grade 3 adverse events of eczema 9 days after first dose and was hospitalized for a serious adverse event of dermatitis on study day 166; the subject received intravenous steroids and intravenous antihistamines, and the dermatitis resolved. The subject tested positive for ADA status months <ref type="bibr">6, 12, 15, and 24</ref> and was neutralizing antibody negative. 4) Subject with SAE dermatitis allergic A 65-year-old with a medical history of allergic rhinitis and a milk allergy had nonserious adverse events of skin tingling for 2 days after the first 3 doses of romosozumab. Approximately 3 weeks after the fifth dose, the subject developed facial edema and generalized rash. The subject was hospitalized with a serious adverse event of dermatitis allergic and received intravenous corticosteroids and topical steroids, intravenous fluids, and oral antihistamine. Study drug was discontinued; the event resolved. The patient remained ADA and neutralizing ADA status negative.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>5) Subject 4 SAEs of dermatitis exfoliative, angioedema, rash macular</head><p>Reference ID: 4093382 A 75-year-old with a medical history of childhood asthma developed nausea, ill being, chills, and burning sternal pressure 8 hours after the initial romosozumab dose. On study day 3, a serious adverse event of macular rash on trunk was reported and a skin biopsy revealed "unspecific superficial dermatitis with urticarial components, drug reaction cannot be excluded." Study drug was withdrawn, and the event resolved on study day 10. On study day 28, the subject was hospitalized with a serious adverse event of dermatitis exfoliative and angioedema. A skin biopsy showed discrete superficial perivascular dermatitis. The subject was treated with topical steroids and creams, and the events resolved on study day 31. On study day 135, the subject was hospitalized for a macular rash and treated with topical steroid creams and oral antihistamines; the event resolved on study day 148. The patient was reported to be ADA negative at months 12, 15, and 24. <ref type="figure" target="#fig_0">are concerning for hypersensitivity in some patients. For example, patient  developed an acute reaction with dyspnea, wheezing, and coughing within 24  hours after the first dose which is concerning for an hypersensitivity reaction to  romosozumab. She subsequently turned ADA positive at month 3 through month 12 before  turning negative by month 15.</ref> </p><formula xml:id="formula_21">(b) (6) (b) (6) (b) (6) (b) (6) (b) (6)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewers Comments: Analysis of the narratives for the SAEs in the romosozumab group for the pivotal study 20070337 is concerning for hypersensitivity in some patients with romosozumab use. Regardless of investigator determination of drug-related reaction or not, these SAEs</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For patient , she had a difficult course after receiving only one dose but developed repeated episodes of macular rash and an episode of dermatitis exfoliative and angioedema which required hospitalization. She tested ADA negative. It is unclear if patient who had a fatal coronary SAE was a hypersensitivity reaction as she developed cardiovascular event 8 days after her 12 th dose of romosozumab. She was negative for ADA during the course of her treatment.</head><p>In summary, there is concern for hypersensitivity reactions with romosozumab use in some patients based on the data and narratives from the pivotal study. This concern should be included in the med guide and in labeling.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AEs:</head><p>For adverse events (AEs), the only preferred term reported for  1.0% of subjects in either treatment group was rash (1.1%, 0.9%). The incidence of recurrent adverse events potentially related to hypersensitivity was 0.6% and 0.5%, respectively. The incidence of adverse events potentially related to hypersensitivity leading to discontinuation of investigational product was 0.3% and 0.2%, respectively. The incidence of adverse events potentially related to hypersensitivity leading to discontinuation from study participation was &lt; 0.1% in both groups. Adverse events potentially related to hypersensitivity occurred within  2 days after <ref type="bibr" target="#b88">(6)</ref> Clinical Review Debuene Chang MD BLA 761062 Evenity (Proposed) -romosozumab CDER Clinical Review Template 2015 Edition 148 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews) administration of investigational product for 1.3% and 0.9%, respectively, and within &gt; 2 to  7 days after administration of investigational product for 1.5% and 1.0%, respectively. Adverse events potentially related to hypersensitivity that were reported at a slightly greater rate in the romosozumab group than the placebo group included injection site rash (0.3%, &lt; 0.1%), generalized rash (0.1%, 0.0%), erythematous rash (0.1%, &lt; 0.1%), macular rash (0.1%, 0.0%), and injection site urticaria (&lt; 0.1%, 0.0%).</p><formula xml:id="formula_22">Reference ID: 4093382 (b) (6) (b) (6) (b)</formula><p>Erythema multiforme (&lt; 0.1%, 0%) developed in 1 subject 1 day after receiving romosozumab. Adverse events of face edema (0.1%, 0.1%), eyelid edema (0.1%, &lt; 0.1%), and allergic edema (&lt; 0.1%, &lt; 0.1%) were generally similar between the romosozumab and placebo groups. Although adverse events of urticaria (0.5%, 0.6%), bronchospasm (&lt; 0.1%, &lt; 0.1%), and angioedema (&lt; 0.1%, &lt; 0.1%) were reported at a slightly greater rate in the placebo group than the romosozumab group, case level details indicated potential causal relationship due to romosozumab with a lack of other confounder for urticarial and angioedema. The subject incidences with percentages of hypersensitivity events that are considered to have a causal association to romosozumab are shown below in <ref type="table" target="#tab_6">Table 48</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>.1 with reviewer edits</head><p>Adverse events potentially related to hypersensitivity that were reported  2 days after administration of investigational product and at a greater rate in the romosozumab group included injection site rash (0.3%, &lt; 0.1%), rash (0.2%, 0.1%), and injection site hypersensitivity (0.1%, &lt; 0.1%). Adverse events potentially related to hypersensitivity that were reported  2</p><p>Reference ID: 4093382 (b) <ref type="bibr" target="#b88">(6)</ref> Clinical Review Debuene Chang MD BLA 761062 Evenity (Proposed) -romosozumab CDER Clinical Review Template 2015 Edition 149 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews) days after administration of investigational product and only in the romosozumab group included injection site urticaria, dermatitis, acneiform dermatitis, erythema multiforme, eyelid edema, face edema, gingival swelling, hypersensitivity, injection site dermatitis, lip swelling, generalized rash, and face swelling (all &lt; 0.1%, 0.0%). Adverse events potentially related to hypersensitivity that were reported &gt; 2 to  7 days after administration of investigational product and only in the romosozumab group included eczema (0.2%, 0.0%); and erythematous rash, macular rash, face edema, injection site rash, generalized rash, application site dermatitis, drug eruption, hypersensitivity, face swelling, and swollen tongue (all &lt; 0.1%, 0.0%). Results for the PMO population were generally similar to the 12-month placebo-controlled population.</p><p>Reviewer Comments: Review of the data confirms the concern for hypersensitivity in some patients with romosozumab. In addition to the concern with SAEs present only in romosozumab patients in the pivotal study (discussed earlier), the subject incidence for AEs for <ref type="figure" target="#fig_0">injection site urticaria, dermatitis, acneiform dermatitis, erythema multiforme, eyelid  edema, face edema, gingival swelling, hypersensitivity, injection site dermatitis, lip swelling,  generalized rash, and face swelling (all &lt; 0.1%, 0.0%) was only found in romosozumab  patients  2 days after dosing. For AEs reported &gt; 2 to  7 days after drug, the following  incidences were only found in romosozumab patients: eczema (0.2%, 0.0%); erythematous  rash, macular rash, face edema, injection site rash, generalized rash, application site  dermatitis, drug eruption, hypersensitivity, face swelling, and swollen tongue (all &lt; 0.1%,  0.0%)</ref>. One subject developed an AE of erythema multiforme in the romosozumab group and no subject in the placebo group. Together this data reinforces the concern for hypersensitivity reaction for some patients with romosozumab and this concern should be reflected in the med guide and labeling.</p><p>In Study 20070337, potential anaphylactic events were identified using the 2012 World Allergy Organization Guidelines and used to further assess the anaphylactic reactions using the Anaphylaxis Reaction SMQ algorithm. The subject incidence of potential anaphylactic reactions was generally similar between both treatment groups and both study periods. The majority of subjects had confounding factors that could potentially explain their adverse events. Based on review of the cases, no anaphylactic reactions associated with romosozumab use were reported.</p><p>Adverse events potentially related to hypersensitivity were generally similar regardless of ADA status and was discussed in section 8.3.8 above. In the 12-month placebo-controlled population, adverse events of injection site reactions were reported for 5.2% of subjects in the romosozumab group and 2.9% of subjects in the placebo group; no serious adverse events of injection site reactions were reported. <ref type="table" target="#tab_6">Table 49</ref> below summarizes these findings for AEs of injection site reaction in the placebo-controlled studies. Preferred terms reported for  1% of subjects in either treatment group were injection site pain (1.7%, 1.2%) and injection site erythema (1.4%, 0.2%). Most adverse events of injection site reactions were mild or moderate; the only severe events reported were injection site pain (1 each romosozumab and placebo). The incidence of adverse events of injection site reactions leading to discontinuation of investigational product was 0.1% and &lt; 0.1, respectively. The subject rate of adverse events of injection site reactions leading to study discontinuations was &lt;0.1% for romosozumab and placebo treatment groups. The median time to onset of the first injection site reaction adverse event was 91.0 days for romosozumab and 62.0 days for placebo. The median duration of injection site reaction adverse events was 3.0 days for romosozumab and 6.0 days for placebo. The incidence of concurrent injection site reactions (ie, &gt; 1 type of injection site reaction on the same investigational product administration date with overlapping start and resolution dates) was 1.0% and 0.1%, respectively; the incidence of recurrent injection site reactions (ie, &gt; 1 injection site reaction on 2 or more different investigational product administration dates) was 1.6% and 0.4%.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: There is no data to support anaphylaxis in the pivotal study, 20070337. AEs do not appear to be related to ADA status in patients.</head><p>Injection site reaction adverse events were reported more frequently in the romosozumab group, regardless of ADA status, than in the placebo group.</p><p>Drug product composition consisted of , The placebo is the same except for romosozumab. <ref type="figure" target="#fig_0">: Patients injected 3 separate injections of 1 cc injections for each dose  which could account for the relatively high number of injection site AEs for both placebo and  romosozumab but there were no SAEs reported for either group. All excipients in the drug  product formulation are standard components, thus the relatively high rate of</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>injection site AEs in both groups might be related to 3 injections for each dose during the study.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The rates of injection site reactions for romosozumab patients is mildly inbalanced in favor of romosozumab when compared to placebo. On the other hand, mean time for the appearance of injection site reaction AE s was longer for romosozumab compared to placebo (91 days versus 62 days) and shorter in duration (3 days versus 6 days). Most injection site reactions were low grade AE. Given these findings, there is no concern for excessive injection site reactions with romosozumab but there is evidence of mild reactions at the injection site to romosozumab. There is evidence that injection site reactions might be due to the number (3) injections required per dose. In the final commercial product, each dose will consist of two injections which will be expected to decrease injection site reactions.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Malignancy (Malignant or Unspecified Tumor) 8.4.3.</head><p>Although sclerostin expression has been reported in a limited number of soft tissue and bone tumors, there is no current evidence that the presence or absence of sclerostin is related to malignant potential. There are no reports of an increased cancer incidence in patients with sclerosteosis or van Buchem disease. In the 12-month placebo-controlled population, adverse events of malignant or unspecified tumors were reported for 1.7% of subjects in the romosozumab treatment group and 1.9% of subjects in the placebo group; serious adverse events were reported for 1.1% and 1.2%, respectively. Preferred terms reported for  0.2% of subjects in either treatment group were basal cell carcinoma (0.2%, 0.5%) and thyroid neoplasm (0.2%, 0.3%).  Non-Hodgkin's lymphoma was reported for 2 romosozumab subjects dosed at 210 mg QM and 1 placebo subject (both treatment groups &lt; 0.1 events per 100 subject-years) of which 1 in each treatment group was serious . Events reported under the high-level group term of leukemias were reported for 2 romosozumab subjects dosed at 210 mg QM (1 each acute lymphocytic leukemia and myeloid leukemia) and 1 placebo subject (chronic lymphocytic leukemia) (both treatment groups &lt; 0.1 per 100 subject-years) of which both events in the romosozumab group were serious.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Recent comments by Koda et al (Nature 2014; 506(7487):240-244) raise concerns that genetic alteration of osteoblasts in the bone marrow microenvironment can induce an aggressive AML in clinical studies as was seen in mice studies where transplanted bone marrow cells from Ctnnb1CAosb leukaemic mice into lethally irradiated wild-type recipients induced all features of haematopoietic dysfunction and AML and early lethality. The clinical studies did not support an increased rate of AML or other hematopoietic malignancies for romosozumab.</head><p>Malignant lung neoplasm with fatal outcome was reported for 4 romosozumab subjects dosed at 210 mg QM and discussed under section 8.3.3 deaths. Pancoast's tumor was reported on study day 254 for 1 romosozumab subject who was dosed at 210 mg QM. The subject was a former smoker and had a history of asthma, chronic obstructive pulmonary disease, and lung abscess.  <ref type="figure" target="#fig_2">does not appear to be a clear signal for malignancy with  romosozumab. As discussed in section 8.3.3, the inbalance of fatal lung carcinoma in the  romosozumab group, (4 romo, 0 placebo) is tempered by a balanced incidence of lung  neoplasms between romosozumab and placebo groups (5, 5). Although the small numbers of  lung neoplasm found in the study limits our ability to interpret the inbalance for fatalities  between groups, the total incidence of lung neoplasm in each group is consist with what is  expected for this patient population with a smoking</ref>  Hyperostosis with adverse neurological consequences is a feature of sclerosteosis and van Buchem disease. It is not a feature of individuals heterozygous for the respective mutations. In the 12-month placebo-controlled population, adverse events of hyperostosis were reported for 0.5% of subjects in the romosozumab treatment group and 0.8% of subjects in the placebo group; serious adverse events in this category were reported for &lt; 0.1% and 0.1%, respectively. Adverse event preferred terms for hyperostosis were similar between treatment groups, as were events under the high level group terms of spinal cord and nerve root disorders, cranial nerve disorders, and hearing disorders. The following <ref type="table" target="#tab_7">Table 51</ref> summarizes AE and SAE rates related to hyperostosis in the placebo-controlled studies.    <ref type="table" target="#tab_6">Table 14</ref> <ref type="bibr">-6.8.6. with</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>reviewer edits</head><p>A potential consequence of hyperostosis is nerve compression which may include facial drooping, numbness, or changes in hearing or vision. Study 20070337 included an audiology substudy of 498 subjects to assess the effect of romosozumab treatment for 12 months compared with placebo on the incidence of hearing loss (defined as subjects meeting the American Speech-Language-Hearing Association criteria for ototoxicity), and mean change from baseline in hearing threshold (assessed as change from baseline in pure tone average; defined as <ref type="bibr">[1]</ref> loss of  20 dB at any single frequency or <ref type="bibr" target="#b84">[2]</ref> loss of  10 dB at any 2 adjacent frequencies or <ref type="bibr">[3]</ref> loss of response at 3 consecutive frequencies where responses were previously obtained). The subject incidence of hearing loss at baseline was similar between romosozumab and placebo groups, and no significant difference in average change in hearing threshold was observed between the romosozumab and placebo groups at month 12 as assessed by the mean change from baseline in pure tone average.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Auditory substudy demonstrated no significant difference in changes of auditory hearing between study groups. Fewer patients presented with AEs consistent with hyperostosis when compared to placebo patients. Thus, the AE data from the clinical studies did not support hyperostosis with romosozumab use.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TNF-mediated Inflammatory Conditions 8.4.5.</head><p>For the 12-month placebo-controlled population, the subject incidence of treatment-emergent TNF-mediated inflammatory adverse events was 0.2% in the romosozumab group and 0.4% the placebo group. No subject in the romosozumab group had a treatment-emergent adverse event of rheumatoid arthritis. The subject incidence rate was also lower in the romosozumab group than placebo group independent of a prior history of a TNF-mediated inflammatory disease   for initial rollout (NME/original BLA reviews) (prior history of TNF-mediated inflammatory disease; no prior history of TNF-mediated inflammatory disease).</p><p>The following two tables summarize TNF mediated inflammatory AEs by preferred term for patients with prior history of TNF mediated inflammatory disease <ref type="table" target="#tab_5">(Table 53</ref>) and without a prior history of TNF mediated inflammatory disease <ref type="table" target="#tab_6">(Table 54</ref>).  In addition, the following 2 events of palindromic rheumatism reported in subjects dosed with romosozumab are not included in the TNF-mediated search strategy: 1 subject in phase 1 study 20150197 had a serious adverse event of palindromic rheumatism reported on study day 10; and 1 subject in study 20070337 with a medical history of palindromic rheumatism had a non-serious adverse event of worsening palindromic rheumatism on study days 76 to 128. <ref type="figure">TNF mediated AE rates for romosozumab group are lower than for  placebo regardless of prior history of TNF mediated inflammatory disease. In addition, no  romosozumab patient develop rheumatoid arthritis. The data supports the use of  romosozumab in the targeted patient population regardless of prior history</ref>  Study 20070337 included an osteoarthritis substudy of 343 subjects to assess the effect of romosozumab compared with placebo at month 12 on the progression of osteoarthritis of the knee (defined as an increase in total Western Ontario and McMaster Universities Arthritis Index [WOMAC] score of at least 10 points on a scale normalized to 100 points). Additional assessments included change from baseline in WOMAC subscale scores for pain and physical function, patient global assessment of change from baseline measured by the EuroQoL-5 Dimensions-5 Levels Health Survey (EQ-5D-5L VAS), and adverse events of osteoarthritis utilizing the events of interest search strategy through month 12.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The</head><p>No significant progression of osteoarthritis of the knee was observed for subjects in the romosozumab group compared with the placebo group at month 12, as assessed by the change from baseline in the WOMAC total and subscale scores. The subject incidence of worsening knee osteoarthritis (defined as &gt; 10-point increase in WOMAC total score) was also similar between the romosozumab and placebo groups at month 12. For subjects' self-assessment of health status via the EQ-5D-5L VAS, the romosozumab group had a mean increase of 2.09 units from baseline, and the placebo group had a mean increase of 1.10 units, with a higher score indicating better overall health.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The osteoarthritis WOMAC results showed similarities between the two study groups in the pivotal study and indicates no increase in osteoarthritis with romosozumab. In addition, the EQ-5D-5L VAS results actually showed romosozumab patients reported better overall health than placebo patients. There are no concerns for osteoarthritis from romosozumab in this patient population based on these results.</head><p>Safety Analyses by Demographic Subgroups 8.4.7.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Age</head><p>The patient population was analyzed by age groups to determine if there are AE differences by age. Overall, results of the subgroup analysis do not indicate an altered safety profile of romosozumab by age subgroup. The overall subject incidence of adverse events was similar across age subgroups and between the romosozumab and placebo treatment groups. Of adverse events that were reported more frequently for romosozumab in an older age subgroup, incidences in the placebo subgroup for that age were also higher.</p><p>The following table 55 summarizes the most frequently reported AEs, stratified by age group in the placebo-controlled clinical studies. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Analysis of the commonly presented AEs demonstrated no significant differences between age groups when comparing romosozumab and placebo groups.</head><p>Based on this data, there is minimal concern for AE differences by age in this patient population.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Race</head><p>Analysis of adverse events by race (white, non-white) using the 12-month placebo-controlled population was performed to determine if there are differences in AE rates based on race for romosozumab. Overall, results of the subgroup analysis do not indicate an altered safety profile of romosozumab by race subgroup. The overall subject incidence of adverse events was similar across race subgroups and between the romosozumab and placebo treatment groups. Individual adverse event preferred terms were generally reported more frequently in the nonwhite subgroup for both romosozumab and placebo groups. The following table 56 summarizes the sub analysis for AE differences between romosozumab and placebo by race and preferred term in the placebo controlled studies:   <ref type="figure" target="#fig_5">groups which were balanced. The pivotal study had a great portion (97.5%)</ref> of the study completed outside the US and it is possible practice differences affect the rate of AEs reported in these other countries. Because the numbers are balanced between romosozumab and placebo groups, there is no concern for racial differences with romosozumab in this patient population.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: AEs by race appears well balanced between romosozumab and placebo groups. Interestingly, non-whites had higher rates of AEs in both placebo and romosozumab</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Body Mass Index</head><p>A sub analysis was conducted to determine if different weight affected AE rates with romosozumab. The overall subject incidence of adverse events was similar across BMI subgroups and between the romosozumab and placebo treatment groups. Cataract was reported more frequently in subjects with lower BMI in both the romosozumab and placebo groups (22.5 kg/m2: 2.3% romosozumab, 1.6% placebo; &gt; 22.5 to  26 kg/m2: 2.0%, 1.1%; &gt; 26 kg/m2: 1.6%, 1.7%). Peripheral edema was reported more frequently in subjects with higher BMI in both the romosozumab and placebo groups ( 22.5 kg/m2: 1.4% romosozumab, 1.2% placebo; &gt; 22.5 to 26 kg/m2: 2.0%, 2.2%; &gt; 26 kg/m2: 3.5%, 2.2%). The following table 57 summarizes AEs by BMI tertile using preferred terms in the placebo controlled clinical studies.   <ref type="table" target="#tab_6">Table 14</ref> <ref type="bibr">-6.3.5</ref>. with reviewer edits. <ref type="figure" target="#fig_0">the low weight group ( 22.5 BMI) favoring romosozumab versus placebo (2.3%, 1.6%) and  inbalance for peripheral edema in the high weight group (&gt;26 BMI) favoring romosozumab  versus placebo (3.5%, 2.2%)</ref>. The overall incidences of these AE are low and the small differences could be within the realm of chance findings. Thus, the risks for these AEs with romosozumab is acceptable. There is minimal concern that weight is a risk factor for romosozumab based on this data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Overall the AE rates appear balanced between placebo and romosozumab groups at the different weight groups. There is a slight inbalance of cataract in</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Geographic Region</head><p>97.5% of the pivotal study was conducted outside the US. A sub analysis was conducted to determine if geographical regional differences affected AEs and romosozumab use. A subgroup analysis of adverse events by geographic region (Western Europe and Australia/ New Zealand, Central and Eastern Europe, Asia Pacific, North America, and Central/Latin America) using the 12-month placebo-controlled population was performed. Subjects in Western Europe and Australia/New Zealand had the highest incidence of adverse events (87.6% romosozumab, 89.0% placebo), followed by North America (84.8%, 81.1%), Asia Pacific (83.9%, 80.2%), Central/Latin America (76.2%, 77.6%), and Central and Eastern Europe (73.9%, 77.6%). Numeric differences were noted across regions in the incidence of certain adverse events. However, no consistent pattern of numeric differences for romosozumab was apparent across regions. Despite regional differences in the incidence of individual adverse events, the incidence of individual adverse events was similar between treatment groups within a region ( 5% difference for nearly all adverse events and regions). The following table 58 summarizes AEs by geographic regions overall and using the preferred term in the most commonly reported AEs in the placebo-controlled study populations.  <ref type="figure" target="#fig_0">America which had more subjects had a comparable AE rate between romosozumab and  placebo of 143 patients (9 %) vs 131 patients (9 %)</ref>. <ref type="figure" target="#fig_38">individual region lessen concerns about regional differences. On the other hand, &gt; 90 % of  subjects were recruited from outside the US, and differences within regions for individual  preferred terms such as noted in the example above for</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Overall reporting of AEs appear balanced between romosozumab and placebo groups but the rate of reporting differs among individual regions and individual preferred term AE. Although the Sponsor indicated that individual regional differences that were 5% or greater when comparing romosozumab group to placebo were affected by low number of subjects with the particular AE, that may not be the case. For instance, looking at nasopharyngitis in Western Europe/New Zealand/ Australia and Asia Pacific, there is an inbalance of AEs for nasopharyngitis between romosozumab and placebo (91 patients(18 %) vs 68 patients (13 %)) and (96 patients (20 %) vs 75 patients (16 %) ) respectively. Yet, Central</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>This reviewer agrees with the Sponsor in that other findings such as for hypersensitivity had such low numbers for each individual AE term. Table 59 below summarizes the AEs for hypersensitivity and it is difficult to interpret the differences because of the infrequency of reports.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The overall balance of AEs reported between romosozumab and placebo groups in each</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>concerns about different practices, reporting, and procedures in these countries as they relate to the US population.</head><p>The following <ref type="table" target="#tab_7">Table 59</ref> summarizes AE by geographic regions for the preferred term for hypersensitivity in the placebo controlled study populations. Monoclonal antibodies are not eliminated via hepatic metabolic mechanisms; therefore, no studies have been conducted in subjects with hepatic impairment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Because romosozumab is not eliminated through the hepatic pathway, it is acceptable for the Sponsor not to have conducted clinical studies in patients with hepatic impairment for this application.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subjects Transitioned from Bisphosphonate Therapy 8.5.2.</head><p>The Sponsor studied patients who transitioned from bisphosphonate therapy in two studies, study 20090289 and study 20060223, to understand safety and efficacy parameters in this patient population.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20080289</head><p>Study 20080289 was a multicenter, randomized, open-label, teriparatide (TPTD)-controlled study in 436 postmenopausal women with osteoporosis (safety analysis set of 432 subjects) who were transitioning from bisphosphonate therapy. Subjects needed to have received at   for initial rollout (NME/original BLA reviews) least 3 years of oral bisphosphonate therapy prior to screening and alendronate in the year immediately prior to screening, with a baseline T-score  2.5 at the lumbar spine, total hip, or femoral neck and history of nonvertebral fracture after the age of 50 or vertebral fracture. This study was designed to evaluate the responses in BMD through 12 months of treatment with romosozumab 210 mg QM, compared with 12 months of treatment with TPTD.</p><p>The percentages of subjects reporting adverse events were generally similar between the TPTD group (148 of 214 subjects [69 %]) and the romosozumab group (164 of 218 subjects [75 %]). The incidences and types of events reported were those that would be expected in the population studied and were generally similar between the TPTD and romosozumab groups. Injection site reactions were observed more frequently with romosozumab (8 %) compared with TPTD (3 %), which led to study drug discontinuation for 1 subject in the romosozumab group. Of the subjects who reported injection site reactions, the median time to the first adverse event was 92.0 days in the romosozumab group and 36.5 days in the TPTD group. The median duration of injection site reaction adverse events was 2.0 days in the romosozumab group and 5.5 days in the TPTD group. The safety findings in this study of subjects transitioning from at least 3 years of oral bisphosphonate therapy and alendronate in the year immediately prior were consistent with the overall safety profile of romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: The safety findings in this study are consistent with the findings in the romosozumab placebo controlled studies. The results from this study do not raise any safety concerns for patients who transition to romosozumab from long-term (&gt;3 years) bisphosphonate therapy.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20060223</head><p>Study 20060223 was a multicenter, randomized, open-label, single-dose study in 40 postmenopausal women with low bone mass who had been receiving alendronate for at least 1 year and in postmenopausal women with low bone mass who were treatment naive (ie, had not received alendronate, other bisphosphonates, or other treatments for osteoporosis/bone loss). Subjects who had been receiving alendronate were randomized to continue alendronate treatment or transition to romosozumab; treatment-naive subjects received romosozumab. Adverse events were similar across all 3 groups in this study. Overall, adverse events were reported for 5 of 10 subjects (50%) who received alendronate only; 10 of 24 subjects (42%) who received romosozumab after previous alendronate treatment; and 5 of 6 subjects (83%) who received romosozumab and were previously treatment naive. These differences may be attributed to the small number of subjects in each group. Adverse events were reported as treatment related for 1 subject (4%) who received romosozumab after previous alendronate treatment (injection site reaction) and for 3 subjects (50%) who received romosozumab and were previously treatment naive (injection site erythema, injection site reaction, and nausea); all of these events were reported as mild in severity. There is no evidence that romosozumab is habit forming or could lead to dependence.</p><p>Withdrawal and Rebound 8.6.5.</p><p>Retreatment efficacy results are discussed in section 7.1.5 Onset Duration and Durability of Efficacy Effects. This section discusses safety with withdrawal and rebound.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Off-treatment</head><p>Off-treatment is defined as a period when subjects transitioned off romosozumab to a period of no active study medication.</p><p>Study 20060326 was designed to study the persistence of romosozumab effects on BMD and bone turnover markers during off-treatment. In this study, subjects who had received either 24 months of romosozumab treatment or 12 months of alendronate followed by romosozumab were randomized to either 12 months of placebo or denosumab treatment (months 24-36). In addition, those groups that received active treatment for the first 48 months (romosozumab from months 0 to 24, denosumab for months 24 to 36 and romosozumab 210 mg QM from month 36 to 48) were assigned to the "no intervention" group from months 48 to 72. Subjects assigned to no intervention had no indication of rebound or withdrawal effects in clinical laboratory values. The summary of the significant finds are the following:</p><p> median percent change in albumin-corrected calcium from month 48 to month 72 was 0.0%  median iPTH level decreased through month 60, then returned to above month 48 level by month 72  mean phosphorus level increased slightly at month 51, then returned to approximately the month 48 level by month 72  mean GFR decreased through month 51, then increased to above month 48 levels by month 72.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Retreatment</head><p>Study 20060326 also studied retreatment after subjects had been off-treatment. In this study, the retreatment phase was from months 36 to 48, during which time all participating subjects received romosozumab 210 mg QM regardless of their initial treatment.</p><p>The safety of romosozumab in the retreatment phase (month 36 to 48) was generally consistent with results seen up to 24 months of romosozumab treatment and in line with expectations based on previous clinical study findings. <ref type="figure" target="#fig_0">: As noted in section 7.1.5, although BMD gains and BTM levels  demonstrate that retreatment with romosozumab achieve similar changes when compared to  initial 12 months of romosozumab therapy, the small number of patients studied (i.e.</ref>   <ref type="figure" target="#fig_0">N=19 for placebo M24-36 group and N=16 for denosumab M24-36 group) limits  extrapolation of results into a larger patient population. This study found no new safety  concerns for patients off-study and with retreatment with</ref>  No postmarketing data are available because romosozumab has not been marketed in any geographic region.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Expectations on Safety in the Postmarket Setting 8.7.2.</head><p>There has been no postmarket experience with this drug as it is a new molecular entity.</p><p>The clinical studies used practitioners who injected romosozumab in the office setting and the post market setting will be expected to be the same. There is a safety concern that each dose requires two syringes injected and new practitioners and patients will need guidance and information to insure proper dosing. Such information should be included in the labeling and med guide.</p><p>There are no additional safety concerns for patients in subpopulations such as older patient populations, different weight status, and different race etc. from the results of the clinical data.</p><p>There are no concerns for abrupt stoppage or discontinuation for romosozumab. Romosozumab has not been studied in other clinical population so there is little information for off-label use.</p><p>There is an increased concern for hypocalcemia in patients with severe renal failure and these patients should be monitored for hypocalcemia during therapy.</p><p>For the targeted patient population from these clinical studies, the following are safety concerns for romosozumab in the post market setting: Review and analysis of the safety data support the following conclusions:</p><formula xml:id="formula_23">Increase</formula><p> The overall subject incidence of adverse events, serious adverse events, fatal adverse events, and adverse events leading to withdrawal of investigational product or study were similar between the romosozumab and placebo groups across the phase 2 and 3 studies. The subject incidence of adverse events was similar between treatment groups in the 12-month placebo-controlled population except for injection site reactions (5 % for romosozumab and 3 % for placebo) and serious adverse events of hypersensitivity.</p><p> The subject incidences of adverse events and serious adverse events were generally balanced between the romosozumab and teriparatide groups in Study 20080289 that enrolled subjects previously treated with bisphosphonate. The types of events reported were those that would be expected in the population studied. Injection site reactions were observed more frequently with romosozumab compared with teriparatide. Most adverse events related to injection site reactions were reported as mild in severity and none was reported to be serious.</p><p>The safety data demonstrated the following key risks: Modification Recommended: Delete section and add language to state that the incidences of nonvertebral fractures were NOT statistically significant at either 12 months or 24 months for romosozumab compared to placebo.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: This reviewer recommends that the sponsor clarify the language or delete the section. Both nonvertebral fracture endpoints, at 12 months and 24 months, were NOT statistically significant when adjusted for multiplicity. The sponsor did a post hoc analysis and determined that regional variations in South America (43% of study population) had lower than expected rates of nonvertebral fractures which affected these fracture endpoints. See section 6.1.2 Study 20070337 results.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="17">PATIENT COUNSELING INFORMATION</head><p>Modification Recommended: Add patient information on ONJ such as the following:</p><p>Osteonecrosis of Jaw Advise patients to practice good mouth care during treatment with EVENITY and tell your dentist that you are receiving EVENITY before you have dental work.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: There is no current patient counseling information on ONJ. Recommend counseling information language to inform patients and health care providers.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Labeling 10.2.</head><p>Medication guide will be incorporated into the labeling as this drug is intended for injection by healthcare providers only.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nonprescription Labeling 10.3.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Not Applicable</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="11">Risk Evaluation and Mitigation Strategies (REMS)</head><p>Drug risks appear to be manageable with labeling and medication guidelines and will not need a </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conditions of Use to Address Safety Issue(s) 11.2.</head><p>Drug will be administered in the healthcare setting by healthcare providers. Labeling and medication guide can manage risks for this drug and there are no anticipated risks requiring REMS.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations on REMS 11.3.</head><p>Recommendation: No REMS required as drug will be administered by healthcare provider.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="12">Postmarketing Requirements and Commitments</head><p>Possible PMC pending, awaiting information request response. An update will be filed to this review if needed. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13">Appendices</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Financial Disclosure 13.2.</head><p>In compliance with 21 CFR Part 54, Amgen forwarded a Certification/ Disclosure Form to the clinical investigators and sub-investigators who participated in covered clinical studies for romosozumab. The investigators were requested to certify to the absence of certain financial interests or arrangements or to disclose, as required, those financial interests or arrangements as delineated in 21 CFR 54.4(a)(3)(iv). Investigators were asked to provide this information for the period covering the dates of their participation in the clinical studies. In addition, investigators were requested to notify Amgen if there is any change to the information given for up to one year after the study ended. No clinical investigators and/or sub-investigators who participated in the studies listed are full or part-time employees of Amgen. Amgen also certifies that it has not entered into any financial arrangements with the clinical investigators whereby the value of compensation to the investigator could be affected by the outcome of the study as defined in 21 CFR 54.2(a), and that these investigators were not the recipients of significant payments of other sorts as defined in 21 CFR 54.2(f).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reasons for not providing information upon request by Amgen include the following:</head><p> Investigator did not respond to at least two requests by the Sponsor to provide financial disclosure information  Investigator was no longer affiliated with the clinical site and therefore did not complete/return a financial disclosure form  Investigator was incorrectly listed on the Form 1572  Investigator was new since the primary analysis  Investigator never signed the disclosure or completed the disclosure incorrectly </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sponsor Efforts to Minimize Bias</head><p>In order to adequately protect against potential bias created by a disclosable financial interest and/or arrangements, Amgen employed the following steps to minimize bias of the clinical study results:</p><p> If there are investigators with disclosable financial interests/arrangements, identify the number of investigators with interests/arrangements in each category (as defined in 21 CFR 54.2(a), (b), (c) and (f)):</p><p>Compensation to the investigator for conducting the study where the value could be influenced by the outcome of the study:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Significant payments of other sorts: 4</head><p>Proprietary interest in the product tested held by investigator: 0 , 25 (OH) vitamin D, PK, and antiromosozumab antibodies, and antidenosumab antibodies for this study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">OBJECTIVES</head><p>For the 12-month double-blind placebo-controlled study period  To assess the effect of romosozumab treatment for 12 months compared with placebo on percent changes in bone formation markers (P1NP, BSAP, and OC) and bone resorption markers (sCTX and TRAP 5b)  To assess the effect of romosozumab treatment for 12 months compared with placebo on percent change in serum sclerostin level  To enable exploratory assessments of novel biomarkers through prospective collection of blood samples</p><p>For the 24-month study period <ref type="bibr">(12-month double-blind placebo-controlled</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>study period followed by the 12-month open-label denosumab follow-up study period)</head><p> To assess the effect of romosozumab treatment for 12 months followed by denosumab treatment for 12 months compared with placebo followed by denosumab treatment on percent changes in the bone formation marker P1NP and the bone resorption marker sCTX  To assess the effect of romosozumab treatment for 12 months followed by denosumab treatment for 12 months compared with placebo followed by denosumab treatment on percent change in serum sclerostin level  To enable exploratory assessments of novel biomarkers through prospective collection of blood samples</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">RATIONALE</head><p>Romosozumab neutralizes the bone formation inhibitor sclerostin and stimulates bone formation without stimulating bone resorption as demonstrated in preclinical and clinical studies <ref type="bibr">(Padhi et al, 2011;</ref><ref type="bibr">Ominsky et al, 2010;</ref><ref type="bibr">Li et al, 2009</ref>). More specifically, romosozumab has been shown to increase markers of bone formation (P1NP, OC, and BSAP) and to decrease the bone resorption marker sCTX compared with placebo. Data from the phase 1 ascending multiple dose study indicated a peak in P1NP around day 15 to 22 with both 2 and 3 mg/kg doses of romosozumab. The phase 2 data confirmed that for all romosozumab doses tested, the bone formation markers increased from baseline at Week 1, achieved peak levels by Month 1 and returned to baseline between Month 2 and Month 9 for P1NP and OC, or by Month 12 for BSAP. For the 210-mg QM dosing regimen, P1NP levels returned to baseline around Month   for initial rollout (NME/original BLA reviews) 6. From Month 6 to Month 12, levels of bone formation decreased below baseline indicating a decrease in bone remodeling. However, it is not known whether bone formation marker levels transiently increase after repeated dosing between Month 2 and Month 12 as P1NP, OC, and BSAP were measured at the end of the dosing interval (ie, before the next monthly injection) in the phase 2 dose-ranging study. From Week 1 to Month 12, sCTX decreased from baseline for all romosozumab doses tested in the phase 2 dose-ranging study, confirming the inhibition of bone resorption observed in the phase 1 studies. Still, the dynamic effects of romosozumab on bone formation and bone resorption are not fully understood. This sub-study will allow further characterization of the effect of romosozumab on bone formation and resorption over time, by assessing the following BTMs:</p><p> P1NP -a marker of the conversion of procollagen to collagen  BSAP -an indicator of osteoblast activity  OC -an indicator of osteoblast activity  SCTX -a marker of collagen breakdown  TRAP 5b -an indicator of osteoclast numbers Sclerostin levels and iPTH will be assessed as biomarkers to gain additional insights into the effect of romosozumab. Results of iPTH will be analyzed as part of the Serum iPTH and Urinary Calcium sub-study. In addition, blood samples will be collected to support the development of potential novel biomarkers of bone metabolism and PMO.</p><p>The effect of transitioning from romosozumab/placebo treatment to denosumab treatment will be studied by assessing BTMs and biomarkers during the 12-month open-label denosumab follow-up study period.</p><p>In combination with the PK sub-study, the PK/PD relationship will be studied in a broader population. A timed urine collection will be performed in subjects participating in the BTM and biomarker sub-study. Results will be analyzed with the Serum iPTH and Urinary Calcium sub-study</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">SUB-STUDY DESIGN</head><p>Enrollment in the PK sub-study is a prerequisite for participation in the BTM and Biomarker substudy. Eligible subjects at all centers may be enrolled into the BTM and Biomarker sub-study: up to approximately 150 subjects (approximately 75 per arm). During the 24-month study period <ref type="bibr">(12-month double-blind placebo-controlled</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">ENDPOINTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">STATISTICAL CONSIDERATIONS</head><p>It is expected that 150 subjects (75 subjects per arm) will provide stable estimates for the BTMs. Considering 7.5% drop out during the 12-month double-blind placebo-controlled study period, 75 subjects per arm will provide an estimate for the percent change from baseline in P1NP with a 9.4% of the half-width of the 95% CI assuming a 40% standard deviation and an estimate for the percent change from baseline in sCTX with an 8.2% of the half-width of the 95% CI assuming a 35% standard deviation.</p><p>BTMs and biomarkers will be analyzed using non-parametric methodology since it is anticipated that the distribution of these parameters will deviate markedly from normality. Rank tests will be used to compare between treatment groups. Lateral spine X-rays, DXA images, and HR-pQCT images were acquired according to specific instructions provided by the central imaging vendor who analyzed the radiographs per the central imaging charter.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">OBJECTIVES</head><p>For the 12-month double-blind placebo-controlled study period To assess the effect of romosozumab treatment for 12 months compared with placebo on:</p><p> Percent changes in DXA BMD at the radius and total body  Percent changes in failure load estimated by FEA at the distal radius and the distal tibia as evaluated by HR-pQCT (XtremeCT)  Percent changes in other HR-pQCT outcomes at the distal radius and the distal tibia</p><p>For the 24-month study period (12-month double-blind placebo-controlled study period followed by the 12-month open-label denosumab follow-up study period)</p><p>To assess the effect of romosozumab treatment for 12 months followed by denosumab treatment for 6 months and for 12 months compared with placebo followed by denosumab treatment on:</p><p> Percent changes in DXA BMD at the radius and the total body  Percent changes in failure load estimated by FEA at the distal radius and the distal tibia as evaluated by HR-pQCT (XtremeCT)  Percent changes in other HR-pQCT outcomes at the distal radius and the distal tibia 2. RATIONALE Romosozumab stimulates bone formation and reduces bone resorption. This unique effect on bone turnover results in marked increase in BMD at the lumbar spine and hip as shown in phase 1 and 2 studies. Yet, the effects of romosozumab on more cortical sites like the radius are not fully elucidated. Preclinical studies with romosozumab at cortical sites in non-human primates showed an increase in periosteal and endosteal bone formation with no increase in cortical porosity <ref type="bibr">(Ominsky et al, 2010)</ref>. A phase 1b study using peripheral QCT indicated a trend to increase Polar Moment of Inertia (PMI), an estimate measure of strength, but did not show major changes in cortical bone area and cortical bone mineral content with 3 mg/kg of romosozumab every 4 weeks over 169 days. Phase 2 data indicated that compared with placebo, there was no statistically significant change in the distal 1/3 radius BMD at Month 12 in any of the romosozumab arms. At Month 12, the percent changes from baseline in distal 1/3 radius BMD in the control arms were -0.9% (placebo), -0.3% (alendronate) and -1.7% (teriparatide); the mean change 210 mg romosozumab QM was -1.2%. DXA BMD measures as well as bone strength are influenced by the bone size and the bone geometric distribution; and neither can be accurately assessed by DXA.</p><p>The proposed DXA and HR-pQCT Imaging sub-study will enhance the understanding of the effects of romosozumab on cortical bone. In addition, the characterization of the effects of romosozumab on bone geometry variables and bone-micro-architecture available from this sub-study will further inform the potential impact of romosozumab on cortical bone strength. For this purpose, in addition to forearm DXA assessments, HR-pQCT (XtremeCT ) scans with an isotropic resolution of 82 m will be performed, allowing longitudinal evaluations of bone structure and micro-architecture parameters <ref type="bibr">(Genant et al, 2008)</ref>. This sub-study will allow the evaluation of the bone density and structural changes in total, cortical and trabecular compartments and relate them to changes in strength estimated by FEA.</p><p>Additionally, to further evaluate the effect of romosozumab as compared with placebo on cortical bone, which comprises 80% of the skeleton, total body BMD with whole body DXA scanning will be assessed.</p><p>The effect of romosozumab treatment for 12 months, followed by denosumab treatment for 12 months will also be studied.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">SUB-STUDY DESIGN</head><p>A subset of centers with access to XtremeCT scanners will participate in the Imaging sub-study I. At those centers, all eligible subjects may be enrolled into the sub-study: up to approximately 200 subjects (approximately 100 per arm). Forearm DXA scans, total body DXA scans, and HR-pQCT scans of the distal radius and the distal tibia will be performed at the Day 1, Month 6, Month 12, Month 18, and Month 24 study visits.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">ENDPOINTS</head><p>During the 12-month double-blind placebo-controlled study period  Percent change from baseline in radius <ref type="bibr">(1/3, ultradistal</ref>  During the 24-month study period <ref type="bibr">(12-month double-blind placebo-controlled</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">ELIGIBILITY Inclusion</head><p> Subject is enrolled at a center participating in the Imaging sub-study I  Subject has provided informed consent for participation in this sub-study Exclusion  Subjects with neither wrist evaluable by DXA (ie, bilateral wrist replacement/fractures)  Subjects with metal prosthesis or significant artifacts affecting the total body DXA scan (eg, hip or knee replacement, pacemaker)  Subject is enrolled in the Lumbar Spine and Proximal Femur DXA sub-study (Imaging sub-study II)  Subject will not be available for protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.">PROCEDURES</head><p>Study visits for the Imaging sub-study I are on Day 1, Month 6, Month 12, Month 18, and Month 24.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">STATISTICAL CONSIDERATIONS</head><p>It is expected that 200 subjects will provide stable estimates for the percent change in DXA BMD. Considering 7.5% dropout during the 12-month double-blind placebo-controlled study period, 100 subjects per arm will provide an estimate for the percent change from baseline in total body BMD without head with a 0.49% of the half-width of the 95% CI assuming a 2.4% standard deviation and an estimate for the percent change from baseline in distal 1/3 radius BMD with an 0.69% of the half-width of the 95% CI assuming a 3.4% standard deviation.</p><p>Percent change from baseline at Month 12 in the failure load at the distal radius was observed in a denosumab study (4.6% mean increase with a 5.3% standard deviation in the denosumab   for initial rollout (NME/original BLA reviews) group and 0.94% mean increase with a 7.8% standard deviation in the placebo group; Amgen data on file). If the same increase is assumed in the Imaging sub-study II, 200 subjects (100 subjects per arm) will provide a 95% power to detect a significant difference between the treatment groups, considering a 7.5% dropout during the 12-month double-blind placebocontrolled study period. If a 4.0% increase is assumed in the romosozumab group, 200 subjects will provide an 87% power to detect a significant difference between the treatment groups at Month 12.</p><p>Percent changes from baseline at Month 12 in DXA BMD will be compared between treatment groups using an ANCOVA model with treatment group, baseline BMD, machine type and interaction of baseline BMD and machine type as independent variables. Any missing value during the 12-month double-blind placebo-controlled study period will be imputed by carrying forward the last non-missing post baseline value prior to the missing value.</p><p>Percent change from baseline at Month 12 in the failure load will be compared between treatment groups using an ANCOVA model with treatment group and baseline value of ultimate load as independent variables. Percent change from baseline at Month 6 in the failure load will be analyzed using same approach.</p><p>Percent change from baseline at Month 24 in the failure load and the other HR-pQCT parameters at Month 24 will be analyzed using the same ANCOVA approach as for the failure load at Month 12. Any missing value during the 12-month open-label denosumab follow-up study period will be imputed by carrying forward the last non-missing post-Month 12 value prior to the missing value.</p><p>Lumbar Spine and Proximal Femur Dual energy X-ray 13.6.3.</p><p>Absorptiometry Sub-study (Imaging Sub-study II)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">OBJECTIVES For the 12-month double-blind placebo-controlled study period</head><p> To assess the effect of romosozumab treatment for 6 months compared with placebo on percent changes in BMD at the lumbar spine, total hip and femoral neck</p><p>For the 24-month study period <ref type="bibr">(12-month double-blind placebo-controlled</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>study period followed by the 12-month open-label denosumab follow-up study period)</head><p> To assess the effect of romosozumab treatment for 12 months followed by denosumab treatment for 6 months compared with placebo followed by denosumab treatment on percent changes in BMD at the lumbar spine, total hip and femoral neck neck This sub-study will allow evaluation of the time course of the effect of romosozumab treatment for 12 months and of romosozumab treatment for 12 months followed by denosumab treatment for 12 months on BMD at the spine and proximal femur.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">RATIONALE</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">SUB-STUDY DESIGN</head><p>Eligible subjects at all centers may be enrolled into the Imaging sub-study II: up to approximately 120 subjects (approximately 60 per arm). Subjects have to provide sub-study specific informed consent to participate. Lumbar spine and proximal femur DXA scans will be performed at the Month 6 and Month 18 study visits.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">ENDPOINTS</head><p>During the 12-month double-blind placebo-controlled study period  Percent change from baseline in BMD at the lumbar spine, total hip, and femoral neck at Month 6</p><p>During the 24-month study period <ref type="bibr">(12-month double-blind placebo-controlled</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>study period followed by the 12-month open-label denosumab follow-up study period)</head><p> Percent change from baseline in BMD at the lumbar spine, total hip, and femoral neck at Month 18</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">ELIGIBILITY Inclusion</head><p> Subject has provided informed consent for participation in this sub-study Exclusion  Subject is enrolled in the Forearm and Total Body DXA and HR-pQCT sub-study (Imaging sub-study I)  Subject will not be available for protocol-required study visits or procedures, to the best of the subject and investigator's knowledge</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.">PROCEDURES</head><p>Study visits for the Imaging sub-study II are on Month 6, and Month 18.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">STATISTICAL CONSIDERATIONS</head><p>Percent change from baseline at Month 6 in the DXA BMD endpoints will be compared between treatment groups using an ANCOVA model with treatment group, baseline value of BMD, machine type and interaction of baseline BMD value and machine type as independent variables. Percent change from baseline at Month 18 in the DXA BMD endpoints will be analyzed using same approach. Bone Biopsy Sub-study 13.6.4.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">OBJECTIVES</head><p>For the 12-month double-blind placebo-controlled study period  To assess the effect of romosozumab treatment for 2 months compared with placebo on parameters of bone histology, and bone histomorphometry  To assess the effect of romosozumab treatment for 12 months compared with placebo on parameters of bone histology, histomorphometry, and micro-CT For the 24-month study period (12-month double-blind placebo-controlled study period followed by the 12-month open-label denosumab follow-up study period)  To assess the effect of romosozumab treatment for 12 months followed by denosumab treatment for 12 months compared with placebo followed by denosumab treatment on parameters of bone histology, histomorphometry, and micro-CT treatment on parameters of bone histology, histomorphometry, and micro-CT.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">RATIONALE</head><p>Romosozumab is a bone forming agent that is currently being studied as an investigational therapy for postmenopausal women with osteoporosis at increased risk for fracture. Bone forming agents can promote larger improvements in bone mass and bone strength compared with antiresorptives and in addition can restore bone architecture. Analogs of parathyroid hormone (PTH 1-34 [teriparatide] and PTH 1-84) increase bone remodeling with greater osteoblast than osteoclast activity, resulting in marked improvement in BMD, as well as indices of bone microstructure that are associated with improved mechanical strength <ref type="bibr">(Lindsay et al, 2006;</ref><ref type="bibr">Lindsay et al, 2003;</ref><ref type="bibr">Jiang et al, 2003)</ref>. Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, thereby promoting osteoblast differentiation/activity, leading to an increase in bone formation, BMD, and bone strength <ref type="bibr">(Ominsky et al, 2010)</ref>.This bone biopsy sub-study is designed to evaluate the effect of romosozumab treatment on bone histomorphometry in the first two months after initiation of treatment when biochemical markers of bone formation are at their peak. In the phase 2 dose-ranging study <ref type="bibr">(Study 20060326)</ref>, markers of bone formation showed increases from baseline at Week 1 and achieved peak levels by Month 1. After the first month, markers of bone formation decreased from their peak, gradually approaching baseline levels. For the romosozumab 210-mg SC QM dosing regimen, median P1NP and OC levels remained above baseline through months 6 and 9, respectively, and median BSAP levels remained above baseline through month 12.</p><p>Biopsies at approximately the Month 2 study visit will be used to evaluate the effect of romosozumab treatment as early as 4 to 6 weeks after initiation of treatment, ie, during a period of robust bone formation, and will be used to explore the modeling and remodeling mechanism of bone formation. The use of a quadruple label procedure permits a comparison of   for initial rollout (NME/original BLA reviews) dynamic bone formation indices at baseline and after administration of romosozumab by measuring characteristics of each set of double labels separately and comparing them to each other in a single biopsy specimen.</p><p>In addition, this bone biopsy sub-study will assess bone microarchitecture and geometry after romosozumab treatment for 12 months and will evaluate if the newly formed bone has normal structure, normal mineralization characteristics and normal marrow. Similarly, long term bone safety will be assessed after romosozumab treatment for 12 months followed by denosumab treatment for 12 months.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">SUB-STUDY DESIGN</head><p>Biopsy procedures using tetracycline quadruple-labeled is discussed in section 6.1.2 under study 20070337 study results. Biopsies will be performed at 3 different time points in the study. Early biopsies to assess short-term changes will be performed after up to 2 months of treatment with romosozumab/placebo. Late biopsies will be performed at the end of the 12month double-blind placebo-controlled study period and at the end of the 12-month open-label denosumab follow-up study period. A subset of centers will participate in the bone biopsy sub-study. At those centers, all eligible subjects may be enrolled into the sub-study: up to approximately 40 subjects into the early biopsy (Month 2) cohort, up to approximately 60 subjects into the late biopsy Month 12 cohort, and up to approximately 40 subjects into the late biopsy Month 24 cohort. Subjects have to provide sub-study specific informed consent to participate. Subjects providing consent for and undergoing a Month 2 biopsy will not be permitted to enroll in the Month 12 biopsy cohort or the Month 24 biopsy cohort. Subjects providing consent for and undergoing a Month 12 biopsy may also enroll in the Month 24 biopsy cohort.</p><p>To participate in the Month 2 early biopsy cohort, subjects must be enrolled into the sub-study and start the first cycle of labeling during the screening period for the main study. Subjects may be enrolled into the Month 12 biopsy cohort at any time during the study up to the Month 11 visit. Subjects may be enrolled into the Month 24 biopsy cohort at any time during the study up to the Month 23 visit.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">ENDPOINTS During the 12-month double-blind placebo-controlled study period  Modeling and remodeling parameters, bone histology, and bone histomorphometry parameters at Month 2  Bone histology and histomorphometry parameters and micro-computer tomography parameters at Month 12</head><p>During the 24-month study period <ref type="bibr">(12-month double-blind placebo-controlled</ref>   Bone histology and histomorphometry parameters and micro-computer tomography parameters at Month 24</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">ELIGIBILITY Inclusion</head><p> Subject has provided informed consent for participation in this sub-study Exclusion  Contraindicated or intolerant to doxycycline or tetracycline or its derivatives  Contraindicated to an iliac crest bone biopsy  Subject will not be available for protocol-required study visits or procedures, to the best of the subject and investigator's knowledge.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.">PROCEDURES</head><p>The Month 2 quadruple labeling procedure, tetracycline double-labeling procedure, and bone biopsy is described in the bone biopsy manual excerpted as follows:</p><p>LABELLING PROCEDURES To participate in the Month 2 early biopsy cohort, subjects must be enrolled into the bone biopsy sub-study and start the first cycle of labelling during the screening period for the main study. Subjects may be enrolled into the Month 12 biopsy cohort at any time during the study up to the Month 11 visit. Subjects may be enrolled into the Month 24 biopsy cohort at any time during the study up to the Month 23 visit.</p><p>Subjects will follow a quadruple (Month 2) or double (Month 12 and 24) labelling procedure prior to undergoing the biopsy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>LABELLING COMPOUNDS</head><p>For determination of the level of bone turnover, bone formation rates, and mineralization defects, labelling of the bone with tetracycline compounds is required before proceeding with the bone biopsy. Tetracycline compounds chelate calcium on bone surfaces and are deposited within the bone at sites of active mineralization. The "labels" can then be visualized in fluorescent light during histomorphometric evaluation.</p><p>Tetracycline, demeclocycline and doxycycline are the most commonly used compounds; tetracycline hydrochloride and demeclocycline are the preferred labelling compounds for this sub-study. In regions where neither tetracycline hydrochloride nor demeclocycline is available, the use of doxycycline is acceptable. In such instances, the investigator must seek Amgen approval of doxycycline confirm the recommended dose and schedule prior to initiating the labelling procedure.</p><p>The following tetracycline derivatives are recommended for the purposes of this study: </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Oral Demeclocycline</head><p>Oral demeclocycline should be used for the first administration cycle for those subjects enrolled into the Month 2 bone biopsy cohort. Oral demeclocycline may also be used as a labelling compound for those subjects enrolled in the Month 12 or Month 24 bone biopsy cohort. If subjects have consented to both Month 12 and Month 24 biopsies, tetracycline should be utilized for Month 12 procedures, and demeclocycline used for Month 24. This is to facilitate distinguishing the labels during analysis.</p><p>The dosage of demeclocycline is 600 mg daily given orally either as 300 mg twice daily regimen or 150 mg four times daily dosing. Each labelling 'cycle' consists of 3 days of demeclocycline 600 mg given daily followed by a 10 day break, then a further 3 days of treatment. Either the 150 mg or 300 mg preparation may be used.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Oral tetracycline</head><p>Oral tetracycline should be used for the second labelling cycle for those subjects enrolled into the Month 2 bone biopsy cohort. Oral tetracycline should also be used as the labelling compound for those subjects enrolled in the Month 12 or Month 24 bone biopsy cohort. If a subject has consented to both Month 12 and Month 24 biopsies, tetracycline should be used for Month 12 labelling procedures. To facilitate distinction of labels during analysis, in those subjects that have consented to both the 12 and 24 month biopsies, demeclocycline is the preferred labelling compound for month 24.</p><p>For Month 2 Oral tetracycline should be used for the second labelling cycle for those subjects enrolled into the Month 2 bone biopsy cohort. Each 'cycle' consists of an oral dose of 1000 mg daily given for 2 days followed by a 10 day break, then a further 2 days of treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For Month 12 or Month 24</head><p>Each 'cycle' of treatment consists of an oral dose of 1000 mg daily given for 3 days followed by a 10 day break, then a further 3 days of treatment. Either the 250 mg or the 500 mg preparation may be used.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Oral Doxycycline</head><p>For Month 2 When demeclocycline is not available, oral doxycycline may be used for the first labelling cycle for those subjects enrolled into the Month 2 bone biopsy cohort.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>For Month 12 or Month 24</head><p>For 12 and 24 month biopsies in regions where neither tetracycline nor demeclocycline is available, the investigator must seek Amgen approval for the usage of doxycycline prior to initiating the labelling procedure. Each 'cycle' of treatment consists of an oral dose of doxycycline 300 mg daily given for 4 days followed by a 10 day break, then a further 4 days of administration.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Concomitant Therapy</head><p>Absorption of tetracycline derivatives is impaired by antacids containing aluminum, calcium, or magnesium, and by iron-containing preparations. Foods and some dairy products also interfere with absorption. As described above, oral forms of tetracycline should be given at least 1 hour before or 2 hours after meals.</p><p>All subjects are required to take calcium and vitamin D supplementation daily during the study. However, subjects enrolled in the bone biopsy sub-study should be instructed not to take their daily calcium supplement on days they are taking oral tetracycline, demeclocycline or doxycycline. Subjects should not take any other tetracycline derivatives prior to the bone biopsy being performed.</p><p>Unused samples from bone biopsy specimens may be utilized to support the development of potential novel biomarkers of bone metabolism and PMO.</p><p>For subjects in the Month 2 early biopsy cohort, romosozumab levels, BTMs (P1NP, sCTX), sclerostin and iPTH will be assessed at the Day 1 and at the Day 14 visits.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">STATISTICAL CONSIDERATIONS</head><p>This sub-study study is not powered for any specific measured parameter. Sample size has been estimated based on previous bone biopsy studies with teriparatide, the only currently approved bone forming agent, as well as regulatory considerations. Subjects in the placebo group will serve as the control group.</p><p>Bone histomorphometric parameters and parameters derived from micro-computer tomography of the transiliac biopsies will be summarized descriptively by actual treatment received. Bone histologic findings by actual treatment group will also be summarized.</p><p>Calcium Sub-study 13.6.5.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">OBJECTIVES</head><p>For the 12-month double-blind placebo-controlled study period  To characterize the subject incidence of hypocalcemia (albumin-corrected serum calcium level &lt; 7.5 mg/dL) associated with the first romosozumab 210-mg dose along with daily calcium and vitamin D supplementation for treatment of PMO Based on the well-known importance of calcium in mineralizing newly formed bone and the unique mechanism of action of romosozumab to increase bone formation, decreases in serum calcium may be seen in subjects treated with romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">RATIONALE</head><p>Phase 1 data indicates that the nadir in serum calcium is expected around Day 14 after the first dose of romosozumab on Day 1. Decreases in serum calcium were less pronounced following subsequent dosing visits. Therefore, in this sub-study, the risk of hypocalcemia will be assessed following the first dose of 210 mg romosozumab while subjects are receiving daily calcium and vitamin D supplementation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">SUB-STUDY DESIGN</head><p>Eligible subjects at all centers may be enrolled into the Calcium sub-study: up to approximately 920 subjects (approximately 460 per arm). Subjects have to provide sub-study specific informed consent to participate. A balanced regional and racial distribution is targeted for enrollment. As mandated by the main study, all subjects will receive daily calcium and vitamin D supplementation that at a minimum is in a range of 500 to 1,000 mg of elemental calcium and 600 to 800 IU of vitamin D from screening to end of study. In addition, subjects with a serum 25 (OH) vitamin D level of  20 ng/mL and  40 ng/mL at screening will receive an initial loading dose of 50,000 to 60,000 IU of vitamin D, preferably by the oral route. Subjects with a serum 25 (OH) vitamin D level of &gt; 40 ng/mL at screening may also receive the vitamin D loading dose at the principal investigator's discretion.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">ENDPOINTS</head><p>During the 12-month double-blind placebo-controlled study period  Subject incidence of hypocalcemia at Day 14, defined as albumin-corrected serum calcium level &lt; 7.5 mg/dL</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">ELIGIBILITY Inclusion Criteria</head><p> Subject has provided informed consent for participation in this sub-study Exclusion Criteria  Subject will not be available for protocol-required study visits or procedures, to the best of the subject and investigator's knowledge</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.">PROCEDURES</head><p>This sub-study requires one additional study visit at Day 14 ( 3 days).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">STATISTICAL CONSIDERATIONS</head><p>It is expected that a sample size of 920 subjects will provide stable estimates of the absolute incidence of hypocalcemia. The absolute incidence of hypocalcemia will be considered low (&lt;   for initial rollout (NME/original BLA reviews) 2%), provided that the upper limit of the 95% 1-sided CI for event rate is &lt; 2%. Assuming that the rate of hypocalcemia is 0.5% in the romosozumab arm, 460 subjects randomized to the romosozumab group will provide 90% power for demonstrating that the absolute incidence of hypocalcemia is &lt; 2%. Subject incidence of hypocalcemia at Day 14 will be calculated and the associated upper limit of 95% 1-sided CI will be estimated based on a binomial distribution.</p><p>Audiology Sub-study 13.6.6.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">OBJECTIVES</head><p>For the 12-month double-blind placebo-controlled study period To assess the effect of romosozumab treatment for 12 months compared with placebo on:  Subject incidence of hearing loss  Change in hearing threshold</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">RATIONALE</head><p>Romosozumab is a humanized monoclonal antibody against sclerostin which is being evaluated as a bone forming agent for the treatment of postmenopausal osteoporosis. Sclerosteosis is an autosomal-recessive disorder caused by absence of the SOST gene which encodes sclerostin <ref type="bibr">(Brunkow et al, 2001)</ref>. Patients with sclerosteosis develop deafness in early childhood in part due to impingement of the vestibulocochlear nerve (cranial nerve VIII) caused by hyperostosis <ref type="bibr">(Hamersma et al, 2003)</ref>. Because romosozumab is a bone forming agent, it may theoretically cause clinical hyperostosis in the vestibulocochlear nerve foramina which could affect the nerve and cause changes in audiometry parameters. In preclinical studies with romosozumab, rats and cynomolgus monkeys treated with supratherapeutic doses developed histologically detectable hyperostosis (Amgen, data on file). To date, clinical studies of romosozumab have not detected an imbalance in incidence of hearing adverse events. The primary purpose of this sub-study is to measure potential changes in hearing during the 12-month double-blind placebo-controlled study period. Approximately 20% of the postmenopausal osteoporosis study population is expected to have baseline incidence of hearing deficit <ref type="bibr">(Cruickshanks et al, 2010)</ref>.</p><p>Pure-tone average (PTA) is the average of hearing sensitivity at 500, 1,000, and 2,000 Hz. This average should approximate the speech reception threshold, within 5 dB, and the speech detection threshold, within 6 to 8 dB. The speech reception threshold is the softest intensity spondee words that an individual can repeat at least 50% of the time. Spondees are bisyllabic words equally emphasizing both syllables. In some cases (eg, for patients with poor word recognition) a limited set of words may be used. The speech detection threshold, also termed the speech awareness threshold, is the lowest intensity speech stimulus that an individual can detect at least 50% of the time. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">SUB-STUDY DESIGN</head><p>A subset of centers with access to specialized audiology labs meeting the standards defined in the audiology manual will participate in the Audiology sub-study. At those centers, all eligible subjects may be enrolled into the Audiology sub-study; up to approximately 400 subjects (approximately 200 per arm). Subjects have to provide sub-study specific informed consent to participate. Assessments for the Audiology sub-study will be performed at the Screening and Month 12 study visits.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">ENDPOINTS</head><p>During the 12-month double-blind placebo-controlled study period  Subject incidence of hearing loss in either ear through Month 12  Change from baseline in hearing threshold at Month 12</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">ELIGIBILITY Inclusion Criteria</head><p> Subject has provided informed consent for participation in this sub-study  Symmetric hearing with air-conduction thresholds no worse than 55 dB hearing level for the test frequencies of 250 Hz through 4,000 Hz  Symmetric hearing with air-conduction thresholds no worse than 65 dB hearing level for the test frequencies of 6,000 through 8,000 Hz  Pure tone air conduction thresholds must replicate within 5 dB for 1,000 and 2,000 Hz</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exclusion Criteria</head><p> Threshold asymmetry  20 dB at any test frequency, including all test frequencies from 250 Hz through 8000 Hz  Significant air-bone gaps, defined as exceeding 15 dB at  2 bone conduction test frequencies  Abnormal otoscopic findings  History of fluctuant hearing  History of otologic surgery  Tumor of the head, neck, or auditory system that, in the opinion of the investigator, may affect the ability to perform assessments required by the sub-study protocol or that may interfere with the interpretation of the results  Head injury that, in the opinion of the investigator, may affect the ability to perform assessments required by the sub-study protocol or that may interfere with the interpretation of the results  Exposure to IV antibiotics such as aminoglycosides or macrolides within 6 months prior to randomization  Unwilling or unable to avoid excessive noise exposure during the 24 hours prior to protocolmandated audiology assessments at baseline and Month 12 (eg, musical concerts, the use of personal stereos with earphones)  Subject will not be available for protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.">PROSCRIBED THERAPIES</head><p> Aminoglycoside or macrolide antibiotics  Chemotherapy with carboplatin, cisplatin, vincristine, or vinblastine 7. PROCEDURES Assessments for the Audiology sub-study are performed at Screening and at the Month 12 study visit. Screening assessments are to be performed after eligibility for the main study has been confirmed and may be completed up to 14 days after the first dose of IP has been received.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.">STATISTICAL CONSIDERATIONS Sample Size</head><p>The sample size of 400 provides at least 90% power for testing non-inferiority of romosozumab and placebo on the endpoint of change from baseline in PTA at Month 12. The power is under the assumptions of 7.5% drop-out over the 12-month double-blind placebo-controlled study period and a standard deviation of PTA change from baseline  26 dB. The non-inferiority testing is based on a 2-sided 95% CI for the treatment difference in mean PTA change from baseline and a 10 dB margin.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Methods (Rauch et al, 2011)</head><p>Subject incidence of hearing loss in either ear through Month 12 will be compared between treatment groups using logistic regression model with treatment group indicator, baseline average hearing threshold for the subject and age as independent variables. The hearing loss is defined as 1) loss of  20 dB at any single frequency or 2) loss of  10 dB at any 2 adjacent frequencies or 3) loss of response at 3 consecutive frequencies where responses were previously obtained.</p><p>The change from baseline in hearing threshold at Month 12 will be compared between treatment groups using a mixed effect model with treatment, test frequency, interaction between treatment and test frequency, baseline hearing threshold, and age as fixed effects and ear as random effect. The treatment effect on hearing threshold for each test frequency will be estimated, and the Tukey's procedure will be used to adjust for multiple comparisons. Osteoarthritis Sub-study 13.6.7.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">OBJECTIVES</head><p>For the 12-month double-blind placebo-controlled study period  To assess the effect of romosozumab treatment for 12 months compared with placebo on the progression of osteoarthritis of the knee</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">RATIONALE</head><p>Romosozumab is a humanized monoclonal antibody against sclerostin, which is being evaluated as a bone forming agent for treatment of postmenopausal osteoporosis. Sclerosteosis is an autosomal-recessive disorder caused by an absence or deficiency of the SOST gene which encodes sclerostin <ref type="bibr">(Brunkow et al, 2001)</ref>. SOST is expressed in articular chondrocytes and may be focally increased in cartilage of patients with osteoarthritis (Chan et al, 2011). To date, clinical studies of romosozumab have not detected an imbalance in the incidence or progression of osteoarthritis.</p><p>The purpose of this sub-study is to evaluate the clinical effect of romosozumab on knee osteoarthritis in patients with clinical history of osteoarthritis. The knee has been selected for evaluation as it represents an anatomic location where osteoarthritis results in significant morbidity, and because the WOMAC PRO instrument has been well-validated to assess clinical progression of the disease <ref type="figure" target="#fig_5">(Tubach et al, 2005</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">SUB-STUDY DESIGN</head><p>Eligible subjects (ie, history of osteoarthritis at the knee) at all centers may be enrolled into the Osteoarthritis sub-study: up to approximately 300 subjects (approximately 150 per arm). Subjects have to provide sub-study specific informed consent to participate. Assessments for the Osteoarthritis sub-study will be performed at the Screening, the Day 1 and the Month 12 study visits.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>4.</head><p>ENDPOINTS During the 12-month double-blind placebo-controlled study period  Change from baseline in WOMAC total score at Month 12  Subject incidence of worsening osteoarthritis of the knee, as measured by the WOMAC, through Month 12</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">ELIGIBILITY Inclusion Criteria</head><p> Subject has provided informed consent for participation in this sub-study  Signal knee pain due to osteoarthritis on most days for at least 1 month within 3 months prior to randomization  Morning stiffness lasting &lt; 30 minutes  Presence of knee crepitus  Signal knee osteoarthritis confirmed by knee x-ray within the past 12 months, to be read and interpreted by principal investigator or qualified delegate Exclusion Criteria  History of knee arthroplasty (either knee) or expected to require knee arthroplasty due to symptoms of osteoarthritis within 12 months of randomization  History of inflammatory arthritis including rheumatoid arthritis or psoriatic arthritis  History of pseudogout or gouty arthropathy  History of meniscal or gouty arthropathy within 12 months prior to randomization  History of knee fracture or other clinically significant trauma or knee surgery to the index knee  Body mass index of &gt; 40 kg/m2  Intraarticular knee injection of corticosteroids or hyaluronan preparations within 3 months prior to randomization  Any other medical condition which in the opinion of the investigator could confound evaluation of the index knee  Subject is unable to complete the WOMAC  Subject will not be available for protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge 6. PROCEDURES Assessments for the Osteoarthritis sub-study are performed at Screening, at the Day 1 study visit and the Month 12 study visit. Screening assessments are to be performed after eligibility for the main study has been confirmed, and Screening and Day 1 assessments may be completed up to 14 days after the first dose of IP has been received.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">PROSCRIBED THERAPIES</head><p> Intraarticular knee injection of corticosteroids or hyaluronan preparations</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.">STATISTICAL CONSIDERATIONS Sample Size</head><p>The sample size of 300 subjects provides at least 90% power for testing non-inferiority of romosozumab and placebo on the WOMAC total score change from baseline at month 12. The power is under the assumptions of 7.5% drop-out over the 12-month double-blind placebo-controlled study period and a 23 point standard deviation of WOMAC total score change from baseline. The non-inferiority testing is based on a 2-sided 95% CI for the treatment difference in the mean WOMAC total score change from baseline and a 10 point margin. Change from baseline in WOMAC total score at month 12 will be compared between treatment groups using analysis of covariance (ANCOVA) with treatment group indicator, baseline WOMAC total score and age as independent variables. The 95% CI for treatment effect on WOMAC total score change will be presented and compared with the value of 10 point. Subject incidence of worsening osteoarthritis of the knee will be compared between treatment groups using logistic regression with baseline WOMAC total score and age as independent variables.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Methods</head><p>Serum Intact Parathyroid Hormone and Urinary Calcium Sub-13.6.8. study</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">OBJECTIVES For the 12-month double-blind placebo-controlled study period</head><p> To characterize the serum iPTH concentration (at baseline, 6 months and 12 months)  To characterize urinary calcium excretion (at baseline, 6 months and 12 months)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">RATIONALE</head><p>Based on the well-known importance of calcium in mineralizing newly formed bone and the unique mechanism of action of romosozumab to increase bone formation, decreases in serum calcium with expected changes in serum intact parathyroid hormone are expected in subjects treated with romosozumab. Sclerostin, the biologic target of romosozumab, is not known to be a regulator of the well described processes of parathyroid cell proliferation or PTH secretion <ref type="bibr">(Kumar, 2011;</ref><ref type="bibr">Naveh-Many, 2010;</ref><ref type="bibr">Akerstrm, 2005;</ref><ref type="bibr">Kifor, 2002)</ref>. In addition, patients with sclerosteosis and lifelong deficiency of sclerostin are not known to have abnormalities in basal secretion of parathyroid hormone or calcitonin secretion <ref type="bibr">(Epstein, 1979)</ref>.</p><p>In patients treated with Teriparatide (a PTH analog and bone anabolic agent), increases in serum calcium lead to increased filtered loads of calcium in the kidney and increased urinary calcium excretion rates. The increase urinary calcium excretion increases the risk of urinary calcium supersaturation and therefore nephrolithiasis. The mechanism of action of romosozumab is distinct from teriparatide; romosozumab is also a bone anabolic agent, but, since it is not a PTH analog, it does not have the calcemic actions of teriparatide. In the Phase 2 study of romosozumab in post-menopausal osteoporosis women (Protocol 20060326), no significant difference, compared to placebo, was observed in the 24 hour urinary calcium excretion 1 month after initiation of romosozumab.</p><p>Because romosozumab is a bone forming agent associated with compensatory increases in serum iPTH following reductions in serum calcium, this sub-study is designed to measure and better characterize changes in serum iPTH during the 12-month double-blind placebo- controlled study period. Urinary calcium excretion will also be monitored because of the observation of nephrolithiasis with teriparatide.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">SUB-STUDY DESIGN</head><p>Eligible subjects at all centers may be enrolled into the Serum iPTH and Urinary Calcium sub-study: up to approximately 450 subjects (approximately 225 per arm). Subjects have to provide sub-study specific informed consent to participate. A balanced regional and racial distribution is targeted for enrollment. As mandated by the main study, all subjects will receive daily calcium and vitamin D supplementation that at a minimum is in a range of 500 to 1,000 mg of elemental calcium and 600 to 800 IU of vitamin D from screening to end of study. In addition, subjects with a serum 25 (OH) vitamin D level of  20 ng/mL and  40 ng/mL at screening will receive an initial loading dose of 50,000 to 60,000 IU of vitamin D, preferably by the oral route. Subjects with a serum 25 (OH) vitamin D level of &gt; 40 ng/mL at screening may also receive the vitamin D loading dose at the principal investigator's discretion. There was no standardization of calcium or 25 (OH) vitamin D levels for this substudy. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">ENDPOINTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">ELIGIBILITY Inclusion Criteria</head><p> Subject has provided informed consent for participation in this sub-study Upon agreement with the Sponsor, subjects may be consented following Day 1. Back-up samples collected for other testing may be analyzed for any PK timepoint that may have been missed due to later consent.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exclusion Criteria</head><p> Subject will not be available for protocol-required study visits or procedures, to the best of the subject and investigator's knowledge  Subjects participating in the BTM and Biomarker sub-study</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.">PROCEDURES</head><p>This sub-study requires no additional study visits.   for initial rollout (NME/original BLA reviews) 7. STATISTICAL CONSIDERATIONS Serum iPTH and urinary calcium data will be collected from the BTM and Biomarker sub-study (approximately 150 subjects) and the Serum iPTH and Urinary Calcium sub-study (approximately 450 subjects). Analysis will be using data pooled from these two sub-studies (approximately 600 subjects in total) for serum iPTH and urinary calcium at Month 6 and Month 12. It is expected that a sample size of 600 subjects (approximately 300 subjects per arm) will provide stable estimates of the changes in serum iPTH and urinary calcium excretion over time. Considering a 7.5% drop out during the 12-month double-blind placebo-controlled study period, 300 subjects per arm will provide an estimate for the percent change from baseline in serum iPTH with 5.9% of the half-width of the 95% CI, assuming a 50% standard deviation. This sample size will provide an estimate for 24-hour urine calcium with 0.24 mmol/d of the half-width of the 95% CI, assuming a 2 mmol/d standard deviation.</p><p>Change and percent change in serum iPTH and urine calcium will be summarized by visit and non-parametric methodology will be used to compare between treatment groups.</p><p>Pharmacokinetics Sub-study 13.6.9.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">OBJECTIVES</head><p>For the 12-month double-blind placebo-controlled study period  To characterize the serum romosozumab concentration</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">RATIONALE</head><p>This sub-study will allow studying the PK of romosozumab in a broader population and enable a population PK analysis. In conjunction with the BTM and Biomarker sub-study and DXA results, the PK/PD relationship will also be studied in a broader population.</p><p>The effect of transitioning from romosozumab/placebo treatment to denosumab treatment will be studied during the 12-month open-label denosumab follow-up study period by assessing PK and the PK/PD relationship (in conjunction with the BTM and Biomarker sub-study and DXA results).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">SUB-STUDY DESIGN</head><p>Eligible subjects at all centers may be enrolled into the PK sub-study: up to approximately 600 subjects (approximately 300 per arm) will be enrolled. Subjects have to provide sub-study specific informed consent to participate. A balanced regional and racial distribution is targeted for enrollment. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">ENDPOINTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">ELIGIBILITY Inclusion</head><p> Subject has provided informed consent for participation in this sub-study Upon agreement with the Sponsor, subjects may be consented following Day 1. Back-up samples collected for other testing may be analyzed for any PK timepoint that may have been missed due to later consent.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exclusion</head><p> Subject will not be available for protocol-required study visits or procedures, to the best of the subject and investigator's knowledge</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.">PROCEDURES</head><p>Study visits for the PK sub-study are Day 1, Day 14, Month 1, Month 3, Month 6, Month 9, Month 12, and Month 13.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">STATISTICAL CONSIDERATIONS</head><p>Enrollment of 600 subjects represents approximately a 10% sampling and as such is expected to be representative of the overall study population. A population PK and PK/PD analysis will be performed and reported separately.</p><p>Pharmacogenetics Sub-study 13.6.10.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">OBJECTIVES</head><p>For the 12-month double-blind placebo-controlled study period  To prospectively collect materials suitable for evaluating the influence of genetic variation on individual drug response</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">RATIONALE</head><p>As the genetic basis for sclerosteosis forms the target validation for romosozumab, the exploration of potential pharmacogenetic associations may be important.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">SUB-STUDY DESIGN</head><p>Pharmacogenetic material will be collected from all subjects providing sub-study specific informed consent at their Day 1 visit, ie, prior to first dose.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">ENDPOINTS</head><p>The collection of pharmacogenetic material in this study does not have a pre-defined endpoint.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">ELIGIBILITY Inclusion</head><p>Subject has provided informed consent for participation in this sub-study </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exclusion</head><p>No sub-study specific exclusion criteria apply</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>6.</head><p>PROCEDURES A separate blood sample will be drawn for the Pharmacogenetics sub-study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">STATISTICAL CONSIDERATIONS</head><p>The degree to which genetic variation may influence a subject's therapeutic response is unknown but potentially rare, suggesting the collection of genetic material from all subjects would be ideal.   <ref type="figure">(NME/original BLA reviews)  -------------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. <ref type="figure">-----------------------------------------------------------------------------------------------------</ref>   <ref type="figure" target="#fig_0">SUMMARY ...........................................................................................4   1.1  INTRODUCTION ................................................................................................</ref>  <ref type="figure" target="#fig_0">NONCLINICAL FINDINGS .......................................................4  1.3  RECOMMENDATIONS .............................................................................................6  1.4  ABBREVIATIONS ..................................................................................................10   2 DRUG INFORMATION ...........................................................................................</ref>  <ref type="figure">REVIEWED ......................................................................</ref>  <ref type="figure">..................................................................................................</ref>  <ref type="figure">.........................................</ref>  <ref type="figure">........................................................................................................</ref>  <ref type="figure" target="#fig_7">........................................................................................72   8 CARCINOGENICITY ...............................................................................................72   9 REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY ................................</ref>  <ref type="figure" target="#fig_0">STUDIES........................................................................82   11 INTEGRATED SUMMARY AND SAFETY EVALUATION......................................83</ref> 1 Executive Summary</p><formula xml:id="formula_24">---- /s/ ---------------------------------------------------- T D</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.1">Introduction</head><p>Amgen seeks to market EVENITY (romosozumab), a humanized anti-sclerostin IgG2 antibody, for the treatment of osteoporosis in postmenopausal women at increased risk for fracture. AMG785 (romosozumab) inhibits the effects of sclerostin and has both anabolic and anticatabolic effects on bone.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.2">Brief Discussion of Nonclinical Findings</head><p>Pharmacology Sclerostin is an extracellular inhibitor of the canonical Wnt signaling pathway. It is produced by the osteocyte, a bone mineral-embedded cell derived from the osteoblast, and is involved in paraand autocrine signaling in bone tissue. AMG785, by neutralizing the actions of sclerostin, can transiently stimulate bone formation and inhibit bone resorption, resulting in increases in bone mass and strength. These effects are achieved through time-dependent transcriptional changes in Wnt target genes in cells of the osteoblast lineage (osteocyte, osteoblast, and bone lining cell).</p><p>The bone formation response appears to be self-regulated, possibly due to an osteocyte-mediated inhibition of osteoprogenitor cell proliferation.</p><p>AMG785 blocked the sclerostin-mediated inhibition of matrix mineralization in an in vitro osteoblast cell-based mineralization assay.</p><p>In 12-month bone quality studies in ovariectomized (OVX) rats and monkeys, at doses equivalent to 1-19x and 1-22x human AUC(0-) of 12888 g.h/mL at the monthly subcutaneous dose of 210 mg, respectively, AMG785 increased bone mass and strength of lumbar spine, tibia, femur, and radius in a dose-and time-dependent manner. Bone formation and resorption markers were rapidly and transiently increased. The bone changes consisted of increases in trabecular thickness in vertebrae and long bone metaphyses, and increases in cortical thickness in long bone meta-and diaphyses. These effects were due to stimulation of bone formation concomitant with suppression of bone resorption mostly at trabecular and endosteal bone surfaces. AMG785 caused slight transient increases in cortical bone porosity.</p><p>Increases in bone strength in the OVX animals were demonstrated by positive effects on whole bone and material strength parameters at all skeletal sites evaluated (vertebral bodies and cores, femoral shaft and femoral neck). Humerus bone material strength was not significantly affected. Based on bone mass vs. strength correlations, bone quality was maintained at all evaluated sites. An improvement in bone quality was observed in the vertebrae of rats and monkeys at 19-22x human exposure multiples. Evaluations of selected bone quality parameters did not show any negative effects.</p><p>In human studies, the AMG785-induced increase in bone mass was accompanied by an increase in bone formation and a decrease in bone resorption markers. The increase in resorption markers in animals was probably due to the more pronounced increase in serum PTH causing increased bone turnover at Haversian and possibly periosteal surfaces.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>5</head><p>General toxicity Toxicity studies of up to 6-month duration were conducted in rats and monkeys. The main findings were related to the pharmacologic effect of AMG785 and included RBC, WBC and platelet decreases, serum calcium and phosphorus decreases, and extramedullary hematopoiesis. The effects were associated with hyperostosis and increases in bone formation and densitometric parameters. Exposure multiples in the 6-month studies ranged from 1-38x and 1-93x human exposure, in rats and monkeys, respectively. Assessments of local tolerance did not reveal significant concerns.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Carcinogenicity</head><p>A carcinogenicity study was conducted in Sprague Dawley rats. The rats were dosed for up to 98 weeks with 0, 3, 10, 50 mg/kg/week, equivalent to 1-19x human exposure. The study did not show any significant increases in tumor incidences. A low incidence of osteosarcoma (2/54) was observed in high dose males at 19x human exposure. However, the lack of statistical significance of this finding and the large exposure multiple suggests that AMG785 is unlikely to increase the human risk of osteosarcoma.</p><p>Osteosarcoma and other bone tumors have previously been observed in rats treated for 2 years with PTH or PTHrP analogues at low human exposure multiples. The absence of bone tumors in the AMG785 study may be related to the self-regulatory nature of the osteoblast bone formation response.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reproductive toxicity</head><p>Reproductive toxicity was evaluated in rat fertility and early embryonic development (FEED), embryofetal development (EFD) and pre-and postnatal development (PPND) studies. Findings in the definitive FEED and EFD studies included reduced ventral processes of the 6 th cervical vertebrae at doses of 100 and 300 mg/kg (17-56x human exposure). However, this anatomical structure is not present in humans and the finding is not considered clinically relevant. Fetal poly-and syndactyly were observed in the definitive EFD study at 32x human exposure, consistent with syndactyly that has been observed in sclerostosis patients and SOST knockout mice. Although it may have been treatment-related, the finding is considered of low clinical relevance based on the exposure multiple, and the timing of digit formation in the first trimester in humans, when placental transfer of immunoglobulins is limited. In the PPND study, there were small decreases in bone mass and size in the F1 offspring at 1.5-56x human exposure of unclear biological significance. None of these findings are considered relevant for the postmenopausal indication.</p><p>Theoretical safety issues Sponsor evaluated multiple potential clinical safety concerns based on the weight of evidence from nonclinical studies, clinical studies and published literature. From a nonclinical perspective there are no indications that AMG75 would increase the risks for osteoarthritis, vascular calcification, increased longitudinal bone growth, hyperostosis, hypercementosis, altered hematopoiesis, sarcopenia, altered glucose metabolism, and exacerbation of TNF-mediated inflammation. Based on nonclinical pharmacology and toxicology data, the concern about tumor induction or promotion due to activation of Wnt signaling is not considered to be substantial.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p><p>6</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nonclinical perspective on clinical bone AEs</head><p>There is some clinical concern about two different skeletal adverse events, atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), one case of which each was observed in the romosozumab treatment group in the pivotal Phase 3 study. The concern was intensified by the identification of romosozumab's antiresorptive properties. However, the nonclinical bone safety evaluations were not suggestive of significant negative effects on bone strength or quality.</p><p>Although the predictive value of the evaluated nonclinical parameters for these events is not entirely clear, this is at least partially reassuring.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>The nonclinical pharmacology and toxicology studies were adequately conducted. The submitted data support the marketing of AMG785 for the postmenopausal osteoporosis indication. The basis of the recommendation to approve is outlined in section 1.3.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3">Recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3.1">Approvability</head><p>Based on the lack of significant concerns about bone quality and the paucity of nonpharmacology related toxicities in animal studies of up to 2-year duration at adequate human exposure multiples, and also based on the lack of significant clinical safety concerns from a nonclinical perspective, the submitted nonclinical data support the use of romosozumab in postmenopausal women at the recommended subcutaneous dose of 210 mg once monthly for 12 months.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3.2">Additional Non-Clinical Recommendations</head><p>No additional nonclinical assessments are needed for approval of the application.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation to the clinical review team:</head><p>If the clinical team has concerns regarding the ability of romosozumab to cause osteonecrosis of the jaw (ONJ), a nonclinical study could be conducted to examine the effects of r13c7 in a rat surgical ONJ model (refer to <ref type="bibr">Kim et al., Bone 81:442-448, 2015)</ref>. Adequate dose selection and inclusion of a bisphosphonate control arm would be recommended for such a study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3.3">Labeling</head><p>At the time of this review, the following initial edits were proposed by the pharmacology/toxicology team for the nonclinical sections of the Sponsor's proposed labeling. This content was also sent to the Sponsor in the first round of labeling negotiations on 3/29/17. A final labeling review will be conducted under separate cover following negotiations with the sponsor. Proposed additions are underlined, while proposed deletions are strikethrough.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p><p>7 EVENITY  (romosozumab) for injection, for subcutaneous use Initial U.S. Approval: 20yy</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>---------------------------INDICATIONS AND USAGE----------------------------</head><p>EVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. (1)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8">USE IN SPECIFIC POPULATIONS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.1">Pregnancy</head><p>Risk Summary</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animal Data</head><p>Reproductive and developmental effects of romosozumab were assessed in the rat in a preliminary and definitive embryo-fetal development study, a combined fertility and embryo-development study, and a pre-and post-natal study.</p><p>Reference ID: 4081796</p><formula xml:id="formula_25">(b) (4) (b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>8</head><p>Skeletal malformations (including syndactyly and polydactyly), occurred in 1 out of 75 litters across all rat reproductive toxicity studies. The abnormalities were observed in the litter of a dam given weekly subcutaneous doses during organogenesis of 300 mg/kg (equivalent to at least 32 times the systemic exposure observed in humans following a monthly subcutaneous dose of 210 mg, based on AUC comparison).</p><p>In the offspring of female rats given weekly doses from 6 weeks before cohabitation and mating through lactation, bone density or size were minimally or slightly decreased at doses of 10, 60 or 300 mg/kg (equivalent to <ref type="bibr">1.5, 19, or 56</ref> times the systemic exposure observed in humans following a monthly subcutaneous dose of 210 mg, based on AUC comparison). Other adverse effects on postnatal growth and development were not observed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.2">Lactation</head><p>Risk Summary EVENITY is not indicated for use in females of reproductive potential. There is no information on the presence of romosozumab in human milk, the effects on the breastfed infant, or the effects on milk production.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="12">CLINICAL PHARMACOLOGY</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="12.1">Mechanism of Action</head><p>Reference ID: 4081796</p><formula xml:id="formula_26">(b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D. 9 13 NONCLINICAL TOXICOLOGY</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.1">Carcinogenesis, Mutagenesis, Impairment of Fertility</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Carcinogenicity</head><p>In a rat carcinogenicity study, once-weekly doses of 3, 10 or 50 mg/kg/ were administered by subcutaneous injection to Sprague-Dawley rats from 8 weeks up to 98 weeks of age, resulting in systemic exposures that were up to 19 times the systemic exposure observed in humans following a monthly subcutaneous dose of 210 mg romosozumab (based on AUC comparison). Romosozumab caused a dose-dependent increase in bone mass with trabecular and cortical bone thickening at all doses. There were no effects of romosozumab on mortality and romosozumab did not cause significant increases in tumor incidence in male or female rats.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mutagenicity</head><p>Mutagenesis has not been evaluated, as monoclonal antibodies are not expected to alter DNA or chromosomes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impairment of Fertility</head><p>No effects on fertility were observed in male and female rats given subcutaneous doses up to 300 mg/kg (up to 56 times the systemic exposure observed in humans following a monthly subcutaneous dose of 210 mg romosozumab, based on AUC comparison).</p><p>No effects were noted in reproductive organs in rats and cynomolgus monkeys dosed subcutaneously for 6 months with weekly doses up to 100 mg/kg exposures up to 38 and 93 times , respectively, the systemic exposure observed in humans administered monthly subcutaneous doses of 210 mg, based on AUC comparison).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.2">Animal Toxicology and/or Pharmacology</head><p>No adverse effects were noted in rats and monkeys after 26 once-weekly subcutaneous injections at doses up to 100 mg/kg, equivalent to systemic exposures of 38 and 93 times , respectively, the systemic exposure observed in humans following a monthly subcutaneous dose of 210 mg romosozumab (based on AUC comparison).</p><p>Bone safety studies of up to 12 month duration were conducted in ovariectomized (OVX) rats and monkeys, with once-weekly doses yielding exposures ranging from 1 to 22 times the systemic exposure in humans given monthly doses of 210 mg, based on AUC comparison. Romosozumab increased bone mass and improved cancellous bone microarchitecture and cortical bone geometry by enhancing bone formation and suppressing bone resorption at trabecular and endocortical surfaces. The increases in bone mass were significantly correlated with increases in bone strength.</p><p>In rats and monkeys, bone quality was maintained at all skeletal sites at doses ranging from 1 to 22 times human exposure, and slightly improved in vertebrae at 19 to 22 times human exposure</p><p>There was no evidence of mineralization defects, osteoid accumulation or woven bone formation. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.4">Abbreviations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GENERAL</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">Drug Formulation</head><p>The antibody is provided in a sterile solution for SC injection, at strength of 90 mg/mL. The product contains the excipients sucrose polysorbate acetate calcium and NaOH at pH 5.2. One dose of 210 mg is administered by injection of 2 x 1.17 mL from a single-use prefilled syringe.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">Comments on Novel Excipients</head><p>The product contains no novel excipients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2.5</head><p>Comments on Impurities/Degradants of Concern Product related impurities do not have properties comparable to those of the product. Additionally, their low levels preclude a significant cause for concern. Since romosozumab is a Reference ID: 4081796</p><formula xml:id="formula_27">(b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>16</head><p>biotechnology-derived product, the impurity qualification requirements as described in ICH Q3A/B guidances are not applicable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6">Proposed Clinical Population and Dosing Regimen</head><p>The proposed clinical population is postmenopausal women with osteoporosis. The proposed dosing regimen is 210 mg once monthly administered by subcutaneous injection.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2.7</head><p>Regulatory Background AMG785 was developed under IND100391 by Amgen Inc. for the osteoporosis indication. The IND was first submitted on October 26, 2006.</p><p>The EOP2 meeting was held on August 19, 2011. The Division recommended that Sponsor conduct a 2-year rodent bioassay to evaluate the carcinogenic potential of AMG785 based on activation of Wnt signaling and the potential implication of the Wnt pathway in tumorigenicity. The Division stated that a 12-month monkey study may be adequate to support a 12-month clinical treatment duration.</p><p>The protocol for a rat carcinogenicity ('life time pharmacology') study was submitted by Sponsor on September 2, 2011, and was reviewed by the Executive Carcinogenicity Assessment Committee (ECAC) on <ref type="bibr">October 11, 2011.</ref> At the Type B pre-BLA meeting on May 18, 2016, no major issues regarding the adequacy of the nonclinical program for romosozumab were identified or discussed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3</head><p>Studies submitted/reviewed 3.1 Studies Reviewed Pivotal pharmacology and toxicology studies submitted to the BLA were reviewed in detail. This included the OVX monkey bone pharmacology study, repeat dose toxicity studies in rats and monkeys, rat carcinogenicity study and rat reproductive toxicity studies. The results of several other pharmacology, toxicity, PK and genotoxicity studies were reviewed and presented in written and/or tabular summaries. Some of the studies described in this review were previously reviewed for IND 100391 or IND 103077, both for AMG785.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.2</head><p>Studies Not Reviewed A number of pharmacology, toxicology and PK/ADME studies were not reviewed or not reviewed in detail. Those studies were considered not to be of immediate or signficant relevance to the safety assessment of the product for the postmenopausal osteoporosis indicaton. The PK/assay validation studies were not reviewed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D. 17</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.3</head><p>Previous Reviews Referenced Several studies submitted to the BLA had been reviewed for IND 100391 and 103077, including the 1-month and 6-month toxicity studies in rats and monkeys and the dose range finding and definitive embryofetal development (EFD) studies.</p><p>Dr. Gemma Kuijpers reviewed the pivotal pharmacology studies in detail as well as several other pharmacology and toxicology studies submitted to the BLA, and integrated the findings in studies previously reviewed for IND 100391 or 103077 in the BLA review.</p><p>Dr Andrea Benedict reviewed the report of the monkey PK comparability study for Process 1 and </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D. 18 4 Pharmacology</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1">Mechanism of Action</head><p>Romosozumab (AMG785) is a humanized IgG2 monoclonal antibody against sclerostin. Sclerostin (Scl) is a cysteine-knot glycoprotein factor produced by osteocytes which plays an important role in the regulation of bone metabolism. Sclerostin was first identified through the discovery of the human genetic high bone mass disorders sclerosteosis and Van Buchem disease (VBD) where sclerostin is absent or subject to decreased expression. The increased bone mass in these populations is thought to be due to the loss of sclerostin's inhibitory effect on bone formation.</p><p>The discovery of sclerostin led to the development of sclerostin antibodies (Scl-Ab) to increase bone mass for therapeutic purposes. The treatment was initially considered anabolic since the antibodies were known to increase bone mass by increasing bone formation. However, it later became evident that sclerostin does not only inhibit bone formation but also activates bone resorption, and Scl-Ab has both anabolic and antiresorptive effects. The Sponsor's nonclinical and clinical studies in this application provide evidence of both actions.</p><p>Sclerostin produced by the osteocyte binds to LRP4, LRP5 and/or LRP6 receptors, which are parts of Wnt receptor complexes, thereby inhibiting Wnt/-catenin signaling and downstream transcriptional events <ref type="figure" target="#fig_0">(Figure 1, below)</ref>. Studies with Scl-Ab in OVX rats have shown complex, time-dependent effects on Wnt target gene expression, mainly in osteocytes but also in osteoblasts and bone lining cells. The targets are directly or indirectly linked to osteoblast and osteoclast generation, differentiation and/or function. The gene transcription changes are most conspicuous in the osteocyte, the cell which is ultimately responsible for the anabolic effect of Scl-Ab. Delayed downregulation of pro-mitotic factors in the osteocyte appears to limit osteoblastic cell proliferation, consistent with the transient or 'self-regulatory' nature of the bone formation response to Scl-Ab. Suppression of bone resorption appears to be at least partly due to blockade of osteocytic RANKL production and stimulation of osteocyte or osteoblast OPG production, while the increase in bone formation involves differentiation of lining cells or osteoprogenitor cells resulting in increased numbers of active osteoblasts.</p><p>It has been suggested that the anabolic effect of intermittent PTH administration occurs at least in part through inhibition of sclerostin which would explain the common anabolic effect of PTH and Scl-Ab treatment. However, PTH can increase bone mass also in the absence of sclerostin, contradicting this hypothesis. The MOA's of these treatments, both probably mediated principally by the osteocyte, have only partly been elucidated.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D. 20</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2">Primary Pharmacology</head><p>The sponsor conducted in vitro and in vivo pharmacology studies with sclerostin-antibodies. The antibodies used in the in vivo studies included rat or mouse Scl-Ab (rat studies) or AMG785 (rat and monkey studies).</p><p>In vitro studies showed high affinity binding of AMG785 to sclerostin, which led to blockade of the sclerostin-mediated inhibition of bone matrix mineralization in a mouse calvarial cell line.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In vivo bone effects</head><p>Long term bone pharmacology studies ('bone quality studies') of up to 12-month duration were conducted with AMG785 in OVX rats and monkeys (Studies 107899 and 107903), at doses up to 50 mg/kg in rats and 30 mg/kg in monkeys (up to 19x and 22x human exposure at the monthly 210 mg dose, based on AUC comparison), respectively. Studies were also conducted in rats and monkeys to evaluate the mechanisms involved in the effects of AMG785 on bone metabolism.</p><p>In both OVX rats and monkeys, AMG785 caused a rapid and dose-related increase in osteoblastic bone formation. Bone marker data also showed increases in osteoclastic bone resorption, which was probably due to PTH-induced stimulation of Haversian and possibly periosteal remodeling. In monkeys, both formation and resorption responses were transient and peaked at 10 weeks.</p><p>The dynamic events led to marked dose-related increases in bone mass and size, evidenced by increases in densitometric and geometric parameters (BMD, BMC, area, perimeter, thickness) , at all evaluated skeletal sites. The increases in bone mass and size were largest in the first 6 months but continued at a slower rate thereafter. Changes occurred at all doses 3 mg/kg, with parameters in the mid and/or high dose groups (10-50 mg/kg in rat, 30 mg/kg in monkey) exceeding those in the sham control groups.</p><p>Histomorphometry of cancellous and cortical bone sites showed enhanced bone formation predominantly at trabecular and endocortical surfaces, and increases in trabecular and cortical thickness. Cortical thickening in both species was mostly due to increased endosteal bone apposition, although there was also a periosteal component. In OVX monkeys, the bone formation increases were most pronounced after 3 months of dosing and declined to control levels at 12 months. Bone resorption indices (eroded surface fractions) at these surfaces were reduced in the AMG785-treated OVX monkeys, particularly at 3 months in rib but were still observed at 12 months in femur. The resorption effect was not significant in the OVX rat. In OVX monkeys, increased bone modeling was evidenced by a reduction in quiescent surface and an increase in formative surface fraction due to activation of bone lining cells.</p><p>In cortical bone, AMG785 also increased periosteal and intracortical ("Haversian") bone formation rates in rats and/or monkeys. Based on lack of significant changes in bone width and porosity in monkeys, resorption at these two surfaces was probably also increased. This was most likely due to the AMG785-induced increase in serum PTH.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>21</head><p>Bone strength was increased in conjunction with bone mass, and there were positive effects on extrinsic as well as intrinsic (geometry-corrected) biomechanical parameters at both cancellous and cortical bone sites. Based on the positive and statistically significant correlations between bone mass and whole bone strength parameters, and between bone density and intrinsic strength parameters, adverse effects on bone quality were not identified in the 12-month studies. In both monkeys and rats, an apparent improvement of vertebral bone quality was seen at the high doses of 30 and 50 mg/kg, respectively.</p><p>Data from a high dose recovery group in the 12-month OVX monkey study with treatment discontinued after 6 months showed that all or most effects of AMG785 reversed towards OVX control levels, including BMD/BMC, trabecular and cortical thickness, and strength parameters.</p><p>One exception was the reduction in endocortical eroded perimeter fraction in femur shaft, which was still significantly decreased vs OVX control at end of recovery.</p><p>In another 6-month study in OVX monkeys (Study 118025) at a clinically equivalent dose of 3 mg/kg dose, a detailed evaluation of changes in radius and tibia was performed. AMG785 caused an increase in intracortical bone turnover mainly in radius but also in tibia. Slight decreases in diaphyseal pQCT-vBMD were also observed in radius in tibia, as seen in the 12-month OVX monkey study. However, DXA-BMD of all radius regions was increased. Histomorphometry showed slight increases in cortical porosity which may have contributed to the decreases in pQCT-vBMD. However, BMC and cortical thickness of both radius and tibia were slightly increased and there were no decreases in diaphyseal and metaphyseal strength of the radius at 3 and/or 6 months.</p><p>Tissue BMD (bone without soft tissue) was minimally but significantly decreased by AMG785 in vertebrae, radius and tibia (cortical and/or cancellous bone) of OVX monkeys. The significance of the tissue BMD effect was not clear.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Kinetics of remodeling</head><p>While AMG785 induces modeling-based bone formation and suppresses bone resorption, residual resorption followed by formation continues to contribute to the bone remodeling process. A reconstruction of the kinetics of the vertebral remodeling cycle was performed using histomorphometry in a 28-week study in aged male monkeys (Study R20150071). Vertebral bone volume and formation were increased, and an increase in MS/OS reflected improved osteoblast efficiency. The kinetic analysis showed decreased resorption and reversal periods, a decrease in erosion depth, an increase in wall thickness and no significant effect on formation period. This resulted in a positive bone balance in the individual bone remodeling units. A reduction of resorption and reversal periods was also observed in iliac cancellous bone after 3 months of treatment in the 12-month study (107903) and explains the decrease in eroded bone surface fractions (ES/BS) in both the 28-week and the 12-month study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exploratory analyses</head><p>Detailed exploratory analyses of bone structural units (BSUs) in intact vertebral and femoral bone using bSEM and FTIRM, and an analysis of Modeling Bone Formation (MBF) and Remodeling Bone Formation (RBF) were included in a 10-week fibula fracture healing study in adolescent male monkeys with 30 mg/kg AMG785 (Study 108088). AMG785 showed positive</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p><p>22 effect on bone healing in this study. MBF was increased and RBF was unaffected at vertebral trabecular and femoral endocortical surfaces. The exploratory analyses showed a very slight shift in vertebral BMDD towards lower values, and a decrease in vertebral BMDD standard deviation suggesting an increase in the homogeneity of trabecular bone with respect to mineral density. There were no global mineralization effects. Matrix and mineral properties were not affected in any bone compartment, but intracortical mineralization appeared temporarily accelerated. Evaluation of MBF and RBF suggested that increases in both modeling and remodeling based bone formation likely contribute to the bone efficacy of AMG785. The data were generally supportive of preservation of bone quality upon AMG785 treatment and did not suggest significant bone safety concerns.</p><p>Mechanistic studies Mechanistic studies provided information about gene transcription in vertebral osteocyte, osteoblast and lining cells in response to acute and chronic Scl-Ab dosing (Studies 105877 and 115777). After initial stimulation of osteoblast number and activity, there was a delayed induction of p53 and an inhibition of mitogenesis and cell cycle progression signaling pathways in the mature osteocyte. This was likely limiting the proliferation of cells in the osteoblast lineage (steoprogenitors) and related to the 'self-regulation' (transient increase) of bone formation. Transcriptional activation of genes involved in osteoclastogenesis and resorption were less clearly self-regulated. The MOA of Scl-Ab appears to include stimulation of osteoblast OPG production, and inhibition of osteocyte RANKL production, together causing a suppression of osteoclast generation and/or function. The sponsor suggested that in contrast to Scl inhibition, activation of bone formation by PTH is not tightly self-regulated, which may explain the pronounced bone tumorigenicity of PTH(rP) analogues (Study 115776).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Species differences</head><p>In general, the effects of AMG785-induced sclerostin inhibition on bone turnover, mass, structure, and strength were similar in OVX rats, OVX monkeys and postmenopausal women, suggesting broad cross-species similarity in the role of sclerostin in bone metabolism. The main difference between animals and humans was the decrease in resorption markers in postmenopausal women vs. the increase in resorption markers in animals. This was probably related to the larger increases in serum PTH observed in animals who did not receive dietary Ca supplementation, causing more stimulation of intracortical and possible also of periosteal bone remodeling. Nonetheless, histologic bone resorption indices at trabecular and endocortical surfaces were reduced in OVX monkeys (Study 107903), an effect that was also observed in humans, and in rats treated with rat Scl-Ab, r13c7 (Study R20110286). The apparent lack of such an effect in the AMG785-treated OVX rats may have been due to the fact that resorption indices were measured only after 12 months of dosing in the pivotal OVX rat study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>23</head><p>In vitro studies Study Number</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Type of Study Methods Findings</head><p>R2006058 Binding affinity of romosozumab to sclerostin Kinexa equilibrium binding assay to determine the binding affinity of romosozumab, r13C7, and m13C7 binding to human, cynomolgus monkey, mouse and/or rat sclerostin.</p><p>Romosozumab binds to human, cynomolgus monkey, and rat sclerostin with Kd of 11 pM, 23 pM, and 3 pM, respectively.</p><p>Antibody r13C7 binds rat sclerostin with Kd of 6 pM.</p><p>Antibody m13C7 binds to human, mouse, and rat sclerostin with Kd of 9 pM, 1 pM, and 3 pM, respectively.</p><p>R20130040 Effects of romosozumab on sclerostin binding to LRP4, LRP5, and LRP6</p><p>Human sclerostin was incubated with or without romosozumab prior to incubation and immunoprecipitation with recombinant ECDs of human LRP4, LRP5 and LRP6. Western blotting was used to evaluate the effect of romosozumab on LRPsclerostin binding.</p><p>Romosozumab did not block the binding of sclerostin to the ECD of the facilitator protein LRP4.</p><p>AMG785 did block the binding of sclerostin to the ECDs of the key Wnt signaling co-receptors, LRP5 and LRP6.</p><p>Reviewer Comment: Sponsor's in vivo data showed that romosozumab suppressed bone resorption in all species studied <ref type="bibr">(rat, monkey, human)</ref>. It has been suggested in the literature that binding of sclerostin to LRP4 plays a role in Scl-mediated stimulation of osteoclast activity. The data from Study R20130040 suggest that the osteoclast stimulating effect of sclerostin is either not mediated by LRP4, or the ECD binding site of LRP4 is not involved in this effect.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>R2006057 Effects of romosozumab in an osteoblastlineage cellbased mineralization bioassay</head><p>This bioassay was conducted in MC3T3-E1-BF cells, a mouse calvaria-derived osteoblast-lineage cell line. Romosozumab (0, 10, 20 and 40 g/mL) was pre-incubated with 1 g/mL of sclerostin and this mixture was added to the MC3T3-E1-BF cells. The extent of mineralization was measured by solubilizing the precipitated calcium phosphate after 12 days and measuring total calcium.</p><p>Recombinant sclerostin from 4 species (human, cynomolgus, rat, and mouse) dose-dependently inhibited matrix mineralization by MC3T3-E1-BF cells.</p><p>Romosozumab blocked the inhibitory effect on mineralization of all 4 sclerostins.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>24</head><p>In vivo studies</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>An 8-Week Compound Section Dose Range-Finding and Pharmacokinetic Study in the Cynomolgus Monkey (Study 105876) (non-GLP)</head><p>This was an 8-week study in intact female cynomolgus monkeys with AMG785 doses of 0, 3, 10, 30 mg/kg once monthly. o Serum OC and P1NP were dose-dependently increased. Tmax of P1NP was 7-14 days <ref type="figure" target="#fig_2">(Figure 3, below)</ref>. o CTx was increased only at the high dose of 30 mg/kg <ref type="bibr">(Study Nr. 107903)</ref> (Study treatment period Jan 2012 -Jan 2013) <ref type="bibr">(GLP/QA Dec 17, 2014)</ref> A detailed review of this study is located in APPENDIX 1.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A 52 Week Bone Quality Study to Determine the Effects of Weekly Subcutaneous Injection of AMG 785 on the Primary Pharmacodynamics of Aged Ovariectomized Cynomolgus Monkey</head><p>Monkeys were sham-operated or OVX-ed and after a 4-month bone depletion period they were treated for 12 months, QW, with 0, 3, or 30 mg/kg AMG785 (1.3x, or 22x human AUC), or with 30 mg/kg followed by vehicle for 6 months each (recovery group). ADA+ animals were excluded from analyses.</p><formula xml:id="formula_28">Reference ID: 4081796 (b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p><p>25 o AMG785 treatment transiently increased bone formation and resorption markers. Effect on formation and resorption markers peaked at 3 months, but were 2.5-fold larger for formation marker P1NP vs resorption marker CTx. o AMG785 caused increases in PTH and Vitamin D that remained above OVX levels at 12 months. Serum Ca was slightly decreased. o Densitometry (DXA) showed increases in BMD and/or BMC and Area in spine, tibia, femur, and distal radius. Increases were most prominent in the first 6 months, and at 12 months levels often exceeded those in sham controls at both 3 and 30 mg/kg. o PQCT showed increases in cortical thickness in tibia and radius diaphysis due to slight increase in bone width and/or decrease in medullary area. Cortical BMD was transiently decreased in tibia (minimally) and radius (slightly), but BMC was slightly increased. o AMG785 increased bone strength of femur diaphysis and did not affect intrinsic cortical bone strength. Bone strength parameters in spine and femur neck were increased consistent with densitometry results. o Correlations between bone mass and strength were positive and suggested maintenance or improvement of bone quality. o Histomorphometry was performed for ilium, vertebrae and femoral neck (cancellous bone), and for rib and femur diaphysis (cortical bone), at interim time points and/or end of study.  Data clearly showed progressive increases in trabecular and cortical thickness over time, and increases in bone formation indices including BFR/BS at trabecular, endocortical, periosteal and Haversian (intracortical) bone surfaces, particularly at the earlier biopsy time points (Wk 13), consistent with the transient nature of the increases in bone formation markers.  Cortical thickness increases in rib and femur were mainly due to endosteal bone apposition consistent with pQCT densitometry.  Numerically, BFR/BS in OVX controls was largest at Haversian &gt; endocortical  trabecular &gt;&gt; periosteal surfaces.  The increase in trabecular and endocortical bone formation was due to an increase in formative vs quiescent fractional bone surface (i.e. bone modeling). Wall thickness was increased in cancellous bone.  The slight increase in cortical porosity at 6-12 months suggested a concomitant increase in Haversian resorption. Similarly, the lack of change in total bone area suggested a concomitant increase in periosteal resorption.  In cancellous bone, eroded surface % was decreased only at Wk 13 in ilium.</p><p>Endocortical eroded surface % was markedly reduced in rib, mostly in Wk 13, to below OVX and sham control levels. However, it was also markedly suppressed in femur diaphysis at 12 months, and was not reversed in the recovery group. Data suggested that at the endocortical surface AMG785 initially causes a marked stimulation of bone formation ("modeling") and a marked and continued reduction in osteoclastic bone resorption. o The increases in systemic resorption markers (reflecting all skeletal surfaces) were probably due to increases in Haversian resorption and to a minor extent to periosteal resorption, outweighing reductions in resorption localized to trabecular and endocortical surfaces. This enhanced resorption was probably related to the AMG785-induced PTH increase, protecting against hypocalcemia.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>26</head><p>o The animal data support the appropriateness of the proposed clinical treatment period of 12 months. Group size N/grp was initially 20, 20, 50, 35, 35 F/grp, but after exclusion of ADA-positive animals or animals with confounding necropsy findings, group size for analysis of findings was reduced to: <ref type="figure" target="#fig_0">N= 10, 15, 15, 10, 15</ref>. A baseline group terminated after bone depletion (N=10/gr) was also included in study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Endpoints/ Methods</head><p>Mortality, clinical observations, body weight/food consumption, Cpl (predose, in <ref type="bibr">Wks 9,</ref><ref type="bibr">17,</ref><ref type="bibr">25,</ref><ref type="bibr" target="#b91">33,</ref><ref type="bibr" target="#b92">41,</ref><ref type="bibr">49,</ref><ref type="bibr">and 52</ref>; by ELISA) bone markers (OC, ALKP, CTx, urine DPD), ADA, DEXA and pQCT (in vivo, necropsy, organ weight, histology, DEXA/pQCT/uCT (ex vivo), histomorphometry (Wk 52 ONLY), biomechanical testing.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>(AMG785 effects)</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Observations/ Pathology</head><p>No Tx-related deaths or observations, no significant effect on BW or FC Cpl AUC Minimal and maximal mean Cpl in retained rats suitable for bone quality assessment (some of whom were binding ADA-positive) ranged from 21.4 to 44.3 ug/mL, 169 to 242 ug/mL, and 793 to1190 ug/mL between weeks 9 to 52, in 3, 10, and 50 mg/kg AMG 785 dosed groups, respectively.</p><p>The AUC multiple calculation for 3, 10, 50 mg/kg was based on data from the 2-year carcinogenicity study which used the same doses as this 12-mo bone quality study.</p><p>Bone markers AMG785 increased bone formation marker osteocalcin (OC) throughout treatment with maximal effect of +30% (vs OVX control) at Wk 11.</p><p>AMG also increased serum resorption marker CTx in Wks 11-39 with maximal effect of +36% vs control at Wk 39). However, AMG had no effect on urine resorption marker DPD.</p><p>Reference ID: 4081796</p><formula xml:id="formula_29">(b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>27</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histomorphometry</head><p>At 52 weeks, trabecular thickness was increased dose-dependently in cancellous bone of L3 vertebrae and proximal tibia metaphysis. This was associated with increases in static and dynamic formation parameters. Wall thickness in L3 was increased dose-dependently at all doses. Also after 52 weeks, cortical thickness and cortical area in tibia diaphysis were increased, associated with non-dose-related increases in endocortical bone formation/apposition at all doses. While Ps.BFR/BS was smaller than Ec.BFR/BS, periosteal BFR was increased by a larger % than Ec.BFR by AMG treatment, also in non-dose-related manner.</p><p>There was a non-dose-related ca. 2x INCREASE in Oc.S/BS in L3 vertebra but this was not significant. Cancellous ES/BS was not measured. A small non-dose-related DECREASE in resorption index Ec.E.Pm/Ec.Pm (up to -20%) was observed in the tibial diaphysis, at all doses, at 52 weeks.</p><p>Intracortical bone remodeling (a minor process in rats) was not assessed.</p><p>There was no impairment of bone mineralization, i.e., no changes in O.Th and Mlt.</p><p>Densitometry AMG increased BMC and BMD (DXA and pQCT) at cancellous bone sites (spine, proximal tibia metaphysis). BMD increases in lumbar spine were +19%, +34%, +48% at Wk 51/52 vs Wk 1 AMG also increased cortical BMC, BMD, and cortical area/thickness (by pQCT) in the proximal tibia diaphysis, due to increased periosteal circumference and decreased endosteal circumference.</p><p>AMG treatment resulted in values often exceeding sham levels at higher dose levels.</p><p>Ex vivo DXA and pQCT data were basically similar to in vivo data. Micro-CT also showed increased bone mass and minimally reduced tissue BMD in cancellous and cortical bone (latter also seen in 12-mo OVX monkey study but may be an artifact)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mechanical testing</head><p>Bone mass and geometry changes resulted in increased bone strength parameters in vertebrae, femur neck and femur diaphysis. Peak load (Fu) increased up to 121% (femur diaphysis), +46% (FN), +270% (LV), compared to OVX controls by Wk 52.</p><p>Bone mass and bone strength positively and significantly correlated at all doses. Based on increased slope of regression line at 50 mg/kg (L4+L5), there were increases in calculated material properties, indicating improvement of vertebral bone quality due to either beneficial micro-architectural properties (most likely) or increases in intrinsic bone material strength.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>28</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments</head><p> Data from rats were consistent with data from the 12-month monkey bone efficacy/quality study.  In another study in OVX rats with Scl-Ab r13c7 (26-week Study R20110286), static histomorphometric resorption indices in both cancellous and cortical bone were clearly decreased by r13c7 (as in humans treated with AMG785).  The OVX rat study was an adequate nonclinical bone efficacy/safety assessment. <ref type="bibr">(Study Nr. 118025) (GLP/QA Dec 23, 2015)</ref> Goal of study was to measure bone mass and strength in radius (vs tibia) specifically, in aged OVX monkeys, at clinical exposure (3 mg/kg).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A 6 Month Subcutaneous Pharmacodynamic Repeated-dose Toxicity Study in the Aged Ovariectomized Cynomolgus Monkey</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>Animals Cynomolgus monkeys (OVX only), <ref type="bibr">9-16 yrs, 3-5.</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>(AMG785 effects)</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Observations/ Pathology</head><p>Several treated animals developed ADAs and were excluded from analyses</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Markers/ Hormones</head><p>Increased formation and resorption markers CTx and P1NP, and increased serum PTH/VitD Densitometry Increase in BMC in spine, proximal tibia, distal radius metaphysis and ultradistal radius due to increased trabecular thickness. Increase in cortical thickness (proximal tibia and distal radius diaphysis) due to increase in periosteal circumference (radius and tibia) and decrease in endosteal circumference (tibia).</p><p>Small decrease in cortical pQCT-BMD in radius meta-and diaphysis, but not in tibia. Increases in pQCT total and cortical area, thickness and BMC, at tibia &gt; radius.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ExtremeCT (HRpQCT)</head><p>Increase in BMC at radius meta-and diaphysis. Decrease in tissue BMD (tBMD, or TMD) in radius meta-and diaphysis at Mo 6, possibly related to increased intracortical remodeling</p><p>Reference ID: 4081796</p><formula xml:id="formula_30">(b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>29</head><p>Histomorphometry (cortical radius/tibia) Transient stimulation of intracortical remodeling from Wk 12-Wk25 (max at Wk 16), in radius&gt;&gt;tibia, based on evaluation of fluorochrome-labelled bone at several time points At 6 months, BFR/BS increased (n.s.) at endosteal and periosteal surfaces, similar to 12-mo study 107903. Significant increase in Haversian BFR/BS was consistent with increased intracortical remodeling and small nonsignificant 40% increase in porosity in radius. No significant change in cortical geometry (thickness, area) in tibia and radius. Decrease in Ec.E.Pm mainly in tibia.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mechanical testing</head><p>Radial diaphysis was weaker in AMG treated group (consistent with BMD data) but that appeared due to fact that 3 mg/kg animals had lower BMC at start of Tx (possibly due to exclusion of several ADA+ animals). This was confirmed by observed increases in peak load, yield load and stiffness when using pre-Tx BMC as covariate, and also by the lack of effects on intrinsic strength parameters, except for a small but significant decrease in radius diaphyseal yield stress (-8%).</p><p>Correlations between radius meta-and diaphyseal BMC and Fu or AUC were unchanged by 3 mg/kg AMG. FEA confirmed lack of an adverse effect on yield load <ref type="figure" target="#fig_8">(Fig. 8</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments</head><p>Study provided detailed information on bone efficacy/safety of tibia and radius. Decrease in radius cortical bone BMD may have been due to increased intracortical modeling, but slightly increased cortical thickness due to bone apposition at both outer and inner surfaces appeared to compensate for potential negative strength effect.</p><p>Decrease in tissue BMD of radial shaft may have contributed to the decrease in yield stress at 6 months. Cause of effect on bone tissue BMD (BMD of bone material), also observed in other studies, is unclear and may be an artifact.</p><p>There was no clear signal of adverse effects on bone material strength by AMG (eg increased brittleness). Correlations between BMC and extrinsic (corrected) strength parameters, or BMD and intrinsic strength parameters, respectively, were not affected, suggesting the same.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>30</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effect of Romosozumab on Bone Remodeling Kinetics in the Cynomolgus Monkey</head><p>(Study Nr.20150071) (Amgen, Inc) <ref type="bibr">(Non-GLP, Report date Jan 26, 2016)</ref> The study objective was to determine the effects of romosozumab on trabecular (vertebral) bone remodeling using a kinetic reconstruction analysis and examination of resorption depth in monkey lumbar vertebrae. The tissues used in this study were from a study to investigate the effects of romosozumab and two other drug treatments for 28 weeks on fracture repair in a critical gap defect model in the monkey ulna.</p><p>Procedure Animals Cynomolgus monkeys (males, 10-12 years old) (aged/mature) Doses AMG785: 0 and 30 mg/kg, Q2W, (30 mg/kg = 22x human AUC) Group size 10-12/ group Duration 28 weeks Procedure Densitometry (DXA, uCT)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histomorphometry:</head><p>o Fluorochrome labels were administered periodically over the time course. o L3 vertebral bodies from N= 9/grp were analyzed by histomorphometry. Kinetic reconstruction of remodeling process was performed. Remodeling formative sites were defined by an underlying scalloped cement line. o Final W.Th was measured in completed packets that contained any label to provide an average effect across the treatment duration; those that contained tetracycline labels, administered early in the treatment period, were separately evaluated to capture the early treatment effect. Final W.Th was also projected for packets near completion at the end of the study to reflect the treatment effect after 28 weeks. o Resorption depth was measured in packets at the reversal line without osteoid with preosteoblasts, by counting lamellae from the deepest point outward along the surface until a quiescent surface was reached. After animal exclusions, final N analyzed was 8/grp.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Densitometry (DXA, uCT)</head><p>Densitometric parameters BMD, BMC, area, and BV/TV were increased in the healed gap defects in AMG vs vehicle-treated Histomorphometry AMG caused a ca. 2X increase in W.Th in active BMUs, which was associated with an increase in MS/OS reflecting improved osteoblast efficiency. Ob.S/BS was not measured.</p><p>Romosozumab reduced eroded surface % (ES/BS) significantly by ca. 70%, explained by a marked reduction (ca. 66%) in the length of the resorption (i.e. resorption + reversal) period. Formation period FP was unaffected.</p><p>Romosozumab reduced final resorption depth by 13%, and together with the increase in W.Th, this resulted in a positive bone balance (+14 m), in contrast to the negative bone balance observed in controls (-13 m) (diagram below).</p><p>Despite the decrease in erosion depth, the rate of osteoclastic resorption appeared to be increased during the shortened resorption period (diagram below).</p><p>Vertebral trabecular bone BFR/BS (surface referent) was increased. This was also observed in 12-month OVX monkey study (107903), in cancellous bone of vertebrae and femur neck (at 52 wks), and ilium (at 13-27 wks), at QW doses of 3 or 30 mg/kg.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>31</head><p>This diagram shows the positive bone balance in remodeling sites in vertebra of monkeys treated with (A) vehicle or (B) 30mg/kg AMG785. Bone balance in BRU is shown in (C). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Solid lines outline the resorption and formation phases of the bone</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p>Romosozumab increased wall thickness and decreased final resorption depth, yielding a positive bone balance that probably contributes to the increased bone volume and mass. RsP+RvP were decreased and FP increased which explains reduction in eroded surface at trabecular surfaces.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments</head><p>Study provided detailed information on the dynamic events in a bone remodeling unit (BRU) in monkey vertebra, specifying the MOA of anti-Scl Ab AMG785 at the tissue level.</p><p>Sponsor did not distinguish resorption from reversal period, and the calculated 'resorption period' was in fact the combination of resorption and reversal periods. According to Reviewer's analysis of histomorphometry data from Study 107903 (cancellous ilium at 13 wks, and femoral neck at 12 months), AMG785 caused a larger reduction in reversal ("resting") period than in resorption period.</p><p>The positive bone balance in the bone remodeling unit may also be achieved during modelingbased bone formation (MBF) at the various bone surfaces</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>32</head><p>The Effects of AMG 785 in a 10-Week Bone Healing Study Following Osteotomy of the Fibula in Young Male Cynomolgus Monkeys <ref type="bibr">(Study Nr.108288</ref>) <ref type="bibr">(Non-GLP, 2015)</ref> Study goal was to evaluate effects of romosozumab on diaphyseal bone healing, but also on bone modeling/ remodeling, tissue composition/mineralization and microarchitecture.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer comment:</head><p>The original study report only describes data on the effects of AMG785 on fibula fracture healing. Subsequent amendments to the report included three types of exploratory analyses <ref type="bibr">(Appendices 36/37,</ref><ref type="bibr">38/39,</ref><ref type="bibr">and 40)</ref>. The latter two were evaluations of bone matrix quality (App 38/39) and of tissue-level mechanisms of Scl-Ab-mediated bone formation (App 40). The data were previously published <ref type="bibr">(Ross et al, JBMR 29: 1597</ref><ref type="bibr">and</ref><ref type="bibr">Ominsky et al, JBMR 29: 1424, 2014, respectively)</ref>. App 36/37 included 3D histomorphometry data (C. Hernandez, Cornell Univ)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animals</head><p>Male monkeys (4-5 yrs old, adolescent). Animals underwent bilateral fibular osteotomy with internal stabilization with pin. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Observations/ Pathology</head><p>After 10 weeks of healing, fibula fractures in AMG group had less callus cartilage, smaller fracture gaps, and contained more bone and less fibrovascular tissue.</p><p>Markers, DXA, pQCT, Increase in P1NP and CTx, and significant increases in bone mass and bone strength in AMGtreated male monkeys in both non-fractured and healed bone.</p><p>Reference ID: 4081796</p><formula xml:id="formula_31">(b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>33</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HMM, strength testing</head><p>Non-fractured bone: Increases in DXA/pQCT BMC and BMD of lumbar spine and cortical thickness of distal radius, and increased bone formation indices at endocortical and periosteal surfaces in femoral shaft and neck. Increase in bone mass in spine and proximal femur were due to greater trabecular thickness in cancellous bone (vertebrae and femur neck). Spine strength was increased along with mass.</p><p>Fibula: Increased callus BMC, torsional bone strength and better fibula fracture healing in AMG-treated male monkeys. Improved correlation between BMC and max torque for fractured/healed fibula in AMG-treated vs controls.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exploratory analyses</head><p>3D histomorphometry:</p><p>AMG caused no new trabeculae, but did cause trabecular thickening and converted rod-like trabeculae into plate-like trabeculae. Matrix/mineral properties (FTIRM) (bone age-specific measurements in L2 and femoral shaft compartments) o No effect of AMG785 on mineral-to-matrix ratio, crystallinity, or collagen cross-linking, in endocortical, intracortical, or trabecular compartments (labelled BSUs). o Non-significant trend toward accelerated mineralization intracortically (temporarily increased mineral:matrix ratio in intracortical compartment at 0.5-2 wks ie young bonetissue age), but not in endocortical or trabecular compartments. o Significant 10% increase in carbonate substitution for tissue older than 2-weeks in the trabecular compartment (mechanical significance unlikely).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments</head><p>The small BMDD decrease in trabecular bone may be related to the slight tissue BMD decrease measured by microCT and HRpQCT in trabecular bone in other monkey studies. However, there was no effect on BMDD in cortical bone in which tissue BMD decreases had also been seen.</p><p>The significance of the decrease in trabecular bone mineralization heterogeneity is unclear. The Sponsor indicated that the effect was a result of the increase in number of pixels in the 5%-95% range (sharper peak).</p><p>Decreased heterogeneity has been observed in long term bisphosphonate treated bone. However this is reflected by a shift and a narrowing of the distribution curve towards higher</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>34</head><p>BMDD values. It is not clear how the decrease in heterogeneity with AMG785 could affect bone quality.</p><p>A temporary increase in mineralization in intracortical bone may be adverse (increased brittleness), however biomechanical measurements and calculation of bone material (intrinsic) properties did not reveal adverse effects on bone strength in any of Sponsor's animal studies. However, these measurements were made after prolonged dosing and may not show early effects.</p><p>Reviewer concludes that there were slight changes in bone properties that signal some minor concerns about bone quality AMG785 and hPTH <ref type="formula" target="#formula_34">(</ref> Assessments included bone mass and histomorphometry parameters (vertebrae, femur). Also performed were immunostaining (Runx2, nestin) and cell histology evaluation to distinguish osteoprogenitor (Opg) from osteoblasts and lining cells (various bone sites).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>Bone markers Scl-Ab: Early increase in formation markers declining markedly after 4 wks with little effect on resorption markers; PTH: more sustained increases in formation and resorption markers.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histomorphometry/ histology</head><p>Greater increases in cancellous and cortical bone mass in AMG785 vs PTH treated animals, correlating with higher BFR in AMG785 vs PTH treated animals in spine/mid-femur at 4 wks.</p><p>Attenuation of BFR/BS after 4 wks was larger in AMG785 than in PTH group. Lower Ob.N at 26-vs-4 wks in AMG vs PTH groups possibly reflected larger degree of selfregulation of bone formation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Increase in resorption indices</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments/ Conclusions</head><p>Compared to PTH, Scl-Ab can cause increases in cancellous bone mass with same/fewer number of osteoblasts, by increasing the osteoblast "footprint" and increasing individual osteoblast activity. This is coordinated with less stimulation of pre-progenitor cells and progenitor cells by Scl-Ab vs PTH, ie, more 'self-regulation'. These differences may be related to the pronounced osteosarcoma development by PTH but not AMG785 in rats.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>35</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Temporal effects of r13c7 on bone; effects of withdrawal or transition to OPG-Fc (Study Number. R20110286) (Amgen; non-GLP)</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>Animals Female Sprague Dawley rats were sham-operated or OVXed at 4 months of age, and underwent a 2-month bone depletion period.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Doses</head><p>After bone depletion, rats were treated SC, QW, with vehicle or 25 mg/kg r13c7 for 6, 12, or 26 weeks (n=12/group). Additional groups of OVX rats were treated for 6 weeks with 25 mg/kg r13c7 (SC Q1W, n=12) followed by 20 weeks of VEH (SC, 2QW, n=12), 10 mg/kg OPG-Fc (SC, 2QW, n=16), or 25 mg/kg r13c7 Q4W (n=12). Sham-operated rats were terminated at baseline (n=10) and after 6, 12, and 26 (n=12 each).</p><p>Group size N=12 or 16/grp</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Endpoints/ Methods</head><p>Endpoints included in vivo longitudinal assessment of DXA BMD and serum biomarkers; ex vivo microCT (Wks 6, 26), bone strength (Wks 6 and 26), histomorphometry (Wks 6, 12 and 26), osteoclastogenesis assay (Wks 6, 12, 26) and vertebra and tibia gene expression.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>(r13c7 effects)</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Observations /Pathology</head><p>Reduced ex vivo osteoclastogenesis in bone marrow collected from femur at Wk 6 and 12.</p><p>Increases in gene expression of Wnt inhibitors SOST and DKK1 at the vertebra through Wk 26.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bone markers</head><p>Increases in bone formation markers OC and P1NP, which peaked early and returned toward control levels over time. Transient mild decrease in bone resorption biomarker TRACP-5b.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histomorphometry</head><p>At week 6, histologic bone formation rate (BFR/BS) was significantly increased on trabecular surfaces in the vertebra and proximal tibia, and on periosteal and endocortical surfaces of the tibia diaphysis.</p><p>The increase in BFR/BS attenuated over time, remaining elevated on tibial, endocortical and trabecular surfaces, but approaching control levels by Wk 26 on tibial, periosteal and vertebral trabecular surfaces.</p><p>R13c7 clearly decreased bone resorption as reflected by decreases in resorption indices in cancellous bone of L3 and proximal tibia (ES/BS, QS/BS, OcS/BS) and in tibial cortex (Ec.ES/BS -marked effects) at Wks 6, 12 and 26.</p><p>This resulted in increases in trabecular thickness (spine and tibia) and cortical thickness (tibia), the latter mainly due to endocortical bone accretion. This was reflected by DXA and uCT data on bone mass.</p><p>Densitometry Progressive increase in bone mass at the lumbar spine and whole hindleg (in vivo DXA). Increased bone mass was also identified by ex vivo microCT analysis of several bone sites.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mechanical testing</head><p>Increase in bone strength (extrinsic/whole bone) of L5, femur shaft and femur neck at Wk 6 and 26. Neutral-to-positive effect on calculated intrinsic strength parameters for L5 and femoral shaft. Bone mass (uCT-vBMC) and bone strength (Fu and AUC) were positively correlated, similarly for all groups.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>36</head><p>Other findings</p><p>Discontinuation of Scl-Ab treatment at week 6 caused loss of bone mass and strength over time. This reversal was prevented by transition to rat OPG-Fc.</p><p>Transition to once-monthly r13c7 dosing after Wk6 preserved previous bone mass and strength gains, but did not achieve the increases observed with continued once weekly dosing.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments/ Conclusions</head><p> Neutralization of Scl in OVX rats by rat-specific Scl-Ab r13c7 (weekly dosing) caused increases in trabecular, endocortical and periosteal bone FORMATION, more prominently in Wk 6 than in Wks 12 and 26.  Scl-Ab r13c7 also caused marked sustained suppression of trabecular and endocortical bone resorption (this is unlike effect of AMG785 which did not clearly affect resorption markers or histologic indices in OVX rat).  This dual effect led to increases in bone mass and strength at various skeletal sites. Bone quality (correlation BMC vs strength) was maintained. This effect was more similar to the effect of AMG785 in postmenopausal women than that of AMG785 in the OVX rat.  After dose discontinuation, treatment with RANKL inhibitor (OPG) or less frequent treatment with r13c7 preserved the gains in bone mass and strength. This correlates with the proposed clinical use of romosozumab for 12 months, followed by a change to treatment with denosumab (Prolia; a RANKL inhibitor).  <ref type="bibr">(Taylor et al, Bone 84: 148-159, 2016)</ref> o 8-month old OVX rats were treated with rat Scl-Ab r13c7 (0, 50 mg/kg), once weekly for 26 weeks, followed by an 18-wk recovery period. o Methodologies included histomorphomtery, pQCT, stereologic analysis, LCM (laser capture microdissection) to separate bone cells, RNA extraction, microarray, and Taqman, and gene network/function analysis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>r13C7: Exploratory Single Dose Subcutaneous Toxicology Study in the Aged</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>37</head><p>o Data showed a rapid and marked increase in BFR/BS and Ob.N with maximal BFR/BS on Day 29, followed by a progressive decline in BFR/BS and Ob.N through dosing Day 183. During recovery, BFR/BS was initially suppressed and then returned to control levels. o Bone resorption (OcS/BS) was dose-dependently decreased from Wk 4-26, ie during the entire dosing period. o Transcriptional changes in Wnt and mitotic cell genes occurred according to specific time patterns in the three dfferent types of bone cells (OB=osteoblasts, LE=lining cells, Ocy=osteocytes) ( <ref type="figure" target="#fig_5">Fig. 5, below</ref>) o Reduction in osteoprogenitors preceded the reduction in osteoblasts and bone formation and correlated with significant transcriptional changes in the osteocyte <ref type="figure" target="#fig_5">(Fig. 5A)</ref>. o Transcriptional changes included induction of signaling pathways that are known to regulate Wnt signaling and suppress mitogenesis and cell cycle progression. o The data suggested that regulation of canonical Wnt signaling is complex and multifactorial and involves (a) induction of pathways such as TGF-1, Hippo, and noncanonical Wnt that are recognized to modulate the output of canonical Wnt signaling, and (b) induction of extracellular inhibitors such as Sost and Dkk1. However, the most significant signaling changes occurred in pathways that would limit cell cycle progression <ref type="figure" target="#fig_5">(Fig. 5B, below)</ref>. o The temporal relationship between these transcriptional changes and changes in BFR/BS suggests that suppression of mitogenesis and cell cycle progression may contribute to the self-regulation of bone formation observed with long-term Scl-Ab treatment. o The induction of p53 and other tumor suppressor signaling would be expected to limit mitogenesis and reduce the potential for bone carcinogenicity. o RANKL/OPG ratio was suppressed during the 26-week dosing phase, consistent with the effects on bone resorption parameters. o Trabecular bone mass progressively increased through Day 183, and declined during recovery. Oc.S/BS (% osteoclast covered surface) was decreased during the dosing and increased in the recovery period, with corresponding changes in expression of major regulators of osteoclastogenesis. Changes of genes important for osteoclastogenesis regulation mirrored the histologic changes in bone resorption. o The potential MOA of acute and chronic Scl-Ab exposure is presented in <ref type="figure" target="#fig_38">Fig.9</ref> below.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Histomorphometry (Bone Biopsy Substudy of Phase 3 Study 20070337)</head><p>This information was informally reviewed in order to better interpret animal findings and their potential relevance to clinical outcomes. Please refer to the clinical review for additional information and interpretation of clinical findings.</p><p>In postmenopausal women treated with SC romosozumab 210 mg QM vs placebo for 12 months (Study 20070337), histomorphometric analysis of iliac biopsies (2 and 12 months) showed the following effects of romosozumab:</p><p>o </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>41</head><p>o Data on Ps.BFR/BS in Dmab-treated were not available.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer's Comment:</head><p>The bone histomorphometry data from rat, monkey and human studies suggests that the bone effects of romosozumab are similar across species. This supports the clinical relevance of the information from the animal studies about the effects of romosozumab at various skeletal sites and surfaces.</p><p>Postmenopausal Women* OVX Monkey** Resorption markers/indices</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Formation markers/indices</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Resorption markers/indices</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Formation markers/indices</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Markers</head><p>Formation </p><formula xml:id="formula_32">  Resorption   HMM indices Trabecular     Endosteal     Intracortical ND ()  ND (-)  Periosteal ND ()  ND (-)  *</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary pharmacology studies not reviewed</head><p>The following studies were not considered critically relevant for the BLA application and were not reviewed: </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>42</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3">Other Pharmacology</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary</head><p>Quantitative RT-PCR analyses of human tissues showed SOST expression at  1 copy/cell (based on 30 pg RNA/cell) in pulmonary artery, left atria, and kidney. Another study showed consistent expression across species in bone and aorta (not rat aorta), with expression in kidney limited to humans.</p><p>Testing in animal models relevant for the target patient population was also performed. Scl-Ab was shown to increase bone mass in the fracture callus, resulting in improvements in functional strength in a rodent fracture repair model.</p><p>Scl-Ab was also effective in increasing bone formation and preventing the disease-associated decrease in bone mass and strength in models of androgen ablation, inflammation, and skeletal disuse/unloading.</p><p>Since sclerostin is expresssed in chondrocytes, the effects of Scl-Ab and Scl-Ab Fab were tested in the rat medial meniscal tear model of osteoarthritis (OA). Results did not indicate a significant effect on the progression of induced osteoarthritis. The study evaluated the mRNA expression of the SOST gene, encoding for sclerostin in a broad range of tissues from normal mouse, rat, cynomolgus monkey, and human, using RNA sequencing.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In vitro studies</head><p>SOST mRNA is most consistently expressed across species in bone (not evaluated in human) and aorta (but not in the rat). Expression in kidney was limited to human. Levels in other tissues were considered (1) not detectable, <ref type="formula" target="#formula_34">(2)</ref> found in only one species and not others, (3) found in one species, but data from other species were not available to confirm the finding.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>43</head><p>In vivo studies Study Number</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Type of Study Methods Findings</head><p>R20090220 Temporal effects of r13c7 on closed fracture healing</p><p>Male SD rats underwent a standard closed femoral mid-diaphyseal fracture stabilized with an intramedullary pin at 12-weeks of age (closed Fx model). Animals were injected SC Q2W with vehicle or r13c7 at 25 mg/kg for 1, 2, 3, 5, 7 and 9 weeks (n = 8/grp for Wks 1-2; n = 26/grp for Wks 3-9). Treatment was initiated 1 day post fracture. Endpoints included histomorphometry, densitometry (DXA, pQCT and micro-CT) and bone strength testing over the time of healing through 9 Wks post fracture.</p><p>Scl-Ab r13c7 increased bone mass in the fractured femur by Wk 3, with increases in torsional strength by Wks 5 and 9. Tx with r13c7 induced increases in bone volume and decreases in marrow volume in the external callus. However, it did not affect the fibrous or cartilaginous portion of the callus.</p><p>In the intact femur, r13c7 increased bone formation in distal metaphysis and midshaft from Wks 2 to 9, corresponding to increases in DXA BMD.</p><p>Scl-Ab r13c7 caused a transient increase (Wk 3 to 7) in longitudinal growth rate of the intact distal femur. However, it returned to control levels at Wk 9 and did not impact the overall length of the femur.</p><p>The results indicated that Scl-Ab improved fracture healing in this animal model mainly by increasing bone volume in the external callus.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Studies not reviewed in detail</head><p>It was show in other studies that Scl-Ab was effective in increasing bone formation and preventing disease-associated bone mass and strength decreases in models of androgen ablation, inflammation, and skeletal disuse/unloading. Effects of Scl-Ab and Scl-Ab Fab were tested in the rat medial meniscal tear model of osteoarthritis (OA), based on expression in chondrocytes.</p><p>Results did not indicate a significant effect on the progression of induced osteoarthritis. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study # Title</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>44</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary Pharmacology/Theoretical Safety Issues</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary</head><p>The Sponsor presented an extensive discussion of theoretical/potential safety issues of romosozumab, based on gene and/or protein expression of sclerostin in various tissues <ref type="table" target="#tab_87">(Table 1</ref>, below), and the potential activation of Wnt signaling by AMG785.</p><p>The issues were considered in the context of published literature as well as Sponsor's own clinical and nonclinical studies, and included: cancer, osteoarthritis, vascular calcification, increased longitudinal bone growth, hyperostosis, hypercementosis, osteonecrosis of the jaw (ONJ), altered hematopoiesis, sarcopenia, altered glucose metabolism, exacerbation of TNFdriven inflammatory disease, and atypical femoral fractures (AFF).</p><p>Since sclerostin is mainly produced by osteocytes, chondrocytes, cementocytes, blood vessels and vascular muscle cells, and para-and autocrine effects are probably most important, issues in mineralized and adjoining tissues (eg bone marrow), teeth, joints, and the vasculature seem most plausible. Carcinogenicity due to enhanced Wnt signaling in Scl target cells is also a potentially relevant issue.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cancer</head><p>Carcinogenicity was considered a potential concern based on the presumed role of the Wnt signaling pathway in tumor development. Factors considered in the Sponsor's discussion included the temporal effects of sclerostin inhibition on bone cell signaling pathways and the self-regulation of bone formation, the pathophysiology of sclerosteosis and Van Buchem disease, findings in SOST-/-(Scl-deficient) mice, data from long term animal studies with AMG785,</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p><p>45 mechanistic data on effects of Scl-Ab vs PTH, and clinical data on cancer incidences. Possible effects on tumor progression were also considered.</p><p>The Sponsor concluded that the weight of evidence supports that romosozumab would not pose a carcinogenic risk to the intended patient population. Reviewer essentially agrees with this conclusion and its underlying rationale. The absence of WBC or lymphocyte increases in the rat and monkey toxicity studies, and the lack of leukemia in the animal toxicology and human studies, in particular of acute myeloid lymphoma (AML), a cancer observed in mice with specific osteoblast B-catenin activation, alleviates the concern about hematopoietic cell tumorigenicity.</p><p>Although the finding of two osteosarcomas in the high dose male group in the rat carcinogenicity study lacked statistical significance, this Reviewer does not exclude the biological relevance of this finding. The tumor incidence was marginally outside the historical control range and the tumors occurred in the group with the largest bone mass increases. However, whether or not this was a chance finding, the low incidence combined with the 20-fold exposure multiple in the affected group renders its clinical relevance unlikely. Inclusion in the product label is not considered necessary.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Osteoarthritis</head><p>Based on the hypothetical role of disrupted Wnt sigaling in osteoarthritis (OA) and the expression of Scl in chondrocytes, there is a theoretical concern about induction or exacerbation of OA. Published literature data, however, are conflicting with regard to the potential for beneficial or adverse effects of sclerostin in OA. Data from Sponsor's nonclinical studies in the rat meniscus tear model (OA model) did not show adverse effects, and data from long term toxicity and bone pharmacology studies did not show degenerative changes in joint cartilage. Sponsor concluded that the available nonclinical and clinical data support the safety of the proposed clinical treatment regimen.</p><p>Osteonecrosis of the Jaw (ONJ) In the pivotal Phase 3 Study 20070337 (12 month placebo or AMG785, followed by 12 months of denosumab), one case of ONJ was seen in the 12-month romosozumab treatment period and one other case was observed in the romosozumab-group after one dose of denosumab given at 12 months. Two cases of ONJ were observed in ongoing Clinical Study 20110142 in Months 22 and 28 during open-label ALN treatment (at least 10 months after AMG785 dosing).</p><p>The pathophysiology of ONJ (necrotic exposed bone in maxillofacial region) is not well understood. There appears to be a strong association with suppressed bone resorption/turnover and use of relatively high doses of antiresorptives (e.g. IV bisphosphonates, and RANKL-Ab denosumab). The event also appears to be linked to underlying infection or inflammation and is often preceded by dental surgical procedures. Accumulation of unrepaired microcracks has been put forward as one of the relevant underlying mechanisms <ref type="bibr">(Kim et al, Clin Oral Invest, 20: 2251</ref><ref type="bibr">-2258</ref>.</p><p>Based on the established association with anti-resorptive treatment, the ONJ cases in Study 20070337 may be related to the suppression of alveolar bone resorption by AMG785. By</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>46</head><p>comparison, in the 2-year rat study alveolar inflammation associated with molar attrition (tooth wear) was not associated with bone necrosis. Sponsor argued that in other animal studies with Scl-Ab (intact, OVX, periodontitis, osteotomy or other models) bone resorption was still partially preserved also in the context of local injury, and fracture callus remodeling was not impaired. This is unlike the results from studies with BPs or RANKL-inhibitor denosumab, in which osteoclastogenesis and callus remodeling can be suppressed or delayed. Sponsor also used clinical bone marker and histomorphometry data, which showed suppression of cancellous bone resorption in both AMG785 and denosumab treated, to conclude that the resorption suppression by romosozumab is less generalized than by denosumab and that it is unlikely that AMG785 would pose a meaningful risk for an increased risk of ONJ in the patient population. In this Reviewer's opinion it is uncertain whether or not this conclusion is justified. This is partly because it is not clear whether the animal data that were used to support the lack of risk have adequate predictive value for pharmacologically induced ONJ in humans. Besides, the clinical histomorphometry data showed more suppression of cancellous bone formation in the romosozumab than the denosumab group. An additional study in an adequate rodent model that has shown bisphosphonate-mediated induction of ONJ, may be useful to provide more relevant information.</p><p>Atypical femoral fractures (AFF) In the pivotal Phase 3 Study 20070337, in the first 12-month study period, there was one case of AFF following 3.5 months of romosozumab treatment, in a patient with apparent prodromal pain in the fracture area before study start. Four cases of AFF have also occurred in Study 20110142, an ongoing trial including romosozumab and alendronate (ALN) treatment periods, but only after 16-28 months of ALN exposure, with or without previous AMG785 exposure. There were no cases in Study 20060326, a multi-dose Phase 2 study, including placebo, romosozumab (various doses of 70-210 mg QM or Q3M, up to 24 months), alendronate and teriparatide arms, and denosumab extension and romosozumab (210 mg QM) retreatment phases.</p><p>The pathogenesis of AFF is unclear, but is thought to be related to sustained suppression of bone resorption. Prolonged treatment with anti-resorptives (eg bisphosphonates) increases the risk of AFF, and the background incidence of 1 in 100,000 patient-years in the normal population can increase to 50 per 100,000 patient-years in bisphosphonate-treated patients. The suppression of bone resorption may be associated with osteocyte aging and death which could adversely affect a number of microscopic bone tissue processes/properties, e.g. microcrack repair, tissue homogeneity, matrix collagen properties (e.g. due to accumulation of advanced glycation end products, AGEs) and extent of mineralization or crystallinity <ref type="bibr">(Geissner et al, J Biomech, 48: 883-894, 2015)</ref>. These factors are all considered important for preservation of bone quality and strength. Long term disruption of any of these processes may lead to reduced toughness of bone material, making it more brittle and susceptible to stress fractures (i.e., fracture due to repetitive loading). Animal studies in intact dogs have shown that bisphosphonates can reduce cortical rib bone toughness/material strength after relatively long treatment periods (Burr et al, <ref type="bibr">Bone 71: 58-62, 2015)</ref>, and this may be related to the occurrence of human AFF. However, an unequivocally predictive marker or mechanical parameter for AFF risk has not been established.</p><p>The Sponsor carried out an in-depth evaluation of the weight of evidence for a potential increased risk of AFF. It was concluded that the nonclinical data did not provide any evidence of</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>47</head><p>bone toxicity, impairments in bone quality (e.g. increased brittleness) or disruption of bone repair or remodeling upon short or long term treatment with AMG785. This Reviewer basically agrees with this assertion, based on the aggregate data from intact and OVX animal studies, several of which included bone mass and biomechanical measurements. There was one femoral/acetabular fracture each in the mid (10 mg/kg) and high dose (100 mg/kg) groups in the 6-month rat and monkey toxicity studies, respectively. However, both cases were not associated with clinical signs and the conclusion that the fractures were probably pre-existing is supported by the lack of a bone safety signal in the other long term nonclinical pharmacology and toxicology studies conducted at equivalent doses.</p><p>Intact mice may be an underused model to test effects on bone quality/strength. In mice treated for relatively short periods with alendronate (8 wks), whole bone strength of the femur was enhanced but this was accompanied by an increase in brittleness or decrease in predicted material strength (Uveges et al, JBMR 24 <ref type="formula" target="#formula_34">(5)</ref>: <ref type="bibr">849-859, 2009;</ref><ref type="bibr">Misof et al, Bone 36: 150-158, 2005)</ref>. By contrast, Scl-Ab decreased femoral bone brittleness in mice <ref type="bibr">(Sinder et al, Bone 71: 115-123, 2015)</ref>. A study in a pharmacologically responsive mouse model with AMG785 and a bisphosphonate control may provide additional information on cortical bone mechanical properties.</p><p>AFF and ONJ are unexpected events with AMG785 treatment, because the product was at least initially considered an anabolic agent. Their small incidence and relatively early occurrence (3-10 months) in the Phase 3 study could support an argument that they are not treatment-related; on the other hand the incidence appears larger than the background incidence, which causes some concern that a specific type or location of Scl-Ab induced resorption suppression, possibly in combination with the enhanced formation effects, may cause unanticipated bone safety issues not signaled by the reassuring nonclinical bone quality data. Additional nonclinical evidence may be obtained from studies to: (1) address the issue of ONJ in an adequate surgical rat model, and (2) assess bone quality in AMG785-or m13c7-treated mice, to help guide future regulatory decisions.</p><p>Other theoretical safety issues Based on nonclinical and clinical safety data, other issues including or regarding vascular calcification, longitudinal bone growth, dental effects, hematopoiesis, sarcopenia, glucose metabolism and inflammatory disease do not appear to be a significant concern. Hyperostosis is the desired effect of the product and at the selected clinical dose of 210 mg QM it does not appear to lead to bone overgrowth with adverse consequences. The animal hematology changes (eg RBC, Hct decreases) at high doses were most likely secondary to the marked bone increases, and have been observed with other products that increase bone mass. The submitted nonclinical information also suggests that issues in other organs in which sclerostin is expressed, such as kidney, heart and lung, are unlikely. Reviewer agrees with Sponsor that the proposed clinical treatment regimen (210 mg romosozumab, QM, for 12 months) is unlikely to pose a significant increase risk related to these theoretical concerns in the intended patient population.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D. 48</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4">Safety Pharmacology</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary</head><p>A neurobehavioral study in rats and a cardiovascular/respiratory study in monkeys did not show significant adverse effects at doses of 30, 100 and 300 mg/kg (100x human dose, mg/kg basis). Also, in the monkey toxicity studies of 1-month and 6-month duration, there were no effects on ECG or blood pressure at doses 300 mg/kg SC or IV, and 100 mg/kg SC, respectively. All studies were GLP compliant.</p><p>AMG785, being a monoclonal antibody, is not expected to interact with the hERG channel current and a hERG test was not performed. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CNS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>5</head><p>Pharmacokinetics/ADME/Toxicokinetics 5.1 PK/ADME Summary AMG785 was measured using ELISA-based methods, mostly validated ones, in rat, rabbit and monkey sera. In some studies, rodent versions of the humanized antibody AMG785 (rat 13c7 (r13c7) and mouse 13c7 (m13c7)) were used because AMG785 causes anti-drug antibody (ADA) formation in those species. PK of AMG785 was evaluated after SC and IV dosing in rats and monkeys. AMG785 has a high and similar affinity to sclerostin across species, and shares more than 90% sequence homology. Single dose PK was evaluated in rats for all three antibodies (humanized AMG785, r13c7 and m13c7), while only AMG785 was evaluated in monkeys. Multiple dose AMG785 TK was evaluated in rats and monkeys. The PK of two formulations of AMG785, made for first in human (FIH) and commercial administration, respectively, was compared in monkeys.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>49</head><p>A single dose of AMG785 given by SC injection yields a Tmax of 24h-48h in rats (1-35 mg/kg), and Tmax of 24h-93h in monkeys (3-30 mg/kg). SC bioavailability in rats ranged from 50-100% in the 1-35 mg/kg dose range. SC bioavailability in monkeys was approximately 100% at 100 mg/kg. Plasma T 1/2 in rats increased and clearance decreased with increasing IV doses, ranging from 6h to 28h at 0.1-10 mg/kg. Terminal T1/2 of an SC dose in monkeys was 36h-88h in the 3-10 mg/kg dose range.</p><p>AMG785 exhibits non-linear PK in rats and monkeys, with greater than dose-proportional increase in exposure at doses &lt;10 mg/kg, and linear PK with dose-proportional exposure increases at  10 mg/kg. Upon weekly dosing in rats and monkeys (3-300 mg/kg), Tmax was 24h-96h and terminal T1/2 upon recovery was 60h-94h (rat) or 74h-116h (monkey). Accumulation was less than 2-fold with weekly dosing. There were no PK sex differences.</p><p>There were no tissue distribution studies. AMG785 was transported across the placental barrier. Volume of distribution (Vss) was 37-59 mL/kg and similar to plasma volume (30 mL/kg). No conventional metabolism studies were conducted since AMG785 is an antibody subject to catabolic peptide and amino acid degradation. Clearance may also involve typical IgG removal by the reticuloendothelial system. No specific excretion studies were conducted. Nonclinical PK interaction studies were also not conducted, since DDI risk is very small.</p><p>TK data were available from all pivotal repeat dose toxicity studies. Anti-drug antibody (ADA) formation was observed in rats and monkeys resulting in lower exposure and reduced PD response. Hence, ADA positive animals were excluded from TK analysis in studies of 6 months or longer duration. This was not an issue in single dose studies since ADA development generally requires 3 to 4 wks of dosing.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assays</head><p>Assays to detected AMG785 antibodies (ADAs) were ECL-based homogenous bridging immunoassays based on the bivalent characteristics of the antibody binding. The testing strategy consists of a screening assay and a specificity assay. The screening assay is performed to detect the presence of binding antibodies. Samples with a signal-to-noise (S/N) value greater than the cut point are then tested to confirm response specificity. Samples that deplete in the presence of excess soluble drug are reported as positive for the presence of anti-romosozumab antibodies. Also, an ECL-based competitive target binding assay was developed to detect the presence of antibodies that are capable of disrupting the binding of romosozumab to sclerostin in serum samples. This assay also follows a tiered two-assay approach consisting of a screening assay and a confirmatory assay.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Absorption</head><p>Single dose studies</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacokinetics and Pharmacodynamics of Antibodies A (m42F4) and B (m13C7) Following Single Intravenous or Subcutaneous Administrations in Sprague-Dawley Rats (Study 105144)</head><p> Male rats were given IV or SC doses of m13c7 at 0.1-10 mg/kg.  PK profile is shown in <ref type="figure" target="#fig_0">Fig. 1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>50</head><p> Exposure was non-linear, with an 800-fold increase in AUC from 0.1 to 10 mg/kg.  Median Tmax was 24h, and Tmax range was 24-72h.  BA was 100% based on 1 mg/kg data <ref type="table" target="#tab_7">(Table 5</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>51</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>An 8 Week Compound Selection Dose Range-finding and Pharmacokinetic Study in the Cynomolgus Monkey (Study 105876)</head><p> Female cynomolgus monkeys (N=3-4/grp) received monthly administrations of romosozumab at 0, 3, 10, and 30 mg/kg SC for two months.  Doses were given with a 4-wk interval, so that most drug was eliminated before the 2 nd dose was given.  The PK concentration-time profiles are shown in <ref type="figure" target="#fig_18">Fig.2, below</ref>.  Exposure increased non-linearly. The 10-fold increase in dose from 0.1-10 mg/kg yielded a 12-fold increase in Cmax and a 21-fold increase in AUCinf <ref type="table" target="#tab_9">(Table 7</ref>, below).  Tmax ranged from 45h to 93h  CL/F values decreased with increasing dose with a 2.1-fold decrease from 3-30 mg/kg.  Mean half-life values increased with increasing dose, ranging from 41h to 71h.   This study was a non-GLP single-dose subcutaneous PK bridging study in nave male cynomolgus monkeys.  The data provided evidence that the AMG785 drug products manufactured using Process 1 and Process 2 are similar from a nonclinical perspective.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Distribution, metabolism, excretion</head><p>No studies were conducted.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PK Drug Interactions</head><p>Romosozumab is not expected to have direct impact on cytochrome P450 and other drug metabolizing enzymes or transporters. In addition, romosozumab is not expected to modulate cytokine levels which could exert an indirect impact on CYP450 activities. Therefore, no pharmacokinetic drug interaction studies were conducted.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D. 53</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2">Toxicokinetics</head><p>Rat toxicity studies </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>54</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Rat reproductive toxicity studies</head><p>In rat reproductive studies with different dosing schedules and durations, measurements of AMG785 plasma concentrations were made on different days in F0 and/or F1 animals. See individual study reviews for TK data. Values are presented as mean with the exception of tmax, which is presented as median. AUC0-168 = Area under serum concentration-time curve from time 0 to 168 hours; AR = accumulation ratio calculated as AUC0-168, last dose /AUC0-168, first dose; C0 = estimated initial concentration after IV administration; Cmax = maximum observed concentration after SC administration; Mon = month; NC = not calculated; tmax = time of Cmax BLA #761062</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Monkey toxicity studies</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>55</head><p>Impact of ADA on PK/TK and PD  Binding anti-drug antibodies (ADA) and their impact on TK were evaluated in 1-month, <ref type="bibr">6-month, 12-month, 2-</ref>year, and all reproductive toxicology or pharmacology studies in rats and monkeys.  Neutralizing ADAs were measured in 1-month, 6-month and 12-month monkey studies, and in the 2-year lifetime pharmacology (ie carcinogenicity) study in rats <ref type="formula" target="#formula_34">(107895)</ref>.  PK in single dose or 1 month studies is not expected to be impacted by ADA development as 3-4 wks of dosing is generally required for an immune response.  The presence of binding or neutralizing ADA resulted in reduced systemic exposure.</p><p>Thus, TK and toxicity data from animals with ADA formation were excluded from 6month rat and monkey toxicity studies <ref type="figure" target="#fig_0">(107425, 107426)</ref>, the lifetime rat pharmacology study (107895), and from the fertility/EFD (108061) and PPND (108062) studies in rats.  In the 12-month bone quality and carcinogenicity studies in rats, trough concentrations of AMG785 were measured only; data from the 12-mo bone quality study showed no evidence of change in exposure over time in ADA-negative animals.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exposure Multiples</head><p>Human PK AMG785 was generally well tolerated and there was no treatment-related mortality in any of the rat studies.</p><p>The 14-day study with weekly doses of 30, 100, 300 mg/kg SC, or 300 mg/kg IV in the rat (Study 105909) showed increased bone formation, hyperostosis and increased spleen hematopoiesis. The NOAEL was 300 mg/kg, with AUC(0-168h) exposures of 254 and 608 mg.h/mL, for SC and IV dosing, respectively.</p><p>The 6-week study with weekly doses of 10 and 50 mg/kg SC in the rat (Study 121854) was conducted to evaluate effects in the skull. Results included increased bone formation as well. Subperiosteal bone was a mixture of woven and lamellar bone, similar but not identical to embryonic intramembranous bone.</p><p>The pivotal studies of 1-and 6-month treatment duration in rats with recovery (Studies 105908 and 107245) mainly showed effects related to the pharmacodynamic activity of AMG785, including dose-related increases in bone formation markers and increases in cancellous and cortical bone mass and thickness as evaluated by densitometry (DXA/pQCT) and histopathology. Resorption markers were not clearly affected, although some increases were observed in recovery periods. A summary of the data follows, but further details can be found in the tabular summary below.</p><p>Anti-AMG785 antibodies were detected in both 1-and 6-month studies, leading to reduced AMG785 exposure. In the 6-month study, ADA positive animals were excluded from PK analysis. AUC was generally dose-proportional and study findings were generally doserelated. AUC was similar in males and females. TK data showed slight but inconsistent accumulation between Day 1 and Week 26.</p><p>The pharmacologic effect on bone led to secondary changes in hematology and the hematopoietic system. The hematologic effects, e.g. RBC decrease and other blood cell changes (eg in platelet count or volume) were most likely an indirect effect of increased bone formation and narrowing of the hematopoietic bone marrow space, although a partially direct effect of AMG785 on marrow hematopoietic cells cannot be entirely excluded. Some non-RBC blood cell changes in female rats (e.g. WBC, lymphocyte decreases) were also observed at 100 mg/kg in the 6-month study. There were no effects on differential WBC counts.</p><p>Serum phosphorus was increased in 100-300 mg/kg males in the 1-and 6-month studies, with unclear cause. Significance of (transient) glucose increases in both studies was unclear.</p><p>Histologic effects included hyperostosis, extramedullary hematopoiesis, injection site findings (males and females), and a few muscle (necrosis), teeth (odontoma) and kidney histopathology findings in single males.</p><p>Hyperostosis consisted of increases in trabecular number and thickness (hyperostosis), firm marrow, and decreases in cortical bone marrow space due to endosteal bone apposition. The bone effects were seen at all doses in all rat studies. The increase in spleen and/or liver extramedullary hematopoiesis was an adaptive response to the anemia secondary to the pharmacologic bone effect. Injection site irritation was observed after 6 months of dosing with 100 mg/kg.</p><p>Minimal skeletal muscle necrosis, seen in 1-and 6-month studies in 1 high dose male each was of unclear relation to treatment. Biological significance of mandibular odontoma (mixed tumor of dental tissue origin) in one high dose male rat in the 6-month study was unlikely to be treatment-related. No dental cell/tissue tumors were seen in the 2-year carcinogenicity study with group sizes of N=60/s/g at doses up to 50 mg/kg. A femoral neck fracture was observed in 1 mid-dose male (10 mg/kg) at Wk 26 (by X-ray) and was still perceptible at Week 40 (end of treatment-free phase). The fracture was chronic and resulted in a non-union and pseudoarthrosis at the left coxo-femoral joint (hip joint). Fibrosis with embedded bone debris and intact femoral head was noted in the acetabulum section and correlated with the thickening noted macroscopically. Sponsor considered the finding incidental and suggested it may have occurred before study initiation as there were no signs of lameness noted during the study and the microscopic changes showed "chronic fracture with pseudoarthrosis". Bone fractures are unusual in rats and the cause of the fracture is uncertain. Considering the lack of clinical signs, the fracture was likely incidental and present before study start. However, the similar location of another femur fracture in a high dose (100 mg/kg) female monkey in the 6-month monkey study renders the finding noteworthy. <ref type="bibr">(1-month and 6-month</ref>  Bone densitometry: DXA: Increase in femur and lumbar spine BMD and BMC, dd (M,F); pQCT: Increase in proximal tibia (metaphyseal (total, trabecular, and cortical) bone area, BMD and BMC. Increase at 3 mg/kg not ss (M,F). Bone increase generally larger in M&gt;F. Spine: BMD and BMC increased up to 1.5-1.7-fold at wk26; Tibia: trabecular BMD and BMC increases up to 2.5-3.5--fold at wk26.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tabular Summary</head><p>Hyperostosis in lumbar vertebra (minimal-marked), sternum (min-moderate) and right tibia (min-severe).</p><p>Increase in extramedullary hematopoiesis in spleen, dd (recovered) </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Rabbit studies</head><p>A 29-day exploratory study was conducted in the rabbit with doses up to 300 mg/kg SC (Study 117870). ADAs were detected first on Day 15, and increased to up to 100% on Day 22, in parallel with up to 10-fold reductions in serum concentrations. Some ADA-positive rabbits showed immune complex disease with vascular injury and inflammation in several organs. Bone did have the expected pharmacologic response (increased formation) but this was attenuated after ADA developed. Rabbit was not considered a suitable species for embryo-fetal developmental studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Monkey studies</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Written Summary</head><p>Studies of 14-day, 1-month, and 6-month duration were conducted in cynomolgus monkeys. The studies were adequately conducted.</p><p>AMG785 was well tolerated. There was no treatment-related mortality and there were no toxicologically relevant clinical signs or body weight effects in the monkey studies.</p><p>The 14-day study with weekly doses of 30, 100, 300 mg/kg (SC), or 300 mg/kg IV) showed increased bone formation markers, but no effect on resorption markers (Study 105779). The NOAEL was 300 mg/kg, with AUC(0-168h) exposures of 487 and 597 mg.h/mL, at 300 mg/kg SC and IV, respectively.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>67</head><p>The pivotal 1-and 6-month studies in monkeys mainly showed effects related to the pharmacodynamic activity of AMG785 in bone, including dose-related increases in bone formation (markers, histomorphometric indices) and increases in cancellous and cortical bone mass and thickness as measured by densitometry (DXA/pQCT of spine, femur, tibia, radius) <ref type="figure" target="#fig_0">(Studies 105776 and 107426)</ref>. Resorption markers were not affected. Bone strength was increased concomitantly and bone quality appeared unaffected. A summary of data from these studies follows, but further details can be found in the tabular summary below.</p><p>Anti-AMG785 antibodies were detected in both 1-and 6-month studies, leading to reduced AMG785 exposure. In the 6-month study, ADA positive animals were excluded from TK analyses.</p><p>AUC was generally dose-proportional and study findings were generally dose-related. Exposure was very similar in males and females. TK data showed slight accumulation.</p><p>Slight, non-dose-related decreases in RBC parameters were observed in males in the 1month study, and in males and females in the 6-month study. They may have been due indirectly to increases in bone mass or a direct effect of AMG785 on bone marrow cells. There were no effects on differential WBC counts.</p><p>Transient and reversible non-dose-related decreases in serum calcium (slight) were observed in females in the 1-month study. Small decreases in serum Ca and P were also seen in the 6-month study (maximal ca. 10-15% at 100 mg/kg).</p><p>Electrocardiogram parameters (wave forms and interval times) and blood pressure were not adversely affected.</p><p>Histological changes in bone included hyperostosis, i.e. increased trabecular and cortical bone thickness. No bone cell changes or woven bone formation were detected at the end of the 6-month dosing phase.</p><p>There was no increase in extramedullary hematopoiesis in any of the monkey studies.</p><p>One female (Animal No. 456) at 100 mg/kg/dose presented bone findings in the left coxofemoral joint, sampled because of macroscopically small acetabulum and small femoral head with irregular surfaces and pale discoloration. Microscopic findings consisted of chronic fracture of the acetabulum (with non-union and hemorrhage), and moderate-marked degeneration of acetabular/femoral articular cartilage, and correlated with the macroscopic observations. The changes were considered initiated by established trauma (fracture) leading to secondary osteoarthrosis. This interpretation is supported by the absence of skeletal clinical signs during the treatment period, suggesting a pre-study event; therefore, the fracture-related findings in this animal were not considered</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D. 68 treatment-related. Reviewer agrees with Sponsor's conclusion. However, the similar location of a femur fracture in a mid-dose (10 mg/kg) male rat in the 6-month rat study makes the finding noteworthy. <ref type="bibr">(1-month and 6-month</ref>  Ectopic ossification in adrenal gland and acute inflammation of bone marrow in 1/4M (relevance uncertain).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tabular Summary</head><p>One HD female had chronic fracture in/near hip joint (see end-of-recovery findings), likely non-treatment-related.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>End of recovery:</head><p>BMD/BMC increase appeared recovered minimally after 14 weeks, but difficult to estimate due to small N/s/g.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>70</head><p>Hematology and serum Ca,P decreases reversed. Hyperostosis still observed in all groups, but with lesser incidence/severity. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.3">Local Tolerance</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary</head><p>Local tolerance at the SC injection site was specifically assessed using solutions with different AMG785 concentrations <ref type="figure" target="#fig_0">(Studies 113234, 112795, 106718</ref>). AMG785 elicited a minimal local response characterized by mononuclear cell infiltrates in repeat dose studies. Single dose administrations showed transient, concentration-dependent inflammatory responses and/or edema. Local tolerance to sodium and calcium acetate formulations appeared similar (Studies 113234 and 112795).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D. 71</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.4">Other Toxicity Studies</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mechanistic Studies</head><p>Mechanistic studies included Studies 115877 and 115777 in OVX SD rats, and Study 115776 in intact SD rats. These studies are described in the Pharmacology section of this review (Primary Pharmacodynamics).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other Studies</head><p>Cross o In this in vitro study biotinylated AMG785 (2 and 20 ug/mL) was used to label tissues with sclerostin protein expression. o Biotinylated AMG 785 specifically stained osteocytes in bone samples from humans, monkeys and rabbits. o Biotinylated AMG 785 failed to stain osteocytes in rat bone samples, possibly raising issues concerning the sensitivity of the immunohistochemical methodology, since clear PD effects of AMG 785 were seen in the rat. o One of three monkeys exhibited specific staining of stromal cells of the tunica media of either the aorta or pulmonary artery. This tissue was unexpectedly present in one of the heart sections. The absence of comparable staining in the other 2 monkey donors or in any of the human, rabbit or rat donors may reflect the absence of aorta tissue in these sections</p><formula xml:id="formula_33">Reference ID: 4081796 (b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>72</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7">Genetic Toxicology</head><p>The genotoxic potential of AMG785 was not evaluated. This is in accordance with Guidance ICH S6(R1). AMG785 is a recombinant protein and contains no linkers or non-protein portions. Thus, it is highly unlikely to react with DNA or other chromosomal material.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8">Carcinogenicity</head><p>The carcinogenic potential of AMG785 was evaluated in a 2-year lifetime pharmacology (carcinogenicity) study in Sprague Dawley rats at weekly doses of 3, 10 and 50 mg/kg. The protocol was discussed with ECAC on October 11, 2011. Dose selection was based on expected multiples of human exposure and pharmacologic effect. The study was considered adequate and negative for neoplastic findings. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>73</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BASIS FOR DOSES SELECTED:</head><p>Doses for this study were based on the expected pharmacologic effect in bone, clinical exposure multiples, and the lack of significant toxicity in a completed 6 month rat toxicity study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PRIOR FDA DOSE CONCURRENCE: Yes</head><p>RAT CARCINOGENICITY: Negative.</p><p>RAT TUMOR FINDINGS: There were no significant AMG785-related tumor findings.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RAT STUDY COMMENTS:</head><p> The 104-week rat study via sc injection was conducted to assess the carcinogenic potential of AMG785. The study was terminated at Week 91 for male groups and</p><p>Week 98 for female groups. The survival at the end of study was between 25-40% and comparable across all groups. Non-neoplastic changes associated with the pharmacological effect of AMG785 included effects in bones (hyperostosis), spleen and liver (secondary extramedullary hematopoiesis), and injection sites (mononuclear cells infiltrate).</p><p> The Sponsor identified two statistically significant neoplastic findings: renal lipoma in females (N = 1, 0, 0, 3 in ctrl, LD, MD, HD; p =0.0486 by trend test; incidence in HD females slightly outside the historical control range of 0-2), and adrenal cortical adenoma in 10 mg/kg males (N = 0, 2, 6, 2 in ctrl, LD, MD, HD; p = 0.0169 by pairwise comparison, within historical control range of 0/120-6/60). Since renal lipoma in females is generally considered a rare tumor, this would be considered a statistically significant trend since the p-value (0.0486) was  0.05. However, due to low incidence and lack of pre-neoplastic precursor lesions, the increased incidence of renal lipoma in HD females was not considered to be of toxicological significance.</p><p>Since adrenal cortical adenoma in males is generally considered a common tumor and a p-value of 0.0169 (&gt; 0.01) does not indicate statistical significance, and since there was a lack of dose response (N=0, 2, 6, 2 across groups), the increased incidence in the 10 mg/kg MD males was not considered of toxicological significance. Sponsor concluded there were no significant neoplastic changes associated with AMG785 administration.</p><p> FDA tumor analysis: Statistical review of the tumor data showed that there was an increase in incidence of adrenal cortical adenoma in 10 mg/kg males, that was statistically significant if considered a rare tumor (pairwise test FDA p=0.0184 &lt; 0.05); and an increase in incidence of pancreatic islet cell adenoma in females (N=0, 0, 3, 3) that was statistically significant if considered a rare tumor (trend test p = 0.0323 &lt; 0.05). However, adrenal cortical adenoma in males was considered a common tumor based on average historical control incidence of ca. 2% (20/1057). Therefore the increase in MD males was not considered statistically significant. The islet cell adenoma incidence in MD and HD females (3/60, 3/60) was within the historical</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>74</head><p>control range provided by Sponsor (0/60-5/60) and was therefore not considered toxicologically significant. The increase in renal lipoma in 50 mg/kg females (p = 0.0429, trend test) was concluded to be not statistically significant based on the concurrent control of 1/60 (i.e. common tumor) and the p-value being &gt;0.01. In conclusion, FDA review did not identify any statistically significant increases in tumor incidences in male or female rats given AMG785 for up to 98 weeks at doses of 3, 10, 50 mg/kg/wk <ref type="figure" target="#fig_0">(equivalent to 0.6, 4x, 19x</ref> the human AUC at the proposed monthly dose of 210 mg).</p><p> There were two osteosarcomas noted in the males dosed with 50 mg/kg/week. The finding was not statistically significant by trend test or pairwise comparison. One of the tumors was detected at gross necropsy as a macroscopic lesion/mass in the brain and also by radiographic skull/frontal bone production (Animal #4069, Day 587, fatal osteosarcoma, skull). The other tumor was detected in the tibia by focal radiographic bone loss followed by tibia histopathology in an animal with death caused by pituitary adenoma (Animal #4041, Day 572, incidental osteosarcoma, tibia). The incidence in the high dose male group was 3.7% (2/54), marginally exceeding the historical control range of 0-3.3%. Sponsor noted that the use of radiography in the current study was responsible for detecting one of the two tumors. Based on this study design feature, late onset and solitary occurrence of bone tumors, and lack of pre-neoplastic findings or other types of bone tumors, the Sponsor considered the osteosarcomas in the high dose males to be spontaneous occurrences. Although not statistically significant, the two osteosarcomas in the high dose male group, in which bone mass increase was largest, may have been treatment-related based on mechanism of action of AMG785, i.e., activation of the (pre)osteoblast. However, the 21-fold human exposure multiple suggests that the clinical significance of the tumor finding, even if treatment-related, is unlikely.</p><p> Macroscopically, there were AMG785-related non-neoplastic findings in bones (miscellaneous, calvarium femur, lumbar vertebrae L5-L6, sternum and tibia) and spleen. AMG785 also caused dose-dependent bone thickening in males and females, correlating with increases in bone mineral content (BMC) by ex vivo peripheral quantitative computed tomography (pQCT) and hyperostosis microscopically. This effect was usually observed in all bones collected per protocol. An increased incidence of spleen enlargement was noted in females at  3 mg/kg and in males at 10 mg/kg, correlating with increased extramedullary hematopoiesis microscopically.</p><p> Microscopically, there were non-neoplastic changes associated with AMG785. Bones: increased incidence of hyperostosis was noted in all dose groups. Spleen: increased incidence of secondary extramedullary hematopoiesis was noted in all dose groups (male: <ref type="bibr">13/60, 38/60, 44/60, 40/54 and female: 37/60, 49/60, 57/60, 60/60</ref> in <ref type="bibr">Groups 1,</ref><ref type="bibr" target="#b84">2,</ref><ref type="bibr">3,</ref><ref type="bibr">and 4 respectively)</ref>. Liver: increased incidence of secondary extramedullary hematopoiesis was noted in all dose groups (male: <ref type="bibr">5/60, 13/60, 13/60, 12/54 and female: 22/60, 25/60, 41/60, 39/60</ref> in <ref type="bibr">Groups 1,</ref><ref type="bibr" target="#b84">2,</ref><ref type="bibr">3,</ref><ref type="bibr">and 4 respectively)</ref>. Injection</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p><p>75 sites: mononuclear cells infiltrate was noted in all dose groups. Changes in bones, spleen, and liver were dose-dependent, whereas changes in injection sites were not dose dependent.</p><p> There were no satellite TK groups included in this study. Blood samples were collected in Week 13 for TK and ADA analysis. Animals positive for binding and neutralizing antibodies were then removed from the study. The retained number of animals was N=60/grp for all male and female groups, except it was N=54/grp for high dose males. In retained animals, anti-drug antibodies (ADAs) were still present in 18 males at 3 mg/kg, 3 males at 10 mg/kg, and 10 males at 50 mg/kg, and in 1 female at 50 mg/kg. The mean AMG785 serum concentration(s) in ADA positive animals were lower than in ADA negative animals among those retained by approx. 0.8x, 0.8x and 0.5x for the LD, MD, HD males, and 0.3x for the HD female.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer comment on rat study findings:</head><p>In rat carcinogenicity studies with daily SC dosing with PTH or PTHrP analogues, marked dose-dependent increases in osteosarcoma, osteoblastoma, osteoma, and/or osteoblast hyperplasia have been observed, also at relatively low human exposure multiples. The concomitant bone mass increases in the animals with bone tumors were similar to or smaller than those observed in the current AMG785 study. This underscores an important difference between sclerostin antibody and PTH products with regard to nonclinical bone tumorigenicity.</p><p>Key Study Findings (From Dr. Tsai-Turton's review)  AMG785 was given to Sprague Dawley rats at 0 (vehicle), 3, 10, 50 mg/kg/week (60/sex/group) weekly via sc injection for a minimum of 91 weeks in males and 98 weeks in females. Blood samples were collected on Week 13 for TK analysis.  There were no AMG785 treated effects on clinical observation, body weight, or food consumption.  There was no AMG785 treatment effect on survival. Prior to the end of treatment period (Week 91 males and Week 98 females), there were between 36-43 rats/sex/group that had died or were euthanized. AMG785 had no effects on the overall survival rate or mortality.  There were increased bone radiopacity in almost all males and females treated with AMG785 that correlated with thickening of the bone (macroscopically) and hyperostosis (microscopically). This was an expected pharmacological effect of AMG785.  Marked dose-related increases in bone mass and geometry were noted at the femur metaphysis and diaphysis. Trabecular bone mineral density (BMD) was 4-fold and 6-fold higher in males and females, respectively, when compared to vehicle controls.  AMG785 did not cause a statistically significant increase in neoplastic findings.  AMG785 did cause non-neoplastic findings. However, findings were limited to pharmacological effect of AMG785, including hyperostosis, secondary extramedullary hematopoiesis in spleen/liver, and mononuclear cell infiltrate at the injection sites.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>76</head><p> There were no satellite TK groups included in this study. TK and ADA analysis was performed in Week 13. ADA-positive animals (up to 33% and 70% of animals in LD female and male groups) had reduced mean serum AMG785 concentration when compared to ADA-negative animals (by 41%, 69%, and 86% in females and by 10%, 43%, and 53% in males, at 3, 10, and 50 mg/kg respectively). Binding and neutralizing ADA positive animals were excluded in Week 13 so that final group size was N=54/grp for HD males and N=60/grp for all female and all other male groups. Anti-drug antibodies (ADAs) were still present in retained animals, in 1 female and 10 males at 50 mg/kg, 3 males at 10 mg/kg, and 18 males at 3 mg/kg. Serum AMG785 concentrations were lower in these animals by up to 50% and 70% (HD males and female, respectively).  AMG785 was not carcinogenic in Sprague-Dawley rats at doses up to 50 mg/kg/week for 91 weeks in males and 98 weeks in females. Expected pharmacological effects of AMG785 (hyperostosis in bones, secondary extramedullary hematopoiesis in spleen and liver, and mononuclear cells infiltrate at injection sites) were observed in AMG-785 treated animals.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>77</head><p>Exposure multiples in rat carcinogenicity study  Reproductive and Developmental Toxicology</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary</head><p>Reproductive studies were conducted in rats, since the product is strongly immunogenic in rabbits. In both the combined fertility/embryo-fetal development (FEED) study and the definitive embryo-fetal development (EFD) study in rats, romosozumab at doses of 100 and/or 300 mg/kg (17x-56x) the proposed monthly 210 mg clinical dose, based on AUC exposure) caused a slight increase in the incidence of reduced ventral processes on the 6 th cervical vertebra, a skeletal variation, in the absence of other developmental delays or maternal toxicity. This finding is sometimes considered a developmental delay in a skeletal process that is not present in this cervical vertebra in humans. Since other delays in vertebral development/ossification were not observed, and the variation is not considered toxicologically relevant or relevant for humans, the finding may not need to be included in the product label.</p><p>External skeletal malformations, including fore-or hindpaw syndactyly (fused digits) and polydactyly (extra digits), occurred in 7/16 fetuses of 1 litter at the high dose of 300 mg/kg in the definitive embryo-fetal development study, at approximately 32x human AUC based on TK data from dose range finding EFD study. The skeletal malformations exceeded historical control values. Other skeletal malformations and variations were also observed in 3 of the 7 affected fetuses in this litter. While these anomalies were not observed in any litters in the combined F/EFD or the PPND study, it is recommended that the findings be included in the label, because incidence exceeded historical control range, and the findings are likely treatment-related based on the known role of sclerostin in the skeleton and the presence of this type of skeletal developmental abnormality in humans and mice with genetic sclerostin deficiency.</p><p>In a pre-and post-natal study in rats, romosozumab caused transient decreases in food intake during the first two weeks of dosing at 60 and 300 mg/kg and increases in incidence of sparse hair coat at 300 mg/kg in the F0 generation females. In the F1 generation, there were slight but statistically significant decreases in bone mass in male and female pups at 60 and 300 mg/kg, and changes in cortical geometry in male pups at doses 10 mg/kg. The doses of 10, 60 and 300 mg/kg are equivalent to 1.5x, 19x and 56x the proposed clinical 210 mg dose, based on GD13 AUC data from the FEED study. No skeletal abnormalities in the C6 cervical vertebrae were observed in the F1 generation pups at any dose.</p><p>Reproductive toxicity study data are included in the label, conforming to regulations, including the findings in animal EFD and PPND studies. The sought indication is the treatment of osteoporosis in postmenopausal women. . Key Study Findings  Male and female Sprague Dawley rats were given once weekly SC doses of AMG 785 before cohabitation, through mating and through the period of organogenesis, at dose levels of 0, 10, 60, 300 mg/kg (N=25/s/g main study; 4/s/g TK). Dams were euthanized and fetuses examined on GD21.  There were no effects on mortality, clinical signs, body weight, food consumption or necropsy observations.  No effects on mating, fertility, male reproductive parameters (sperm analyses or organ weights), ovarian or uterine parameters, embryo-fetal survival or fetal body weights were observed.  At 300 mg/kg, there were 3 fetuses from 3 litters that had reduced ventral processes (which develop into the rat carotid tubercles) on the 6th cervical vertebrae, slightly exceeding the historical range of the test facility, which was considered to represent a developmental delay (development of the ventral processes of the cervical vertebrae proceed in an anterior to posterior direction and the ventral processes on the 7th cervical vertebrae had not started to develop at gestation day 21). No other fetal morphology changes were observed at any dose level. Key Study Findings  A dose range finding study was conducted in pregnant SD rats given two SC doses of 0, 30, 100, 300 mg/kg, on Gestation Days (GD) 6 and 13 (N=8/s/g main study, N=8/s/g for TK). C-sections and maternal/fetal observations were performed on GD21. Exposure was determined on Days 6 (AUC 0-168h ) and GD13 (AUC 0-144h ).  AMG 785 was well-tolerated. No treatment related effects were observed on maternal or fetal parameters at any dose tested.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.2">Embryonic Fetal Development</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subcutaneous Dose-Range Finding Development Study of AMG785 in Rats</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>80</head><p> There were no dose-dependent differences in litter or fetal incidences of any gross external, soft tissue or skeletal alterations.  Fetal ossification site averages were generally comparable among the four dose groups. Key study findings:  AMG 785 was administered to pregnant SD rats at doses of 0, 30, 100, 300 mg/kg, twice, subcutaneously, on Gestation Days 6 and 13 (N=25 F/grp). Dams were euthanized on GD21 and fetuses were examined.  Toxicokinetics (serum concentrations only) and antibody assessment of each dam were determined on GD 21 after euthanization.  No treatment related effects were observed on maternal parameters at any dose tested.  At 0, 30, 100, and 300 mg/kg, the litter incidence of malformations or variations was 5 (21.7%), 5 (26.3%), 10 (41.7%) and 9 (40.9%), respectively.  Seven fetuses from one litter in the 300 mg/kg dose group had extra digits (polydactyly) on the fore-and/or hindpaws and six of these fetuses also had fused digits (syndactyly).  One to 3 fetuses from the same litter at 300 mg/kg also had incompletely ossified phalanges, misaligned metacarpals, large ulnae, misaligned metatarsals and large tibias, irregularly shaped metacarpals, broad ribs, and irregularly shaped ilia.  Irregular shaping of the arch in the 6th cervical vertebra was also observed in 4 to 5 fetuses from 4 litters in the 100 and 300 mg/kg group. The incidence of litters and fetuses with irregular shaped 6 th vertebrae at 100 (litters 17%; fetuses 2%) and 300 mg/kg (litters 18%; fetuses 3%) was greater than the historical control range (litters 0-12.5%; fetuses 0-1.7%) for the testing facility and should be considered AMG 785 related.  There was a dose responsive increase in anti-AMG 785 binding antibodies with 4% of the controls expressing antibodies and 25%, 20%, and 64% of the 30, 100 and 300 mg/kg groups expressing antibodies on GD 21.  NOAEL for maternal toxicity was 300 mg/kg (56x the proposed 210 mg clinical dose, AUC comparison).  NOAEL for fetal toxicity was 30 mg/kg (4.9x the proposed 210 mg clinical dose, AUC comparison) based on fore-and hindlimb skeletal malformations at 300 mg/kg, and the cervical vertebral ossification delay at 100 and 300 mg/kg. Key Study Findings  AMG 785 was administered at SC doses of 0, 10, 60, and 300 mg/kg, weekly, to female Sprague Dawley rats beginning 6 weeks before cohabitation, and continuing weekly through the gestation and lactation periods.  F0 generation:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subcutaneous Developmental Toxicity Study of AMG785 in Rats</head><p>o Dosing of females did not result in any unscheduled deaths or macroscopic observations, and there were no effects on body weights or body weight gain at any dose level. o AMG 785 transiently reduced food intake during the first two weeks of dosing at  60 mg/kg and increased the incidence of sparse hair coat at 300 mg/kg, during the premating, gestation and lactation periods. o AMG 785 administration did not result in any effects on mating, fertility, or natural delivery parameters. o There were no effects on any litter parameters, including pup viability or pup body weights during the pre-weaning period.  F1 generation pups:</p><p>o Distal femur, metaphysis (pQCT) (Day 21 pp):</p><p> Slight, but mostly statistically significant decreases in total, (sub/) cortical and/or trabecular BMC and BMD, at 60 and 300 mg/kg, in males and females (NAOEL = 10 mg/kg). Effects were the same at both doses of 60 and 300 mg/kg (ca. -8 to -9% decrease). No effect on total bone area at any dose.  Slight but significant increases in total and trabecular (not cortical) BMD, at 10 mg/kg, in males and females. Effect size for trabecular BMD was +14% in M, +9% in F. o Distal femur, diaphysis (pQCT) (Day 21 pp):</p><p> Males only: Minimal decreases in total area, periosteal circumferences, endosteal circumference and CSMI, at all doses, significant at 10 and/or 60 and/or 300 mg/kg (NOAEL 10 mg/kg). Also in males, cortical thickness increased slightly (ca. 10%) but significantly at 300 mg/kg. o The significance of the decreases in bone mass and/or size in rat pups exposed in utero and during lactation, which were different from the increases seen in adult animals, is unclear. Sponsor noted that the data were consistent with delayed postnatal development of high bone mass in SOST -/-mice and </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="10">Special Toxicology Studies</head><p>Mechanistic studies to evaluate the bone cell responses to AMG785 are described in the Pharmacology section of this review.</p><p>The tissue cross reactivity study conducted with biotin-AMG785 (Study 105783) is described in the Toxicology section <ref type="bibr">(6.4</ref> Other toxicity studies) of this review.</p><p>No other special toxicology studies were conducted.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D. <ref type="bibr" target="#b43">83</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>11</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Integrated Summary and Safety Evaluation</head><p>The Sponsor of BLA 761062, Amgen Inc, is seeking regulatory approval of their marketing application for romosozumab (210 mg once monthly, by subcutaneous (SC) injection) for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.</p><p>Romosozumab (AMG785) is a humanized IgG2 sclerostin antibody. It inhibits the action of sclerostin, a negative regulator of bone formation. The consequence is an increase in bone formation, a decrease in bone resorption, and an increase in bone mass and/or size. In clinical trials with once monthly doses of 210 mg SC, this led to a statistically significant reduction in incidence of new vertebral fractures (-73%) and non-statistically significant reductions in nonvertebral (-25%) and hip fractures (-46%). BMD increases were observed in spine, total hip and femur neck, but small decreases in BMD were detected in distal radius. Bone formation markers were increased and resorption markers decreased.</p><p>The applicant completed an adequate nonclinical development program that consisted of in vitro and in vivo pharmacology studies, mechanistic studies, PK/ADME studies, and toxicology studies. The latter included general toxicity studies in rats and monkeys, local tolerance studies in rats and monkeys, a 2-year rat carcinogenicity study, and rat reproductive toxicity studies. Most studies were conducted using the SC dosing route. Dosing frequency in the animal studies was usually once weekly.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mechanism of Action</head><p>Sclerostin-antibodies bind the osteocyte glycoprotein product sclerostin with high affinity, preventing its interaction with LRP4, LRP5 and LRP6 co-receptors of the Wnt receptor complex. This activates para-and autocrine canonical Wnt signaling in cells of the osteoblast lineage (osteocytes, osteoblasts and lining cells). The transcriptional changes that ensue lead to a rapid increase in bone formation and a decrease in bone resorption. The process involves time-dependent alterations in the expression of a multitude of Wnt targets, extracellular matrix genes and bone cell activity modulators. Upon chronic dosing, the osteoblast bone formation response appears to be subject to negative feedback or self-regulation. The effects of Scl-Ab are highly bone tissue-specific due to predominant expression of Scl protein in the osteocyte.</p><p>Primary Pharmacology AMG785 binds with similar affinity to sclerostin from human, monkey and rat (Kd = 11, 23, and 3 pM, respectively). In vitro assays showed that AMG785 was able to prevent the sclerostin-mediated inhibition of bone mineralization.</p><p>Long term bone pharmacology ("bone quality") studies were conducted in OVX rat and monkey models of postmenopausal osteoporosis. Treatment with AMG785 was started after 2-month (rat) or 4-month (monkey) bone depletion periods. The 12-month OVX rat study was conducted at weekly doses of <ref type="bibr">3, 10 and 50 mg/kg (0.6x, 4x, 19x</ref> human AUC exposure at the</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>84</head><p>QM dose of 210 mg), and the 12-month OVX monkey study at 3 and 30 mg/kg <ref type="bibr">(1.3x and 22x</ref> human AUC exposure at the QM 210 mg dose). The monkey study included a 6-month posttreatment recovery group.</p><p>The main effects in these studies consisted of dose-related increases in bone formation and cancellous and cortical bone mass (BMD/BMC) at all skeletal sites evaluated (spine, femur, tibia, radius), correlating with increases in bone strength. Bone mass increased most rapidly in the first months of treatment and continued to increase progressively albeit at a slower rate through 12 months. DXA-BMD increases were most pronounced in spine, proximal tibia, proximal femur and femoral neck, and least pronounced at distal femur and distal radius (all regions). While cortical BMD (pQCT) was minimally decreased in the first 6 months in distal radius diaphysis, cortical BMC and thickness were not affected or slightly increased. Densitometry, structural and mechanical parameters in the higher dose groups were usually increased to levels exceeding those in sham controls. Most bone effects diminisheded in the 6month recovery group in the monkey study. The effects observed in the animals were generally consistent with the BMD effects observed in clinical studies with a romosozumab dose of 210 mg QM. Based on monkey and human data, a 12-month clinical treatment period appears to be adequate, since the BMD increases occurred mainly in the first months and strength changes are likely to parallel these effects.</p><p>Bone formation markers peaked in both species during the first 3 months of treatment, returning towards control levels at 12 months. Resorption markers, however, were increased in both rats and monkeys with maximal effects at 3 (monkey) or 6-9 months (rat). The latter was probably due to enhanced bone resorption/remodeling at intracortical and possibly other bone surfaces caused by the treatment-related increase in serum PTH, outweighing the decreases in resorption at trabecular and endocortical surfaces at a systemic level. By contrast, data from clinical studies showing that increases in formation markers were accompanied by decreases in resorption markers. Serum PTH was also increased in romosozumab treated clinical study subjects but this effect was less pronounced than in animals probably due to adequate calcium and vitamin D supplementation in the clinical studies.</p><p>Histomorphometry of cancellous and cortical bone parameters was performed at 3, 6, and 12 months in OVX monkeys, and at 12 months in rats. Treatment-related increases in cancellous bone volume were due to increases in trabecular thickness, and increases in cortical bone thickness were due to enhanced endosteal and/or periosteal bone apposition. Dynamic bone formation indices were increased at all surfaces (trabecular, endosteal, periosteal and intracortical/Haversian), particularly at earlier time points. Bone formation rates, largest at trabecular, endosteal and intracortical surfaces in control animals, were all increased by AMG785, but periosteal bone formation was usually increased to the largest extent.</p><p>In both rats and monkeys, the increases in periosteal and endosteal bone formation rates were probably accompanied by increases in resorption (not measured) based on comparatively small changes in bone thickness. This also pertained to Haversian surfaces where increased formation rates resulted merely in non-significant or transient increases in cortical porosity.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>85</head><p>Resorption as indicated by eroded surface fraction was decreased in cancellous and cortical bone of monkey ilium and rib, respectively, and in monkey femoral cortex and rat tibia at end of study, although the effect in rat was very small. There were no significant effects on Mlt and O.Th. An increase in wall thickness in vertebral bone was the result of decreases in both resorption and reversal periods and a slight increase in formation period.</p><p>Biomechanical testing demonstrated increases in compressive, bending and shear strength parameters in vertebrae, femur shaft and femur neck, respectively. In monkeys, material strength of humerus cortical beams was not affected. Bone quality is comprised of bone material and structural properties. Statistically significant correlations between bone mass and strength parameters indicated that bone quality, when defined as slope of mass vs. strength regression lines, was maintained upon AMG785 treatment at all bone sites evaluated. Bone quality was slightly improved at the 30 mg/kg dose in rat and monkey vertebrae, probably due to improvements in architectural, not material properties. The data did not raise any concerns about potential adverse effects on extrinsic (whole bone) or intrinsic (material) bone strength.</p><p>A 6-month OVX monkey study with a dose of 3 mg/kg, equivalent to clinical exposure, was performed to further evaluate the transient decreases in cortical vBMD in radius and tibia observed in the 12-month OVX monkey study. The study showed that AMG785 caused slight decreases in pQCT-derived volumetric BMD (radius and tibia), while DXA-BMD of all radius regions was increased. The pQCT vBMD decreases were associated with increased intracortical bone turnover and cortical porosity, which was most prominent in radius but also observed in tibia. However, pQCT-BMC and cortical thickness of both radius and tibia were increased and there were no decreases in dia-and metaphyseal bone strength of the radius.</p><p>In a 10-week study in adolescent male monkeys with a Q2W dose of 30 mg/kg there were no adverse effects on bone tissue characteristics, evidenced by bSEM and FTIRM analyses. Global mineralization was not affected by AMG785, BMDD was minimally affected in trabecular bone, and matrix/mineral properties, crystallinity and collagen cross linking were not affected in any bone compartment. The small changes in some of the measured parameters were unlikely to have negative effects on bone tissue quality.</p><p>A detailed analysis of vertebral remodeling kinetics in a 28-week study in male monkeys at 30 mg/kg Q2W showed that AMG785 caused decreases in resorption depth and resorption period as well as an enhanced resorption rate. Combined with a (transient) increase in formation period this resulted in increased wall thickness and a positive bone balance in individual bone remodeling units. Data from the 12-month OVX monkey study and the 10-week study in male monkeys showed that AMG785-mediated increases in bone formation were initially modeling-based, resulting from a rapid activation of bone lining cells. The modeling-based formation attenuated with time, and remodeling-based formation continued steadily increasing bone mass as described above. The study results generally showed skeletal site-and surfacespecific effects of AMG785 in rats and monkeys.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>86</head><p>Several other studies were conducted in OVX rats with a rat surrogate Scl-Ab, r13c7, to avoid an immunogenic response. The results again showed increases in vertebral and femoral BMD, improved trabecular bone structure, and increases in vertebral and femoral strength. Suppression of resorption markers and histologic resorption indices in the r13c7-treated rat resembled the anti-resorptive effect of AMG785 in humans, in contrast to the increases in resorption parameters in the AMG785-treated OVX rats. Additional animal studies showed positive effects of AMG785 on bone mass and strength in models of other bone loss models, and positive effects on bone healing without untoward effects on bone remodeling in macroscopic fracture repair models.</p><p>Mechanistic studies confirmed the self-regulation of the osteoblastic bone formation response with initial increases in osteoblast numbers due to activation of lining cells, followed by reductions in osteoprogenitor number, upregulation of osteocyte transcription factors involved in inhibition of cell cycle progression, and upregulation of extracellular Wnt inhibitors (e.g. SOST).</p><p>In conclusion, the bone study data showed positive effects on bone mass and strength and did not reveal any obvious signals of impairments in bone quality or bone mechanical properties. The effects of AMG785 resembled those of increased mechanical loading. This is not surprising in light of the recognized role of sclerostin in the bone response to loading.</p><p>Safety pharmacology AMG785 had no adverse effects on neurobehavioral effects in the rat at single doses up to 300 mg/kg (IV). Single IV doses up to 300 mg/kg had no effects on cardiovascular parameters and respiratory rate in monkeys. Also in monkeys, there were no ECG or blood pressure changes in 1-month and 6-month repeat dose studies at doses up to 300 mg/kg (SC or IV) or 100 mg/kg (SC), respectively.</p><p>PK/ADME AMG785 exhibits non-linear PK in rats and monkeys, with greater than dose-proportional increases in exposure at doses &lt;10 mg/kg, and linear PK with dose-proportional exposure increases at  10 mg/kg. This is consistent with target mediated drug disposition for IgGs. In rats, SC bioavailability in rats was 100% at 1 mg/kg, and 50% at 35 mg/kg, and in monkeys it was approximately 100% at 100 mg/kg. Plasma T 1/2 in rats increased and clearance decreased with increasing IV doses, ranging from 6h to 28h at 0.1-10 mg/kg. Terminal T1/2 of an SC dose in monkeys was 36h-88h in the 3-10 mg/kg dose range.</p><p>Upon weekly dosing in rats and monkeys (3-300 mg/kg), Tmax was 24h-96h, and terminal T1/2 upon recovery was 60h-94h (rat) or 74h-116h (monkey). Accumulation was less than 2-fold with weekly dosing. There were no sex differences in TK in repeat dose studies. Elimination occurs by catabolic peptide and amino acid degradation, or IgG removal by the reticuloendothelial system. In the embryofetal development studies, AMG785 was detected in fetal rat serum (35-90% of maternal serum concentrations), indicating transplacental transfer.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>87</head><p>Two different drug substance formulations were manufactured and used during development. The Process 1 drug substance formulation (70 mg/mL AMG785) was used in Phase 1-2 clinical studies, in early nonclinical studies, and in 6-month rat and monkey toxicity studies. The commercial Process 2 drug substance formulation was used in Phase 1-3 clinical studies, and in rat reproductive toxicity and carcinogenicity studies. An SC singledose monkey PK bridging study provided support that AMG 785 Process 1 and Process 2 drug products are similar from a nonclinical perspective.</p><p>Anti-drug antibody (ADA) formation was observed in rats and monkeys resulting in lower exposure and reduced PD response, particularly when ADAs were neutralizing. Hence, neutralizing ADA-and/or binding ADA-positive animals were either removed from longer term studies, or removed from data analysis including PK evaluations. AMG785 was highly immunogenic in rabbits and this species was not used for toxicity assessments.</p><p>A tissue cross-reactivity immunohistochemistry study showed binding of AMG785 to osteocytes in human, cynomolgus monkey, and rabbit, but not rat bone. Binding was also observed in aorta or pulmonary artery in a monkey. The cause of the lack of rat osteocyte staining is unclear. It is unlikely to be related to the lack of resorption suppression in the AMG785, but not the r13c7 treated rat, since the rat did have a clear and most likely osteocyte-mediated anabolic response to AMG785.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Toxicity</head><p>Repeat dose studies of 14-day, 1-month and 6-month duration were conducted in rats and monkeys. Pharmacological bone responses were seen at all study doses in both species, evidenced by increases in bone formation markers, bone mass and bone volume, changes in resorption markers and histomorphometric formation indices, bone thickening, hyperostosis and firm marrow. In both species, bone effects were present at the lowest doses equivalent to expected human exposure. Based on pharmacologic responsiveness, rats and monkeys were adequate test species.</p><p>Other findings included decreases in RBC in rats and monkeys, and decreases in platelet counts, reticulocyte count or % and WBC (all cell types), and increased compensatory spleen and/or liver extramedullary hematopoiesis in rats. These changes were most likely secondary to the bone effects. Serum calcium (Ca) and phosphorus (P) were decreased in monkeys, possibly due to enhanced bone mineral formation. A direct effect of AMG785 on blood forming elements in the marrow, in particular myeloid cell proliferation, was a concern based on the finding of acute myeloid leukemia (AML) in mice with constitutively activated osteoblast Wnt/-catenin activation <ref type="bibr">(Kode et al, Nature 506(7687): 240-244, 2014)</ref>. However, this concern was allayed by the lack of significant changes in WBC cell or differential counts and the likely transient nature of the enhanced -catenin signaling in the osteoblast upon treatment with Scl-Ab.</p><p>Reference ID: 4081796 (b) <ref type="bibr" target="#b86">(4)</ref> Incidental findings in a few animals in high-dose rat and monkey study groups at large human exposure multiples were of uncertain or unlikely toxicological significance. Serum glucose and phosphorus increases in rats may have been treatment-related but were of unclear significance. Compared to the 1-month studies, the 6-month studies did not show significant additional toxicities. Recovery group findings demonstrated partial reversibility of the bone findings and reversibility of the hematology and serum Ca and P changes.</p><p>In aged OVX monkeys treated for up to 12 months with doses of 3 and/or 30 mg/kg/wk, equivalent to 1 and 22 times human exposure at 210 mg QM, radiography did not show exacerbation of arthritis or spondylosis and did not result in aortic calcification. Immunophenotyping of peripheral blood lymphocytes did not indicate changes in absolute or relative numbers of various types of B-cells.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>89</head><p>Rat studies: NOAEL and exposure multiples Safety monitoring in clinical trials was adequate to address potential issues identified by animal data. Clinical safety data did not show hematological or clinical chemistry effects. Changes in calcium included decreases in serum Ca at Month 1 to 12 (-2% to -1% vs pbo), decrease in urine Ca from . Serum phosphorus was decreased at Month 12 by ca. 3% vs pbo. Serum PTH was increased in human subjects at Month 3 (+45% vs pbo) and Month 12 (+20% vs pbo). In monkeys, PTH was increased at Wk 10 (+90% to +130% vs OVX controls) and Wk 50 (+110% to +50% vs OVX controls), at 3 to 30 mg/kg, respectively, consistent with a larger stimulation of bone resorption/remodeling at intracortical and possibly periosteal surfaces. There was no imbalance in the number of leukemia cases in placebo and romosozumab groups and AML was not observed in romosozumab-treated study subjects.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Local tolerance</head><p>Local tolerance at the SC injection site was specifically assessed using solutions with different AMG785 concentrations. Single dose administrations showed transient, concentrationdependent inflammatory responses in male rats. Local tolerance to sodium and calcium acetate formulations (Process 1 and Process 2, respectively) appeared similar. Both were associated with minimal inflammatory infiltrates in repeat dose rat and monkey studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Genotoxicity</head><p>Genotoxicity testing was not performed. The product is a recombinant IgG2 protein of naturally occurring amino acids and is not expected to react with DNA or other chromosomal material.</p><p>Carcinogenicity AMG785 was evaluated for carcinogenicity in a 2-year 'life-time pharmacology' study in Sprague Dawley rats. Doses used were 3, 10, and 50 mg/kg/week, equivalent to human exposure multiples of 0.6x, 4x, and 19x, based on AUC comparison. AMG785 had no effect</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>91</head><p>on mortality or cause of death. Effects included marked bone mass increases and increased skeletal opacity, histologic hyperostosis, and extramedullary hematopoiesis. There were no statistically significant increases in tumor incidences at any dose.</p><p>Two osteosarcomas were found in the 50 mg/kg male group, one at necropsy in tibia and one by radiography in skull. The incidence (3.7%) marginally exceeded historical control range (0-3.3%). While there was a concern about osteosarcoma based on the precedence of bone tumorigenicity with PTH, and the two tumors were observed in the dose group with the highest bone mass increase, the lack of statistical significance, the potentially increased assay sensitivity based on use of radiography, and the high 20x exposure multiple, all suggest that these tumors are not of toxicological or clinical relevance. In addition, mechanistic data from OVX rat studies have suggested lack of osteoprogenitor proliferative activity of Scl-Ab. Hence, inclusion of the finding in the product label is not warranted.</p><p>The absence of bone tumors in this study, even at high human exposure multiples and marked bone mass increases, is in striking contrast with the bone tumor response observed with anabolic PTH-or PTHrP-related peptides. These compounds have caused osteosarcomas in <ref type="bibr">2-</ref>year rat studies at relatively low human exposure multiples based on unknown mechanism and of uncertain clinical relevance. The lack of tumors with AMG785 may be related to the transient self-limiting bone formation response. Lack of tumorigenicity of AMG785 is also suggested by other evidence including clinical data, offsetting potential limitations in the relevance of data from the AMG-785 treated rat.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reproductive Toxicity</head><p>A fertility and embryo-fetal development (FEED) study was conducted in rats at doses of 10, 60 and 300 mg/kg, equivalent to 1.5x, 19x, and 56x human exposure, based on AUC comparison. There were no effects on male or female fertility. AMG785 caused a slight increase in the incidence of reduced ventral processes on the 6th cervical vertebra at 300 mg/kg (56x human AUC), in the absence of maternal toxicity. Other adverse effects on vertebral development/ossifications were not observed. The reduction in the ventral process represents a developmental delay and was absent in pups postnatally (see PPND study). This particular anatomical structure is not present in humans. Therefore, while the finding is treatment-related, it is not considered clinically relevant and does not need to be included in the product label.</p><p>The definitive embryo-fetal development (EFD) study was conducted in rats at doses of 30, 100 and 300 mg/kg. This was equivalent to at least 5x, 17x, and 32x human exposure, based on TK data from dose range finding Study 108057 with the same doses and human PK data at 210 mg QM. In 4/25 litters in the 100 and 300 mg/kg groups each, fetuses were found to have reduced ventral processes on the 6 th cervical vertebrae, with fetal and litter incidences exceeding historical control ranges. External and skeletal malformations including syndactyly and polydactyly were observed in 7 of 16 fetuses in one of the 22 litters, at the high dose of 300 mg/kg. Some of the 7 affected fetuses also had associated skeletal malformations. Litter and fetal incidences exceeded historical control ranges in this study. The anomalies were not</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D. 92 present in the other two pivotal reproductive toxicity studies. Across studies, litter incidence was 1/75, and fetal incidence was 7/1021, i.e. 0.7%. The Sponsor eventually concluded this finding was not treatment-related. However, this reviewer believes that treatment-relatedness cannot be excluded, in part based on the occurrence of syndactyly in SOST -/mice and humans with sclerosteosis. NOAEL is 100 mg/kg, or 17x human exposure. The reviewer recommends that this finding be mentioned in the product label.</p><p>In a pre-and post-natal study in rats, conducted at doses of 10, 60 and 300 mg/kg, <ref type="figure" target="#fig_0">equivalent  to 1.5x, 19x, and 56x</ref> human exposure, based on AUC comparison, minimal or slight but significant decreases in femoral bone mass <ref type="bibr">(vBMD, vBMC)</ref> were observed in F1 males and females at 60 and 300 mg/kg, and altered femur cortical geometry (smaller bones) was seen in males at 10, 60 and 300 mg/kg (NOAEL &lt;1.5x human exposure). Increases in bone BMD and thickness were also observed. The significance of the small bone decreases is unclear but being negative the findings constitute a slight safety concern. The changes are the opposite of those expected upon sclerostin inhibition. Lack of consistent bone mass increases might be in analogy with the delay in the postnatal development of high bone mass in SOST-/-mice until 4-8 wks of age. However, the bone decreases were not expected. Skeletal abnormalities in the 6th cervical vertebrae or digital malformations were not observed in the F1 pups. The lack of these abnormalities supports the hypothesis that the observation of reduced processes in the EFD study represented a developmental delay. There were no effects on any developmental endpoint including reproductive performance of F1 pups after lactation day 21.</p><p>Nonclinical assessment of clinical concerns An extensive discussion of theoretical safety issues and potentially increased risks of various adverse effects was included by the Sponsor in the Secondary Pharmacology section of the BLA. Based on all submitted nonclinical and clinical information and information from published literature, the weight of evidence suggested that carcinogenicity is unlikely to be a significant concern with AMG785 treatment. The issues related to osteoarthritis, vascular calcification, increased longitudinal bone growth, hyperostosis, hypercementosis, altered hematopoiesis, sarcopenia, altered glucose metabolism, and exacerbation of TNF-mediated inflammation are also unlikely to constitute significant safety concerns for the intended clinical treatment population.</p><p>The clinical team has expressed concern about the anti-resorptive effects of romosozumab. This is based on one case each of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ) in Phase 3 study 20070337 in the initial 12-month romosozumab treatment period, and one additional case of ONJ after one dose of denosumab in the second 12-month treatment period. Increases in the risks of these serious adverse events are known to be associated with long term use of anti-resorptives such as bisphosphonates and denosumab, hence the clinical concern. Indeed, histomorphometry data from clinical Study 20070337 clearly showed romosozumab-related decreases in endocortical and trabecular eroded surface, the latter to a similar extent as denosumab. Animal histomorphometry data provided similar information.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>93</head><p>An animal model for AFF does not exist. However, in long term studies in alendronate treated dogs, resorption suppression has been associated with reductions in strength parameters, particularly post-yield toughness, which indicates an increase in bone brittleness often considered an underlying cause of AFF. The bone mechanical changes may be due to lack of repair of microcracks resulting from drug-induced resorption inhibition. The Sponsor's nonclinical AMG785 studies, several of which included adequate bone strength assessments, provided strong evidence of a lack of bone quality or strength impairments. Regarding ONJ, there were no adverse effects on jaw bone in the Sponsor's chronic toxicity studies and data from a published study in a rat periodontal ligation model showed increases in alveolar bone and continued resorptive activity although clinical endpoints were not included in the study. Nevertheless, the ideal nonclinical model and the bone quality parameter(s) that are most predictive for increased risks of clinical AFF and/or ONJ are not well established.</p><p>A study to evaluate the effect of AMG785 on femoral bone strength in mice to address the concern about AFF does not seem warranted, as data from published literature suggest that Scl-Ab increases cortical bone material strength and does not cause the increase in femur brittleness observed with alendronate treatment <ref type="bibr">(Sinder et al, Bone 71: 115-123, 2015;</ref><ref type="bibr">Misof et al, Bone 36: 150-158, 2005;</ref><ref type="bibr">Uveges et al, JBMR 24(5): 849-859, 2009</ref>).</p><p>If the clinical team has concerns regarding the ability of romosozumab to cause osteonecrosis of the jaw (ONJ), a nonclinical study could be conducted to examine the effects of r13c7 in a rat surgical ONJ model (refer to <ref type="bibr">Kim et al., Bone 81:442-448, 2015)</ref>. Adequate dose selection and inclusion of a bisphosphonate control arm would be recommended for such a study. Zoledronic acid treatment, in combination with dental extraction, has been shown to induce ONJ in this model, and the ONJ was accompanied by a shift in alveolar bone microcrack size to larger values. Such a nonclinical study would be useful if it could provide helpful information from a clinical or regulatory perspective.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p>Taken together, the submitted nonclinical information is adequate and supports the safety of the proposed treatment with once-monthly subcutaneous doses of 210 mg in the intended treatment population. AMG785 was generally well tolerated by animals at doses equivalent to large human exposure multiples, and apart from indirect effects related to the pharmacological activity, little toxicity was observed. Information available from humans with sclerostin deficiency disorders or SOST knockout mice is also generally reassuring regarding bone safety, general toxicity and carcinogenicity. The embryofetal digit anomalies observed with AMG785 treatment replicate similar observations in humans and mice with sclerostin deficiencies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>94</head><p>Label Pharmacology/Toxicology Labeling Recommendations are included in the Executive Summary.</p><p> Section 8: Edit section and language to comply with current PLLR policies  Section 12.1: Mechanism of Action: Edit language based on above discussion  Section 13.1 Carcinogenicity, Mutagenesis, Impairment of Fertility: Edit language  Section 13.2: Animal Toxicology and/or Pharmacology: Edit language to adequately describe findings in nonclinical bone pharmacology studies  <ref type="bibr">(Dec 8, 2014)</ref> Batch/Lot Nr: 0010085638, FDP Batch #1026275, Material #20009614AI1</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head><p>Cynomolgus monkeys ages 8.5-17.5 years, weight 3-5kg, were acclimatized for 6-8 weeks before an 8-week baseline period. They were then sham-operated or ovariectomized (OVX-ed) and AMG785 treatment was started after a 17-week bone depletion period. Sham-operated animals were dosed with vehicle (0 mg/kg/wk) once weekly for 52 weeks (Grp 1). OVX groups were treated with subcutaneous doses (1.45 mL/kg) of 0, 3, 30 mg/kg/wk for 52 weeks <ref type="bibr">(Grps 2,</ref><ref type="bibr">3,</ref><ref type="bibr" target="#b86">4)</ref>, or for 26 weeks followed by vehicle for 26 weeks (30/0 mg/kg/wk; <ref type="bibr">Grp 5)</ref>. Dose levels were aimed at achieving an increase in spine BMD of ca. 10-15% at 3 mg/kg, and a higher but less than saturated response at 30 mg/kg. Monkeys were not supplemented with calcium (Ca) or Vitamin D (VitD).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In-life observations/measurements in main study animals:</head><p>o  <ref type="bibr" target="#b86">(4)</ref> o Samples taken at 7 time points, up to 7 days post-dosing, on <ref type="bibr">Day 1,</ref><ref type="bibr">and Wks 10,</ref><ref type="bibr">26,</ref><ref type="bibr">52</ref>; also pre-dose samples taken in <ref type="bibr" target="#b87">5,</ref><ref type="bibr" target="#b53">13,</ref><ref type="bibr">15,</ref><ref type="bibr">19,</ref><ref type="bibr">26,</ref><ref type="bibr">29,</ref><ref type="bibr" target="#b91">33,</ref><ref type="bibr">37,</ref><ref type="bibr" target="#b92">41,</ref><ref type="bibr">45,</ref><ref type="bibr">52;</ref><ref type="bibr"></ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Anti-drug antibodies</head><p>o Several animals had (A) Binding ADAs (B) Neutralizing ADAs (Text <ref type="table" target="#tab_5">Tables 33 and  34</ref>) o This led to exclusion of several treated animals, resulting in data for statistical analysis from <ref type="bibr">N=16,</ref><ref type="bibr">16,</ref><ref type="bibr" target="#b88">6,</ref><ref type="bibr">15,</ref><ref type="bibr">14,</ref><ref type="bibr">in Grps 1,</ref><ref type="bibr" target="#b84">2,</ref><ref type="bibr">3,</ref><ref type="bibr" target="#b86">4,</ref><ref type="bibr">5 (Text</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>104</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Organ weignts</head><p>o Reduced uterus weight in OVX vs Sham (-67%), as expected; no effect of AMG785.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Gross pathology</head><p>o Absence of ovaries in all OVX animals; uterus small in a few OVX animals; No remarkable effects of AMG785.</p><p>Histopathology o Mononuclear cell infiltration (minimal-slight) at injection sites in 3 but not in 30 mg/kg group, possibly immunologically mediated, since there was also a larger ADA response in this group. o Increase in amount but not incidence of woven bone in rib (absent in recovery animals), but not iliac bone biopsy defect sites at 30 mg/kg. o No AMG 785-related microscopic changes in bone or marrow, such as a defective organization of osteoid matrix or marrow fibrosis in any samples examined at any timepoint.</p><p>Hormones (Text <ref type="figure" target="#fig_6">Fig. 6, below)</ref> o OVX effect: slight decreases in serum PTH and VitD (not shown) o AMG effect: Significant increases in PTH and VitD, both continuing throughout treatment period</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DKK1 and FGF23</head><p>FGF23 increased in OVX vs sham, and transiently decreased at Wk 9/10 by 30 mg/kg AMG785.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Radiography</head><p>No evidence of proliferative changes or aorta mineralization.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bone turnover markers (Text Figs. 3 and 4)</head><p>o OVX  Increases in formation <ref type="bibr">(2-3x)</ref> and resorption markers (2x) vs sham, due to OVX-induced stimulation of turnover (data not shown). o AMG785:</p><p> Increases in bone formation markers BAP, PINP and OC, as expected based on neutralization of sclerostin, at both 3 and 30 mg/kg.  Increases in resorption markers CTx and NTx, at both doses. Urine NTx data were probably least reliable.  Increases in formation and resorption were maximal at the two earlier time points (Wks 9/10-23/24) and decreased thereafter, but markers remained above OVX levels at Wk 52.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer comments:</head><p>o Both formation and resorption markers were dose-dependently and transiently increased by AMG785. o Maximum effect was at Wks 9/10, except NTx showed continued increase through Wk 52. NTx data are probably least reliable. o The transient increase in bone resorption (and part of the increase in formation) markers by AMG785 may be related to the observed increase in PTH leading to stimulation of bone turnover (ie resorption and formation). o The increase in formation markers is consistent with the increases in bone formation parameters (eg BFR) at trabecular and cortical (endosteal, intracortical and periosteal) bone surfaces. o The increase in resorption markers is in apparent contrast to the decreases in histomorphometric resorption parameters in cancellous bone of ilium <ref type="bibr">(ES/BS,</ref><ref type="bibr">Wk 13)</ref> and cortical bone of rib <ref type="bibr">(Ec.E.Pm %,</ref><ref type="bibr">Wks 13,</ref><ref type="bibr">27,</ref><ref type="bibr">52)</ref> and femur (Wk 52). However it is consistent with the likely increases in intracortical and periosteal bone resorption or turnover.</p><p>o In OVX rats, one of two analyzed resorption markers (CTx) was also increased, but resorption marker DPD was unaffected. o In humans, in the 24-month Phase 3 study 20070337 with an initial <ref type="bibr">12-month</ref> AMG785-only Tx period, formation markers were increased and resorption markers decreased. The increase in BF markers was largest in <ref type="bibr">Month 1 (ca. 120% vs pbo)</ref> and no longer seen after ca. 9 months, while the decrease in BR markers was maximal in   o Results for thoracic spine (T9-T12) were very similar</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>110</head><p>Reviewer Comment:</p><p>The increase in vertebral BMD at Wk 52 was ca. 17% at the 3 mg/kg dose, a dose equivalent to 1.4x the human 210 mg dose based on AUC. This was very similar to the spine BMD change vs placebo at the end of the 12-month AMG treatment period in <ref type="bibr">Phase 3 Study 20070337 (ca. 13%</ref>), suggesting similar bone efficacy in monkeys and humans. <ref type="figure" target="#fig_0">Fig 14)</ref>: o OVX: o Small decreases in Area (UD part), BMD and BMC during 4-month bone depletion period, and continuing mainly in first 24/25 wks of Tx period (see Text <ref type="figure" target="#fig_0">Fig 14)</ref>. o AMG treatment:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DXA Distal Radius (Text</head><p>o Significant increases in Area, BMD and BMC in total distal radius at 30 mg/kg (Text <ref type="figure" target="#fig_0">Fig 14)</ref>. Increase in BMD vs. OVX control was +9%, +8% and +11 % for total, 1/3 and UD radius, respectively. o Increases occurred mainly after Wk 11/12 at 30 mg/kg and after 24/25 weeks at 3 mg/kg o Increases at 3 mg/kg were much smaller than at 30 mg/kg, and 1/3 Radius-Area was not increased at this dose.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>111</head><p>o Parameters in 30 mg/kg grp exceeded OVX levels by Wk 24/25 and sham levels by Wk 52. o Tx withdrawal caused a non-significant reversal of effects. <ref type="figure" target="#fig_0">Fig 16)</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DXA Proximal Femur (Text</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>114</head><p>Reviewer Comment:</p><p>The DXA data showed increases in all parameters and are consistent with the increases in bone formation markers. They showed the largest effects in the first 3-6 months of treatment for all bones except distal radius. In human study 0337, BMD of lumbar spine was also increased mainly in the first 6 months of the 12-mo Tx period; in total hip, BMD increased at slower rate after 6 months, and femoral neck BMD increased throughout the 12 months Tx. It is not clear which bone site and surface contributes most to the changes in markers. Trabecular bone mass is smaller than cortical mass (20% vs 80%) but total trabecular surface is probably larger.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>pQCT (in vivo)</head><p>Metaphysis (proximal tibia and distal radius) o OVX (tibia and radius) (Text <ref type="figure" target="#fig_0">Fig. 21</ref> Reviewer Comment (pQCT diaphyses): pQCT showed that AMG785 caused increases in cortical BMC, periosteal circumference, total and cortical area, and cortical thickness in both bones. These changes were more pronounced for proximal tibia than distal radius. Cortical BMD was transiently decreased in distal radius more than in proximal tibia. Endosteal circumference was DECREASED for proximal tibia, and INCREASED for distal radius.</p><p>Schematic drawing of changes in cortical bone after 12 months (Effects at 30 mg/kg, inflated)  OVX caused cortical thickness (Ct.Th) decrease due to decreased periosteal circumference with no effect on endosteal circumference in both bones.  In proximal tibia, AMG caused cortical thickness increase mainly through endosteal bone apposition and a little through bone widening.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>121</head><p> In distal radius, AMG caused bone thickness increase too, but that was mainly due to increased periosteal bone circumference, since endosteal circumference was increased as well.  At the radius endosteal surface, resorption outperformed formation, while in tibia endosteal formation dominated resorption.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sham control OVX control Proximal tibia Distal radius</head><p>Selected data summary:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>122</head><p>Reviewer Comment:</p><p>The monkey finding of decreased distal radius pQCT-vBMD (Study 107903) was reproduced using HRpQCT in a <ref type="bibr">6-month OVX monkey study 118025 (0, 3 mg/kg)</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>126</head><p>L3+L4 Vertebral Bodies <ref type="figure" target="#fig_2">(Text Fig. 33</ref> Reviewer Comment: o The decrease in tissue BMD may be an artifact due to larger sizes (BMC) of the bone specimens in which tBMD was decreased <ref type="bibr">(Fajardo et al 2009)</ref>; this is supported by lack of tBMD change in cortical beams (see below)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>132</head><p>L6 caudal core o Changes upon OVX and AMG treatment were very similar to those observed in the trabecular region of the vertebral body L3.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Femoral neck</head><p>o Changes upon OVX and AMG treatment were very similar to those observed in the trabecular region of the vertebral body L3. o However, magnitude of changes was smaller and they were most often not significant for the 3 mg/kg and the 30 mg/kg-recovery groups.</p><p>Humeral cortical beam (Text <ref type="figure" target="#fig_3">Fig. 42</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>133</head><p>Reviewer Comment: o The micro-CT data were consistent with data from densitometry and histomorphometry evaluations. o Tissue BMD means the tissue mineral density of bone without its internal or surrounding soft tissue compartments. The reliability of the vertebral tissue BMD values is uncertain, since measurement of this parameter by micro-CT is subject to possible methodological errors.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>134</head><p>Biomechanical testing <ref type="bibr">(Femur shaft and neck, humerus beam, and lumbar vertebral bodies and cores)</ref> Femur shaft 3-point bending <ref type="figure" target="#fig_2">(Text Fig. 43)</ref>: o OVX effect: Some expected changes of OVX were observed (decreases in peak load Fu, yield load, stiffness) but they were not statistically significant. o AMG effects:</p><p>o Dose-related increases in peak load, yield load, stiffness and AUC, some significant, of 20-25% vs OVX controls (15-40% vs sham control) at 30 mg/kg; also increases in geometry-corrected parameters o Increases in total toughness and post-yield toughness (and possibly also preyield toughness), not significant o Recovery group:</p><p> Reversal of most parameters, except (post-yield) toughness; wholebone values remained above OVX control. o Correlations density-strength:</p><p>o Peak load correlated well with ex-vivo pQCT femoral diaphysis cortical BMC <ref type="figure" target="#fig_3">(Text Fig. 44</ref>), and also with mid-femur ex vivo DXA BMC (not shown).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>136</head><p>Humerus <ref type="formula">beam</ref>   <ref type="figure" target="#fig_3">Fig. 48</ref>) and BMD (not shown), except in 3 mg/kg group (low N). o Slope of OVX control regression line slightly steeper than for other groups;</p><p>slopes of sham and 30 mg/kg groups similar.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>138</head><p>Vertebral body L3+L4 compression (Text <ref type="figure" target="#fig_5">Fig. 50)</ref>: o OVX effect: o Decreases in peak load Fu, yield load, stiffness and AUC, but they were not statistically significant (similar to femur diaphysis results  <ref type="figure" target="#fig_0">Fig. 51)</ref>, and apparent strength correlated with BMD (not shown), in all groups except 3 mg/kg (probably due to low N). o Slope of 30 mg/kg regression line steeper than for other groups, suggesting improved bone quality, when 'quality' is defined as the slope of this regression line.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>140</head><p>Vertebral cores L5+L6 compression (Text <ref type="figure" target="#fig_2">Fig. 53</ref> o Peak load correlated well with ex vivo pQCT-BMC <ref type="figure" target="#fig_3">(Text Fig. 54)</ref>, and apparent strength correlated with BMD (not shown); correlation significant for all groups except 3 mg/kg.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>141</head><p>o Negative shift of regression line BMC vs Fu in 30 mg/kg recovery group suggested possible impairment in bone quality in this group; however it is not clear whether this was a biologically significant finding.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>142</head><p>Reviewer Comments: o Strength parameters were generally positively affected at either 30 mg/kg (femur diaphysis), or at both <ref type="bibr">3 and 30 mg/kg (vertebral bone and femoral neck)</ref>. o Good correlations between mass and strength were observed in vertebrae and femur diaphysis, and reasonable correlations in femoral neck (typical for these studies   o The increases in BFR were consistent with the increases in systemic bone formation markers <ref type="bibr">(PINP, OC, BSAP)</ref> o Erosion/resorption activity at the endocortical surface (EcEPm, %) was markedly suppressed especially at the earlier time points in rib <ref type="bibr">(13-27 wks)</ref>, but also still at the last time point (52 wks) in femur diaphysis. Also, endocortical formative surface % was increased while quiescent surface % was decreased. This suggests that bone formation at the endocortical rib surface was modeling-based rather than remodelingbased.</p><p>o Overall, Haversian bone formation in rib was increased in Wk 13 and 27 at both doses. Considering the small increase in cortical porosity in Wk 27, this formation increase was probably accompanied by increased intracortical resorption.</p><p>o Daily dosing with teriparatide or PTH1-84 is known to have much larger effects on cortical porosity (2x-5x OVX control), particularly near the endocortical surface <ref type="bibr">(Burr et al 2001</ref><ref type="bibr">, Fox et al, 2007</ref>. By comparison, AMG785 in rib caused Po.Ar to increase merely by a factor of 1.5x from 4 to 6%.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>160</head><p>o Based on Ps.BFR data, resorption stimulation probably also occurred at periosteal surfaces. The increase in rib Ps.BFR/BS at 30 mg/kg was 6x, 4x and 3x in <ref type="bibr">Wk 13,</ref><ref type="bibr">27,</ref><ref type="bibr">52. Concomitantly,</ref><ref type="bibr">Tt.T.Ar (i.e. external bone width)</ref> was increased <ref type="bibr">1.07x,</ref><ref type="bibr">1.06x,</ref><ref type="bibr">1.2x (Wk 13,</ref><ref type="bibr">27,</ref><ref type="bibr">52)</ref>. Ps.BFR was also increased at 3 mg/kg <ref type="bibr">(Wk 13)</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>161</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSIONS</head><p>Study design  Monkeys were sham-operated or OVX-ed followed by a 17-wk bone depletion period. Sham-operated monkeys were dosed s.c. with 0 mg/kg/wk for 12 months. OVX groups were given 0, 3, or 30 mg/kg/wk for 12 months, or 30/0 mg/kg for 6/6 months (recovery group).</p><p>ADA  Several animals in the 3 mg/kg weekly dosing group developed binding or neutralizing antibodies against AMG785. The result was that the initial number of 16/grp was reduced to <ref type="bibr">16,</ref><ref type="bibr">16,</ref><ref type="bibr" target="#b88">6,</ref><ref type="bibr">15,</ref><ref type="bibr">14</ref> in the 0, 0, 3, 30, and 30/0 (recovery) groups, respectively. (data from 6-month toxicity study 107426; from 3, 10 and 100 mg/kg dose groups). This is 2.5 to 4 times shorter than the observed half-life in humans at the 3 mg/kg dose <ref type="bibr">(12.8 days;</ref><ref type="bibr">Clinical Overview,</ref><ref type="bibr">p.19)</ref>.  Cumulative monthly monkey vs monthly human AUC multiples at 3 and 30 mg/kg are 1.3x and 22x, respectively, which would be 1.3x and 2.2x larger than multiples calculated based on mg/kg comparison (1x and 10x, respectively).The difference may be due to the fact that half-life in monkeys is less than 1/4x half-life in humans while doses were given ca. 4 more frequently in monkeys vs humans.</p><p>Bone resorption and formation  AMG785 transiently increased overall skeletal bone formation and resorption indicated by serum or urine circulating bone biomarkers. The increases were largest at 3 months (the earliest sampling time point) and decreased thereafter. However, markers were still increased as compared to OVX controls after 12 months. Effects were approx. 2.5-fold larger for formation marker P1NP vs resorption marker CTx. The formation increase was due to the primary pharmacologic effect of AMG785 to neutralize sclerostin and prevent inhibition of osteoblastic bone matrix deposition and mineralization.  The resorption increase was probably related to the AMG-induced increase in serum PTH. The increase in resorption markers was also transient but, like the increase in</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>162</head><p>serum PTH, CTx and NTx values were still above OVX controls at 12 months. The PTH increase most likely reflected an attempt to compensate for hypocalcemia caused by osteoblastic bone mineral formation. PTH is known to stimulate Haversian (intracortical) bone remodeling and can increase cortical porosity. These events were confirmed by an early increase in H.BFR and small increases in Po.Ar in rib cortex (histomorphometry, see below).  Serum calcium was slightly decreased.</p><p>Densitometry DXA (spine, femur, tibia and radius)</p><p> OVX led to expected decreases in DXA parameters BMD, Bone Area and BMC at cancellous and cortical bone sites.  AMG increased bone mass evidenced by dose-related increases in BMC, Area and/or BMC in whole body, lumbar spine and long bones, including proximal tibia, proximal and distal femur, and distal radius. Increases occurred in both cancellous and cortical long bone regions.  Increases were most prominent in the first 6 months, but continued thereafter.  At 12 months, parameters usually exceeded sham levels at both 3 and 30 mg/kg doses.  Upon recovery, the effects in the 30 mg/kg group were reversed to the levels achieved in the 3 mg/kg or sham group.  Extent, time-dependence and dose-dependence of the AMG effects on DXA parameters were different for different bone sites and regions.  PQCT confirmed increases in trabecular BMD in metaphyseal part of proximal tibia and distal radius.</p><p>pQCT (tibia and radius, meta-and diaphysis) o OVX caused decreases in trabecular and cortical/subcortical BMD and BMC, and cortical thinning due to decrease in bone width with no change in medullary area. o In proximal tibia and distal radius metaphysis, AMG increased total bone area/width, trabecular and (sub)cortical BMD and BMC. Effects were more pronounced in tibia. o In proximal tibia and distal radius diaphysis, total area and periosteal circumference were slightly increased (effect in radius &gt; in tibia), and cortical thickness was increased. Cortical BMD was increased in tibia. However it was transiently decreased in distal radius. In tibial diaphysis, endosteal circumference was decreased but in radius diaphysis endosteal circumference was slightly increased. PQCT of proximal or mid femur was not performed. It is not clear whether any other bones respond to AMG785 in a similar way as cortical bone of distal radius. The cause of the decrease in cortical BMD with AMG785 is not clear. It may in part be due to increased cortical remodeling and porosity, although the histomorphometry data are not entirely consistent with this interpretation. PTH receptor agonists also cause a slight decrease in BMD of the mostly cortical distal radius, possibly due to increased cortical porosity. o AMG generally restored bone parameters to sham levels at 3 mg/kg and above sham levels at 30 mg/kg.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>163</head><p>o The effects in the 30 mg/kg recovery group were reversed usually to the levels attained in the 3 mg/kg group.</p><p>Densitometry (ex vivo)  Data from ex vivo DXA/pQCT of femur, vertebrae and vertebral cores to be used for mechanical testing at 52 wks showed effects very similar to those observed for vertebrae (by in vivo DXA), and proximal tibia (by in vivo pQCT). AMG effects in femur diaphysis included increased BMC and BMD, increased cortical thickness and decreased endosteal circumference. Cortical BMD was not affected.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Micro-CT (ex vivo)</head><p> Micro-CT after 52 wks showed that AMG785 increased L3 trabecular parameters (vBMD, BMC, Tb.Th and/or Tb.N, Bone Area, BV/TV) in a dose-related manner. Changes were similar in vertebral bodies and cores. AMG785 also increased vertebral cortical bone vBMD, BMC, area, and thickness.  Tissue BMD was decreased by AMG in vertebral trabecular and cortical regions. This may be related to increased bone porosity, or it may be a technical artefact.  In femoral neck, AMG785 effects were similar to those in L3 trabecular bone.  AMG785 did not significantly affect humerus cortical porosity or tissue BMD.  The AMG785-induced decrease in L3 SMI probably indicated a change to a more plate-like trabecular structure.  In the 30 mg/kg recovery group, the AMG785-induced changes were partially reversed to levels achieved in the 3 mg/kg group (cortical part of L3) or levels intermediate between OVX and 3 mg/kg groups (trabecular part of L3).  Data were consistent with densitometric and histomorphometric results.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biomechanical testing</head><p> AMG increased bone strength parameters of the femur shaft. Effects were dose-related with some statistically significant at 30 mg/kg. Effects included increases in peak load, yield load, stiffness, AUC and (postyield)-toughness.  The intrinsic cortical bone strength (material strength) of the humerus cortical beam was not significantly affected by AMG.  AMG increased the strength (peak load, stiffness, AUC) of the femoral neck, consistent with significant increase in ex vivo DXA proximal femur BMD and BMC.  AMG increased bone strength parameters in lumbar vertebrae bodies and cores, with most effects statistically significant at both 3 and 30 mg/kg. Effects included increases in peak load, yield load, stiffness, AUC and (postyield)-toughness.  For femur shaft and vertebrae, correlations between ex vivo densitometric measures of bone mass (BMC or BMD) and bone strength (peak load or apparent strength) were very good and statistically significant. For femoral neck, there was a reasonably good significant correlation between BMC and peak load (except for the 3 mg/kg group of N=6).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>164</head><p> In vertebral L3+L4 bodies, bone quality appeared to be increased vs sham and OVX groups at 30 mg/kg, when bone quality was defined as the slope of the regression line between ex vivo BMC and peak load (ie as BMD increases strength increased more in 30 mg/kg vs other groups).  There was no indication of an adverse effect of AMG treatment on bone quality or integrity. All bone strength parameters were positively affected by AMG treatment, at least after 12 months of treatment, and correlated significantly with densitometric measures. However, bone strength measurements in the current study were carried out after the 12-month treatment period only. Based on the marked decrease of endocortical resorption and the increase in cortical porosity during the initial weeks of treatment, not yet accompanied by significant endocortical and/or periosteal bone deposition, there may be a transient period of cortical bone mechanical vulnerability. However, data from the 6-month monkey Study 118025, in which meta-and diaphyseal distal radius and tibia were evaluated in more detail, allayed this concern at least to some extent. Mechanical strength may also be correlated to other aspects of bone quality that were not evaluated in the animal studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histomorphometry</head><p>Cancellous bone of ilium (Wks 13 and 27), vertebrae and femoral neck (Wk 52)  AMG caused increases in Tb.Th (with increase in Tb.Sp), BV/TV and BFR (bone formation rate), and an increase in formative and decrease in quiescent surface throughout treatment at all (2 or) 3 bone sites. Increases in osteoid and osteoblast surfaces were only apparent in Wk 13. The structural changes were due to the expected stimulatory effect of AMG on trabecular bone formation, particularly in the first few weeks/months of treatment.  Eroded surface in AMG treated animals decreased from 20% to 16-10% <ref type="bibr">in Wk 13 (ilium)</ref> only. This decrease was not seen at 6 months or later. At 52 weeks, there was a slight increase in ES/BS in vertebral bone.  AMG increased Wall Thickness in <ref type="bibr">Wk 13 and 27 (Ilium)</ref> and Wk 52 <ref type="bibr">(FN, vert)</ref> indicating positive bone balance at the BRU level.  AcF was increased (ie stimulation of remodeling), significantly in Wk 13.  At the human equivalent dose of 3 mg/kg, significant effects included changes in trabecular parameters (e.g. Tb.Th), BV/TV, BFR and formative/quiescent surface ratio.</p><p>Cortical bone of rib and femur diaphysis  AMG markedly increased BFR rates at endosteal surfaces, Haversian and periosteal surfaces, particularly in Wk 13 (rib). Also, endocortical formative perimeter was increased and quiescent perimeter decreased at Wk 13 (rib).  AMG markedly suppressed % endocortical eroded surface in rib (Wk 13&gt;27&gt;52) and in femoral diaphysis (Wk 52) to below OVX control as well as sham levels (from 9 to &lt;0.3% in femur). Rib data suggested that the effect subsided with time, but it was still pronounced in femur at study end. The data suggest a large suppression of the osteoclasts at that surface. The concomitant increase in Ec.BFR and the changes in</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>165</head><p>formative/quiescent perimeter fractions indicated modeling rather than remodeling at the endocortical surface.  AMG increased total and cortical area%, and cortical width of rib and femoral diaphysis, mainly at 30 mg/kg at Wk 52. Medullary area% was decreased in both bones, especially at later time points, consistent with pQCT data.  At the Haversian surface, H.BFR was also enhanced at <ref type="bibr">Wk 13 and 27 (rib)</ref> and Po.Ar % (porosity) was slightly increased in Wk 27 and 52 (rib and femur). Rib and femur medullary areas were both decreased by AMG treatment at 3 and 30 mg/kg, similar to that in the tibia according to pQCT.  The slight AMG-induced increase in endosteal circumference in distal radius (pQCT data) suggests that resorption outperformed formation at this bone surface. There were no morphometric data for the distal radius to provide information.  Bone width (TtTAr) at 3 mg/kg was only slightly affected at Wk 52, while periosteal BFR was markedly increased particularly early in treatment. This suggested a parallel increase in resorption at the periosteal surface. However, based on the actual BFR numbers and the relatively small total periosteal skeletal surface this resorption probably did not contribute much to the increase in average skeletal resorption.  The histomorphometry data showed that the increases in resorption markers (NTx, CTx) were probably due, for the most part, to an early enhancement of Haversian/intracortical bone resorption, possibly with some contribution of periosteal resorption, and of trabecular resorption at later time points. The increase in resorption was likely to be PTH-dependent.  The increases in formation markers were due to enhanced bone formation at trabecular (mostly) and cortical bone surfaces. The latter probably included mostly Haversian and endocortical surfaces but also periosteal surfaces. This is based on control BFR/BS values at different cortical surfaces (endocortical &gt; Haversian &gt; periosteal) and probable relative sizes of these surfaces (Haversian &gt; endocortical and periosteal).  <ref type="figure">-------------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>---------------------------------------------------------------------------------------------------------</head><formula xml:id="formula_35">/s/ ---------------------------------------------------- GEMMA</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.2">Brief Discussion of Nonclinical Findings</head><p>In fertility and embryo-fetal studies in rats, romosozumab (300 mg/kg; 56-fold the proposed clinical dose) caused a slight increase in the incidence of reduced ventral processes on the sixth cervical vertebra, in the absence of other developmental delays or maternal toxicity. (This finding is sometimes considered a developmental delay in a skeletal process not found in humans.) In addition, skeletal abnormalities (including syndactyly and polydactyly), occurred in 1 litter at the high dose in one embryo-fetal study (300 mg/kg; approximately 32-fold the proposed clinical dose).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3">Recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3.2">Non Clinical Recommendations</head><p>Both the incidence of reduce ventral processes and the skeletal abnormalities of syndactyly and polydactyly should be included in the label.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.3.3">Labeling</head><p>Risk summary:</p><p>Animal Data: </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fetal skeletal alterations</head><p>At 300 mg/kg, there were 3 fetuses from 3 litters that had reduced ventral processes (which develop into the carotid tubercles) on the 6th cervical vertebrae, slightly exceeding the historical range of the test facility, which was considered to represent a developmental delay (development of the ventral processes of the cervical vertebrae proceed in an anterior to posterior direction and the ventral processes on the 7th cervical vertebrae had not started to develop at gestation day 21). No other fetal effects were observed at any dose level. Satellite groups: 8 for toxicokinetics Study design: All main study rats were euthanized on GD 21, and blood samples were collected for toxicokinetic and antibody analyses. All rats assigned to toxicokinetic evaluation were euthanized on GD 19, and maternal and fetal blood samples were collected for toxicokinetic, placental transfer and antibody analyses. Deviation from study protocol: None significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fetal skeletal alterations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Observations and Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mortality</head><p>All rats survived until scheduled sacrifice.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Signs</head><p>No treatment related effects were observed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Body Weight/ Feed Consumption</head><p>No treatment related effects were observed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Toxicokinetics</head><p>Mean toxicokinetic parameters (provided by the sponsor in a Study Report Amendment from October 27, 2015)</p><p>Reference ID: 4076742</p><formula xml:id="formula_36">(b) (4) (b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dosing Solution Analysis</head><p>Mean measured AMG 785 concentrations for all dose formulations were within the acceptable limits (10% of nominal concentration), and homogeneity was acceptable (5% RSD) for all dose formulations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Necropsy</head><p>No treatment related effects were observed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cesarean Section Data</head><p>No treatment related effects were observed on corpora lutea, implantations, litter sizes, live fetuses, sex ratio, fetal body weights, resorptions or on placentae.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Offspring</head><p>There were no dose-dependent differences in the litter or fetal incidences of any gross external, soft tissue or skeletal alterations. Fetal ossification site averages were generally comparable among the four dose groups.</p><p>One fetus in the 100 mg/kg/dose group had a thin area of skin surrounding the umbilicus. At skeletal examination, this fetus had fused arches in the 5th through 7 th thoracic vertebrae, a small arch in the 8th thoracic vertebra, a bifid centrum in the 9 th thoracic vertebra, unilateral ossification of the centra in the 6th and 8th thoracic vertebrae and fused ribs (right 6th and 7th, proximal to distal; 10th and 11th, medial to distal). In addition to malformations, the fetus had alterations including unilateral ossification of the centrum in several thoracic vertebrae.</p><p>There was a minor reduction in the average number of ossified caudal vertebrae in the 300 mg/kg/dose group in comparison to the vehicle control group value. The average value for ossified caudal vertebrae (6.81) was below the historical range of the Testing Facility. Despite the reduction in the average number of ossified caudal vertebrae per fetus per litter that occurred in the 300 mg/kg/dose group, this minor delay in skeletal ossification was considered unrelated to maternal treatment with AMG 785 because: 1) there was no grossly observed shortening of the length of the tail; 2) there were no associated reductions in fetal body weights; and 3) average value was within the historical range of the Testing Facility (49 studies) conducted between June 2006 and June 2008 (1062 control group litters; 7853 fetuses; litter averages were 7.58 per fetus (range 6.75 to 8.01 per study) for caudal vertebrae).</p><p>Soft tissue alterations occurred in one fetus in the 300 mg/kg/dose group, and included transposed major vessels, abnormal descent of the aorta (to the right rather than the left), a persistent truncus arteriosus, extra lung lobes (one extra on the right lobe and two extra on the left lobe), an interventricular septal defect (proximal to the semilunar valves), thickening of the heart septum and small ventricles.</p><p>developmental delay (development of the ventral processes of the cervical vertebrae proceed in an anterior to posterior direction and the ventral processes on the 7th cervical vertebrae had not started to develop at gestation day 21). No other fetal effects were observed at any dose level.</p><p>The doses examined in this study <ref type="bibr" target="#b48">(10,</ref><ref type="bibr">60</ref>, 300 mg/kg) represent exposure multiples of 1.5X, 19X and 56X the proposed clinical dose of 210 mg (Human AUC = 12888 g*h/mL; Report 119384A).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose ranging study:</head><p>AMG 785 was well-tolerated in pregnant rats at doses up to 300 mg/kg, administered twice during the gestation period <ref type="bibr">(GDs 6 and 13)</ref>. No treatment related effects were observed on maternal or fetal parameters at any dose tested. There were no dosedependent differences in the litter or fetal incidences of any gross external, soft tissue or skeletal alterations. Fetal ossification site averages were generally comparable among the four dose groups.</p><p>One fetus in the 100 mg/kg/dose group had a thin area of skin surrounding the umbilicus. At skeletal examination, this fetus had fused arches in the 5th through 7 th thoracic vertebrae, a small arch in the 8th thoracic vertebra, a bifid centrum in the 9 th thoracic vertebra, unilateral ossification of the centra in the 6th and 8th thoracic vertebrae and fused ribs (right 6th and 7th, proximal to distal; 10th and 11th, medial to distal). In addition to malformations, the fetus had alterations including unilateral ossification of the centrum in several thoracic vertebrae.</p><p>The doses examined in this study (30, 100, 300 mg/kg) represent exposure multiples of 4.9X, 16.5X and 32X the proposed clinical dose of 210 mg (Human AUC = 12888 g*h/mL; Report 119384A).</p><p>Definitive embryo-fetal study: (Study 108059; previously reviewed by Dr. Eric Andreasen -see final BLA review) AMG 785 was well-tolerated in pregnant rats at doses up to 300 mg/kg, administered twice, subcutaneously, during the gestation period <ref type="bibr">(GDs 6 and 13)</ref>. No treatment related effects were observed on maternal parameters at any dose tested. At 0, 30, 100, and 300 mg/kg, the litter incidence of malformations or variations was 5 (21.7%), 5 (26.3%), 10 (41.7%) and 9 (40.9%), respectively.</p><p>Seven fetuses from one litter in the 300 mg/kg dose group had extra digits (polydactyly) on the fore-and/or hindpaws and six of these fetuses also had fused digits (syndactyly).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NDA/BLA # 761062</head><p>Reviewer: Laurie McLeod-Flynn</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>13</head><p>One to 3 fetuses from the same litter at 300 mg/kg also had incompletely ossified phalanges, misaligned metacarpals, large ulnae, misaligned metatarsals and large tibias, irregularly shaped metacarpals, broad ribs, and irregularly shaped ilia.</p><p>Irregular shaping of the arch in the 6th cervical vertebra was also observed in 4 to 5 fetuses from 4 litters in the 100 and 300 mg/kg group. The incidence of litters and fetuses with irregular shaped 6 th vertebrae at 100 (litters 17%; fetuses 2%) and 300 mg/kg (litters 18%; fetuses 3%) was greater than the historical control range (litters 0-12.5%; fetuses 0-1.7%) for the testing facility and should be considered AMG 785 related.</p><p>The doses examined in this study (30, 100, 300 mg/kg) represent exposure multiples of 4.9X, 16.5X and 32X the proposed clinical dose of 210 mg (Human AUC = 12888 g*h/mL; Report 119384A), based on animal PK from dose range finding Study 108057.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Integrated analysis:</head><p>In the definitive embryo-fetal study, at 300 mg/kg (32-fold higher than the proposed clinical dose based on AUC), extra digits on the fore-and/or hindpaws (polydactyly; 7 fetuses in one litter) and fused digits (syndactyly; six fetuses in one litter) were observed. Also observed in 1-3 fetuses of this same litter were incompletely ossified phalanges, misaligned metacarpals, large ulnae, misaligned metatarsals and large tibias, irregularly shaped metacarpals, broad ribs, and irregularly shaped ilia. No related digital alterations were observed in the dose ranging study or in the fertility study.</p><p>Adverse vertebral findings were observed across the multiple studies. In the definitive embryo-fetal study, irregularly shaped 6 th vertebrae were observed in 4 to 5 fetuses from 4 litters in the 100 and 300 mg/kg groups (16.5 and 32-fold higher than the proposed clinical dose). The incidence of litters and fetuses with irregular shaped 6 th vertebrae at 100 (litters 17%; fetuses 2%) and 300 mg/kg (litters 18%; fetuses 3%) was greater than the historical control range (litters 0-12.5%; fetuses 0-1.7%) for the testing facility. Variations of vertebrae were also observed at 100 mg/kg in one fetus in the dose ranging study; the fetus had fused arches in the 5th through 7 th thoracic vertebrae, a small arch in the 8th thoracic vertebra, a bifid centrum in the 9 th thoracic vertebra, unilateral ossification of the centra in the 6th and 8th thoracic vertebrae and fused ribs (right 6th and 7th, proximal to distal; 10th and 11th, medial to distal) and unilateral ossification of the centrum in several thoracic vertebrae. In the fertility study at 300 mg/kg (56-fold higher than the proposed clinical dose), 3 fetuses from 3 litters had reduced ventral processes (which develop into the carotid tubercles) on the 6th cervical vertebrae, slightly exceeding the historical range of the test facility. Although this variation is often considered to represent a developmental delay (development of the ventral processes of the cervical vertebrae proceed in an anterior to posterior direction and the ventral processes on the 7th cervical vertebrae have not started to develop at gestation day 21), this interpretation should be made with caution in the absence of any generalized developmental delay and in the absence of toxicity. These effects are NDA/BLA # 761062</p><p>Reviewer: Laurie McLeod-Flynn 14 estimated to occur at approximately 16.5-fold the proposed clinical exposure, with a no adverse effect level at approximately 1.5-5-fold the proposed dose.</p><p>It is recommended that both types of effect be described in the animal data section of the pregnancy label, as follows:</p><p>Risk summary: <ref type="figure">------------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. <ref type="figure">-----------------------------------------------------------------------------------------------------</ref>   <ref type="figure">..............................................................................................................</ref>  <ref type="figure">INFORMATION .......................................................................................................................</ref>  <ref type="figure">SUBMITTED.......................................................................................................................</ref>  <ref type="figure">.............................................................</ref>    </p><formula xml:id="formula_37">Reference ID: 4076742 (b) (4) -</formula><formula xml:id="formula_38">---- /s/ --------------------------------------------------</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.1">Introduction</head><p>Romosozumab (AMG785) is a humanized murine monoclonal IgG2 antibody against sclerostin, a glycoprotein that blocks bone formation by inhibiting the Wnt/-catenin pathway in the osteoblast. Romosozumab is expected to increase bone formation and bone mass. The sought indication for the BLA is the treatment of postmenopausal osteoporosis. Romosozumab was evaluated in Phase III studies in postmenopausal women at a dose of 210 mg by subcutaneous injection every month (QM). The intended treatment duration is 1 year.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.2">Brief Discussion of Nonclinical Findings</head><p>In a pre-and post-natal study in rats, romosozumab caused transient decreases in food intake during the first two weeks of dosing at  60 mg/kg, increases in incidence of sparse hair coat at 300 mg/kg in F0 generation females, and slight but significant changes in bone mass or cortical geometry in F1 generation male and/or female pups at  10 mg/kg. No skeletal abnormalities in the C6 cervical vertebrae were observed in the F1 generation pups at any dose, such as those observed in the fertility and embryofetal development study. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA # 761062</head><p>Reviewer: Miyun Tsai-Turton Page 6 of 21 transiently reduced food intake during the first two weeks of dosing at  60 mg/kg and increased the incidence of sparse hair coat at 300 mg/kg, during the premating, gestation and lactation periods. AMG 785 administration did not result in any effects on mating, fertility, or natural delivery parameters. There were no effects on any litter parameters, including pup viability or pup body weights during the pre-weaning period.  In the F1 generation pups, there were no effects on femur length or microscopic changes in bone on Day 21 postpartum. Slight, but significant changes were noted in bone mass or cortical geometry in males and/or females at 10 mg/kg. There were no skeletal abnormalities in the C6 cervical vertebrae at any dose. There were also no AMG 785-related effects on survival, growth, sexual maturation, behavioral endpoints, mating and fertility, male reproductive organ weights or ovarian and uterine parameters. Females were treated with AMG785 or control article by subcutaneous injection once weekly on Study Days (DS) <ref type="bibr">1,</ref><ref type="bibr" target="#b41">8,</ref><ref type="bibr">15,</ref><ref type="bibr">22,</ref><ref type="bibr">29</ref>, and 36 during pre-cohabitation, cohabitation, gestation, and/or lactation periods. At Week 6 (Study Day 36), blood samples were collected to determine AMG785 serum concentration and anti-drug antibodies. The number of females retained on study after exclusion based on ADA data and were pregnant was 23, 24, 25, and 24 in the 0, 10, 60, and 300 mg/kg/day groups, respectively. Various endpoints were examined from F0 generation females to F1 generation pups.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Doses</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Deviation from study protocol:</head><p>Yes but they did not interfere with the study findings. Body weight:  There were no AMG 785-related effects on maternal body weights or maternal body weight gain in the F0 generation females <ref type="figure" target="#fig_0">(Figure 1</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Feed consumption:</head><p> At  60 mg/kg, AMG 785 transiently decreased mean absolute food consumption during the premating period for the intervals of DS 1 to 8 (91% and 90% of controls, respectively) and DS 8 to 15 (93% of controls) compared to controls. Thereafter, mean food consumption at 60 mg/kg was similar to controls. At 10 mg/kg, there were no AMG 785-related effects on mean food intake <ref type="figure" target="#fig_18">(Figure 2</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mating and fertility:</head><p> There were no AMG 785-related effects on days needed for mating (2.2 to 2.7 days), mating index (100%) or fertility index (92.0% to 100.0%) in the F0 generation rats at any dose ( <ref type="table" target="#tab_4">Table 2)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Delivery and litter observation:</head><p> Pregnancy was confirmed in 23, 24, 25, and 24 rats in the 0, 10, 60, and 300 mg/kg dose groups, respectively. All pregnant rats delivered their litters, with the exception of one female in the 300 mg/kg dose group. There were no AMG 785-related effects on estrous cycling, natural delivery parameter in the F0 generation females <ref type="table" target="#tab_5">(Table 3)</ref>.  There were no AMG785-related effects on any litter parameter at any dose <ref type="table" target="#tab_6">(Tables 4 and 5</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Necropsy observation:</head><p> There were no AMG 785-related macroscopic observations in the F0 generation females.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Toxicokinetics:</head><p>Maternal Rats <ref type="table" target="#tab_92">(Table 6)</ref>  On Study Day 36, overall mean AMG 785 serum concentrations in maternal rats were 30400, 685000, and 1780000 ng/mL at 10, 60, and 300 mg/kg, respectively.  Plasma concentrations of AMG 785 for F0 generations females on Lactation Day (LD) 21 were separated into two groups: 1) for animals for which the last dose was administered between LD 14 and LD 16 (those animals received 12 doses) and 2) those that received the last dose between LD 18 and LD 20 (those animals received 13 doses).  For animals receiving 12 doses, mean AMG 785 serum concentrations collected at 5 to 7 days post the 12th dose were 9510, 120000, and 539000 ng/mL at 10, 60, and 300 mg/kg, respectively.  For animal receiving 13 doses, mean AMG 785 serum concentrations collected at 1 or 2 days post the 13th dose were 61500, 396000, and 1610000 ng/mL at 10, 60, and 300 mg/kg, respectively. F1 Generation Pups ( Dosing Solution Analysis  All study samples that were analyzed had mean concentrations that were within or equal to the acceptance criteria of  10% (individual values within or equal to  10%) of their theoretical concentrations.</p><p>Other: ADAs  On DS 36, after 6 weekly doses of AMG 785, the percentage of ADA positive females was 18% at 10 mg/kg, 30% at 60 mg/kg, and 56% at 300 mg/kg. In all dose groups, the signal to noise ratio (S/N) ranged from less than 2 to more than 1000.  Of the animals retained on study following culling prior to the estimated day of natural delivery, all animals at 10 and 60 mg/kg were negative for anti-AMG 785 antibodies and 12% (3/25) of the animals at 300 mg/kg were positive for anti-AMG 785 antibodies with low S/N ratios (less than 2.0) indicating a weak ADA response <ref type="table" target="#tab_9">(Table 7)</ref>.  Weekly AMG 785 administration of each female continued until euthanasia on Lactation Day (LD) 21. On LD 21, 1 animal at 10 mg/kg, 1 at 60 mg/kg, and 5 at 300 mg/kg were positive for anti-AMG 785 antibodies. All these animals showed a weak antibody response with S/N values less than 5 <ref type="table" target="#tab_9">(Table 7)</ref>.  In 60 and 300 mg/kg dose groups, circulating AMG 785 exceeded assay limits and therefore may have interfered in the assay and prevented the detection of binding anti-</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA # 761062</head><p>Reviewer: Miyun Tsai-Turton Page 14 of 21 Clinical signs:  There were no AMG 785-related clinical signs or macroscopic observations in the F1 generation pups during the preweaning <ref type="table" target="#tab_11">(Table 8)</ref> or postweaning period at any dose.</p><p>Body weight:  There were no effects on body weight.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Feed consumption:</head><p> There were no effects on food consumption.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Physical development:</head><p> There were no AMG785-related effects on sexual maturation (the age of balano-preputal separation in males or the age of vaginal patency in females) at any dose level <ref type="table" target="#tab_13">(Table 9</ref>).</p><p>Neurological assessment:  There were no AMG 785-related behavioral endpoints including learning and memory <ref type="table" target="#tab_16">(Table 10</ref>) and motor activity in the F1 generation rats.</p><p>Reproduction:  There were no AMG 785-related effects on days needed for mating (2.4 to 2.9 days), mating index (100%) or fertility index (84.0% to 96.0%) in the F1 generation rats at any dose <ref type="table" target="#tab_4">(Tables 11 and 12</ref>).  There were no statistically significant difference between control and any AMG 785-treated group for terminal body weight and paired absolute weights for testes or epididymides. <ref type="table" target="#tab_5">(Table 13)</ref>.  There were no AMG 785-related effects on any ovarian or uterine parameter in the F1 generation rats. Pregnancy was confirmed in 21 (84.0%), 22 (88.0%), 23 (92.0%), and 24 (96.0%) F1 generation females in the 0, 10, 60, and 300 mg/kg/day dose groups, respectively. <ref type="table" target="#tab_6">(Table 14)</ref>.</p><p>Other: bone  Pre-weaning (at Day 21 postpartum)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA # 761062</head><p>Reviewer: Miyun Tsai-Turton</p><p>Page 15 of 21  There were no AMG785-related effects on the femur length <ref type="table" target="#tab_7">(Table 15)</ref>.  There were minimally decreased total and cortical/subcortical BMC and BMD (-8 to -9%) at 60 and 300 mg/kg, generally attaining statistical significance <ref type="table" target="#tab_27">(Table 16)</ref>.  There were also minimally decreased total area (-4 to -8%), periosteal circumference (-2 to -4%), endosteal circumference (-5 to -6%) and CSMI (-2 to -10%) at all doses in males that were associated with trends for increases in cortical thickness (+3 to +7%) <ref type="table" target="#tab_9">(Table 17)</ref>.</p><p>No changes were noted in females.  No AMG785-related microscopic changes in the femur of F1 generation pups at any dose.  There were no skeletal abnormalities in the C6 cervical vertebrae in the F1 generation pups at any dose <ref type="table" target="#tab_11">(Table  18</ref>). Note: This finding was observed in the fertility and embryo-fetal development study.</p><p>- <ref type="figure">------------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.</p><p>- <ref type="figure">----------------------------------------------------------------------------------------------------</ref></p><formula xml:id="formula_39">---- /s/ ---------------------------------------------------- MIYUN M TSAI-TURTON Page 4 of 41</formula><p>response, they were considered of no toxicological significance. FDA statistical review showed that there was no statistically significant in tumor incidence in tumor types tested in male rats (except adenoma cortical in MD groups p = 0.0184 &lt; 0.05) and female rats (except pancreatic islet cell adenoma, p = 0.0323 &lt; 0.05, within the historical control provided by the sponsor). As a result, AMG785 had no carcinogenic potential in rats.</p><p>Page 7 of 41</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Observations and Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival/Mortality: twice daily</head><p>There were 36-43 rats per sex per group died or were euthanized prior to the end of the treatment period (Week 91 males; Week 98 females). Among these unscheduled deaths, in both control and treated animals, common findings were noted (neoplastic findings: pituitary gland adenoma, mammary gland fibroadenoma/adenocarcinoma; non-neoplastic findings: kidney nephropathy and heart cardiomyopathy).</p><p>With regards to neoplastic findings, pituitary gland adenoma (pars distalis) was the most common cause of death in both genders. AMG 785 treatment had no effect on the incidence of fatal pituitary adenoma compared to the vehicle control group. A higher incidence of fatal mammary gland adenocarcinoma was noted in females of the 10 mg/kg/dose (13.88%) and 50 mg/kg/dose (18.6%) dose group compared to the vehicle control females (5%). However, such increased incidence was not statistically significant by trend or pairwise comparison tests. Mammary gland neoplasms, including adenocarcinoma, are frequently encountered in Sprague-Dawley rats and the lack of relationship to AMG 785 treatment was further supported by the lack of a continuum of pre-neoplastic to neoplastic changes. The incidence of fibroadenoma and adenocarcinoma observed in this study are within the range reported for these two tumors in the in-house historical data.</p><p>With regards to non-neoplastic findings, common age-related renal (nephropathy) and cardiac (cardiomyopathy) degenerative changes were the most frequent non-neoplastic cause of death in this study and incidence was similar across control and AMG 785</p><p>Page 13 of 41</p><p>The TK analysis of retained animals showed that the mean serum AMG785 at 3, 10, and 50 mg/kg were 4.91, 74.6, and 836 g/mL in retained females and 9.66, 79.5, and 589 g/mL in retained males, respectively. There were no gender differences ( 2-fold) in mean AMG785 serum concentrations at Week 13.</p><p>Among ADA-positive retained animals, 1 female at 50 mg/kg had serum AMG 785 concentration of 282 g/mL (3.0 fold lower than mean serum AMG 785 concentration of ADA negative female rats) and 31 male rats had serum AMG785 concentrations of 8.31, 63, and 310 g/mL, at 3, 10, and 50 mg/kg respectively, which were lower than the mean serum AMG785 concentration of ADA negative males; 10.2, 80.4, and 653 g/mL at 3, 10, and 50 mg/kg, respectively). At 50 mg/kg, ADA positive males had 2.1-fold lower mean AMG785 serum concentration when compared to ADA negative males, indicating the minimal difference.</p><p>Page 18 of 41</p><p>In summary, the weekly subcutaneous administration of AMG 785 at 3, 10 or 50 mg/kg for a minimum of 91 weeks for males and 98 weeks for females resulted in expected pharmacological effects on bones (increased skeletal radiopacity (whole body), and increased bone mass and geometry at the femur metaphysis and diaphysis at all dose levels).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Gross Pathology: At necropsy</head><p>There were AMG785-related macroscopic findings in bones (miscellaneous, calvarium femur, lumbar vertebrae L5-L6, sternum and tibia) and spleen. There was also AMG785related thickening of the bone in males and females, in a dose dependent manner, correlating with the increase in bone mineral content (BMC by ex vivo pQCT) and hyperostosis microscopically. This effect was systemic, usually affecting all routinely collected bones.</p><p>An increased incidence of spleen enlargement was noted in females at  3 mg/kg and in males at 10 mg/kg/dose, correlating with increased extramedullary hematopoiesis microscopically.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histopathology: At necropsy [Peer Review: Yes]</head><p>Neoplastic There were two tumors, renal lipoma in females and adrenal cortical adenoma in males, where incidence reached statistical significance.</p><p>With renal lipoma, a rare tumor, there was a statistically significant increase in females only, by trend test (p =0.0486). The incidence of renal lipoma was marginally increased in females at 50 mg/kg/dose when compared to concurrent control, and marginally above the historical data range for the testing facility. However, this finding was not considered AMG-785 related due low incidence, lack of pre-neoplastic precursors lesions and comparable nature and morphology to the renal lipoma in the concurrent control female.</p><p>Page 19 of 41</p><p>With adrenal cortical adenoma, a common tumor, there was a slight increase in males only, by pairwise comparisons test (0 vs. 10 mg/kg; p = 0.0169). However, this finding was not considered AMG 785-related due to the incidence being within historical control data range, the absence of a dose-related trend, and the absence of a precursor preneoplastic change.</p><p>In addition, other common tumors with numerical imbalances were benign pheochromocytoma and thyroid c-cell adenoma in females at 3 mg/kg/dose and keratoacanthoma in the skin of the males at 10 mg/kg. However, the presence of these tumors showed lack of statistical significance (for common tumors, by pairwise comparisons), lack of relationship of these imbalances to AMG 785 treatment, absence of a dose-response relationship, and absence of precursor pre-neoplastic change. These incidences of the tumors were also within historical control data range. In addition, the incidences of pancreatic tumors seemed to be increased at 10 and 50 mg/kg/dose. However, they were within historical control for both males and females. its cause of death (a local extension in the brain). Bone neoplasms and osteosarcomas (OSA) are rare in Sprague-Dawley rats. The incidence of spontaneous OSA in male and females Sprague-Dawley rats in two years studies conducted at the test facility ranged from 0 to 3.33%. The incidence of OSA in males at 50 mg/kg was 3.7%, marginally higher than the historical range. However, the sponsor argues that this historical data is based on studies where whole body radiography was not conducted and detection of OSA was limited to microscopic evaluation of sternum and macroscopic abnormalities.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA761062 -ECAC Review</head><p>Historical data from studies where whole body radiographs have been employed to detect bone neoplasms and other bone changes are not currently available. There were no other bone tumors in this study contrasting with results of long term administration of PTH in F344 and Sprague-Dawley rats that resulted in OSA, osteoblastoma, osteoma, and osteoblast hyperplasia. In the end, the sponsor considered the OSA observed in males at 50 mg/kg as spontaneous based on the low incidence that falls within the range of reported OSA in the historical data of the test facility, late onset and solitary nature and lack of a continuum that includes proliferative precursor osteoblastic changes and benign bone tumors.</p><p>Note 1: Detailed summary of neoplastic findings and historical data provided by the sponsor are included in Appendix.</p><p>Note 2: Osteosarcomas have been seen in all rodent carcinogenicity studies with PTH and its related peptides. PTH-induced bone tumors can be mediated by sclerostin inhibition. AMG785 is an anti-sclerostin (IgG2) humanized antibody.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Non-neoplastic</head><p>Microscopic non-neoplastic changes were limited to hyperostosis of bones, secondary extramedullary hematopoiesis in spleen and liver, and mononuclear cells infiltrate at the injection sites.</p><p>Hyperostosis (an increased thickness of the trabeculae in the epiphysis and metaphysis as well as cortical thickening) occurred in a dose-dependent manner, resulting in reduction of the marrow space. There was no woven bone or other morphological changes, indicating altered bone quality. The hyperostosis was of comparable severity between bone sites (femur, tibia, L5-L6, calvarium) of the same animal, except for the sternum which was generally affected to a lesser degree. In addition, at comparable doses, it was generally more pronounced in females when compared to males. Higher femoral metaphyseal BMD was observed in females when compared to males.</p><p>Splenic extramedullary hematopoiesis was noted in both sexes with increased incidence/severity at  3 mg/kg, correlating with the macroscopic observation of spleen enlargement. Hepatic extramedullary hematopoiesis was observed in males at  3 mg/kg and in females at  10 mg/kg. The splenic and hepatic extramedullary hematopoiesis was considered compensatory and secondary to the reduced bone marrow space as a consequence of the generalized bone hyperostosis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA761062 -ECAC Review</head><p>Reviewer: Miyun Tsai-Turton Page 22 of 41 AMG785-related mononuclear cell infiltration (focal to multifocal perivascular aggregates of lymphocytes and/or plasma cells; minimal to slight in severity) was observed at injection sites with increased incidence in males at  3 mg/kg and in females at  10 mg/kg.</p><p>A variety of spontaneous non-neoplastic (non-AMG785 related) skeletal changes were noted in the examined bones (miscellaneous, calvarium, femur, lumbar vertebrae L5-L6, sternum and tibia) and other tissues. These changes included osteophyte, bone proliferation, ectopic ossification, fibrous osteodystrophy and degenerative joint disease. However, AMG785 treatment did not modify the incidence and/or severity of these bone, <ref type="figure">-------------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.</p><p>- <ref type="figure">----------------------------------------------------------------------------------------------------</ref> </p><formula xml:id="formula_40">---- /s/ ---------------------------------------------------</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclaimer</head><p>Except as specifically identified, all data and information discussed below and necessary for approval of BLA 761062 are owned by Amgen, Inc. or are data for which Amgen, Inc. has obtained a written right of reference. Any information or data necessary for approval of BLA 761062 that Amgen, Inc. does not own or have a written right to reference constitutes one of the following: (1) published literature, or (2) a prior FDA finding of safety or effectiveness for a listed drug, as reflected in the drug's approved labeling. Any data or information described or referenced below from reviews or publicly available summaries of a previously approved application is for descriptive purposes only and is not relied upon for approval of BLA 761062.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA # 761062</head><p>Reviewer: Andrea L. Benedict, Ph.D.  <ref type="figure">SUMMARY ........................................................................................</ref>  <ref type="figure">INFORMATION ...........................................................................................</ref>  <ref type="figure">....................................................................................</ref>  <ref type="figure">...............................................</ref>   Amgen has submitted BLA 761062 for romosozumab (AMG 785). The product is a humanized anti-sclerostin IgG2 antibody that neutralizes sclerostin, the product of the SOST gene and an inhibitory factor in the bone formation process. Romosozumab is proposed to be indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. The recommended human dosage is 210 mg administered subcutaneously once every month for 12 doses. Romosozumab is supplied in a singleuse prefilled syringe (90 mg/mL).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table of Tables</head><p>The sponsor submitted a nonclinical pharmacokinetic (PK) bridging study of subcutaneously administered AMG 785 Process 1 and Process 2 material in the male cynomolgus monkey to the BLA for the purposes of establishing a bridge to the chronic toxicity studies in the rat and cynomolgus monkey. This PK bridging study is reviewed herein.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.2">Brief Discussion of Nonclinical Findings</head><p>The evidence from the non-GLP single-dose subcutaneous PK bridging study in the nave male cynomolgus monkey (Study 113155) provides support that AMG 785 Process 1 and Process 2 drug products are similar from the nonclinical perspective. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Structure or Biochemical Description</head><p>Romosozumab (AMG 785) is a humanized anti-sclerostin monoclonal antibody expressed in a Chinese hamster ovary (CHO) cell line. Romosozumab consists of 2 heavy chains of the lgG2 subclass and 2 light chains of the human kappa subclass. Each heavy chain contains 449 amino acids with 4 intrachain disulfides. Each light chain contains 214 amino acids with 2 intrachain disulfides. The schematic structure with one of the known disulfide bonding patterns (IgG2-A) is shown in <ref type="figure" target="#fig_0">Figure 1</ref> (excerpted from the sponsor's submission).  <ref type="table" target="#tab_87">Table 1</ref> provides a summary of the AMG 785 drug product process materials and formulations used during drug development. The Process 1 drug substance formulation was . The Process 2 drug substance formulation, which is the commercial process and formulation, is</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">Drug Formulation</head><p>The Process 1 drug substance formulation was used in phase 1 and phase 2 clinical studies, as well as in early nonclinical studies and in the 6-month chronic toxicity studies in the rat and cynomolgus monkey. The commercial Process 2 drug substance formulation was used in clinical studies during phase 1 through 3 of development, as well as in the nonclinical developmental and reproductive toxicity and carcinogenicity studies in the rat. The sponsor has provided a PK bridging study in the male cynomolgus monkey, to bridge between the nonclinical studies utilizing the two different process materials and formulations, which is reviewed herein.</p><p>Under the IND (IND 100391), the changes in the manufacturing process and comparability between the Process 1 and Process 2 drug substance and drug product were evaluated by the Product Quality Team. The product quality information submitted by the sponsor under the IND amendment (SDN 120 [eCTD 0118], dated <ref type="bibr">October 11, 2011)</ref> was considered adequate to support the changes in the manufacturing process and to establish comparability between the Process 1 and Process 2 drug substance and drug product, and the Process 2 drug product was allowed to proceed for use in clinical studies under the IND. See the Product Quality Review of Dr. Dougherty, dated December 5, 2012, for further information. Internal discussion with the NDA's Product Quality Team on February 9, 2017, confirmed that the comparability of AMG 785 Process 1 and Process 2 materials has been adequately demonstrated from the Product Quality perspective for the NDA. </p><formula xml:id="formula_41">(b) (4) (b) (4) (b) (4) (b) (4) (b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA # 761062</head><p>Reviewer: Andrea L. Benedict, Ph.D. 8</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">Comments on Novel Excipients</head><p>There are no novel excipients for the subcutaneous route of administration. Comments on acceptability of levels of excipients in the to-be-marketed formulation will be addressed in a subsequent review.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5">Comments on Impurities/Degradants of Concern</head><p>Comments on impurities and degradants of concern in the to-be-marketed formulation will be addressed in a subsequent review.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6">Proposed Clinical Population and Dosing Regimen</head><p>Romosozumab is being proposed for the treatment of osteoporosis in postmenopausal women at an increased risk of fracture. The proposed dosing regimen is 210 mg romosozumab administered subcutaneously once every month for 12 doses in the abdomen, thigh, or upper arm. Age: Not given Weight: Not given Satellite groups: N/A Unique study design: N/A Deviation from study protocol: 1) *Due to an error in the certificate of analysis for the AMG 785 CPD material, animals in the CPD treatment group received 2.75 mg/kg instead of the targeted 3 mg/kg AMG 785 (~91.5% of the nominal dose). The certificates of analysis were not provided in the report. Also study report notes an actual concentration AMG785 CPD as 118 mg/mL but the COA was not available for confirmation. Additionally, no formulation information was provided. 2) One animal from FIH treatment group (C38468) had no measurable drug exposure and was excluded entirely from all analyses and summary statistics. Reviewer Comment: These deviations were determined to not significantly impact the outcome of the study. See further discussion below.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.7">Regulatory Background</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA # 761062</head><p>Reviewer: Andrea L. Benedict, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>11</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Objective</head><p>This non-GLP study was conducted to determine the relative bioavailability of two AMG 785 treatments (i.e., FIH and CPD) when administered as a single subcutaneous injection to nave male cynomolgus monkeys. The FIH and CPD treatments differ in formulation and are made using different AMG 785 manufacturing processes (i.e., Process 1 and Process 2 materials, respectively).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>The study report states that serum samples for PK analysis were collected from each animal at pre-dose and at <ref type="bibr">1,</ref><ref type="bibr" target="#b86">4,</ref><ref type="bibr" target="#b41">8,</ref><ref type="bibr" target="#b52">12,</ref><ref type="bibr">24,</ref><ref type="bibr">48,</ref><ref type="bibr">72,</ref><ref type="bibr">96,</ref><ref type="bibr">144,</ref><ref type="bibr">192,</ref><ref type="bibr">240,</ref><ref type="bibr">312,</ref><ref type="bibr">408</ref>, and 504 hours post-dose. Serum AMG 785 concentrations were determined using a validated ELISA (MET-000018 v 4.0) with a lower limit of quantitation (LLOQ) of 22.9 or 50.0 ng/mL. Serum samples for antibody analysis were collected and analyzed for the presence of binding and neutralizing antibodies using a validated immunoassay.</p><p>The study report did not provide information on the drug product formulation, certificates of analysis, or dosing solution analysis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments:</head><p>The validated ELISA method (MET-000018 v 5.0 and Study 108574) indicates that the LLOQ for this method is 50 ng/mL and the upper limit of quantitation (ULOQ) is 2500 ng/mL. It is unclear from the study report what the "LLOQ of 22.9 or 50.0 ng/mL" is referring to as described.</p><p>Additionally, the study report methods section states that serum samples were analyzed for binding and neutralizing antibodies; however, no method was given or results discussed or presented in the report. One monkey in the FIH group (Animal No. C38468) did not have measureable AMG 785 exposure at any time point; however, as the other 9 monkeys in this group had measurable AMG 785 serum exposure that was relatively similar over the 504-hour observation period, it is unlikely that neutralizing antibodies greatly influenced the study outcome. Therefore, the absence of data on binding and neutralizing antibody formation from the study report does not preclude the review of this study.</p><p>The study report provided lot numbers for the FIH and CPD treatments of 00089336 and 0010039243, respectively. The lot numbers given for FIH and CPD were determined to be nonclinical drug product batches representing the Process 1 drug substance formulation and the Process 2 drug substance formulation, respectively, based on information obtained from Section 3.2.P.2.3: Lot History -Manufacturing Details [Process 1 Vial] and [Process 2 Vial]. The drug product lot indicated for FIH (i.e., 00089336) was also used in the 6-month rat and monkey subcutaneous toxicity studies. The drug product lot indicated for CPD (i.e., 0010039243) appears to only have been used to represent the Process 2 drug substance formulation for this PK bridging study.</p><p>Based on the Quality Overall Summary: Drug Product: Formulation Development (Section 3.2.P.2.2), Process 1 and Process 2 differ in both the manufacturing process utilized as well as product formulation.</p><p>The drug products formulations are stated as follows:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA # 761062</head><p>Reviewer: Andrea L. Benedict, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>12</head><p>Process 1 drug product formulation:</p><p>Process 2 (commercial process) drug product formulation:</p><p>Certificates of analysis and dosing solution analysis for FIH or CPD drug product were not provided in the report. The study report notes the following deviation: "After an in-life portion of the study, it was discovered the certificate of analysis for the CPD material contained an error. The AMG 785 concentration was actually 118 mg/mL instead of the indicated 129 mg/mL. As a result, animals in the CPD treatment group received 2.75 mg/kg AMG 785 instead of the targeted 3 mg/kg (approximately 91.5% of the nominal dose)." The lack of both certificates of analysis and dosing solution analysis preclude the ability to confirm the stated AMG 785 concentrations for the FIH and CPD treatments. Upon review, it has been determined that this deviation did not adversely affect the results of this study. <ref type="figure" target="#fig_18">Figure 2</ref> and <ref type="figure" target="#fig_2">Figure 3</ref> present the AMG 785 Concentration-Time profile on a semi-log and linear scale, respectively (excerpted from sponsor's submission). The pharmacokinetic (PK) parameters are presented in <ref type="table" target="#tab_4">Table 2</ref> as both absolute values and as dose normalized values.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Observations and Results</head><p>Due to the error in dosing concentrations, a slightly higher dose of 3.0 mg/kg AMG 785 FIH (Process 1) was administered as compared to AMG 785 CPD (Process 2) at 2.75 mg/kg. Therefore, the absolute difference between the FIH and CPD doses was approximately 8% or approximately 91.5% of the target nominal dose for CPD.</p><p>The systemic exposure of a single-dose of FIH given at 3 mg/kg was found to be slightly greater than the systemic exposure of a single-dose of CPD given at 2.75 mg/kg. The absolute values for mean C max and AUC indicate a difference of -11% and -17%, respectively, between the FIH-and CPD-treated animals. When corrected for the difference in dose, the mean C max and AUC indicate a difference of -2.5% and approximately -10%, respectively, between the FIH-and CPD-treated animals.</p><p>Additionally, the mean T max value for the CPD-treated animals was earlier, at approximately 24 hours post-dose, as compared to the FIH-treated animals that occurred at 48 hours post-dose.</p><p>Reference ID: 4063752</p><formula xml:id="formula_42">(b) (4) (b) (4) (b) (4) (b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA # 761062</head><p>Reviewer: Andrea L. Benedict, Ph.D.</p><p>13  15</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion and Conclusions</head><p>This non-GLP study was conducted to determine the relative bioavailability of AMG 785 Process 1 drug substance formulation (FIH) and AMG 785 Process 2 drug substance formulation (CPD) when administered as a single 3 mg/kg subcutaneous injection to nave male cynomolgus monkeys. However, due to a dosing error the CPD-treated group received an AMG 785 dose of 2.75 mg/kg. Therefore, the PK parameters C max and AUC were reviewed from both the perspective of absolute values as well as dose normalized values.</p><p>The differences observed between AMG 785 systemic exposures in male monkeys administered either a single SC dose of FIH at 3 mg/kg or CPD at 2.75 mg/kg were within 17% when comparing absolute C max and AUC values and within 10% when C max and AUC values were normalized for dose.</p><p>The study report states that "It is likely that raw systemic exposure values between FIH and CPD treatments would have been more similar (&lt;10% different) if equivalent doses were given. A comparison of systemic exposures parameters were made after dose normalization and expressed as a ratio. It is known that the pharmacokinetics of AMG 785 are greater than dose proportional; and thus a linear correction via dose normalization will under correct for the difference in dose and the actual difference in systemic exposure between treatments is likely less than that reflected in the ratio of dose normalized parameters."</p><p>In the 6-month SC repeat-dose cynomolgus monkey study (Study 107426) which used the same AMG 785 Process 1 lot (i.e., Lot # 00089336) as in the current study, the results indicated that serum exposure to AMG 785 increased in a slightly greater than dose proportional manner between the doses of 3 to 100 mg/kg/day on Day 1 of dosing and that the mean T max for all doses examined was 48 hours post-dose for male monkeys (see the Nonclinical review of Dr. Andreasen, IND 103077, dated June 18, 2009). It is plausible that the remaining difference in exposure between CPD and FIH after dose normalization could be a result of the greater than dose proportional PK for AMG 785, as was observed in the 6-month monkey toxicity study. Therefore, the differences observed between the systemic exposure after a single SC dose of 3 mg/kg FIH and 2.75 mg/kg CPD are considered acceptably similar from the nonclinical perspective.</p><p>Additionally, the mean T max shift noted in the CPD-treated group towards an earlier time point of 24 hours fell within the T max range for FIH-treated animals (i.e., 24-72 hours) and is not considered a concern at this time for a subcutaneously administered drug product.</p><p>Furthermore, the comparability between the Process 1 and Process 2 drug substance and drug product were evaluated by the Product Quality Team under the IND and NDA and the information provided was considered adequate to establish comparability between Process 1 and Process 2 drug substance formulations from the Product Quality perspective (see discussion under Section 2.3 Drug Formulation above). This provides evidence that the manufacturing and formulation changes made between Process 1 and Process 2 did not significantly alter the drug product quality.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA # 761062</head><p>Reviewer: Andrea L. Benedict, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>16</head><p>Taken together, the evidence from this non-GLP single-dose SC study in the male cynomolgus monkey provides support that AMG 785 Process 1 and Process 2 drug products are similar from the nonclinical perspective.</p><p>- <ref type="figure">------------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.</p><p>- <ref type="figure">----------------------------------------------------------------------------------------------------</ref> </p><formula xml:id="formula_43">---- /s/ ---------------------------------------------------</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">Data Source</head><p>The data analyzed in this review are located at: \\cdsesub1\evsprod\bla761062\0054\m5\datasets\crr\analysis\adam\datasets</p><p>The data were sufficient to perform the review.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">STATISTICAL EVALUATION</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">Study Design and Population</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.1">Study 337</head><p>Study 337 is a randomized, double-blind, placebo-controlled, fracture study in postmenopausal women with osteoporosis. A total of 7180 subjects were randomized in a 1:1 ratio to receive either romosozumab (N = 3589) or placebo (N = 3591) for 12 months, followed by a 24-month open-label treatment period of denosumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.2">Study 142</head><p>Study 142 is a randomized, double-blind, alendronate-controlled fracture study in postmenopausal women with osteoporosis. A total of 4093 subjects were randomized in a 1:1 ratio to receive romosozumab <ref type="bibr">(N= 2046)</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.3">Study 174</head><p>Study 174 is a randomized, double-blind, placebo-controlled, bridging study that assessed changes in bone mineral density in men with osteoporosis. A total of 245 subjects were randomized in a 2:1 ratio to receive romosozumab (N = 163) or placebo (N = 82) for 12 months and followed for an additional 3 months after completion of the double-blind period for evaluation of safety and immunogenicity. No follow-on therapy was administered.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">Safety Population and Endpoint</head><p>The analysis population was the safety population, which included all randomized subjects who received at least one dose of either romosozumab, placebo, or alendronate in the 12-month double-blind study period. The main safety endpoint of interest was major adverse cardiac events (MACE), defined as a composite endpoint of CV death, myocardial infarction (MI), and stroke. CV serious adverse events (CV SAEs) was the secondary endpoint of interest and was a composite endpoint of the following: death, cardiac ischemic events (MI, angina, coronary revascularization), cerebrovascular events (stroke, transient ischemic attack), noncoronary revascularization, hospitalization for heart failure, and peripheral vascular event not requiring revascularization. CV death included fatal events adjudicated as cardiovascular-related or undetermined. CV adverse events were adjudicated by the Duke University Clinical Research Institute (DCRI) and re-adjudicated by Thrombolysis in Myocardial Infarction (TIMI) Study Group. Because the DCRI and TIMI adjudications yielded similar results, the review is focused on the original DCRI-adjudication rather than the post-hoc TIMI-adjudication.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">Statistical Methods</head><p>The sponsor submitted a statistical analysis plan for the CCR on April 23, 2018, and submitted the CCR on June 28, 2018. The sponsor analyzed the outcome of interest, the time to the first occurrence of MACE, using a Cox regression model for each study. Subjects who did not have MACE in the double-blind period were censored either by loss to follow-up or at the end of double-blind period. In the analysis of the individual components of MACE, subjects were not censored when they experienced another type of CV event. The sponsor conducted the analysis using the double-blind 12-month period and the overall study period. The sponsor used the same model to analyze the CV SAEs. Also, the sponsor conducted a meta-analysis of the three studies, which compared the combined alendronate and placebo arms to the romosozumab group.</p><p>In addition to the sponsor's analysis, the reviewer conducted a meta-analysis only using the two studies in women (Studies 337 and 142), the indicated population. This meta-analysis did not distinguish the effect of the active control, alendronate, on the outcomes from the placebo effect, nor does it directly compare alendronate and placebo. Therefore, the reviewer conducted a network meta-analysis which compares multiple treatments simultaneously in a single analysis by combining direct and indirect evidence within a network of randomized controlled trials. Therefore, the analysis provides estimates that compare romosozumab to placebo and alendronate to placebo. The network meta-analyses were conducted on MACE and CV SAE events. The analysis used the same censoring criteria used in the sponsor's analyses. Additionally, the reviewer conducted network meta-analysis on individual components of MACE. The reviewer conducted two network meta-analyses based on fixed-effects models; univariate analysis with treatment group adjusted only and multivariate analysis with treatment group and age adjusted and stratified by countries.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4">Demographics and Baseline Characteristics</head><p>The mean age of study subjects was balanced between treatment groups within each study and ranged from 70.8 to 74.4 years old ( <ref type="table" target="#tab_4">Table 2</ref>). Cardiovascular medical histories were relatively balanced between the two trials within each study. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.1">MACE</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.1.1">Incidence and Hazard Ratios</head><p>A total of 130 events across the three trials were adjudicated as MACE events in the 12-month double blind period; 77 MACE events in romosozumab group and 53 MACE events in placebo/alendronate group. In Study 337, the hazard ratio (HR) [95% confidence interval (CI)] of MACE comparing romosozumab to placebo was 1.03 [0.62, 1.72], indicating no difference in risk. However, the HR of MACE comparing romosozumab to alendronate was 1.87 <ref type="bibr">[1.11, 3.14]</ref> in Study 142, indicating a higher risk in the romosozumab arm. The men study (Study 174) results indicated a trend in risk of MACE (HR = 1.55; [0.31, 7.69]) ( <ref type="table" target="#tab_5">Table 3</ref>).  <ref type="table" target="#tab_7">Table 5</ref> MACE: major adverse cardiac events; HR: hazard ratio; CV: cardiovascular; MI: myocardial infarction</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.1.2">Meta-Analysis</head><p>In the 12-month double-blind period, across the three trials, the total number (%) of MACE events was 77 (1.3%) among the romosozumab subjects and 53 (0.9%) among the control (placebo or alendronate) subjects. The HR [95% CI] of the meta-analysis of the three trials was 1.40 [0.99, 1.99] <ref type="figure" target="#fig_0">(Figure 1)</ref>.</p><p>In the 12-month double blind period of the two studies in women, <ref type="figure" target="#fig_0">(Studies 337 and 142</ref>  <ref type="table" target="#tab_6">(Table 4</ref>). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.1.4">Network Meta-Analysis of MACE Components</head><p>The HRs for CV death and MI, when comparing romosozumab to placebo were approximately 1.1, indicating a slightly higher risk in the romosozumab arm. However, that of stroke was 0.8, indicating a slightly lower risk in the romosozumab arm. The CIs for all three endpoints were wide.</p><p>When comparing the hazard of alendronate arm to placebo arm for the components, the network meta-analysis yielded HRs less than one, indicating a lower risk in the alendronate arm compared to placebo.  <ref type="table" target="#tab_92">(Table 6</ref>).  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.2.3">Network Meta-Analysis</head><p>The  <ref type="table" target="#tab_9">(Table 7)</ref>. The key safety endpoints were major adverse cardiac events (MACE) and cardiovascular serious events (CV SAEs) adjudicated by Duke University Research Institute. Events were observed during the double-blind 12-month period.</p><p>The sponsor estimated the incidence and hazard ratio (HR) of MACE and CV SAE in each study. They conducted a meta-analysis, which compared romosozumab to alendronate and placebo combined. To distinguish the effect of alendronate on CV risk from the placebo effect, the reviewer conducted a network meta-analysis which compares multiple treatments simultaneously in a single analysis by combining direct and indirect evidence within a network of randomized controlled trials. The reviewer's analysis only included studies conducted in women with postmenopausal osteoporosis (Studies 337 and 142).</p><p>The HR of Study 337 was approximately 1, whereas that was 1.87 <ref type="bibr">[1.11, 3.14]</ref>   <ref type="figure">------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record. <ref type="figure">----------------------------------------------------------------------------------------</ref>  <ref type="figure" target="#fig_3">SUMMARY.................................................................................................................................................................... 4   2  INTRODUCTION ................................................................................................................................................................................</ref>  <ref type="figure">EVALUATION ..........................................................................................................................................................</ref>  <ref type="figure" target="#fig_2">Design and Endpoints ....................................................................................................................................................... 6  3.2.2 Statistical Methodologies ............................................................................................................................................................</ref>  <ref type="bibr">9 3.2.3 Patient Disposition,</ref><ref type="bibr">Demographic and Baseline Characteristics ...</ref> <ref type="figure">..........................................................................................</ref>  <ref type="bibr">10 3.2.4 Results and Conclusions ...</ref> <ref type="figure">....................................................................................................................................................</ref>  <ref type="figure">POPULATIONS ...............................................................................................................</ref>  <ref type="figure">...........................................................................................................................................</ref>  <ref type="figure">................................................................................................................................................................................................</ref>  </p><formula xml:id="formula_44">---- /s/ -----------------------------------------------------------</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>LIST OF TABLES</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">EXECUTIVE SUMMARY</head><p>The Applicant submitted two randomized, double-blind phase 3 studies to provide evidence in support of the safety and efficacy of romosozumab 210 mg (90 mg/ml concentration) for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. One phase 3 studies was designed to demonstrate superiority of romosozumab 210 mg in 70 mg/ml concentration compared to placebo, while the second study was designed to demonstrate non-inferiority of romosozumab 210 mg in 90 mg/ml concentration, the intended dose for marketing, to romosozumab 210 mg in 70 mg/ml concentration.</p><p>The key efficacy endpoints were the reduction in the incidence of new vertebral fractures and increase in the bone mineral density (BMD) after 12 and 24 months of treatment. FDA analysis shows that treatment with romosozumab 210 mg (70 mg/ml concentration) compared to placebo reduced the risk of new vertebral fracture by 73% and 76%, at 12 and 24 month, respectively. Compared to placebo, treatment with romosozumab also significantly increased BMD at lumbar spine, total hip and femoral neck through 12 and 24 months.</p><p>The analysis further shows that romosozumab 210 mg in 90 mg/ml concentration was non-inferior to romosozumab 210 mg in 70 mg/ml concentration with respect to the percent change in BMD at lumbar spine.</p><p>The two studies provide evidence demonstrating the efficacy of romosozumab for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">INTRODUCTION</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">Overview</head><p>The Applicant, Amgen, seeks approval of EVENITY (romosozumab) injection for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. The proposed dose for marketing is 210 mg (90 mg/mL solution) subcutaneously once every month for 12 doses in the abdomen, thigh, or upper arm by a healthcare professional.</p><p>According to the Applicant: Romosozumab is a humanized monoclonal antibody that binds to and inhibits sclerostin, a negative regulator of bone formation. Romosozumab has a dual effect on bone, increasing bone formation and decreasing bone resorption. Romosozumab increases trabecular and cortical bone mass and improves bone structure and strength.</p><p>This statistical review is based on two pivotal phase 3 studies (20070337 and 20120156). <ref type="table" target="#tab_87">Table 1</ref> presents a brief summary of both studies. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">Data Sources</head><p>The study reports, data and additional information were submitted electronically. These items are located in the Electronic Document Room at \\cdsesub1\evsprod\BLA761062 under submission dates 07/19/2016 and 03/02/2017. <ref type="bibr" target="#b88">6</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">STATISTICAL EVALUATION</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">Data and Analysis Quality</head><p>The Applicant submitted analysis data and statistical programs for both studies. Data sets were complete and documented. Statistical analyses of efficacy endpoints in each study were carried out following pre-specified statistical analysis plan.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">Evaluation of Efficacy</head><p>This statistical review is based on both phase 3 studies listed in <ref type="table" target="#tab_87">Table 1</ref>. Study 20070337 was designed to demonstrate superiority of romosozumab 210 mg (70 mg/ml concentration) compared to placebo, whereas study 20120156 was designed to demonstrate romosozumab 210 mg in 90 mg/ml concentration, the intended dose for marketing, is not inferior to romosozumab 210 mg in 70 mg/ml concentration.</p><p>From this point, romosozumab will be referred as romo in the rest of the review.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.1">Study Design and Endpoints</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20070337</head><p>Study 20070337 was a multicenter, international, randomized, double-blind, placebo-controlled, phase 3 study of the safety and efficacy of romo 210 mg (in 70 mg/ml concentration) injection in ambulatory, postmenopausal women aged 55 to 90 years with osteoporosis at increased risk of fracture. Main enrollment criteria included:</p><p> a BMD T-score  -2.5 and &gt; -3.50 at the total hip or femoral neck;</p><p> at least 2 vertebrae in the L1 through L4 region and at least one hip are evaluable by DXA;</p><p> no history of hip fracture;</p><p> No severe or more than 2 vertebral fractures.</p><p>The study consisted of a screening period (up to 35 days), a double blind placebo-controlled period <ref type="formula" target="#formula_34">(12 months)</ref>, an open-label period with denosumab (12 months) and an extension period <ref type="bibr">(12 months)</ref>. The extension period is currently ongoing. This review is for the first 24-month period after screening.</p><p>After screening, eligible subjects were equally randomized to receive either romo or matching placebo. Randomization was stratified by age (&lt; 75 years,  75 years) and prevalent vertebral fracture (yes, no). During the 12-month double-blind study period, subjects received 3 subcutaneous (SC) injections of romo (i.e., 3 injections of 70 mg romo for a total dose of 210 mg) or matched placebo at each IP dosing visit (i.e., Day 1 study visit and monthly study visits thereafter to <ref type="bibr">Month 11)</ref>. During the 12-month open-label denosumab follow-up study period and the 12-month extension period, subjects received one SC injection of 60 mg denosumab Q6M in an openlabel fashion. All SC injections must be administered by a healthcare professional. Calcium and vitamin D supplements were taken daily.</p><p>Efficacy assessments included evaluation by x-ray at Months 12, 24 and 36 and evaluations of bone mineral density (BMD) by dual energy x-ray absorptiometry (DXA) after 12, 24 and 36 months. Serum markers of bone metabolism, romo antibody, and patient report outcomes were also measured and recorded during the treatment period.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>7</head><p>The co-primary objectives of the study were  to assess the effect of romo treatment for 12 months compared with placebo on the subject incidence of new vertebral fracture and;  to assess the effect of romo treatment for 12 months followed by denosumab treatment for additional 12 months compared to placebo on the subject incidence of new vertebral fracture.</p><p>The co-primary endpoints were  subject incidence of new vertebral fracture through Month 12.</p><p> subject incidence of new vertebral fracture through Month 24.</p><p>The secondary endpoints are presented in <ref type="table" target="#tab_4">Table 2</ref> and assessed through Months 12 and 24, respectively. The three efficacy populations used for analyses are described below:</p><p> Primary Analysis Set For Vertebral Fractures: all randomized subjects who had a baseline and  1 postbaseline evaluation of vertebral fracture at or before the time point under consideration. Subjects who had vertebrae with missing Genant semi quantitative scores at baseline and whose first post-baseline spinal radiograph showed no fracture on the same vertebrae were also included.</p><p> Full Analysis Set: all randomized subjects. The full analysis set was used as the primary analysis set for nonvertebral fracture, clinical fracture, major non-vertebral fracture, major osteoporotic fracture and hip fracture efficacy endpoints.</p><p> Primary Efficacy Analysis Set for BMD and PRO/ClinRO Endpoints: all randomized subjects who had a baseline and  1 post-baseline evaluation at or before the time point under consideration in the study period.</p><p>To control the overall type I error, the primary and secondary efficacy endpoints were tested sequentially in the following order.</p><p>1. Subject incidence of new vertebral fracture through months 12 and 24;</p><p>2. Subject incidence of clinical fracture through month 12; 3. Subject incidence of non-vertebral fracture through months 12 and 24 (testing for months 12 and 24 were controlled by Hochberg procedure at 0.05 level within the step);</p><p>4. Subject incidence of clinical fracture through month 24;</p><p>5. Subject incidence of major non-vertebral fracture through months 12 and 24 (testing for months 12 and 24 were controlled by Hochberg procedure at 0.05 level within the step);</p><p>6. Subject incidence of new or worsening vertebral fracture through months 12 and 24 (testing for months 12 and 24 were controlled by Hochberg procedure at 0.05 level within the step); 7. Subject incidence of hip fracture through months 12 and 24 (testing for months 12 and 24 were controlled by Hochberg procedure at 0.05 levels within the step).</p><p>In the fixed-sequential testing procedure, the formal inferential testing was performed for a step only when the statistical significance was declared for all the endpoints tested in the previous steps. If the testing sequence was stopped at a particular step, the remaining endpoints in the testing sequence were not formally tested and were considered exploratory.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20120156</head><p>Study 20120156 was a multicenter, randomized, phase 3 study to evaluate the non-inferiority of a 6-month romo 210 mg treatment at a 90 mg/mL concentration compared with a 6-month romo 210 mg treatment at a 70 mg/mL concentration in postmenopausal women with osteoporosis.</p><p>After screening, eligible subjects were randomized in a 22:5:22:5 ratios to the following treatment groups:</p><p> romo 90 mg/mL: romo 210 mg QM, administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL pre-filled syringe (PFS)</p><p> placebo 90 mg/mL: placebo QM, administered as 2 SC injections of matched placebo to romo 90 mg/mL in the 1.17 mL PFS</p><p> romo 70 mg/mL: romo 210 mg QM, administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL PFS</p><p> placebo 70 mg/mL: placebo QM, administered as 3 SC injections of matched placebo to romo 70 mg/mL in the 1.0 mL PFS Randomization was double blind within the concentrations (romo 90 mg/mL and placebo 90 mg/mL; romo 70 mg/mL and placebo 70 mg/mL).</p><p>After completing a 6-month treatment period, subjects entered a 3-month follow-up period with end of study at month 9.</p><p>The primary analysis was performed after all subjects had the opportunity to complete the month 6 visit. The final analysis was performed after all subjects had the opportunity to complete the month 9 visit.</p><p>The primary endpoint was the percent change from baseline in DXA BMD at the lumbar spine (non-inferiority) and the secondary endpoints were  percent change from baseline in DXA BMD at the total hip;  percent change from baseline in DXA BMD at the femoral neck;</p><p> percent change from baseline in BTMs P1NP and CTX.</p><p>The three efficacy populations used for analyses are described below:</p><p> Primary efficacy analysis subset: all randomized subjects who had a baseline lumbar spine DXA BMD measurement and at least one post baseline lumbar spine DXA BMD measurement.</p><p> Hip BMD Efficacy Analysis Subset: all randomized subjects who had a baseline hip DXA BMD measurement and at least one post-baseline hip DXA BMD measurement.  Bone Turnover Marker Efficacy Analysis Subset: all randomized subjects who had a baseline measurement and at least one post-baseline measurement for the endpoint of interest.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.2">Statistical Methodologies</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20070337</head><p>The co-primary efficacy endpoints, the incidence of new vertebral fractures through months 12 and 24 were analyzed by a logistic regression model using the primary analysis set for vertebral fractures. The model included the treatment as the main effect and age and prevalent vertebral fracture as covariates. The odds ratio and the corresponding 95% 2-sided confidence interval and p-values using a score test were provided. Point estimates of absolute risk reduction (difference in proportions, control -treatment), risk ratio (ratio of proportions, treatment over control) and the relative risk reduction (100*(1-risk ratio)) as well as the corresponding 95% confidence intervals were also calculated via the Mantel-Haenszel method, adjusting for age and prevalent vertebral fracture strata.</p><p>The secondary fracture efficacy endpoints (i.e., incidences of non-vertebral fracture, clinical fracture, major nonvertebral fracture, major osteoporotic fracture and hip fracture) through months 12 and 24 were analyzed using the full analysis set. The cumulative incidence of fractures was summarized using the Kaplan-Meier estimates, and the hazard ratios and the confidence intervals for the risk reduction relative to placebo were based on the stratified Cox proportional hazards model.</p><p>The percent changes from baseline in lumbar spine, total hip and femoral neck by DXA at month 12 and month 24 were analyzed using the ANCOVA model with LOCF imputation using the primary efficacy analysis set for BMD and PRO/ClinRO endpoints. The ANCOVA model included treatment, age and prevalent vertebral fracture strata (stratification factors), and baseline value of the endpoint. Additional covariates of machine type and machine type-by-baseline value interaction were also included in the model to adjust for the effect of machine type on baseline value for parameters derived by DXA.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20120156</head><p>The primary endpoint, the percent change from baseline in lumbar spine DXA BMD at Month 6 was analyzed by an analysis of covariance (ANCOVA) model using the primary efficacy analysis subset. The ANCOVA model included treatment (placebo, romo 70 mg/mL, romo 90 mg/mL) and baseline lumbar spine BMD T-score. For the evaluation of the non-inferiority hypothesis, the least squares mean of the treatment difference between romo treatment groups only (romo 90 mg/mL -romo 70mg/mL) and the corresponding lower one-sided 97.5% CI were estimated. Romo 90 mg/mL would be declared not inferior to romo 70 mg/mL if the lower bound of the one-sided 97.5% CI for the treatment difference was greater than the pre-specified NI margin of -2%.</p><p>The secondary BMD endpoints (total hip and femoral neck) were analyzed in the same way as the primary endpoint using the hip BMD efficacy subset. Least square mean estimates and two-sided 95% CIs for differences from placebo (romo 70 mg/mL -placebo, romo 90 mg/mL -placebo), and the least squares mean and corresponding two-sided 95% CI of the treatment difference between romo treatment groups only (romo90 mg/mL -romo 70 mg/mL) were provided.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.3">Patient Disposition, Demographic and Baseline Characteristics</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20070337</head><p>Patient disposition is summarized in <ref type="table" target="#tab_5">Table 3</ref>. In Study 20070337, a total of 7180 patients were randomized to two treatment groups. The discontinuation rate was 10.7% in the placebo group and 11.3% in the romo group. The most common reason for discontinuation was consent withdrawal. Demographic and baseline characteristics are summarized in the Appendix <ref type="table" target="#tab_6">(Table 14 and Table 15</ref>). In Study 20070337, demographic and baseline characteristics were balanced among treatment groups. All patients were postmenopausal women aged 55 to 90 years. The mean age was 70.9 years with 31.2% of women being 75 years of age at enrollment. The median number of years since menopause was 20. Approximately 57% of the patients were white and 39.6% were Hispanic or Latino. The mean body mass index (BMI) was approximately 24.7 kg/m 2 . About 18% of patients had prevalent vertebral fractures.</p><p>The majority of patients were from Central/Latin America (43.0%), followed by Central and Eastern Europe (29.2%), Western Europe and Australia/New Zealand (13.6%), and Asia Pacific (11.5%). However, only 1.8% of the randomized patients were from US.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 20120516</head><p>Patient disposition for study 20120516 is summarized in <ref type="table" target="#tab_6">Table 4</ref>. A total of 294 patients were randomized into two treatment groups. The study discontinuation rate was 11.3% in the placebo group and about 5.8% in the two romo groups. The most common reason for discontinuation was consent withdrawal. Most subjects were White (99%); with only one Black (0.3%) and 2 Asian (0.7%). Overall, 277 (94.2%) subjects were not Hispanic or Latino and 17 (5.8%) subjects were Hispanic or Latino. The mean (SD) age of the subjects in this study was 67.7 (7.5) years and this was comparable across the 3 treatment groups; 61% of subjects were  65 years (see <ref type="table" target="#tab_27">Table 16</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.4">Results and Conclusions</head><p>This reviewer was able to replicate the Applicant's analysis results.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.4.1">Analysis results for Study 20070337</head><p>New Vertebral Fracture <ref type="table" target="#tab_7">Table 5</ref> presents the primary efficacy results for Study 20070337. The incidence of new vertebral fracture was 0.5% in the romo group compared to 1.8% in the placebo group (P-value: &lt;0.001) through Month 12. The relative risk reduction in new vertebral fracture was 73% in patients receiving romo compared to placebo. The incidence of new vertebral fracture was 0.6% in the romo/denosumab group compared to 2.5% in the placebo/denosumab group (P-value: &lt;0.001) through Month 24. The relative risk reduction in new vertebral fracture was 75% in patients receiving romo/denosumab compared to placebo/denosumab. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Fracture and Non-vertebral Fracture</head><p>The study protocol pre-defined the clinical fractures as non-vertebral fractures and clinical (i.e. symptomatic) vertebral fractures. <ref type="table" target="#tab_92">Table 6</ref> shows that non-vertebral fractures accounted for more than 85% of clinical fractures.</p><p>The incidence of clinical fracture was 1.6% in the romo group compared to 2.5% in the placebo group (P-value: 0.008) through Month 12. Romo significantly reduced the risk of clinical fractures by 36% (95% CI: 11%, 54%) through Month 12.</p><p>Following the pre-specified testing sequence for type I error control, the incidence of non-vertebral fracture through month 12 and subject incidence of non-vertebral fracture through month 24 did not show statistically significant difference between the romo and placebo groups. No further testing on other endpoints proceeded from this point per the pre-specified testing sequence.</p><p>The incidence rate difference for clinical fractures between romo and placebo was mainly due to the difference for the clinical vertebral fractures, which were already included in the primary efficacy endpoint. Therefore, we believe that clinical fracture may not be an appropriate endpoint for fracture risk evaluation.  <ref type="table" target="#tab_16">Table 10</ref>-2 in study report. Steps 1 to 3 are the order in the testing sequence. Relative risk reduction is calculated from the hazard ratio as 100 x (1 -hazard ratio). Absolute risk reduction is based on inverse-weighted method adjusting for age and prevalent vertebral fracture stratification variables. P-values are based on Cox proportional hazards model adjusting for age and prevalent vertebral fracture stratification variables.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bone Mineral Density</head><p>Baseline bone mineral density (BMD) values were similar across all treatment groups for the total hip, femoral neck and lumbar spine <ref type="table" target="#tab_9">(Tables 7-9</ref>). At month 12, compared with placebo, romo significantly (p&lt;0.001) increased BMD at the lumbar spine by 12.7%, at total hip by 5.8%, and at femoral neck by 5.2%. Romo followed by denosumab resulted in continued increases in BMD at the lumbar spine, total hip and femoral neck at month 24. Mean differences in percent change from baseline to month 24 in BMD were significantly greater for subjects in the romo/denosumab group compared with the placebo/denosumab group (p &lt; 0.001 at each site).  <ref type="bibr">(10.8, 11.4)</ref> &lt;0.001 Source: Reviewer's analysis, <ref type="table" target="#tab_16">Table 10</ref>-3 in study report. % change from baseline, LS means difference, 95% CI and P-value from ANCOVA model.  <ref type="table" target="#tab_16">Table 10</ref>-3 in study report. % change from baseline, LS means difference, 95% CI and P-value from ANCOVA model.  The percent change of BMD at total hip and femoral neck were also analyzed using the same approach for primary endpoint for exploratory purpose. Romo 90 mg/mL and romo 70 mg/mL, compared to placebo, showed similarly numerical treatment effect for the BMD percent change at total hip and lumbar spine at Month 6 ( <ref type="table" target="#tab_4">Tables  11 and 12</ref>).  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">Evaluation of Safety</head><p>Refer to the clinical reviewer's review for evaluation of safety data.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">FINDINGS IN SPECIAL/SUBGROUP POPULATIONS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1">Race, Age, and Geographic Region</head><p>The new vertebral fracture through months 12 and 24 was evaluated by subgroups of age, race, and region as defined in <ref type="table" target="#tab_5">Table 13</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2">Other Special/Subgroup Populations</head><p>The applicant also evaluated the new vertebral fracture endpoint with each subgroup based on baseline characteristics as follows:</p><p> prevalent vertebral fracture status (yes, no)</p><p> history of fragility fracture (yes, no)</p><p> history of non-vertebral fracture at age 55 years (yes, no)</p><p> baseline lumbar spine BMD T-score ( -3, &gt; -3 and  -2.5, &gt; -2.5)</p><p> baseline total hip or femoral neck BMD T-score  -3 vs both total hip and femoral neck BMD T-score &gt; -3  baseline body mass index (BMI) (tertiles)  World Health Organization Fracture Risk Assessment tool (FRAX) score for major osteoporotic fracture (tertiles)</p><p>To assess the consistency of the treatment effect in different subgroups, the incidence of new vertebral fractures was analyzed within each subgroup stratum listed above. The treatment-by-subgroup interaction was tested using a logistic regression model including treatment, age and prevalent vertebral fracture strata, individual subgroup, and treatment-by-subgroup interaction. All p-values on tests of quantitative interactions were &gt; 0.05, and therefore, no relevant treatment-by-subgroup interactions (quantitative or qualitative) were identified through month 12 or through month 24 for any subgroup for the co-primary endpoints.</p><p>Subgroup analyses of the co-primary endpoints of subject incidence of vertebral fracture through 12 and 24 months demonstrated a consistent treatment effect (relative risk reduction romo over placebo and romo/denosumab over placebo/denosumab) in all subgroups of baseline characteristics examined (see <ref type="figure" target="#fig_0">Figures 1  and 2</ref> in Appendix A2).</p><p>The percent changes from baseline in lumbar spine BMD and total hip BMD at month 12 and month 24 were analyzed by the following subgroups:</p><p> baseline lumbar spine BMD T-score (-3, &gt;-3 and -2.5, &gt;-2.5; for lumbar spine BMD analysis only)</p><p> baseline total hip BMD T-score (-3, &gt;-3 and -2.5, &gt;-2.5; for total hip BMD analysis only)</p><p>In the analyses of percent changes in BMD endpoints, treatment differences across the predefined subgroups (i.e., age, race and geographic region) for the lumbar spine and the total hip were consistent with the treatment differences observed for the overall population (see <ref type="figure" target="#fig_2">Figures 3 to 8</ref> in Appendix A2).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer's comments: The applicant provided post-hoc subgroup analysis of BMD endpoint for femoral neck and for all BMD endpoints by race per reviewer's request.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">SUMMARY AND CONCLUSIONS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.1">Statistical Issues</head><p>No major statistical issues were noted in this NDA.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2">Collective Evidence</head><p>One submitted study provides evidence that treatment with romo 210 mg (70 mg/ml concentration)</p><p> reduced the incidence rate of new vertebral fracture compared to placebo (0.5% vs. 1.8%, P-value&lt;0.0001) at month 12. The relative risk reduction in new vertebral fracture was 73%.  reduced the incidence rate of new vertebral fracture compared to placebo (0.6% vs. 2.5%, P-value&lt;0.0001) at month 24. The relative risk reduction in new vertebral fracture was 76%.  increased bone mineral density at the total hip, femoral neck and lumbar spine by <ref type="bibr">5.8%, 5.2% and 12.7%</ref> compared to placebo at month 12.</p><p> increased bone mineral density at the total hip, femoral neck and lumbar spine by 5.3%, 4.9% and 11.1% compared to placebo at month 24.</p><p>The second study provides evidence that romo 210 mg in 90 mg/ml concentration was non-inferior to the 70  <ref type="figure">-----------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.</p><p>- <ref type="figure">----------------------------------------------------------------------------------------------------</ref>   <ref type="figure" target="#fig_0">.......................................................................................................................................................... 3   2  BACKGROUND .................................................................................................................................................. 3   3  RAT STUDY-107895 ...........................................................................................................................................</ref>   <ref type="figure" target="#fig_0">Analysis ................................................................................................................................... 4  3.1.2</ref> Tumor <ref type="figure">Data Analysis .........................................................................................................................</ref>  <ref type="figure">Analysis ...............................................................................................................................</ref>.... <ref type="bibr">6 3.2.2</ref> Tumor <ref type="figure" target="#fig_3">Data Analysis ............................................................................................................................. 6   4  APPENDIX ........................................................................................................................................................</ref>.. 8  <ref type="figure" target="#fig_0">................................................................................................................................................ 18</ref> </p><formula xml:id="formula_45">---- /s/ ---------------------------------------------------</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">Summary</head><p>This review evaluates statistically the tumorigenicity data of carcinogenicity study of romosozumab (AMG-785), 2-year study in rats. The review analyzes the dose-response relationship of tumor incidence and mortality (including tumor-related mortality).</p><p>Rat Study: Rats (60/sex/dose, except there were only 54 rats for male HD group) were dosed by subcutaneous injection with AMG-785 once weekly for up to 104 weeks. The AMG-785 was administered at doses of 0, 3, 10, and 50 mg/kg/day for male and female rats for at least 104 weeks. This review refers these dose groups as the vehicle control (VC), low (LD), mid (MD), and high (HD) dose groups, respectively. All surviving animals were terminated at Week 91 for males and 98 for females.</p><p>The survival analyses didn't show a statistically significant dose response relationship in mortality across control and treated groups in both male and female rats. The respective survival rates in the VC, LD, MD, and HD groups at the termination were 33%, 35%, 33%, and 30% in male rats and 33%, 35%, 40%, and 28% in female rats.</p><p>The tumor analysis did not show any statistically significant dose-response relationship in tumor incidence in tumor types tested in male rats. The pairwise comparison did show a statistically significant increase in incidence of adenoma cortical in MD groups compared to the control (p=0.0184&lt;0.05) in male rats if this tumor was considered as a rare tumor; in female rats, a statistically significant positive dose response relationship was noted in adenoma islet cell for pancreas of female rats (p=0.0323&lt;0.05) if this tumor was considered as a rare tumor. No other statistically significant findings were noted for female rats.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">Background</head><p>BLA761062 is the initial biologics licensing application for romosozumab (AMG-785) for the indication of: treatment of osteoporosis in postmenopausal women at increased risk of fracture. The sponsor conducted one 24-month subcutaneous carcinogenicity study in the Sprague Dawley rats (107895). This review analyzed the SAS data sets of these studies received from the sponsor on 7/20/2016 via submission BLA761062/S0001.</p><p>The phrase "dose response relationship" refers to the linear component of the effect of treatment, and not necessarily to a strictly increasing or decreasing mortality or tumor incidence rate as dose increases. Results of this review have been discussed with the reviewing pharmacologist Dr. Gemma Kuijpers.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">Rat Study-107895</head><p>Study Report: -107895.pdf; SAS data: tumor.xpt</p><p>This study assessed the carcinogenic potential of AMG-785 in male and female rats. The test material (AMG-785) was administered weekly via subcutaneous injection at doses of 0, 3, 10, and 50 mg/kg/day for male rats and female rats for at least 104 weeks. This review refers these dose groups as the vehicle control (VC), low (LD), mid (MD), and high (HD) dose groups, respectively. There were 60 rats/sex/dose, except there were only 54 rats for male HD group. All surviving animals were terminated at Week 91 for males and 98 for females. Assessments of carcinogenicity included mortality, clinical observations (including mass observations), body weight, food consumption, ophthalmological evaluations, and clinical and anatomic pathology.</p><p>[Source: page 3108 of study report of 107895.pdf]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">Sponsor's Analyses</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.1">Survival Analysis</head><p>The statistical analyses for mortality data were performed for each sex separately. The survival function of each group was estimated using the Kaplan-Meier product-limit method applied on daily intervals and graphs were produced. Any animal with accidental injury that causes its death or its unscheduled sacrifice was censored in the estimation. In addition, all animals still alive at the end of the experimental period were censored at the following day.</p><p>The log-rank test was applied to the four groups in order to assess the significance of the overall group effect on mortality data. When significant differences among groups (p  0.05) were revealed, then the significance of an overall dose-related trend in mortality across all groups was evaluated using Tarone's method. <ref type="bibr" target="#b86">4</ref> Using the Multtest procedure (SAS/STAT), Tarone's test was implemented as a Peto two-sided test, with all uncensored deaths coded as 2 and all censored deaths coded as 0. The corresponding arithmetic dose level scores (0, 3, 10, and 50) was used to perform the overall trend test. Furthermore, the vehicle control group was compared to each of the other three groups using a Peto two-sided test. The sign of the statistic was used to indicate if either an increase or a decrease of the mortality rate across dose levels was observed for the trend test and each pairwise comparison.</p><p>Sponsor's concluded: The numbers of death were listed in follow table. The test results show no significance for both male and female datasets, with p-value = 0.9751 and p-value = 0.5922 respectively. Therefore, no post-hoc testing was done for these datasets, that is neither Tarone's trend test 4 nor the pairwise comparisons were performed.</p><p>[Source: page 55 of study report of 107895.pdf]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.1.2</head><p>Tumor Data Analysis Neoplastic findings classified as fatal and incidental were processed using the death rate method and the prevalence method, respectively. The processing of incidental tumors was done by creating a single separate interval for the time period following the experimental period (terminal sacrifice period) and by dividing the experimental period into the following fixed intervals: 1-52 weeks, 53-78 weeks, 79-90 weeks for males, and 1-52 weeks, 53-78 weeks, 79-92 weeks, 92-97 for females. Using the derived outcomes from the processing of both fatal and incidental tumors, a test statistic was built to perform a global survival-adjusted trend test (Peto's test) on tumor data observed in a "mortality dependent" context. <ref type="bibr" target="#b87">5</ref> For each data set within each sex, the significance of an overall linear dose-related increase in tumor occurrence rates across the four groups was evaluated using Peto's survival-adjusted one-tailed test. The corresponding arithmetic dose level scores (0, 3, 10, and 50) was used to perform the overall trend test. Furthermore, Peto's upper-tailed test was used to check if the tumor rate in each test item treated group was significantly higher than the one in the vehicle control group. When performing a pairwise comparison, only the data corresponding to the two compared groups were submitted to the statistical analysis.</p><p>Adjustment for multiple testing: As mentioned by <ref type="bibr">Lin 6</ref> , the discrete permutation distribution was used to compute the corresponding p-value for each statistical test performed on a dataset containing 10 or less tumor occurrences. Each trend test (the overall trend and the pairwise comparison tests) was conducted at the 5% significance level but was discussed in the statistical report according to the tumor prevalence classification (common or rare) and the FDA's recommendations. More precisely, given that this chronic study is in only one species, significance of the results for common and rare tumors were respectively discussed at 0.01 and 0.05 levels for the overall trend test, and at 0.025 and 0.10 levels for the pairwise comparisons.</p><p>Sponsor's concluded: There was no neoplastic change attributed to the weekly administration of AMG 785.</p><p>There was a statistically significant increase in renal lipoma, a rare tumor, by trend test (p =0.0486 versus cutoff of p&lt;=0.05), in females only. The incidence of renal lipoma was marginally increased in females at 50 mg/kg/dose compared to concurrent control and marginally above the testing facility historical data range and reported literature. However, this finding was not considered AMG-785 related based on low incidence, lack of preneoplasic precursors lesions and comparable nature and morphology to the renal lipoma in the concurrent control female.</p><p>The slight increased incidence of adrenal cortical adenoma, a common tumor, noted in males only at 10 mg/kg dose was statistically significant (p = 0.0169 versus cutoff of p&lt;= 0.025) by pairwise comparison test. However, this finding was not considered AMG 785-related based on the incidence being within historical control data range, the absence of a dose-related trend, and the absence of a precursor preneoplastic change.</p><p>[Source: page 3111 of study report of 107895.pdf]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">Reviewer's Analyses</head><p>To verify the sponsor's analyses and to perform additional analyses suggested by the reviewing pharmacologist, this review analyzed the SAS data sets of these studies received on 7/20/2016 via submission BLA761062/eCTD S-0001.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.2.1</head><p>Survival Analysis The survival distributions of rats in all treatment groups were estimated using the Kaplan-Meier product limit method. For control, low, medium, and high dose groups, the dose response relationship was tested using the likelihood ratio test and the homogeneity of survival distributions was tested using the log-rank test. The Kaplan-Meier curves for survival rates are given in <ref type="figure" target="#fig_0">Figures 1A and 1B</ref> in the appendix for male and female rats, respectively. The intercurrent mortality data are given in <ref type="table" target="#tab_87">Tables 1A and 1B</ref> in the appendix for male and female rats, respectively. Results of the tests for dose response relationship and homogeneity of survivals, are given in Tables 1A and 1B in the appendix for male and female rats, respectively.</p><p>Reviewer's findings: All surviving animals were terminated at Week 91 for males and 98 for females. This reviewer's analysis showed the numbers (percent) of death were 40 (67%), 41 (68%), 40 (67%), and 38 (70%) in male rats and 40 (67%), 39 (65%), 36 (60%), and 43 (72%) in female rats in the VC, LD, MD, and HD groups, respectively. The tests did not show any statistically significant dose response relationships or pairwise comparisons in mortality in male or female rats.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.2.2</head><p>Tumor Data Analysis The tumor data were analyzed for dose response relationships and pairwise comparisons of control group with each of the treated groups. Both the dose response relationship tests and pairwise comparisons were performed using the Poly-k method described in the paper of Bailer and Portier <ref type="bibr">[1]</ref> and Bieler and Williams <ref type="bibr" target="#b84">[2]</ref>. In this method an animal that lives the full study period ( max w ) or dies before the terminal sacrifice but develops the animals live up to the end of the study or if each animal that dies before the terminal sacrifice develops at least one tumor, otherwise the adjusted group size is less than N. These adjusted group sizes are then used for the dose response relationship (or the pairwise) tests using the Cochran-Armitage test. One critical point for Poly-k test is the choice of the appropriate value of k, which depends on the tumor incidence pattern with the increased dose. For long term 104 week standard rat and mouse studies, a value of k=3 is suggested in the literature. Hence, this reviewer used k=3 for the analysis of this data. For the calculation of p-values the exact permutation method was used. The tumor rates and the p-values of the tested tumor types are listed in Tables 3A and 3B in the appendix for male and female rats, respectively.</p><p>Multiple testing adjustment: For the adjustment of multiple testing of dose response relationship, the FDA guidance for the carcinogenicity study design and data analysis suggests the use of test levels =0.005 for common tumors and =0.025 for rare tumors for a submission with two chronic studies in species, and a significance level =0.01 for common tumors and =0.05 for rare tumors for a submission with one chronic study species in order to keep the false-positive rate at the nominal level of approximately 10%. A rare tumor is defined as one in which the published spontaneous tumor rate is less than 1%. For multiple pairwise comparisons of treated group with control the FDA guidance suggested the use of test levels =0.01 for common tumors and =0.05 for rare tumors for a submission with two chronic studies in two species, in order to keep the false-positive rate at the nominal level of approximately 10% for both submissions with two or one species.</p><p>It should be noted that the FDA guidance for multiple testing for dose response relationship is based on a publication by Lin and Rahman <ref type="bibr">[3]</ref>. In this work the authors investigated the use of this rule for Peto analysis. However, in a later work Lin and Rahman <ref type="bibr">[3]</ref> showed that this rule for multiple testing for dose response relationship is also suitable for Poly-K tests.</p><p>The tumor rates and the p-values of the tested tumor types are listed in <ref type="table" target="#tab_5">Tables 3A and 3B</ref> in the appendix for male and female rats, respectively.</p><p>Reviewer's findings: Based on the criteria of adjustment for multiple testing discussed above, there was no tumor types or combined tumor types which were considered to have a statistically significant positive dose response relationship in male rats. The pairwise comparison did show a statistically significant increase in incidence of adenoma cortical in Adrenal (which was considered as a rare tumor) in MD groups compared to the control (p=0.0184&lt;0.05).</p><p>In female rats, a statistically significant positive dose response relationship was noted in adenoma islet cell for pancreas of female rats (p=0.0323&lt;0.05) if this tumor was considered as a rare tumor. No other statistically significant findings were noted for female rats.             <ref type="figure">-----------------------------------------------------------------------------------------------------</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hepei Chen and Feng Zhou Mathematical Statisticians</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>FENG ZHOU 03/24/2017</head><p>General dosing instructions The proposed dosing recommendation is 210 mg monthly for 12 months.</p><p>The dose-response relationship for efficacy from the Phase 2 dosefinding study and the efficacy data from the pivotal Phase 3 study, which evaluated only one dose level, support the dosing recommendation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dosing in patient subgroups</head><p>No dose individualization is recommended based on intrinsic or extrinsic factors.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Drug interactions</head><p>Disease-drug-drug interactions are not applicable because postmenopausal women with osteoporosis do not have much elevated proinflammatory cytokins based on the current understanding.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunogenicity</head><p>Immunogenicity has a negative impact on systemic exposure of romosozumab. But it does not appear to impact efficacy and safety of romosozumab following 12 monthly dosing in the pivotal Phase 3 study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bridge between the to-bemarketed and clinical trial formulations</head><p>The drug product tested in the pivotal Phase 3 study is the single-use glass prefilled syringe (PFS) containing 70 mg/mL romosozumab and the proposed to-be-marketed formulation is the single-use PFS containing 90 mg/mL romosozumab.</p><p>In addition, romosozumab containing drug substance (DS) manufactured at Amgen Thousand Oaks (ATO) was evaluated in the pivotal Phase 3 study 20070337. The commercial DS is being manufactured at Amgen Rhode Island (ARI).</p><p>We found the bridge between the to-be-marketed product and the clinical trial product established based on the PK comparability studies 20120277 (70 mg/mL PFS vs. 90 mg/mL PFS) and 20150197 (ATO vs. ARI).</p><p>Inspection reports for analytical and clinical sites for both studies are pending.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Labeling</head><p>The proposed labeling was generally acceptable. The Clinical Pharmacology review team has recommendations for specific content and formatting changes.</p><p>Reference ID: 4076576 (b) (4) 5</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.2">Post-Marketing Requirements and Commitments</head><p>None.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">SUMMARY OF CLINICAL PHARMACOLOGY ASSESSMENT</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">Pharmacology and Clinical Pharmacokinetics</head><p>Romosozumab is a humanized IgG2 monoclonal antibody that binds and inhibits sclerostin. By blocking sclerostin, romosozumab increases bone formation due to the activation of bone lining cells, increased bone matrix production by osteoblasts, and recruitment of osteoprogenitor cells. Additionally, romosozumab results in changes to expression of osteoclast mediators, thereby decreasing bone resorption.</p><p>The following is a summary of clinical pharmacokinetics of romosozumab:</p><p>Romosozumab exhibited nonlinear pharmacokinetics across the SC and IV dose ranges of 0.1 to 10 mg/kg and 1 to 5 mg/kg, respectively. Exposure increased greater than dose proportionally (e.g., 550-fold increase in mean AUC from time 0 to infinity [AUCinf] for the 100-fold increase in SC dose from 0.1 to 10 mg/kg).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Absorption:</head><p>Administration of a single dose of 210 mg romosozumab in healthy male and female subjects (n = 90, age range: 21 to 65 years) resulted in a mean (standard deviation [SD]) maximum serum concentration (Cmax) of 22.2 (5.8) mcg/mL and a mean area under the concentration-time curve (AUC) of 389 (127) mcg*day/mL. The median time to maximum romosozumab concentration (Tmax) was 5 days (range: 2 to 7 days). Steady-state concentrations were achieved by month 3 following the monthly administration of 210 mg to postmenopausal women. Trough serum romosozumab mean concentration values from samples collected prior to dosing at months 3, 6, 9, and 12 ranged from 8.46 to 9.78 mcg/mL.</p><p>For a 210-mg SC dose of romosozumab, the estimated bioavailability was 81%.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Distribution:</head><p>The population PK analysis estimated volume of distribution at steady-state was 3.92L.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Eliminaiton:</head><p>The metabolic pathway of romosozumab has not been characterized. The clearance of romosozumab decreased as dose increased. Mean systemic clearance (CL/F) of romosozumab 7 EVENITY should be administered by a healthcare professional and a full dose of EVENITY requires two single-use prefilled syringes (one after another), each delivering 105 mg of romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.2">Therapeutic individualization</head><p>Therapeutic individualization is not recommended at this time.</p><p>No dose individualization is recommended based on intrinsic or extrinsic factors although renal function (as measured by eGFR) and body weight have been identified as significant covariates in the population PK modeling analysis. However, use of romosozumab in patients with severe renal impairment and with ESRD requiring or without dialysis should be carefully monitored for hypocalcemia.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Renal function</head><p>Population pharmacokinetic analysis indicated an increase in romosozumab exposure with increasing severity of renal impairment. The dedicated renal impairment study also showed that mean Cmax and AUC were 29% and 44% higher in patients with severe renal impairment as compared to healthy subjects while mean romosozumab exposure was similar between patients with ESRD requiring hemodialysis and healthy subjects. Dose adjustment based on renal function is not warranted for the following two reasons: 1) the fixed dosing regimen (210 mg) was given to all subjects, including 10 subjects with severe renal impairment in the Phase 3 study and had an acceptable safety profile, and 2) data from the dedicated renal impairment study indicated that the incidence of hypocalcemia was associated with severity of renal impairment, but not with exposure of romosozumab. The number of subjects reported hypocalcemia was 0/8 in healthy subjects, 1/8 in subjects with severe renal impairment, and 4/8 in subjects had ESRD requiring hemodialysis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Body weight</head><p>The population PK model predicts increasing exposure for decreasing body weight. The predicted exposure for subjects in the lowest quartile of body weight was ~50% higher than that in the highest quartile of body weight. Because the fixed dosing regimen (210 mg) was given to all subjects in the Phase 3 study and had an acceptable safety profile, dose adjustment based on body weight is not warranted.</p><p>See Section 3.3.3 for more information.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">Outstanding Issues</head><p>None from a Clinical Pharmacology's perspective.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">Summary of Labeling Recommendations</head><p>In general the Applicant has provided adequate clinical pharmacology information to support the product labeling. We recommend including the following labeling concepts in the product labeling:  6.2 Immunogenicity: Add a summary statement about impact of immunogenicity on PK of romosozumab. Detailed PK data will be presented in Section 12.3.</p><p> 7. Drug Interactions: Delete the whole section because no drug interaction study was conducted. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">COMPREHENSIVE CLINICAL PHARMACOLOGY REVIEW</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">Overview of the Product and Regulatory Background</head><p>The Product Romosozumab is a humanized IgG2 kappa monoclonal antibody that binds to sclerostin with high affinity. Romosozumab has an approximate molecular weight of 145 kDa.</p><p>EVENITY (romosozumab) Injection is supplied as a sterile, preservative free, clear to opalescent, colorless to light yellow solution for subcutaneous injection in a single-use prefilled syringe. Each single use prefilled syringe delivers 1.17 mL of solution containing 105 mg of romosozumab (90 mg/mL), acetate ( 3.8 mg) , calcium (0.61 mg), sucrose (70 mg), and polysorbate 20 (0.07 mg) in Water for Injection, USP. Sodium hydroxide to a pH of 5.2.</p><p>A full dose of EVENITY (210 mg) requires two single-use prefilled syringes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Available Treatments for Osteoporosis</head><p>Treatment for osteoporosis and the prevention of osteoporotic fractures consist of 1 class of bone-forming agents and several types of antiresorptive therapies, including bisphosphonates <ref type="table" target="#tab_87">(Table 1)</ref>.  Study 20120277 and 20150197 were the two pivotal PK comparability studies to bridge the drug product tested in Phase 3 studies (the single-use glass prefilled syringe (PFS) containing 70 mg/mL romosozumab) and the proposed drug product for marketing (the single-use PFS containing 90 mg/mL romosozumab). Details of these two studies can be found in Section 4.3.  Study 20060220 was the first-in-human study for romosozumab in which single ascending doses of romosozumab up to 10 mg/kg for SC and 5 mg/kg for IV were tested in healthy men and postmenopausal women.  Study 20060221 was the first multiple-dose study in patients with low bone mass.</p><p>Subjects enrolled in this study were treated with placeo, 1 mg/kg Q2W, 2 mg/kg Q2W, 2 mg/kg Q4W, or 3 mg/kg Q4W for 3 months, all by SC administration.  Study 20110227 was the dedicated renal impairment study.This study was conducted because of the following reasons: 1) Despite the large molecular weight, eGFR was found to be a significant factor in the PK of several monoclonal antibodies <ref type="bibr">(Zhu et al, 2009;</ref><ref type="bibr">Frey et al, 2010;</ref><ref type="bibr">Struemper et al, 2013)</ref>. 2) Additionally, chronic kidney disease (CKD) has been implicated with disturbances of the Wnt pathway with an elevated level of serum sclerostin reported in CKD subjects <ref type="bibr">(de Oliveira et al, 2013;</ref><ref type="bibr">Brandenbury et al, 2013;</ref><ref type="bibr">Drueke and Lafage-Proust, 2011</ref>). An inverse relationship was found between serum sclerostin and eGFR in CKD subjects <ref type="bibr">(Pelletier et al, 2013;</ref><ref type="bibr">Cejka et al, 2014)</ref>.  Study 20060223 was a single-dose study in postmenopausal women with low bone mass who had been receiving alendronate for at least 1 year and in postmenopausal women with low bone mass who were treatment-nave for osteoporosis/bone loss. The objective of the study was to investiage PK, PD, safety and tolerability of romosozumab in subjects transitioning from alendronate to romosozumab study.  In addition, Study 20090153 and 20110253 also provided supportive PK information of romosozuamb while the primary objectives of these two studies were to evaluate the PD of romosozumab. Study 20090153 was designed to evaluate the effect of romosozumab on parameters of bone quality of the forearm using peripheral quantitative computed tomography and Study 20110253 invesitgated the percent change from baseline in lumbar spine BMD after 3 months of romosozumab administration in postmenopausal women with low bone mineral density previously treated with alendronate.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Phase 2:</head><p>Study 20060326 was the primary dose-finding study with a retreatment period from Month 36 to 48. Study 20101291 was the dose finding study in the Japanese population, which was a short study with fewer dosing arms compared to Study 20060326. More details about Study 20060326 can be found in Section 4.3.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Phase 3:</head><p>Study 20070337 was the pivotal Phase 3 study, enrolled 7180 subjects. Study 20120156 was a placebo-controlled noninferiority study in PMO subjects comparing two romosozumab formulations, i.e., a formulation with 90 mg/mL (QM, 2 x 1.17mL subcutaneous [SC]) concentration to another formulation with 70 mg/mL (QM, 3 x 1mL SC) concentrations, and Study 20080289 was a Phase 3 teriparatide-controlled study in PMO subjects transitioning from oral bisphosphonates. Study 20110142 (the 4 th study) is an alendronate-controlled, fracture outcome trial that is ongoing and not included in this BLA. More details about Study 20070337 can be found in Section 4.3.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">General Pharmacology and Pharmacokinetic Characteristics</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacology</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mechanism of Action</head><p>Romosozumab is a humanized IgG2 monoclonal antibody that binds and inhibits sclerostin. By blocking sclerostin, romosozumab increases bone formation due to the activation of bone lining cells, the increased bone matrix production by osteoblasts, and the recruitment of osteoprogenitor cells. Additionally, romosozumab results in changes to expression of osteoclast mediators, thereby decreasing bone resorption.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacodynamics</head><p>Results from the pivotal <ref type="bibr">Phase 3 trial (20070337)</ref> in postmenopausal women with osteoporosis showed that EVENITY increased the bone formation marker P1NP early in treatment, with a peak increase of approximately 145% relative to placebo 2 weeks after initiating treatment, followed by a return to comparable levels as the placebo treatment at Month 9, and a decline to approximately 15% below placebo at Month 12. EVENITY decreased the bone resorption marker CTX-I with a maximal reduction of approximately 55% relative to placebo 2 weeks after initiating treatment. CTX-I levels in the EVENITY treated group remained below those of placebo treated group and by approximately 25% at Month 12.</p><p>Results from the primary Phase 2 dose finding study <ref type="bibr">(20060326)</ref> showed that after discontinuation of EVENITY therapy, P1NP levels returned to baseline within 12 months; CTX-I increased above baseline levels within 3 months and returned toward baseline levels by Month 12, reflecting reversibility of effect. Upon retreatment with EVENITY after being off-treatment for 12 months, the level of increase in P1NP and decrease in CTX-I by EVENITY was similar to that observed during the initial treatment.</p><p>Please note that bone turnover markers (BTM) are not validated biomarker for either fracture (the clinical endpoint for treatment of osteoporosis) or BMD (the surrogate maker for clinical outcome used for dose-finding purpose).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>General Information</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bioanalysis</head><p>Romosozumab concentrations in human serum were quantified by a validated enzyme-linked immunosorbent assay (ELISA) using specific anti-idiotype antibodies for capture and detection of romosozumab.</p><p>Briefly, microplate wells were coated with mouse anti-humanromosozumab antibody to capture romosozumab. Unbound materials were removed by washing the wells. Horseradish peroxidase-labelled mouse anti-human-romosozumab antibody was used for the detection of the captured romosozumab. The nominal assay range for lower limits of quantification and upper limits of quantification was 50.0 to 2500 ng/mL, and the dilution linearity was established for up to 1:10000 dilution. See Section 4.1 for more information.</p><p>PK model The PK of romosozumab was described by a three-compartment PK model with linear distribution to peripheral compartments, parallel linear elimination in the central compartment and target-mediated nonlinear elimination in the peripheral compartments.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Heathy subjects vs PMO patients</head><p>Population PK analysis indicated no significant differences in PK between PMO patients and healthy subjects when body weight has been accounted for.</p><p>Drug exposure at steady state Steady-state concentrations were achieved by Month 3 following the monthly administration of 210 mg dose in the pivotal Phase 3 study 20070337. The mean values of trough serum romosozumab concentration ranged from 8460 to 9780 ng/mL in samples collected prior to dosing at Months 3, 6, 9, and 12.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose Linearity</head><p>Romosozumab exhibited nonlinear pharmacokinetics across the SC and IV dose ranges of 0.1 to 10 mg/kg and 1 to 5 mg/kg, respectively. Exposure increased greater than dose proportionally (e.g., 550-fold increase in mean AUC from time 0 to infinity [AUCinf] for the 100-fold increase in SC dose from 0.1 to 10 mg/kg).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Body weight</head><p>Romosozumab trough concentrtions were higher in subjects with lower body weight. The predicted exposure for subjects in the lowest quartile of body weight was ~50% higher than that in the highest quartile of body weight.</p><p>Renal Impairment Mean romosozumab exposure, as measured by Cmax and AUC values, in subjects with severe renal impairmentcohort was numerically greater than the healthy subject cohort (29% for Cmax and 44% for AUC, respectively) based on data from a dedicated study; however, most of the subjects (6-7 of 8 subjects in the cohort) with severe renal impairment had values that were within the range of healthy subjects.</p><p>Mean romosozumab exposure was similar between subjects with ESRD requiring hemodialysis and healthy subjects. Romosozumab PK in subjects with ESRD not on dialysis has not been evaluated.</p><p>The PopPK analysis showed that renal impairment has an effect on the CL of romosozumab. See section 3.3.3 and 4.5 for additional details.</p><p>Hepatic Impairment No formal trial was conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of romosozumab.</p><p>Prior exposure to Alendronate Compared to subjects with osteoporosis/low bone mass who are treatment-nave, postmenopausal women with low bone mass who had been receiving alendronate for at least 1 year had similar extent of exposure after treatment with one single dose (210 mg) of romosozumab. Mean Cmax values differed by less than 4% between prior exposure to alendronate group and treatment nave group and median tmax values were similar (4.9 days and 4.5 days). Mean AUClast and AUCinf were also similar (&lt; 12% difference) and mean terminal half-life was approximately 7.5 days for both groups.</p><p>PopPK analysis also concluded that prior exposure to alendronate did not have a significant impact on the exposure of romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ADME</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Absorption</head><p>Administration of a single dose of 210 mg romosozumab in healthy male and female subjects (n = 90, age range: 21 to 65 years) resulted in a mean (SD) maximum serum concentration (Cmax) of 22.2 (5.8) mcg/mL and a mean area under the concentration-time curve (AUC) of 389 (127) mcg*day/mL. The median time to maximum romosozumab concentration (Tmax) was 5 days (range: 2 to 7 days).</p><p>Steady-state concentrations were achieved by month 3 following the monthly administration of 210 mg in postmenopausal women. Trough serum romosozumab mean concentration values from samples collected prior to dosing at months 3, 6, 9, and 12 ranged from 8.46 to 9.78 mcg/mL.</p><p>For a 210-mg SC dose of romosozumab the bioavailability was estimated to be 81%.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Distribution</head><p>The population PK analysis estimated volume of distribution at steadystate was 3.92L.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Elimination</head><p>The clearance of romosozumab decreased as dose increased. Mean systemic clearance (CL/F) of romosozumab was estimated to be 0.383 mL/hr/kg, following a single SC administration of 3 mg/kg.</p><p>The mean effective t1/2 was 12.8 days after 3 SC doses of Q4W 3 mg/kg.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Metabolism</head><p>The metabolic pathway of romosozumab has not been characterized.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Excretion</head><p>Romosozuamb is a humanized monoclonal antibody of the IgG2 subclass and has a molecular weight of approximately 145 kDa; therefore, intact romosozumab are unlikely to be filtered by kidney or excreted in urine.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunogenicity</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Incidence</head><p>In Phase 1 studies, about 7.9% (66 of 832) of subjects developed binding antibodies after at least 1 dose of romosozumab. All positive subjects showed a persistent binding response with a positive result at the last time point tested. Neutralizing antibodies were detected in 27.3% (18 of 66) of binding antibody positive subjects.</p><p>The incidence of anti-romosozumab binding ntibodies in clinical studies with repeated dosing was higher than the antibody incidence following a single dose. About 20% (852 of 4289) of subjects exposed to romosozumab in the Phase 2 and 3 studies developed binding antibodies. The antibody responses were transient (i.e., became negative by the last time point tested) for 48.6% (414 of 852) of the binding antibody positive subjects. Neutralizing antibodies were detected in 5.4% (46 of 852) of binding antibody positive subjects, 23.9% of which (11 of 46) were transient.</p><p>The incidence of binding and neutralizing antibodies in subject dosed with 210 mg QM was 19.1% (758 of 3959) and 4.1% (31 of 758), respective; which were similar to the incidences in the overall studies.</p><p>Impact on PK Development of anti-drug antibodies (ADA) was associated with reduced serum romosozumab concentrations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impact on efficacy</head><p>Overall, ADA appeared to have no impact on efficacy. While it is not feasible to draw a definitive conclusion on the impact of ADA on fracture, due to the small number of subjects who had fracture in the Phase 3 trial. In addition, ADA did not affect romosozumab treatment effect on BMD.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impact on safety</head><p>No associations could be made between the presence of antiromosozumab binding and/or neutralizing antibodies and the worsening of immune mediated symptoms even after multiple dosing with romosozumab. Notable association was observed in the development of injection site reactions with romosozumab dosing when compared to placebo, however, this was irrespective of the immunogenicity.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">Clinical Pharmacology Review Questions</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.1">To what extent does the available clinical pharmacology information provide pivotal or supportive evidence of effectiveness?</head><p>The clinical pharmacology information provides supportive evidence of effectiveness. Romosozumab treatment produced pharmacodynamic effects in changes of bone turnover markers (an increase in P1NP and a reduction in CTX-I) as well as an increase in the bone mineral density (BMD). During clinical development multiple studies evaluated these PD effects, including two Phase 3 studies (Study 20080289 and Study 20120156) that had bone mineral density (BMD) at Month 6 as the primary efficay endpoint and the pivotal Phase 3 study (Study 20070337) which had BMD and bone turnover markers as secondary endpoints.</p><p>The pivotal evidence of effectiveness is from the Phase 3 pivotal trial (Study 20070337) which is a randomized double-blind placebo-controlled study with 2-year fracture data.</p><p>The following sub-sections further provide details of the fracture data, the BMD data, and the data for bone turnover markers.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary efficacy (fracuture) results in Phase 3 trials</head><p>Study 20070337 was a randomized double-blind placebo-controlled study with 2-year fracture data. A total of 7180 women were randomized in a 1:1 ratio to receive either romosozumab 210 mg SC QM or matched placebo in a blinded fashion for the duration of the 12-month double-blind, placebo controlled study period. After the double-blind period, subjects entered a 12-month denosumab follow-on study period in which they received denosumab 60 mg SC <ref type="formula">Q6M</ref> in an open-label fashion while remaining blinded to their initial treatment assignment. The primary analysis was conducted after all subjects completed the 24-month visist. The co-primary efficacy endpoints were subject incidence of new vertebral fracture through Month 12 and Month 24.</p><p>The applicant's analysis showed that romosozumab significantly reduced the risk of new vertebral fractures compared with placebo through Month 12 (odds ratio = 0.27, p &lt; 0.001), with a relative risk reduction of 73% (risk ratio = 0.27 [95% CI: 0.16, 0.47]). After an additional 12 months of treatment with denosumab, vertebral fracture risk reduction persisted over the 24month study period for subjects initially randomized to romosozumab compared to subjects initially treated with placebo (odds ratio = 0.24, p &lt; 0.001), with a relative risk reduction of 75% (risk ratio = 0.25 [95% CI: 0.16, 0.40]). See <ref type="table" target="#tab_4">Table 2</ref> for more details. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy (BMD) results in Phase 2 and 3 trials</head><p>Lumbar spine, total hip, and femoral neck BMD were secondary efficacy endpoints for the pivotal Phase 3 study (20070337) and lumbar spine BMD was the primary efficacy endpoint for Phase 2 dose-finding studies. While BMD is not a qualified surrogate marker for fracture, lumbar spine BMD is considered an acceptable marker for dose-finding in osteoporosis development programs.</p><p>In Study 20070337, romosozumab significantly increased BMD at the lumbar spine, total hip, and femoral neck compared with placebo at Month 12. Romosozumab followed by denosumab resulted in continued increases in BMD at the lumbar spine, total hip, and femoral neck at Month 24. The mean percent change from baseline to Month 24 in BMD were significantly greater for subjects in the romosozumab/denosumab group compared with the placebo/denosumab group (p &lt; 0.001 at each site). Only lumbar spine BMD data are show in <ref type="table" target="#tab_5">Table 3</ref>. For more details, please see <ref type="table" target="#tab_16">Table 10</ref>-3 of the clinical study report for Study 20070337. ANCOVA = analysis of covariance; LOCF = last observation carried forward; LS = least squares; N = number of randomized subjects; n = number of subjects with values at baseline and at the time point of interest. Source: <ref type="table" target="#tab_16">Table 10</ref> <ref type="bibr">-3 of 02-csr-2007-0337-rpt-body.pdf</ref> The lumbar spine BMD results of Phase 2 dose-ranging study 20060326 and 20101291 also supported the effectiveness of romosozumab 210 mg monthly for 12 months for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. See Sections 3.3.2 and 4.7.3 for more information.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacodynamics (bone turnover markers) results from Phase 2 and 3 studies</head><p>In the pivotal Phase 3 study 20070337, romosozumab increased the bone formation marker P1NP early in treatment, with a peak increase of approximately 145% relative to placebo 2 weeks after initiating treatment, followed by a return to placebo levels at Month 9 and a decline to approximately 15% below placebo at Month 12. EVENITY decreased the bone resorption marker (CTX-I with a maximal reduction of approximately 55% relative to placebo 2 weeks after initiating treatment. After EVENITY treatment, CTX-I levels remained below placebo and were approximately 25% below placebo at Month 12.</p><p>Results from the primary Phase 2 dose finding study <ref type="bibr">(20060326)</ref> showed that after discontinuation of romosozumab therapy, P1NP levels returned to baseline within 12 months; CTX-I increased above baseline levels within 3 months and returned toward baseline levels by Month 12. Upon retreatment with romosozumab after 12 months off treatment, the level of increase in P1NP and decrease in CTX-I by romosozuamb was similar to that observed during the initial treatment.</p><p>It should be noted that bone turnover markers are not validated biomarker for either fracture (the clinical endpoint for treatment of osteoporosis) or BMD (the endpoint for clinical outcome used for dose-finding purpose). See details about the CTX-I and PINP assays in Section 4.1.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.2">Is the proposed dosing regimen appropriate for the general patient population for which the indication is being sought?</head><p>Yes, the proposed dosing regimen is appropriate. The dose-response relationship for efficacy from the Phase 2 dose-finding study <ref type="bibr">(Study 20060326)</ref> and the efficacy data from the pivotal Phase 3 study (Study 20070337), where only one dose level was studies, support a recommendation of the 210 mg monthly dosing for 12 months.</p><p>Study 20060326 was a multicenter, international, randomized, placebo-controlled, parallel-group study in postmenopausal women with low BMD at the lumbar spine, total hip, or femoral neck. The study included the following treatment phases:</p><p>1. a 24-month treatment phase (Months 1-24), during which subjects received 1 of 5 doses of romosozumab (70 mg SC QM, 140 mg SC QM, 210 mg SC QM, 140 mg SC Q3M, and 210 mg SC Q3M), placebo, or active controls [alendronate (ALN) 70 mg PO QW for 12 months + denosumab 60 mg SC Q6M for 12 months or teriparatide (TPTD) 20 mcg SC QD for 12 months only]. 2. followed by re-randomization to a 12-month extension phase (months 24-36) with either denosumab SC 60 mg or placebo SC Q6M treatment 3. followed by a 12-month retreatment phase (months 36-48)with romosozumab. Subjects initially randomized to romosozumab or placebo received romosozumab 210 SC QM.</p><p>Subjects who initially received ALN ended their participation at month 36 and were not retreated with romosozumab 4. followed by a 24-month follow-on phase (months 48 to 72) with 1 dose level of zoledronic acid or no intervention.</p><p>The primary efficacy endpoint was the percent change from baseline at Month 12 in BMD at the lumbar spine.</p><p>At Month 12, as shown in <ref type="table" target="#tab_6">Table 4</ref>, the increase in mean percent change in BMD at the lumbar spine was statistically significant for all romosozumab dose groups when compared with placebo (p &lt; 0.0001). The romosozumab 140 mg QM and 210 mg QM dose groups also demonstrated statistically significant increases when compared with ALN (p &lt; 0.0001) and TPTD (p  0.0276). Lumbar spine BMD continued to increase from Month 12 to Month 24 in all but the 140 mg Q3M romosozumab dosing group; the BMD increases were greatest in the 210 mg QM group <ref type="figure" target="#fig_0">(Figure 1.</ref>) Compared with the placebo group, each of the romosozumab groups showed a significantly increased lumbar spine BMD (p &lt; 0.0001) at month 18 and 24. Subjects randomized to the ALN-to-romosozumab transition group (ALN/romosozumab) began treatment with romosozumab 140 mg QM at Month 12. Increases in lumbar spine BMD improved with romosozumab treatment during months 12 to 24. Note: Subjects assigned to TPTD SC PO 20 mcg QD arm only received TPTD for 12 months and there was no data on this dosing arm beyond 12 months.  <ref type="figure" target="#fig_0">Figure 10-8 of 02-csr-20060326-rpt-</ref> The dose and dosing regimen selected for the pivotal Phase 3 study is 210 mg QM for 12 months for the following reasons: 1) Dosing arm 210 QM showed the highest increased in mean percent change in BMD at the lumbar spine compared to other dosing arms. At the End of Phase 2 meeting, the Agency recommended that the sponsor test both 140 mg QM and 210 mg QM in their pivotal Phase 3 trials because 140 mg QM also showed reasonable amount increase in lumbar BMD after 12-month treatment and the Applicant decided to study only one dose level in the pivotal Phase 3 study.</p><p>2) The increase in BMD slowed down between Month 12 and Month 24. 3) There are uncertainties about the safety of long-term treatment (&gt;18 months) of an anabolic agent based on data from TPTD.</p><p>Fracture and BMD data from the pivotal Phase 3 study (20070337) support the proposed dose and dosing regimen of romosozumab 210 mg QM for 12 months. See Section 3.3.1 for details.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.3">Is an alternative dosing regimen and/or management strategy required for subpopulations based on intrinsic factors?</head><p>No. There is no need for alternative dosing regimen for subpopulations based on the intrinsic factors. The proposed dosing regimen with a fixed dose of 210 mg given monthly is appropriate for the general indicated population.</p><p>However, use of romosozumab in patients with severe renal impairment and with ESRD requiring or without dialysis should be carefully monitored for hypocalcemia.</p><p>The applicant conducted a dedicated renal impairment study investigating PK of romosozumab in healthy subjects (n=8), subjects with severe renal impairment (n=8), and subjects who have ESRD requiring hemodialysis (n=8). Subjects have ESRD without dialysis was not enrolled into this study. The exposure in patients with severe renal impairment was higher than that in healthy subjects. Mean Cmax and AUC were 29% and 44% higher in patients with severe renal impairment as compared to healthy subjects. However, the exposure range in these two groups have substantial overlap. Most of the subjects with severe renal impairment had values that were within the range of healthy subjects, specifically, Cmax in 7 out of 8 subjects and AUC in 6 out of 8 subjects. Meanwhile, romosozumab PK was similar between healthy subjects and ESRD subjects requiring hemodialysis. The scientific explanations behind this observation are unclear at this time. When it comes to safety, the most frequently reported treatment-emergent adverse events in the dedicated renal impairment study was hypocalcemia. Data suggested that the incidence of hypocalcemia was associated with severity of renal impairment, but not with exposure of romosozumab. The number of subjects reported hypocalcemia was 0/8 in healthy subjects, 1/8 in subjects with severe RI, and 4/8 in subjects had ESRD requiring hemodialysis.</p><p>Based on the population PK (PopPK) analysis (Section 4.5), no significant impact of gender, age, race (Japanese/non-Japanese), prior alendronate, and drug product manufacturing process on romosozumab exposure were identified. However, body weight and severity of renal impairment would affect PK of romosozumab. The impact on romosozumab exposure are listed in <ref type="table" target="#tab_7">Table 5</ref> (Source: Section 4.5 <ref type="table" target="#tab_92">Table 6</ref>) . The methods used for each study was listed in   . The Serum CrossLaps ELISA is an enzyme-linked immunosorbent assay based on the capture of the analyte (CTX-I) and its revelation by two highly specific monoclonal antibodies, one is biotinylated and the other is conjugated with peroxidase. The complex Mab1-CTX-I-Mab2 generated binds to streptavidin coated on microwell surface an dthe addition of a chromogenic substrate allows to obtaina color reaction. The CTX-I concentration in the sample is determined spectrophotometrically and calculated from a standard calibration curve. Validated parameters for "Serum CrossLaps ELISA" are summarized in <ref type="table" target="#tab_6">Table 4</ref>.1.4. For a longer period at -70C minimum. A maximum of 4 freez and thaw cycles is acceptable.</p><p>Determination of serum P1NP concentration in samples from Study 20060326 used a kit called "Intact P1NP RIA Kit" . The assay is based on a competitive radioimmunoassay technique. The P1NP to meaure competes with P1NP -125 I for a liminted number of high affinity binding sites of a polyclonal antibody. After the separation of the free P1NP from the P1NP-antibody complex, the radioactivity of the latter is counted and is reversely proportional to the amount of P1NP in the reaction mixture. The concentration in the sample is calculated with a standard curve. Validation of the assay was conducted by . Validated parameters for "Intact P1NP RIA Kit" are summarized in <ref type="table" target="#tab_6">Table 4</ref>.1.5. For a conservation of 2 weeks the serum will be stored at -20C. For a longer period at -70C minimum. A maximum of 6 freez and thaw cycles is acceptable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.2.2">Assays for Study 20070337</head><p>Validation reports for assays measuring CTX-I and P1NP in Human Serum for Study 20070337 are adequate.</p><p>Determination of serum CTX-I concentration in samples from Study 20070337 used the CTX-I (CrossLaps) Assay. This CTX-I assay is based on chemiluminescence techonology. Two highly specific monoclonal antibodies are used. The antibodies are against the amino acid sequence of EKAHD--GGR, where the aspartic acid residue is (D) -isomerized. In order to obtain a specific signal in CTX-I assay, two chains of EKAHD--GGR must be cross-linked.</p><p>Samples are incubated with both labelled antibodies for a period of time. Streptavidin coated magnetic particles are then added and following a further incubation step, the particles are "captured" using a magnet. After a washing step and addition of trigger reagents, the light emitted by the acridinium label is directly proportional to the concentration of CTX-I in the original sample. Validated parameters for " CTX-1 assay" are summarized in <ref type="table" target="#tab_6">Table  4</ref>.1.6. Room temperature stability was acceptable for up to 72 h, and refrigerated and frozen (&lt;-10C) stabiligy acceptable for up to 7 days. Long term frozen stability (-20, -80, and -150C) for up to 3 years has been reported but not tested in this validation exercise. Freeze/thaw stability was acceptable for up to 6 freeze/thaw cycles.</p><p>Determination of serum P1NP concentration in samples from Study 20070337 used a kit called "UniQTM PINP 100 test kit" . Based on the product number, the kit is the same as what was used for Study 20060326 and a description of the assay can be found above <ref type="table" target="#tab_6">Table 4</ref>.1.5. The validation report was done by . Validated parameters for "UniQTM PINP 100 test kit" are summarized in <ref type="table" target="#tab_6">Table 4</ref>.1.7 and 4.1.8. The accuracy of the PINP assay was established using UniQ TM PINP Kit Control Levels 1 &amp; 2 assayed in 10 replicates. The achieved means were acceptable within manufacturer's ranges for both levels of QC (  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.3">Bioanalytical assays for immunogenicity assessment</head><p>Two validated assays were used to detect the presence of anti-romosozumab antibodies in human serum. Samples were first tested in an ECL-based bridging immunoassay to detect antibodies capable of binding to romosozumab (binding antibody [Bab] assay). Samples confirmed to be positive for binding antibodies were subsequently tested in a non-cell-based assay to determine neutralizing activity against romosozumab (neutralizing antibody [Nab] assay) for all studies. If a sample was positive for binding antibodies and demonstrated neutralizing activity, the sample was defined as positive for neutralizing antibodies. See Product Quality Review (immunogenicity section) for more detailed information regarding the immunogenicity assay validations.</p><p>This section provides a summary of assay information relevant to clinical pharmacology assessments.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.3.1">Binding Antibody Assay</head><p>This ECL-based homogenous bridging immunoassay method is based on the bivalent characteristics of the antibody binding and utilizes the Meso Scale Discovery (MSD) platform. The testing strategy follows a two-tiered assay approach consisting of a screening assay and a specificity assay. The screening assay is performed to detect the presence of binding antibodies to romosozumab. Samples with a signal-to-noise (S/N) value greater than the assay cut-point are then tested to confirm the specificity of the response. Samples from drug-treated subjects tested in the specificity assay that deplete in the presence of excess soluble drug are reported as positive for the presence of anti-romosozumab antibodies.</p><p>Samples are treated with acetic acid to enable antibody complex dissociation before the analysis. Samples are then incubated overnight with conjugate/neutralization mixture consisting of biotinylated romosozumab: ruthenylated romosozumab (50:50), Tris pH 9.5, and soluble drug (only in the specificity assay). During this overnight incubation, the 2 antigen binding sites of anti-romosozumab antibodies are able to form a bridge between the labeled romosozumab molecules. The biotinylated-romosozumab molecule binds to the streptavidin-coated surface of the well resulting in the immobilization of the bridged ADA-conjugate complex. The plate is then washed, treated with tripropylamine MSD read buffer, and read on a MSD plate reader. The result is a luminescent signal from a series of electrically induced oxidation-reduction reactions involving ruthenium (from the captured complex) and tripropylamine. The consequent ECL signal is measured by photodiodes and is quantified as ECL units. The amount of ECL signal is proportional to the amount of anti-romosozumab antibodies in the sample.</p><p>The binding antibody assay sensitivity and drug tolerance in human serum are provided in <ref type="table" target="#tab_6">Table  4</ref>.1.4. In the pivotal Phase 3 study, afte 210 mg monthly dosing, trough serum romosozumab mean concentration values from samples collected prior to dosing at months 3, 6, 9, and 12 ranged from 8460 to 9780 ng/mL. In the same study, samples for anti-romosozumab antibody were collected at baseline, months <ref type="bibr">1, 3, 6, 9, 12, 15 and 24</ref>. Except for the sample taken at Month 1, the expected romosozumab levels are lower than the drug tolerance level, and do not interfere with the measurement of anti-romosozumab antibody in the immunogenicity samples.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.3.1">Neutralizing Antibody Assay</head><p>To detect the presence of antibodies that are capable of disrupting the binding of romosozumab to sclerostin in serum samples, an ECL-based competitive target binding assay was developed. This assay utilizes the MSD platform and follows a tiered, two-assay approach consisting of a screening assay and a confirmatory assay. Samples that show reactivity in the screening assay are placed in a confirmatory assay that confirms that the interruption of the binding between romosozumab and sclerostin observed in the screening assay is due to the presence of antiromosozumab neutralizing antibodies. The combined results of the screening assay and confirmatory assay are used to determine if a sample is positive or negative for neutralizing antibodies against romosozumab.</p><p>The method for the detection of anti-romosozumab neutralizing antibodies uses ruthenylated romosozumab and biotinylated sclerostin. In this assay, the anti-romosozumab antibodycontaining sample is incubated with ruthenylated romosozumab and biotinylated sclerostin and allowed to form a binding complex. The binding complex is captured on an avidin-coated MSD plate. The plate is then washed and read on a MSD plate reader. The result is a luminescent signal from a series of electrically induced oxidation-reduction reactions involving ruthenium (from the captured complex) and tripropylamine. The consequent ECL signal is measured by photodiodes and is quantified as ECL units. If there are anti-romosozumab neutralizing antibodies present in the sample, they will compete with biotinylated sclerostin for the binding to the ruthenylated romosozumab; therefore, the amount of binding complex captured on the plate is reduced and the result is a decrease in ECL signal in the assay. To confirm that a sample contains anti-romosozumab-specific neutralizing antibodies, an excess amount of romosozumab is added exogenously to the sample, which will bind to anti-romosozumab antibodies and reduce the amount of anti-romosozumab antibodies available to bind to ruthenylated romosozumab, thus resulting in an increase in ECL signal in the assay.</p><p>The assay sensitivity and drug tolerance for human serum for romosozumab bioassay are listed in <ref type="table" target="#tab_6">Table 4</ref>.1.5. In the pivotal Phase 3 study, samples for anti-romosozumab antibody were collected at baseline, months <ref type="bibr">1, 3, 6, 9, 12, 15 and 24</ref>. Due to the low drug tolerance level of the neutralizing assay, only samples taken at Month 15 and Month 24 can have a reliable reading.</p><p>Samples have high concentration of neutralizing antibody can still be detected as positive for neutralizing antibody even when the romosozumab level in the samples are higher than the tolerance level. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2">Biopharmaceutics: Comparative PK Studies</head><p>A summary outlining the use of romosozumab drug substance and drug product in the clinical program is provided in <ref type="table" target="#tab_6">Table 4</ref>.2.1.  Study 20150197 compared the pharmacokinetic profile after administration of a single 210-mg SC romosozumab dose of the romosozumab 90-mg/mL concentration (administered as two 1.17-mL PFS injections) using drug substance produced at ATO (Process 2, scale) versus at ARI (Process 2, scale). -Drug product #3 vs. #5. Note: The applicant is not seeking marketing authorization for the AI presentation of romosozumab in this marketing application.  <ref type="table" target="#tab_6">Table  4</ref>.2.2 contains the Cmax, AUC0-t, AUC0-inf data and the statistical comparisons of these parameters between the test product and the reference product for both studies. <ref type="figure" target="#fig_2">Figure 4.2.3</ref> shows the PK profiles.   </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer's analysis:</head><p> Study 20120277</p><p>The sponsor's BE analysis excluded 6 subjects (Subjects ) using the criteria of "The PK parameter analysis set included subjects for whom at least one of the PK parameters (AUCinf, AUClast, Cmax) could be adequately estimated for the purpose of primary analysis". The sponsor's analysis showed that the lower bound of 90% CI for AUCinf was 0.813. When the reviewer repeated the analysis in Pheonix 64, only two subjects need to be excluded (Subject due to protocol violation and Subject had %AUCinf extrapolated close to 50%). Reviewer's analyis showed that the lower bound of 90% CI for AUCinf was 0.799 and 90% CI for Cmax and AUClast both fall within the range of 0.8 to 1.25.</p><p>Although 0.799 barely missed the cutoff of 0.800, we consider that the PK comparability between the reference and test products in this study is established because 1) AUCinf was extrapolated and the extrapolation method may not be the most appropriate one for romosozumab, which has target mediated drug disposition and 2) The small difference in AUCinf is not expected to have any clinical implications.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head> Study 20150197</head><p>Reviewer's analysis confirmed the sponsor's analysis. The PK comparability using BE criteria between the reference and test products in this study is established.</p><p> Overall, we found the bridge between the to-be-marketed formulation (90 mg/mL PFS (Process 2 ARI) and clinical trial formulation (70 mg/mL glass PFS (Process 2 ATO) established based on data from the two PK comparability studies, Study 20120277 and 20150197.  Inspection reports for analytical and clinical sites for both studies are pending. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3">Pharmacokinetics: Individual Study Summary</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.1.">Study 20120277 and 20150197 (The Two Pivotal PK Comparability Studies)</head><p>Study 20120277 compared the pharmacokinetic profile after administration of a single 210-mg SC romosozumab dose, delivered as either three 1.0-mL PFS injections of 70-mg/mL concentration (Process 2 ATO), or two 1.17-mL PFS injections of 90-mg/mL concentration (Process 2 ATO).</p><p>Study 20150197 compared the pharmacokinetic profile after administration of a single 210-mg SC romosozumab dose of the romosozumab concentration (administered as two 1.17-mL PFS injections) using drug substance produced at ATO (Process 2, scale) versus at ARI (Process 2, scale).</p><p>Detailed information of these two studies are listed in Section 4.2 Biopharmaceutics: Comparative PK Studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.2">Study 20060220 (The First in Human Study)</head><p>Study 20060220 was a randomized, double-blind, placebo-controlled, single ascending dose Phase 1 study conducted in healthy men and postmenopausal women. Subjects received romosozumab SC (0.1, 0.3, 1, 3, 5, and 10 mg/kg) or romosozumab IV (1 and 5 mg/kg).</p><p>The romosozumab concentration-time profiles by treatment groups are shown in <ref type="figure" target="#fig_3">Figure 4</ref>.3.1 and <ref type="figure" target="#fig_3">Figure 4</ref>.3.2. PK parameters estimated by non-compartment analysis are listed in <ref type="table" target="#tab_5">Table 4.3.1 and  Table 4</ref>.3.2. The exposure (AUC) of romosozuamb increased in a greater than dose-proportional manner, indicating the concentration-dependent nature of drug clearance.    <ref type="figure" target="#fig_0">Figure 10-2 of CSR Study 20060220)</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.2.">Study 20090387 (The PK Study in Japansese Population)</head><p>Study 20090387 was a randomized, double-blind, placebo-controlled, single-dose Phase 1 study conducted in healthy postmenopausal women and non-Japanese women residing in the United States. Subjects received romosozumab SC (1, 3, or 5 mg/kg).</p><p>The romosozumab PK parameters estimated following single-dose SC administration are shown in <ref type="table" target="#tab_6">Table 4</ref>.3.3. At the 3-mg/kg dose, the PK profile was not substantially different for healthy postmenopausal Japanese and non-Japanese women. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.3.">Study 20060221 (The First Multiple-dose Study)</head><p>Study 20060221 was a randomized, double-blinded, placebo-controlled, ascending multiple dose study in healthy men and postmenopausal women with low bone mass. Forty-eight subjects were enrolled into 1 of 6 cohorts as shown in <ref type="table" target="#tab_6">Table 4</ref>.3.4. The romosozumab concentration-time profiles are shown in <ref type="figure" target="#fig_3">Figure 4</ref>  <ref type="table" target="#tab_6">Table 4</ref>.3.5 and <ref type="table" target="#tab_6">Table  4</ref>.3.6. For the Q2W dose groups, mean C max and AUC 0-14 days values increased 2.0-to 2.3-fold, respectively, for the 2-fold increase in dose (1 mg/kg to 2 mg/kg). For the Q4W dose groups, mean values of C max and AUC 0-28 days increased approximately 1.8-to 2-fold, respectively, for the 1.5-fold increase in dose (2 mg/kg to 3 mg/kg). No marked ( 2-fold) accumulation was observed with Q4W dosing.   The romosozumab concentration-time profiles by renal function group are shown in <ref type="figure" target="#fig_3">Figure 4</ref>.3.5. Descriptive statistics of PK parameter estimates by renal function group are presented in <ref type="table" target="#tab_6">Table  4</ref>.3.7. A comparison of the PK parameters (tmax, Cmax, and AUC) between subjects with stage 4 RI (group 1), subjects with ESRD requiring hemodialysis (group 2), and healthy subjects (group 3) dosed at 210 mg SC are presented in <ref type="table" target="#tab_6">Table 4</ref>.3.8 and <ref type="table" target="#tab_6">Table 4</ref>.3.9. Individual PK parameters (Cmax and AUC) plot by group are presented in <ref type="figure" target="#fig_3">Figure 4</ref>.3.6.</p><p>Mean romosozumab exposure, as measured by Cmax and AUC values, in the stage 4 RI cohort was greater than the healthy cohort; mean Cmax and AUC were 29% and 44% higher in patients with severe renal impairment as compared to healthy subjects. However, the exposure range in these two groups have substantial overlap. Most of the subjects with stage 4 RI had values that were within the range of healthy subjects, specifically, Cmax in 7 out of 8 subjects and AUC in 6 out of 8 subjects. In addition, mean romosozumab exposure was similar between subjects with ESRD requiring hemodialysis and healthy subjects.</p><p>The geometric least square mean point estimates and 90% CIs for the ratio of Cmax in subjects in stage 4 RI or subjects with ESRD requiring hemodialysis compared with healthy subjects were 1.313 (0.945, 1.824) ( We note that, mechanistically speaking, it is unclear how the renal function/hemodialysis affects the exposure of romosozumab.</p><p>When it comes to safety, the most frequently reported treatment-emergent adverse events in the dedicated RI study was hypocalcemia. Data suggested that the incidence of hypocalcemia was associated with severity of RI, but not with exposure of romosozumab. The number of subjects reported hypocalcemia was 0/8 in healthy subjects, 1/8 in subjects with severe RI, and 4/8 in subjects had ESRD requiring hemodialysis.     </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.5.">Study 20060223 (Transitioning from Alendronate to Romosozumab Study)</head><p>Study 20060223 was a randomized, open-lable, single-dose study in postmenopausal women with low bone mass who had been receiving alendronate for at least 1 year and in postmenopausal women with low bone mass who were treatment-nave for osteoporosis/bone loss. Subjects were to 1 of 3 groups as shown below.</p><p> Group A: Subjects who had been receiving alendronate for at least 1 year and continued receiving alendronate (12 weekly dose of 70 mg alendronate or equivalent), beginning on day 1  Group B: Subjects who had been receiving alendronate for at least 1 year and discontinued alendronate and received a single 3-mg/kg SC dose of romosozumab on day 1  Group C: treatment-nave subjects who received a single 3 mg/kg dose of romosozumab on day 1.</p><p>The romosozumab serum concentration-time profiles are shown in <ref type="figure" target="#fig_3">Figure 4</ref>.3.7. Descriptive statistics of PK parameter estimates by treatment group are presented in <ref type="table" target="#tab_6">Table 4</ref>.3.10.</p><p>Mean Cmax values differed by less than 4% between groups B and C and median tmax values were similar (4.9 days and 4.5 days). The extents of exposure as measured by mean AUClast and AUCinf were also similar (&lt; 12% difference) and mean terminal half-life was approximately 7.5 days for both groups.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.6.">Study 20060326 (The Dose-finding and Retreatment Study)</head><p>Study 20060326 was a randomized, placebo-controlled Phase 2 study to determine the effect of treatment with romosozumab versus placebo on lumar spine BMD in postmenopausal women with low BMD. The study included a 24-month initial treatment phase during which subjects received romosozumab (419 subjects randomized to receive 70 mg, 140 mg, or 210 mg), placebo, or active control. Romosozumab and placebo were given QM or Q3M; one active control group received alendronate for the first 12 months followed by romosozumab for another 12 months, and the other active control group only received teriparatide 20 mcg QD for 12 months. Following initial treatment, subjects were re-randomized to a 12-month extension phase with denosumab or placebo; followed by a 12-month retreatment phase with romosozumab (the same dose regimen as in the initial treatment); followed by a 24-month follow-on phase with zoledronic acid or no intervention. Study design and treament schema of Study 20060326 are shown in <ref type="figure" target="#fig_3">Figure 4</ref>  Serum concentration-time profiles during 24-month romosozumab treatment phase followed by 12-Month Denosumab Extension Phase and a 12-Month Romosozumab Retreatment Phase are shown in <ref type="figure" target="#fig_3">Figure 4</ref>.3.10. Brief summaries of the PK results in each treatment phase is provided below.</p><p> 24-month romosozumab treatment phase For the QM cohorts, the peak serum romosozumab concentrations increased 3.7-fold after the first dose and 4.4-fold after the 12th dose for the 3-fold increase in dose from 70 to 210 mg. The peak concentration after the 12th dose ranged from 1.2-to 1.5-fold greater than the peak after the first dose for the 70, 140, and 210 mg QM doses.</p><p>Pharmacokinetic data for the QM cohorts were available before dosing, i.e., at trough concentration (Ctrough) time points at months <ref type="bibr">1, 2, 3, 6, 9, and 12</ref> during the first year and ranged from 675 to 1070 ng/mL at the 70 mg QM dose, 2780 to 4770 ng/mL at the 140 mg QM dose, and 5640 to 9320 ng/mL at the 210 mg QM dose. During the second year, Ctrough data were collected at months <ref type="bibr">13, 14, 15, 18, 21, and 24</ref>, and ranged from 757 to 1120 ng/mL, 4880 to 6320 ng/mL, and 8310 to 10900 ng/mL, at the 70, 140, and 210 mg QM doses, respectively. Trough concentration values increased greater than dose proportionally. At Month 12 and Month 24, mean Ctrough at the 210 mg QM dose were 10-fold greater than concentrations at the 70 mg QM dose. Overall, the data indicate a greater extent of accumulation for 210 mg QM dosing than at 70 mg QM dosing.</p><p>For the Q3M cohorts, accumulation was minimal. The peak serum romosozumab concentrations increased 1.6-fold after the first dose and after the 12th dose for the 1.5-fold increase in dose from 140 to 210 mg. Mean romosozumab concentrations at trough time points for Q3M cohorts were below the quantitation limit (BQL).</p><p>The mean peak concentrations after the first dose of romosozumab at 140 mg QM for the cohort that received ALN treatment for the first year and for the cohort that received 24 months of romosozumab at 140 mg QM were similar at 12500 and 12400 ng/mL, respectively. Serum romosozumab Ctrough values ranged from 2590 to 5150 ng/mL for the ALN cohort and ranged from 2780 to 4770 ng/mL for the romosozumab 140 mg QM cohort. Mean Ctrough values after 12 doses of romosozumab at 140 mg in both groups were similar.</p><p> Month 24 to 36 (denosumab extension) and month 36 to 48 (romosozumab retreatment) After receiving denosumab or placebo during the third year of the study, subjects across all cohorts showed similar exposure during the retreatment phase regardless of their various treatments for the first 2 years.</p><p>For the cohort of subjects who received romosozumab treatment at 210 mg QM during the initial 2-year treatment followed by 12 months of denosumab prior to romosozumab retreatment, the average Ctrough values at steady state during the first 2 years of treatment (average concentration of the last 3 time points-months 18, 21, and 24) and average retreatment Ctrough at steady-state (average of concentrations at months <ref type="bibr">42, 45, and 48)</ref> were similar at 8940 ng/mL and 9420 ng/mL, respectively.</p><p>For the cohort that received romosozumab treatment at 210 mg QM during the initial 2-year treatment followed by 12 months of placebo prior to romosozumab retreatment, the average Ctrough values at steady state during the first 2 years and the average Ctrough at steady state during the retreatment phase were similar at 11300 ng/mL and 10900 ng/mL, respectively.</p><p>The average Ctrough value of the last 3 time points for the cohort that received placebo QM or Q3M during the initial 2-year treatment followed by 12 months of denosumab prior to romosozumab 210 mg QM in the retreatment period was 13900 ng/mL, 1.5-fold greater than the average Ctrough value over the last 3 time points of the first 2 years of romosozumab 210 mg treatment. Study 20101291 was a double-blind, randomized, placebo-controlled, multiple dose Phase 2 study in Japanese women with postmenopausal osteoporosis. Subjects received placebo or romosozumab 70 mg, 140 mg, or 210 mg by SC injection QM for 12 months.</p><p>The concentration-time profile of romosozumab is shown in <ref type="figure" target="#fig_3">Figure 4</ref>.3.11. Peak romosozumab concentrations increased 3.6-fold over the romosozumab 70 to 210 mg dose range (3-fold increase in dose). Mean serum concentrations measured 1 week after the administration of the first dose of romosozumab (day 8) were 7150, 16500, and 25600 ng/mL for the romosozumab 70, 140, and 210 mg groups, respectively. Trough serum romosozumab mean concentration values (from samples collected before dose administration at months <ref type="bibr">1, 2, 3, 6, 9, and 12)</ref> after multiple administrations with romosozumab ranged from 777 to 911 ng/mL, 3730 to 4590 ng/mL, and 6060 to 10400 ng/mL in the romosozumab 70, 140, and 210 mg groups, respectively. Trough concentrations demonstrated greater than dose proportional increases with ascending dose in the dose range of 70 mg to 210 mg, with the Month 12 time point exhibiting a 12-fold increase in concentration for a 3-fold increase in dose. Steady state was generally achieved by month 3 for all dose levels.  <ref type="figure" target="#fig_0">Figure  11-1, CSR of Study 20101291)</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.8.">Study 20070337 (The Pivotal Phase 3 Trial)</head><p>Study 20070337 was a multicenter, international, randomized, double-blind, placebo-controlled, parallel group study in postmenopausal women with osteoporosis, to assess the effect of romosozumab treatment for 12 months compared with placebo on the incidence of vertebral and other fractures, and to assess the effect of romosozumab treatment for 12 months followed by denosumab treatment for 12 months compared to placebo followed by denosumab treatment on the incidence of vertebral and other fractures (N = 7180).</p><p>Romosozumab PK were assessed in a PK substudy (931 subjects: romosozumab = 466, placebo = 465) to allow a PopPK analysis. Romosozumab serum concentrations were measured at day 1, day 14, month 1, month 3, month 3 + 14 days, month 6, month 6 + 14 days, month 9, month 12, and month 13.</p><p>After monthly administrations of romosozumab 210 mg to postmenopausal women with osteoporosis, exposure appeared to reach steady-state by month 3. Mean Ctrough from samples collected prior to dosing at months <ref type="bibr">3, 6, 9, and 12</ref> ranged from 8050 to 9780 ng/mL. Two weeks after the fourth and seventh doses of romosozumab (month 3 plus 14 days and month 6 plus 14 days, respectively), peak concentrations were evaluated. Mean serum concentrations ranged from 21200 to 21900 ng/mL and were comparable after steady-state was reached.</p><p>Descriptive statistics of peak and trough serum romosozumab concentration-time data are shown in <ref type="table" target="#tab_6">Table 4</ref>.3.11. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4">Immunogenicity</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.1.">Immunogenicity incidences of ADA and NAb</head><p>In Phase 1 studies, about 7.9% (66 of 832) of subjects developed binding antibodies after at least 1 dose of romosozumab. All ADA positive subjects showed a persistent binding response with a positive result at the last time point tested. Neutralizing antibodies were detected in 2.1% (18 of 832) of all romosozumab dosed subjects, which is 27.3% (18/66) of all ADA+ subjects. See more detailed in <ref type="table" target="#tab_9">Table 7</ref> of Integrated Immunogenicity Report.</p><p>The incidence of anti-romosozumab binding antibodies in clinical studies with repeated dosing was higher than the antibody incidence following a single dose. About 20% (852 of 4289) of subjects exposed to romosozumab in the Phase 2 and 3 studies <ref type="bibr">(Study 20070337, 20060326, 20101291, 20120156 and 20080289)</ref> developed binding antibodies. The antibody responses were transient (i.e., became negative by the last time point tested) for 9.7% (414 of 4289) of the overall dosed subjects. Neutralizing antibodies were detected in 1.1% (46 of 4289) of overall dosed subjects, 0.3% of which (11 of 4289) were transient. The percentage of ADA+ subjects who were NAb positive was 5.4% <ref type="bibr">(46/852)</ref>. See more detailed in <ref type="table" target="#tab_13">Table 9</ref> of Integrated Immunogenicity Report.</p><p>The incidence of binding and neutralizing antibodies in subject dosed with 210 mg QM was 19.1% (758 of 3959) and 0.8% (31 of 3959), respective. The percentage of ADA+ subjects who were NAb positive was 4.1% (31/758). This was similar to the incidences in the overall Phase 2 and 3 studies. See more detailed in <ref type="table" target="#tab_13">Table 9</ref> of Integrated Immunogenicity Report.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.2.">Impact of ADA on PK</head><p>Overall, development of ADA was associated with reduced serum romosozumab concentrations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.2.1">Impact of ADA on PK based on ADA+/ADA-status</head><p>In the Applicant's initial submission, the impact of immunogenicity on PK exposures was assessed by comparing romosozumab concentrations in subjects with anti-romosozumab antibodies to antibody-negative subjects in studies <ref type="bibr">20060326, 20101291 and 20070337.</ref> In these 3 studies, romosozumab levels were reduced in some subjects with binding antibodies (approximately 25% lower exposure at months 3, 6, and/or 9 and comparable to each other with approximate 10% difference in mean values) at Month 12 <ref type="table" target="#tab_6">(Table 4</ref>.4.1). Greater reduction in romosozumab levels at same time points were observed for subjects with neutralizing antibodies (  In Study 20060326, an initial 24-month treatment phase with romosozumab, placebo, or active control was followed by a 12-month extension phase with denosumab or placebo, which was then followed by a 12-month retreatment phase with romosozumab. Thirteen subjects who developed ADAs during the first 2 years, participated in the extension and re-treatment phases and tested for ADA again during year 4. The year 4 mean Ctrough in these 13 subjects were 26% to 30% lower at months 6, 9, and 12 than the exposure observed in subjects without ADA detected during the entire 4-year treatment (  During the review cycle, the clinical pharmacology review team requested that the Applicant conduct further analysis regarding the relationship between titer and romosozumab concentration. The applicant did not have titer of immunogenicity samples and proposed to conduct the analysis between S/N ratio and romosozumab concentration. The new analysis was conducted based on data from Subject in Phase 1, the Phase 2 dose finding study <ref type="bibr">(20060326)</ref>, and the pivotal <ref type="bibr">Phase 3 study (20070337)</ref>. The scope of the analysis was decided for the following reasons: 1) Subject showed significant impact of immunogenicity on PK. 2) Study 20060326 had a retreatment period after subjects were off romosozumab for 12 months and, therefore, provided a good opportunity of investigating immunogenicity after retreatment. 3) The pivotal Phase 3 Study 20070337 enrolled 7180 postmenopausal women with osteoporosis, which represents about 80% of the entire patient population in this submission. In general, the higher S/N ratio is, the lower the romosozumab exposure is. Impact of immunogenicity on PK based on S/N ratio is summarized as follows:</p><p> One of the neutralizing antibody positive subjects (Subject ) from Phase 1 study 20060220 was inadvertently enrolled and dosed in a subsequent ascending multi-dose pharmacology/pharmacodynamic study 20060221. A rapid decline in romosozumab serum concentrations was observed in this subject after the first dose in study 20060221, and serum concentrations were not measurable after day 6, despite continued dosing once every two weeks <ref type="figure" target="#fig_3">(Figure 4</ref>  Conc.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Time</head><p>Subject had high signal-to-noise (S/N) ratio. Despite the intereference from romosozumab in the sample, she was tested positive for neutralizing antibodies. Below is the narrative on this subject from the applicant,</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subject</head><p>received an initial single dose of romosozumab at 10 mg/kg subcutaneous (SC) on in the romosozumab first-in-human Study 20060220. Of note, 10 mg/kg was the highest dose tested in the romosozumab clinical development program. On , a non-serious adverse event of injection site erythema was reported as mild in severity, related to study drug and resolved on with no further action taken. The subject was positive for binding antibodies on (study day 57; S/N value = 1.61) and for neutralizing antibodies on (end of study [study day 85]; S/N value = 37.30). The subject returned for follow-up antibody testing as specified in the protocol. Prior to re-exposure of romosozumab in study 20060221, the subject's S/N values ranged from 382.05 to 1019.50. The subject was still positive for neutralizing antibodies when, in violation with the protocol in/exclusion criteria, she enrolled in romosozumab Study 20060221 (subject number ) and received a second dose of romosozumab at 1 mg/kg SC on and then every 2 weeks until . At the time the subject was enrolled into Study 20060221, the investigator was not aware of her prior participation in the first-in-human study. The subject was tested for anti-romosozumab antibodies as per protocol, every month during Study 20060221 and approximately every 3 months after last dose: she remained positive for neutralizing antibodies as of and was then lost to follow up. Throughout the study, the range of S/N for subject was between 333.40 (before first dose) and 7,454.68; following the peak S/N value of 7,454.68 on study day 141, the values decreased over time to 639.83 at the subject's last follow-up visit. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>57</head><p> Among a total of 478 subjects enrolled in the PK substudy of 20070337, 95 subjects tested positive for anti-romosozumab binding antibodies at one or more time points postbaseline. Among the subjects with evaluable PK information, 9 subjects had S/N ratios &gt; 10 at Month 6 or 12, and their mean romosozumab serum concentrations were lower at these visits compared with the concentration values in subjects who tested negative for anti-romosozumab antibodies <ref type="figure" target="#fig_3">(Figure 4</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.3.">Impact of ADA on efficacy</head><p>Overall, ADA appeared to have no impact on efficacy. It is not feasible to draw a definitive conclusion on the impact of ADA on fracture, due to the small number of subjects who were ADA positive and fractured. There is lack of impact of ADA positive on BMD changes. Although the presence of ADA appeared to have a negatie impact on bone turnover markers, the correlation between BTM and BMD, or between BTM and fracture is unclear.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.3.1">Impact of ADA on efficacy based on ADA+/ADA-status</head><p>In the Applicant's initial submission, the impact of immunogenicity on BMD was assessed by comparing romosozumab concentrations in subjects with anti-romosozumab antibodies to antibody-negative subjects in studies <ref type="bibr">20060326, 20101291 and 20070337</ref>. In each of these three studies, the effect of ADA on BMD change is similar for ADA positive and negative subjects. See Section 7 of Integrated Immunogenicity Report for more details.</p><p>4.4.3.2 Impact of ADA on efficacy based on signal-to-noise (S/N) ratio</p><p>During the review cycle, we requested that the Applicant conduct further analysis regarding the relationship between titer and efficacy of romosozumab. The applicant did not have titer of immunogenicity samples and proposed to conduct the analysis between S/N ratio and efficacy of romosozumab. The scope of the new analysis is listed in Section 4.4.2.2 of this review.</p><p>The impacts of immunogenicity on efficacy based on S/N ratio are summarized below:</p><p> Subjects experiencing a new vertebral fracture through Month 24 had an incidence of anti-romosozumab antibodies consistent with the overall patient population <ref type="bibr">[4/21 (19.0%)</ref>]. The 4 subjects who tested positive for anti-romosozumab binding antibodies had S/N values ranging from 1.42 to 7.61 and tested negative for neutralizing antibodies.</p><p> Analysis focused on the relationship between the immunoassay S/N values from Study 20070337 with percent change in BMD from baseline at months 12 and 24, showed no impact of the magnitude of the anti-romosozumab binding antibody response on BMD change from baseline across all anatomical sties and timepoints. Lumbar spine BMD data are listed as an example <ref type="table" target="#tab_6">(Table 4.</ref> <ref type="bibr">4.4)</ref>.</p><p> Consistent with those pharmacokinetic data shown in <ref type="figure" target="#fig_3">Figure 4</ref>   <ref type="bibr" target="#b41">8,</ref><ref type="bibr">8.3 2.5,</ref><ref type="bibr">9.2 Min,</ref><ref type="bibr">30.9</ref> N = Number of subjects randomized to romosozumab, with BMD values at baseline and at least one post-baseline visit at or before Month 24 and with at least one post-baseline positive binding antiromosozumab antibody data through month 15; n = Number of subjects with evaluable data at the time point of interest;</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.4">Impact of ADA on safety</head><p>Overall, ADA appeared to have no impact on safety. We defer to the clinical team regarding the impact of ADA on safety.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.4.1">Impact of ADA on safety based on ADA+/ADA-status</head><p>In the Applicant's initial submission, the impact of ADA on safety was based on data from the pivotal placebo-controlled Phase 3 study <ref type="formula" target="#formula_34">(20070337)</ref>, with additional safety data coming from an active-controlled Phase 3 study with teriparatide <ref type="formula" target="#formula_34">(20080289)</ref>, a dose-ranging placebo-and active-controlled (teriparatide or alendronate) study <ref type="formula" target="#formula_34">(20060326)</ref>, a dose-ranging placebocontrolled study in Japanese women <ref type="formula" target="#formula_34">(20101291)</ref>, and a placebo-controlled noninferiority study (20120156).</p><p>The following adverse events were evaluated for the timing of antibody onset and the corresponding antibody status: hypersensitivity, injection site reactions and autoimmune disorders. No associations could be made related to presence of anti-romosozumab binding and neutralizing antibodies and the worsening of immune mediated symptoms even after multiple dosing with romosozumab. Notable association was observed in the development of injection site reactions with romosozumab dosing when compared to placebo, however this was irrespective of the immunogenicity. See <ref type="table" target="#tab_6">Table 14-</ref> There were no notable differences in adverse reactions between subjects with S/N values &gt; 10 and placebo subjects, anti-romosozumab antibody negative subjects, or anti-romosozumab antibody positive subjects with S/N values  10 <ref type="table" target="#tab_6">(Table 4.</ref> <ref type="bibr">4.5)</ref>. While the incidence of autoimmune disorders was slightly higher in the subset of antibody positive subjects with a S/N &gt; 10, this is likely due to the small size of this subset, as the 2 reported disorders (chronic gastritis and type IIa hyperlipidaemia) are unlikely to be a consequence of anti-drug antibodies. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5">Population PK Analyses</head><p>The population PK review is comprised of two parts: first part is the Applicant's analysis (Section 4.5.1) and the second part is the Reviewer's comments and analysis (Section 4.5.2).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.1">Applicant's analysis</head><p>A population PK analysis was conducted by the Applicant to characterize the pharmacokinetics of romosozumab administered IV or SC in healthy subjects and postmenopausal women with low BMD or osteoporosis. The clinically relevant covariates which may explain the variability of the PK parameters were explored and the individual exposure estimates were computed for the subsequent exposureresponse analyses.</p><p>Overall, 11 clinical studies were pooled for population PK analysis including 8 <ref type="bibr">Phase 1 studies (20060220, 20060221, 20060223, 20090378, 20101180, 20120277, 20110227, and 20110253)</ref>, 2 Phase 2 studies (20060326 and 20101291), and 1 pivotal Phase 3 studies <ref type="formula" target="#formula_34">(20070337)</ref>. In these studies, romosozumab was administered as a single IV dose (N=12 subjects) of 1 mg/kg or 5 mg/kg; a single SC dose (N=359 subjects) of 0.1 mg/kg to 10 mg/kg or 210 mg; or as multiple SC doses (N=1098 subjects) ranging from 1 to 3 mg/kg given every 2 or 4 weeks or fixed doses of 70, 140, or 210 mg given every month or 3 months for up to 48 months.</p><p>A nonlinear mixed effect modeling approach was implemented to characterize the population PK of romosozumab using NONMEM 7.2. A three-compartment PK model with linear distribution to peripheral compartments and parallel linear elimination in the central compartment and targetmediated non-linear elimination in the peripheral compartments was selected as the structural model. A saturable FcRn-mediated absorption process was used to describe romosozumab absorption and bioavailability after SC administration. The model schematic and parameters are shown in <ref type="figure" target="#fig_0">Figure 1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 1 Model Schematic for Romosozumab PKPD</head><p>Source: Applicant's population PK report, <ref type="figure" target="#fig_0">Figure 13-12</ref>, Page 96.</p><p>The covariates considered for the analysis were demographic factors, including sex, age, race (Japanese vs non-Japanese), body weight; renal function estimated using the Modification of Diet in Renal Disease (MDRD) formula, prior alendronate administration, and drug product manufacturing process (1: clinical process; 2: commercial process). The summary statistics of covariates by study were listed in <ref type="table" target="#tab_87">Table 1</ref>. The final dataset contained 13346 serum concentrations of romosozumab from 1459 subjects, including 341 (138 male, 203 female) healthy subjects, 35 (12 male, 23 female) with low BMD, and 419 osteopenic or 664 osteoporotic postmenopausal women. The median body weight was 61 kg and ranged from 33 to 109 kg. The overall median age was 66 years and ranged from 20 to 89 years. The median eGFR was 80 mL/min/1.73 m 2 and ranged from 7 to 144 mL/min/1.73 m 2 . The majority of subjects were Caucasian (51%), 14% Japanese, 7% Hispanic, 4% Black, and rest from other races.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 1 Summary Statistics of Covariates by Clinical Study</head><p>Source: Applicant's population PK report, <ref type="table" target="#tab_4">Table 12</ref>-7, Page 65.</p><p>The final covariate model included effects of baseline body weight, eGFR, Japanese race, and manufacturing process on CL and baseline body weight, age, and sex on V2. Prior alendronate or postmenopausal osteoporosis (PMO) treatments, patient populations (eg, healthy/low-BMD, osteopenic, and osteoporotic), and baseline sclerostin had no significant association with romosozumab PK parameters. Therefore, these covariates had no impact on romosozumab exposures or dosing. The final parameters and their precision are shown in <ref type="table" target="#tab_4">Table 2</ref>. The diagnostic plots and VPC are presented in <ref type="figure" target="#fig_18">Figure 2</ref>, <ref type="figure" target="#fig_2">Figure 3</ref> and <ref type="figure" target="#fig_3">Figure 4</ref> demonstrating good predictability.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 2 Goodness of Fit Plot for the Final Population PK Model</head><p>Green and grey data points reflect observations following IV and SC dosing, respectively.</p><p>Source: Applicant's population PK report, <ref type="figure" target="#fig_0">Figure 13</ref>-25, Page 117. Source: Applicant's population PK report, <ref type="figure" target="#fig_0">Figure 13</ref>-29, Page 125.</p><p>The final population PK model was used to evaluate the impact of covariates on romosozumab exposure and compare the fixed dosing with body weight based dosing.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Impact of covariates on romosozumab exposure</head><p>The impact of other covariates, in addition to body weight, on steady-state romosozumab exposure parameters (AUCss and Cmax,ss) after a clinical dose of 210 mg SC QM is shown using a forest plot ( <ref type="figure" target="#fig_5">Figure 5</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 5 Fold Change and 95%PI in Steady-state AUC and Cmax across the Range of Covariates:</head><p>Vertical reference lines refer to 0.8, 1.0 and 1.25 fold-changes in median model predicted AUC and Cmax at steady state, compared to the reference subject. Renal function based on eGFR: normal (90 mL/min/1.73 m 2 ), mild (60 to&lt;90 mL/min/1.73 m 2 ), moderate (30 to &lt;60 mL/min/1.73 m 2 ), severe (15 to &lt;30 mL/min/1.73 m 2 ), ESRD <ref type="bibr">(5 to &lt;15 mL/min/1.73 m 2 )</ref>.</p><p>Source: Applicant's population PK report, <ref type="figure" target="#fig_0">Figure 13-30</ref>, Page 126.</p><p>The reference subject is a subject with weight of 61 kg, age of 66 years, mild renal function, male, race of non-Japanese, and using the formulation utilized in the clinical studies. Although these covariates have significant associations with romosozumab PK parameters, the distributions of romosozumab AUCss and Cmax,ss fold change with respect to the reference subject overlapped greatly across covariate ranges, suggesting their impact on overall PK variability is small and resulted in less than 20% difference in exposure for most covariates. Body weight and advanced renal impairment (severe renal impairment and ESRD without hemodialysis) showed PK changes beyond the empirically defined region of clinical importance (0.8 -1.25).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Justification of a non-weight Based Dosing for Clinical use in PMO Patients</head><p>The median and 90% prediction interval of the simulated serum concentration-time profile of romosozumab after 210 mg QM or 3 mg/kg SC QM is shown in <ref type="figure" target="#fig_6">Figure 6</ref> for PMO subjects with a body weight range from 33 to 98 kg. Source: Applicant's population PK report, <ref type="figure" target="#fig_0">Figure 13</ref>-31, Page 127.</p><p>In addition, <ref type="table" target="#tab_5">Table 3</ref> provides the mean and the standard deviation of the AUCss, Cmax, Tmax for the 1st and 12th dose stratified by low (1st quartile, &lt;50 kg), mid (2 nd and 3 rd quantile , 50 kg  weight  65 kg) and high (4 th quartile, &gt;65 kg) body weight, as well as the accumulation ratio. The fixed dosing regimen of 210 mg SC QM had approximately 27% and 28% increase in median AUCss and Cmax,ss in the 2 nd and 3 rd quantile of body weight compared to a weight-based regimen of 3 mg/kg SC QM. Compared to PMO subjects with body weight in the 2 nd and 3 rd quantile, a romosozumab fixed dose of 210 mg administered to PMO patients with body weight lower than 50 kg resulted in a 27% and 23% increase in median AUCss and Cmax,ss, respectively. Conversely, in PMO patients with body weight higher than 67 kg, a fixed dose of 210 mg resulted in a 19% and 21% lower median AUCss and Cmax,ss respectively, Additionally, 210 mg QM dosing does not result in a substantial increase in variability. The percent CV for low versus high body weight quartiles with 3 mg/kg dosing are 33.9 and 34.3, whereas that using fixed dosing (210 mg) are 38.5 and 39.1 respectively.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 3 Impact of Weight Based (3 mg/kg) or Fixed Dosing (210 mg) on Romosozumab Exposures in PMO Subjects</head><p>Source: Applicant's population PK report, <ref type="figure" target="#fig_0">Figure 12</ref>-16, Page 77.</p><p>To conclude, prior alendronate or PMO treatments, patient populations (eg, healthy/low-BMD, osteopenic, and osteoporotic), antibody status (eg, negative, binding vs. neutralizing), and baseline sclerostin had no significant association with romosozumab PK parameters. Therefore, these covariates had no impact on romosozumab exposures and no dose adjustments are proposed based on these factors. Body weight and renal function (as measured by eGFR) were significant covariates with increasing exposure predicted for decreasing body weight or eGFR. Considering the fixed dosing regimen was given to Phase 3 study with an acceptable safety profile, dose adjustment based on body weight or renal function is not warranted.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.2">Reviewer's comments:</head><p>The reviewer found the Applicant's population PK model structure for romosozumab reasonable. The applicant's population PK dataset included ESRD patients with hemodialysis from study 20110227 (the dedicated renal impairment study) When the reviewer reran the population PK analysis, these patients were removed for the following reasons.</p><p>1. Data from the dedicated renal impairment study showed that the exposure in severe renal impairment subjects was 44% higher than that in subject with normal renal function, whereas the exposure in ESRD subjects with hemodialysis was comparable to that in subjects with normal function ( <ref type="table" target="#tab_6">Table 4</ref>). The reason behind the scene is unknown as hemodialysis does hardly remove large molecules. In the dedicated renal impairment study, PK samples were intensively collected over 85 days after a single dose of 210 mg. When hemodialysis occurred on a day of sample collection, sample collections were performed before hemodialysis. The frequency of hemodialysis in ESRD patients was not specified. It appears that the impact of hemodialysis on PK of romosozumab is inconclusive. 2. On the other hand, the VPC plot ( <ref type="figure" target="#fig_2">Figure 3</ref>) from study 20110227 shows that the observations of severe renal impairment subjects were slightly under-predicted and observations of ESRD subjects with hemodialysis were slightly over-predicted. When reviewer reran the population PK analysis without the ESRD subjects, the parameter estimates were consistent with Applicant's results except that the power-law coefficient estimate of estimated glomerular filtration rate (eGFR) was changed from 0.189 to 0.219 1 .</p><p>One thing to mention, the eGFR values used in the Applicant's population PK model was calculated using the following equation:</p><p>= 186  ( ) -1.154  ( ) -0.203  0.742( )  1.212( )</p><p>The coefficient (186) was different from the value (175) used in the <ref type="bibr">Phase 3 dataset (adbase.xpt)</ref>. The coefficient of 175 is recommended in FDA guidance with regard to dedicated renal impairment study (http://www.fda.gov/downloads/Drugs/Guidances/UCM204959.pdf). However, the difference is not expected to result in significant change in population PK results. Thus, the reviewer used the dataset as provided by the Applicant.</p><p>Based on the reviewer's assessment, except bodyweight and renal function, other covariats , including gender, age, race (Japanese/non-Japanese), prior alendronate, and drug product manufacturing process do have not signifant impact on romosozumab exposure.</p><p>The impact of body weight and renal function were independently evaluated by the Reviewer using the updated population PK model. Summary values based on these covariates for the Phase 3 data are provided below in <ref type="table" target="#tab_7">Table 5</ref>. The reviewer is presenting information in this manner so that it is easier to compare exposures differ between patients with various degrees of renal impairment to exposures in patients with normal renal function. The exposures were comparable for normal, mild and moderate renal impairment patients. The exposure in severe renal impairment patients was imprecise due to the limited number of patients with severe renal impairment included in the Phase 3 trials. According the simulation, the exposure in severe renal impairment are expected to be 1.6-fold higher than that in normal renal function patients, respectively. Considering the fixed dosing regimen was given to Phase 3 study with an acceptable safety profile, no dose adjustment is needed for patients based on renal impairment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.6">Exposure-Response Analyses</head><p>In each subsection, the applicant's analysis is presented first and the reveiwer's comments and analysis follow.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.6.1">Dose-BMD analysis</head><p>The effect of romosozumab dose regimen on the time course of bone mineral density (BMD) change in postmenopausal women with osteoporosis was analyzed by the Applicant. Data from two <ref type="bibr">Phase 2 studies (20060326 and 20101291)</ref> one <ref type="bibr">Phase 3 study (20070337)</ref> were used in the romosozumab dose-BMD analysis. A summary of the study designs is provided in <ref type="table" target="#tab_92">Table 6</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 6 Summary of Clinical Studies</head><p>Source: Applicant's dose-BMD analysis report, Study 20060326: A total of 393 subjects with low BMD were randomized to placebo, teriparatide 20 g SC QD, alendronate 70 mg PO QW, or romosozumab 70 mg SC QM, 140 mg SC QM, 210 mg SC QM, 140 mg SC Q3M or 210 mg SC Q3M. After 12 months on study, subjects in the teriparatide cohort discontinued from the study and subjects in the alendronate cohort were transitioned to romosozumab 140 mg SC QM; subjects in the other cohorts continued receiving their original treatment for an additional 12 months. After 24 months, subjects were either followed for 3 more months (27 months on study), or transitioned to placebo or denosumab 60 mg SC Q6M for an additional 12 months. After 36 months, subjects were discontinued or transitioned to romosozumab 210 mg SC QM for an additional 12 months. BMD at lumbar spine and total hip were collected for up to 48 months.</p><p>Study 20101291: A total of 241 Japanese PMO subjects were randomized to placebo, 70 mg SC QM, 140 mg SC QM, or 210 mg SC QM romosozumab (n = 63 per cohort). BMD at lumbar spine and total hip data were collected for up to 12 months.</p><p>Study 20070337: A total of 7180 PMO subjects were randomized to receive placebo (n = 3591) or romosozumab 210 mg SC QM (n = 3589) for up to 12 months. After 12 months, all subjects were transitioned to denosumab 60 mg SC QM for an additional 12 months. BMD at lumbar spine and total hip were collected for up to 24 months. Only subjects with non-missing measurements of bone turnover markers at baseline (P1NP and sCTx-I) were included in the analysis as they were found to be significant covariates in the initial model based on the index dataset (n=142).</p><p>Summary statistics for continuous and categorical covariates are presented in <ref type="table" target="#tab_9">Table 7</ref>. A previously published time-varying dose-BMD model of postmenopausal osteoporosis treatments was modified to describe the percent change from baseline in BMD at lumbar spine and total hip after SC administration of monthly and quarterly romosozumab dosing schedules to postmenopausal women with osteoporosis. The model parameters for the final model are presented in <ref type="table" target="#tab_11">Table 8</ref>. Romosozumab maximal response was estimated to be 11.4% (95%CI: 10.5 to 12.2) for lumbar spine and 6.0% (95%CI: 5.1 to 6.7) for total hip. The time to achieve 50% of E max for romosozumab for the lumbar spine was estimated to be 5.4 months (bootstrap 95% prediction interval: 4.5 to 6.7), whereas that for total hip was 8.25 months (bootstrap 95% prediction interval: 6.1 to 10.9).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 8 Parameter Estimates for the Final Model</head><p>Source: Applicant's dose-BMD analysis report, <ref type="table" target="#tab_4">Table 12</ref>-10, Page 50.</p><p>Subjects who were on prior alendronate treatment had a slower rate of onset for romosozumab treatment effect (19.1 months at lumbar spine and 40 months at total hip). Subjects who were on prior denosumab treatment had a slower rate of onset for romosozumab treatment effect at lumbar spine (6.2 months) but showed no total hip gain when transitioned to romosozumab. The BMD gain during the romosozumab retreatment after off-treatment period were similar to that in nave subjects.</p><p>In the final model, the proportional effect for Japanese subjects on E max was estimated to be 1.23 (95%CI: 1.1 to 1.3) for the lumbar spine and 0.752 (95%CI: 0.581 to 0.917) for total hip. Study effect (Japanese study) and sCX on E max for lumbar spine and total hip, and body weight on E max for lumbar spine were identified as significant covariates in the final model. <ref type="figure" target="#fig_7">Figure 7</ref> show the goodness-of-fit plots for BMD lumbar spine and total hip, respectively, for the final model fit to the dataset. The observed versus predicted plots (upper panels) show random normal scatter around the identity line, indicating the absence of major systematic bias and the adequacy of the model to describe the data. In addition, conditional weighted residuals (middle panels) also show random normal scatter around a value of 0 over time and the range of predicted values with no specific pattern suggesting model misspecification.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 7 Goodness of Fit Plots for BMD at Lumbar Spine (Left) and Total Hip (Right) for the Final Model</head><p>Source: Applicant's dose-BMD analysis report, .</p><p>The internal evaluation of the final model using visual predictive check (VPC) demonstrated good predictability of the final model to describe the time course of the mean (and 95% confidence interval) BMD change from baseline at lumbar spine and total hip in each of the cohorts <ref type="figure" target="#fig_8">(Figure 8</ref> for study 20070337). The observed mean (95% CI) shown in points and error bars were within the corresponding simulation-based 95%CI shown in shaded areas, across all studies and cohorts.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 8 Visual Predictive Check for the Final Model Stratified by 20070337 Study Cohort</head><p>Source: Applicant's dose-BMD analysis report, <ref type="figure" target="#fig_0">Figure 13</ref>-23, Page 81.</p><p>To conclude, a dosing regimen of 210 mg SC QM provided the greatest and fastest BMD gain compared to the other dosing regimens evaluated with predicted mean placebo corrected BMD gains at lumbar spine and total hip at 12 months of 11.4% (95%CI: 10.5 to 12.2) and 6.0% (95%CI: 5.1 to 6.7), respectively.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer's comments:</head><p>The reviewer reviewed the dose-BMD model. The dose-response model can well describe the observations under different dosing regimens and switch between on-treatment and off-treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.6.2">Exposure-BMD analysis</head><p>The effect of romosozumab concentrations on the time course of BMD changes in postmenopausal women with osteoporosis was analyzed by the Applicant. The studies included in this PK/PD analysis are:</p><p>Protocol 20060326: A multi-center, international, randomized, placebo-controlled, parallel group study in approximately 400 postmenopausal women with low BMD at the lumbar spine, total hip or femoral neck. The study consisted of three phases: 1) 24-month romosozumab treatment phase (day 1 to Month 24); 2) 12-month denosumab/placebo phase (Month 24 to month 36); 3) 12-month romosozumab retreatment phase (month 36 to month 48).</p><p>Protocol 20101291: A multi-center, randomized, double-blind, placebo-controlled, parallel-group study in Japanese women with osteoporosis defined as low BMD at the lumbar spine, total hip or femoral neck. Approximately 220 subjects were to be randomized 1:1:1:1 to receive either70 mg, 140 mg or 210 mg romosozumab SC QM or matched placebo SC QM for the duration of the 12-month treatment period.</p><p>Patient demographics at screening are summarized in <ref type="table" target="#tab_13">Table 9</ref> and <ref type="table" target="#tab_16">Table 10</ref>. The study population consisted of 522 females with ages ranging from 55.3 to 84.8 years, PMO ranging from 1 to 45 years, and weights ranging from 32.5 to 95.9 kg. There were 301 non-Japanese and 251 Japanese subjects, and all but one Japanese subject was enrolled in study 1291.  Initial modeling was performed using the mechanistic PK/PD model developed to describe the ontreatment PD efficacy (BMD) effects of romosozumab using the 24-month initial treatment phase Study 60326 and 12-month Study 1291 data. Individual romosozumab PK parameter estimates for PK/PD modeling were derived in population PK analysis (section 4.5). The effects of study (1291 vs. 60326) on baseline BMD were included in the base model. The base model also included an effect of DXA (hologic vs. lunar) machine type on baseline BMD.</p><p>In the final model, the body weight and PMO were added to the population PK/PD model. Diagnostic plots revealed that the model was consistent with the observed data and little systematic bias was evident ( <ref type="figure" target="#fig_38">Figure 9</ref>). The VPC results revealed that the full model for two-year efficacy provided a reliable description of the data with adequate precision of structural model and variance parameter estimates ( <ref type="figure" target="#fig_0">Figure 10</ref>). Parameter estimates are listed in <ref type="table" target="#tab_87">Table 11</ref>. The population mean estimate for logit(Ima x ) was -0.812 (67.0%), corresponding to an I max value of 0.307. Estimates for IC 50 and SC 50 were 70.4 ng/mL and 22,600 ng/mL. Differences in baseline BMD for study 1291 subjects (approximately 15% lower) and lunar machine measurements (15% higher) were identified.   Once a suitable population PK/PD model was developed, an extension to the base model was developed to describe the on-treatment, off-treatment and re-treatment PD efficacy (BMD) effects of romosozumab using only Study 60326 data that included the off-treatment (nominal months 24-36) and romosozumab re-treatment. Additional model development was driven by deviances between the model-predicted and observed markers for the off-treatment and re-treatment periods. The final model was updated by adding a rebound and rebound precursor pool with the precursor affecting the resorption cavity input. VPC results for the re-treatment model are presented in <ref type="figure" target="#fig_0">Figure 11</ref>. These VPC plots were stratified by the romosozumab dose regimen that was administered prior to the offtreatment period. Results were presented for the entire study period (0-48 months), the off-treatment phase only (24-36 months), and the re-treatment phase only (36-48 months).</p><p>To conclude, the two-year efficacy of romosozumab was described by exposure-BMD model. The model provides a reasonable representation of the effects of romosozumab on BMD.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer's comments:</head><p>The reviewer reviewed the exposure-BMD analysis conducted by Applicant and the results show that the data can be reasonably characterized by the PK/PD model.</p><p>The reviewer conducted an independent analysis for BMD percentage change from baseline (%CFB) and new vertebral facture separated by body weight and renal function. The information was summarized at 12 and 24 month from Phase 3 studies and listed in <ref type="table" target="#tab_4">Table 12 and Table 13</ref>.   <ref type="figure">----------------------------------------------------------------------------------------------------</ref> </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc>Cross-section showing microscopic structure of the aorta ........................................... 47 Figure 2: Diagram of typical sclerostin location in human atherosclerotic plaques .................... 48 Figure 3 Serum Romosozumab Concentrations in Subjects Who Experienced MACE and Had PK Data Available in Studies 20070337, 20110142 and 20110174 ................................................... 59 Figure 4: Study 20110142 Schema................................................................................................ 63 Figure 5 Lumbar Spine BMD Percent Change from Baseline (Study 326 Months 0-36) ............ 102 Figure 6 Annual Incidence of MACE in Study 20110142 (DCRI Adjudication of Study 20110142) ..................................................................................................................................................... 142 Figure 7: Subgroup Analysis by Modified RUTH Score: Subject Incidence of MACE in the Doubleblind Period (DCRI Adjudication of Studies 20070337, 20110142, and 20110174) ................... 144 Figure 8: Lumbar Spine BMD Percent Change from Baseline (Study 326 Months 0-36) .......... 154 Figure 9: Effect of Covariates on Romosozumab PK: Steady-state AUC and Cmax ................... 176 Figure 10. Study 20110142 Subject Incidence of New Vertebral Fracture Through Month 24 by Demographic and Physical Characteristic Subgroups (Primary Analysis Set for Vertebral Fractures, LOCF Imputation) ....................................................................................................... 177 Figure 11. Study 20110142 Subject Incidence of New Vertebral Fracture Through Month 24 by Risk Factor Subgroups (Primary Analysis Set for Vertebral Fractures, LOCF Imputation) ......... 177 Figure 12. Study 20110142-Subject Incidence of New Vertebral Fracture Through Month 24 by Fracture History Subgroups (Primary Analysis Set for Vertebral Fractures, LOCF Imputation) . 178 Figure 13. Study 20110142-Subject Incidence of Clinical Fracture Through Primary Analysis Period by Demographic and Physical Characteristic Subgroups (Full Analysis Set) ................... 178 Figure 14. Study 20110142-Subject Incidence of Clinical Fracture Through Primary Analysis Period by Risk Factor Subgroups (Full Analysis Set) ................................................................... 179 Figure 15. Study 20110142-Subject Incidence of Clinical Fracture Through Primary Analysis Period by Fracture History Subgroups (Full Analysis Set) ........................................................... 179 Figure 16. Study 20110142-Subject Incidence of Nonvertebral Fracture Through Primary Analysis by Risk Factor Subgroups (Full Analysis Set) ................................................................. 180 Figure 17. Study 20110142-Subject Incidence of Nonvertebral Fracture Through Primary Analysis Period by Demographic and Physical Characteristic Subgroups (Full Analysis Set) ..... 180 Figure 18. Study 20110142-Subject Incidence of Nonvertebral Fracture Through Primary Analysis Period by Fracture History Subgroups (Full Analysis Set) ............................................. 181 Figure 19. Study 20110142 -Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 by Subgroups (Primary Analysis Set for BMD) ....................................................... 181 Figure 20. Study 20110142 -Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24 by Subgroups (Primary Analysis Set for BMD) ....................................................... 182 Figure 21. Study 20110142 -Total Hip Bone Mineral Density Percent Change From Baseline at Month 12 by Subgroups (Primary Analysis Set for BMD) ........................................................... 182 Figure 22. Study 20110142 -Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 by Subgroups (Primary Analysis Set for BMD) ....................................................... 183 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 1 2</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 :Figure 2 :</head><label>12</label><figDesc>Cross-section showing microscopic structure of the aorta NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 48 Diagram of typical sclerostin location in human atherosclerotic plaques</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3</head><label>3</label><figDesc>Serum Romosozumab Concentrations in Subjects Who Experienced MACE and Had PK Data Available in Studies 20070337, 20110142 and 20110174 Source of data: FDA Reviewer's analysis and plot based on clinical study report for Study 20070337, 20110142, 20100174 and the comprehensive cardiovascular report. d, cardiovascular-</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 :</head><label>4</label><figDesc>Study 20110142 Schema Source: Figure 8-1 of CSR</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure</head><label></label><figDesc>in Appendix 14.4).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 5</head><label>5</label><figDesc>Lumbar Spine BMD Percent Change from Baseline (Study 326 Months 0-36) *Source: modified from Figure 10-11 of Study 326 Clinical Study Report</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>NDAFigure 6</head><label>6</label><figDesc>Annual Incidence of MACE in Study 20110142 (DCRI Adjudication of Study 20110142) *Source: Figure 6 of CCR Subgroup Analyses</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 7</head><label>7</label><figDesc>Subgroup Analysis by Modified RUTH Score: Subject Incidence of MACE in the Double-blind Period (DCRI Adjudication of Studies 20070337, 20110142, and 20110174) *Source:</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>Figure 8</head><label>8</label><figDesc>Lumbar Spine BMD Percent Change from Baseline (Study 326 Months 0-36) *Source: modified from Figure 10-11 of Study 326 Clinical Study Report</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head></head><label></label><figDesc>investigators identified: 270 Number of investigators who are Sponsor employees (including both full-time and part-time employees): 0 Number of investigators with disclosable financial interests/arrangements (Form FDA 3455): 10 If there are investigators with disclosable financial interests/arrangements, identify the number of investigators with interests/arrangements in each category (as defined in 21 CFR 54.2(a), (b), (c) and (f)):</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head>Figure 9 :Figure 10 .</head><label>910</label><figDesc>Effect of Covariates on Romosozumab PK: Steady-state AUC and CmaxOriginal Model Updated Models AUCss Cmax Source of data:Figure 2-1 in population PK report 119384A (left column) andFigure 16in population PK report 119384A-Addendum 1 (right column). Note that estimates of covariates are almost identical between Addendum 1 and Addendum 3.NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {EvenityStudy 20110142 Subject Incidence of New Vertebral Fracture Through Month 24 by Demographic and Physical Characteristic Subgroups (Primary Analysis Set for Vertebral Fractures, LOCF Imputation) N = Number of subjects randomized; N1 = Number of subjects in the primary analysis set for vertebral fractures Relative risk reduction -Haenszel method adjusted for age strata, baseline total hip BMD T--2.5, &gt; -2.5), and presence of severe vertebral fracture at baseline Source: Figure 2 in rtq-12oct2018.pdf, submitted on 10/19/2018, eseq0061</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_11"><head>Figure 11 .Figure 12 .</head><label>1112</label><figDesc>Study 20110142 Subject Incidence of New Vertebral Fracture Through Month 24 by Risk Factor Subgroups (Primary Analysis Set for Vertebral Fractures, LOCF Imputation) N = Number of subjects randomized; N1 = Number of subjects in the primary analysis set for vertebral fractures -Haenszel method adjusted for age strata, baseline total hip BMD T--2.5, &gt; -2.5), and presence of severe vertebral fracture at baseline Source: Figure 1 in rtq-12oct2018.pdf, submitted on 10/19/2018, eseq0061 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 178 Study 20110142-Subject Incidence of New Vertebral Fracture Through Month 24 by Fracture History Subgroups (Primary Analysis Set for Vertebral Fractures, LOCF Imputation) N = Number of subjects randomized; N1 = Number of subjects in the primary analysis set for vertebral fractures-Haenszel method adjusted for age strata, baseline total hip BMD T-score -2.5, &gt; -2.5), and presence of severe vertebral fracture at baseline Source:Figure 3in rtq-12oct2018.pdf, submitted on10/19/2018, eseq0061    </figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_12"><head>Figure 13 .Figure 14 .</head><label>1314</label><figDesc>Study 20110142-Subject Incidence of Clinical Fracture Through Primary Analysis Period by Demographic and Physical Characteristic Subgroups (Full Analysis Set) N/N1 = Number of subjects randomized BMD T-score, and presence of severe vertebral fracture at baseline. Source: Figure 5 in rtq-12oct2018.pdf, submitted on 10/19/2018, eseq0061 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 179 Study 20110142-Subject Incidence of Clinical Fracture Through Primary Analysis Period by Risk Factor Subgroups (Full Analysis Set) N/N1 = Number of subjects randomized BMD T-score, and presence of severe vertebral fracture at baseline. Source: Figure 4 in rtq-12oct2018.pdf, submitted on 10/19/2018, eseq0061</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_13"><head>Figure 15 .Figure 16 .</head><label>1516</label><figDesc>Study 20110142-Subject Incidence of Clinical Fracture Through Primary Analysis Period by Fracture History Subgroups (Full Analysis Set) N/N1 = Number of subjects randomized Relative risk BMD T-score, and presence of severe vertebral fracture at baseline. Source: Figure 6 in rtq-12oct2018.pdf, submitted on 10/19/2018, eseq0061 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 180 Study 20110142-Subject Incidence of Nonvertebral Fracture Through Primary Analysis by Risk Factor Subgroups (Full Analysis Set) N/N1 = Number of subjects randomized model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Source: Figure 7 in rtq-12oct2018.pdf, submitted on 10/19/2018, eseq0061</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_14"><head>Figure 17 .Figure 18 .</head><label>1718</label><figDesc>Study 20110142-Subject Incidence of Nonvertebral Fracture Through Primary Analysis Period by Demographic and Physical Characteristic Subgroups (Full Analysis Set) N/N1 = Number of subjects randomized strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline. Source: Figure 8 in rtq-12oct2018.pdf, submitted on 10/19/2018, eseq0061 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 181 Study 20110142-Subject Incidence of Nonvertebral Fracture Through Primary Analysis Period by Fracture History Subgroups (Full Analysis Set) N/N1 = Number of subjects randomizedBMD T-score, and presence of severe vertebral fracture at baseline. Source:Figure 9in rtq-12oct2018.pdf, submitted on10/19/2018, eseq0061    </figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_15"><head>Figure 19 .Figure 20 .</head><label>1920</label><figDesc>Study 20110142 -Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 by Subgroups (Primary Analysis Set for BMD) N = Number of subjects with values at baseline and at least one post-baseline visit at or before month 12; n = Number of subjects with non-missing data Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction; Mean= LS Mean; Missing values are imputed by carrying forward the last non-missing post-baseline value. Source: Figure 10 in rtq-12oct2018.pdf, submitted on 10/19/2018, eseq0061 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 182 Study 20110142 -Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24 by Subgroups (Primary Analysis Set for BMD) N = Number of subjects with values at baseline and at least one post-baseline visit at or before month 24; n = Number of subjects with non-missing data Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction; Mean= LS Mean; Missing values are imputed by carrying forward the last non-missing post-baseline value. Source: Figure 10 in rtq-12oct2018.pdf, submitted on 10/19/2018, eseq0061</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_16"><head>Figure 21 .Figure 22 .</head><label>2122</label><figDesc>Study 20110142 -Total Hip Bone Mineral Density Percent Change From Baseline at Month 12 by Subgroups (Primary Analysis Set for BMD) N = Number of subjects with values at baseline and at least one post-baseline visit at or before month 12; n = Number of subjects with non-missing data Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction; Mean= LS Mean; Missing values are imputed by carrying forward the last non-missing post-baseline value. Source: Figure 12 in rtq-12oct2018.pdf, submitted on 10/19/2018, eseq0061 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 183 Study 20110142 -Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 by Subgroups (Primary Analysis Set for BMD) N = Number of subjects with values at baseline and at least one post-baseline visit at or before month 24; n = Number of subjects with non-missing data Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction; Mean= LS Mean; Missing values are imputed by carrying forward the last non-missing post-baseline value.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_17"><head>Figure 1 :</head><label>1</label><figDesc>Overview of DCRI and TIMI Adjudication Processes of Cardiovascular Adverse Events in studies 20070337, 20110142, and 20110174Source: Comprehensive Cardiovascular Report (figure 22)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_18"><head>Figure 2 :</head><label>2</label><figDesc>Incidence of coronary and cerebrovascular events during the Multiple Outcomes of Raloxifene Evaluation (MORE) trialSource:<ref type="bibr" target="#b27">Keech, 2005</ref> </figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_19"><head>Figure 6 :Figure 7 :</head><label>67</label><figDesc>Hazard Ratio of Positively Adjudicated Cardiovascular Adverse Events leading to Death, Myocardial Infarction, or Stroke based on DCRI, DCRI-matched TIMI, and Full TIMI through Month 12: study 20110142 Source: Comprehensive Cardiovascular Report (Figure 14-6.16.1.2) Hazard Ratio of Positively Adjudicated Cardiovascular Adverse Events leading to Death, Myocardial Infarction, or Stroke based on DCRI, DCRI-matched TIMI, and Full TIMI through Month 12: study 20070337 Source: Comprehensive Cardiovascular Report (Figure 14-6.16.1.3)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_20"><head>Figure 11 Figure 12 :Figure 13 Figure 15 :FigureFigure 21 :Figure 22 :FigureFigure 27 :FigureFigure 33 :Figure 34 :FigureFigure 38 :</head><label>11121315212227333438</label><figDesc>TIMI Adjudication: Time to First Occurrence of Positively Adjudicated Cardiovascular Adverse Events Leading to Death, Myocardial Infarction, or Stroke through Month 12 Source: Comprehensive Cardiovascular Report (Figure 14-6.1.1.2 page 3511) DCRI Adjudication: Time to First Occurrence of Positively Adjudicated Cardiovascular Adverse Events Leading to Death, Myocardial Infarction, or Stroke through Month 12 by Modified RUTH Score Subgroup Source: Comprehensive Cardiovascular Report (Figure 14-6.4.1.1) DCRI Adjudication: Time to First Occurrence of Positively Adjudicated Cardiovascular Adverse Event leading to Death for Overall Study Period Source: Comprehensive Cardiovascular Report (Figure 14-6.1.2.3) TIMI Adjudication: Time to First Occurrence of Positively Adjudicated Cardiovascular Adverse Event leading to Death for Overall Study Period Source: Comprehensive Cardiovascular Report (Figure 14-6.1.2.4) DCRI Adjudication: Time to First Occurrence of Positively Adjudicated Cerebrovascular Serious Adverse Event through Month 12 Source: Comprehensive Cardiovascular Report (Figure 14-6.1.5.1) DCRI Adjudication: Time to First Occurrence of Positively Adjudicated Serious Stroke for Overall Study Period Source: Comprehensive Cardiovascular Report (Figure 14-6.1.4.3) TIMI Adjudication: Time to First Occurrence of Positively Adjudicated Stroke for Overall Study Period Source: Comprehensive Cardiovascular Report (Figure 14-6.1.4.4) TIMI Adjudication: TIMI Adjudication: Time to First Occurrence of Positively Adjudicated Cardiac Ischemic Adverse Event for Overall Study Period Source: Comprehensive Cardiovascular Report (Figure 14-6.1.6.4)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_21"><head>Figure 10 - 8 .</head><label>108</label><figDesc>Least Square Means (95% CI) of Percent Change From Baseline in DXA Lumbar Spine BMD (source: CSR 20060326, page 220)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_22"><head>Figure 10 -</head><label>10</label><figDesc>11. Lumbar Spine BMD Percent Change From Baseline by VisitSource: CSR 20060326Figure 10-11, page 225    </figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_23"><head>Figure 10 -</head><label>10</label><figDesc>14. DXA Lumbar Spine BMD Percent Change From Baseline by VisitSource: CSR 20060326 Figure 10-14, page 234</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_24"><head></head><label></label><figDesc>Source: CSR 20070337, page 5658 Reference ID: 4123729 Cross Discipline Team Leader Review 39</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_25"><head>Site 1 -</head><label>1</label><figDesc>52SFOU, Magda Dabrowska, M.D., Poland: This site had high enrollment</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_26"><head>Figure 1 :</head><label>1</label><figDesc>Relative Risk of Subsequent Fractures in Women Ages 50-80 with Clinical Fracture ... 23 Figure 2: Graphic Representation of Mechanism of Action for Romosozumab ........................... 30 Figure 3: Pre-specified Fixed-Sequence Fracture Endpoint Testing Procedure ........................... 41 Figure 4: P1NP Percent Changes from Baseline by Study Visit ..................................................... 60 Figure 5: sCTX Percent Changes from Baseline by Study Visit. ..................................................... 61 Figure 6: BMD Percent Change from Baseline by Visit for Lumbar Spine, Total Hip, and Femoral Neck. ............................................................................................................................................. 62 Figure 7 Study 20070326 Study Design Schematic of the Study .................................................. 69 Figure 8: Lumbar Spine Percent Change from Baseline (95% CI) by DEXA scan up to Month 24 79 Figure 9: Total Hip Spine Percent Change from Baseline (95% CI) by DEXA scan up to Month 24 ....................................................................................................................................................... 79 Figure 10: Femoral Neck Percent Change from Baseline (95% CI) by DEXA scan up to Month 24 ....................................................................................................................................................... 80 Figure 11: Sponsor's Simulated BMD Placebo-corrected Percent Change at Lumbar Spine and Total Hip as Function of Romosozumab Dose. ............................................................................. 97 Figure 12: BMD Percent Changes at Lumbar Spine with Romosozumab Retreatment in Patients Transitioning from Placebo or Denosumab. ............................................................................... 101 Figure 13: Endocortical Eroded Surface Figure 14: Cancellous Eroded Surface Bone Substudy Analysis Set 119 Figure 15: Endocortical Bone Formation Rate Figure 16: Cancellous Bone Formation Rate (Bone Biopsy Substudy Analysis Set) .......................................................................................... 120 Figure 17: Percent Change from Baseline in Calcium Corrected by Albumin ............................ 126 Figure 18: Intact Parathyroid Hormone Percent Change From Baseline by Visit iPTH substudy130 Figure 19: Mean Intact Parathyroid Hormone (iPTH) by Time CRF study 20110227 ................. 131</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_27"><head>Figure 1 :</head><label>1</label><figDesc>Relative Risk of Subsequent Fractures in Women Ages 50-80 with Clinical Fracture</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_29"><head>Figure 3 :</head><label>3</label><figDesc>Pre-specified Fixed-Sequence Fracture Endpoint Testing Procedure Source: CSR 20070337 Stat Analysis Plan with reviewer edits</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_30"><head></head><label></label><figDesc>amended with respect to prior administration of osteoporosis medications, medical history of sclerosteosis, possible diagnosis of multiple myeloma or related lymphoproliferative disorder, known to have HIV, hepatitis C virus or hepatitis-B infection or reported history or hearing loss due to excessive bone growth. Removed exclusion criteria of androgen deprivation therapy as it was not applicable to</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_31"><head>Figure 4 :</head><label>4</label><figDesc>P1NP Percent Changes from Baseline by Study Visit Source: CSR 20070337 figure 10-3 with reviewer edits</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_32"><head>Figure 5 :</head><label>5</label><figDesc>sCTX Percent Changes from Baseline by Study Visit. Source: CSR 20070337 Figure 10-4 with reviewer edits.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_33"><head>Figure 6 :</head><label>6</label><figDesc>BMD Percent Change from Baseline by Visit for Lumbar Spine, Total Hip, 20070337 Figure 10-2 with reviewer edits.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_34"><head>Figure 7</head><label>7</label><figDesc>Study 20070326 Study Design Schematic of the Study Source: From CSR20060326 Figure 10-2 with reviewer edits.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_35"><head>Sample Size :</head><label>:</label><figDesc>Approximately 400 subjects Summary of Subject Eligibility Criteria: Key Inclusion Criteria for the 24-month AMG 785 treatment phase (study day 1 to month 24):  Ambulatory, postmenopausal women, aged  55 to  85  Low BMD measured by Dual energy X-ray Absorptiometry (DXA) and assessed by the central imaging vendor (see eligible BMD values below). Eligible BMD values: Lunar (g/cm2) or Hologic (g/cm2) 618 and  0.438 a Values correspond to T-scores between -2.0 and -3.5 as determined by the manufacturer b Values correspond to T-scores between -2.0 and -3.5 Based on data for Caucasian women from the National Health and Nutritional Examination (NHANES) 1998</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_36"><head></head><label></label><figDesc> 70 mg subcutaneous (SC) administration every month (QM)  140 mg SC administration QM  210 mg SC administration QM  140 mg SC administration every 3 months (Q3M)  210 mg SC administration Q3M</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_37"><head>Figure 8 :</head><label>8</label><figDesc>Lumbar Spine Percent Change from Baseline (95% CI) by DEXA scan up to Month 24 ALN = alendronate; AMG 785 = romosozumab; BL = baseline; Source: CSR20060326 Figure 10-8 with reviewer edits.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_38"><head>Figure 9 :</head><label>9</label><figDesc>Total Hip Spine Percent Change from Baseline (95% CI) by DEXA scan up to Month 24 ALN = alendronate; AMG 785 = romosozumab; BL = baseline;</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_39"><head>Figure 10 :</head><label>10</label><figDesc>Femoral Neck Percent Change from Baseline (95% CI) by DEXA scan up to Month 24 ALN = alendronate; AMG 785 = romosozumab; BL = baseline;</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_40"><head></head><label></label><figDesc> The percent change from baseline at Month 6 in BMD at the lumbar spine  The percent change from baseline at Month 6 and Month 12 in BMD at the total hip and femoral neck  The percent change from baseline at Day 1 plus 1 week, Month 1, Month 2, Month 3, Month 6, Month 9, and Month 12 in bone turnover markers (BTMs)  Area under the curve (AUC) through Month 12 for P1NP</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_41"><head></head><label></label><figDesc>Despite a general trend toward baseline, transient responses in markers of bone turnover still occurred 14 days post romosozumab dose at months 3 and 6 in Study 20070337. This same pattern was observed at the same time points in Study 20080289 and 1 week post the 12 month dose in Study 20060326. Thus across the 3 studies, BTMs responded to each romosozumab administration with transient increases over the 12 month treatment period.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_42"><head>Figure 11 :</head><label>11</label><figDesc>Sponsor's Simulated BMD Placebo-corrected Percent Change at Lumbar Spine and Total Hip as Function of Romosozumab Dose.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_43"><head>Figure 12</head><label>12</label><figDesc>20060326 Figure 10-14 with reviewer edits.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_44"><head></head><label></label><figDesc>This safety review focuses on data from 8274 postmenopausal women in the phase 2 and phase 3 studies including 7157 subjects with osteoporosis in the pivotal study (Study 20070337), 218 subjects with osteoporosis who were transitioning from bisphosphonate therapy (Study 20080289), 353 subjects with low bone mass (Study 20060326), 252 Japanese subjects with osteoporosis in a dedicated study in Japan (Study 20101291), and 294 subjects with osteoporosis enrolled in a non-inferiority study (Study 20120156).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_45"><head>phase 2 ,</head><label>2</label><figDesc>dose-finding Study 20060326 (up to year 6)  Safety with long-term safety follow-up from the pivotal phase 3 study for the PMO indication (Study 20070337, 24-month data)  Safety after transition to romosozumab from prior bisphosphonate therapy (Studies 20080289 and 20060223)  Safety of the 90 mg/mL concentration (proposed for commercial use) compared with a 70 mg/mL concentration (used in other phase 3 studies) in Study 20120156  Device-related safety Reviewer Comment: Inclusion of these key data evaluations from individual studies are reasonable and appropriate.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_46"><head></head><label></label><figDesc>month placebo-controlled population. 4) Serum calcium changes: actual value (albumin-adjusted, in mg/dL and mmol/L), change from baseline, percentage change from baseline, and maximum decrease of CTCAE  1 grade shift from baseline using the 12-month placebo-controlled population and PMO population.5) Calcium substudy (Study 20070337) for hypocalcemia associated with the first romosozumab 210 mg dose along with daily calcium and vitamin D supplementation. 6) Intact parathyroid hormone (iPTH) and urinary calcium substudy (Study 20070337) to characterize serum iPTH concentration and urinary calcium excretion through month 12. 7) Phosphorus and magnesium changes: from baseline and percentage change from baseline across studies using the 12-month placebo-controlled population. 8) Fasting glucose (Study 20070337, 24-month data) changes: with fasting defined as sample collected within 60 minutes of a laboratory blood draw for bone turnover markers. 9) Potential Hy's Law cases as well as serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) &gt; 3 x upper limit of normal (ULN), &gt; 5 x ULN, &gt; 10 x ULN, and &gt; 20 x ULN using the 12-month placebo-controlled population and PMO population. 10) Immunogenicity (formation of anti-romosozumab antibodies):</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_47"><head>2 )</head><label>2</label><figDesc>Audiology substudy (Study 20070337) results on hearing loss 3) Excessive BMD gains: BMD analyses to assess the possibility of excessive BMD gains at lumbar spine, total hip, and femoral neck using the 12-month placebo-controlled population and shift from baseline to the maximum post-baseline (up to month 12) of BMD T-scores.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_48"><head>4 )</head><label>4</label><figDesc>Bone histology for new bone and bone quality inStudies 20070337, 20060326, and  20080289  5)  Osteoarthritis substudy(Study 20070337)  to assess the effect of romosozumab compared with placebo at month 12 on the progression of osteoarthritis of the knee. 6) Lean body mass changes: percentage changes from baseline at months6, 12, 18, and  24  in Imaging substudy subjects (Study 20070337)Reviewer Comment: The above categories of vital signs and other observations are reasonable and appropriate given the molecular mechanism and preclinical study results. 0.7% of subjects) in 7384 unique subjects in the 12-month placebo-controlled population were reported.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_49"><head>Figure 13 :</head><label>13</label><figDesc>Endocortical Eroded Surface Figure 14: Cancellous Eroded Surface Bone Substudy Analysis Set</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_50"><head>Figure 15 :</head><label>15</label><figDesc>Endocortical Bone Formation Rate Figure 16: Cancellous Bone Formation Rate (Bone Biopsy Substudy Analysis Set)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_51"><head>Figure 17 :</head><label>17</label><figDesc>Percent Change from Baseline in Calcium Corrected by Albumin Source: 20070337 CSR Figure 14-7.5 with reviewer edits Study 20070337 included a calcium substudy which characterized hypocalcemia (defined as albumin-corrected serum calcium level &lt; 7.5 mg/dL) with the first 210 mg dose of</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_52"><head>Figure 18 :</head><label>18</label><figDesc>Intact Parathyroid Hormone Percent Change From Baseline by Visit iPTH substudySource:Figure 14b-7.1 with reviewer edits.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_53"><head></head><label></label><figDesc>AST: romosozumab 3 subjects [&lt; 0.1%], placebo 6 [0.2%]; ALT: 2 [&lt; 0.1%], 10 [0.3%]). The subject incidence of elevated baseline AST &gt; 5 x ULN was lower in the romosozumab group than the placebo group, and elevated baseline ALT &gt; 5 x ULN was similar between groups (AST: 0 [0.0%], 1 [&lt;0.1%]; ALT: 1 [&lt;0.1%], 2 [&lt;0.1%]). No subject in either group had elevated baseline transaminases &gt; 10 x ULN or &gt; 20 x ULN. During Study: The subject incidence of on-study elevation of AST and ALT &gt; 3 x ULN and &gt; 5 x ULN was lower in the romosozumab group than the placebo group (AST &gt; 3 x ULN: romosozumab 15 subjects [0.3%], placebo 29 subjects [0.8%]; AST &gt; 5 x ULN: 3 [&lt; 0.1%], 6 [0.2%]; ALT &gt; 3 x ULN: 23 [0.5%], 31 [0.9%]; ALT &gt; 5 x ULN: 6 [0.1%], 11 [0.3%]). On-study elevations of AST &gt; 10 x ULN were similar between treatment groups (both 2 subjects [&lt; 0.1%]), while on-study elevation of ALT &gt; 10 x ULN were lower in the romosozumab group than the placebo group (2 [&lt;0.1%], 4 [0.1%]). No subject in the romosozumab group and 1 subject in the placebo group had an on-study elevation of AST or ALT &gt; 20 x ULN.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_54"><head></head><label></label><figDesc> for initial rollout (NME/original BLA reviews) Diez-Perez A, Hooven FH, Adachi JD, et al.Regional  differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011; 49:493-498. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004; 19:745-751. Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013; 8:136 Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001; 285(3):320-323. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008; 93(10):3785-3793. National Osteoporosis Foundation (NOF) Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation. 2014. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008 Oct; 23(10):1591-1600. Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General. Public Health Service, U.S. Department of Health and Human Services, Washington, DC, 2004. Sarpong EM. The impact of obesity on medication use and expenditures among nonelderly adults with asthma. J Health Care Poor Underserved. 2014; 25:1245-1261. van Geel TA, van Helden S, Geusens PP, et al. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009; 68:99-102. van Helden S, Cals J, Kessels F, et al. Risk of new clinical fractures within 2 years following a fracture. Osteoporos Int 2006; 17:348-354.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_55"><head></head><label></label><figDesc>Use of multiple clinical sites  Clinical site monitoring  Clinical site audits  Independent and centralized assessment of efficacy response data Covered Clinical Study (Name and/or Number): 20070337 Was a list of clinical investigators provided:  Yes No (Request list from Applicant) Total number of investigators identified: 222 centers Number of investigators who are Sponsor employees (including both full-time and part-time employees): 0 Number of investigators with disclosable financial interests/arrangements (Form FDA 3455): 5</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_56"><head></head><label></label><figDesc>study period followed by the 12-month open-label denosumab follow-up study period)  Percent change from baseline in radius (1/3, ultradistal and total) DXA BMD at Month 18 and Month 24  Percent change from baseline in total body (without head) DXA BMD at Month 18 and Month 24  Percent change from baseline in ultimate load at the distal radius and the distal tibia as measured by FEA from HR-pQCT scans at Month 18 and Month 24  Percent change from baseline in HR-pQCT parameters (eg, bone volume/total volume, total volumetric BMD, cortical volumetric BMD, trabecular volumetric BMD, cortical thickness, trabecular thickness, and trabecular separation) at the distal radius and the distal tibia at Month 18 and Month 24</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_57"><head></head><label></label><figDesc>During the 12-month double-blind placebo-controlled study period  Percent change from baseline in serum iPTH at Month 6 and Month 12  Change from baseline in serum iPTH at Month 6 and Month 12  Percent change from baseline in estimated 24 hour urinary calcium excretion at Month 6 and Month 12  Change from baseline in estimated 24 hour urinary calcium excretion at Month 6 and Month 12 These results are discussed in section 8.3.8 for serum iPTH levels and urinary calcium.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_58"><head></head><label></label><figDesc>......................................................................................18 4.2 PRIMARY PHARMACOLOGY ..................................................................................20 4.3 OTHER PHARMACOLOGY .....................................................................................42 4.4 SAFETY PHARMACOLOGY ....................................................................................48 5 PHARMACOKINETICS/ADME/TOXICOKINETICS...</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_59"><head></head><label></label><figDesc>Process 2 drug products (Study 113155). The review was filed in DARRTS for BLA 761062 (SD1) on March 2, 2017. Dr. Eric Andreased reviewed the 1-month and 6-month rat and monkey toxicity studies and the definitive embryofetal development study, submitted to AMG785 IND 100377. The review was filed in DARRTS for IND 103077 (SD4) for AMG785-IND 103077 on June 18, 2009. Dr. Miyun Tsai-Turton reviewed the final report of the rat carcinogenicity study report (Study 107895). The results were discussed with the Executive Carcinogenicity Assessment Committee (ECAC) on February 14, 2017. The study review was filed in DARRTS for BLA 761062 (SD1) on March 27, 2017. The statistical review of the carcinogenicity study data was conducted by Dr. Hepei Chen and Dr. Feng Zhou (Division of Biometrics VI) and the review was filed in DARRTS for BLA 761062 (SD1) on March 24, 2017. The Meeting Minutes of the February 14, 2017, ECAC meeting were filed in DARRTS for BLA 761062 by Dr. Leuenroth-Quinn on February 17, 2017. The Minutes are attached to this review (APPENDIX 2). Dr. Laurie McLeod-Flynn reviewed the reports of the rat embryofetal development study (EFD Study 108057) and the rat fertility and early embryonic development study (FEED Study 108061). The review was filed in DARRTS for BLA 761062 (SD1) on March 29, 2017. Dr. Miyun Tsai-Turton reviewed the report of the rat pre-and postnatal development study (PPND Study 108062). The review was filed in DARRTS for BLA 761062 (SD1) on March 27, 2017. Information request were sent to Sponsor on February 15, February 21, March 6 and March 10, 2017. The responses submitted by Sponsor to the BLA resolved the issues.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_60"><head></head><label></label><figDesc>Histomorphometry to determine "tissue level mechanisms" responsible for AMG785-induced bone formation (Ominsky et al 2014): o Marked increase in extent of MBF on trabecular and endocortical surfaces by AMG. o No significant effect on extent of RBF despite decreased eroded surface (ES/BS and ES/OS) on trabecular and endocortical surfaces; this was explained by likely increase in formation and total remodeling periods concomitant with increase in wall thickness (based on extent of observed fluorescent label) o Increase in proportion of RBF and MBF containing sequential labels from week 2 indicated increase in lifespan of formative site. Bone matrix quality determination (Ross et al 2014): Mineralization kinetics (BSEM) (L2, femur shaft) o Mean global mineralization of trabecular and cortical bone (vertebra L2, femur) relatively unaffected o Small increase in the number of trabecular bone pixels with a low mineralization value, and modest decrease in the standard deviation of BMDD distribution in LV2. The latter made trabecular bone slightly less heterogeneous.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_61"><head></head><label></label><figDesc>Oc.S/bS in vertebrae by PTH but not AMG785. Similar increases in Ob.N and Ob.N/Ob.S at 4 wks in AMG785 and PTH treated animals. However, larger MAR at 4 wks in AMG785 vs PTH-treated animals suggested increased individual Ob cell activity At Wk 26, increase in BFR/BS by AMG785 was maintained by lower Ob.N, lower Ob.N/ObS (ie higher bone surface area occupied per osteoblast) and higher MAR vs. PTH. At Wk 26, the lower Ob.N/Ob.S was associated with lower number of Opg cells (Opg.N); Opg.N generally correlated with Ob.N.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_62"><head></head><label></label><figDesc>in parentheses are extrapolated by the reviewer based on effects on formation markers/indices and structural parameters</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_63"><head>Figure 2 .</head><label>2</label><figDesc>Mean (SD) Concentration-Time Profiles Following 2 Monthly SC Administration of Romosozumab at 3, 10 and 30 mg/kg to Cynomolgus Monkey)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_64"><head></head><label></label><figDesc>168h) values for the 50 mg/kg dose were calculated based on population PK analysis of the data from the 6-month rat toxicity study (#107425) Data from ADA-positive animals were not included. ** Exposure Multiple = [Animal AUC(0-168h) x 4]/[Human AUC(0-) at the proposed clinical dose of 210 mg];(Human AUC(0-) = 12888 ug.h/mL, based on Population PK Report 119384A)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_65"><head></head><label></label><figDesc>108059 was reviewed by Dr. Eric Andreasen. The review was filed in DARRTS for AMG785-IND 103077 on June 18, 2009.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_66"><head>Figure 1 ,</head><label>1</label><figDesc>below) o Increases in BFR/BS (and BFR/BV) (bone formation rate), larger in Wk 13 than in Wk27 (Text Fig. 2) o Dose-related decrease in ES/BS (eroded surface %) (indicates suppression of resorption) at Wk 13 only (Text Fig. 1) o Dose-related increase in Ac.F (activation frequency), Wk 13 &gt; Wk 27 o Dose-related increase in Fo.S/BS (formative bone surface %); and decrease in QS/BS (quiescent surface %)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_68"><head>Figure 1</head><label>1</label><figDesc>Figure 1: Romosozumab (AMG 785) Structure</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_69"><head>Figure 2 :Figure 3 :</head><label>23</label><figDesc>Mean (SD) AMG 785 Concentration-Time profiles following a single 3 mg/kg SC dose of AMG 785 given as 3 mg/kg FIH or 2.75 mg/kg CPD (semi-log scale) Mean (SD) AMG 785 Concentration-Time profiles following a single 3 mg/kg SC dose of AMG 785 given as 3 mg/kg FIH or 2.75 mg/kg CPD (linear scale)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_70"><head>Figure 2 .</head><label>2</label><figDesc>Time to First Occurrence of CV SAEs through Month 12 Source: Sponsor's, CCR page 3538, Figure 14-6.1.7.1.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_71"><head>Figure 1 .Figure 2 :Figure 3 :Figure 4 Figure 8 .</head><label>12348</label><figDesc>Subject Incidence of New Vertebral Fracture Through Month 12 by Demographics and Baseline Characteristics (20070337 Primary Analysis Set for Vertebral Fractures, LOCF Imputation) Subject Incidence of New Vertebral Fracture Through Month 24 by Demographics and Baseline Characteristics (20070337 Primary Analysis Set for Vertebral Fractures, LOCF Imputation) Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 by Subgroups (20070337 Primary Analysis Set for BMD, LOCF) Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 by Subgroups (20070337 Primary Analysis Set for BMD, LOCF)--</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_72"><head></head><label></label><figDesc>tumor type being tested gets a score of h s =1. An animal that dies at week h w without developing the tumor before the end of the study gets a score of h s = adjusted group size is defined as  h s . As an interpretation, an animal with score h s =1 can be considered as a whole animal while an animal with score h s &lt; 1 can be considered as a partial animal. The adjusted group size  h s is equal to N (the original group size) if all</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_73"><head>Figure</head><label></label><figDesc>Figure 1A: Kaplan-Meier Survival Functions for Male Rats</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_75"><head> 8 . 6</head><label>86</label><figDesc>Hepatic Impairment: Delete the whole section because no hepatic impairment study was conducted.  12.3 Pharmacokinetics: PK information presented in this section is reorganized as subsections of Absorption, Distribution, Elimination, Intrinsice factors and Special populations..</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_76"><head>Figure 1 .</head><label>1</label><figDesc>Least Square Means (95% CI) of Percent Change From Baseline in DXA Lumbar Spine BMD by Visit (Primary Efficacy Subset) based on Month 24 Interim Analysis of Study 20060326 (Source:</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_77"><head></head><label></label><figDesc>body.pdf) ALN = alendronate; AMG 785 = romosozumab; BL = baseline; BMD = bone mineral density; CI = confidence interval; DXA = dual-energy X-ray absorptiometry; N = Number of subjects randomized and have baseline and at least one post baseline BMD measurements on or prior to the Month 12.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_79"><head>Figure 4 . 2 . 1 .</head><label>421</label><figDesc>Mean (SD) Serum Romosozumab Concentration-time Profiles Following Single SC Doses from TwoComparative PK studies of Romosozumab (Source:Figure 11-1 in CSR Study 20120277 and  Figure 11-1 in CSR Study 20150197)    </figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_80"><head>Figure 4 Figure 4 . 3 . 2 .</head><label>4432</label><figDesc>Mean (+SD) Serum Concentration-time Profiles Following a Single Intravenous Administration of Romosozumab to Healthy Postmenopausal Women andHealthy Men (Source:Figure 10-2 of CSR Study 20060220)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_81"><head></head><label></label><figDesc>.3.3 and Figure 4.3.4. The PK parameter estimates from noncompartmental analysis are shown in</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_82"><head>Figure 4 Figure 4 . 3 . 4 .</head><label>4434</label><figDesc>Mean (SD) Serum Romosozumab Concentration-time Profiles Following a SC Administration of 3 Q4W Doses of Romosozumab to Healthy Men and Postmenopausal Women With Low Bone Mass (Study 20060221) (Source:Figure 10-2 of CSR Study 20060221)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_83"><head>Figure 4 . 3 . 5 .</head><label>435</label><figDesc>Mean (+SD) Serum Romosozumab Concentration-time Profiles After SC Administration of 210 mg Romosozumab in Subjects with Stage 4 RI, Subjects with ESRD Requiring Hemodialysis, and Healthy Subjects. (Source: Figure 11-6 of CSR Study 20110227)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_84"><head>Figure 4 . 3 . 6 .</head><label>436</label><figDesc>Individual Romosozumab Pharmacokinetic Parameter (Cmax, AUClast and AUCinf) Plots After SC Administration of 210 mg Romosozumab in Subjects with Stage 4 RI (Group 1), Subjects with ESRD Requiring Hemodialysis (Group 2), and Healthy Subjects (Group 3). (Source: Figure 11-8 of CSR Study 20110227)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_85"><head>Figure 4 .</head><label>4</label><figDesc>3.7. Mean (SD) Serum Romosozumab Concentration-time ProfilesAfter SC Administration of Romosozumab 3 mg/kg in Postmenopausal Women with Low Bone Mass. Group B: Alendronate switch to Romosozuamb; Group C: Treatment-nave Subjects (Source:Figure 12 of CSR Study 20060223)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_86"><head></head><label></label><figDesc>.3.8 and 4.3.9.   </figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_87"><head>Figure 4 Figure 4 . 3 . 9 .</head><label>4439</label><figDesc>Study Design and Treatment Schema_12-Month Denosumab Extension Phase and 12-Month Romosozumab Retreatment Phase) (Source: Figure 8-2 of CSR Study 20060326) ALN = alendronate; AMG785 = romosozumab; EOS = end of study; PO = orally; QD = every day; QM = every month; Q3M = every 3 months; Q6M = every 6 months; QW = every week; All subjects were to take at least 1000 mg elemental calcium and 800 IU vitamin D daily. Note: Numbersin parentheses represented planned enrollment numbs, not actual. End of study is at 72 months.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_88"><head>Figure 4 . 3 . 10 .</head><label>4310</label><figDesc>Mean Serum Romosozuamb Concentration-time Profiles during 24-month romosozumab treatment phase followed by 12-Month Denosumab Extension Phase and a 12-Month Romosozumab Retreatment Phase (Source: Fgiure 11-2 of Study 20060326) 4.3.7. Study 20101291 (The Dose Finding Study in Japanese Population)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_89"><head>Figure 4 . 3 . 11 .</head><label>4311</label><figDesc>Mean (SD) Serum Concentration-time Profiles After SC Administrations of 70, 140, or 210 mg QM Romosozumab to Japanese Subjects with Postmenopausal Osteoporosis (Source:</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_90"><head></head><label></label><figDesc>.4.1).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_91"><head>Figure 4</head><label>4</label><figDesc>Figure 4.4.1 Serum Romosozumab Concentration (ng/mL) following 6 SC Q2W 1mg/kg doses (Subject in Study 20060221) (Source of data: Appendix Table 1.3-2 of CSR-20060221)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_92"><head>Figure 4 . 4 . 3 .</head><label>443</label><figDesc>Serum Romosozuamb Concentration Versus S/N ratio at Month 12 in Antibody Binding Positive Subjects (Study 20070337) (Source: Figure 3 of Applicant's Supplemental Integrated Immunogenicity Report submitted on 2/15/17)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_93"><head></head><label></label><figDesc>.4.1, Subject had no notable changes in pharmacodynamic markers (ie, increases in P1NP and BMD) in Study 20060221.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_94"><head></head><label></label><figDesc>8.3.7 of Module 5.3.5.3 -Integrated Summary of Safety for more details. 4.4.4.2 Impact of ADA on safety based on signal-to-noise (S/N) ratio In response to our information request described above, the Applicant further evaluated the impact of ADA on safety based on S/N ratio and safety data from Study 20070337. The pivotal Phase 3 Study 20070337 enrolled 7180 postmenopausal women with osteoporosis, which represents about 80% of the entire patient population in this submission.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_95"><head>Figure 3 Figure 4</head><label>34</label><figDesc>Visual Predictive Check for the Final Population PK Model for Phase 1 and 2 studies by dose Visual Predictive Check for the Final Population PK Model for Phase 3 study</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_96"><head>Figure 6</head><label>6</label><figDesc>Model-based Simulation of the Time Course of Romosozumab Serum Concentration at Steady-state for 3 mg/kg or 210 mg Every Month Dosing in PMO Patients with a Body Weight Range of 33 to 98 kg</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_97"><head>Figure 9 83 Figure 10 BMD</head><label>98310</label><figDesc>Diagnostic plots for PK/PD model based on BMD Source: Applicant's exposure-BMD analysis report, Figure 26-27, 29 and 31, Page 78-Visual Predictive Check: Hologic. Results from 500 simulated trials are summarized as the median, 5th, and 95 h percentiles (solid black lines) with associated 95% CIs. Observed values are plotted as red circles, with observed median, 5th, and 95th percentiles (dashed red lines) Source: Applicant's exposure-BMD analysis report, Figure 108, Page 160</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_98"><head>Figure 11</head><label>11</label><figDesc>Re-Treatment Model BMD Visual Predictive Check for Hologic Machine: All Data. Results from 500 simulated trials are summarized as the median, 5t h, and 95t h percentiles (solid black lines) with associated 95% CIs. Observed values are plotted as red circles, with observed median, 5th, and 95th percentiles (dashed red lines) Source: Applicant's exposure-BMD analysis report, Figure 139, Page 191</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table of TablesTable 26 .</head><label>of26</label><figDesc>Table 1. Effect of Romosozumab on the Risk of New Vertebral Fractures, Clinical Fractures, and Nonvertebral Fractures in Studies 337 and 142 ........................................................................... 15 Table 2: Patient Experience Data Relevant to this Application .................................................... 24 Table 3: Summary of FDA-Approved Pharmacologic Treatment Options for Postmenopausal Osteoporosis ................................................................................................................................. 26 Table 4. PMO Fracture Trials: New Morphometric Vertebral Fractures, Risk Reductions by Year (Compared to Placebo) ................................................................................................................. 28 Table 5 PMO Fracture Trials: Nonvertebral Fractures, Risk Reductions by Year (compared to placebo) ........................................................................................................................................ 29 Table 6: New Nonclinical Pharmacology Studies .......................................................................... 39 Table 7: Experimental Design of Amgen Study No. 124609 (Study #2) ........................................ 41 Table 8 Patient Profile for Subjects Who Experienced MACE and Had PK Data Available in Studies 20070337, 20110142 and 20110174 ............................................................................... 58 Table 9. Listing of Clinical Trials Relevant to this Supplemental BLA ........................................... 60 Table 10: Study 142 Sample Size Considerations ......................................................................... 70 Table 11 Contract Research Organizations and Responsibilities .................................................. 77 Table 12 Central Laboratories and Responsibilities ...................................................................... 78 Table 13 Subject Disposition (Full Analysis Set) (Primary Analysis).............................................. 80 Table 14. Important Protocol Deviations (Full Analysis Set) (Primary Analysis) .......................... 82 Table 15. Demographic Characteristics (Full Analysis Set) (Primary Analysis) ............................. 84 Table 16: Study 20110142 -Incidence of New Vertebral Fracture Through Month 24 -Primary analysis Set for Vertebral Fractures .............................................................................................. 87 Table 17: Study 20110142 -Time to First Clinical Fracture Through Primary Analysis Period (Full Analysis Set) .................................................................................................................................. 88 Table 18. Study 20110142 -Percent Change From Baseline in BMD at Lumbar Spine at Months 12, 24, and 36 (ANCOVA LOCF, Primary Efficacy Analysis Set for BMD) ...................................... 89 Table 19. Study 20110142 -Percent Change From Baseline in BMD at Total Hip at Months 12, 24, and 36 (ANCOVA LOCF, Primary Efficacy Analysis Set for BMD) ............................................ 89 Table 20. Study 20110142 -Percent Change From Baseline in BMD at Femoral Neck at Months 12, 24, and 36 (ANCOVA LOCF, Primary Efficacy Analysis Set for BMD) ...................................... 90 Table 21. Study 20110142 -Time to First Nonvertebral Fracture through Primary Analysis Period (Full Analysis Set) .......................................................................................................................... 91 Table 22: Study 20110142 -Incidence of New Vertebral Fracture Through Month 12 -Primary Analysis Set for Vertebral Fractures ............................................................................................. 91 Table 23. Study 20110142 -Subject Incidence of Clinical Fracture through Month 12 and Month 24 (Full Analysis Set) ..................................................................................................................... 92 Table 24. Study 20110142 -Subject Incidence of Nonvertebral Fracture through Month 12 and Month 24 (Full Analysis Set) ......................................................................................................... 93 Table 25. Study 20110142 -Subject Incidence of Hip Fracture through Month 12, Month 24 and Primary Analysis (Full Analysis Set) ............................................................................................... 94 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 6 Study 20110142 -Bone Mineral Density Percent Change From Baseline by Antiromosozumab Antibody Status Through Month 18 (Romosozumab Arm in Primary Analysis Set for BMD: Descriptive Statistics, Observed Data) (20110142 Primary Analysis Period) ......... 95 Table 27: Trial 20070337 Fracture Endpoints ............................................................................. 100 Table 28: Trial 20070337 Bone Mineral Density, Mean Percent Change, LOCF, ANCOVA ........ 101 Table 29. Bone Mineral Density Percent Change From Baseline at Month 12 in the Pivotal Fracture Studies (ANCOVA Model) (Primary Efficacy Analysis Set for BMD, LOCF) ................... 105 Table 30 Summary of Subject Incidence of Treatment-emergent Adverse Events (Safety Analysis Set -20110142 Primary Analysis)............................................................................................... 109 Table 31. Subject Incidence of Treatment-emergent Fatal Adverse Events by System Organ Class (Safety Analysis Set -20110142 Primary Analysis) ..................................................................... 111 Table 32. Subject Incidence of Treatment-emergent Serious Adverse Events by SOC and (20110142 Primary Analysis) ...................................................................................................... 113 Table 33. Summary of Subject Incidence of Treatment-emergent Adverse Events of Interest (Safety Analysis Set -20110142 Primary Analysis) ..................................................................... 117 Table 34. Subject Incidence of Treatment-Subject Incidence in Either Treatment Group) (Safety Analysis Set) (20110142 Primary Analysis) ..................................................................................................................................................... 124 Table 35 CTCAE (Version 3) Grades and Associated Abnormal Albumin-corrected Serum Calcium Values .......................................................................................................................................... 126 Table 36 CTCAE (Version 3) Grades for Abnormal Serum Phosphorus Values .......................... 128 Table 37 Subject Incidence of Treatment-emergent Injection Site Reaction, Hypersensitivity, and Autoimmune Disorders in the 12-Month Double-blind Period by Binding Anti-romosozumab Antibody Status Through Month 18 by Preferred Term (Safety Analysis Set) (20110142 Primary Analysis) ...................................................................................................................................... 131 Table 38. Subject Incidence of Positively-adjudicated Cardiovascular Serious Adverse Events by Category and Study in the 12-Month Double-blind Period (Safety Analysis Set) (DCRI Adjudication of Studies 337, 142, and 174) ................................................................................ 135 Table 39. Subject Incidence of Positively-adjudicated Cardiovascular Serious Adverse Events by Study in the Overall Study Period (Safety Analysis Set) (DCRI Adjudication of Studies 337, 142, and 174) ...................................................................................................................................... 137 Table 40. Summary of MACE Composite and Individual Components Through Month 12 and in the Overall Study Period (Safety Analysis Set) (DCRI Adjudication of Studies 20070337, 20110142, and 20110174) .......................................................................................................... 139 Table 41 Modified-RUTH Criteria for Defining a High-risk Population for Cardiovascular Events ..................................................................................................................................................... 143 Table 42. Subject Incidence of Positively-adjudicated Cardiovascular Serious Adverse Event or Negatively Adjudicated Due to Insufficient Documentation (Safety Analysis Set) (DCRI Adjudication of Studies 20110174, 20070337, and 20110142) ................................................. 146 Table 43. Comparison of Subject Incidences of All-Cause Death, Myocardial Infarction, and Stroke Based on Treatment-emergent Adverse Event Reporting and Adjudication by DCRI and NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 7 the TIMI Study Group During the 12-Month Double-blind Period (Safety Analysis Set) (Studies 20110142, 20070337, and 20110174) ........................................................................................ 147 Table 44 Impact of Immunogenicity on Steady-State Trough Serum Romosozumab Concentrations in Pooled</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 45 Table of Figures</head><label>45of</label><figDesc>Effect of Immunogenicity on Lumbar Spine Bone Mineral Density Percent Change from Baseline in Study 20110142 ........................................................................................................ 172 Table 46 Effect of Immunogenicity on Safety by Immunogenicity Status Through Month 18 in Study 20110142 .......................................................................................................................... 172 Table 47 Serum Romosozumab Concentrations in Study 20110142 ......................................... 173 Table 48 Impact of Immunogenicity on Serum Romosozumab Concentrations in Study 20110142 ..................................................................................................................................................... 173 Table 49: Summary of PK Dataset and Identified Significant Covariates in the Original and Updated Population PK Reports ................................................................................................. 175 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 8</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2 : Patient Experience Data Relevant to this Application</head><label>2</label><figDesc>The patient experience data that was submitted as part of the application, include: Section where discussed, if applicable Qualitative studies (e.g., individual patient/caregiver interviews, focus group interviews, expert interviews, Delphi Panel, etc.)Patient-focused drug development or other stakeholder meeting summary reports</figDesc><table><row><cell cols="2">X X Clinical outcome assessment (COA) data, such as</cell><cell></cell></row><row><cell>X</cell><cell>Patient reported outcome (PRO)</cell><cell>Section 8.1.2 Study</cell></row><row><cell></cell><cell></cell><cell>Results</cell></row><row><cell></cell><cell>Observer reported outcome (ObsRO)</cell><cell></cell></row><row><cell>X</cell><cell>Clinician reported outcome (ClinRO)</cell><cell>Section 8.1.2 Study</cell></row><row><cell></cell><cell></cell><cell>Results</cell></row><row><cell></cell><cell>Performance outcome (PerfO)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 3 : Summary of FDA-Approved Pharmacologic Treatment Options for Postmenopausal Osteoporosis</head><label>3</label><figDesc>approved only for osteoporotic patients at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy **approved only for osteoporotic patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). Fracture efficacy for calcitonin-salmon has not been established.</figDesc><table><row><cell>Drug Class</cell><cell>Product Name</cell><cell>Year of</cell><cell>Dosing/</cell><cell>Important Safety and</cell></row><row><cell></cell><cell></cell><cell>Approval</cell><cell>Administration</cell><cell>Tolerability Issues</cell></row><row><cell>Bisphosphonates</cell><cell>Fosamax</cell><cell>1995</cell><cell>70 mg PO weekly (tablet</cell><cell>Osteonecrosis of the jaw (ONJ)</cell></row><row><cell></cell><cell>(alendronate)</cell><cell></cell><cell>or solution)</cell><cell>fractures (AFF) fractures (AFF)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>10 mg PO daily (tablet)</cell><cell>Hypocalcemia</cell></row><row><cell></cell><cell>Fosamax Plus D</cell><cell>2005</cell><cell>70 mg alendronate/2800</cell><cell>Not recommended or</cell></row><row><cell></cell><cell>(alendronate/</cell><cell></cell><cell>or 5600 IU</cell><cell>contraindicated in patients with</cell></row><row><cell></cell><cell>cholecalciferol)</cell><cell></cell><cell>cholecalciferol,</cell><cell>severe renal impairment</cell></row><row><cell></cell><cell></cell><cell></cell><cell>1 tablet weekly</cell><cell>Upper gastrointestinal adverse</cell></row><row><cell></cell><cell>Binosto</cell><cell>2012</cell><cell>70 mg PO weekly</cell><cell>events with oral formulations</cell></row><row><cell></cell><cell>(alendronate)</cell><cell></cell><cell>(effervescent tablet for</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>oral solution)</cell><cell></cell></row><row><cell></cell><cell>Actonel</cell><cell>2000</cell><cell>Tablets: 5 mg PO daily</cell><cell></cell></row><row><cell></cell><cell>(risedronate)</cell><cell></cell><cell>35 mg PO weekly</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>150 mg PO monthly</cell><cell></cell></row><row><cell></cell><cell>Atelvia</cell><cell>2010</cell><cell>35 mg PO weekly</cell><cell></cell></row><row><cell></cell><cell>(risedronate)</cell><cell></cell><cell>(delayed release tablet)</cell><cell></cell></row><row><cell></cell><cell>Boniva</cell><cell>2003</cell><cell>150 mg PO monthly</cell><cell></cell></row><row><cell></cell><cell>(ibandronate)</cell><cell></cell><cell>(tablet)</cell><cell></cell></row><row><cell></cell><cell>Boniva</cell><cell>2006</cell><cell>3 mg IV q3 months</cell><cell>ONJ, AFF, hypocalcemia</cell></row><row><cell></cell><cell>(ibandronate)</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Reclast</cell><cell>2007</cell><cell>5 mg IV yearly</cell><cell>ONJ, AFF, hypocalcemia, renal</cell></row><row><cell></cell><cell>(zoledronic acid)</cell><cell></cell><cell></cell><cell>toxicity, acute phase reactions</cell></row><row><cell>RANKL antagonist</cell><cell>Prolia*</cell><cell>2010</cell><cell>60 mg SC q6 months</cell><cell>ONJ, AFF, hypocalcemia</cell></row><row><cell></cell><cell>(denosumab)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Estrogen</cell><cell>Evista</cell><cell>1997</cell><cell>60 mg PO daily</cell><cell>Venous thromboembolism</cell></row><row><cell>agonist/antagonist</cell><cell>(raloxifene)</cell><cell></cell><cell>(tablet)</cell><cell>Death due to stroke</cell></row><row><cell>PTH analog/</cell><cell>Forteo*</cell><cell>2002</cell><cell>20 mcg SC daily</cell><cell>Osteosarcoma risk (animal data)</cell></row><row><cell>PTHrP analog</cell><cell>(teriparatide)</cell><cell></cell><cell></cell><cell>limiting use duration to 2 years,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>hypercalcemia</cell></row><row><cell></cell><cell>Tymlos*</cell><cell>2017</cell><cell>80 mcg SC daily</cell><cell>Osteosarcoma risk (animal data)</cell></row><row><cell></cell><cell>(abaloparatide)</cell><cell></cell><cell></cell><cell>limiting use duration to 2 years,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>hypercalcemia</cell></row><row><cell>Calcitonin-salmon</cell><cell>Miacalcin**</cell><cell>1986</cell><cell>SC or IM injection,</cell><cell>Hypersensitivity, hypocalcemia,</cell></row><row><cell></cell><cell></cell><cell></cell><cell>100 IU every other day</cell><cell>malignancy</cell></row><row><cell></cell><cell>Miacalcin**</cell><cell>1995</cell><cell>Nasal spray, 200 IU daily</cell><cell></cell></row><row><cell></cell><cell>Fortical**</cell><cell>2005</cell><cell>Nasal spray, 200 IU daily</cell><cell></cell></row></table><note>*</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 4 . PMO Fracture Trials: New Morphometric Vertebral Fractures, Risk Reductions by Year (Compared to Placebo)</head><label>4</label><figDesc></figDesc><table><row><cell>Drug</cell><cell cols="2">12 Months</cell><cell cols="2">24 Months</cell><cell cols="2">36 Months</cell></row><row><cell></cell><cell>ARR (%)</cell><cell>RRR (%)</cell><cell>ARR (%)</cell><cell>RRR (%)</cell><cell>ARR (%)</cell><cell>RRR (%)</cell></row><row><cell>Teriparatide</cell><cell></cell><cell></cell><cell>9.3*</cell><cell>65*</cell><cell></cell><cell></cell></row><row><cell>(Forteo)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Abaloparatide</cell><cell></cell><cell></cell><cell>3.9**</cell><cell>87**</cell><cell></cell><cell></cell></row><row><cell>(Tymlos)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Denosumab (Prolia)</cell><cell>1.4</cell><cell>61</cell><cell>3.5</cell><cell>71</cell><cell>4.8</cell><cell>68</cell></row><row><cell>Zoledronic acid</cell><cell>2.2</cell><cell>60</cell><cell>5.5</cell><cell>71</cell><cell>7.6</cell><cell>70</cell></row><row><cell>(Reclast)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Alendronate</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>7.1</cell><cell>47</cell></row><row><cell>(Fosamax-FIT 1)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Alendronate</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2.3***</cell><cell>48***</cell></row><row><cell>(Fosamax-FIT-2)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Risedronate</cell><cell>4.0</cell><cell>65</cell><cell>5.9</cell><cell>55</cell><cell>5.0</cell><cell>41</cell></row><row><cell>(Actonel-NA)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Risedronate</cell><cell>7.7</cell><cell>61</cell><cell>13.1</cell><cell>59</cell><cell>10.9</cell><cell>49</cell></row><row><cell>(Actonel-MN)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ibandronate</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>4.9</cell><cell>52</cell></row><row><cell>(Boniva PO)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Raloxifene</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>6.1</cell><cell>30</cell></row><row><cell>(Evista)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>racture</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Raloxifene</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2.4</cell><cell>55</cell></row><row><cell>(Evista)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>no baseline fracture</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">ARR = Absolute Risk Reduction; RRR= Relative Risk Reduction</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">*Forteo trial: 19 months median exposure</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="7">**Tymlos trial: risks at 25 months (18 months exposure to Tymlos or placebo, 1 month of no treatment, followed</cell></row><row><cell cols="3">by 6 months of alendronate therapy)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">***Fosamax FIT-2 trial: 48-month assessment</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>MN=multinational</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>NA=North America</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Sources: Unites States Prescribing Information</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 5 PMO Fracture Trials: Nonvertebral Fractures, Risk Reductions by Year (compared to placebo)</head><label>5</label><figDesc></figDesc><table><row><cell>Drug</cell><cell>12 Months</cell><cell cols="2">24 Months</cell><cell></cell><cell>36 Months</cell></row><row><cell>ARR (%)</cell><cell>RRR (%)</cell><cell>ARR (%)</cell><cell>RRR (%)</cell><cell>ARR (%)</cell><cell>RRR (%)</cell></row><row><cell>Teriparatide</cell><cell></cell><cell>2.9*</cell><cell>53*</cell><cell></cell><cell></cell></row><row><cell>(Forteo)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Abaloparatide</cell><cell></cell><cell>2.9**</cell><cell>52**</cell><cell></cell><cell></cell></row><row><cell>(Tymlos)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Denosumab</cell><cell></cell><cell></cell><cell></cell><cell>1 . 5</cell><cell>2 0</cell></row><row><cell>(Prolia)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Zoledronic</cell><cell></cell><cell></cell><cell></cell><cell>2 . 7</cell><cell>2 5</cell></row><row><cell>acid</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(Reclast)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8"><head>Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety Office of Scientific Investigations (OSI)</head><label></label><figDesc>Inspections of clinical sites participating in Study 2011142 were deemed not necessary. Many of the clinical sites in Study 142 were the same as those participating in Study 337. During the initial BLA submission, four clinical sites participating in Study 337 were audited. The rationale for selection of these sites and final inspection results are as follows:</figDesc><table><row><cell>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell></row><row><cell>4 Significant</cell></row><row><cell>32</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_9"><head>Table 7 : Experimental Design of Amgen Study No. 124609 (Study #2)</head><label>7</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_10"><head>Clinical Pharmacology Questions 6.3.2.1. Do PK results in romosozumab clinical trials suggest a potential exposure-response relationship for MACE?</head><label></label><figDesc>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab} 58 No, the available PK data do not support a clear exposure-response relationship for MACE.</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_11"><head>Table 8 Patient Profile for Subjects Who Experienced MACE and Had PK Data Available in Studies 20070337, 20110142 and 20110174</head><label>8</label><figDesc>FDA Reviewer's analysis based on clinical study report forStudies 20070337, 20110142, 20100174   and the comprehensive cardiovascular report</figDesc><table><row><cell>Subject ID</cell><cell>Body</cell><cell>Age</cell><cell>Sex</cell><cell>Race</cell><cell>Dose</cell><cell>eGFR</cell><cell>CV-related</cell><cell>MACE</cell><cell>MACE</cell></row><row><cell></cell><cell>Weight</cell><cell>(year)</cell><cell></cell><cell></cell><cell>(mg)</cell><cell>Category</cell><cell>Death?</cell><cell>from the</cell><cell>from the</cell></row><row><cell></cell><cell>(kg)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>first dose</cell><cell>last dose</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(days)</cell><cell>(days)</cell></row><row><cell></cell><cell>41</cell><cell>64</cell><cell>F</cell><cell>White</cell><cell>210</cell><cell>Mild</cell><cell>Yes</cell><cell>106</cell><cell>17</cell></row><row><cell></cell><cell>42</cell><cell>85</cell><cell>F</cell><cell>White</cell><cell>210</cell><cell>Mild</cell><cell>No</cell><cell>70</cell><cell>10</cell></row><row><cell></cell><cell>82</cell><cell>79</cell><cell>M</cell><cell>White</cell><cell>210</cell><cell>Normal</cell><cell>No</cell><cell>96</cell><cell>6</cell></row><row><cell></cell><cell>64</cell><cell>72</cell><cell>M</cell><cell>White</cell><cell>210</cell><cell>Normal</cell><cell>No</cell><cell>98</cell><cell>10</cell></row><row><cell></cell><cell>75</cell><cell>72</cell><cell>M</cell><cell>White</cell><cell>210</cell><cell>Mild</cell><cell>No</cell><cell>138</cell><cell>16</cell></row><row><cell></cell><cell>72</cell><cell>82</cell><cell>M</cell><cell>White</cell><cell>210</cell><cell>Mild</cell><cell>No</cell><cell>348</cell><cell>19</cell></row><row><cell></cell><cell>70</cell><cell>79</cell><cell>M</cell><cell>Other</cell><cell cols="2">210 Moderate</cell><cell>No</cell><cell>324</cell><cell>23</cell></row><row><cell></cell><cell>61</cell><cell>80</cell><cell>M</cell><cell>Other</cell><cell>210</cell><cell>Mild</cell><cell>Yes</cell><cell>317</cell><cell>16</cell></row><row><cell>Source of data:</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note>(b)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_12"><head>Table of</head><label>of</label><figDesc></figDesc><table /><note>Clinical Studies</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_13"><head>Table 9 . Listing of Clinical Trials Relevant to this Supplemental BLA Trial Identity/ NCT no. Trial Design Regimen/ schedule/ route Primary Endpoint Treatment Duration/ Follow Up No. of Pts. Study Population No. of Centers/ Count- ries Controlled Studies to Support Efficacy and SafetyStatistical and Clinical Evaluation Review of Relevant Individual Trials Used to Support Efficacy Study 20110142: Design Study Title</head><label>9</label><figDesc>The efficacy evaluation is based on efficacy results from Study 337 and 142. Efficacy results from Study 142 are thoroughly reviewed in Section 8.1.2. Since efficacy results from Study 337 were previously reviewed with the original submission, this review only provides a summary of the efficacy results from Study 337 (in Section 8.1.5). Efficacy results from Study 174 are not addressed in this review, as the study population is not one for which an indication is currently sought. The safety evaluation is based on safety results from Study 337, Study 142 and Study 174. All safety results from Study 142 are thoroughly reviewed in Section 8.2. Since the safety results of Study 337 were previously reviewed in detail with the original submission, this review will only summarize key safety results of Study 337 in Section 8.2. General safety results from Study 174 are not addressed in this review, as the study population is not one for which an indication is currently sought. The cardiovascular safety results from Study 337 and Study 174, however, are included in this review alongside those of Study 142 (in Section 8.2.5, Analysis of Cardiovascular Safety). The study was conducted at 270 centers in 41 countries (89 centers in Western Europe and Australia/New Zealand, 88 centers in Central and Eastern Europe and the Middle East, 49 centers in Central/Latin America, 26 centers in North America, and 18 centers in Asia Pacific and South Africa).</figDesc><table><row><cell>20070337/</cell><cell>Randomized,</cell><cell>Romosozumab 210</cell><cell>Incidence of</cell><cell>24 months</cell><cell>7180</cell><cell>Post-</cell><cell>222</cell></row><row><cell>01575834</cell><cell>double-blind,</cell><cell>mg SC QM or</cell><cell>new vertebral</cell><cell>with 12</cell><cell></cell><cell>menopausal</cell><cell>centers</cell></row><row><cell></cell><cell>placebo-</cell><cell>placebo SC QM for</cell><cell>fracture at</cell><cell>month</cell><cell></cell><cell>osteoporosis</cell><cell>countries</cell></row><row><cell></cell><cell>controlled</cell><cell>12 months followed</cell><cell>month 12 and</cell><cell>extension</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>by denosumab</cell><cell>month 24 (co-</cell><cell>period with</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>60mg SC Q6M for</cell><cell>primary)</cell><cell>open-label</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>12 months</cell><cell></cell><cell>denosumab</cell><cell></cell><cell></cell><cell></cell></row><row><cell>20110142/</cell><cell>Randomized,</cell><cell>Romosozumab 210</cell><cell>Subject</cell><cell>Event driven</cell><cell>4093</cell><cell>Post-</cell><cell>270</cell></row><row><cell>01631214</cell><cell>double-blind,</cell><cell>mg SC QM or</cell><cell>incidence of</cell><cell>median</cell><cell></cell><cell>menopausal</cell><cell>centers</cell></row><row><cell></cell><cell>active-</cell><cell>alendronate 70 mg</cell><cell>clinical fracture</cell><cell>follow-up 33</cell><cell></cell><cell>osteoporosis</cell><cell>41</cell></row><row><cell></cell><cell>controlled</cell><cell>po QW for 12</cell><cell>and new</cell><cell>months;</cell><cell></cell><cell></cell><cell>countries</cell></row><row><cell></cell><cell></cell><cell>months followed by</cell><cell>vertebral</cell><cell>minimum 24</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>alendronate 70 mg</cell><cell>fracture</cell><cell>months</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>po QW</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">Studies to Support Safety</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>20110174/</cell><cell>Randomized,</cell><cell>Romosozumab 210</cell><cell>Percent change</cell><cell>12 month</cell><cell>245</cell><cell>Men with</cell><cell>31 centers</cell></row><row><cell>02186171</cell><cell>double-blind,</cell><cell>mg SC QM or</cell><cell>from baseline in</cell><cell>treatment</cell><cell></cell><cell>osteoporosis</cell><cell>10</cell></row><row><cell></cell><cell>placebo-</cell><cell>placebo SC QM</cell><cell>lumbar spine</cell><cell>period</cell><cell></cell><cell></cell><cell>countries</cell></row><row><cell></cell><cell>controlled</cell><cell></cell><cell>BMD at 12</cell><cell>15 months</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>months</cell><cell>total follow-</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>up</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">SC = subcutaneous; QM = once monthly; po = orally</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note>: A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis Investigators and Study Centers:</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_14"><head></head><label></label><figDesc>Number of Subjects Planned:Approximately 4000 subjects (2000 subjects per treatment group)</figDesc><table><row><cell>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell></row><row><cell>6 4</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_15"><head></head><label></label><figDesc>the primary analysis period: o nonvertebral fracture (key secondary endpoint) o all fractures (nonvertebral fractures and new or worsening vertebral fractures) o hip fracture o major osteoporotic fracture o clinical vertebral fracture At the final analysis: o nonvertebral fracture o major nonvertebral fracture o hip fracture Percent change from baseline in BMD at the lumbar spine, total hip, and femoral neck at month 36</figDesc><table><row><cell>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell></row><row><cell>o major nonvertebral fracture</cell></row><row><cell>o hip fracture</cell></row><row><cell>Through month 24:</cell></row><row><cell>o new or worsening vertebral fracture</cell></row><row><cell>o multiple new or worsening vertebral fractures</cell></row><row><cell>o clinical fracture</cell></row><row><cell>o nonvertebral fracture</cell></row><row><cell>o hip fracture</cell></row><row><cell>o clinical vertebral fracture</cell></row><row><cell>Through month 12:</cell></row><row><cell>o clinical fracture</cell></row><row><cell>o new vertebral fracture</cell></row><row><cell>o all fractures</cell></row><row><cell>o nonvertebral fracture</cell></row><row><cell>6 9</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_16"><head>Table 10 : Study 142 Sample Size Considerations</head><label>10</label><figDesc></figDesc><table><row><cell>Endpoint</cell><cell>Assumptions</cell><cell>Power</cell></row><row><cell cols="2">New Vertebral Fracture One-year incidence i</cell><cell></cell></row><row><cell></cell><cell>Romosozumab decreases this incidence by</cell><cell></cell></row><row><cell>Clinical Fracture</cell><cell>Ro</cell><cell>Need 330 events</cell></row><row><cell></cell><cell>compared to ALN</cell><cell></cell></row><row><cell>BMD endpoints</cell><cell>See</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_17"><head></head><label></label><figDesc>Period: The time period from the randomization date to the end of double-blind period date, inclusive. Open-label ALN Period: The time period from the end of double-blind period date to the end of study date, inclusive. Month 12 to Month 24 ALN Study Period: For subjects entering the ALN open-label period, the time period from the end of double-blind period date to the Month 24 visit date, study day 761, or end of study date, whichever is the earliest, inclusive. The Month 24 visit date is defined as the latest assessment collected at Month 24. 24-month ALN Study Period: The time period from the randomization date to the Month 24 visit date, study day 761, or end of study date, whichever is the earliest, inclusive Primary Analysis Period: The time period from the randomization date to the end of primary analysis period date, inclusive.</figDesc><table><row><cell>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell></row><row><cell>7 1</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_18"><head></head><label></label><figDesc>value prior to the missing value from the same anatomical site). For the open-label period endpoints, only the open-label period value was used for imputation, the values in the doubleblind period were not carried forward into the open-label period. The LOCF imputation was done up to Month 36. Missing post-baseline data were NOT imputed when a repeated measures model was used as a sensitivity analysis.</figDesc><table><row><cell>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell></row><row><cell>7 2</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_20"><head></head><label></label><figDesc>). Added clinical vertebral fracture as a new Month-12 secondary endpoint. Added new endpoints to the overall study period and the Month 12 to 24 open-label alendronate period. Added the following new secondary endpoints through Month 24 during the primary analysis period: clinical fracture, nonvertebral fracture, hip fracture, and clinical vertebral fracture. DXA BMD endpoints were added to the testing sequence for multiplicity adjustment.</figDesc><table><row><cell>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell></row><row><cell>77</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_21"><head>Table 12 Central Laboratories and Responsibilities</head><label>12</label><figDesc></figDesc><table><row><cell>Reference ID: 4416253</cell></row></table><note>* Source: Table 8-2 of CSR.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_22"><head>Table 13 Subject Disposition (Full Analysis Set) (Primary Analysis)</head><label>13</label><figDesc></figDesc><table><row><cell></cell><cell>Alendronate 70</cell><cell>Romosozumab</cell><cell></cell></row><row><cell></cell><cell>mg QW/</cell><cell>210 mg QM/</cell><cell></cell></row><row><cell></cell><cell>Alendronate 70</cell><cell>Alendronate 70</cell><cell>All</cell></row><row><cell></cell><cell>mg QW</cell><cell>mg QW</cell><cell>n (%)</cell></row><row><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell></cell></row><row><cell>Randomized</cell><cell>2047</cell><cell>2046</cell><cell>4093</cell></row><row><cell cols="3">12-Month Double-blind Period</cell><cell></cell></row><row><cell>Discontinued during double-blind period</cell><cell>224 (10.9)</cell><cell>215 (10.5)</cell><cell>439 (10.7)</cell></row><row><cell>Consent withdrawn</cell><cell>139 (6.8)</cell><cell>129 (6.3)</cell><cell>268 (6.5)</cell></row><row><cell>Death</cell><cell>24 (1.2)</cell><cell>27 (1.3)</cell><cell>51 (1.2)</cell></row><row><cell>Adverse event</cell><cell>25 (1.2)</cell><cell>25 (1.2)</cell><cell>50 (1.2)</cell></row><row><cell>Lost to follow-up</cell><cell>16 (0.8)</cell><cell>13 (0.6)</cell><cell>29 (0.7)</cell></row><row><cell>Other</cell><cell>6 (0.3)</cell><cell>9 (0.4)</cell><cell>15 (0.4)</cell></row><row><cell>Noncompliance</cell><cell>4 (0.2)</cell><cell>7 (0.3)</cell><cell>11 (0.3)</cell></row><row><cell>Ineligibility determined</cell><cell>5 (0.2)</cell><cell>2 (&lt;0.1)</cell><cell>7 (0.2)</cell></row><row><cell>Protocol deviation</cell><cell>3 (0.1)</cell><cell>3 (0.1)</cell><cell>6 (0.1)</cell></row><row><cell>Administrative decision</cell><cell>1 (&lt;0.1)</cell><cell>0 (0)</cell><cell>1 (&lt;0.1)</cell></row><row><cell>Requirement for alternative therapy</cell><cell>1 (&lt;0.1)</cell><cell>0 (0)</cell><cell>1 (&lt;0.1)</cell></row><row><cell>Completed double-blind period</cell><cell>1823 (89.1)</cell><cell>1831 (89.5)</cell><cell>3654 (89.3)</cell></row><row><cell cols="3">Primary Analysis (PA) Period</cell><cell></cell></row><row><cell>Discontinued during PA period</cell><cell>471 (23)</cell><cell>472 (23.1)</cell><cell>943 (23)</cell></row><row><cell>Consent withdrawn</cell><cell>251 (12.3)</cell><cell>263 (12.9)</cell><cell>514 (12.6)</cell></row><row><cell>Death</cell><cell>97 (4.7)</cell><cell>95 (4.6)</cell><cell>192 (4.7)</cell></row><row><cell>Adverse event</cell><cell>43 (2.1)</cell><cell>45 (2.2)</cell><cell>88 (2.2)</cell></row><row><cell>Lost to follow-up</cell><cell>35 (1.7)</cell><cell>32 (1.6)</cell><cell>67 (1.6)</cell></row><row><cell>Other</cell><cell>16 (0.8)</cell><cell>16 (0.8)</cell><cell>32 (0.8)</cell></row><row><cell>Noncompliance</cell><cell>12 (0.6)</cell><cell>14 (0.7)</cell><cell>26 (0.6)</cell></row><row><cell>Requirement for alternative therapy</cell><cell>7 (0.3)</cell><cell>2 (&lt;0.1)</cell><cell>9 (0.2)</cell></row><row><cell>Protocol deviation</cell><cell>4 (0.2)</cell><cell>3 (0.1)</cell><cell>7 (0.2)</cell></row><row><cell>Ineligibility determined</cell><cell>5 (0.2)</cell><cell>2 (&lt;0.1)</cell><cell>7 (0.2)</cell></row><row><cell>Administrative decision</cell><cell>1 (&lt;0.1)</cell><cell>0 (0)</cell><cell>1 (&lt;0.1)</cell></row><row><cell>Safety analysis</cell><cell>2014 (98)</cell><cell>2040 (99.7)</cell><cell>4054 (99.0)</cell></row><row><cell>Primary analysis</cell><cell>1576 (77.0)</cell><cell>1574 (76.9)</cell><cell>3150 (77.0)</cell></row><row><cell>Overall study analysis</cell><cell>1576 (76.9)</cell><cell>1574 (76.9)</cell><cell>3150 (76.9)</cell></row><row><cell>*Source: adapted from Table 14-1.1 of CSR</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_24"><head></head><label></label><figDesc>kg, mean (SD) height of 152 (8) cm, and mean (SD) body mass index (BMI) of 25.4 (4.4) kg/m 2 . The mean number of years since menopause was 26.9 years.</figDesc><table><row><cell cols="2">NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell><cell></cell></row><row><cell cols="3">Subjects were from the following geographic regions: Western Europe and Australia/New</cell></row><row><cell>Zealand (13</cell><cell cols="2">Europe and the Middle East (40</cell></row><row><cell>randomized subjects), Central/Latin America (34</cell><cell></cell><cell>America (2</cell></row><row><cell cols="2">of randomized subjects), and Asia Pacific and South Africa (11</cell></row><row><cell></cell><cell>included Colombia (16</cell><cell>oland</cell></row><row><cell>(17</cell><cell></cell></row><row><cell>8 4</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_25"><head>Table 15 . Demographic Characteristics (Full Analysis Set) (Primary Analysis)</head><label>15</label><figDesc>Overall, the subject composition is very similar to Study 337, with the following exceptions:Subjects in Study 142 were 3.5 years older on average (mean age 74.3 years, with 52 31</figDesc><table><row><cell>Alendronate 70</cell><cell>Romosozumab</cell><cell></cell></row><row><cell>mg QW/</cell><cell>210 mg QM/</cell><cell>All</cell></row><row><cell>Alendronate 70</cell><cell>Alendronate 70</cell><cell>(N=4093)</cell></row><row><cell>mg QW</cell><cell>mg QW</cell><cell></cell></row><row><cell>(N=2047)</cell><cell>(N=2046)</cell><cell></cell></row></table><note>with mostly non-US subjects have demonstrated applicability to the US population, the efficacy results of Study 142 are applicable to the US population. However, we are uncertain about the applicability of the cardiovascular safety findings to the US population (as discussed in Section 8.2.5).</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_27"><head>Table 16</head><label>16</label><figDesc></figDesc><table><row><cell>presents the primary efficacy results for new vertebral fractures through Month 24 for</cell></row><row><cell>sozumab group</cell></row><row><cell>alendronate group (p-value: &lt;0.001) through Month 24. The absolute</cell></row><row><cell>sozumab</cell></row><row><cell>compared to alendronate</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_28"><head>Table 16 : Study 20110142 -Incidence of New Vertebral Fracture Through Month 24 -Primary analysis Set for Vertebral Fractures Statistic Alendronate 70 mg QW/ Alendronate 70 mg QW (N=2047) Romosozumab 210 mg QM/ Alendronate 70 mg QW (N = 2046)</head><label>16</label><figDesc></figDesc><table><row><cell>Incidence, n/N1</cell><cell>147/1834 (8.0)</cell><cell>74/1825 (4.1)</cell></row><row><cell>Comparison vs. ALN/ALN</cell><cell></cell><cell></cell></row><row><cell>Absolute risk reduction a</cell><cell>)</cell><cell>4.03 (2.50, 5.57)</cell></row><row><cell>Relative risk reduction b</cell><cell></cell><cell></cell></row><row><cell>p-value c</cell><cell></cell><cell>&lt; 0.001</cell></row><row><cell>Source:</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_29"><head>Table 17 :</head><label>17</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>Alendronate 70 mg QW/</cell><cell>Romosozumab 210 mg QM/</cell></row><row><cell>Clinical fracture</cell><cell></cell><cell>Alendronate 70 mg QW</cell><cell>Alendronate 70 mg QW</cell></row><row><cell></cell><cell></cell><cell>(N=2047)</cell><cell>(N = 2046)</cell></row><row><cell cols="2">Through primary analysis period</cell><cell></cell></row><row><cell cols="2">Subjects with fractures -n</cell><cell>266 (13.0)</cell><cell>198 (9.7)</cell></row><row><cell cols="2">Comparison vs. ALN/ALN</cell><cell></cell></row><row><cell>Hazard ratio a</cell><cell>)</cell><cell></cell><cell>0.73 (0.61, 0.88)</cell></row><row><cell>p-value</cell><cell></cell><cell></cell><cell>&lt; 0.001</cell></row></table><note>Study 20110142 -Time to First Clinical Fracture Through Primary Analysis Period (Full Analysis Set)Source: Table 10-2 in study 20110142 report. ALN/ALN is Alendronate 70 mg QW/Alendronate 70 mg QW; CI = confidence interval; N = Number of subjects randomized; QM = every month; QW = weekly; a The hazard ratio estimate is based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score -2.5, &gt; -2.5) , and presence of severe vertebral fracture at baseline.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_31"><head>Table 18 . Study 20110142 -Percent Change From Baseline in BMD at Lumbar Spine at Months 12, 24, and 36 (ANCOVA LOCF, Primary Efficacy Analysis Set for BMD)</head><label>18</label><figDesc></figDesc><table><row><cell>Time Point</cell><cell>Statistic</cell><cell>Alendronate 70 mg QW/</cell><cell>Romosozumab 210 mg QM/</cell></row><row><cell></cell><cell></cell><cell>Alendronate 70 mg QW</cell><cell>Alendronate 70 mg QW</cell></row><row><cell></cell><cell></cell><cell>(N = 1757)</cell><cell>(N = 1750)</cell></row><row><cell>Month 12</cell><cell></cell><cell>5.0 (0.1)</cell><cell>13.7 (0.2)</cell></row><row><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>8.7 (0.2)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(8.3, 9.1)</cell></row><row><cell></cell><cell>P-value</cell><cell></cell><cell>&lt;0.001</cell></row><row><cell>Month 24</cell><cell></cell><cell>7.2(0.2)</cell><cell>15.3 (0.2)</cell></row><row><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>8.1 (0.3)</cell></row><row><cell></cell><cell>CI</cell><cell></cell><cell>(7.6, 8.6)</cell></row><row><cell></cell><cell>P-value</cell><cell></cell><cell>&lt;0.001</cell></row><row><cell>Month 36 a</cell><cell></cell><cell>7.8 (0.2)</cell><cell>15.2 (0.2)</cell></row><row><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>7.4 (0.3)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(6.8, 7.9)</cell></row><row><cell>Source:</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_32"><head>Table 19 . Study 20110142 -Percent Change From Baseline in BMD at Total Hip at Months 12, 24, and 36 (ANCOVA LOCF, Primary Efficacy Analysis Set for BMD)</head><label>19</label><figDesc>Table 10-5 in study 20110142 study report. N=Number of subjects with values at baseline and at least one post-baseline visit at or before month 36. LOCF=last-observation-carried-forward a BMD endpoint at Month 36 was not under multiplicity control. Based on ANCOVA model adjusting for treatment, age strata, presence of severe vertebral fracture at baseline, baseline BMD value, machine type, and baseline BMD value-by-machine type interaction. Missing values are imputed by carrying forward the last non-missing post-baseline value prior to the missing value and within the treatment period.</figDesc><table><row><cell>Time Point</cell><cell>Statistic</cell><cell>Alendronate 70 mg QW/</cell><cell>Romosozumab 210 mg QM/</cell></row><row><cell></cell><cell></cell><cell>Alendronate 70 mg QW</cell><cell>Alendronate 70 mg QW</cell></row><row><cell></cell><cell></cell><cell>(N = 1757)</cell><cell>(N = 1750)</cell></row><row><cell>Month 12</cell><cell></cell><cell>2.8 (0.1)</cell><cell>6.2 (0.1)</cell></row><row><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>3.3 (0.1)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>3.0, 3.6</cell></row><row><cell></cell><cell>P-value</cell><cell></cell><cell>&lt;0.001</cell></row><row><cell>Month 24</cell><cell></cell><cell>3.5 (0.1)</cell><cell>7.2 (0.1)</cell></row><row><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>3.8 (0.2)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>3.4, 4.1</cell></row><row><cell></cell><cell>P-value</cell><cell></cell><cell>&lt;0.001</cell></row><row><cell>Month 36 a</cell><cell></cell><cell>3.5(0.1)</cell><cell>7.2 (0.1)</cell></row><row><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>3.7 (0.2)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>3.3, 4.0</cell></row><row><cell>Source:</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_33"><head>Table 20 . Study 20110142 -Percent Change From Baseline in BMD at Femoral Neck at Months 12, 24, and 36 (ANCOVA LOCF, Primary Efficacy Analysis Set for BMD)</head><label>20</label><figDesc></figDesc><table><row><cell>Time Point</cell><cell>Statistic</cell><cell>Alendronate 70 mg QW/</cell><cell>Romosozumab 210 mg QM/</cell></row><row><cell></cell><cell></cell><cell>Alendronate 70 mg QW</cell><cell>Alendronate 70 mg QW</cell></row><row><cell></cell><cell></cell><cell>(N = 1757)</cell><cell>(N = 1750)</cell></row><row><cell>Month 12</cell><cell></cell><cell>1.7 (0.1)</cell><cell>4.9 (0.1)</cell></row><row><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>3.2 (0.1)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>2.9, 3.5</cell></row><row><cell></cell><cell>P-value</cell><cell></cell><cell>&lt;0.001</cell></row><row><cell>Month 24</cell><cell>SE)</cell><cell>2.3 (0.1)</cell><cell>6.0 (0.2)</cell></row><row><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>3.8 (0.2)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>3.4, 4.1</cell></row><row><cell></cell><cell>P-value</cell><cell></cell><cell>&lt;0.001</cell></row><row><cell>Month 36 a</cell><cell></cell><cell>2.4(0.2)</cell><cell>6.0 (0.2)</cell></row><row><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>3.6 (0.2)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>3.2, 4.0</cell></row><row><cell>Source:</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_34"><head>Table 21 . Study 20110142 -Time to First Nonvertebral Fracture through Primary Analysis Period (Full Analysis Set)Efficacy Results -Secondary endpoints not controlled for type I error</head><label>21</label><figDesc></figDesc><table><row><cell cols="2">Alendronate 70 mg QW/</cell><cell>Romosozumab 210 mg QM/</cell><cell>Romosozumab 210 mg QM/</cell></row><row><cell cols="2">Alendronate 70 mg QW</cell><cell>Alendronate 70 mg QW</cell><cell>Alendronate 70 mg QW</cell></row><row><cell>Nonvertebral Fractures</cell><cell>(N = 2047)</cell><cell>(N = 2046)</cell><cell>vs.</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Alendronate 70 mg QW/</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Alendronate 70 mg QW</cell></row><row><cell>Through Primary Analysis Period</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Subjects with fractures -n</cell><cell>217 (10.6)</cell><cell>178 (8.7)</cell><cell></cell></row><row><cell>Hazard ratio a</cell><cell></cell><cell></cell><cell>0.81 (0.66, 0.99)</cell></row><row><cell>Nominal p-value (1-sided) b</cell><cell></cell><cell></cell><cell>0.019</cell></row><row><cell cols="4">a The hazard ratio estimate is based on a Cox proportional hazards model adjusting for age strata and presence of</cell></row><row><cell>severe vertebral fracture at baseline.</cell><cell></cell><cell></cell><cell></cell></row><row><cell>b</cell><cell></cell><cell></cell><cell>at primary</cell></row><row><cell cols="4">analysis (Lan-DeMets alpha spending function that approximates a Pocock boundary) was determined to be 0.0233 (1-</cell></row><row><cell>sided).</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Source: Table 10-3 in Study 20110142 report.</cell><cell></cell><cell></cell></row><row><cell cols="3">New vertebral fractures through Month 12</cell><cell></cell></row><row><cell cols="4">Through Month 12, romosozumab demonstrated a relative risk reduction for new vertebral</cell></row><row><cell></cell><cell cols="2">-54 ) compared with alendronate.</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_35"><head>Table 22 : Study 20110142 -Incidence of New Vertebral Fracture Through Month 12 -Primary Analysis Set for Vertebral Fractures</head><label>22</label><figDesc>Clinical Fracture through Month 12 and Month 24A reduction in the percentage of subjects with clinical fractures was observed at the end of the 12-month double-blind treatment period (romosozumab: 3.</figDesc><table><row><cell></cell><cell></cell><cell>Alendronate 70 mg QW/</cell><cell cols="2">Romosozumab 210 mg QM/</cell></row><row><cell>Statistic</cell><cell></cell><cell>Alendronate 70 mg QW</cell><cell cols="2">Alendronate 70 mg QW</cell></row><row><cell></cell><cell></cell><cell>(N=2047)</cell><cell>(N = 2046)</cell></row><row><cell></cell><cell></cell><cell>85/1703 (5.0)</cell><cell>55/1696 (3.2)</cell></row><row><cell>Comparison vs. ALN/ALN</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Absolute risk reduction a</cell><cell>(</cell><cell>)</cell><cell cols="2">1.84 (0.51, 3.17)</cell></row><row><cell>Relative risk reduction b</cell><cell></cell><cell></cell><cell>3 6</cell></row><row><cell>Odds ratio c</cell><cell></cell><cell></cell><cell cols="2">0.63 (0.44, 0.89)</cell></row><row><cell cols="5">N1 = Number of subjects in the primary analysis set for vertebral fractures with non-missing verified stratification</cell></row><row><cell>values</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">a Based on the Mantel-Haenszel method adjusted for verified age strata, baseline total hip BMD T-</cell><cell>-2.5, &gt; -2.5), and</cell></row><row><cell cols="3">presence of severe vertebral fracture at baseline status</cell><cell></cell></row><row><cell cols="3">b Calculated from risk ratio as 100 x (1 -risk ratio)</cell><cell></cell></row><row><cell cols="5">c Based on logistic regression model adjusted for verified age strata, baseline total hip BMD T-score, and presence of</cell></row><row><cell cols="2">severe vertebral fracture at baseline;</cell><cell></cell><cell></cell></row><row><cell cols="3">Source: Table 14-4.1.1 in study 20110142 report.</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_36"><head>Table 23 . Study 20110142 -Subject Incidence of Clinical Fracture through Month 12 and Month 24 (Full Analysis Set)</head><label>23</label><figDesc>The hazard ratio estimate is based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD Tscore, and presence of severe vertebral fracture at baseline. Source: Table 14-4.2.1 in study 20110142 report.</figDesc><table><row><cell></cell><cell cols="2">Alendronate 70 mg QW/</cell><cell>Romosozumab 210 mg QM/</cell><cell>Romosozumab 210 mg QM/</cell></row><row><cell></cell><cell></cell><cell>Alendronate 70 mg QW</cell><cell>Alendronate 70 mg QW</cell><cell>Alendronate 70 mg QW</cell></row><row><cell>Nonvertebral Fractures</cell><cell></cell><cell>(N = 2047)</cell><cell>(N = 2046)</cell><cell>vs.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Alendronate 70 mg QW/</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Alendronate 70 mg QW</cell></row><row><cell>Through Month 12</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Subjects with fractures -n</cell><cell>110 (5.4)</cell><cell>79 (3.9)</cell><cell></cell></row><row><cell>KM estimate a</cell><cell>-</cell><cell>5.6 (4.7, 6.8)</cell><cell>3.9 (3.1, 4.9)</cell><cell>1.8 (0.5, 3.1)</cell></row><row><cell>Hazard ratio b</cell><cell></cell><cell></cell><cell></cell><cell>0.72 (0.54, 0.96)</cell></row><row><cell>Through Month 24</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Subjects with fractures -n</cell><cell>197 (9.6)</cell><cell>146 (7.1)</cell><cell></cell></row><row><cell>KM estimate a</cell><cell>-</cell><cell>10.2 (8.9, 11.7)</cell><cell>7.4 (6.3, 8.7)</cell><cell>2.7 (0.8, 4.5)</cell></row><row><cell>Hazard ratio b</cell><cell></cell><cell></cell><cell></cell><cell>0.74 (0.59, 0.91)</cell></row><row><cell>KM=Kaplan-Meier</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">a Absolute risk difference is based on inverse-</cell><cell></cell><cell></cell><cell>-2.5,</cell></row><row><cell cols="3">&gt; -2.5), and presence of severe vertebral fracture at baseline.</cell><cell></cell><cell></cell></row><row><cell cols="4">Nonvertebral Fracture through Month 12 and Month 24</cell><cell></cell></row><row><cell cols="5">A reduction in the percentage of subjects with nonvertebral fractures was observed at the end</cell></row><row><cell cols="3">of the double-blind treatment period through M</cell><cell></cell><cell>ronate:</cell></row><row><cell cols="4">hazard ratio: 0.74). Through Month 24, nonvertebral frac</cell><cell></cell></row><row><cell cols="3">subjects in the romosozumab/alendronate group and 7</cell><cell></cell><cell></cell></row><row><cell cols="3">alendronate/alendronate group (hazard ratio: 0.81).</cell><cell></cell><cell></cell></row></table><note>b</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_37"><head>Table 24 . Study 20110142 -Subject Incidence of Nonvertebral Fracture through Month 12 and Month 24 (Full Analysis Set)</head><label>24</label><figDesc>The hazard ratio estimate is based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD Tscore, and presence of severe vertebral fracture at baseline. Source: Table 14-4.3.1 in study 20110142 report.</figDesc><table><row><cell></cell><cell cols="2">Alendronate 70 mg QW/</cell><cell cols="2">Romosozumab 210 mg QM/</cell><cell>Romosozumab 210 mg QM/</cell></row><row><cell></cell><cell></cell><cell>Alendronate 70 mg QW</cell><cell cols="2">Alendronate 70 mg QW</cell><cell>Alendronate 70 mg QW</cell></row><row><cell cols="2">Nonvertebral Fractures</cell><cell>(N = 2047)</cell><cell>(N = 2046)</cell><cell></cell><cell>vs.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Alendronate 70 mg QW/</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Alendronate 70 mg QW</cell></row><row><cell>Through Month 12</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Subjects with fractures -n</cell><cell>95 (4.6)</cell><cell>70 (3.4)</cell><cell></cell></row><row><cell>KM estimate a</cell><cell>-</cell><cell>4.9 (4.0, 6.0)</cell><cell>3.6 (2.9, 4.6)</cell><cell></cell><cell>1.4 (0.1, 2.6)</cell></row><row><cell>Hazard ratio b</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.74 (0.54, 1.01)</cell></row><row><cell>Through Month 24</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Subjects with fractures -n</cell><cell>159 (7.8)</cell><cell>129 (6.3)</cell><cell></cell></row><row><cell>KM estimate a</cell><cell>-</cell><cell>8.4 (7.2, 9.8)</cell><cell>6.8 (5.7, 8.0)</cell><cell></cell><cell>1.6 (-0.1, 3.3)</cell></row><row><cell>Hazard ratio b</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.81 (0.64, 1.02)</cell></row><row><cell>KM=Kaplan-Meier</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">a Absolute risk difference is based on inverse-</cell><cell></cell><cell></cell><cell></cell><cell>-2.5,</cell></row><row><cell cols="3">&gt; -2.5), and presence of severe vertebral fracture at baseline.</cell><cell></cell><cell></cell></row><row><cell cols="5">Hip Fracture through Month 12, Month 24 and Primary Analysis Period</cell></row><row><cell cols="3">Through Month 12, hip fractures were reported for</cell><cell cols="3">of the subjects in the romosozumab</cell></row><row><cell>group and</cell><cell cols="5">of subjects in the alendronate group (hazard ratio: 0.64). Through Month 24,</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="3">hazard ratio: 0.72). Through the</cell></row><row><cell cols="4">primary analysis period, hip fractures were reported for 2.0</cell><cell>in the</cell></row><row><cell cols="2">romosozumab/alendronate group</cell><cell></cell><cell cols="3">alendronate/alendronate group</cell></row><row><cell cols="2">(hazard ratio: 0.62).</cell><cell></cell><cell></cell><cell></cell></row></table><note>b</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_38"><head>Table 25 . Study 20110142 -Subject Incidence of Hip Fracture through Month 12, Month 24 and Primary Analysis (Full Analysis Set)</head><label>25</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>Alendronate 70 mg QW/</cell><cell>Romosozumab 210 mg QM/</cell><cell>Romosozumab 210 mg QM/</cell></row><row><cell></cell><cell></cell><cell>Alendronate 70 mg QW</cell><cell>Alendronate 70 mg QW</cell><cell>Alendronate 70 mg QW</cell></row><row><cell>Hip Fractures</cell><cell></cell><cell>(N = 2047)</cell><cell>(N = 2046)</cell><cell>vs.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Alendronate 70 mg QW/</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Alendronate 70 mg QW</cell></row><row><cell>Through Month 12</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Subjects with fractures -n</cell><cell>22 (1.1)</cell><cell>14 (0.7)</cell><cell></cell></row><row><cell>KM estimate a</cell><cell>-</cell><cell>1.1 (0.7, 1.7)</cell><cell>0.7 (0.4,1.2)</cell><cell>0.3 (-0.3, 0.9)</cell></row><row><cell>Hazard ratio b</cell><cell></cell><cell></cell><cell></cell><cell>0.64 (0.33, 1.26)</cell></row><row><cell>Through Month 24</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Subjects with fractures -n</cell><cell>43 (2.1)</cell><cell>31 (1.5)</cell><cell></cell></row><row><cell>KM estimate a</cell><cell>-</cell><cell>2.3 (1.7, 3.1)</cell><cell>1.6 (1.1, 2.3)</cell><cell>0.6 (-0.2, 1.4)</cell></row><row><cell>Hazard ratio b</cell><cell></cell><cell></cell><cell></cell><cell>0.72 (0.46, 1.15)</cell></row><row><cell cols="2">Through Primary Analysis Period</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Subjects with fractures -n</cell><cell>66 (3.2)</cell><cell>41 (2.0)</cell><cell></cell></row><row><cell>Hazard ratio b</cell><cell></cell><cell></cell><cell></cell><cell>0.62 (0.42, 0.92)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_39"><head>Table 26 . Study 20110142 -Bone Mineral Density Percent Change From Baseline by Antiromosozumab Antibody Status Through Month 18 (Romosozumab Arm in Primary Analysis Set for BMD: Descriptive Statistics, Observed Data) (20110142 Primary Analysis Period) Antiromosozumab Antibody Status through Month 18Imaging and Pharmacokinetics/Bone Turnover Marker/Biomarker Substudy</head><label>26</label><figDesc>At Month 12, the mean percent changes in BMD at the femoral neck were 5 (negative antibody status), 5 tiromosozumab antibody), and 8 neutralizing antiromosozumab antibody). Corresponding values at M 8</figDesc><table><row><cell>Percent change from</cell><cell>Antibody Negative</cell><cell>Binding Antibody</cell><cell cols="2">Neutralizing Antibody</cell></row><row><cell>baseline</cell><cell>(N=1450)</cell><cell>Positive (N=289)</cell><cell cols="2">Positive (N=11)</cell></row><row><cell>Lumbar Spine</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Month 12</cell><cell>14</cell><cell>14</cell><cell>14</cell></row><row><cell>Month 24</cell><cell>15</cell><cell>15</cell><cell>14</cell></row><row><cell>Total Hip</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Month 12</cell><cell>6</cell><cell>6</cell><cell>6</cell></row><row><cell>Month 24</cell><cell>7</cell><cell>8</cell><cell>7</cell></row><row><cell>Femoral neck</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Month 12</cell><cell>5</cell><cell>5</cell><cell>8</cell></row><row><cell>Month 24</cell><cell>6</cell><cell>7</cell><cell>8</cell></row><row><cell cols="5">At Month 12, the mean percent changes in BMD at the lumbar spine were 14 (negative</cell></row><row><cell>antibody status), 14</cell><cell cols="3">iromosozumab antibody), and 14</cell></row><row><cell cols="5">neutralizing antiromosozumab antibody). Corresponding values at Month 24 were 15</cell></row><row><cell>and 14</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">At Month 12, the mean percent changes in BMD at the total hip were 6</cell></row><row><cell>status), 6</cell><cell></cell><cell>, and 6</cell><cell></cell></row><row><cell cols="4">antiromosozumab antibody). Corresponding values at Month 24 were 7 8</cell><cell>7</cell></row><row><cell>respectively.</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_40"><head></head><label></label><figDesc>). After Month 12 (i.e., when all subjects received open-label alendronate), the median P1NP value in the romosozumab/alendronate group decreased below baseline at Month 15 and remained consistently reduced through Month 36. The median P1NP values in the alendronate/alendronate group at Months 15, 18, 24, and 36 did not vary appreciably from the Month 12 value and were similar to the median P1NP values in the romosozumab/alendronate group (i.e., no significant differences between the romosozumab/alendronate group and alendronate/alendronate group after Month 12). Similar to P1NP, serum concentrations of the other bone formation markers, BSAP and OC, peaked at Month 1 in romosozumab-treated subjects and declined through Month 12 (last assessment time point for these BTMs), returning to baseline by Month 9.</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_41"><head></head><label></label><figDesc>Incidence of non-vertebral fracture through Months 12 and 24 (testing for Months 12 and 24 were controlled by Hochberg procedure at 0.05 level within the step) 4. Incidence of clinical fracture through Month 24 5. Incidence of major non-vertebral fracture through Months 12 and 24 (testing for Months 12 and 24 were controlled by Hochberg procedure at 0.05 level within the step) 6. Incidence of new or worsening vertebral fracture through Months 12 and 24 (testing for Months 12 and 24 were controlled by Hochberg procedure at 0.05 level within the step) 7. Incidence of hip fracture through Months 12 and 24 (testing for Months 12 and 24 were controlled by Hochberg procedure at 0.05 levels within the step)</figDesc><table><row><cell>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell></row><row><cell>3. Spine radiographs were obtained at screening, Month 6, Month 12, and Month 24.</cell></row><row><cell>Morphometric vertebral fractures were determined using the semiquantitative method of</cell></row><row><cell>1. Incidence of new vertebral fracture through Months 12 and 24</cell></row><row><cell>2. Incidence of clinical fracture through Month 12</cell></row><row><cell>99</cell></row></table><note>Genant. Nonvertebral fractures were confirmed using radiographs, CT, or MRI. If these were not available, a medical report was acceptable. Bone mineral density of the hip and lumbar spine by DXA was obtained at baseline, Month 12 and Month 24. DXA and fracture outcomes were assessed using a central read facility.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_42"><head>. Fracture :</head><label>Fracture</label><figDesc>As outlined in the table below, the primary efficacy endpoints were met, with an absolute risk reduction in morphometric vertebral fract at Month at Month 24. The first secondary endpoint was clinical fracture at Month 12. The applicant defined clinical fracture as all nonvertebral fractures plus all symptomatic vertebral fractu were nonvertebral fractures. While treatment with romosozumab resulted in a significant reduction in clinical fractures at Month 12, the reduction in nonvertebral fractures was not significant at Month 12.</figDesc><table><row><cell>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell></row><row><cell>100</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_43"><head>Table 27 : Trial 20070337 Fracture Endpoints</head><label>27</label><figDesc></figDesc><table><row><cell></cell><cell>P l a c e b o /</cell><cell>Romosozumab/</cell><cell>Absolute Risk</cell><cell>Relative Risk</cell><cell></cell></row><row><cell></cell><cell>Denosumab</cell><cell>Denosumab</cell><cell>Reduction</cell><cell>Reduction</cell><cell>p-value</cell></row><row><cell>Primary Endpoints</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Vertebral Fracture,</cell><cell>1.8</cell><cell>0.5</cell><cell>1.3</cell><cell>73</cell><cell>&lt;0.001</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(0.8, 1.8)</cell><cell>(53, 84)</cell><cell></cell></row><row><cell></cell><cell>2.5</cell><cell>0.6</cell><cell>1.9</cell><cell>75</cell><cell>&lt;0.001</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(1.3, 2.5)</cell><cell>(60, 84)</cell><cell></cell></row><row><cell>Secondary Endpoints</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>2.5</cell><cell>1.6</cell><cell>1.2</cell><cell>36</cell><cell>0.008</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(0.4, 1.9)</cell><cell>(11, 54)</cell><cell></cell></row><row><cell cols="2">Nonvertebral Fracture, month 12, 2.1</cell><cell>1.6</cell><cell>0.8</cell><cell>25</cell><cell>0.096</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(0.1, 1.4)</cell><cell>(-5, 47)</cell><cell></cell></row><row><cell cols="2">Nonvertebral Fracture, month 24, 3.6</cell><cell>2.7</cell><cell>1.0</cell><cell>25</cell><cell>Testing</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(0.2, 1.9)</cell><cell>(3, 43)</cell><cell>stopped</cell></row><row><cell></cell><cell>4.1</cell><cell>2.8</cell><cell>1.4</cell><cell>33</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(0.5, 2.4)</cell><cell>(13, 48)</cell><cell></cell></row><row><cell></cell><cell>0.4</cell><cell>0.2</cell><cell>0.9</cell><cell>46</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(0.0, 0.6)</cell><cell>(-35, 78)</cell><cell></cell></row><row><cell></cell><cell>0.6</cell><cell>0.3</cell><cell>0.4</cell><cell>50</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>(0.0, 0.7)</cell><cell>(-4, 76)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>At Month</cell></row><row><cell cols="3">12, compared with placebo, romosozumab increased BMD</cell><cell></cell><cell></cell><cell>,</cell></row><row><cell>total hip, and</cell><cell cols="5">at the femoral neck. Romosozumab followed by denosumab maintained the</cell></row><row><cell cols="5">increases in BMD at the lumbar spine, total hip and femoral neck at Month 24.</cell><cell></cell></row></table><note>- Bone mineral density was not included in the hierarchy of secondary endpoints. It is an important metric for osteoporosis therapies and therefore, included in this efficacy discussion. As outlined in the table below, romosozumab significantly increased BMD at all sites.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_44"><head>Table 28 : Trial 20070337 Bone Mineral Density, Mean Percent Change, LOCF, ANCOVA</head><label>28</label><figDesc></figDesc><table><row><cell>Placebo/</cell><cell>Romosozumab/</cell><cell>LS Mean Difference</cell></row><row><cell>Denosumab</cell><cell>Denosumab</cell><cell>(95% CI)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_45"><head></head><label></label><figDesc>based on 464 subjects with clinical fractures with a median follow-up of 33 months. The clinical fracture risk reduction at Month 12 did not meet statistical significance when adjusted for multiplicity.</figDesc><table><row><cell>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell></row><row><cell>alendronate alone,</cell></row><row><cell>104</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_46"><head></head><label></label><figDesc>This section includes a comprehensive review of all safety results from Study 142. In addition, this section includes an evaluation of cardiovascular safety results from Studies 337 and 174 alongside those of Study 142. Since the safety results of Study 337 were reviewed in detail with the first review cycle, this section does not include detailed general safety results from Study 337. Rather, this section references key safety findings from Study 337 alongside the safety results of Study 142 (where references or comparisons are necessary).</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_47"><head>Table 30 Summary of Subject Incidence of Treatment-emergent Adverse Events (Safety Analysis Set -20110142 Primary Analysis) Double-blind Period Primary Analysis</head><label>30</label><figDesc></figDesc><table><row><cell>Period</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_48"><head></head><label></label><figDesc>During the 12-month double-blind treatment period, fatal adverse events occurred in 30 (1.5 subjects in the romosozumab group and 21 (1.0 events (preferred terms) resulting in death, which occurred in 2 or more subjects in the romosozumab or alendronate groups, respectively, were acute myocardial infarction</figDesc><table><row><cell cols="2">NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell><cell></cell></row><row><cell></cell><cell>(3</cell></row><row><cell cols="2">subjects; 0 subjects), cardiac failure (2 subjects; 1 subject), urosepsis (2 subjects; 0 subjects),</cell></row><row><cell cols="2">pneumonia (1 subject; 3 subjects), cerebrovascular accident (1 subject; 2 subjects), death (1</cell></row><row><cell cols="2">subject; 2 subjects), and sudden death (1 subject; 2 subjects).</cell></row><row><cell cols="2">During the primary analysis period, there was a cumulative total of 90 (4.4</cell></row><row><cell>romosozumab/alendronate group and 90 (4.</cell><cell>e alendronate/alendronate group.</cell></row><row><cell cols="2">romosozumab/alendronate or alendronate/alendronate treatment groups, respectively, were</cell></row><row><cell cols="2">acute myocardial infarction (5 subjects; 4 subjects), cardiac failure (3 subjects; 4 subjects),</cell></row><row><cell cols="2">cardiac failure congestive (2 subjects; 4 subjects), pneumonia (7 subjects; 8 subjects),</cell></row><row><cell cols="2">cerebrovascular accident (4 subjects; 3 subjects), death (13 subjects; 17 subjects), and sudden</cell></row><row><cell>death (4 subjects; 3 subjects).</cell><cell></cell></row><row><cell>110</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_50"><head>Table 31 . Subject Incidence of Treatment-emergent Fatal Adverse Events by System Organ Class (Safety Analysis Set -20110142 Primary Analysis</head><label>31</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>)</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">Double-blind Period</cell><cell cols="2">Primary Analysis Period</cell></row><row><cell>SOC</cell><cell>ALN</cell><cell>Romo</cell><cell>ALN 70 mg QW/</cell><cell>Romo 210 mg</cell></row><row><cell></cell><cell>70 mg QW</cell><cell>210 mg QM</cell><cell>ALN 70 mg QW</cell><cell>QM/</cell></row><row><cell></cell><cell>(N = 2014)</cell><cell>(N = 2040)</cell><cell>(N = 2014)</cell><cell>ALN 70 mg QW</cell></row><row><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>(N = 2040)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>n (%)</cell></row><row><cell>No. of subjects reporting</cell><cell>21 (1.0)</cell><cell>30 (1.5)</cell><cell>90 (4.5)</cell><cell>90 (4.4)</cell></row><row><cell>fatal TEAEs</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cardiac disorders</cell><cell>3 (0.1)</cell><cell>9 (0.4)</cell><cell>24 (1.2)</cell><cell>20 (1.0)</cell></row><row><cell>Infections and</cell><cell>5 (0.2)</cell><cell>5 (0.2)</cell><cell>13 (0.6)</cell><cell>15 (0.7)</cell></row><row><cell>infestations</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Neoplasms benign,</cell><cell>3 (0.1)</cell><cell>4 (0.2)</cell><cell>7 (0.3)</cell><cell>10 (0.5)</cell></row><row><cell>malignant and</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>unspecified (incl. cysts</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>and polyps)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Nervous system disorders</cell><cell>2 (&lt;0.1)</cell><cell>3 (0.1)</cell><cell>5 (0.2)</cell><cell>11 (0.2)</cell></row><row><cell>Vascular disorders</cell><cell>0</cell><cell>3 (0.1)</cell><cell>0</cell><cell>4 (0.2)</cell></row><row><cell>General disorders and</cell><cell>5 (0.2)</cell><cell>2 (&lt;0.1)</cell><cell>23 (1.1)</cell><cell>19 (0.9)</cell></row><row><cell>administration site</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>conditions</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Injury, poisoning and</cell><cell>0</cell><cell>2 (&lt;0.1)</cell><cell>3 (0.1)</cell><cell>3 (0.1)</cell></row><row><cell>procedural complications</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Respiratory, thoracic and</cell><cell>2 (&lt;0.1)</cell><cell>1 (&lt;0.1)</cell><cell>9 (0.4)</cell><cell>6 (0.3)</cell></row><row><cell>mediastinal disorders</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Psychiatric disorders</cell><cell>0</cell><cell>1 (&lt;0.1)</cell><cell>0</cell><cell>1 (&lt;0.1)</cell></row><row><cell>Hepatobiliary disorders</cell><cell>1 (&lt;0.1)</cell><cell>0</cell><cell>2 (&lt;0.1)</cell><cell>0</cell></row><row><cell>Gastrointestinal disorders</cell><cell>0</cell><cell>0</cell><cell>2 (&lt;0.1)</cell><cell>1 (&lt;0.1)</cell></row><row><cell>Renal and urinary</cell><cell>0</cell><cell>0</cell><cell>2 (&lt;0.1)</cell><cell>0</cell></row><row><cell>disorders</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Surgical and medical</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>1 (&lt;0.1)</cell></row><row><cell>procedures</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">ALN=alendronate; Romo=romosozumab</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">*Source: modified from Table 12-6 of CSR</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>further in</cell></row></table><note>In summary, the incidence of fatal adverse events (overall and by systems organ class) was similar between the two treatment groups in Study 142, with the exception of deaths due to cardiac disorders in the 12-month double-blind period, which occurred in 3 alendronate-treated subjects and in 9 romosozumab-treated subjects. Cardiac disorders are discussed</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_52"><head>Table 32 . Subject Incidence of Treatment-emergent Serious Adverse Events by SOC and (20110142 Primary Analysis) Double-blind Period Primary</head><label>32</label><figDesc></figDesc><table><row><cell>Analysis Period</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_53"><head>Table 33 . Summary of Subject Incidence of Treatment-emergent Adverse Events of Interest (Safety Analysis Set -20110142 Primary Analysis) Double-blind Period Primary Analysis Period Event of</head><label>33</label><figDesc>in the romosozumab/alendronate group and 1 in the alendronate/alendronate group), both of which occurred in the alendronate open-label treatment phase. Six events of AFF occurred (2 in the romosozumab/alendronate group and 4 in the alendronate/alendronate group), all of which occurred in the alendronate open-label treatment phase.</figDesc><table><row><cell>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_54"><head></head><label></label><figDesc>Hyperostosis with adverse neurologic consequences is a feature of diseases of sclerostin underexpression (sclerosteosis and van Buchem disease). The applicant constructed a MedDRA search strategy to identify events related to hyperostosis.</figDesc><table><row><cell>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell><cell></cell></row><row><cell>{Evenity, romosozumab}</cell><cell></cell></row><row><cell>Adverse Events of Hyperostosis</cell><cell></cell></row><row><cell>During the 12-month double-</cell><cell>and</cell></row><row><cell>ported to have adverse events of</cell><cell></cell></row><row><cell cols="2">hyperostosis. Adverse events (preferred terms) reported by subjects in the romosozumab and</cell></row><row><cell>Adverse events of exostosis were primarily heel and calcaneal spurs. Serious hyperostosis</cell><cell></cell></row><row><cell>events were reported for</cell><cell></cell></row><row><cell cols="2">romosozumab group. Serious hyperostosis events occurring in the alendronate group were</cell></row><row><cell cols="2">cervical spinal stenosis and lumbar spinal stenosis; both subjects were hospitalized and treated</cell></row><row><cell>with medication.</cell><cell></cell></row><row><cell cols="2">b/alendronate group</cell></row><row><cell cols="2">have adverse</cell></row><row><cell>events of hyperostosis. Adverse events (preferred terms) reported by</cell><cell></cell></row><row><cell cols="2">romosozumab/alendronate and alendronate/alendronate groups, respectively, were exostosis</cell></row><row><cell>121</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_56"><head>Table 34 . Subject Incidence of Treatment- Subject Incidence in Either Treatment Group) (Safety Analysis Set) (20110142 Primary Analysis</head><label>34</label><figDesc></figDesc><table><row><cell>)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>12-Month Double-blind Study Period</cell><cell></cell></row><row><cell></cell><cell>A L N</cell><cell>Romo</cell></row><row><cell></cell><cell>70 mg QW</cell><cell>210 mg QM</cell></row><row><cell></cell><cell>(N = 2014)</cell><cell>(N = 2040)</cell></row><row><cell></cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>Number of subjects</cell><cell>1584 (78.6)</cell><cell>1544 (75.7)</cell></row><row><cell>reporting TEAEs</cell><cell></cell><cell></cell></row><row><cell>Nasopharyngitis</cell><cell>218 (10.8)</cell><cell>213 (10.4)</cell></row><row><cell>Back pain</cell><cell>228 (11.3)</cell><cell>186 (9.1)</cell></row><row><cell>Arthralgia</cell><cell>193 (9.6)</cell><cell>166 (8.1)</cell></row><row><cell>Fall</cell><cell>152 (7.5)</cell><cell>131 (6.4)</cell></row><row><cell>Upper respiratory tract</cell><cell>132 (6.6)</cell><cell>130 (6.4)</cell></row><row><cell>infection</cell><cell></cell><cell></cell></row><row><cell>Pain in extremity</cell><cell>131 (6.5)</cell><cell>121 (5.9)</cell></row><row><cell>Osteoarthritis</cell><cell>112 (5.6)</cell><cell>116 (5.7)</cell></row><row><cell>Hypertension</cell><cell>132 (6.6)</cell><cell>114 (5.6)</cell></row><row><cell>Headache</cell><cell>110 (5.5)</cell><cell>105 (5.1)</cell></row><row><cell>Urinary tract infection</cell><cell>134 (6.7)</cell><cell>104 (5.1)</cell></row><row><cell>Diarrhea</cell><cell>93 (4.6)</cell><cell>103 (5.0)</cell></row><row><cell>Bronchitis</cell><cell>101 (5.0)</cell><cell>89 (4.4)</cell></row><row><cell></cell><cell>Primary Analysis Period</cell><cell></cell></row><row><cell></cell><cell>ALN 70 mg QW/</cell><cell>Romo 210 mg</cell></row><row><cell></cell><cell>ALN 70 mg QW</cell><cell>QM/</cell></row><row><cell></cell><cell>(N = 2014)</cell><cell>ALN 70 mg QW</cell></row><row><cell></cell><cell>n (%)</cell><cell>(N = 2040)</cell></row><row><cell></cell><cell></cell><cell>n (%)</cell></row><row><cell>Number of subjects</cell><cell>1784 (88.6)</cell><cell>1766 (86.6)</cell></row><row><cell>reporting TEAEs</cell><cell></cell><cell></cell></row><row><cell>Nasopharyngitis</cell><cell>373 (18.5)</cell><cell>363 (17.8)</cell></row><row><cell>Back pain</cell><cell>393 (19.5)</cell><cell>329 (16.1)</cell></row><row><cell>Arthralgia</cell><cell>363 (18.0)</cell><cell>329 (16.1)</cell></row><row><cell>Fall</cell><cell>336 (16.7)</cell><cell>282 (13.8)</cell></row><row><cell>Hypertension</cell><cell>225 (11.2)</cell><cell>227 (11.1)</cell></row><row><cell>Pain in extremity</cell><cell>246 (12.2)</cell><cell>225 (11.0)</cell></row><row><cell>Upper respiratory tract</cell><cell>220 (10.9)</cell><cell>200 (9.8)</cell></row><row><cell>infection</cell><cell></cell><cell></cell></row><row><cell>Osteoarthritis</cell><cell>203 (10.1)</cell><cell>195 (9.6)</cell></row><row><cell>Urinary tract infection</cell><cell>243 (12.1)</cell><cell>186 (9.1)</cell></row><row><cell>Bronchitis</cell><cell>180 (8.9)</cell><cell>177 (8.7)</cell></row><row><cell>Diarrhea</cell><cell>166 (8.2)</cell><cell>163 (8.0)</cell></row><row><cell>Headache</cell><cell>186 (9.2)</cell><cell>160 (7.8)</cell></row><row><cell>Dizziness</cell><cell>150 (7.4)</cell><cell>150 (7.4)</cell></row><row><cell>Cough</cell><cell>111 (5.5)</cell><cell>140 (6.9)</cell></row><row><cell>Musculoskeletal pain</cell><cell>151 (7.5)</cell><cell>138 (6.8)</cell></row><row><cell>Muscle spasms</cell><cell>125 (6.2)</cell><cell>119 (5.8)</cell></row><row><cell>Constipation</cell><cell>131 (6.5)</cell><cell>118 (5.8)</cell></row></table><note>The overall pattern and distribution of TEAEs does not raise any additional new safety concerns.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_57"><head>Table 35 CTCAE (Version 3) Grades and Associated Abnormal Albumin-corrected Serum Calcium Values</head><label>35</label><figDesc>No subject had a greater than grade 2 below-normal serum corrected calcium result at any time during the study.</figDesc><table><row><cell>Hypocalcemia</cell><cell>Hypercalcemia</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_58"><head>Table 36 CTCAE (Version 3) Grades for Abnormal Serum Phosphorus Values</head><label>36</label><figDesc></figDesc><table><row><cell>Hypophosphatemia</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_59"><head>Table 37 Subject Incidence of Treatment-emergent Injection Site Reaction, Hypersensitivity, and Autoimmune Disorders in the 12-Month Double-blind Period by Binding Anti- romosozumab Antibody Status Through Month 18 by Preferred Term (Safety Analysis Set) (20110142 Primary Analysis) Antiromosozumab Antibody Status through Month 18</head><label></label><figDesc></figDesc><table><row><cell></cell><cell>Antibody Negative</cell><cell>Binding Antibody</cell><cell>Neutralizing Antibody</cell></row><row><cell></cell><cell>(N=1639)</cell><cell>Positive (N=316)</cell><cell>Positive (N=12)</cell></row><row><cell>Immune-Related</cell><cell>174 (10.6)</cell><cell>30 (9.5)</cell><cell>1 (8.3)</cell></row><row><cell>Treatment-Emergent</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Adverse Event</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Autoimmune</cell><cell>23 (1.4)</cell><cell>1 (0.3)</cell><cell>0</cell></row><row><cell>disorders</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hypersensitivity</cell><cell>104 (6.3)</cell><cell>17 (5.4)</cell><cell>0</cell></row><row><cell>Injection site</cell><cell>68 (4.1)</cell><cell>16 (5.1)</cell><cell>1 (8.3)</cell></row><row><cell>reactions</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">The immunogenicity results of Study 142 are generally consistent with those of Study 337.</cell></row><row><cell cols="4">pre-existing binding antibodies at baseline; none had pre-existing neutralizing antibodies. For</cell></row><row><cell></cell><cell></cell><cell></cell><cell>s developed neutralizing</cell></row><row><cell>antibodies.</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_60"><head></head><label></label><figDesc>Serious adverse events were defined in all clinical studies based on the International Conference on Harmonisation Guideline for Good Clinical Practice (E6). 2. Posthoc review of all adverse event data (serious and nonserious) in Studies 337, 142,</figDesc><table><row><cell>NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab}</cell></row><row><cell>adjudication.</cell></row><row><cell>133</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_62"><head>Table 38 . Subject Incidence of Positively-adjudicated Cardiovascular Serious Adverse Events by Category and Study in the 12-Month Double-blind Period (Safety Analysis Set) (DCRI Adjudication of Studies 337, 142, and 174)</head><label>38</label><figDesc></figDesc><table><row><cell>*Source: Modified from Table 14-6.2.9 of CV report.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_64"><head>Table 39 . Subject Incidence of Positively-adjudicated Cardiovascular Serious Adverse Events by Study in the Overall Study Period (Safety Analysis Set) (DCRI Adjudication of Studies 337, 142, and 174)</head><label>39</label><figDesc></figDesc><table><row><cell cols="2">*Source: Modified from Table 14-6.2.11 of CV report.</cell></row><row><cell cols="2">For the meta-analysis of events during the overall study periods, the subject incidence of</cell></row><row><cell cols="2">positively-adjudicated CV SAEs was balanced between the romosozumab/follow-on therapy</cell></row><row><cell>group (i.e.</cell><cell></cell></row><row><cell>follow-</cell><cell>.e.</cell></row><row><cell></cell><cell>e overall study period;</cell></row><row><cell>hazard ratio 1.06 (</cell><cell>0.89, 1.25).</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_65"><head>139 Table 40. Summary of MACE Composite and Individual Components Through Month 12 and in the Overall Study Period (Safety Analysis Set) (DCRI Adjudication of Studies 20070337, 20110142, and 20110174)</head><label></label><figDesc></figDesc><table><row><cell cols="2">NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell cols="2">{Evenity, romosozumab} {Evenity, romosozumab}</cell></row><row><cell cols="3">For the meta-analysis of Studies 142, 337, and 174, the incidence of MACE through Month 12</cell></row><row><cell></cell><cell>.</cell><cell>tio: 1.40</cell></row><row><cell cols="3">The FDA performed an additional meta-analysis of MACE incidence through Month 12 utilizing</cell></row><row><cell cols="3">only Study 337 and Study 142, as this analysis includes only the intended population of women</cell></row><row><cell></cell><cell></cell><cell>rom</cell></row><row><cell cols="3">that of the applicant's meta-analysis of all 3 studies (as listed above), which is not unexpected</cell></row><row><cell cols="2">given the few MACE events in Study 174.</cell></row><row><cell cols="3">Additionally, given the discrepant results between Study 337 and Study 142, the FDA also</cell></row><row><cell cols="3">investigated whether there might be a cardioprotective effect of alendronate by conducting an</cell></row><row><cell cols="3">exploratory network meta-analysis to indirectly estimate the hazard ratio of MACE for</cell></row><row><cell cols="3">alendronate from Study 142 vs. placebo from Study 337 during the first year of the two studies.</cell></row><row><cell></cell><cell cols="2">0.27-1.14) for alendronate vs. placebo.</cell></row><row><cell cols="3">Similar results were obtained when Study 174 was also included in the meta-analysis (hazard</cell></row><row><cell>ratio 0.57</cell><cell cols="2">-1.17), suggesting a potential cardioprotective effect of alendronate.</cell></row><row><cell cols="3">However, this exploratory network analysis cannot definitively address the cardiovascular risk</cell></row><row><cell cols="3">of alendronate. In addition, review of the literature and placebo-controlled alendronate trials</cell></row><row><cell cols="3">reviewed previously by FDA does not suggest a cardioprotective effect of alendronate.</cell></row><row><cell cols="2">*Source: Table 5 of Comprehensive Cardiovascular Report</cell></row><row><cell cols="2">12-Month Double-blind Period</cell></row><row><cell cols="3">In Study 142, the hazard ratio for MACE during the 12-month double-blind period was 1.87</cell></row><row><cell cols="3">subjects in the alendronate group with MACE. Higher incidences in positively-adjudicated</cell></row><row><cell></cell><cell>.</cell><cell>.</cell></row><row><cell cols="3">in the romosozumab group vs. the alendronate group contributed to the imbalance in the first</cell></row><row><cell>year of treatment. T</cell><cell></cell></row><row><cell>respectively.</cell><cell></cell></row><row><cell cols="3">Study 337 showed no imbalance between treatment groups in the incidence of MACE during</cell></row><row><cell>the double-</cell><cell></cell></row><row><cell>CI: 0.62, 1.72).</cell><cell></cell></row><row><cell></cell><cell>140</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_66"><head>Table 41 Modified-RUTH Criteria for Defining a High-risk Population for Cardiovascular Events</head><label>41</label><figDesc></figDesc><table><row><cell>*Source: Table 1 of Supplemental Statistical Analysis Plan</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_69"><head>Table 42 . Subject Incidence of Positively-adjudicated Cardiovascular Serious Adverse Event or Negatively Adjudicated Due to Insufficient Documentation (Safety Analysis Set) (DCRI Adjudication of Studies 20110174, 20070337, and 20110142)</head><label>42</label><figDesc></figDesc><table><row><cell>*Source: Table 9 of CCR</cell></row><row><cell>Reference ID: 4416253</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_70"><head>Table 43 . Comparison of Subject Incidences of All-Cause Death, Myocardial Infarction, and Stroke Based on Treatment-emergent Adverse Event Reporting and Adjudication by DCRI and the TIMI Study Group During the 12-Month Double-blind Period (Safety Analysis Set) (Studies 20110142, 20070337, and 20110174)</head><label>43</label><figDesc></figDesc><table><row><cell>*Source: Table 10 of CCR</cell></row><row><cell>In summary, the comprehensive clinical assessment did not result in differences in the</cell></row><row><cell>interpretation of the imbalance in cardiovascular events in Study 142 between adjudication</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_78"><head>Prescription Drug Labeling</head><label></label><figDesc></figDesc><table><row><cell cols="5">NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062}</cell></row><row><cell>{Evenity, romosozumab} {Evenity, romosozumab}</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="3">pre-existing hypocalcemia.</cell><cell>correction of hypocalcemia</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>prior to initiation of therapy.</cell></row><row><cell cols="2">5 (Warnings and Precautions) 5.1 entitled</cell><cell cols="2">(b) (4)</cell><cell>5.1 retitled "Major Adverse</cell></row><row><cell></cell><cell cols="2">(b) (4)</cell><cell>; no</cell><cell>Cardiac Events"</cell></row><row><cell></cell><cell>discussion of specific</cell><cell></cell><cell></cell><cell>Added that EVENITY should</cell></row><row><cell></cell><cell cols="2">population for whom</cell><cell></cell><cell>not be prescribed for</cell></row><row><cell></cell><cell cols="3">EVENITY should not be</cell><cell>patients who have had a</cell></row><row><cell></cell><cell>prescribed</cell><cell></cell><cell></cell><cell>myocardial infarction or</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>stroke within one year, and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>to consider whether the</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>benefits outweigh the risks in</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>patients with other</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>cardiovascular risk factors.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Added recommendation to</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>discontinue EVENITY if</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>myocardial infarction or</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>stroke occurs while on</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>therapy.</cell></row><row><cell>6.1 (Adverse Reactions,</cell><cell cols="2">Did not include major</cell><cell></cell><cell>Added results for major</cell></row><row><cell>Clinical Trials Experience)</cell><cell cols="3">adverse cardiac event results</cell><cell>adverse cardiac events in</cell></row><row><cell></cell><cell cols="3">(instead had this in Section</cell><cell>Studies 337 and 142.</cell></row><row><cell></cell><cell>5).</cell><cell></cell><cell></cell></row><row><cell>14 (Clinical Studies)</cell><cell>Results of Study 142</cell><cell></cell><cell></cell><cell>Results of Study 337</cell></row><row><cell></cell><cell>presented first.</cell><cell></cell><cell></cell><cell>presented first (the placebo-</cell></row><row><cell cols="5">Summary of Significant Labeling Changes (High level changes and not direct quotations) controlled study that was</cell></row><row><cell>Section</cell><cell cols="3">Proposed Labeling</cell><cell>Approved Labeling completed first)</cell></row><row><cell>Boxed Warning</cell><cell cols="3">No mention of specific</cell><cell>Added that EVENITY should</cell><cell>(b) (4)</cell></row><row><cell></cell><cell cols="2">population for whom</cell><cell></cell><cell>not be prescribed for</cell></row><row><cell></cell><cell cols="3">EVENITY should not be</cell><cell>patients who have had a</cell></row><row><cell></cell><cell>prescribed.</cell><cell></cell><cell></cell><cell>myocardial infarction or</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>stroke within one year, and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>to consider whether the</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>benefits outweigh the risks in</cell></row><row><cell></cell><cell cols="3">Included results for new</cell><cell>patients with other Removed all results that did</cell></row><row><cell></cell><cell cols="3">vertebral, nonvertebral and</cell><cell>cardiovascular risk factors. not meet statistical</cell></row><row><cell></cell><cell cols="3">hip fractures at all major</cell><cell>Added recommendation to significance.</cell></row><row><cell></cell><cell cols="3">timepoints, regardless of</cell><cell>discontinue EVENITY if</cell></row><row><cell></cell><cell cols="3">statistical significance.</cell><cell>myocardial infarction or</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>stroke occurs while on</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>therapy.</cell></row><row><cell>1 (Indications and Usage)</cell><cell cols="3">Did not discuss limitations of</cell><cell>Added language regarding</cell></row><row><cell></cell><cell>use.</cell><cell></cell><cell></cell><cell>one-year limitation of use.</cell></row><row><cell>4 (Contraindications)</cell><cell cols="4">Did not discuss correction of Added language regarding</cell></row><row><cell></cell><cell>165 166</cell><cell></cell><cell></cell></row><row><cell>Reference ID: 4416253</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_79"><head>Table 44 Impact of Immunogenicity on Steady-State Trough Serum Romosozumab Concentrations in Pooled Studies 20060326, 20101291, 20070337, and 20110142. Time MeanSD Serum Romosozumab Concentrations, mcg/mL (n) ADA Negative ADA positive NAb positive</head><label>44</label><figDesc></figDesc><table><row><cell>Month 3</cell><cell>8.655.83 (420)</cell><cell>7.035.17 (100)</cell><cell>4.761.86 (3)</cell></row><row><cell>Month 6</cell><cell>9.246.36 (462)</cell><cell>7.215.85 (112)</cell><cell>3.492.92 (7)</cell></row><row><cell>Month 9</cell><cell>10.46.83 (444)</cell><cell>8.837.62 (112)</cell><cell>3.844.17 (6)</cell></row><row><cell>Month 12</cell><cell>10.67.27 (475)</cell><cell>9.727.48 (110)</cell><cell>4.074.39 (7)</cell></row><row><cell cols="4">Source of data: Table 7&amp;8, Summary of Clinical Pharmacology studies. Postmenopausal Women with Low BMD or</cell></row><row><cell cols="4">Osteoporosis received romosozumab 210 monthly SC. ADA, anti-drug antibodies; NAb, neutralizing antibodies</cell></row><row><cell cols="4">Overall, there is no evidence that immunogenicity had an impact on efficacy or safety of</cell></row><row><cell>romosozumab.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">The Office of Clinical Pharmacology Review (DARRTS Reference ID 4076576) for the original BLA</cell></row><row><cell cols="4">submission determined that there was no evidence that development of ADA had an impact on</cell></row><row><cell cols="4">efficacy measured by bone mineral density (BMD). This finding was further supported by the</cell></row><row><cell cols="4">results from Study 20110142 in the resubmission, in which the BMD percent change from</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_80"><head>Table 45 Effect of Immunogenicity on Lumbar Spine Bone Mineral Density Percent Change from Baseline in Study 20110142 Time Lumbar Spine BMD Change% from Baseline (n) ADA Negative ADA Positive NAb Positive</head><label>45</label><figDesc></figDesc><table><row><cell>Month 12</cell><cell>13.77.2 (1421)</cell><cell>13.87.1 (283)</cell><cell>13.88.5 (11)</cell></row><row><cell>Month 24</cell><cell>15.48.4 (1299)</cell><cell>14.88.7 (263)</cell><cell>14.07.6 (11)</cell></row><row><cell>Month 36</cell><cell>15.19.3 (600)</cell><cell>14.49.5 (134)</cell><cell>18.17.1 (6)</cell></row><row><cell cols="2">Source of data: Table 14f-10.3.1 of the CSR 20110142</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_81"><head>Table 46 Effect of Immunogenicity on Safety by Immunogenicity Status Through Month 18 in Study 20110142 Adverse Events Alendronate Subjects (N = 2014) a Romosozumab Subjects b ADA negative</head><label></label><figDesc></figDesc><table><row><cell></cell><cell>ADA Positive</cell><cell>NAb Positive</cell></row><row><cell>(N = 1639)</cell><cell>(N = 316) c</cell><cell>(N=12)</cell></row><row><cell>Injection site reactions, n (%)</cell><cell></cell><cell></cell></row><row><cell>Hypersensitivity, n (%)</cell><cell></cell><cell>0</cell></row><row><cell>Autoimmune disorders, n (%)</cell><cell></cell><cell>0</cell></row><row><cell cols="3">a: Subjects who received at least one dose of investigational product in the 12-month double-blind period.</cell></row><row><cell cols="2">Immunogenicity testing was not conducted in subjects randomized to alendronate.</cell><cell></cell></row><row><cell cols="3">b: Subjects who received at least one dose of romosozumab and with at least one post-baseline anti-romosozumab</cell></row><row><cell>antibody data through month 18</cell><cell></cell><cell></cell></row><row><cell cols="3">c: Sum of subjects who had pre-existing ADA (n=6) and subjects who had treatment-emergent ADA (n=310).</cell></row><row><cell>Source of data: Table 14-10.2.1.and 14-10.2.2 of the CSR 20110142.</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_82"><head>Table 47 Serum Romosozumab Concentrations in Study 20110142 Trough Serum Romosozumab Concentrations (mcg/mL),</head><label>47</label><figDesc></figDesc><table><row><cell></cell><cell>Baseline</cell><cell>Month 1</cell><cell>Month 3</cell><cell>Month 6</cell><cell>Month 9</cell><cell>Month 12</cell></row><row><cell>MeanSD</cell><cell>0</cell><cell>7.74.5</cell><cell>10.26.5</cell><cell>10.77.1</cell><cell>13.29.5</cell><cell>13.48.9</cell></row><row><cell>(N)</cell><cell>(143)</cell><cell>(121)</cell><cell>(101)</cell><cell>(110)</cell><cell>(94)</cell><cell>(104)</cell></row><row><cell cols="6">Source of data: Table 11-3, Clinical Study Report 20110142. Subjects received SC administration of 210</cell><cell></cell></row><row><cell cols="7">romosozumab QM. Romosozumab concentrations in human serum were determined using a validated enzyme-</cell></row><row><cell cols="7">linked immunosorbent assay (ELISA). Refer to Office of Clinical Pharmacology Review (DARRTS Reference ID</cell></row><row><cell cols="5">4076576) for detailed information of the assay performance and validation results.</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_83"><head>Table 48 Impact of Immunogenicity on Serum Romosozumab Concentrations in Study 20110142 Time MeanSD Serum Romosozumab concentrations, mcg/mL (n) ADA Negative ADA Positive</head><label></label><figDesc></figDesc><table><row><cell>Month 1</cell><cell>8.04.4 (95)</cell><cell>6.94.7 (26)</cell></row><row><cell>Month 3</cell><cell>10.46.4 (81)</cell><cell>9.67.0 (20)</cell></row><row><cell>Month 6</cell><cell>11.27.1 (83)</cell><cell>9.06.9 (27)</cell></row><row><cell>Month 9</cell><cell>13.38.3 (75)</cell><cell>12.713.5 (19)</cell></row><row><cell>Month 12</cell><cell>13.59.0 (83)</cell><cell>12.58.8 (21)</cell></row><row><cell cols="3">Source of data: Table 11-4, Clinical Study Report 20110142. Subjects received SC administration of 210</cell></row><row><cell cols="3">romosozumab QM. Romosozumab concentrations in human serum were determined using a validated enzyme-</cell></row><row><cell cols="3">linked immunosorbent assay (ELISA). Refer to Office of Clinical Pharmacology Review (DARRTS Reference ID</cell></row><row><cell cols="2">4076576) for detailed information of the assay performance and validation results.</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_84"><head>Table 49 : Summary of PK Dataset and Identified Significant Covariates in the Original and Updated Population PK Reports Report</head><label>49</label><figDesc></figDesc><table><row><cell></cell><cell>119384A (Original)</cell><cell>Addendum 1</cell><cell>Updated Model</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(Addendum 3)</cell></row><row><cell>Study</cell><cell>Eight phase 1 studies:</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_87"><head>Table 1 : Study 20070337 DCRI-Adjudicated Positive Cardiovascular SAEs</head><label>1</label><figDesc></figDesc><table><row><cell>12 Months</cell><cell cols="2">Placebo Romosozumab</cell><cell>Odds Ratio (95% CI)</cell></row><row><cell>N</cell><cell>3576</cell><cell>3581</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_88"><head>Table 2 : Study 20110142 and Study 20110174 DCRI-Adjudicated cardiovascular SAEs Study 20110142 (12 months)MACE defined as composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke</head><label>2</label><figDesc></figDesc><table><row><cell>Alendronate</cell><cell>Romosozumab</cell><cell>Odds Ratio (95% CI)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_89"><head>Table 3 : Events triggering Adjudication for DCRI and TIMI DCRI TIMI Death-all events -Cardiovascular (due to MI, sudden cardiac death, HF or shock, stroke, cardiovascular interventions, cardiovascular hemorrhage, other cardiovascular causes-pulmonary embolism or peripheral arterial) -non-Cardiovascular (cancer, lower respiratory, renal, GI, infection, accidents, non-intracranial hemorrhage, complications of elective non- Cardiovascular surgery, neurodegenerative conditions) -undetermined Death-all events -Cardiovascular (due to MI, sudden cardiac death, HF or shock, stroke, cardiac procedures, cardiovascular hemorrhage, other cardiovascular causes-pulmonary embolism or peripheral arterial) -non-Cardiovascular (pulmonary, renal, GI, hepatobiliary, pancreatic, infection, inflammatory/autoimmune, hemorrhage, non- Cardiovascular procedure) -undetermined Cerebrovascular Event -Stroke (Ischemic, Hemorrhagic, Uncertain) -TIA Cerebrovascular Event -Stroke (Ischemic, Hemorrhagic, Uncertain) -TIA Cardiac Ischemic Event -MI (STE, ST-dep, TWA, Path QW, biomarkers, MI Types 1-T5) -Angina requiring hospitalization -Coronary Revascularization (PCI or CABG) Cardiac Ischemic Events -MI (STE, ST-dep, TWA, Path QW, biomarkers, MI Types T1-T5) -Hospitalization for Unstable Angina -Coronary Revascularization (PCI or CABG) Heart Failure Hospitalization (signs &amp; symptoms) Heart Failure (signs &amp; symptoms) -Heart Failure Hospitalization -Urgent Visit (no hospitalization) Non-coronary Revascularization Non-coronary Revascularization Peripheral Vascular Events not needing revasc (requires hospitalization and symptoms: dry gangrene, ulceration, severe claudication, acute kidney injury, amputation) Peripheral Vascular Events not needing revasc. (requires hospitalization and symptoms: dry gangrene, ulceration, severe claudication, acute kidney injury, amputation)</head><label>3</label><figDesc></figDesc><table><row><cell>Source: Clinical Events Classification Charter (DCRI: pages 1-96; TIMI: pages 96-169)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_90"><head>Table 4 : Comparative Sample Source Documents for Adjudication: DCRI and TIMI Event DCRI TIMI Death -Death summary -Autopsy report -Investigator Narrative -Death Summary -Autopsy Report -Investigator Narrative (if no source documents available) -Death Certificate Cerebrovascular Event -Discharge Summary -Neurology Consult Notes -CT/MR report -Autopsy report -Investigator Narrative -Discharge Summary -Neurology Consult Notes -CT/MR/Angiogram Reports -Autopsy Report -Investigator Narrative (if no source documents available) -Admission History / Physical -Progress Notes Cardiac Ischemic Event -Discharge Summary -Procedure Reports (PCI/CABG) -ECGs (event, pre/post event) -Cardiac Markers with ULN -Investigator Narrative -Discharge Summary -Procedure Reports -ECGs (event, pre/post event) -Cardiac Biomarkers prior 30 days and during hospitalization -Investigator Narrative (if no source documents available) -Admission History / Physical -Coronary Revascularization Report (PCI or CABG) -Autopsy Report Heart Failure -Discharge Summary -Admission Hx / Physical -Medication Records -Chest X-ray Reports -BNP Results -Pulmonary Wedge Pressure -Investigator Narrative -Discharge Summary -Admission History / Physical -Progress / Consult Notes -Chest X-ray/ Imaging Reports -BNP / NT-pro BNP Results -Right Heart Cath Results -Investigator Narrative (if no source documents available) -Cardiac Echo -Cardiac Ischemia Biomarkers Non-coronary revascularization -Discharge Summary -Procedure Reports -Investigator Narrative -Discharge Summary -Admission History / Physical -Admission History / Physical -Fontaine / Rutherford Claudication scales -Imaging Reports -Ankle/Brachial Index -Percutaneous Procedure Reports -Surgical Revascularization Reports -Autopsy Report -Investigator Narrative (if no source documents available) Peripheral vascular event not needing revasc. -Discharge Summary -Procedure Reports -Discharge Summary -Admission History / Physical -Fontaine / Rutherford Claudication scales -Imaging Reports -Ankle/Brachial Index -Procedures other than revasc (i.e., amputation) -Autopsy Report -Investigator Narrative (if no source documents available)</head><label>4</label><figDesc></figDesc><table><row><cell>Source: Clinical Events Classification Charter (DCRI: page 32; TIMI: page 128-129)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_91"><head>Table 5 : Baseline Demographics Study 20070337 Study 20110142 Study 20110174 Placebo Romosozumab Alendronate Romosozumab Placebo Romosozumab N=3576</head><label>5</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>N= 3581</cell><cell>N= 2014</cell><cell>N=2040</cell><cell>N=81</cell><cell>N=163</cell></row><row><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>Age (years)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (SD)</cell><cell>71 (7)</cell><cell>71 (7)</cell><cell>74 (8)</cell><cell>74 (8)</cell><cell>71 (7)</cell><cell>72 (7)</cell></row><row><cell>Median</cell><cell>70</cell><cell>70</cell><cell>75</cell><cell>75</cell><cell>72</cell><cell>73</cell></row><row><cell>Min, Max</cell><cell>55, 89</cell><cell>55, 90</cell><cell>55, 90</cell><cell>55, 90</cell><cell>55, 85</cell><cell>56, 89</cell></row><row><cell>Age Group</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt; 75 years</cell><cell cols="2">2641 (69) 2464 (69)</cell><cell>965 (48)</cell><cell>970 (48)</cell><cell>53 (65)</cell><cell>93 (57)</cell></row><row><cell>&gt; 75 years</cell><cell cols="2">1115 (31) 1117 (31)</cell><cell>1049 (52)</cell><cell>1070 (53)</cell><cell>28 (35)</cell><cell>70 (43)</cell></row><row><cell>Smoking Hx</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Current/Former</cell><cell cols="2">1037 (29) 982 (27)</cell><cell>591 (29)</cell><cell>533 (26)</cell><cell>51 (63)</cell><cell>81 (50)</cell></row><row><cell>Never</cell><cell cols="2">2539 (71) 2599 (73)</cell><cell>1423 (71)</cell><cell>1506 (74)</cell><cell>30 (37)</cell><cell>82 (50)</cell></row><row><cell>Unknown</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>1 (&lt;0.1%)</cell><cell>0</cell><cell>0</cell></row><row><cell>eGFR (mL/min/1.73m 2 )</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;15</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>15-&lt;30</cell><cell>8 (0.2)</cell><cell>10 (0.3)</cell><cell>7 (0.3)</cell><cell>4 (0.2)</cell><cell>0</cell><cell>0</cell></row><row><cell>30-&lt;60</cell><cell>625 (18)</cell><cell>734 (21)</cell><cell>479 (24)</cell><cell>509 (25)</cell><cell>13 (16)</cell><cell>21 (13)</cell></row><row><cell>60-&lt;90</cell><cell cols="2">2526 (71) 2406 (67)</cell><cell>1195 (59)</cell><cell>1259 (62)</cell><cell>55 (68)</cell><cell>111 (68)</cell></row><row><cell>&gt;90</cell><cell>416 (12)</cell><cell>431 (12)</cell><cell>333 (17)</cell><cell>267 (13)</cell><cell>13 (16)</cell><cell>31 (19)</cell></row><row><cell>Missing</cell><cell>1 (&lt;0.1)</cell><cell>0</cell><cell>0</cell><cell>1 (&lt;0.1)</cell><cell>0</cell><cell>0</cell></row><row><cell cols="5">Source: Comprehensive Cardiovascular Report (section 4.1)</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_92"><head>Table 6 : Cardiovascular Related Medical History Study 20070337 Study 20110142 Study 20110174 Safety Dataset Placebo Romosozumab Alendronate Romosozumab Placebo Romosozumab Disease</head><label>6</label><figDesc></figDesc><table><row><cell>History</cell><cell>N=3576</cell><cell>N= 3581</cell><cell>N= 2014</cell><cell>N=2040</cell><cell>N=81</cell><cell>N=163</cell></row><row><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>Any CV related ds</cell><cell cols="2">2703 (76) 2649 (74)</cell><cell>1603 (80)</cell><cell>1618 (79)</cell><cell>58 (72)</cell><cell>126 (77)</cell></row><row><cell>Hyperlipidemia</cell><cell cols="2">1408 (39) 1379 (39)</cell><cell>675 (34)</cell><cell>709 (35)</cell><cell>32 (40)</cell><cell>63 (39)</cell></row><row><cell>Hypertension</cell><cell cols="2">1919 (54) 1890 (53)</cell><cell>1227 (61)</cell><cell>1248 (61)</cell><cell>44 (54)</cell><cell>83 (51)</cell></row><row><cell>Diabetes</cell><cell>472 (13)</cell><cell>452 (13)</cell><cell>276 (14)</cell><cell>245 (12)</cell><cell>14 (17)</cell><cell>22 (14)</cell></row><row><cell>Cardiovascular</cell><cell cols="2">2331 (65) 2327 (65)</cell><cell>1456 (72)</cell><cell>1497 (73)</cell><cell>54 (67)</cell><cell>108 (66)</cell></row><row><cell>-Ischemic Heart</cell><cell>343 (10)</cell><cell>318 (9)</cell><cell>257 (13)</cell><cell>295 (15)</cell><cell>18 (22)</cell><cell>26 (16)</cell></row><row><cell>-MI</cell><cell>77 (2)</cell><cell>76 (2)</cell><cell>50 (3)</cell><cell>71 (4)</cell><cell>6 (7)</cell><cell>9 (6)</cell></row><row><cell cols="2">-Revascularization 48 (1)</cell><cell>51 (1)</cell><cell>42 (2)</cell><cell>40 (2)</cell><cell>11 (14)</cell><cell>10 (6)</cell></row><row><cell>-Afib/flutter</cell><cell>76 (2)</cell><cell>58 (2)</cell><cell>76 (4)</cell><cell>93 (4)</cell><cell>4 (5)</cell><cell>7 (4)</cell></row><row><cell>Cerebrovascular*</cell><cell>198 (6)</cell><cell>179 (5)</cell><cell>186 (9)</cell><cell>149 (7)</cell><cell>11 (14)</cell><cell>15 (9)</cell></row><row><cell cols="2">-Ischemic CVA/TIA 185 (5)</cell><cell>169 (5)</cell><cell>176 (9)</cell><cell>140 (7)</cell><cell>10 (12)</cell><cell>15 (9)</cell></row><row><cell>-Stroke</cell><cell>95 (3)</cell><cell>83 (2)</cell><cell>81 (4)</cell><cell>58 (3)</cell><cell>6 (7)</cell><cell>6 (4)</cell></row><row><cell>RUTH Score</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (SD)</cell><cell>3.6 (2.5)</cell><cell>3.5 (2.5)</cell><cell>4.1 (2.5)</cell><cell>4.0 (2.6)</cell><cell cols="2">5.2 (3.1) 4.2 (2.7)</cell></row><row><cell>Median</cell><cell>3.0</cell><cell>3.0</cell><cell>3.0</cell><cell>3.0</cell><cell>5.0</cell><cell>3.0</cell></row><row><cell>Min, Max</cell><cell>0, 13</cell><cell>0, 13</cell><cell>0, 13</cell><cell>0, 13</cell><cell>0, 13</cell><cell>0, 13</cell></row><row><cell>m-RUTH Score &gt;8</cell><cell>306 (9)</cell><cell>287 (8)</cell><cell>213 (11)</cell><cell>241 (12)</cell><cell>17 (21)</cell><cell>18 (11)</cell></row><row><cell cols="3">m-RUTH Score &lt; 8 3270 (91) 3294 (92)</cell><cell>1801 (89)</cell><cell>1799 (88)</cell><cell>64 (79)</cell><cell>145 (89)</cell></row><row><cell>m-RUTH Score &gt; 6</cell><cell>794</cell><cell>761</cell><cell>598</cell><cell>556</cell><cell>NA</cell><cell>NA</cell></row><row><cell cols="2">m-RUTH Score &lt; 6 2872</cell><cell>2820</cell><cell>1416</cell><cell>1484</cell><cell>NA</cell><cell>NA</cell></row><row><cell cols="2">m-RUTH Score &gt; 4 1438</cell><cell>1360</cell><cell>936</cell><cell>923</cell><cell>NA</cell><cell>NA</cell></row><row><cell cols="2">m-RUTH Score &lt; 4 2138</cell><cell>2221</cell><cell>1078</cell><cell>1117</cell><cell>NA</cell><cell>NA</cell></row><row><cell cols="7">Source: Comprehensive Cardiovascular Report (section 4.2, Table 14-6.4.1.3 for study</cell></row><row><cell cols="7">20110142, Table 14-6.4.1.5 for study 2007033); Note: * Cerebrovascular includes CNS</cell></row><row><cell cols="7">hemorrhage; m-RUTH = modified RUTH = modified-Raloxifene Use for The Heart; NA = not</cell></row><row><cell>available</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_93"><head>Table 7 : Modified RUTH Score Baseline Cardiovascular Risk Factor: Modified Ruth Score Points Ischemic heart disease, CNS hemorrhage, Cerebrovascular Conditions 4 Diabetes Mellitus 3 Age &gt; 70 years 2 65-69 years 1 Former/Current smoker 1 1 Hypertension 1 1 High Cholesterol 1 1 1: extra point if all three are present. Score ranges from 0 (no cardiovascular risk) to 13 (highest cardiovascular risk).</head><label>7</label><figDesc></figDesc><table><row><cell>Source: Supplemental Statistical Analysis Plan-23 Apr 2018</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_94"><head>Table 8 : Cardiovascular-related Baseline Concomitant Medications Study 20070337 Study 20110142 Study 20110174 Placebo Romosozumab Alendronate Romosozumab Placebo Romosozumab N=3576</head><label>8</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>N= 3581</cell><cell>N= 2014</cell><cell>N=2040</cell><cell>N=81</cell><cell>N=163</cell></row><row><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>Subjects with</cell><cell cols="2">2065 (58) 2018 (56)</cell><cell>1238 (62)</cell><cell>1254 (62)</cell><cell>53 (65)</cell><cell>94 (58)</cell></row><row><cell>Cardiovascular</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Meds</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Aspirin</cell><cell>713 (20)</cell><cell>751 (21)</cell><cell>437 (22)</cell><cell>449 (22)</cell><cell>24 (30)</cell><cell>45 (28)</cell></row><row><cell>Antiplatelet Drugs</cell><cell>755 (21)</cell><cell>801 (22)</cell><cell>473 (24)</cell><cell>483 (24)</cell><cell>28 (35)</cell><cell>46 (28)</cell></row><row><cell>Beta-Blockers</cell><cell>729 (20)</cell><cell>716 (20)</cell><cell>478 (24)</cell><cell>518 (25)</cell><cell>21 (26)</cell><cell>39 (24)</cell></row><row><cell>Anticoagulants</cell><cell>815 (23)</cell><cell>837 (23)</cell><cell>559 (28)</cell><cell>578 (28)</cell><cell>31 (38)</cell><cell>47 (29)</cell></row><row><cell>A-II Receptor</cell><cell>600 (17)</cell><cell>578 (16)</cell><cell>374 (19)</cell><cell>347 (17)</cell><cell>15 (19)</cell><cell>23 (14)</cell></row><row><cell>Antagonists</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Statins</cell><cell>943 (26)</cell><cell>913 (26)</cell><cell>476 (24)</cell><cell>498 (24)</cell><cell>31 (38)</cell><cell>45 (28)</cell></row><row><cell>ACE Inhibitors</cell><cell>702 (20)</cell><cell>730 (20)</cell><cell>490 (24)</cell><cell>532 (26)</cell><cell>20 (25)</cell><cell>29 (18)</cell></row><row><cell cols="5">Source: Comprehensive Cardiovascular Report (section 4.3)</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_95"><head>Table 9 : Cardiovascular-related Baseline Concomitant Medications in Subjects with Cardiovascular-related Past Medical History Study 20070337 Study 20110142 Study 20110174 Placebo Romosozumab Alendronate Romosozumab Placebo Romosozumab N=2703Aspirin 681 (25) 717 (27) 422 (26) 437 (27) 23 (40) 45 (35) Antiplatelet Drugs 721 (27) 764 (29) 456 (28) 471 (29) 26 (45) 46 (37) Beta-Blockers 713 (26) 703 (27) 473 (30) 508 (31) 20 (35) 38 (30) Anticoagulants 783 (29) 802 (30) 538 (34) 563 (35) 29 (50) 47 (37) A-II Receptor Antagonists 599 (22) 577 (22) 374 (23) 347 (21) 15 (26) 23 (18) Statins</head><label>9</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>N= 2649</cell><cell>N= 1603</cell><cell>N=1618</cell><cell>N=58</cell><cell>N=126</cell></row><row><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>Subjects with</cell><cell cols="2">2007 (74) 1965 (74)</cell><cell>1212 (76)</cell><cell>1228 (76)</cell><cell>50 (86)</cell><cell>93 (74)</cell></row><row><cell>Cardiovascular</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Meds</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>941 (35)</cell><cell>912 (34)</cell><cell>475 (30)</cell><cell>495 (31)</cell><cell>31 (53)</cell><cell>45 (36)</cell></row><row><cell>ACE Inhibitors</cell><cell>699 (26)</cell><cell>730 (28)</cell><cell>489 (31)</cell><cell>529 (33)</cell><cell>20 (35)</cell><cell>29 (23)</cell></row><row><cell cols="5">Source: Comprehensive Cardiovascular Report (section 4.3)</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_98"><head>Table 14</head><label>14</label><figDesc></figDesc><table /><note>-1.2</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_99"><head>Table 10 : Sensitivity Analysis: Impact of Negative Adjudication due to Insufficient Information</head><label>10</label><figDesc></figDesc><table><row><cell>Control</cell><cell>Romosozumab</cell><cell>HR (95%CI)</cell></row><row><cell>N=5671</cell><cell>N=5784</cell><cell></cell></row><row><cell>n (%)</cell><cell>n (%)</cell><cell></cell></row></table><note>Source: Comprehensive Cardiovascular Report (Table 9)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_100"><head>Table 11 :# Subjects with TEAEs 38 (1.9) 53</head><label>11</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">TEAE Reporting</cell><cell cols="2">DCRI Adjudicated</cell><cell cols="2">TIMI Adjudicated</cell></row><row><cell>Study</cell><cell>Control</cell><cell cols="2">Romosozumab Control</cell><cell cols="2">Romosozumab Control</cell><cell>Romosozumab</cell></row><row><cell>AE Category</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>Study 20070337</cell><cell>N=3576</cell><cell>N=3581</cell><cell>N=3576</cell><cell>N=3581</cell><cell>N=3576</cell><cell>N=3581</cell></row><row><cell cols="2"># Subjects with TEAEs 43 (1.2)</cell><cell>48 (1.3)</cell><cell>38 (1.1)</cell><cell>42 (1.2)</cell><cell>34 (1.0)</cell><cell>38 (1.1)</cell></row><row><cell>-All-cause deaths</cell><cell>24 (0.7)</cell><cell>29 (0.8)</cell><cell>24 (0.7)</cell><cell>29 (0.8)</cell><cell>20 (0.6)</cell><cell>27 (0.8)</cell></row><row><cell>-Myocardial Infarction</cell><cell>12 (0.3)</cell><cell>14 (0.4)</cell><cell>8 (0.2)</cell><cell>9 (0.3)</cell><cell>8 (0.2)</cell><cell>7 (0.2)</cell></row><row><cell>-Stroke</cell><cell>12 (0.3)</cell><cell>10 (0.3)</cell><cell>10 (0.3)</cell><cell>8 (0.2)</cell><cell>8 (0.2)</cell><cell>8 (0.2)</cell></row><row><cell>Study 20110142</cell><cell cols="2">N= 2014 N=2040</cell><cell cols="2">N= 2014 N=2040</cell><cell cols="2">N= 2014 N=2040</cell></row><row><cell></cell><cell></cell><cell>(2.6)</cell><cell>32 (1.6)</cell><cell>53 (2.6)</cell><cell>31 (1.5)</cell><cell>51 (2.5)</cell></row><row><cell>-All-cause deaths</cell><cell>22 (1.1)</cell><cell>30 (1.5)</cell><cell>22 (1.1)</cell><cell>30 (1.5)</cell><cell>21 (1.0)</cell><cell>27 (1.3)</cell></row><row><cell>-Myocardial Infarction</cell><cell>8 (0.4)</cell><cell>16 (0.8)</cell><cell>5 (0.2)</cell><cell>16 (0.8)</cell><cell>6 (0.3)</cell><cell>16 (0.8)</cell></row><row><cell>-Stroke</cell><cell>12 (0.6)</cell><cell>15 (0.7)</cell><cell>7 (0.3)</cell><cell>13 (0.6)</cell><cell>5 (0.2)</cell><cell>13 (0.6)</cell></row><row><cell>Study 20110174</cell><cell>N=81</cell><cell>N=163</cell><cell>N=81</cell><cell>N=163</cell><cell>N=81</cell><cell>N=163</cell></row><row><cell cols="2"># Subjects with TEAEs 2 (2.5)</cell><cell>5 (3.1)</cell><cell>2 (2.5)</cell><cell>6 (3.7)</cell><cell>2 (2.5)</cell><cell>6 (3.7)</cell></row><row><cell>-All-cause deaths</cell><cell>1 (1.2)</cell><cell>2 (1.2)</cell><cell>1 (1.2)</cell><cell>2 (1.2)</cell><cell>1 (1.2)</cell><cell>2 (1.2)</cell></row><row><cell>-Myocardial Infarction</cell><cell>0</cell><cell>1 (0.6)</cell><cell>0</cell><cell>1 (0.6)</cell><cell>0</cell><cell>1 (0.6)</cell></row><row><cell>-Stroke</cell><cell>1 (1.2)</cell><cell>2 (1.2)</cell><cell>1 (1.2)</cell><cell>3 (1.8)</cell><cell>1 (1.2)</cell><cell>3 (1.8)</cell></row></table><note>Comparison of Subject Incidences of All-cause death, myocardial infarction, and stroke based on treatment-emergent adverse events adjudicated by DCRI and TIMI for the 12-month Double Blind PeriodSource: Comprehensive Cardiovascular Report (Table 10)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_101"><head></head><label></label><figDesc>From Hylton V. Joffe, M.D., M.M.Sc.</figDesc><table><row><cell cols="2">Division Director Summary Review for Regulatory Action</cell></row><row><cell>Date</cell><cell>(electronic stamp)</cell></row><row><cell>Subject</cell><cell>Division Director Summary Review</cell></row><row><cell>NDA/BLA #</cell><cell>BLA 761062</cell></row><row><cell>Supplement # Applicant 09/27/2018 Date of Submission SENATORE</cell><cell>000 Amgen July 19, 2016</cell></row><row><cell cols="2">PDUFA Goal Date MARTIN ROSE Proprietary Name / 09/28/2018 Non-Proprietary Name Make sure markup does not show in final document July 19, 2017 Evenity Romosozumab Dosage Form(s) / Strength(s) 105 mg/1.17 mL solution in a single-use prefilled</cell></row><row><cell></cell><cell>syringe for subcutaneous injection</cell></row><row><cell>NORMAN L STOCKBRIDGE</cell><cell>Health care providers administer two prefilled syringes</cell></row><row><cell>09/28/2018</cell><cell>for the full 210 mg romosozumab dose</cell></row><row><cell>Applicant Proposed</cell><cell>Treatment of osteoporosis in postmenopausal women at</cell></row><row><cell>Indication(s)/Population(s)</cell><cell>increased risk of fracture</cell></row><row><cell cols="2">Action/Recommended Action for NME: Complete Response</cell></row><row><cell>Approved/Recommended</cell><cell>N/A</cell></row><row><cell>Indication/Population(s) (if applicable)</cell><cell></cell></row><row><cell>Material Reviewed/Consulted Action Package, including:</cell><cell>Names of discipline reviewers</cell></row><row><cell>Medical Officer Review</cell><cell>Debuene Chang</cell></row><row><cell>Statistical Review</cell><cell></cell></row><row><cell></cell><cell>and Sam</cell></row><row><cell></cell><cell>Haidar</cell></row><row><cell>Office of Scientific Investigations</cell><cell>Bei Yu, Janice Pohlman, and Kassa Ayalew</cell></row><row><cell>Cross-Discipline Team Leader Review</cell><cell>Theresa Kehoe</cell></row><row><cell>Office of Surveillance and Epidemiology (OSE)/ Division of Medication Error Prevention and Analysis</cell><cell>Walter Fava, Lolita White, and QuynhNhu Nguyen</cell></row><row><cell></cell><cell>1</cell></row></table><note>Jia Guo, Mahboob Sobhan, Hepei Chen, Karl Lin, and Feng Zhou Pharmacology Toxicology Review Gemma Kuijpers, Andrea Benedict, Miyun Tsai-Turton, Laurie McLeod- Flynn, and Kimberly Hatfield Office of Pharmaceutical Quality Review Chen Sun, Juhong Liu, Joel Welch, Bo Chi, Lakshmi Narasimhan, Patricia Hughes Troost, Zhihao Qiu, Michael Shanks, and Melinda Bauerlien, David Frucht Center for Devices and Radiological Health Sarah Mollo and Alan Stevens Clinical Pharmacology Review Lin Zhou, Yow-Ming Wang, Luning Zhuang, Jeffry Florian, and Hae Young Ahn Office of Study Integrity and Surveillance Mohsen Rajabi Abhari, Stanley Au, Gopa Biswas, Arindam Dasgupta, Seongeun (Julia) Cho, Xingfang Li, Michael Skelly, Elise Murphy,</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_102"><head></head><label></label><figDesc>95% confidence interval 0.62, 1.72) in the pivotal Phase 3 trial o 1.87 (95% confidence interval1.11, 3.14)  in the alendronate trial o 1.55 (95% confidence interval 0.31, 7.69) in the male osteoporosis trial  Romosozumab's remaining safety concerns include:</figDesc><table><row><cell>Dimension</cell><cell>Evidence and Uncertainties</cell><cell>Conclusions and Reasons</cell></row><row><cell cols="2">cardiovascular death were:</cell><cell></cell></row><row><cell>o 1.03 (</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_103"><head></head><label></label><figDesc>Percentage of patients with clinical fracture (composite of nonvertebral fractures 1 and symptomatic vertebral fractures) through Month 12  Percentage of patients with nonvertebral fracture through Months 12 and 24 2  Percentage of patients with clinical fracture through Month 24  Percentage of patients with major nonvertebral fracture (pelvis, distal femur, proximal tibia, ribs, proximal humerus, forearm, and hip) through Months 12 and 24 2  Percentage of patients with new or worsening vertebral fracture through Months 12 and 24 2  Percentage of patients with hip fracture through Months 12 and 24 2</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_104"><head>Table 1 . Co-Primary Efficacy Endpoints: Incidence of First Vertebral Fracture (Adapted from Table 5 in the Statistical Review</head><label>1</label><figDesc></figDesc><table><row><cell>)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_105"><head>Table 2 . Bone Mineral Density Changes (Adapted from Tables 7-9 in the Statistical Review) Through Month 12 Through Month 24 Baseline Change from Baseline</head><label>2</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>LS Mean Difference</cell><cell>Change from</cell><cell>LS Mean Difference from</cell></row><row><cell></cell><cell></cell><cell>(%)</cell><cell>from Placebo 1</cell><cell>Baseline (%)</cell><cell>Placebo/Denosumab 1</cell></row><row><cell>Lumbar Spine</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Romosozumab 2</cell><cell>0.8</cell><cell>13.1</cell><cell>12.7 (12.4, 12.9)</cell><cell>16.6</cell><cell>11.1 (10.8, 11.4)</cell></row><row><cell>Placebo 3</cell><cell>0.8</cell><cell>0.4</cell><cell>p&lt;0.001</cell><cell>5.5</cell><cell>p&lt;0.001</cell></row><row><cell>Total Hip</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Romosozumab 2</cell><cell>0.7</cell><cell>6.0</cell><cell>5.8 (5.6, 6.0)</cell><cell>8.5</cell><cell>5.3 (5.1, 5.5)</cell></row><row><cell>Placebo 3</cell><cell>0.7</cell><cell>0.3</cell><cell>p&lt;0.001</cell><cell>3.2</cell><cell>p&lt;0.001</cell></row><row><cell>Femoral Neck</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Romosozumab 2</cell><cell>0.6</cell><cell>5.5</cell><cell>5.2 (4.9, 5.4)</cell><cell>7.3</cell><cell>4.9 (4.7, 5.2)</cell></row><row><cell>Placebo 3</cell><cell>0.6</cell><cell>0.3</cell><cell>p&lt;0.001</cell><cell>2.3</cell><cell>p&lt;0.001</cell></row></table><note>1 Includes 95% confidence interval in parentheses and nominal p-value for the treatment difference2 Romosozumab through Month 12; Romosozumab then denosumab through Month243 Placebo through Month 12; Placebo then denosumab through Month 24</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_111"><head>Trial 20060326: Percent Change in Lumbar Spine BMD at Month 12, Linear Mixed Effect Model romosozumab</head><label></label><figDesc></figDesc><table><row><cell></cell><cell>placebo</cell><cell>70 qM</cell><cell>140 q3M</cell><cell>140 qM</cell><cell>210 q3M</cell><cell>210 qM</cell></row><row><cell>Randomized</cell><cell>50</cell><cell>49</cell><cell>52</cell><cell>48</cell><cell>53</cell><cell>50</cell></row><row><cell>Analysis Dataset</cell><cell>47</cell><cell>44</cell><cell>49</cell><cell>46</cell><cell>51</cell><cell>49</cell></row><row><cell>LS Mean</cell><cell>-0.1</cell><cell>5.4</cell><cell>5.4</cell><cell>9.1</cell><cell>5.5</cell><cell>11.3</cell></row><row><cell>Treatment Difference</cell><cell></cell><cell>5.5</cell><cell>5.6</cell><cell>9.2</cell><cell>5.6</cell><cell>11.5</cell></row><row><cell>95% CI</cell><cell></cell><cell>4.0 , 7.0</cell><cell>4.1 , 7.0</cell><cell>7.8 , 10.7</cell><cell>4.2 , 7.2</cell><cell>10.0 , 12.9</cell></row><row><cell cols="3">Source: Table 10.2, page 200, CSR 20060326</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_113"><head></head><label></label><figDesc>Demographics:The demographics of the enrolled population are well matched between the treatment groups and are outlined in the table below. The mean age of enrolled postmenopausal women is 71 years and 31% of the population was over age 75. The predominant race was white and not Hispanic or Latino ethnicity. The mean weight of the population was 58 kg with a large weight range of 22 to 133 kg. The mean lumbar spine Tscore was -2.7, 18% had a vertebral fracture at baseline, and 35% had a history of any osteoporotic fracture after age 45.</figDesc><table><row><cell>Trial 20070337: Subject Disposition</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Placebo/</cell><cell>Romosozumab/</cell><cell>Total</cell></row><row><cell></cell><cell>Denosumab</cell><cell>Denosumab</cell><cell></cell></row><row><cell>Completed to month 12</cell><cell>3205 (89)</cell><cell>3185 (89)</cell><cell>6390 (89)</cell></row><row><cell>completed study drug to month 12</cell><cell>3135 (87)</cell><cell>3103 (86)</cell><cell>6238 (87)</cell></row><row><cell>Completed to month 24</cell><cell>3032 (84)</cell><cell>2994 (83)</cell><cell>6026 (84)</cell></row><row><cell>completed study drug to month 24</cell><cell>3001 (84)</cell><cell>2932 (82)</cell><cell>5932 (83)</cell></row><row><cell cols="4">*Other includes administrative decision, noncompliance, ineligibility determined, protocol deviation, and other</cell></row><row><cell>(not defined by Applicant)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Source: CSR20070327, table 14-1.1</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Trial 20070337: Subject Demographics</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Placebo/</cell><cell>Romosozumab/</cell><cell>Total</cell></row><row><cell></cell><cell>Denosumab</cell><cell>Denosumab</cell><cell></cell></row><row><cell>Randomized</cell><cell>3591</cell><cell>3589</cell><cell>7180</cell></row><row><cell>Age (mean (SD)</cell><cell>71 (6.9)</cell><cell>71 (7.0)</cell><cell>71 (7.0)</cell></row><row><cell>age range, years</cell><cell>55 -90</cell><cell>55 -90</cell><cell>55 -90</cell></row><row><cell> 65 years, n (%)</cell><cell>2834 (79)</cell><cell>2821 (79)</cell><cell>5655 (79)</cell></row><row><cell> 75 years, n (%)</cell><cell>1121 (31)</cell><cell>1119 (31)</cell><cell>2240 (31)</cell></row><row><cell>Race</cell><cell></cell><cell></cell><cell></cell></row><row><cell>White</cell><cell>2052 (57)</cell><cell>2063 (58)</cell><cell>4115 (57)</cell></row><row><cell>Asian</cell><cell>441</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>3)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_115"><head></head><label></label><figDesc>Morphometric Vertebral Fracture: Radiographs for evaluation of new morphometric vertebral fractures were obtained at months 6, 12, and 24. The coprimary endpoint is the incidence of new morphometric vertebral fracture at month 12 and month 24. As outlined in the table below, at month 12, the incidence of new vertebral fractures is 1.8% in the placebo group and 0.5% in the romosozumab group. The absolute risk reduction is 1.3% with a relative risk reduction of 73%. At month 24, the incidence of new vertebral fractures is 2.5% in the placebo/denosumab group and 0.6% in the romosozumab/denosumab group. The absolute risk reduction is 1.9% with a relative risk reduction of 75%.</figDesc><table><row><cell cols="2">Trial 20070337: New Morphometric Vertebral Fracture</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Placebo/</cell><cell>Romosozumab/</cell><cell></cell></row><row><cell></cell><cell>Denosumab</cell><cell>Denosumab</cell><cell></cell></row><row><cell>N</cell><cell>3591</cell><cell>3589</cell><cell></cell></row><row><cell>Month 12</cell><cell></cell><cell></cell><cell></cell></row><row><cell>N, primary analysis population</cell><cell>3322</cell><cell>3321</cell><cell></cell></row><row><cell>Crude incidence, n (%)</cell><cell>59 (1.8)</cell><cell>16 (0.5)</cell><cell></cell></row><row><cell>Absolute Risk Reduction (95% CI)</cell><cell>1.3%</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">(0.79 , 1.80)</cell><cell></cell></row><row><cell>Relative Risk Reduction (95% CI)</cell><cell>73%</cell><cell></cell><cell></cell></row><row><cell></cell><cell>(53 , 84)</cell><cell></cell><cell></cell></row><row><cell>p-value</cell><cell>&lt;0.001</cell><cell></cell><cell></cell></row><row><cell>Month 24</cell><cell></cell><cell></cell><cell></cell></row><row><cell>N, primary analysis population</cell><cell>3327</cell><cell>3325</cell><cell></cell></row><row><cell>Crude incidence, n (%)</cell><cell>84 (2.5)</cell><cell>21 (0.6)</cell><cell></cell></row><row><cell>Absolute Risk Reduction (95% CI)</cell><cell>1.9%</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">(1.30 , 2.49)</cell><cell></cell></row><row><cell>Relative Risk Reduction (95% CI)</cell><cell>75%</cell><cell></cell><cell></cell></row><row><cell></cell><cell>(60 , 84)</cell><cell></cell><cell></cell></row><row><cell>p-value</cell><cell>&lt;0.001</cell><cell></cell><cell></cell></row><row><cell>weight range, kg</cell><cell>28 -133</cell><cell>22 -127</cell><cell>22 -133</cell></row><row><cell>Lumbar spine T-score, mean (SD)</cell><cell>-2.7 (1.04)</cell><cell>-2.7 (1.04)</cell><cell>-2.7 (1.04)</cell></row><row><cell>Prevalent vertebral fracture, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>yes</cell><cell>645 (18)</cell><cell>672 (19)</cell><cell>1317 (18)</cell></row><row><cell>no</cell><cell>2839 (79)</cell><cell>2795 (78)</cell><cell>5634 (78)</cell></row><row><cell>not readable</cell><cell>107 (3)</cell><cell>122 (3)</cell><cell>229 (3)</cell></row><row><cell>Any osteoporotic fracture, n(%)</cell><cell>1258 (35)</cell><cell>1270 (35)</cell><cell>2528 (35)</cell></row><row><cell>*Other (not defined by Applicant)</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Source: CSR20070327, tables 9-2, 9-3, pages 129-133</cell><cell></cell><cell></cell></row></table><note>Source: Primary statistical review, table 5, page 11</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_116"><head></head><label></label><figDesc>Clinical fracture is defined as all nonvertebral fractures plus all symptomatic vertebral fractures. As noted in the table below, of the 148 clinical fractures in the first 12 months, 131 (88%) were nonvertebral fractures. In the first 12 months, treatment with romosozumab resulted in a significant 36% decrease in clinical fractures. However, the reduction in nonvertebral fractures was not significant in this time period.</figDesc><table><row><cell>Cross Discipline Team Leader Review</cell><cell></cell><cell></cell></row><row><cell cols="2">24. Trial 20070337: Clinical and Nonvertebral Fracture</cell><cell></cell></row><row><cell></cell><cell>Placebo/</cell><cell>Romosozumab/</cell></row><row><cell></cell><cell>Denosumab</cell><cell>Denosumab</cell></row><row><cell>N</cell><cell>3591</cell><cell>3589</cell></row><row><cell>Clinical Fracture, Month 12</cell><cell></cell><cell></cell></row><row><cell>Incidence, n (%)</cell><cell>90 (2.5)</cell><cell>58 (1.6)</cell></row><row><cell>Absolute Risk Reduction, % (95% CI)</cell><cell cols="2">1.2 (0.4 , 1.9)</cell></row><row><cell>Relative Risk Reduction, % (95% CI)</cell><cell></cell><cell>36% (11 , 54)</cell></row><row><cell>p-value (alpha level)</cell><cell></cell><cell>0.008 (0.05)</cell></row><row><cell>Nonvertebral Fx, Month 12</cell><cell></cell><cell></cell></row><row><cell>Incidence, n (%)</cell><cell>75 (2.1)</cell><cell>56 (1.6)</cell></row><row><cell>Absolute Risk Reduction, % (95% CI)</cell><cell></cell><cell>0.8 (0.1 , 1.4)</cell></row><row><cell>Relative Risk Reduction, % (95% CI)</cell><cell></cell><cell>25 (-5 , 47)</cell></row><row><cell>p-value (alpha level)</cell><cell></cell><cell>0.096 (0.05)</cell></row><row><cell>Nonvertebral Fx, Month 24</cell><cell></cell><cell></cell></row><row><cell>Incidence, n (%)</cell><cell>129 (3.6)</cell><cell>96 (2.7)</cell></row><row><cell>Absolute Risk Reduction, % (95% CI)</cell><cell></cell><cell>1.0 (0.2 , 1.9)</cell></row><row><cell>Relative Risk Reduction, % (95% CI)</cell><cell></cell><cell>25% (3 , 43)</cell></row><row><cell>p-value (alpha level)</cell><cell></cell><cell>0.029 (0.025)</cell></row><row><cell>Clinical Fracture, Month 24</cell><cell></cell><cell></cell></row><row><cell>Incidence, n (%)</cell><cell>147 (4.1)</cell><cell>99 (2.8)</cell></row><row><cell>Absolute Risk Reduction (95% CI)</cell><cell></cell><cell>1.4 (0.5 , 2.4)</cell></row><row><cell>Relative Risk Reduction (95% CI)</cell><cell></cell><cell>33 (13 , 48)</cell></row><row><cell>p-value</cell><cell cols="2">not tested, based on statistical plan</cell></row><row><cell></cell><cell></cell><cell>27</cell></row><row><cell>Reference ID: 4123729</cell><cell></cell><cell></cell></row></table><note>Source: Primary statistical review, table 6, page 12</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_117"><head>Trial 20070337: Changes in Bone Mineral Density at Month 12, LOCF Placebo</head><label></label><figDesc></figDesc><table><row><cell></cell><cell cols="2">Romosozumab</cell></row><row><cell>N</cell><cell>3591</cell><cell>3589</cell></row><row><cell>Lumbar Spine, n</cell><cell>3148</cell><cell>3151</cell></row><row><cell>% change from baseline, mean (SE)</cell><cell>0.4 (0.1)</cell><cell>13.1 (0.1)</cell></row><row><cell>Treatment Difference, LS mean</cell><cell>12.7%</cell><cell></cell></row><row><cell>(95% CI)</cell><cell>(12.4 , 12.9)</cell><cell></cell></row><row><cell>p-value vs placebo)</cell><cell>&lt;0.001</cell><cell></cell></row><row><cell>Total Hip, n</cell><cell>3210</cell><cell>3197</cell></row><row><cell>% change from baseline, mean (SE)</cell><cell>0.3 (0.1)</cell><cell>6.0 (0.1)</cell></row><row><cell>Treatment Difference, LS mean</cell><cell>5.8%</cell><cell></cell></row><row><cell>(95% CI)</cell><cell>(5.6 , 6.0)</cell><cell></cell></row><row><cell></cell><cell>&lt;0.001)</cell><cell></cell></row><row><cell>Femoral Neck, n</cell><cell>3210</cell><cell>3197</cell></row><row><cell>% change from baseline, mean (SE)</cell><cell>0.3 (0.1)</cell><cell>5.5 (0.1)</cell></row><row><cell>Treatment Difference, LS mean</cell><cell>5.2%</cell><cell></cell></row><row><cell>(95% CI)</cell><cell>(4.9 , 5.4)</cell><cell></cell></row><row><cell></cell><cell>&lt;0.001)</cell><cell></cell></row><row><cell cols="3">Source: adapted from primary statistical review, Tables 7-9, page 13; and from CSR 20070337</cell></row><row><cell>table 10-3, pages 144-145</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_119"><head></head><label></label><figDesc>Common Adverse Events: This discussion of common adverse events focuses on the 12 month romosozumab vs. placebo treatment period in trial 20070337, which will appear in product labeling. During trial 20070337, 2850 (80%) placebo subjects and 2806 (78%) romosozumab treated subjects experienced an adverse event/reaction. As outlined in the table below, the most common adverse events were arthralgia, nasopharyngitis, and back pain.</figDesc><table><row><cell cols="3">Trial 20070337 Common Treatment Emergent Adverse Events by PT</cell></row><row><cell cols="2">( 5% subject incidence in any treatment group)</cell><cell></cell></row><row><cell></cell><cell>Placebo</cell><cell>Romosozumab</cell></row><row><cell>Treated</cell><cell>3576</cell><cell>3581</cell></row><row><cell>At least 1 TEAE</cell><cell>2850 (80)</cell><cell>2806 (78)</cell></row><row><cell>Arthralgia</cell><cell>429</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_120"><head>Trial 20070337 Adjudicated Positive Cardiovascular Serious Adverse Events Placebo</head><label></label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>Romosozumab</cell></row><row><cell>Treated</cell><cell>3576</cell><cell>3581</cell></row><row><cell>Any cardiovascular SAE, n (%)</cell><cell>41 (1.1)</cell><cell>44 (1.2)</cell></row><row><cell>Odds Ratio (95% CI)</cell><cell cols="2">1.07 (0.70 , 1.65)</cell></row><row><cell>Death, n (%)</cell><cell>15 (0.4)</cell><cell>17 (0.5)</cell></row><row><cell>Odds Ratio (95% CI)</cell><cell cols="2">1.13 (0.56 , 2.27)</cell></row><row><cell>Cardiac ischemic event, n (%)</cell><cell>14 (0.4)</cell><cell>15 (0.4)</cell></row><row><cell>Odds Ratio (95% CI)</cell><cell cols="2">1.07 (0.52 , 2.22)</cell></row><row><cell>Heart failure, n (%)</cell><cell>4 (0.1)</cell><cell>7 (0.2)</cell></row><row><cell>Odds Ratio (95% CI)</cell><cell cols="2">1.75 (0.51 , 5.98)</cell></row><row><cell>Cerebrovascular event, n (%)</cell><cell>11 (0.3 )</cell><cell>10 (0.3)</cell></row><row><cell>Odds Ratio (95% CI)</cell><cell cols="2">0.91 (0.38 , 2.14)</cell></row><row><cell>Peripheral vascular event not requiring</cell><cell>1 (&lt;0.1)</cell><cell>3 (&lt;0.1)</cell></row><row><cell>revascularization, n (%)</cell><cell></cell><cell></cell></row><row><cell>Odds Ratio (95% CI)</cell><cell cols="2">3.00 (0.31 , 28.82)</cell></row></table><note>Source: CSR20070337, table 12-10, page 221</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_121"><head></head><label></label><figDesc>Dr. Kehoe's recommendation that this application receive a Complete Response letter. See the Division Director memorandum.</figDesc><table><row><cell></cell><cell>BLA Clinical Review Update and Addendum</cell></row><row><cell>Application Type</cell><cell>BLA</cell></row><row><cell>Application Number(s)</cell><cell>762061</cell></row><row><cell>Priority or Standard</cell><cell>-Standard</cell></row><row><cell>Submit Date(s) THERESA E KEHOE Received Date(s) 07/12/2017 PDUFA Goal Date</cell><cell>July 19, 2016 July 19, 2016 July 19, 2017</cell></row><row><cell>Division/Office HYLTON V JOFFE 07/12/2017</cell><cell>Division of Bone, Reproductive, and Urologic Products Office of Drug Evaluation III Center for Drug Evaluation and Research</cell></row><row><cell cols="2">Reviewer Name(s) Review Addendum Date Established Name (Proposed) Trade Name Applicant Formulation(s) Dosing Regimen Applicant Proposed Indication(s)/Population(s) Regulatory Action I concur with Page 1 Debuene Chang MD June 13, 2017 romosozumab (Proposed) Evenity Amgen 90 mg/mL solution (1.17mL) in each single-use plastic prefilled syringe (PFS); 2 injections per dose (210 mg) 210 mg subcutaneously once a month Treatment of osteoporosis in postmenopausal women at increased risk of fracture Recommendation on Updated Recommendation: Complete Response (CR)</cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_122"><head>Table 1 : Positively Adjudicated CV Events in Study 20110142: Category 12-Month Double-blind Period Primary Analysis Period AlnC. CV Results in Study 20070337 (Current Submission):</head><label>1</label><figDesc>Amgen recently completed Study 20110174, a smaller study (N = 244 subjects) in men with osteoporosis, which was also not completed in time for submission to the BLA. In light of the recent findings for Study 20110142, Amgen analyzed Study 20110174 for CV events and found similar results with an imbalance of subjects reporting CV SAEs in the romosozumab group versus placebo (4.9% versus 2.5%). There were balanced rates of CV SAEs in Study 20070337 between romosozumab and placebo patients (1.3% versus 1.3%).</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Romo/</cell></row><row><cell></cell><cell>Romo (N =</cell><cell>Aln/Aln (N =</cell><cell>Aln</cell></row><row><cell>(N =</cell><cell>2040)</cell><cell>2014) n (%)</cell><cell>(N =</cell></row><row><cell>2014)</cell><cell>n (%)</cell><cell></cell><cell>2040)</cell></row><row><cell>n (%)</cell><cell></cell><cell></cell><cell>n (%)</cell></row></table><note>*Death events include fatal adverse events adjudicated as cardiovascular-related or undetermined to be cardiovascular Source: Amgen presentation May 19, 2017 meeting(slide 16) B. CV Results in Small Men Only Study 20110174:</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_123"><head>Table 2 : Subject Incidence of Adjudicated Positive CV SAEs 12 Month Double-blind Period: Source: Amgen presentation May 19, 2017 meeting (slide17).</head><label>2</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_124"><head>Table 3 : Inclusion and Exclusion Criteria for Study 20110142 (Alendronate-controlled Study-ARCH) and Study 20070337 (BLA Study-FRAME): Study 20110142 Alendronate-Controlled Study (ARCH) Study 20070337 BLA Study (FRAME) Inclusion Criteria Source: Amgen presentation May 19, 2017 (slide 7) with reviewer edits.</head><label>3</label><figDesc>Postmenopausal women age 55 to 90 years  BMD T-score  -2.5 at the total hip or femoral neck and at least one moderate or severe vertebral fracture or at least 2 mild vertebral fractures or  BMD T-score  -2.00 at the total hip or femoral neck and at least 2 moderate (SQ2) or severe (SQ3) vertebral fractures or a recent hip fracture (within 3 to 24 months)</figDesc><table><row><cell></cell><cell>Postmenopausal women age 55 to</cell></row><row><cell></cell><cell>90 years</cell></row><row><cell></cell><cell>BMD T-score  -2.5 at the total hip</cell></row><row><cell></cell><cell>or femoral neck</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_126"><head>Table of Contents</head><label>of</label><figDesc>Glossary ......................................................................................................................................... 10 1 Executive Summary ............................................................................................................... 13 Product Introduction ...................................................................................................... 13 1.1. Conclusions on the Substantial Evidence of Effectiveness ............................................ 14 1.2.2 Therapeutic Context .............................................................................................................. 22 Analysis of Condition ...................................................................................................... 22 2.1. Analysis of Current Treatment Options ......................................................................... 23 2.2. 3 Regulatory Background ......................................................................................................... 27 U.S. Regulatory Actions and Marketing History ............................................................. 27 3.1. Summary of Presubmission/Submission Regulatory Activity ........................................ 27 3.2. Foreign Regulatory Actions and Marketing History ....................................................... 28 3.3. 4 Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety ................................................................................................................. 28 Office of Scientific Investigations (OSI) .......................................................................... 28 4.1.Product Quality .............................................................................................................. 29 4.2. Clinical Microbiology ...................................................................................................... 29 4.3. Nonclinical Pharmacology/Toxicology ........................................................................... 29 4.4. Clinical Pharmacology .................................................................................................... 30 4.5. Mechanism of Action .............................................................................................. 30 4.5.1. Pharmacodynamics ................................................................................................. 31 4.5.2. Pharmacokinetics .................................................................................................... 32 4.5.3. Devices and Companion Diagnostic Issues .................................................................... 35 4.6. Consumer Study Reviews ............................................................................................... 35 4.7. 5 Sources of Clinical Data and Review Strategy ....................................................................... 35 Table of Clinical Studies .................................................................................................. 35 5.1. Review Strategy .............................................................................................................. 37 5.2. 6 Review of Relevant Individual Trials Used to Support Efficacy ............................................. 37 Study 20070337 .............................................................................................................. 37 6.1. Dropouts and/or Discontinuations Due to Adverse Effects ................................. 113 8.3.5. Significant Adverse Events .................................................................................... 113 8.3.6. Treatment Emergent Adverse Events and Adverse Reactions ............................. 124 8.3.7. Laboratory Findings .............................................................................................. 125 8.3.8. Vital Signs .............................................................................................................. 138 8.3.9. Electrocardiograms (ECGs) ............................................................................ 138 8.3.10. QT ................................................................................................................... 138 8.3.11. Immunogenicity ............................................................................................. 141 8.3.12. Analysis of Submission-Specific Safety Issues .............................................................. 145 8.4. Adverse Events Potentially Related to Hypersensitivity ....................................... 145 8.4.1. Injection Site Reactions ......................................................................................... 150 8.4.2. Malignancy (Malignant or Unspecified Tumor) .................................................... 151 8.4.3. Hyperostosis and Audiology Substudy ................................................................. 153 8.4.4. TNF-mediated Inflammatory Conditions .............................................................. 154 8.4.5. Osteoarthritis ........................................................................................................ 156 8.4.6. Safety Analyses by Demographic Subgroups ........................................................ 156 8.4.7. Specific Safety Studies/Clinical Trials ........................................................................... 161 8.5. Hepatic Impairment .............................................................................................. 161 8.5.1. Subjects Transitioned from Bisphosphonate Therapy .......................................... 161 8.5.2. Drug Drug Interactions .......................................................................................... 163 8.5.3. Additional Safety Explorations ..................................................................................... 163 8.6. Human Carcinogenicity or Tumor Development .................................................. 163 8.6.1. Human Reproduction and Pregnancy ................................................................... 163 8.6.2. Pediatrics and Assessment of Effects on Growth ................................................. 164 8.6.3. Overdose, Drug Abuse Potential, Withdrawal, and Rebound .............................. 164 8.6.4. Withdrawal and Rebound ..................................................................................... 165 8.6.5. Safety in the Postmarket Setting.................................................................................. 166 8.7. Safety Concerns Identified Through Postmarket Experience ............................... 166 8.7.1. Expectations on Safety in the Postmarket Setting ............................................... 166 8.7.2.Additional Safety Issues From Other Disciplines .......................................................... 166 8.8. Integrated Assessment of Safety ................................................................................. 167 8.9. Serum Intact Parathyroid Hormone and Urinary Calcium Sub-study ........... 206 13.6.8. Pharmacokinetics Sub-study ......................................................................... 208 13.6.9. Pharmacogenetics Sub-study ........................................................................ 209 13.6.10. Adverse Events Toxicity Grading CTCAE  Grade 3 for Study 20070337 ................. 211 13.7.</figDesc><table><row><cell>Clinical Review Clinical Review Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD Debuene Chang MD Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062 BLA 761062 BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab Evenity (Proposed) -romosozumab Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition CDER Clinical Review Template 2015 Edition CDER Clinical Review Template 2015 Edition</cell><cell>4 6 7</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews) Version date: November 5, 2015 for initial rollout (NME/original BLA reviews) Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_127"><head>Table of Tables</head><label>of</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_128"><head>Table 1 :Table 8 :</head><label>18</label><figDesc>Pharmacologic Treatments for Osteoporosis ................................................................. 24 Table 2: PMO fracture trials: New morphometric vertebral fractures, risk reductions by year .. 26 Table 3: BMD at LS, TH, FN at Months 12 and month 24 in Study 20070337 .............................. 32 Table 4: Table of Phase 2 and 3 Clinical Studies Supporting Application ..................................... 36 Table 5: Summary of Analysis Methods for Fracture and BMD Endpoints Study 20070337 ....... 43 Table 6: Summary of Important Changes in Study Design 20070337 .......................................... 44 Table 7: Select List of Investigators from 3 Sites (Columbia) Participating in Study 20070337 Not Providing Financial Disclosure Information .................................................................................. 46 Disposition of Subjects for the Double-Blind Period to Month 12. .............................. 47 Table 9: Subject Disposition for Double-Blind Period with Extension Period to Month 24 ......... 47 Table 10: Baseline Demographic Characteristics Study 20070337 .............................................. 49 Table 11: Prevalent Fracture History of Subjects in 20070336 .................................................... 50 Table 12: Incidence Rates of New Vertebral Fracture Through Month 12 and Through Month 24: Co-Primary Endpoints ................................................................................................................... 52 Table 13: Sensitivity Analysis of Co-Primary Endpoints with Sites 68001, 68002, and 68006 removed. ....................................................................................................................................... 54 Table 14: Clinical Fracture Results at 12 months (Step 2 of Multiplicity Adjustment Fixed-Sequence Procedure) .................................................................................................................... 55 Table 15: Nonvertebral Fracture Results Through Month 12 and Month 24 (Step 3 of Multiplicity Adjustment Fixed-Sequence Procedure) ...................................................................................... 55 Table 16: Clinical Fracture Results Through Month 24 (Step 4 of Multiplicity Adjustment Fixed-Sequence Procedure) .................................................................................................................... 56 Table 17: Summary of Other Secondary Fracture Endpoints through Month 12 and 24 ............ 58 Table 18: Percent Change BMD at Lumbar Spine, Total Hip, and Femoral Neck at 12 and 24 Months. ......................................................................................................................................... 59 Table 19: DXA Lumbar Spine BMD Percent Change From Baseline to Month 12 -Linear Mixed Effects Model Showing Each of Romosozumab Groups ............................................................... 76 Table 20: DXA Percent Change From Baseline of the Total Hip and Femoral Neck at Months 12 ....................................................................................................................................................... 77 Table 21: DXA BMD Percent Change From Baseline at Distal 1/3 Radius .................................... 78 Table 22: QCT Changes from Baseline for BMD, BMC, and Cortical Thickness at the Lumbar Spine at Month 12 for the Treatment Groups. ............................................................................. 81 Table 23: Lumbar Spine BMD Percent Change From Baseline at Month 12 ................................ 85 Table 24: BMD at Lumbar Spine at 6 months comparing dose concentrations 70 mg/ mL and 90 mg/ mL. ......................................................................................................................................... 89 Table 25: Lumbar Spine BMD Percent Change from Baseline in Placebo-controlled Efficacy Studies. .......................................................................................................................................... 92 Table 26: Lumbar Spine BMD gains in Response to Romosozumab Retreatment. .................... 100 Table 27: Romosozumab Exposure-Number of Patients by Months of Exposure or Dose ....... 105</figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_129"><head>Table 28 :Table 38: 24 Hour Urinary Calcium Excretion Percent Change From Baseline at 6 months and 12 months (Serum Intact Parathyroid Hormone and Urinary Calcium Substudy of 20070337).</head><label>28</label><figDesc>Treatment-emergent Fatal Adverse Events by Preferred Term (Safety Analysis Set) 110 Table 29: Adverse Events of Lung Neoplasms by Preferred Term ............................................. 111 Table 30: SAEs in the Safety Population ..................................................................................... 112 Table 31: AEs Leading to Discontinuation of Study .................................................................... 113 Table 32: Adverse Events of Adjudicated Positive Atypical Femoral ......................................... 114 Table 33: Adjudicated Positive Osteonecrosis of the Jaw by Preferred Term .......................... 121 Table 34: Adverse Events in Romosozumab 210 mg QM and Placebo ...................................... 124 Table 35: Subject Incidence of Laboratory CTCAE Grade  2 in the Placebo Control Period ..... 125 Table 36: Subject Incidence of Hypocalcemia by CTCAE Grade in Study 20110227 .................. 127 Table 37: Glucose CTCAE Grade  2 in the Placebo Control Period ........................................... 129 ..................................................................................................................................................... 132 Table 39: Subject Incidence of Serum Aspartate Aminotransferase (AST) Elevations ............... 134 Table 40: Subject Incidence of Serum Alanine Aminotransferase (ALT) Elevations ................... 134 Table 41: Selected subject with elevated AST and ALT &gt; 5 x ULN on study 20060220 .............. 135 Table 42: Potential Hy's Law Cases ............................................................................................. 137 Table 43: Anti-Romosozumab Antibody Summary (Safety Analysis Set) ................................... 142 Table 44: Incidence of Injection Site Reaction, Hypersensitivity and Autoimmune Disorder by Binding Anti-Romosozumab Antibody Status ............................................................................. 143 Table 45: Incidence of Injection Site Reaction, Hypersensitivity and Autoimmune Disorder by Neutralizing Anti-Romosozumab Antibody Status ..................................................................... 143 Table 46: Summary Adverse Events of Hypersensitivity ............................................................ 145 Table 47: SAEs of Hypersensitivity in Subjects Receiving Romosozumab (Study 20070337) .... 145 Table 48: Hypersensitivity Events Considered being Causally Related to Romosozumab ......... 148 Table 49: Adverse Events Injection site reactions (Safety Analysis Set) ..................................... 150 Table 50: AE of Malignant or Unspecified Tumors by Preferred Term ...................................... 152 Table 51: Summary of AE and SAE for Hyperostosis .................................................................. 153 Table 52: Adverse Events of Hyperostosis by Preferred Term ................................................... 154 Table 53: TNF Mediated Inflammatory Adverse Events for Subjects with Prior History ........... 155 Table 54: TNF Mediated Inflammatory Adverse Events for Subjects without Prior History ...... 155 Table 55: Adverse Events by Age Group and Preferred Term .................................................... 157 Table 56: Adverse Events by Race and Preferred Term ............................................................. 158 Table 57: Adverse Events by BMI Tertile and Preferred Term ................................................... 159 Table 58: Adverse Events by Geographic Regions and Preferred Term Overall and by Commonly Reported Preferred Term ........................................................................................................... 160 Table 59: Adverse Events by Geographic Regions and Preferred Term for hypersensitivity. .... 161 Table 60: AE CTCAE  Grade 3 in Study 20070337 in the Double-Blind Period. ........................ 211</figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_130"><head>Table of Figures</head><label>of</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_132"><head></head><label></label><figDesc>The proposed proprietary name is not acceptable from a safety perspective. The proposed name is vulnerable to name confusion with the pending proprietary name, Unamity. "Subsequently, the DMEPA review team reversed their decision and found the proposed name, Evenity, acceptable as UNAMITY was no longer a viable name for approval. In their review(10/17/16), the DMEPA review team stated:"The proposed proprietary name is acceptable."</figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>14</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_136"><head>Treatment Options</head><label></label><figDesc>Many drugs are effective: bisphosphonates, denosumab, teriparatide, raloxifene  Different formulations, dosing schedules and routes of administration: oral tablets/solution, nasal spray, injection (subcutaneous, intravenous)  Treatment can reduce nonvertebral fractures by up to about 50%;vertebral fractures by up to 70%  Minor side effects are common, and contribute to poor compliance  Fear of rare, more severe side effects is a major obstacle to treatment Under-diagnosis and under-treatment of PMO is a critical public health issue in the US. Treatment is effective when used, but does not prevent all fractures. Availability of additional treatment options, especially those with high levels of fracture efficacy, will benefit PMO patients.</figDesc><table><row><cell>Clinical Review</cell><cell></cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell><cell></cell></row><row><cell>Dimension</cell><cell>Evidence and Uncertainties</cell><cell>Conclusions and Reasons</cell></row><row><cell cols="2"> Even after a major fracture or with multiple risk factors, most patients</cell><cell></cell></row><row><cell cols="2">do not receive appropriate treatment</cell><cell></cell></row><row><cell cols="2"> Romosozumab significantly reduced the risk of new vertebral fracture</cell><cell></cell></row><row><cell cols="2">by 73% through month 12 compared with placebo with absolute</cell><cell></cell></row><row><cell cols="2">risk reduction of 1.3. The risk reduction at month 12 persisted</cell><cell></cell></row><row><cell cols="2">through month 24, with a 75% risk reduction after both treatment</cell><cell></cell></row><row><cell cols="2">groups transitioned to antiresorptive therapy (denosumab) with an</cell><cell></cell></row><row><cell cols="2">absolute risk reduction of 1.9. Fewer new vertebral fractures</cell><cell></cell></row><row><cell cols="2">occurred during follow-on treatment in subjects who had received</cell><cell></cell></row><row><cell cols="2">romosozumab (5 fractures) compared with subjects who had</cell><cell></cell></row><row><cell cols="2">received placebo (25 fractures) in the first year of study.</cell><cell></cell></row><row><cell>Benefit</cell><cell></cell><cell></cell></row><row><cell cols="2">CDER Clinical Review Template 2015 Edition</cell><cell>18</cell></row><row><cell cols="2">Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row><row><cell>Reference ID: 4093382</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_143"><head>Table 1 : Pharmacologic Treatments for Osteoporosis</head><label>1</label><figDesc>approved only for osteoporotic patients at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy **approved only for osteoporotic patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies)Excluding the calcitonin products (which were approved based on total body calcium and/or BMD data), the 7 molecular entities represented in the above table were approved for treatment of PMO based on reduction of morphometric vertebral fractures, consistent with 1994 FDA guidelines on osteoporosis drug development. Such fractures are defined solely by radiographic criteria. Although the clinical effects of such fractures vary, they are a strong</figDesc><table><row><cell>Drug class</cell><cell>Product name</cell><cell>Year of</cell><cell>Dosing/</cell><cell>Important Safety and</cell></row><row><cell></cell><cell></cell><cell>Approval</cell><cell>Administration</cell><cell>Tolerability Issues</cell></row><row><cell>Bisphospho</cell><cell>Fosamax</cell><cell>1995</cell><cell>70 mg PO weekly (tablet</cell><cell>Osteonecrosis of</cell></row><row><cell>-nates</cell><cell>(alendronate)</cell><cell></cell><cell>or solution)</cell><cell>the jaw (ONJ)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>10 mg PO daily (tablet)</cell><cell>Atypical femoral</cell></row><row><cell></cell><cell>Fosamax Plus D (alendronate/</cell><cell>2005</cell><cell>70 mg alendronate/2800</cell><cell>fractures (AFF)</cell></row><row><cell></cell><cell>cholecalciferol)</cell><cell></cell><cell>or 5600 IU cholecalciferol,</cell><cell>Hypocalcemia</cell></row><row><cell></cell><cell></cell><cell></cell><cell>1 tablet weekly</cell><cell>Upper GI AEs</cell></row></table><note>*predictor of subsequent fracture (vertebral and nonvertebral) and also are associated with increased mortality, therefore are considered by the Division of Bone, Reproductive, and Urology Products (DBRUP) to be a clinically relevant (rather than surrogate) endpoint.CDER Clinical Review Template 2015 Edition 26 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_144"><head>Table 2 : PMO fracture trials: New morphometric vertebral fractures, risk reductions by year</head><label>2</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">12 months</cell><cell cols="2">24 months</cell><cell cols="2">36 months</cell></row><row><cell></cell><cell>ARR (%)</cell><cell>RRR (%)</cell><cell>ARR (%)</cell><cell>RRR (%)</cell><cell>ARR (%)</cell><cell>RRR (%)</cell></row><row><cell></cell><cell>(95% CI)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell></row><row><cell>Teriparatide</cell><cell></cell><cell></cell><cell>9.3*</cell><cell>65</cell><cell></cell><cell></cell></row><row><cell>(Forteo)</cell><cell></cell><cell></cell><cell>(5.5, 13.1)</cell><cell>(45, 78)</cell><cell></cell><cell></cell></row><row><cell>Denosumab</cell><cell>1.4</cell><cell>61</cell><cell>3.5</cell><cell>71</cell><cell>4.8</cell><cell>68</cell></row><row><cell>(Prolia)</cell><cell>(0.8, 1.9)</cell><cell>(42, 74)</cell><cell>(2.7, 4.3)</cell><cell>(61, 79)</cell><cell>(3.9, 5.8)</cell><cell>(59, 74)</cell></row><row><cell>Zoledronic acid</cell><cell>2.2</cell><cell>60</cell><cell>5.5</cell><cell>71</cell><cell>7.6</cell><cell>70</cell></row><row><cell>(Reclast)</cell><cell>(1.4, 3.1)</cell><cell>(43, 72)</cell><cell>(4.4, 6.6)</cell><cell>(62, 78)</cell><cell>(6.3, 9.0)</cell><cell>(62, 76)</cell></row><row><cell>Alendronate</cell><cell></cell><cell></cell><cell>7.2</cell><cell>62</cell><cell>7.0</cell><cell>47</cell></row><row><cell>(Fosamax-FIT 1)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Alendronate</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2.3**</cell><cell>48</cell></row><row><cell>(Fosamax-FIT-2)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Risedronate</cell><cell>4.0</cell><cell>65</cell><cell>5.9</cell><cell>55</cell><cell>5.0</cell><cell>41</cell></row><row><cell>(Actonel-NA)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Risedronate</cell><cell>7.7</cell><cell>61</cell><cell>13.1</cell><cell>59</cell><cell>10.9</cell><cell>49</cell></row><row><cell>(Actonel-MN)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ibandronate</cell><cell>0.6</cell><cell>58</cell><cell>2.3</cell><cell>61</cell><cell>4.9</cell><cell>62</cell></row><row><cell>(Boniva PO)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Raloxifene</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>6.1</cell><cell>30</cell></row><row><cell>(Evista)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(14, 44)</cell></row><row><cell>1 baseline fx</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Raloxifene</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2.4</cell><cell>55</cell></row><row><cell>(Evista)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(29, 71)</cell></row><row><cell>no baseline fx</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Reference ID: 4093382</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_145"><head></head><label></label><figDesc>EOP2 meeting, and subsequent correspondences and interactions including the November 10, 2014 Type C Clinical Written Response. These agreements including the following: The coprimary endpoints of subject incidence of new vertebral fracture at 12 and 24 months for the pivotal, placebo-controlled study of postmenopausal women with osteoporosis are adequate to demonstrate the efficacy of romosozumab.</figDesc><table><row><cell>Clinical Review</cell></row><row><cell>Debuene Chang MD</cell></row><row><cell>BLA 761062</cell></row><row><cell>Evenity (Proposed) -romosozumab</cell></row><row><cell> DBRUP agreed that a single multi-centered pivotal study, Study 20070337, appeared</cell></row><row><cell>adequate to support submission of an initial marketing application for this indication but</cell></row><row><cell>the level of efficacy evidence must be more persuasive (p &lt; 0.01) and supported by</cell></row><row><cell>efficacy data from other nonpivotal studies (see DBRUP's November 10, 2014 Type C</cell></row><row><cell>Clinical Written Response [Ref ID: 3656395]).</cell></row><row><cell>Reference ID: 4093382</cell></row></table><note>The design of the pivotal Study 20070337 was agreed with input from DBRUP during the 2011CDER Clinical Review Template 2015 Edition 28 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_150"><head>Table 3 : BMD at LS, TH, FN at Months 12 and month 24 in Study 20070337</head><label>3</label><figDesc></figDesc><table><row><cell></cell><cell cols="3">Antiromosozumab Antibody Status at Month 15</cell></row><row><cell>Percent</cell><cell></cell><cell>Any Binding</cell><cell>Any Neutralizing</cell></row><row><cell>Change From</cell><cell>All Negative</cell><cell>Positive</cell><cell>Positive</cell></row><row><cell>Baseline</cell><cell>Mean (SD)</cell><cell>Mean (SD)</cell><cell>Mean (SD)</cell></row><row><cell>Lumbar spine</cell><cell></cell><cell></cell><cell></cell></row><row><cell>N</cell><cell>2534</cell><cell>636</cell><cell>25</cell></row><row><cell>Month 12</cell><cell>13.1 (6.0)</cell><cell>13.1 (5.9)</cell><cell>11.6 (5.0)</cell></row><row><cell>Month 24</cell><cell>16.7 (7.0)</cell><cell>16.7 (7.2)</cell><cell>15.1 (7.7)</cell></row><row><cell>Total hip</cell><cell></cell><cell></cell><cell></cell></row><row><cell>N</cell><cell>2588</cell><cell>650</cell><cell>25</cell></row><row><cell>Month 12</cell><cell>6.0 (4.2)</cell><cell>6.1 (4.2)</cell><cell>7.4 (4.6)</cell></row><row><cell>Month 24</cell><cell>8.5 (4.8)</cell><cell>8.8 (5.1)</cell><cell>9.0 (7.6)</cell></row><row><cell>Femoral neck</cell><cell></cell><cell></cell><cell></cell></row><row><cell>N</cell><cell>2588</cell><cell>650</cell><cell>25</cell></row><row><cell>Month 12</cell><cell>5.5 (4.6)</cell><cell>5.7 (4.7)</cell><cell>7.3 (6.4)</cell></row><row><cell>Month 24</cell><cell>7.5 (5.1)</cell><cell>7.7 (5.6)</cell><cell>9.3 (8.9)</cell></row><row><cell cols="4">Source CSR 20070337 Tables 14-10.3.1, 14-10.3.2, and 14-10.3.3 with reviewer edits.</cell></row></table><note>Reviewer Comments: This data in totality support that a lower dose of romosozumab could have comparable efficacy than 210 mg QM when considering that BMD increased at LS, TH, and FN regardless of ADA status and that binding status decreased exposure by approximately 25%. For safety, PK values and exposure were comparable between ADA positive and negative patients by month 12. There was no increased safety AEs associated with ADA status. See section 8.3.12 Immunogenicity. Pharmacokinetics 4.5.3.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_152"><head>Reviewer Comments: The renal failure study 20110227 studied single dosing of 210mg in renal failure patients</head><label></label><figDesc></figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>34</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_154"><head>Table of Clinical Studies 5.1.</head><label></label><figDesc>followingTable 4lists the phase 3 study, 20070337, and four supportive studies (Study</figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>(b)</cell><cell>(b)</cell></row><row><cell>(4)</cell><cell>(4)</cell></row><row><cell>The Reference ID: 4093382</cell><cell></cell></row></table><note>CDER Clinical Review Template 2015 Edition 36 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_155"><head>Table 4 : Table of Phase 2 and 3 Clinical Studies Supporting Application</head><label>4</label><figDesc></figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note>Source: Clinical Overview Table 5 with reviewer edit</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_156"><head>6 Review of Relevant Individual Trials Used to Support Efficacy Study 20070337 6.1. Study Design 6.1.1. Overview and Objective</head><label></label><figDesc></figDesc><table /><note>A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_157"><head></head><label></label><figDesc>1.2 efficacy results. Five substudies (calcium, serum intact PTH [iPTH] and urinary calcium, audiology and osteoarthritis) as well as bone biopsy results are discussed in the safety section 8. The remaining two substudies, pharmacokinetics or pharmacogenetic substudies, are discussed within clinical pharmacology. Each of the Study 20070337 substudies is summarized in Appendix 13.6.</figDesc><table><row><cell>Clinical Review</cell></row><row><cell>Debuene Chang MD</cell></row><row><cell>BLA 761062</cell></row><row><cell>Evenity (Proposed) -romosozumab</cell></row><row><cell>Reference ID: 4093382</cell></row></table><note>CDER Clinical Review Template 2015 Edition 38 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_159"><head></head><label></label><figDesc>A third reader will adjudicate if the primary and secondary readers disagree on the presence of a new vertebral fracture.  Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. A single, central imaging center radiologist confirmed clinical fractures from either local radiology reports or from local radiographs sent to the central imaging center.  Nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of a reported fracture, November 5, 2015 for initial rollout (NME/original BLA reviews)fractures associated with high trauma severity or pathologic fractures were excluded.  Major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.  Hip fracture was a subset of nonvertebral fractures including femur neck, femur intertrochanter, and femur subtrochanter.  Major osteoporotic fractures included hip, forearm, or humerus fractures that were not associated with a pathologic fracture regardless of trauma severity, and clinical vertebral fractures.  hip fracture  major osteoporotic fracture (hip, wrist, humerus, and clinical vertebral)  multiple new or worsening vertebral fracture B) Percent change from baseline in BMD at the lumbar spine, total hip, and femoral neck  Safety endpoints through month 12 and through month 24 were: subject incidence of adverse events by system organ class and preferred term  changes from baseline in laboratory assessments (serum chemistry and hematology)  and the shift between baseline and the worst value  changes from baseline in vital signs  subject incidence of antiromosozumab antibodies  subject incidence of antidenosumab antibodies (from month 12 to month 24)</figDesc><table><row><cell>Clinical Review Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062 BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition Version date: Study Endpoints</cell><cell>40</cell></row><row><cell>Reference ID: 4093382</cell><cell></cell></row></table><note>excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, The co-primary endpoints were the subject incidence of new vertebral fracture through month 12 and through month 24. Secondary endpoints evaluated through month 12 and through month 24 were as follows: A) The subject incidence of:  clinical fracture (nonvertebral fracture and clinical vertebral fracture)  nonvertebral fracture  new or worsening vertebral fracture  major nonvertebral fracture (pelvis, distal femur, proximal tibia, ribs, proximal humerus, forearm, and hip) Exploratory efficacy endpoints that describe new vertebral fractures through month 6, clinical vertebral fractures, tooth loss, health-related quality of life, pain experience andCDER Clinical Review Template 2015 Edition 41 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_162"><head>Table 5 : Summary of Analysis Methods for Fracture and BMD Endpoints Study 20070337</head><label>5</label><figDesc></figDesc><table><row><cell>Source: CSR Study 20070337: Table 8-13 with reviewer edits.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_164"><head>Table 6 : Summary of Important Changes in Study Design 20070337</head><label>6</label><figDesc></figDesc><table><row><cell></cell><cell>Protocol</cell><cell></cell></row><row><cell></cell><cell>Amendment</cell><cell></cell></row><row><cell>Study</cell><cell>(Submission</cell><cell></cell></row><row><cell>Number</cell><cell>Date)</cell><cell>Description of Change</cell></row><row><cell cols="2">Change of primary endpoints during conduct of trial</cell><cell></cell></row><row><cell>20070337</cell><cell>Protocol</cell><cell></cell></row><row><cell></cell><cell>Amendment 1</cell><cell></cell></row><row><cell></cell><cell>(30 August 2012)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_168"><head>Table 7 : Select List of Investigators from 3 Sites (Columbia) Participating in Study 20070337 Not Providing Financial Disclosure Information Source</head><label>7</label><figDesc>: Financial DisclosureTable 8with reviewer edits.</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_170"><head>Table 8 : Disposition of Subjects for the Double-Blind Period to Month 12.</head><label>8</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_171"><head>Table 9 : Subject Disposition for Double-Blind Period with Extension Period to Month 24</head><label>9</label><figDesc></figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note>CDER Clinical Review Template 2015 Edition 48 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews) Both Table 7 and 8 Source: CSR20070337 Table 14-1.1. with reviewer edits.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_173"><head>Table 10 : Baseline Demographic Characteristics Study 20070337</head><label>10</label><figDesc></figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note>CDER Clinical Review Template 2015 Edition 50 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews) Source: CSR 20070337: Table 14-2.1 with reviewer edits.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_174"><head>Table 11 : Prevalent Fracture History of Subjects in 20070336</head><label>11</label><figDesc></figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_176"><head>Table 12 : Incidence Rates of New Vertebral Fracture Through Month 12 and Through Month 24: Co-Primary Endpoints</head><label>12</label><figDesc>Number of subjects randomized Note: Subjects who missed the 12 month visit are not included in the 12 month analysis but could have been included in the 24 month analysis if these subjects went on to complete the study. N1 = Number of subjects in the primary analysis set for vertebral fractures Positive values for absolute risk reduction and values &lt; 1 for risk ratio and odds ratio favor romosozumab. Based on logistic regression model adjusted for age and prevalent vertebral fracture stratification variables; p-value based on score test e SE represents the standard error of log (odds ratio). Source: CSR 20070337 Table 10-1 and Table 14-4.1.1 with statistics reviewer input and reviewer edits.</figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note>a Based on the Mantel-Haenszel method adjusted for age and prevalent vertebral fracture stratification variablesb SE represents the standard error of log (risk ratio).c Calculated from risk ratio as 100 x (1 -risk ratio)d</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_178"><head>Table 13 : Sensitivity Analysis of Co-Primary Endpoints with Sites 68001, 68002, and 68006 removed.</head><label>13</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">Through Month 12</cell><cell cols="2">Through Month 24</cell></row><row><cell>Statistic</cell><cell></cell><cell></cell><cell>Placebo/</cell><cell>Romosozumab /</cell></row><row><cell></cell><cell>Placebo</cell><cell>Romosozumab</cell><cell>Denosumab</cell><cell>Denosumab</cell></row><row><cell></cell><cell>(N = 3591)</cell><cell>(N = 3589)</cell><cell>(N = 3591)</cell><cell>(N = 3589)</cell></row><row><cell>Incidence, n/N1 (%)</cell><cell>56/2867 (1.95)</cell><cell>15/2887 (0.52)</cell><cell>77/2872 (2.68)</cell><cell>19/2891 (0.66)</cell></row><row><cell></cell><cell cols="2">Risk Comparison Estimates</cell><cell></cell><cell></cell></row><row><cell>Absolute risk reduction (%)*</cell><cell></cell><cell>1.4%</cell><cell></cell><cell>2.0%</cell></row><row><cell>95% CI</cell><cell cols="2">(0.9%, 2.0%)</cell><cell cols="2">(1.4%, 2.7%)</cell></row><row><cell>Relative risk reduction *</cell><cell></cell><cell>73%</cell><cell></cell><cell>75%</cell></row><row><cell>95% CI</cell><cell cols="2">(53%, 85%)</cell><cell cols="2">(60%, 85%)</cell></row><row><cell>p-value  </cell><cell cols="2">&lt; 0.001</cell><cell cols="2">&lt; 0.001</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_180"><head>Table 14 : Clinical Fracture Results at 12 months (Step 2 of Multiplicity Adjustment Fixed- Sequence Procedure)Reviewer Comments: Clinical fractures results through 12 months were statistically significant both nominally and when adjusted for multiplicity. Clinical fractures through 24 months were not included in this step 2 of the fixed sequence testing strategy and are located further down the sequence at step 4. Further discussion of clinical fractures results is included below under step 4 .</head><label>14</label><figDesc>Source: CSR 20070337  Table 10.2 with reviewer edits</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_181"><head>Table 15 Reviewer Comments: Neither nonvertebral fracture endpoints (through 12 months or 24 months) met statistical significance when adjusted for multiplicity, both adjusted p-value &gt; 0.05. The testing sequence ends at this step and further fracture analysis in the sequential testing strategy will result in adjusted p-values &gt; 0.05.</head><label>15</label><figDesc></figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note>: Nonvertebral Fracture Results Through Month 12 and Month 24 (Step 3 of Multiplicity Adjustment Fixed-Sequence Procedure) Step 4: Clinical fractures at 24 months: The fourth step of the fixed-sequence testing was for an analysis of clinical fractures through 24 months. As the testing sequence ended at the previous step, clinical fractures through 24 months will not be statistically significant when adjusted for multiplicity. The following table 16 summarizes the clinical fractures through month 24.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_182"><head>Table 16 :</head><label>16</label><figDesc></figDesc><table /><note>Clinical Fracture Results Through Month 24 (Step 4 of Multiplicity Adjustment Fixed- Sequence Procedure) Source: CSR 20070337 Table 10-2 with reviewer edits.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_184"><head>romosozumab group compared to placebo are from clinical vertebral fractures which were already counted in the primary endpoint.</head><label></label><figDesc>Fracture Endpoints: The relative risk reductions (95% CI) for the following fracture endpoints resulted in nominal pvalues &lt; 0.05 but adjusted multiplicity p-values were &gt; 0.05 for major nonvertebral, new or worsening vertebral, and hip fracture categories:</figDesc><table><row><cell>Clinical Review</cell></row><row><cell>Debuene Chang MD</cell></row><row><cell>BLA 761062</cell></row><row><cell>Evenity (Proposed) -romosozumab</cell></row><row><cell>Other  Month 12: new or worsening vertebral fracture (71% [95% CI: 51, 83]), major</cell></row><row><cell>osteoporotic fracture (40% [95% CI: 10, 60]), multiple new or worsening vertebral</cell></row><row><cell>fracture (89% [95% CI: 13, 99]).  Month 24: nonvertebral fracture (25% [95% CI: 3, 43]), clinical fracture (33% [95% CI: 13,</cell></row><row><cell>48]), major nonvertebral fracture (33% [95% CI: 9, 51]), new or worsening vertebral</cell></row><row><cell>fracture (74% [95% CI: 58, 84]), major osteoporotic fracture (38% [95% CI: 16, 54]),</cell></row><row><cell>multiple new or worsening vertebral fracture (94% [95% CI: 56, 99]).</cell></row></table><note>CDER Clinical Review Template 2015 Edition 58 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_185"><head>Table 17 : Summary of Other Secondary Fracture Endpoints through Month 12 and 24</head><label>17</label><figDesc>Source: CSR 2070337Table 10-2 with reviewer edits.</figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note>CDER Clinical Review Template 2015 Edition 59 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_186"><head>Table 18 : Percent Change BMD at Lumbar Spine, Total Hip, and Femoral Neck at 12 and 24 Months.Comments: Romosozumab effects were statistically significant at LS, total hip, and femoral neck and its effects were consistent regardless of age groups, baseline BMD values, and regions differences. Although the Sponsor did not control BMD parameters for type 1</head><label>18</label><figDesc>Source: CSR 20070337Table 10-3 with statistic reviewer confirmation and reviewer edits.</figDesc><table><row><cell>Reviewer</cell></row></table><note>CDER Clinical Review Template 2015 Edition 60 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_189"><head>into denosumab at 12months. Measurements were made every 6 months and are statistically significant at each timepoint.</head><label></label><figDesc></figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>63</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row><row><cell>Reference ID: 4093382</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_192"><head>and 6.2. 20120156) and Active-Comparator Controlled Study (20080289)Primary Objective: For the 24-month AMG 785 treatment phase (study day 1 to month 24)</head><label></label><figDesc>Together these studies support efficacy and safety of the single pivotal study 20070337 (in section 6.1) for BMD, BTM, dosing, drug concentration, and retreatment but only the pivotal study examined fracture endpoints. Each supportive study synopsis and study schedule is in Appendix 13.4. Section 7 will integrate the pivotal and supportive clinical studies.Title: A Randomized, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of romosozumab (AMG 785) in the Treatment of Postmenopausal Women With Low Bone Mineral Density Indication: Postmenopausal women with low bone mineral density</figDesc><table><row><cell cols="2">Clinical Review</cell></row><row><cell cols="2">Debuene Chang MD</cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell cols="2">Evenity (Proposed) -romosozumab</cell></row><row><cell>6.2.1.</cell><cell>Study 20060326</cell></row></table><note>This section summarize each of the four supportive studies: three placebo-controlled studies: Study 20060326, 20101291, and 20120156 and one supportive active-comparator (teriparatide) controlled study 20080289.CDER Clinical Review Template 2015 Edition 66 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_204"><head>Table 19 : DXA Lumbar Spine BMD Percent Change From Baseline to Month 12 -Linear Mixed Effects Model Showing Each of Romosozumab Groups</head><label>19</label><figDesc></figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note>Source: CSR20060326 Table 10-2 with reviewer edits.CDER Clinical Review Template 2015 Edition 77 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_205"><head>Table 20 : DXA Percent Change From Baseline of the Total Hip and Femoral Neck at Months 12</head><label>20</label><figDesc>Source: CSR20060326Table 10-4 with reviewer edits.Compared with placebo, there was no statistically significant change in the distal 1/3 radius BMD at month 12. The following table 21 summarizes the lack of change at the distal 1/3 radius by BMD at month 12.</figDesc><table><row><cell>Clinical Review</cell></row><row><cell>Debuene Chang MD</cell></row><row><cell>BLA 761062</cell></row><row><cell>Evenity (Proposed) -romosozumab</cell></row></table><note>CDER Clinical Review Template 2015 Edition 78 Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_206"><head>Table 21 : DXA BMD Percent Change From Baseline at Distal 1/3 Radius</head><label>21</label><figDesc></figDesc><table /><note>Source: CSR20060326 Table 10-5 with reviewer edits.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_210"><head>Table 22 : QCT Changes from Baseline for BMD, BMC, and Cortical Thickness at the Lumbar Spine at Month 12 for the Treatment Groups.Reviewer Comments: QCT substudy results showed that only the 210 mg dose of romosozumab significantly increased cortical BMD and BMC when compared to placebo and teriparatide treated patients which gives supporting evidence for bone quality at this dose.</head><label>22</label><figDesc>Source: CSR 20060326Table 10-7 with reviewer edits.For the cortical parameters at the total femur, only cortical BMC was significantly greater in the 24 subjects in this substudy who had received romosozumab 210 mg QM in Study 20060326.</figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_211"><head></head><label></label><figDesc> for initial rollout (NME/original BLA reviews) Percent change from baseline in BMD at the total hip and femoral neck at Month 6 and Month 12  Percent change from baseline in BTMs (P1NP, sCTX, OC, and BSAP) at Day 1 plus 1 week, Month 1, Month 2, Month 3, Month 6, Month 9, and Month 12  AUC for P1NP through Month 12</figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition  Romosozumab serum concentrations at Day 1, Day 1 plus 1 week, Month 1, Month 2, Version date: Exploratory Endpoint(s): Month 3, Month 6, Month 9, and Month 12</cell><cell>83</cell></row><row><cell>Reference ID: 4093382</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_218"><head>Table 24 : BMD at Lumbar Spine at 6 months comparing dose concentrations 70 mg/ mL and 90 mg/ mL.</head><label>24</label><figDesc></figDesc><table><row><cell>Source CSR20120156 Table 10-1 with reviewer edits.</cell></row><row><cell>Reference ID: 4093382</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_219"><head>7.1.1.</head><label></label><figDesc></figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>91</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row><row><cell>Reference ID: 4093382</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_221"><head>Table 25 : Lumbar Spine BMD Percent Change from Baseline in Placebo-controlled Efficacy Studies.</head><label>25</label><figDesc></figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note>Source: ISE Table 14-4.1.1 with reviewer edits.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_228"><head>Table 26 : Lumbar Spine BMD gains in Response to Romosozumab Retreatment.</head><label>26</label><figDesc></figDesc><table><row><cell>Source CSR 20060326 Table 10-10 with reviewer edits.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_231"><head></head><label></label><figDesc>Romosozumab significantly reduced the risk of new vertebral fracture by 73% through month 12 compared with placebo. The risk reduction at month 12 persisted through</figDesc><table><row><cell>Clinical Review Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062 BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell> month 24, with a 75% risk reduction after both treatment groups transitioned to</cell><cell></cell></row><row><cell cols="2">antiresorptive therapy (denosumab). Fewer new vertebral fractures occurred during</cell></row><row><cell cols="2">follow-on treatment in subjects who had received romosozumab (5 fractures) compared</cell></row><row><cell>with subjects who had received placebo (25 fractures) in the first year of study. See</cell><cell></cell></row><row><cell>section 6.1.2 Study 20070337 Results.</cell><cell></cell></row><row><cell>(b) (4)</cell><cell></cell></row><row><cell cols="2"> For new vertebral fracture, the treatment effects were consistent (relative risks favored</cell></row><row><cell cols="2">romosozumab over placebo and romosozumab/denosumab over placebo/denosumab)</cell></row><row><cell>in all subgroups of baseline characteristics examined, including age, race, geographic</cell><cell></cell></row><row><cell cols="2">region, a range of baseline BMD T-scores, and subjects with a history of prior vertebral,</cell></row><row><cell>nonvertebral, or fragility fracture. See section 7.1.3 Integrated Subpopulations.</cell><cell></cell></row><row><cell cols="2">2 Study 20070337</cell></row><row><cell>Results.</cell><cell></cell></row><row><cell>c) 85% of clinical fractures is composed of nonvertebral fractures which were not</cell><cell></cell></row><row><cell>statistically significant at either 12 or 24 months. The remaining 15% of clinical</cell><cell></cell></row><row><cell cols="2">fractures is composed of vertebral fractures which was already counted in the co-</cell></row><row><cell>primary endpoints of the study (vertebral fractures at 12 and 24 months). See</cell><cell></cell></row><row><cell>section 6.1.2 Study 20070337 Results.</cell><cell></cell></row><row><cell> The nonvertebral fracture risk reduction with romosozumab was not statistically</cell><cell></cell></row><row><cell>significant, a result potentially influenced by low nonvertebral fracture rates overall,</cell><cell></cell></row><row><cell>especially in a high-enrolling region (Central/Latin America). See section 6.1.2. Study</cell><cell></cell></row><row><cell>20070337 results.</cell><cell></cell></row><row><cell> The results for other fracture types (major nonvertebral, hip, major osteoporotic)</cell><cell></cell></row><row><cell>were directionally consistent with the results for new vertebral fracture and clinical</cell><cell></cell></row><row><cell cols="2">fracture (ie, fracture risk appeared lower for romosozumab and romosozumab followed</cell></row><row><cell cols="2">by denosumab than for placebo and placebo followed by denosumab). See section 6.1.2</cell></row><row><cell>Study 20070337 Results.</cell><cell></cell></row><row><cell>Improvement in BMD</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition CDER Clinical Review Template 2015 Edition</cell><cell>103 104</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews) Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row><row><cell>Reference ID: 4093382 Reference ID: 4093382</cell><cell></cell></row></table><note> Although romosozumab significantly reduced the risk of clinical (ie, symptomatic) fractures by 36% through month 12, the following issues negate this clinical fracture claim: a) Clinical fracture lacks clinical meaningfulness as defined in the clinical study.b) Clinical fracture risk through 24 months was not tested for statistical significance as the fixed-sequence testing ended before this step. See section 6.1.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_232"><head>of the Safety Database 8.2. Overall Exposure 8.2.1.</head><label></label><figDesc>When possible, additional adverse event assessments used prespecified standardized Medical Dictionary for Regulatory Activities (MedDRA) queries (SMQs). The Sponsor's MedDRA search strategies were used when a SMQ was not available in the categories of hypocalcemia, injection site reactions, hyperostosis, and osteoarthritis.</figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>3) events theoretically associated with sclerostin inhibition</cell><cell></cell></row><row><cell> Osteoarthritis</cell><cell></cell></row><row><cell> Malignancy</cell><cell></cell></row><row><cell>4) adverse events associated with injectable monoclonal antibodies</cell><cell></cell></row><row><cell> Hypersensitivity events</cell><cell></cell></row><row><cell> Injection site reactions</cell><cell></cell></row><row><cell>5) adverse events associated with anti-resorptive therapies</cell><cell></cell></row><row><cell> Osteonecrosis of the jaw [ONJ]</cell><cell></cell></row><row><cell> Atypical femoral fracture [AFF]</cell><cell></cell></row><row><cell>6) Adverse events potentially related to tumor necrosis factor- (TNF-) mediated</cell><cell></cell></row><row><cell>inflammatory disease</cell><cell></cell></row><row><cell> Subjects with or without prior history of TNF-mediated inflammatory disease</cell><cell></cell></row><row><cell>7) Adjudicated positive cardiovascular events</cell><cell></cell></row><row><cell>Review The following table 27 summarizes overall exposure to romosozumab in the clinical</cell><cell></cell></row><row><cell>development program:</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>105</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row><row><cell>Reference ID: 4093382</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_233"><head>Table 27 : Romosozumab Exposure-Number of Patients by Months of Exposure or Dose</head><label>27</label><figDesc></figDesc><table /><note>a Placebo includes studies</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_234"><head></head><label></label><figDesc>Includes study 20070337(12 months). c Placebo includes studies 20060326 (24 months), 20101291 (12 months), and 20120156(6 months); romosozumab includes studies 20060326 (24 months, 48 subjects who received romosozumab after one year of alendronate are included), 20080289 (12 months), 20101291 (12 months), and 20120156 (6 months).</figDesc><table><row><cell cols="2">Clinical Review</cell></row><row><cell cols="2">Debuene Chang MD</cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell cols="2">Evenity (Proposed) -romosozumab</cell></row><row><cell cols="2">Source from 2.7.4 Summary of Clinical Safety Table 2 and modified by reviewer</cell></row><row><cell>8.2.2.</cell><cell>Relevant characteristics of the safety population:</cell></row><row><cell cols="2">CDER Clinical Review Template 2015 Edition</cell><cell>106</cell></row><row><cell cols="2">Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell></row></table><note>b</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_235"><head>Issues Regarding Data Integrity and Submission Quality 8.3.1.</head><label></label><figDesc></figDesc><table><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>107</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_236"><head></head><label></label><figDesc>The committee determined whether the event met the case definition criteria for ONJ.  Atypical Femur Fracture (AFF) o Predefined search of MedDRA terms were submitted to an independent external adjudication committee for review and adjudication. o The committee determined whether the event met the American Society for Bone and Mineral Research case definition criteria for AFF.</figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell> Cardiovascular events(Study 20070337)</cell><cell></cell></row><row><cell>Hypersensitivity and Malignancy</cell><cell></cell></row><row><cell>o Search terms standardized MedDRA queries (SMQs) (captured by the</cell><cell></cell></row><row><cell>"unspecified or malignant tumors" SMQ for malignancy)</cell><cell></cell></row><row><cell> Hypocalcemia, Injection Site reactions, Hyperostosis, and Osteoarthritis</cell><cell></cell></row><row><cell cols="2">o Internal Amgen search strategies for the events of interest that did not have a</cell></row><row><cell>MedDRA SMQ.</cell><cell></cell></row><row><cell cols="2">o Subject incidences are provided using the 12-month placebo-controlled safety</cell></row><row><cell>analysis set; Exposure-adjusted incidence rate used the PMO safety analysis</cell><cell></cell></row><row><cell>set.</cell><cell></cell></row><row><cell> Osteonecrosis of Jaw (ONJ)</cell><cell></cell></row><row><cell>o Predefined search of MedDRA terms were submitted to an independent</cell><cell></cell></row><row><cell>external adjudication committee for review and adjudication</cell><cell></cell></row><row><cell>o  Tumor necrosis factor- (TNF-)-mediated inflammatory disease in subjects with or</cell><cell></cell></row><row><cell>without a prior history of TNF-mediated inflammatory disease</cell><cell></cell></row><row><cell cols="2">o Internal Amgen search strategy using the 12-month placebo-controlled safety</cell></row><row><cell>analysis set.</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>108</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_239"><head>Table 28 : Treatment-emergent Fatal Adverse Events by Preferred Term (Safety Analysis Set)</head><label>28</label><figDesc></figDesc><table><row><cell>Source ISS Table 14-6.2.9 with reviewer edits</cell></row><row><cell>Reference ID: 4093382</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_240"><head>Table 29 : Adverse Events of Lung Neoplasms by Preferred Term</head><label>29</label><figDesc></figDesc><table><row><cell>Source ISS Table 14-6.8.5 with reviewer edits and modifications.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_241"><head>Table 30 : SAEs in the Safety PopulationReviewer Comment: SAEs in the 12 month placebo controlled population are relativelybalanced between the romosozumab and placebo groups. There was a slight inbalance of pneumonia (0.</head><label>30</label><figDesc></figDesc><table><row><cell>Source: Modified ISS Table 14-6.2.2 with reviewer edits</cell></row><row><cell>Reference ID: 4093382</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_243"><head>Table 32 :</head><label>32</label><figDesc>Adverse Events of Adjudicated Positive Atypical FemoralSource from ISSTable 14-6.8.8 with reviewer edits.    </figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_245"><head></head><label></label><figDesc>were 3.0 at the hip and 3.57 at the femoral neck. The subject received alendronate for 1 year then rolled over to receive open-label alendronate. Approximately 5 months after rolling over to the open label alendronate (Month</figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>(b) (6)</cell><cell></cell></row><row><cell>(b) (6)</cell><cell></cell></row><row><cell>(b) (6)</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>117</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row><row><cell>Reference ID: 4093382</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_250"><head>Table 33 : Adjudicated Positive Osteonecrosis of the Jaw by Preferred Term Sourced from ISS: Table 14-6.8.9 with reviewer edits.</head><label>33</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_254"><head>Table 34 : Adverse Events in Romosozumab 210 mg QM and Placebo</head><label>34</label><figDesc></figDesc><table><row><cell>Source: Modified from ISS Table 14a-6.1.1 with reviewer edits</cell></row><row><cell>Reference ID: 4093382</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_255"><head>Table 35 : Subject Incidence of Laboratory CTCAE Grade  2 in the Placebo Control Period</head><label>35</label><figDesc></figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note>Source: Modified from ISS Table 14-7.1.508 with reviewer edits.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_256"><head></head><label></label><figDesc>romosozumab and found that no patients had hypocalcemic values as defined.</figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>127</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_257"><head>Table 36 : Subject Incidence of Hypocalcemia by CTCAE Grade in Study 20110227</head><label>36</label><figDesc></figDesc><table><row><cell>Source: CSR 20110227 Table 14-6.2.1.2 with reviewer edits.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_260"><head>Table 37 :</head><label>37</label><figDesc>Glucose CTCAE Grade  2 in the Placebo Control Period</figDesc><table><row><cell>Source: Modified from ISS Table 14-7.1.508 with reviewer edits.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_262"><head>Table 38 : 24 Hour Urinary Calcium Excretion Percent Change From Baseline at 6 months and 12 months (Serum Intact Parathyroid Hormone and Urinary Calcium Substudy of 20070337).</head><label>38</label><figDesc></figDesc><table><row><cell>Source CSR 20070337 substudy Table 14u-7.3.2 with reviewer edits.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_264"><head>Table 40 )</head><label>40</label><figDesc>elevations across the 12 month placebo controlled studies based on 3X, 5X, 10X, or 20X &gt; ULN.</figDesc><table><row><cell>Clinical Review</cell></row><row><cell>Debuene Chang MD</cell></row><row><cell>BLA 761062</cell></row><row><cell>Evenity (Proposed) -romosozumab</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_265"><head>Table 39 : Subject Incidence of Serum Aspartate Aminotransferase (AST) Elevations</head><label>39</label><figDesc></figDesc><table><row><cell>Source: Modified from ISS Table 14-7.1.501 with reviewer edits.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_266"><head>Table 40 : Subject Incidence of Serum Alanine Aminotransferase (ALT) Elevations</head><label>40</label><figDesc></figDesc><table><row><cell>Source: ISS: Table 14-7.1.509 with reviewer edits.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_268"><head>Table 41 : Selected subject with elevated AST and ALT &gt; 5 x ULN on study 20060220</head><label>41</label><figDesc>ALT and AST). Past medical history did not include liver disease, gallstones, or peptic ulcer. Concomitant medications included acetaminophen.</figDesc><table><row><cell cols="2">Source Appendix 11, CSR 20060220 with reviewer edits and modification</cell></row><row><cell>Subject</cell><cell>brief SAE narrative: This 53-year-old Hispanic or Latino woman (no.</cell></row><row><cell></cell><cell>) enrolled in cohort 6a (10 mg/kg SC AMG 785) of AMG 785 first-in-human study and</cell></row><row><cell cols="2">developed elevated liver function tests (Reference ID: 4093382</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_270"><head>Table 42 : Potential Hy's Law Cases</head><label>42</label><figDesc></figDesc><table><row><cell>Source: ISS Table 14-7.2</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_274"><head>1</head><label></label><figDesc>QTc of 453 msec, 454 msec, and 462 msec; month 1 QTc of 476 msec; month 3 QTc of 485 msec; and month 9 QTc of 498 msec. The subject had a history of hypertension, depression, bipolar disorder, chronic obstructive pulmonary disease, hypercholesterolemia, Parkinsonian rest tremor, and environmental allergies. The subject's</figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>141</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_276"><head>Table 43 : Anti-Romosozumab Antibody Summary (Safety Analysis Set)</head><label>43</label><figDesc></figDesc><table><row><cell>Sourced from ISS: Table 14-8.1. with reviewer edits</cell></row><row><cell>Reviewer Comments: 17.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_278"><head>Table 44 : Incidence of Injection Site Reaction, Hypersensitivity and Autoimmune Disorder by Binding Anti-Romosozumab Antibody Status</head><label>44</label><figDesc></figDesc><table><row><cell>Source: ISS Table 14-8.2.1 modified by reviewer</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_279"><head>Table 45 : Incidence of Injection Site Reaction, Hypersensitivity and Autoimmune Disorder by Neutralizing Anti-Romosozumab Antibody Status</head><label>45</label><figDesc></figDesc><table><row><cell>Source: ISS Table 14-8.2.2 modified by reviewer</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_281"><head>Analysis of Submission-Specific Safety Issues 8.4. Adverse Events Potentially Related to Hypersensitivity 8.4.1.</head><label></label><figDesc></figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>145</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_282"><head>Table 46 : Summary Adverse Events of HypersensitivityTable 47: SAEs of Hypersensitivity in Subjects Receiving Romosozumab (Study 20070337)</head><label>46</label><figDesc>SAEs potentially related to hypersensitivity all occurred in the pivotal study 20070337and a detailed breakdown of each SAE by preferred term is listed in the followingTable 47.</figDesc><table><row><cell>Source: Modified from ISS Table 14-6.8.1 with reviewer edits and modification</cell></row><row><cell>SAEs:</cell></row><row><cell>The 7</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_284"><head>Table 48 : Hypersensitivity Events Considered being Causally Related to Romosozumab</head><label>48</label><figDesc></figDesc><table><row><cell>Source: ISS Table 14-6.2</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_286"><head>Table 49 : Adverse Events Injection site reactions (Safety Analysis Set)</head><label>49</label><figDesc></figDesc><table><row><cell>Source: Modified from ISS Table 14-6.8.1 with reviewer edits</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_288"><head>Table 50</head><label>50</label><figDesc>below summarizes the incidence of malignant or unspecified tumors in the placebo-controlled studies.</figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_289"><head>Table 50 : AE of Malignant or Unspecified Tumors by Preferred Term Source</head><label>50</label><figDesc>: ISS Table 14-6.8.5 with reviewer modification and edits.</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_291"><head>history. Hyperostosis and Audiology Substudy 8.4.4.</head><label></label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_292"><head>Table 51 : Summary of AE and SAE for Hyperostosis Modified</head><label>51</label><figDesc>from Summary of Clin Safety Table 17 with reviewer edits.</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_293"><head>Table 52</head><label>52</label><figDesc>details and summarizes component preferred terms in the search for hyperostosis.</figDesc><table><row><cell>Reference ID: 4093382</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_294"><head>Table 52 : Adverse Events of Hyperostosis by Preferred Term</head><label>52</label><figDesc></figDesc><table /><note>Source: ISS</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_296"><head>Table 53 : TNF Mediated Inflammatory Adverse Events for Subjects with Prior History</head><label>53</label><figDesc></figDesc><table><row><cell>Source: Modified from ISS Table 14-6.4.500 with reviewer edits.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_297"><head>Table 54 : TNF Mediated Inflammatory Adverse Events for Subjects without Prior History</head><label>54</label><figDesc></figDesc><table><row><cell>Sourced from modified ISS Table 14-6.4.501 with reviewer edits.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_299"><head>with TNF mediated inflammatory disease. Osteoarthritis 8.4.6.</head><label></label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_301"><head>Table 55 : Adverse Events by Age Group and Preferred Term</head><label>55</label><figDesc></figDesc><table><row><cell>Source: Modified from ISS: Table 14-6.3.2 with reviewer edits.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_303"><head>Table 56 : Adverse Events by Race and Preferred Term</head><label>56</label><figDesc></figDesc><table><row><cell>Source: Modified from ISS Table 14-6.3.3 with reviewer edits.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_305"><head>Table 57 : Adverse Events by BMI Tertile and Preferred Term</head><label>57</label><figDesc></figDesc><table /><note>Source: Modified from ISS</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_307"><head>Table 58 : Adverse Events by Geographic Regions and Preferred Term Overall and by Commonly Reported Preferred Term</head><label>58</label><figDesc></figDesc><table><row><cell>Source: Modified from ISS Table 14-6.3.4 with reviewer edits.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_308"><head>nasopharngyitis AEs do not alleviate</head><label></label><figDesc></figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>161</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row><row><cell>Reference ID: 4093382</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_309"><head>Table 59 : Adverse Events by Geographic Regions and Preferred Term for hypersensitivity.Specific Safety Studies/Clinical Trials 8.5. Hepatic Impairment 8.5.1.</head><label>59</label><figDesc></figDesc><table><row><cell>Source: Reviewer modified from ISS Table 14-6.3.4</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_313"><head>romosozumab. Safety in the Postmarket Setting 8.7. Safety Concerns Identified Through Postmarket Experience 8.7.1.</head><label></label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_314"><head>Additional Safety Issues From Other Disciplines 8.8.</head><label></label><figDesc>risk for AFF, especially in early treatment with romosozumab Increase risk for ONJ Increased risk for hypocalcemia in patients with renal failure Risk of hypersensitivity reactions</figDesc><table><row><cell cols="2">Clinical Review</cell></row><row><cell cols="2">Debuene Chang MD</cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell cols="2">Evenity (Proposed) -romosozumab</cell></row><row><cell>8.9.</cell><cell>Integrated Assessment of Safety</cell></row><row><cell>Not Applicable</cell><cell></cell></row><row><cell cols="2">CDER Clinical Review Template 2015 Edition</cell><cell>167</cell></row><row><cell cols="2">Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell></row><row><cell>Reference ID: 4093382</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_315"><head> AFF :</head><label>AFF</label><figDesc>Since romosozumab has antiresorptive activity, as demonstrated by BTM profiles and histomorphometry data from bone biopsies, AFF is an important potential risk for romosozumab. Atypical low-energy or low trauma fractures of the femoral shaft have been reported in patients receiving romosozumab See section 8.3.6 Significant Adverse Events. Labeling can manage this risk as the number of AFF cases observed to date is low and all cases had confounding factors. Since romosozumab has antiresorptive activity, as demonstrated by BTM profiles and histomorphometry data from bone biopsies, ONJ is an important potential risk for romosozumab. Osteonecrosis of the jaw, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients receiving romosozumab. See section 8.3.6 Significant Adverse Events. Labeling can manage this risk as the number of ONJ cases observed to date is low and all cases had confounding factors. Like other monoclonal antibodies, romosozumab could be associated with hypersensitivity reactions. Based on medical review of the integrated safety data, hypersensitivity is considered an important identified risk with romosozumab. Clinically significant hypersensitivity reactions, including angioedema, erythema multiforme, and urticaria, occurred in the romosozumab group. See sections 8.4.1 hypersensitivity.</figDesc><table><row><cell>Clinical Review Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062 BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>14 CLINICAL STUDIES</cell><cell></cell></row><row><cell>Sponsor Proposed:</cell><cell></cell></row><row><cell></cell><cell>(b) (4)</cell></row><row><cell>Sponsor Proposed:</cell><cell></cell></row><row><cell>(b) (4)</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition CDER Clinical Review Template 2015 Edition</cell><cell>171 172</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews) Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row><row><cell>Reference ID: 4093382</cell><cell></cell></row></table><note> ONJ: Hypersensitivity:</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_316"><head>Issue(s) that Warrant Consideration of a REMS 11.1.</head><label></label><figDesc>REMS in the post marketing setting.</figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell></cell><cell>(b) (4)</cell></row><row><cell>Safety None Identified</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>173</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row><row><cell>Reference ID: 4093382</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_318"><head>Study 20070337 Substudy Details 13.6. Bone Turnover Marker and Biomarker Sub-study 13.6.1.</head><label></label><figDesc>Number of investigators with certification of due diligence (Form FDA 3454, box 3) Central laboratories and vendors were used to analyze all screening and on-study samples for serum chemistry, hematology, biomarker and BTMs (P1NP, osteocalcin [OC], bone-specific alkaline phosphatase [BSAP], serum Type I collagen C-telopeptide [sCTX], tartrate-resistant acid phosphatase 5b [TRAP 5b])</figDesc><table><row><cell>Clinical Review</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell><cell></cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Is an attachment provided with the</cell><cell> Yes</cell><cell>No</cell><cell>(Request explanation</cell></row><row><cell>reason:</cell><cell></cell><cell cols="2">from Applicant)</cell></row><row><cell cols="2">Significant equity interest held by investigator in</cell><cell></cell><cell></cell></row><row><cell>Sponsor of covered study: 1</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Is an attachment provided with</cell><cell> Yes</cell><cell>No</cell><cell>(Request details from</cell></row><row><cell>details of the disclosable financial</cell><cell></cell><cell cols="2">Applicant)</cell></row><row><cell>interests/arrangements:</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Is a description of the steps taken to</cell><cell> Yes</cell><cell>No</cell><cell>(Request information</cell></row><row><cell>minimize potential bias provided:</cell><cell></cell><cell cols="2">from Applicant)</cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell></cell><cell></cell><cell>177</cell></row><row><cell cols="4">Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_320"><head></head><label></label><figDesc> Percent change from baseline at Day 14, Month 1, Month 3, Month 3 plus 14 days, Month 6, Month 6 plus 14 days, Month 9, and Month 12 in sclerostin</figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>During the 12-month double-blind placebo-controlled study period</cell><cell></cell></row><row><cell cols="2"> Percent change from baseline at Day 14, Month 1, Month 3, Month 3 plus 14 days, Month 6,</cell></row><row><cell>Month 6 plus 14 days, Month 9, and Month 12 in P1NP, and sCTX</cell><cell></cell></row><row><cell cols="2"> Percent change from baseline at Day 14, Month 1, Month 3, Month 3 plus 14 days, Month 6,</cell></row><row><cell>Month 6 plus 14 days, and Month 9 in BSAP, OC, and TRAP 5b</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>189</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_321"><head></head><label></label><figDesc>Subject will not be available for protocol-required study visits or procedures, to the best of the subject and investigator's knowledge  Subject participating in the Serum iPTH and Urinary Calcium sub-study</figDesc><table><row><cell>study period</cell></row><row><cell>followed by the 12-month open-label denosumab follow-up study period)</cell></row><row><cell> Percent change from baseline at Month 13, Month 18, and Month 24 in P1NP, and sCTX</cell></row><row><cell> Percent change from baseline at Month 13, Month 18, and Month 24 in sclerostin</cell></row><row><cell>5. ELIGIBILITY</cell></row><row><cell>Inclusion</cell></row><row><cell> Subject has provided informed consent for participation in this sub-study</cell></row><row><cell> Subject is enrolled in the PK sub-study</cell></row><row><cell>Exclusion</cell></row><row><cell> Subject has experienced a nonvertebral fracture or clinical vertebral fracture within</cell></row><row><cell>6 months prior to enrollment</cell></row><row><cell> 6. PROCEDURES</cell></row><row><cell>Study visits for the BTM and Biomarker sub-study are Day 1, Day 14, Month 1, Month 3, Month</cell></row><row><cell>3 plus 14 days, Month 6, Month 6 plus 14 days, Month 9, Month 12, Month 13, Month 18, and</cell></row><row><cell>Month 24.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_322"><head>Forearm and Total Body Dual-energy X-ray Absorptiometry and 13.6.2. Hi Resolution Peripheral Quantitative Computed Tomography Sub-study (Imaging Sub-study I)</head><label></label><figDesc></figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>190</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_324"><head></head><label></label><figDesc>and total) DXA BMD at Month 6 and Month 12  Percent change from baseline in total body (without head) DXA BMD at Month 6 and Month 12  Percent change from baseline in ultimate load at the distal radius and the distal tibia as measured by FEA from HR-pQCT scans at Month 6 and Month 12  Percent change from baseline in HR-pQCT parameters (eg, bone volume/total volume, total volumetric BMD, cortical volumetric BMD, trabecular volumetric BMD, cortical thickness, trabecular thickness, and trabecular separation) at the distal radius and the distal tibia at Month 6 and Month 12</figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell></cell><cell>APPEARS THIS WAY ON ORIGINAL</cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>192</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row><row><cell>Reference ID: 4093382</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_343"><head>Adverse Events Toxicity Grading CTCAE  Grade 3 for Study 13.7. 20070337</head><label></label><figDesc></figDesc><table><row><cell>Clinical Review</cell><cell></cell></row><row><cell>Debuene Chang MD</cell><cell></cell></row><row><cell>BLA 761062</cell><cell></cell></row><row><cell>Evenity (Proposed) -romosozumab</cell><cell></cell></row><row><cell cols="2">The following table 61 outlines grade 3 or higher laboratory results in Study 20070337. Details</cell></row><row><cell>are discussed within section 8.3.8 Laboratory Findings:</cell><cell></cell></row><row><cell>CDER Clinical Review Template 2015 Edition</cell><cell>211</cell></row><row><cell>Version date: November 5, 2015 for initial rollout (NME/original BLA reviews)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_344"><head>Table 60 : AE CTCAE  Grade 3 in Study 20070337 in the Double-Blind Period.</head><label>60</label><figDesc></figDesc><table><row><cell cols="2">CTCAE = Common Terminology Criteria for Adverse Events</cell></row><row><cell cols="2">Source: CSR20070337 Table 14-7.5.3 with reviewer edits.</cell></row><row><cell cols="2">Adverse Event Toxicity Grading Scale</cell></row><row><cell cols="2">For grading of adverse events, the Common Terminology Criteria for Adverse Events</cell></row><row><cell cols="2">(CTCAE) version 3.0 is to be used.</cell></row><row><cell cols="2">Grade CTCAE version 3.0</cell></row><row><cell>1</cell><cell>MILD AE</cell></row><row><cell>2</cell><cell>MODERATE AE</cell></row><row><cell>3</cell><cell>SEVERE AE</cell></row><row><cell>4</cell><cell>LIFE-THREATENING OR DISABLING AE</cell></row><row><cell>5</cell><cell>DEATH RELATED to AE</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_345"><head>DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH PHARMACOLOGY/TOXICOLOGY BLA REVIEW AND EVALUATION</head><label></label><figDesc></figDesc><table><row><cell cols="2">BLA #761062</cell><cell>Reviewer: Gemma Kuijpers, Ph.D.</cell></row><row><cell cols="2">CHANG</cell><cell></cell></row><row><cell>05/03/2017</cell><cell></cell><cell></cell></row><row><cell cols="2">THERESA E KEHOE Application number:</cell><cell>BLA # 761062</cell></row><row><cell>05/03/2017</cell><cell>Supporting document/s:</cell><cell>SD 1 (SN 0001)</cell></row><row><cell></cell><cell>Applicant's letter date:</cell><cell>07/19/2016</cell></row><row><cell></cell><cell>CDER stamp date:</cell><cell>07/20/2016</cell></row><row><cell></cell><cell>Product:</cell><cell>Romosozumab (IgG2 sclerostin antibody)</cell></row><row><cell></cell><cell>Indication:</cell><cell>Treatment of osteoporosis in postmenopausal women at</cell></row><row><cell></cell><cell></cell><cell>increased risk of fracture</cell></row><row><cell></cell><cell>Applicant:</cell><cell>Amgen Inc, Thousand Oaks, CA</cell></row><row><cell></cell><cell>Review Division:</cell><cell>Division of Bone, Reproductive and Urologic Products</cell></row><row><cell></cell><cell>Reviewer:</cell><cell>Gemma Kuijpers, Ph.D.</cell></row><row><cell cols="2">Supervisor/Team Leader:</cell><cell>Kimberly Hatfield, Ph.D.</cell></row><row><cell></cell><cell>Division Director:</cell><cell>Hylton Joffe, M.D., M.M.Sc.</cell></row><row><cell></cell><cell>Project Manager:</cell><cell>Samantha Bell, B.S., B.A.</cell></row><row><cell></cell><cell></cell><cell>2</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_346"><head>TABLE OF CONTENTS</head><label>OF</label><figDesc></figDesc><table /><note>1 EXECUTIVE</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_348"><head></head><label></label><figDesc>DRUG ................................................................................................................14 2.2 RELEVANT INDS, NDAS, BLAS AND DMFS..........................................................15 2.3 DRUG FORMULATION ..........................................................................................15 2.4 COMMENTS ON NOVEL EXCIPIENTS ......................................................................15 2.5 COMMENTS ON IMPURITIES/DEGRADANTS OF CONCERN ........................................15 2.6 PROPOSED CLINICAL POPULATION AND DOSING REGIMEN.....................................16 2.7 REGULATORY BACKGROUND ...............................................................................16</figDesc><table><row><cell>.14</cell></row><row><cell>2.1</cell></row></table><note>3 STUDIES SUBMITTED/</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_349"><head></head><label></label><figDesc>STUDIES REVIEWED ............................................................................................16 3.2 STUDIES NOT REVIEWED.....................................................................................16 3.3 PREVIOUS REVIEWS REFERENCED ......................................................................17</figDesc><table><row><cell>.16</cell></row><row><cell>3.1</cell></row><row><cell>4 PHARMACOLOGY</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_350"><head></head><label></label><figDesc>ADME .........................................................................................................48 5.2 TOXICOKINETICS.................................................................................................53</figDesc><table><row><cell>....48</cell></row><row><cell>5.1 PK/6 TOXICOLOGY</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_351"><head></head><label></label><figDesc>DOSE TOXICITY ......................................................................................61 6.2 REPEAT-DOSE TOXICITY .....................................................................................61 6.3 LOCAL TOLERANCE .............................................................................................70 6.4 OTHER TOXICITY STUDIES...................................................................................71</figDesc><table><row><cell></cell><cell>.59</cell></row><row><cell>6.1</cell><cell>SINGLE-</cell></row></table><note>7 GENETIC TOXICOLOGY</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_352"><head></head><label></label><figDesc>FERTILITY AND EARLY EMBRYONIC DEVELOPMENT................................................79 9.2 EMBRYONIC FETAL DEVELOPMENT.......................................................................79 9.3 PRE-AND POSTNAL DEVELOPMENT .....................................................................81</figDesc><table><row><cell>BLA #761062</cell><cell>Reviewer: Gemma Kuijpers, Ph.D.</cell></row><row><cell>10 SPECIAL TOXICOLOGY</cell><cell></cell></row><row><cell></cell><cell>.78</cell></row><row><cell>9.1</cell><cell></cell></row><row><cell>3</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_354"><head>A 12-Month Bone Quality Study to Determine the Effects of Weekly Subcutaneous Injection of AMG 785 in the Ovariectomized Sprague Dawley Female Rat</head><label></label><figDesc></figDesc><table><row><cell cols="2">(Study Nr. 107899)</cell><cell></cell></row><row><cell cols="3">(Study treatment period Aug 2011-Aug 2012)</cell></row><row><cell cols="2">(GLP/QA May 16, 2014)</cell><cell></cell></row><row><cell>Methods</cell><cell>Animals</cell><cell>Sprague Dawley rats. Animals were sham-operated or OVXed at 6 months of age, and then</cell></row><row><cell></cell><cell></cell><cell>underwent a 2-month bone depletion period.</cell></row><row><cell></cell><cell>Doses</cell><cell>Sham group: 0 mg/kg, once weekly, SC injection</cell></row><row><cell></cell><cell>(AMG785)</cell><cell>OVX groups: 0, 3, 10, 50 mg/kg, weekly, SC injection (AUC (0-1mo) multiples of</cell></row><row><cell></cell><cell></cell><cell>approximately 0.6x, 4.3x, 19x the human AUC(0-) at 210 mg q4w) (Sponsor multiples:</cell></row><row><cell></cell><cell></cell><cell>0.6x, 3.9x, 19.2x)</cell></row><row><cell></cell><cell></cell><cell>Treatment was started after the 2-mo bone depletion period.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_360"><head></head><label></label><figDesc>Significant increases in Tb.Th (35%) and W.Th (ca. 10%). o Increase in cortical thickness (Ct.Th) (ca. 10%) at Month 12 but not Month 2. o Increases in MS/BS and BFR/BS at cancellous and endocortical surfaces at Month 2, consistent with the (transient) bone formation marker P1NP increase. At Month 12, cancellous BFR/BS was similar to placebo (cortical Month 12 data not available). o Increase in intracortical/Haversian bone formation based on ca. 2X increase in MS/BS (% mineralizing surface) (statistically significant) and intracortical BFR/BS (not-statisticallysignificant), but no change in MAR (osteoblast activity parameter). o No effect on cortical porosity, thus intracortical resorption was likely increased too. o Marked decrease in Ps.BFR/BS (due to decreases in MS/BS and MAR) at Month 2 (change from baseline) that was marginally significant (p=0.08), in a small number of biopsies. However, there was no change in average Ps.BFR/BS at Month 2 in a larger study group. Data on Ps.BFR/BS at 12 months were not available. o Mlt increase in cancellous bone at Month 12, and slight significant O.Th increase at Month 2 but not Month 12. However, in light of normal bone histology, the data did not appear to indicate a significant mineralization defect. Increase or maintenance of the romosozumab-induced increase in bone mass (i.e. BV/TV, Tb.Th). o Decreases in cancellous ES/BS and Oc.S/BS, as compared to placebo (0-12 mo). The decreases appeared to be smaller than those caused by romosozumab, indicated by increases in these parameters as compared to those in romosozumab-treated (0-12 mo). Data on effect of Dmab on Ec.ES/BS were not available. o Reversal of increase in W.Th in romosozumab-treated, at 24 vs 12 months. o Decrease in cancellous MS/BS and BFR/BS at 24 vs 12 months, in both groups, as expected based on anti-resorptive effects of Dmab; values at Month 24 were similar in both groups. o Decreased AcF in both groups at Month 24 vs Month 12. o No effect on Co.Po% at Month 24 vs 12; no difference between groups. o No effect on O.Th or Mlt at Month 24 vs 12 and no difference between the 2 groups.</figDesc><table><row><cell>Significant decreases in erosion surface ES/BS% and Oc.S/BS at the cancellous surface</cell></row><row><cell>(Effect at Month 12 larger than at Month 2) and decrease in endocortical Ec.ES/BS</cell></row><row><cell>(Month 2 data only), consistent with the decrease in systemic resorption markers (e.g.</cell></row><row><cell>serum CTx).</cell></row><row><cell>o Denosumab (Dmab, 60 mg SC, once every 6 months) administered in the 12-24 month period,</cell></row><row><cell>after placebo or 210 mg/mo romosozumab, had the following effects:</cell></row><row><cell>o</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_365"><head>Table 7 . Mean (SD) PK Parameters Following Single SC Administration of Romosozumab to Female Cynomolgus Monkey (Study 105876)Single Subcutaneous Dose Pharmacokinetic Study of AMG 785 Manufactured by the FIH Process and CPD Process in Nave Male Cynomolgus</head><label>7</label><figDesc></figDesc><table><row><cell>Dose, Route</cell><cell>t max</cell><cell>C max</cell><cell>AUC inf</cell><cell></cell><cell>CL/F</cell><cell>t 1/2,z</cell></row><row><cell>(n)</cell><cell>(hr)</cell><cell>(g/mL)</cell><cell>(ghr/mL)</cell><cell cols="2">(mL/hr/kg</cell><cell>(hr)</cell></row><row><cell>3 mg/kg, SC</cell><cell>45</cell><cell>17.7</cell><cell>2570</cell><cell>)</cell><cell>1.19</cell><cell>40.7</cell></row><row><cell>(3)</cell><cell>(45-93)</cell><cell>(0.6)</cell><cell>(440)</cell><cell></cell><cell>(0.20)</cell><cell>(12.6)</cell></row><row><cell>10 mg/kg, SC</cell><cell>45</cell><cell>79.9</cell><cell>13600</cell><cell></cell><cell>0.739</cell><cell>51.1</cell></row><row><cell>(3)</cell><cell>(45-93)</cell><cell>(6.3)</cell><cell>(1400)</cell><cell></cell><cell>(0.074)</cell><cell>(6.6)</cell></row><row><cell>30 mg/kg, SC</cell><cell>45</cell><cell>210</cell><cell>54300</cell><cell></cell><cell>0.559</cell><cell>71.4</cell></row><row><cell>(3)</cell><cell>(45-93)</cell><cell>(18)</cell><cell>(6600)</cell><cell></cell><cell>(0.071)</cell><cell>(21.0)</cell></row><row><cell cols="2">Pharmacokinetic Report for "A Monkeys"</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">(Study 113155, non-GLP)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="7">NOTE: Study 113155 was reviewed by Dr. Andrea Benedict. The review was filed in DARRTS on</cell></row><row><cell>March 2, 2017.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_366"><head>Table 8 . Romosozumab TK Parameter Summary After 14-Day, 1-Month and 6-Month Weekly Subcutaneous Dosing in Sprague-Dawley Rats</head><label>8</label><figDesc></figDesc><table><row><cell></cell><cell>Dose</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Study</cell><cell>in</cell><cell></cell><cell cols="2">First Dose</cell><cell></cell><cell></cell><cell></cell><cell>Last Dose</cell><cell></cell></row><row><cell></cell><cell>mg/kg</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>(route)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Tmax</cell><cell>C 0 or</cell><cell>AUC 0-168h</cell><cell></cell><cell>Tmax</cell><cell>C 0 or</cell><cell>AUC 0-168h</cell><cell>AR</cell><cell>t 1/2,z (hr)</cell></row><row><cell></cell><cell></cell><cell>(hr)</cell><cell>Cmax</cell><cell cols="2">(ug.hr/mL)</cell><cell>(hr)</cell><cell>Cmax</cell><cell>(ug.hr/mL)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>(ug/mL)</cell><cell></cell><cell></cell><cell></cell><cell cols="2">(ug/mL)</cell><cell></cell></row><row><cell>105909</cell><cell>30 (SC)</cell><cell>72</cell><cell>204</cell><cell>24400</cell><cell></cell><cell>72</cell><cell>315</cell><cell>41700</cell><cell>1.71</cell><cell>NC</cell></row><row><cell>(14-day)</cell><cell>100 (SC)</cell><cell>72</cell><cell>504</cell><cell>68400</cell><cell></cell><cell>72</cell><cell>855</cell><cell>107000</cell><cell>1.56</cell><cell>NC</cell></row><row><cell></cell><cell>300 (SC)</cell><cell>48</cell><cell>1150</cell><cell>158000</cell><cell></cell><cell>48</cell><cell>2090</cell><cell>254000</cell><cell>1.60</cell><cell>NC</cell></row><row><cell></cell><cell>300 (IV)</cell><cell>NA</cell><cell>6760</cell><cell>437000</cell><cell></cell><cell>NA</cell><cell>7990</cell><cell>608000</cell><cell>1.39</cell><cell>NC</cell></row><row><cell>105908</cell><cell>10 (SC)</cell><cell>72</cell><cell>46.4</cell><cell>5400</cell><cell></cell><cell>72</cell><cell>55.7</cell><cell>5960</cell><cell cols="2">1.10 61.6</cell></row><row><cell>(1-month)</cell><cell>100 (SC)</cell><cell>96</cell><cell>519</cell><cell>66400</cell><cell></cell><cell>48</cell><cell>1190</cell><cell>147000</cell><cell cols="2">2.22 75.5</cell></row><row><cell></cell><cell>300 (SC)</cell><cell>96</cell><cell>1160</cell><cell>157000</cell><cell></cell><cell>48</cell><cell>1540</cell><cell>176000</cell><cell cols="2">1.12 81.0</cell></row><row><cell>107425 a</cell><cell>3 (SC)</cell><cell>72</cell><cell>15.8</cell><cell>1420</cell><cell></cell><cell>72</cell><cell>16.5</cell><cell>1840</cell><cell>1.29</cell><cell>NC</cell></row><row><cell>(6-month)</cell><cell>10 (SC)</cell><cell>72</cell><cell>64.9</cell><cell>6930</cell><cell></cell><cell>48</cell><cell>89.8</cell><cell>12900</cell><cell cols="2">1.86 59.5</cell></row><row><cell></cell><cell>100 (SC)</cell><cell>72</cell><cell>684</cell><cell>80500</cell><cell></cell><cell>96</cell><cell>1030</cell><cell>124000</cell><cell cols="2">1.55 84.0</cell></row><row><cell cols="10">a TK parameter data from anti-drug antibody positive animals were excluded from analyses.</cell></row><row><cell cols="9">Values are presented as mean with the exception of Tmax, which is presented as median.</cell><cell></cell></row><row><cell cols="11">C0 = Estimated initial concentration after IV administration; Cmax = maximum observed concentration after SC</cell></row><row><cell cols="11">administration; AUC0-168 = Area under serum concentration-time curve from time 0 to 168 hours; tmax = time of</cell></row><row><cell cols="11">Cmax; AR = accumulation ratio calculated as AUC0-168, last dose /AUC0-168, first dose; NC = not calculated</cell></row><row><cell cols="4">Rat 2-year carcinogenicity study</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Study</cell><cell>Species</cell><cell cols="2">Study</cell><cell>Doses</cell><cell cols="3">N/sex/group</cell><cell>Male Cpl</cell><cell cols="2">Female Cpl</cell></row><row><cell>Number</cell><cell></cell><cell cols="2">Duration, Dose</cell><cell>(mg/kg)</cell><cell></cell><cell></cell><cell></cell><cell>(ng/mL)</cell><cell cols="2">(ng/mL)</cell></row><row><cell></cell><cell></cell><cell cols="2">Frequency</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>107895</cell><cell>Rat/</cell><cell cols="2">12 months,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Wk 13</cell><cell cols="2">Wk 13</cell></row><row><cell></cell><cell>Sprague-Dawley</cell><cell cols="2">weekly dosing</cell><cell>3 10</cell><cell></cell><cell>60 60</cell><cell></cell><cell>9660 79500</cell><cell cols="2">4910 74600</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>50</cell><cell></cell><cell cols="2">54(M), 60(F)</cell><cell>589000</cell><cell cols="2">836000</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_367"><head>Table 9 . Romosozumab TK Parameter Summary After 14-Day, 1-Month, 6-Month and 12-Month Weekly Subcutaneous Dosing in Cynomolgus Monkeys</head><label>9</label><figDesc></figDesc><table><row><cell></cell><cell>Dose in</cell><cell></cell><cell cols="2">First Dose</cell><cell></cell><cell></cell><cell>Last Dose</cell><cell></cell><cell></cell></row><row><cell>Study</cell><cell>mg/kg, Route</cell><cell>Tmax (hr)</cell><cell>C 0 or Cmax</cell><cell>AUC 0-168h (ug.hr/mL)</cell><cell>Tmax (hr)</cell><cell>C 0 or Cmax</cell><cell>AUC 0-168h (ug.hr/mL)</cell><cell>AR</cell><cell>t 1/2,z (hr)</cell></row><row><cell></cell><cell>(n, sex)</cell><cell></cell><cell>(ug/mL)</cell><cell></cell><cell></cell><cell>(ug/mL)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>105779 (14-day)</cell><cell>30, SC (3F)</cell><cell>72</cell><cell>221</cell><cell>29600</cell><cell>72</cell><cell>353</cell><cell>43400</cell><cell>1.47</cell><cell>NC</cell></row><row><cell></cell><cell>100, SC (3F)</cell><cell>48</cell><cell>979</cell><cell>121000</cell><cell>48</cell><cell>1270</cell><cell>140000</cell><cell>1.44</cell><cell>NC</cell></row><row><cell></cell><cell>300, SC (3F)</cell><cell>48</cell><cell>2400</cell><cell>295000</cell><cell>48</cell><cell>3800</cell><cell>487000</cell><cell>1.65</cell><cell>NC</cell></row><row><cell></cell><cell>300, IV (3F)</cell><cell>NA</cell><cell>5180</cell><cell>413000</cell><cell>NA</cell><cell>7290</cell><cell>597000</cell><cell>1.30</cell><cell>NC</cell></row><row><cell>105776 (1-month)</cell><cell>10, SC (5M/5F)</cell><cell>48</cell><cell>67.5</cell><cell>8270</cell><cell>24</cell><cell>205</cell><cell>23800</cell><cell cols="2">3.06 100</cell></row><row><cell></cell><cell>30, SC (5M/5F)</cell><cell>48</cell><cell>289</cell><cell>37800</cell><cell>24</cell><cell>569</cell><cell>77200</cell><cell cols="2">2.05 114</cell></row><row><cell></cell><cell>300 , SC (5M/5F)</cell><cell>48</cell><cell>2500</cell><cell>304000</cell><cell>48</cell><cell>5180</cell><cell>645000</cell><cell cols="2">2.17 144</cell></row><row><cell></cell><cell>300, IV (5M/5F)</cell><cell>NA</cell><cell>5910</cell><cell>407000</cell><cell>NA</cell><cell>7630</cell><cell>588000</cell><cell cols="2">1.43 149</cell></row><row><cell>107426 a</cell><cell>3, SC</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(6-month)</cell><cell>(5-6M,</cell><cell>48</cell><cell>29.5</cell><cell>3060</cell><cell>48</cell><cell>30.6</cell><cell>3490</cell><cell cols="2">1.12 90.7</cell></row><row><cell></cell><cell>5-6F)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>10, SC</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>(5-6M,</cell><cell>48</cell><cell>107</cell><cell>13100</cell><cell>48</cell><cell>139</cell><cell>17100</cell><cell cols="2">1.28 73.7</cell></row><row><cell></cell><cell>4-6F)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>100, SC (6M, 6F)</cell><cell>48</cell><cell>1590</cell><cell>178000</cell><cell>24</cell><cell>2280</cell><cell>301000</cell><cell cols="2">1.74 116</cell></row><row><cell>107903 a (12-month)</cell><cell>3, SC (6F)</cell><cell>48</cell><cell>23.0</cell><cell>122</cell><cell>24</cell><cell>32.3</cell><cell>172</cell><cell>1.42</cell><cell>NC</cell></row><row><cell></cell><cell>30, SC (15F)</cell><cell>48</cell><cell>295</cell><cell>1620</cell><cell>24</cell><cell>538</cell><cell>2950</cell><cell>1.85</cell><cell>NC</cell></row><row><cell cols="9">a TK parameter data from anti-drug antibody positive animals during the treatment phase were excluded</cell><cell></cell></row><row><cell>from analysis.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_369"><head>Rat toxicity study findings and AUC/exposure multiples Study Number Treatment/ Recovery Group size Route/ Frequency Dose (mg/kg) AUC(0-168h) (mg.hr/mL) / Exposure Multiple * Main Effects (listed at lowest dose observed</head><label></label><figDesc></figDesc><table><row><cell cols="2">BLA #761062</cell><cell></cell><cell></cell><cell></cell><cell>Reviewer: Gemma Kuijpers, Ph.D.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Decreased RBC/Hct, slight, non-dd (M); increased</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>RDW, slight, non-dd (F); increased reticulocyte count,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>dd, min-to-moderate (i.e. regenerative anemia) (M,F)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Decrease platelet count and volume, slight, non-dd (M)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Urea increase, slight (mainly in F)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Hyperostosis sternum and tibia, with dose-related</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>incidence/severity (M,F)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Increase in extramedullary hematopoiesis, dd,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>compensatory (M,F)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>100</cell><cell>147/ 46x</cell><cell>Decreased platelet count, non-dd (F)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Serum phosphorus increase, slight, dd (M)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>300</cell><cell>176/ 55x</cell><cell>NOAEL (excluding effects secondary to PD)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Decrease in deoxypyridinoline (DPD), moderate (M)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Glucose increase, slight (M)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Skeletal muscle necrosis, minimal (1/10 M)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>End of recovery</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Bone formation normalized; increase in resorption</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>markers observed in recovery; bone mass</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>maintained/increased, platelet changes persisted</cell></row><row><cell></cell><cell></cell><cell></cell><cell>3</cell><cell>1.84 / 0.6x</cell><cell>Anti-AMG 785 binding antibodies in all groups (60%,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>25%, 18% in 3, 10, 100 mg/kg grps; 34% avg</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>incidence). TK: Slight, variable accumulation between</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Day 1 and Wk26.</cell></row><row><cell></cell><cell></cell><cell cols="2">studies in rats)</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>)</cell></row><row><cell>105908</cell><cell>1 month /</cell><cell>SC; QW</cell><cell>10</cell><cell>5.96 / 1.9x</cell><cell>Anti-AMG 785 binding antibodies detected in 4% (10</cell></row><row><cell></cell><cell>10-week</cell><cell></cell><cell></cell><cell></cell><cell>mg/kg) and 17% (300 mg/kg) of rats. Animals not</cell></row><row><cell></cell><cell>recovery</cell><cell></cell><cell></cell><cell></cell><cell>excluded for analyses.</cell></row><row><cell></cell><cell>N= 10/s/g</cell><cell></cell><cell></cell><cell></cell><cell>Increased bone formation (markers, non-dd)</cell></row><row><cell></cell><cell>main study;</cell><cell></cell><cell></cell><cell></cell><cell>Bone densitometry:</cell></row><row><cell></cell><cell>N= 5/s/g</cell><cell></cell><cell></cell><cell></cell><cell>Increase in tibial trabecular and cortical densitometric</cell></row><row><cell></cell><cell>recovery; N=</cell><cell></cell><cell></cell><cell></cell><cell>bone density, content and thickness (dd) (M,F).</cell></row><row><cell></cell><cell>12/s/g for TK</cell><cell></cell><cell></cell><cell></cell><cell>Tibia: Total and trabecular BMC metaphysis increased</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>up to 1.4x and 1.75x, after 1 month</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Bone increase generally larger in M than in F.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>64</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_370"><head></head><label></label><figDesc>Data from both ADA + and ADAanimals) (Data from ADA-negative rats in TK section of review)</figDesc><table><row><cell cols="3">BLA #761062 BLA #761062</cell><cell></cell><cell cols="5">Reviewer: Gemma Kuijpers, Ph.D. Reviewer: Gemma Kuijpers, Ph.D.</cell></row><row><cell cols="9">CTx elevated (Wk 12, M,F) or reduced (Wk 26, F) Toxicokinetics of AMG 785 in Rats (6 month study, weekly dosing, SC)\</cell></row><row><cell cols="2">(Time</cell><cell>Parameter</cell><cell></cell><cell>Males</cell><cell></cell><cell cols="3">Slight decrease in platelet number (F) and increase in platelet volume (M) Females</cell></row><row><cell></cell><cell></cell><cell></cell><cell>3</cell><cell>10</cell><cell cols="4">Serum glucose increase, transient, dd (F) 100 3 10 100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>mg/kg</cell><cell>mg/kg</cell><cell cols="4">Thickening of bone including skull cap (M,F) mg/kg mg/kg mg/kg mg/kg</cell></row><row><cell></cell><cell>Week 1</cell><cell>Tmax (hr)</cell><cell>72</cell><cell>96</cell><cell>72</cell><cell>Bone marrow, firm 72</cell><cell>72</cell><cell>96</cell></row><row><cell></cell><cell></cell><cell cols="2">Cmax (g/ml) AUC 0-168h (g h/ml) 1,370 15.1</cell><cell>57.1 6,260</cell><cell cols="4">500 57,500 Increase in extramedullary hematopoiesis in liver, dd 16.6 81.5 912 (recovered) 1,450 7,570 103,000</cell></row><row><cell></cell><cell>Week 12</cell><cell>Tmax (hr)</cell><cell>100 72</cell><cell>124 / 39x 168</cell><cell>168</cell><cell cols="3">NOAEL (excluding effects secondary to PD) 72 48 96</cell></row><row><cell></cell><cell></cell><cell>Cmax (g/ml)</cell><cell>15.0</cell><cell>92.3</cell><cell cols="4">Increase in % reticulocytes (15-90%) (F&gt;M) 1160 11.6 103 1540</cell></row><row><cell></cell><cell></cell><cell cols="2">AUC 0-168h (g h/ml) 679</cell><cell>10,500</cell><cell cols="4">Decrease in WBC, lymphocyte, basophil, monocyte, 132,000 900 9,780 174,000</cell></row><row><cell></cell><cell>Week 26</cell><cell>Tmax (hr) Cmax (g/ml)</cell><cell>72 14.6</cell><cell>ND 102</cell><cell>ND 687</cell><cell cols="3">and eosinophil counts (F only, some effects transient). 72 48 96 No effects on WBC differential counts. 17.3 109 1,280</cell></row><row><cell></cell><cell></cell><cell cols="2">AUC 0-168h (g h/ml) 779</cell><cell>10,200</cell><cell cols="3">ALKP increase, slight (M,F) 66,700 1,110 10,600</cell><cell>112,000</cell></row><row><cell></cell><cell cols="2">Week 27-40 Terminal T 1/2 (hr)</cell><cell>NC</cell><cell>62.6</cell><cell cols="4">Serum P increased (M), reversible 93.2 NC NC 107</cell></row><row><cell cols="4">AUC (0-) (g h/mL) 173 ND = No data; NC = Not calculated</cell><cell>5,840</cell><cell cols="4">Minimal skeletal muscle degeneration/necrosis (2/11 130,000 NC 1,370 86,000 M); Mandibular odontoma (1/11M); Renal pelvis dilated (2M); various kidney histopath in 1-2M</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Injection site mononucl. infiltration (M,F)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>End of recovery:</cell><cell></cell></row><row><cell>107425</cell><cell>6 months /</cell><cell>SC</cell><cell></cell><cell></cell><cell></cell><cell cols="3">Increase in DPD in M,F (all groups), OC normalized.</cell></row><row><cell></cell><cell>14-week</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Bone increases were diminished (3, 10), or increased</cell></row><row><cell></cell><cell>recovery</cell><cell>Weekly</cell><cell></cell><cell></cell><cell></cell><cell>further (100 mg/kg).</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Hyperostosis slightly diminished, skull hyperostosis</cell></row><row><cell></cell><cell cols="2">Initial grp size</cell><cell></cell><cell></cell><cell></cell><cell>newly observed.</cell><cell></cell></row><row><cell></cell><cell>Main:</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">FEMUR (HIP) FRACTURE in 1/5 MD (10 mg/kg)</cell></row><row><cell></cell><cell>N= 10/s/g</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">male, probably incidental since no clin signs.</cell></row><row><cell></cell><cell>Recovery:</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">ADA incidence maintained at 3 mg/kg and increased in</cell></row><row><cell></cell><cell>N= 5/s/g</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">10 and 100 mg/kg grps (52% avg incidence).</cell></row><row><cell></cell><cell cols="2">(no separate</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="9">TK animals) * Exposure Multiple = [Animal AUC(0-168h) x 4]/[Human AUC(0-) at the proposed clinical dose of 210 mg]</cell></row><row><cell cols="9">(Human AUC = 12888 ug h/mL; data from Clinical Population PK Report 119384A). Data from ADA-positive</cell></row><row><cell cols="8">animals with Cpl&lt;50% than avg for ADA-negative animals were not included in the analysis.</cell></row><row><cell cols="5">Final grp size Abbreviations: dd=dose-dependent; ss = statistically significant</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>(after</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">elimination</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>based on</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>ADA):</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Main:</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">10,6,6,7 (M)</cell><cell>10</cell><cell>12.9 / 4.0x</cell><cell></cell><cell>Bone densitometry:</cell><cell></cell></row><row><cell></cell><cell>9,6,9,8 (F)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">pQCT: Increase in proximal tibia diaphyseal thickness</cell></row><row><cell></cell><cell>Recovery:</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">and periosteal circumference, and decrease in endosteal</cell></row><row><cell></cell><cell cols="2">5,3,4,5 (M)</cell><cell></cell><cell></cell><cell></cell><cell cols="2">circumference, dd (M,F)</cell></row><row><cell></cell><cell>5,3,5,5 (F)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Transient increase in osteocalcin (OC, bone formation</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">marker), dd, max at Wk 4 (M,F)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>65 66</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_371"><head>Monkey toxicity study findings and AUC/exposure multiples Study number Treatment/ Recovery Group size Route/ Frequency Dose (mg/kg) AUC(0-168h) (mg.hr/mL) / Exposure Multiple * Main Effects (Findings listed at lowest dose)</head><label></label><figDesc></figDesc><table><row><cell cols="2">BLA #761062</cell><cell></cell><cell></cell><cell cols="2">Reviewer: Gemma Kuijpers, Ph.D.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>BMD and tibial cortical area still ca. 1.3x pre-TX level</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>after 10-wk recovery).</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Hyperostosis increased during recovery.</cell></row><row><cell>107426</cell><cell>6 months</cell><cell>SC, QW</cell><cell>3</cell><cell>3.49 / 1.1x</cell><cell>Anti-AMG785 antibodies developed in 8/36 monkeys</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(22%), with 5/26 (14%) developing neutralizing</cell></row><row><cell></cell><cell>14-week</cell><cell></cell><cell></cell><cell></cell><cell>antibodies (Nab). TK: Slight accumulation between Day</cell></row><row><cell></cell><cell>recovery</cell><cell></cell><cell></cell><cell></cell><cell>1 and Wk25.</cell></row><row><cell></cell><cell>Initial grp size Main: N= 4/s/g Recovery: N= 2/s/g</cell><cell cols="3">studies in monkeys)</cell><cell>Bone densitometry: DXA/pQCT: Increase in DXA BMD and BMC at lumbar spine and femur, dd, at all doses (M,F). Increase in QCT BMD /BMC at proximal tibia metaphysis and diaphysis, more pronounced in metaphysis. QCT of radius showed BMD and/or BMC increase in F&gt;M, mostly at 10-100</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>mg/kg.</cell></row><row><cell></cell><cell>Final grp size</cell><cell></cell><cell></cell><cell></cell><cell>No effects on BP and EKG</cell></row><row><cell>105776</cell><cell>1 month (after elimination</cell><cell>SC, QW (high dose</cell><cell>10</cell><cell>23.8 / 7.4x</cell><cell>Anti-AMG 785 antibodies detected in 6/40 (15%) of monkeys in 30 and 300 mg/kg grps, mainly during Decrease in RBC and Hct, minimal-slight</cell></row><row><cell></cell><cell>based on</cell><cell>SC/IV)</cell><cell></cell><cell></cell><cell>recovery period, with 2 of 6/40 (5%) developing Decrease in serum calcium and phosphorus, minimal-</cell></row><row><cell></cell><cell>10-week ADA):</cell><cell></cell><cell></cell><cell></cell><cell>neutralizing antibodies. Animals not excluded for slight, transient, dd, possibly due to increased bone</cell></row><row><cell></cell><cell>recovery Main:</cell><cell></cell><cell></cell><cell></cell><cell>analyses. formation</cell></row><row><cell></cell><cell>N=3/s/g (main study) N=2/s/g 4,3,4,4 (M) 4,3,3,4 (F) Recovery: 2,1,2,2 M (recovery) 2,1,2,2 F</cell><cell></cell><cell></cell><cell></cell><cell>Bone densitometry: DXA/QCT: Increase in Bone area, BMC, BMD and/or cortical thickness (lumbar spine, proximal femur and Hyperostosis in vertebrae, sternum and tibia at all doses, with dd incidence and severity (incr trabecular plus reduced medullary space) proximal tibia). Bone increase generally larger in F than expected dose-related increases, mostly in early dosing in M. Histomorphometry and mechanical testing showed</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Increases in osteocalcin, BSAP and PINP (bone phase, in bone formation on cancellous and cortical</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>formation markers), non-dd (M,F) surfaces and increases in strength, similar to those in</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>OVX animal bone quality studies. Endocortical bone Increase in DPD (F only), non-dd formation effect was longest lived. Bone quality</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Decrease in RBC and Hb, slight, non-dd (M) (correlation mass vs strength) maintained, and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>mineralization was normal. No adverse neurological Decrease in serum calcium, transient D15, slight (F) effects by clinical observation.</cell></row><row><cell></cell><cell></cell><cell></cell><cell>10</cell><cell>17.1 / 5.3x</cell><cell>Hyperostosis of sternum and tibia, dose-related severity Transient increases in markers BSAP and osteocalcin, not (M,F) at 3mg/kg. Resorption markers unaffected.</cell></row><row><cell></cell><cell></cell><cell></cell><cell>30</cell><cell>77.2 / 24x</cell><cell>Decrease in Hb, minimal (M) Injection site inflammation in males.</cell></row><row><cell></cell><cell></cell><cell></cell><cell>300 100</cell><cell>SC: 645 / 301 / 93x</cell><cell>NOAEL (excluding effects secondary to PD) NOAEL (excluding effects secondary to PD)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(SC or IV)</cell><cell>200x</cell><cell>No spleen/liver extramedullary hematopoiesis Transient increase in P1NP in F (Wk 4)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>IV: 588 / 182x</cell><cell>Liver cellular infiltration (M,F)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Skeletal muscle degeneration/necrosis in 1/3M (IV)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(minimal)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Injection site fibrosis or inflammation (severity?) (M)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>End of recovery:</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Formation markers declined late in recovery.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>RBC/Hb and serum Ca decreases recovered.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Bone increase maintained or further increased (spine</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>69</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_375"><head>TK Parameters and Multiples of Human Exposure in the Lifetime Pharmacology Study in SD rats</head><label></label><figDesc></figDesc><table><row><cell>Study</cell><cell>Species</cell><cell>N/s/g</cell><cell>Duration,</cell><cell>Doses</cell><cell>N/s/g</cell><cell>Male</cell><cell>Female</cell></row><row><cell>Number</cell><cell></cell><cell></cell><cell>Dose Frequency</cell><cell>(mg/kg)</cell><cell></cell><cell>Cmin (ng/mL)</cell><cell>Cmin (ng/mL)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(Wk 13)</cell><cell>(Wk 13)</cell></row><row><cell>107895</cell><cell>Rat/</cell><cell>N=60/group</cell><cell>24 months,</cell><cell>3</cell><cell>60</cell><cell>9660</cell><cell>4910</cell></row><row><cell></cell><cell>Sprague-Dawley</cell><cell>or N=54/group</cell><cell>weekly dosing</cell><cell>10 50</cell><cell cols="2">60 54(M), 60(F) 589000 79500</cell><cell>74600 836000</cell></row><row><cell></cell><cell></cell><cell>(50 mg/kg</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>males)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>AUC (0-168h)</cell><cell>AUC (0-1month)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(g hr/mL)</cell><cell>(g.hr/mL)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(M and F,</cell><cell>(M and F,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>average)</cell><cell>average)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(4xAUC (0-168h) )</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>3</cell><cell>N/A</cell><cell>1840</cell><cell>7360</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>10</cell><cell>N/A</cell><cell>12900</cell><cell>51600</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>50*</cell><cell>N/A</cell><cell>59800</cell><cell>239200</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">Exposure Multiple**</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">(M and F, average)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>3</cell><cell>N/A</cell><cell>0.6x</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>10</cell><cell>N/A</cell><cell>4.0x</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_379"><head></head><label></label><figDesc>However, this reviewer does not agree with that assessment since the changes included increases in bone BMD and thickness. o No skeletal abnormalities in the C6 cervical vertebrae at any dose. o No effects on femur length or microscopic changes in bone on Day 21 postpartum. o No AMG 785-related effects on survival, growth, sexual maturation, behavioral endpoints, mating and fertility, male reproductive organ weights or ovarian and uterine parameters.</figDesc><table><row><cell cols="2">BLA #761062</cell><cell></cell><cell></cell><cell cols="2">Reviewer: Gemma Kuijpers, Ph.D.</cell></row><row><cell cols="5">(b) (4) sclerosteosis subjects. Multiples of human exposure in rat reproductive toxicity studies</cell><cell></cell></row><row><cell>Study</cell><cell>Dose</cell><cell>AUC (0-168h)</cell><cell>AUC (0-1mo)</cell><cell>Human Exposure</cell><cell>Human Exposure</cell></row><row><cell>Number</cell><cell>(mg/kg)</cell><cell>(ug.h/mL)</cell><cell>(ug.h/mL)</cell><cell>Multiple</cell><cell>Multiple</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(4xAUC (0-168h)</cell><cell>(based on AUC (0-1mo) comparison)*</cell><cell>(based on mg/kg comparison)*</cell></row><row><cell>108061</cell><cell>10</cell><cell>4752</cell><cell>19008</cell><cell>1.5x</cell><cell>3.3x</cell></row><row><cell></cell><cell>60</cell><cell>60480</cell><cell>241920</cell><cell>19x</cell><cell>20x</cell></row><row><cell></cell><cell>300</cell><cell>179760</cell><cell>719040</cell><cell>56x</cell><cell>100x</cell></row><row><cell>Study</cell><cell>Dose</cell><cell>AUC (0-144h)</cell><cell>AUC (0-1mo)</cell><cell>Human Exposure</cell><cell>Human Exposure</cell></row><row><cell>Number</cell><cell>(mg/kg)</cell><cell>(ug.h/mL)</cell><cell>(ug.h/mL)</cell><cell>Multiple</cell><cell>Multiple</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(4xAUC (0-144h)</cell><cell>(based on AUC (0-1mo) comparison)*</cell><cell>(based on mg/kg comparison)*</cell></row><row><cell>108057</cell><cell>30</cell><cell>15800</cell><cell>63200</cell><cell>4.9x</cell><cell>10x</cell></row><row><cell></cell><cell>100</cell><cell>53300</cell><cell>213200</cell><cell>16.5x</cell><cell>33x</cell></row><row><cell></cell><cell>300</cell><cell>103000</cell><cell>412000</cell><cell>32x</cell><cell>100x</cell></row><row><cell cols="6">*Human AUC (0-1month) at 210 mg (3 mg/kg) = 12888 ug.h/mL (Clinical Population PK Report 119384A).</cell></row><row><cell></cell><cell></cell><cell></cell><cell>82</cell><cell></cell><cell></cell></row><row><cell>Reference ID: 4081796</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_383"><head></head><label></label><figDesc>Grp 5 samples taken during the week after Wk 26 o AMG785 measured by validated ELISA o Parameters Cmax, Tmax (median), AUC0-t (until last time with quantifiable PQCT of several bone sites (1x during baseline, end of bone depletion, and Wks 11/12, 24/25, 51/52), with parameters: o Metaphysis: Area, BMC, BMD (total, trabecular, cortical/subcortical) o Diaphysis: Area, BMC and BMD (Total, cortical), Ct.Th., and periosteal and endosteal circumference</figDesc><table><row><cell>BLA #761062 BLA #761062 BLA #761062</cell><cell>Reviewer: Gemma Kuijpers, Ph.D. Reviewer: Gemma Kuijpers, Ph.D. Reviewer: Gemma Kuijpers, Ph.D.</cell></row><row><cell cols="2">concentration) o Anti-drug antibodies: o Samples taken in Wks -1, 13, 26, 52 o ADA measured by validated electrochemiluminescence immune-assay o ADA-positive samples analyzed for Ab neutralization activity by bioassay o Neutralizing ADA-positive and part of ADA-positive animals excluded from analyses o Biochemical markers of bone resorption CTx (serum) and NTx (urine), and bone formation BAP, PINP and OC (serum) at end of baseline, at end of bone depletion, Wks 9/10, 23/24, 37, 49/50, and pre-sacrifice o Hormones (estradiol, PTH, VitDOH2) (same times as turnover markers) o DKK1/FGF23 (similar times as turnover markers) o Radiography in vivo (end of Tx, end of recovery) o Immunophenotyping of lymphocytes (CD45+ Total Lymphocytes, CD45+/CD3-/CD20+ B cells) in Wk35. This evaluation was done because changes in bone marrow Densitometry (ex vivo) o DXA: of each bone specimen destined for biomechanical strength testing o Peripheral QCT: of all specimens destined for biomechanical testing Bone ash testing o Tissue mineralization (%) calculated as ratio of ash to dry weight Statistical analysis o The number of animals was 16F/grp, but due to Ab (ADA) formation fewer animals were available to provide reliable data. For statistical analyses and result interpretation, the following numbers of animals/group were generally used: o 16 (sham and OVX vehicle groups) (Grps 1 and 2) o 6 (3 mg/kg groups) (Grp 3) o 15 (30 mg/kg group dosed for 52 week) (Grp 4) o Terminal procedures o 14 (30 mg/kg group dosed for 26 weeks with 26 weeks of recovery) (Grp 5)</cell></row><row><cell cols="2">B cell numbers have been reported in sclerostin knock-out mice o Complete necropsy, organ weight (uterus), tissue collection, histology evaluation of</cell></row><row><cell cols="2">bone (left femur, ilium-biopsy site, rib-biopsy site, L2 vertebra), lesions/masses, o Labeling for histomorphometry (15 and 5 days pre-sampling) (tetracycline pre-Wk 13, alizarin complexone pre-Wk 27, calcein pre-necropsy); biopsies for interim injection site</cell></row><row><cell cols="2">histomorphometry at Weeks 13 and 27: Rib and ilium</cell></row><row><cell cols="2">Histology and histomorphometry (undecalcified tissue; static and dynamic parameters)</cell></row><row><cell cols="2">Densitometry (in vivo) (same side throughout study) o Interim biopsy samples (Wk 13 and 27): rib (cortical bone) and ilium (cancellous</cell></row><row><cell cols="2">bone) o DXA of several bone sites, of all animals, taken during acclimation/baseline, at end of bone depletion, and Wks 11/12, 24/25, 51/52; parameters: Area, BMD, BMC o End of study:</cell></row><row><cell cols="2">o Vertebrae (L2) (cancellous bone) Micro CT scanning o Femur (neck -cancellous bone; and diaphysis -cortical bone) o Micro-CT (ex vivo) of L3, Femoral Neck (FN), humeral cortical beam, L6 core o Rib (cortical bone) o Parameters: vBMD mgHA/cm 3 , BMC mg HA or mg HA/mm, Region Area (mm 2 ),</cell></row><row><cell cols="2">Bone Area (mm 2 ), tissue BMD mg HA/cm 3 , trabecular BV/TV (%) and Tb</cell></row><row><cell cols="2">parameters, Ct.Th (mm), porosity, SMI (structure model index, reflecting rod vs plate</cell></row><row><cell>structure), DA (degree of anisotropy)</cell><cell></cell></row><row><cell>Biomechanical testing</cell><cell></cell></row><row><cell cols="2">o Vertebral body (L3, L4) and core (L5, L6): compression</cell></row><row><cell>o Femur: 3-point bending test</cell><cell></cell></row><row><cell>o Femoral neck: shear test</cell><cell></cell></row><row><cell cols="2">o Humerus (cortical beams): 3-point bending test</cell></row><row><cell cols="2">o Correlation analysis between densitometry and ex-vivo densitometry parameters</cell></row><row><cell>97 99 100</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_384"><head>Table 35</head><label>35</label><figDesc></figDesc><table><row><cell>)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_386"><head></head><label></label><figDesc>Significant increases in Area, BMD and BMC in global Proximal Femur, trochanter, and femoral neck, of similar magnitude at both doses. o BMD increase +22% and +26% at 3 and 30 mg/kg, for global proximal femur; +28% and +34% for Femoral Neck at Wk 51/52) (vs. OVX control). o Increases in all parameters occurred mainly in first 24/25 weeks at both doses. o Parameters exceeded sham levels at both doses by Wk 11/12. o In the 30mg/kg recovery group, Tx withdrawal led to significant reversal of effects on Area BMD and BMC.</figDesc><table><row><cell>: o Decreases in Area, BMD and BMC during 4-month bone depletion period, and o OVX: continuing through first 11/12 wks of Tx period. o AMG treatment: Reviewer: Gemma Kuijpers, Ph.D. DXA Distal Femur (Text Fig 18): o OVX: o Decreases in Area, BMD and BMC during 4-month bone depletion period, continuing through first 11/12 wks of Tx period. o AMG treatment: o Significant dose-related increases in Area, BMD and BMC. o BMD increase +6% and +18% at 3 and 30 mg/kg at Wk 51/52 (values not OVX ctrl-corrected). o Increases occurred mainly in first 24/25 weeks at both doses. o Parameters exceeded sham levels by Wk 24/25 (or earlier at 30 mg/kg) at both doses. Reviewer Comment (DXA femur): Global BMD increase at 3 mg/kg at 12 months vs OVX control was approx. 20% (global proximal femur) and 25% (femoral neck). This was much larger than the change vs placebo in Phase 3 study 20070337 at 12 months (total hip 5.8% and femoral neck 5.2%). DXA Proximal Tibia Diaphysis (Text Fig 20): o OVX: o Decreases in BMC, BMD and Area in OVX animals relative to sham controls during 4-month bone depletion period (decrease was -2% for BMD). Decreases continued during Tx period. o AMG treatment: o Dose-related increase in Area (small) and BMD at 3 and 30 mg/kg resulting in dose-related increase in BMC. o BLA #761062 o In the 30mg/kg recovery group, Tx discontinuation led to very slight reversal o Change in BMD vs OVX control was +5% (at 3 mg/kg) and +18% (at 30</cell></row><row><cell>of effects on Area BMD and BMC mg/kg) by Wk 52 (-8% in OVX controls).</cell></row><row><cell>o Parameters Area, BMD and BMC exceeded sham levels at 30 mg/kg by Wk</cell></row><row><cell>11/12.</cell></row><row><cell>o BMD and BMC increased clearly in first 6 months, but continued to increase</cell></row><row><cell>after 6 months.</cell></row><row><cell>112</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_387"><head></head><label></label><figDesc>Dose-related increases in Total, Trabecular and Cortical BMC and BMD at both doses. Trabecular BMD increase at 3 and 30 mg/kg was +9% and 27%, by 52 wks. o Increases in Total Area at both doses with same time dependence o Metaphyseal (sub)cortical area (ie thickness) was not significantly affected, based on BMC vs BMD comparison. o Bone parameters in AMG-treated OVX groups surpassed sham levels in both 3 and 30 mg/kg groups by end of Tx. In the 30 mg/kg recovery group, there were decreases in BMD, BMC and Area effects vs the 30 mg/kg groups after Wk 24/25. Dose-related increase in Cortical Thickness and Cortical Area (Ct.Th up to 20%) o Dose-related increase in Cortical BMC (+5% and +23% at 3 and 30 mg/kg, by 52 wks) o Minimal, non-dose-related transient DECREASE in Cortical BMD, maximal at</figDesc><table><row><cell>BLA #761062 BLA #761062</cell><cell>Reviewer: Gemma Kuijpers, Ph.D. Reviewer: Gemma Kuijpers, Ph.D.</cell></row><row><cell cols="2">o Wk 11/12 o Dose-related decrease in Endosteal Circumference (up to -9%) o In the 30 mg/kg recovery group, all effects (except cortical BMD) were o o In the 30mg/kg recovery group, Tx discontinuation led to decreases in BMD reversed towards untreated OVX levels.</cell></row><row><cell cols="2">and BMC but not Area effects vs the 30 mg/kg group after Wk 24/25. Diaphysis Distal Radius (Text Fig. 28)</cell></row><row><cell cols="2">Distal Radius (Text Fig. 24): o Dose-related increase in Total Area and periosteal circumference (Circ. up to</cell></row><row><cell cols="2">o Dose-related increases in Total, Trabecular and Cortical BMC and BMD at 8%)</cell></row><row><cell cols="2">both doses. Effects on BMD and BMC were generally smaller than in proximal o Dose-related increase in Cortical Thickness and Cortical Area (Ct.Th. up to</cell></row><row><cell>tibia. 10%)</cell><cell></cell></row><row><cell cols="2">o Slight increases in Total Area at both doses, with increase occurring earlier in 3 o Dose-related increase in Cortical BMC; at 3 mg/kg, the effect did not occur</cell></row><row><cell>vs 30 mg/kg group until after Wk 24/25.</cell><cell></cell></row><row><cell cols="2">o Metaphyseal (sub)cortical area (ie thickness) was not significantly affected, o Small, non-dose-related transient DECREASE in Cortical BMD, maximal at</cell></row><row><cell cols="2">based on BMC vs BMD comparison. Wk 24/25</cell></row><row><cell cols="2">o Parameters exceeded sham levels in both 3 and 30 mg/kg AMG785 groups by o Small, non-dose-related, INCREASE in endosteal circumference beyond OVX</cell></row><row><cell cols="2">end of Tx. control significant at 30 mg/kg (increase up to +5%)</cell></row><row><cell cols="2">o In the 30 mg/kg recovery group, all effects were reversed towards untreated o Reviewer Comment (pQCT metaphyses): OVX levels.</cell></row><row><cell cols="2">AMG caused marked increases in BMD and BMC particularly in trabecular but also</cell></row><row><cell cols="2">(sub)cortical bone compartments, along with slight increases in bone area in both tibia and</cell></row><row><cell cols="2">radius metaphyses. Changes were more pronounced for proximal tibia than distal radius.</cell></row><row><cell>pQCT</cell><cell></cell></row><row><cell>Diaphysis (proximal tibia and distal radius)</cell><cell></cell></row><row><cell>o OVX:</cell><cell></cell></row><row><cell cols="2">o Decrease in Total Area (Bone Slice) and periosteal circumference (Text Fig.</cell></row><row><cell>25)</cell><cell>):</cell></row><row><cell cols="2">o Decrease in Cortical BMD, BMC, Area and Thickness. BMC loss was -5% and o Decrease in BMD, Area and BMC during bone depletion period, continuing through 11/12 weeks (cortical BMD) to 52 weeks (trabecular BMD). -3% during bone depletion and -4% and -3% during the 52-wk Tx period (tibia</cell></row><row><cell cols="2">and radius, respectively). o Total slice BMD was decreased by -4% and -5% during depletion (tibia and radius, resp). o No clear effect on endosteal circumference</cell></row><row><cell cols="2">o AMG-treatment: o Clear decreases in all BMC and BMD values (total, cortical, trabecular) Diaphysis Proximal Tibia (Text Fig. 27) o AMG785-treatment Proximal Tibia (Text Fig. 23): o Dose-related increase in Total Area and periosteal circumference (Circ. up to</cell></row><row><cell>4%)</cell><cell></cell></row><row><cell cols="2">115 118</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_388"><head></head><label></label><figDesc>with extensive bone evaluations. Serum PTH was increased in humans and OVX monkeys and may be responsible for this BMD effect through stimulation of intracortical bone remodeling and increased porosity. A discussion of this effect is included in the pharmacology and integrated summaries of this BLA review. Dose-related increases in BMD and BMC at 3 and 30 mg/kg, significant at 30 mg/kg. Both BMC and BMD increased to above-sham levels at the high dose of 30 mg/kg. o Change in global BMD at 30 mg/kg was +22%/14% vs OVX/sham controls. Decreases in BMC and BMD (not area) vs sham controls o AMG effect:o Dose-related increases in BMD and BMC at 3 and 30 mg/kg (not in area),</figDesc><table><row><cell cols="2">BLA #761062</cell><cell>Reviewer: Gemma Kuijpers, Ph.D.</cell></row><row><cell cols="2">L3+L4 vertebrae (Text Fig. 30)</cell></row><row><cell cols="2">o OVX effect:</cell></row><row><cell></cell><cell cols="2">o significant at both doses, values exceeding sham</cell></row><row><cell></cell><cell cols="2">o Change in BMD at 3 and 30 mg/kg was +41%/+22% and +75%/+51% vs</cell></row><row><cell></cell><cell>OVX/sham controls</cell></row><row><cell></cell><cell cols="2">o Recovery grp: Decrease in BMD and BMC vs 30 mg/kg treated, to levels</cell></row><row><cell cols="2">Densitometry -ex vivo between OVX and 3 mg/kg groups</cell></row><row><cell cols="3">Ex vivo measurements were done on bones to be used for biomechanical testing, including:</cell></row><row><cell cols="3">o DXA (femur: global, proximal, mid; L3+L4 vertebral bodies; L5+L6 vertebral cores)</cell></row><row><cell cols="3">o pQCT (femur diaphysis; L3+L4 vertebral bodies, L5+L6 vertebral cores).</cell></row><row><cell>DXA</cell><cell></cell></row><row><cell cols="2">Femur (entire) (Text Fig. 29)</cell></row><row><cell cols="2">o OVX effect:</cell></row><row><cell>pQCT</cell><cell cols="2">o Decreases in BMC and BMD (not area) vs sham</cell></row><row><cell cols="2">o AMG effect: Femur diaphysis (Text Fig. 32)</cell></row><row><cell cols="3">o OVX effect: o Decreases in Total BMC and BMD, Cortical BMC and area (not BMD) vs sham controls, not significant o Cortical BMD decrease was -3% vs sham control. o o After recovery from 6 months of 30 mg/kg, values reversed in all bone regions o AMG effect: relative to the continuous 30 mg/kg group, but stayed above OVX levels (near o Dose-related increases in Total BMD and BMC, Cortical Area, Cortical 3 mg/kg levels). Thickness and Cortical BMC at both doses, significant at 3 and/or 30 mg/kg.</cell></row><row><cell></cell><cell cols="2">Parameters increased to above-sham levels at 30 mg/kg.</cell></row><row><cell></cell><cell cols="2">o Increase in BMC at 30 mg/kg was +12%/+10%, cortical thickness +18%/+16%</cell></row><row><cell cols="3">and endosteal circumference -10% vs OVX/sham controls. L5+L6 cores (Text Fig. 31) o No significant effect on Total Area or periosteal circumference. o OVX effect: o No effect on Cortical BMD. o Decreases in BMC and BMD (not in area) vs sham controls. BMD decrease o Small decrease in endosteal circumference at 3 and 30 mg/kg. was -14% vs sham control. o Slight increase in I (moment of inertia, reflecting distribution of mass around o AMG effect: center) at 30 mg/kg. o Dose-related increases in BMD and BMC at 3 and 30 mg/kg, significant at both o Recovery grp: Marginal reversal of AMG-induced changes (except I), with doses, with values exceeding sham controls. o Increase in core BMD at 3 and 30 mg/kg was +58%/36% and +117%/87% vs values staying above OVX and sham levels (between 3 and 30 mg/kg levels).</cell></row><row><cell></cell><cell>OVX/sham controls, respectively.</cell></row><row><cell></cell><cell cols="2">o Recovery grp: Reversal of BMD and BMC effects to levels slightly above OVX</cell></row><row><cell></cell><cell>and lower than 3 mg/kg group values.</cell></row><row><cell></cell><cell>125</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_389"><head></head><label></label><figDesc>Increases in total BMD were +31%/+18% and +50%/+44% vs OVX and sham controls, respectively. o Increases in trabecular BMD were +47%/+26% and +99%/+71% vs OVX and sham controls, respectively. o No significant effect on Total Area.</figDesc><table><row><cell>BLA #761062 BLA #761062 BLA #761062</cell><cell>Reviewer: Gemma Kuijpers, Ph.D. Reviewer: Gemma Kuijpers, Ph.D. Reviewer: Gemma Kuijpers, Ph.D.</cell></row><row><cell cols="2">increased by +55%/+37% and +96%/+73% at 3 and 30 mg/kg vs OVX/sham ctrls)  TbN slightly increased at 30 mg/kg only  Dose-related decrease in Trabecular region Area (-18%), significant at 30 mg/kg o o Recovery grp: Marked reversal of AMG-induced changes; Wk-52 values  Dose-related decrease in Tb.Sp (small) and SMI (indicting more plate-</cell></row><row><cell cols="2">similar to sham levels. like trabecular structure); no effect on DA (degr of anisotropy).</cell></row><row><cell cols="2">o Cortical Region:  Dose-related increases (significant) in vBMD, BMC, Area, Area BMC,</cell></row><row><cell></cell><cell>Bone Area, and Cortical Thickness (latter increased by +17%/+16%</cell></row><row><cell></cell><cell>and +60%/+59% at 3 and 30 mg/kg, vs OVX/sham controls)</cell></row><row><cell cols="2">o All Regions:  Small, but significant, non-dose-related decreases in tissue BMD</cell></row><row><cell></cell><cell>(=BMD of bone material only), at 3 and 30 mg/kg, of approx. -4% vs</cell></row><row><cell></cell><cell>OVX and sham controls for the trabecular region, and -3% for the</cell></row><row><cell></cell><cell>cortical region.</cell></row><row><cell cols="2">o Recovery grp:  Marked reversal of all AMG-induced changes; Wk-52 values similar to</cell></row><row><cell>Reviewer Comments:</cell><cell>sham levels.</cell></row><row><cell cols="2">o The ex vivo data on femur and vertebra (DXA and pQCT) generally showed similar</cell></row><row><cell cols="2">results as in vivo DXA and pQCT of these and other bones.</cell></row><row><cell cols="2">o Femur ex vivo pQCT corresponded better to tibia than radius in vivo pQCT, showing</cell></row><row><cell cols="2">mainly endosteal bone apposition.</cell></row><row><cell>Micro-CT -ex vivo</cell><cell></cell></row><row><cell cols="2">L3 Vertebral Body (Text Figs. 35, 36, 37)</cell></row><row><cell>o OVX effect:</cell><cell></cell></row><row><cell cols="2">o Total and Trabecular Region:  Decreases (non-significant) in vBMD, BMC, Area, Area BMC, Bone</cell></row><row><cell></cell><cell>Area, BV/TV, and/or Tb.Th. Slight increase in trabecular SMI (ie more</cell></row><row><cell cols="2">) o Decreases in Total Area, BMC and BMD, and in Trabecular BMC and BMD o OVX effect: vs sham controls, not significant. Decrease in trabecular BMD was approx. 20% vs sham controls. o AMG effect: rod-like structure). No significant effect on tissue BMD (i.e. BMD of L5+L6 Vertebral Cores (Text Fig. 34) bone material per se). Decreases in various parameters after 52 wks o OVX effect: were -5 to -15% (total), larger for trabecular and smaller for cortical o Decreases in Trabecular BMC and BMD regions. o AMG effect: o AMG effect: o Dose-related increases in trabecular BMD and BMC, significant at 3 and/or 30 mg/kg. Parameters increased to above-sham levels at both 3 and 30 mg/kg. o Total Region:  Dose-related increases (significant) in Total vBMD, BMC, Area BMC, o Recovery grp: Reversal of AMG-induced changes (except I) Bone Area (no effect on Area); vBMD increase was +35%/+22% and o Effects very similar to those in L3+L4 vertebral bodies +68%/+52%, at 3 and 30 mg/kg, vs OVX/sham controls</cell></row><row><cell cols="2">o Dose-related increases in Total BMD and BMC, and trabecular BMD and BMC, significant at 3 and/or 30 mg/kg. Parameters increased to above-sham o Trabecular Region:  Dose-related increases (significant) in Trabecular vBMD, BMC, Area</cell></row><row><cell cols="2">levels at 3 mg/kg. BMC, Bone Area, and BV/TV (+45% to +98%), and in Tb.Th (latter</cell></row><row><cell></cell><cell>127 128 129</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_391"><head></head><label></label><figDesc>Decreases in peak load Fu, stiffness and AUC, but they were not statistically significant.</figDesc><table><row><cell>Femoral neck shear (Text Fig. 47):</cell></row><row><cell>o OVX effect:</cell></row><row><cell>o o AMG effects:</cell></row><row><cell>o Marked increases in peak load, stiffness, AUC, significant at 30 mg/kg (35-</cell></row><row><cell>75% vx OVX control; 25-50% vs sham)</cell></row><row><cell>o Recovery group:  Reversal of all parameters to levels significantly lower than those in</cell></row><row><cell>non-recovery group and similar to sham controls.</cell></row><row><cell>o Correlation mass-strength</cell></row><row><cell>o Peak load correlated significantly with ex-vivo DXA proximal femur BMC</cell></row><row><cell>(Text</cell></row><row><cell>3-point bending:</cell></row><row><cell>o OVX effect: None significant</cell></row><row><cell>o AMG effects:</cell></row><row><cell>o None significant</cell></row><row><cell>o Recovery group:  Small decreases in AUC and toughness vs 30 mg/kg group, but effects</cell></row><row><cell>were not statistically significant</cell></row><row><cell>o No correlation analysis</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_392"><head></head><label></label><figDesc>Peak load correlated significantly with ex-vivo pQCT BMC (Text</figDesc><table><row><cell>BLA #761062</cell><cell>Reviewer: Gemma Kuijpers, Ph.D.</cell></row><row><cell>o Correlations mass-strength:</cell><cell></cell></row><row><cell>o</cell><cell></cell></row><row><cell></cell><cell>). No effect on height.</cell></row><row><cell>o AMG effects:</cell><cell></cell></row><row><cell cols="2">o Increases in peak load, yield load, stiffness, AUC; and increases in related</cell></row><row><cell cols="2">normalized parameters (app strength, yield strength, modulus, toughness).</cell></row><row><cell>o No effects on height</cell><cell></cell></row><row><cell cols="2">o Recovery group:  Reversal of all parameters, to levels signif diff from non-recovery</cell></row><row><cell>group.</cell><cell></cell></row><row><cell>139</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_395"><head></head><label></label><figDesc>Small non-significant increase in cortical width (Ct.Wi), as in rib o Periosteal:  Marked dose-rated increase in Ps.L.Pm/Ps.Pm and Ps.BFR/BS, as in rib  Effect on periosteal labeled and eroded perimeter, and periosteal Decrease in Ec/L.Pm% and Ec.BFR vs 30 mg/kg grp (no effect on these parameters in 30 mg/kg grp)  Increase in Ec.Fo.Pm/Ec.Pm and decrease in Ec.Q.Pm/Ec.Pm vs 30 mg/kg grp There were no adverse effects on bone histology at these cortical sites. Decreases in ES/BS and OcS/BS in Wk 13 suggested transient suppression of resorption in cancellous bone of ilium (and also possibly of femoral neck and vertebrae at Wk 52).</figDesc><table><row><cell>BLA #761062 BLA #761062 BLA #761062</cell><cell>Reviewer: Gemma Kuijpers, Ph.D. Reviewer: Gemma Kuijpers, Ph.D. Reviewer: Gemma Kuijpers, Ph.D.</cell></row><row><cell cols="2">probably largest for trabecular bone, followed by Haversian cortical, and then Cortical bone o AMG effects Reviewer Comments (Cancellous HMM):</cell></row><row><cell cols="2">periosteal and endocortical bone. Femoral Neck (End of Tx) o OVX effects: o Decrease in BV/TV o Increases in parameters reflecting osteoblastic activity (OV/BV, OS/BS, Ob.S/BS) o Increases in ES/BS and W.Th o Increase in BFR/BS and BFR/BV Rib biopsies (Wk 13 and 27; and end-of-Tx Wk 52) (Text Tables 7,8,11): o OVX effects: o Increase in cortical porosity (Po.Ar %) at Wk 13, 27 and 52, decreasing with time o Increase in Haversian BFR/BS (intracortical remodeling), similar at Wk 13, 27 and 52 o Formative/Quiescent surface fraction was not measured o o Lack of increases in O.Th (osteoid thickness) or Mlt (mineralization lag time) o Endocortical:  No effects on Ec.L.Pm/Ec.Pm and Ec.BFR/BS suggested there were no adverse effects on new bone matrix mineralization. o AMG effects: o Significant dose-related increase in cortical width (Ct.Wi) and cortical area (Ct.Ar), increasing over entire 52-wk Tx period (Text Fig. 3)  Marked non-dose-related suppression of Ec.E.Pm/Ec.Pm (-97% at both doses) Reviewer Comments (Cortical HMM): o AMG effects o Dose-related increases in BV/TV and Tb.Th (with decrease in Tb.Sp) o Slight increase in porosity (Po.Ar%) maximal at Wk 27  Dose-related increase in Ec.Fo.Pm/Ec.Pm (formative bone surface %); o Small-to-moderate changes in structural (i.e static) bone formation indices (TtT.AR.</cell></row><row><cell cols="2">o Increase in W.Th (wall thickness is thickness of bone deposited after resorption in individual BRU) and decrease in Ec.Q.Pm/Ec.Pm (quiescent surface %) Ct.Ar. Ct.Th. Me.Ar and Po.Ar) were observed in cortical bone. Changes were time-o Periosteal:  Marked dose-rated increase in Ps.L.Pm/Ps.Pm (labeled periosteal perimeter %) and Ps.BFR/BS (periosteal BFR), most prominent at Wk dependent. o Intracortical  No effect on H.BFR/BS, as in rib at Wk 52 o Continued increase in BFR/BS and BFR/BV (bone formation rate) o Slight increase in Fo.S/BS and decrease in QS/BS o Recovery group 30 mg/kg:  Reversal of trabecular bone volume and thickness increase (ie DE-crease), 13, but also seen in Wks 27 and 52 (Text Fig. 4)  No effect on cortical porosity o The decrease in % Me.Ar was consistent with the decrease in pQCT endosteal  Effect on periosteal labeled and eroded perimeter, and periosteal Formative/Quiescent surface fraction was not measured  Reversal of effects for the following parameters: o Recovery group 30mg/kg (Wk 52): circumference.</cell></row><row><cell cols="2">BFR increases (ie DE-creases), and % formative and quiescent surface changes o Endocortical:  Dose-related increase in Ec.L.Pm/Ec.Pm (endocortical labeled Pm %)  Ct.Wi (ie DE-creased vs 30 mg/kg group) o The changes in % Me.Ar and Po.Ar were preceded or accompanied by increases in  Ps.L.Pm % and Ps.BFR (IN-creased vs 30 mg/kg group) endosteal and Haversian (=intracortical) bone formation parameters (eg BFR),</cell></row><row><cell cols="2"> No change in W.Th vs pre-recovery (ie W.Th still increased vs OVX and Ec.BFR/BS (endocortical BFR), at Week 13 (Text Fig 4)  No reversal of suppression of Ec.E.Pm % respectively.</cell></row><row><cell cols="2">control)  Large increase in ES/BS (ES/BS not affected in 30 mg/kg grp) L2 vertebra (End of Tx) o OVX effects: o Decreases in BV/TV and trabecular parameters (Text Fig. 1) o Increases in parameters reflecting osteoblastic activity (OV/BV, OS/BS, Ob.S/BS) o Slight increase in BFR (n.s.) o Dose-related increases in BV/TV and Tb.Th (with decrease in Tb.Sp) (Text Fig. 1)  Increase in cortical porosity at 3 mg/kg, mainly in Wk 27  The highlighted numbers in the Text Tables of Histomorphometric Variables indicate o AMG effects  Marked (non)dose-related suppression of Ec.E.Pm/Ec.Pm (endocortical eroded perimeter %), most prominent at Wk 13 (opposite of resorption marker result) (Text Fig 3)  Dose-related increase in Ec.Fo.Pm/Ec.Pm (formative perimeter %); and decrease in Ec.Q.Pm/Ec.Pm (quiescent perimeter %) (measured at Wk 13 only) o Intracortical  Increase in H.BFR/BS (haversian formation/remodeling) at 3 mg/kg in Wk13 and at 30 mg/kg in Wk 27, but not in Wk 52 (Text Fig 4) o BFR/BS was increased at all three cortical bone surfaces, especially early in Wk 13. The increases at endosteal and Haversian surfaces were most significant due to higher  Reviewer's comment: control values and larger effects.</cell></row><row><cell cols="2">Reviewers Comment: Comparing the values of BFR/BS in OVX controls, for cancellous bone of ilium, femoral neck, vertebra, and rib and femur diaphysis shows the following: o Increase in W.Th  Reversal of trabecular bone increase  Ps.L.Pm % and Ps.BFR (ie DE-creased) o Recovery group 30 mg/kg:  Ct.Wi (ie DE-creased vs 30 mg/kg AMG785 grp) o Increase in BFR/BS (bone formation rate) o Recovery group 30mg/kg (Wk 52):  Reversal of effects on statistically significant effects</cell></row><row><cell cols="2"> No change in W.Th vs pre-recovery (ie W.Th still increased vs OVX  Ps.BFR (ie IN-creased)  Cancellous bone BFR/BS is larger in ilium at Wks 13 and 27 than in vertebra and bone (rib and femur)  No increase in ES/BS (unlike FN) femoral neck at Wk 52, and the value is similar to endocortical BFR/BS in cortical control)  Ec.E.Pm % (ie IN-creased)</cell></row><row><cell cols="2"> Cortical bone BFR/BS is ca. 1-2x larger at Haversian surfaces (rib all time points, Femoral diaphysis (Wk 52, end of Tx) (Text Table 12):</cell></row><row><cell cols="2">and femur Wk52) than at endocortical surfaces (rib and femur); BFR/BS value is There were no adverse effects on bone histology at these cancellous sites. o OVX effects:</cell></row><row><cell cols="2">smallest at periosteal surfaces (rib and femur) (ca. 1/10x BFR/BS at endocortical o Increase in cortical porosity (Po.Ar %), as in rib</cell></row><row><cell cols="2">surface, approx.)  This comparison puts the systemic bone formation and resorption indices in Reviewer's comment: o Marked increase in Ec.E.Pm/Ec.Pm (not seen in rib)  The highlighted numbers in the Text Tables of Histomorphometric Variables indicate o Increase in Ec.L.Pm/Ec.Pm and Ec.BFR/BS</cell></row><row><cell cols="2">perspective, since they reflect formation/turnover at all surfaces with contributions statistically significant effects o Increase in Haversian BFR/BS (intracortical remodeling), as in rib</cell></row><row><cell cols="2">proportional to the total area of the different surfaces. The total surface area is</cell></row><row><cell>144 151 152</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_402"><head>TABLE OF CONTENTS</head><label>OF</label><figDesc></figDesc><table /><note>1 EXECUTIVE SUMMARY ...</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_403"><head></head><label></label><figDesc>INTRODUCTION ..............................................................................................................................5 1.2 BRIEF DISCUSSION OF NONCLINICAL FINDINGS................................................................................5</figDesc><table><row><cell></cell><cell>....5</cell></row><row><cell></cell><cell>1.1</cell></row><row><cell>2</cell><cell>DRUG</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_404"><head></head><label></label><figDesc>DRUG............................................................................................................................................5</figDesc><table><row><cell></cell><cell>.5</cell></row><row><cell></cell><cell>2.1</cell></row><row><cell>3</cell><cell>STUDIES</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_405"><head></head><label></label><figDesc>STUDIES REVIEWED .......................................................................................................................5</figDesc><table><row><cell></cell><cell>.5</cell></row><row><cell></cell><cell>3.1</cell></row><row><cell>9</cell><cell>REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_406"><head></head><label></label><figDesc>PRENATAL AND POSTNATAL DEVELOPMENT ....................................................................................5</figDesc><table><row><cell>BLA # 761062</cell><cell>Reviewer: Miyun Tsai-Turton</cell></row><row><cell></cell><cell>.5</cell></row><row><cell>9.3</cell><cell></cell></row><row><cell>Page 3 of 21</cell><cell></cell></row><row><cell>Reference ID: 4075261</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_407"><head>Table of Tables</head><label>of</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_408"><head>Table 1</head><label>1</label><figDesc>Study No 108062: PPND Study Design...........................................................................................6 Table 2 Study No 108062: F0 generation Female Rats Mating &amp; Fertility..................................................10 Table 3 Study No 108062: F0 generation Female Rats Natural Delivery Observations.............................10 Table 4 Study No 108062: F1 generation Litter Observations....................................................................11 Table 5 Study No 108062: F1 Generation Pups (Birth to LD21) ................................................................13 Table 6 Study No 108062: TK Parameters F0 Generation &amp; F1 Generation Pups. ...................................13 Table 7 Study No 108062: ADA Positive F0 Generation. ...........................................................................14 Table 8 Study No 108062: F1 Generation Pups Mortality &amp; Necropsy.......................................................15 Table 9 Study No 108062: F1 Generation Pups Sexual Maturation...........................................................16 Table 10 Study No 108062: F1 Generation Pups Passive Avoidance .......................................................16 Table 11 Study No 108062: F1 Generation Pups Mating &amp; Fertility (Males) ..............................................17 Table 12 Study No 108062: F1 Generation Pups Mating &amp; Fertility (Females)..........................................17 Table 13 Study No 108062: F1 Generation Pups Reproductive Organ Weights (Males)...........................18 Table 14 Study No 108062: F1 Generation Pups Ovarian and Uterine Contents (Females) .....................18 Table 15 Study No 108062: F1 Generation Pups Right Femur Length ......................................................18 Table 16 Study No 108062: F1 Generation Right Femur Metaphysis ........................................................19 Table 17 Study No 108062: F1 Generation Right Femur Diaphysis...........................................................20 Table 18 Study No 108062: F1 Generation Skeletal Evaluation ................................................................21</figDesc><table><row><cell>Reference ID: 4075261</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_409"><head>Table of Figures</head><label>of</label><figDesc>Figure 1 Study No 108062: F0 Generation Female Rat Body Weight..........................................................9 Figure 2 Study No 108062: F0 Generation Female Rat Food Consumption................................................9</figDesc><table><row><cell cols="2">BLA # 761062</cell><cell>Reviewer: Miyun Tsai-Turton</cell></row><row><cell>1</cell><cell>Executive Summary</cell></row><row><cell></cell><cell>Page 5 of 21</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_410"><head>9 Reproductive and Developmental Toxicology 9.3 Prenatal and Postnatal Development Study title: AMG785: Pre-and Postnatal Development Study in the Sprague Dawley Rat Study</head><label></label><figDesc>Subcutaneous administration of AMG 785 at doses of 0, 10, 60, and 300 mg/kg/week was given to female Sprague Dawley rats beginning 6 weeks before cohabitation and continuing weekly through the gestation and lactation periods.  In the F0 generation females, there were no unscheduled deaths or macroscopic observations, and there were no effects on body weights or body weight gain at any dose level. AMG 785</figDesc><table><row><cell>2</cell><cell>Drug Information</cell></row><row><cell cols="2">2.1 Drug</cell></row><row><cell cols="2">Code Name: AMG 785</cell></row><row><cell cols="3">Pharmacologic Class: Anti-sclerostin monoclonal antibody</cell></row><row><cell>3</cell><cell>Studies Submitted</cell></row><row><cell cols="2">3.1 Studies Reviewed</cell></row><row><cell cols="2">Study No 108062 -PPND Study</cell></row><row><cell cols="3">AMG 785: Pre-and Postnatal development study in the Sprague-Dawley rat</cell></row><row><cell></cell><cell>no.:</cell><cell>108062</cell></row><row><cell></cell><cell>Study report location:</cell><cell>Amgen Inc (Thousand Oaks, CA)</cell></row><row><cell></cell><cell>Conducting laboratory and location:</cell><cell>(b) (4)</cell></row><row><cell></cell><cell>Date of study initiation:</cell><cell>06/27/2014</cell></row><row><cell></cell><cell>GLP compliance:</cell><cell>Yes</cell></row><row><cell></cell><cell>QA statement:</cell><cell>Yes</cell></row><row><cell></cell><cell>Drug, lot #, and % purity:</cell><cell>AMG785, Lot 0010191791, 100%</cell></row><row><cell cols="2">Key Study Findings</cell></row><row><cell cols="2"> Reference ID: 4075261</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_412"><head>Table 1 Study No 108062: PPND Study Design.</head><label>1</label><figDesc>observed during the premating, gestation, and lactation periods (2 of 23 litters). At 10 and 60 mg/kg, there were no AMG 785-related clinical signs.</figDesc><table><row><cell>Observations and Results</cell><cell></cell></row><row><cell>F 0 Dams</cell><cell></cell></row><row><cell>Survival:</cell><cell>All F0 generation rats survived to scheduled euthanasia.</cell></row><row><cell>Clinical signs:</cell><cell> At 300 mg/kg, AMG 785-related clinical signs of an</cell></row><row><cell></cell><cell>increase in sparse hair coat (total and/or on the limbs) was</cell></row><row><cell>Reference ID: 4075261</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_413"><head>Table 6</head><label>6</label><figDesc>There was no difference in mean AMG 785 serum concentrations between male and female pups.  For mothers receiving 12 doses, F1 generation pups had mean AMG 785 serum concentrations, collected at 5 to 7 days post the 12th maternal dose, of 1610, 266000, and 963000 ng/mL at 10, 60, and 300 mg/kg, respectively.</figDesc><table><row><cell>)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_414"><head>Table 7 Study No 108062: ADA Positive F0 Generation.</head><label>7</label><figDesc></figDesc><table><row><cell>F 1 Generation</cell><cell></cell></row><row><cell>Survival:</cell><cell> No AMG785-related death during the Postweaning period.</cell></row><row><cell></cell><cell> All F1 generation female rats survived to scheduled</cell></row><row><cell></cell><cell>euthanasia.</cell></row><row><cell></cell><cell> There were two unscheduled necropsies (1 male at 10</cell></row><row><cell></cell><cell>mg/kg due to injury and 1 male at 300 mg/kg found dead</cell></row><row><cell></cell><cell>with no macroscopic findings).</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_415"><head></head><label></label><figDesc>Lastly, two osteosarcomas were noted in the males at 50 mg/kg, which were not statistically significant by trend test and pairwise comparison. One osteosarcoma (with no metastases) was noted in the left proximal tibia of Male No 4041 at Day 572, correlating with the focal radiographic bone loss (microscopically). The cause of death of this animal, determined by the sponsor, was attributed to a pituitary adenoma. The other osteosarcoma (with no metastases) was noted on the frontal bone/skull of Male No 4069 at Day 587, correlating with the gross and radiographic findings and attributing to</figDesc><table><row><cell>Reviewer: Miyun Tsai-Turton</cell></row><row><cell>Page 20 of 41 Page 21 of 41</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_416"><head>FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH PHARMACOLOGY/TOXICOLOGY BLA REVIEW AND EVALUATION</head><label></label><figDesc></figDesc><table><row><cell></cell><cell cols="2">DEPARTMENT OF HEALTH AND HUMAN SERVICES</cell></row><row><cell></cell><cell></cell><cell>PUBLIC HEALTH SERVICE</cell></row><row><cell></cell><cell></cell><cell>-</cell></row><row><cell cols="2">MIYUN M TSAI-TURTON</cell><cell></cell></row><row><cell>03/27/2017</cell><cell>Application number:</cell><cell>761062</cell></row><row><cell cols="2">KIMBERLY P HATFIELD Supporting document/s:</cell><cell>SDN 1 (eCTD 0001)</cell></row><row><cell>03/27/2017</cell><cell>Applicant's letter date:</cell><cell>7/19/2016</cell></row><row><cell></cell><cell>CDER stamp date:</cell><cell>7/19/2016</cell></row><row><cell></cell><cell>Product:</cell><cell>Romosozumab, AMG 785</cell></row><row><cell></cell><cell>Indication:</cell><cell>Osteoporosis in postmenopausal women at</cell></row><row><cell></cell><cell></cell><cell>increased risk of fracture</cell></row><row><cell></cell><cell>Applicant:</cell><cell>Amgen, Inc.</cell></row><row><cell></cell><cell>Review Division:</cell><cell>Division of Bone, Reproductive, and Urologic</cell></row><row><cell></cell><cell></cell><cell>Products</cell></row><row><cell></cell><cell>Reviewer:</cell><cell>Andrea L. Benedict, Ph.D.</cell></row><row><cell></cell><cell>Team Leader:</cell><cell>Kimberly P. Hatfield, Ph.D.</cell></row><row><cell></cell><cell>Division Director:</cell><cell>Hylton Joffe, MD, MMSc</cell></row><row><cell></cell><cell>Project Manager:</cell><cell>Samantha S. Bell</cell></row><row><cell cols="3">Template Version: September 1, 2010</cell></row><row><cell></cell><cell></cell><cell>1</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_417"><head>TABLE OF CONTENTS</head><label>OF</label><figDesc></figDesc><table /><note>1 EXECUTIVE</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_418"><head></head><label></label><figDesc>INTRODUCTION .................................................................................................... 5 1.2 BRIEF DISCUSSION OF NONCLINICAL FINDINGS ...................................................... 5</figDesc><table><row><cell>. 5</cell></row><row><cell>1.1</cell></row><row><cell>2 DRUG</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_419"><head></head><label></label><figDesc>DRUG ................................................................................................................. 5 2.2 RELEVANT INDS, NDAS, BLAS AND DMFS ........................................................... 6 2.3 DRUG FORMULATION ........................................................................................... 7 2.4 COMMENTS ON NOVEL EXCIPIENTS ....................................................................... 8 2.5 COMMENTS ON IMPURITIES/DEGRADANTS OF CONCERN ......................................... 8 2.6 PROPOSED CLINICAL POPULATION AND DOSING REGIMEN ...................................... 8 2.7 REGULATORY BACKGROUND ................................................................................ 8</figDesc><table><row><cell>. 5</cell></row><row><cell>2.1</cell></row></table><note>3 STUDIES SUBMITTED ...</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_420"><head></head><label></label><figDesc>STUDIES REVIEWED ............................................................................................. 8 3.3 PREVIOUS REVIEWS REFERENCED........................................................................ 8</figDesc><table><row><cell>..... 8</cell></row><row><cell>3.1</cell></row></table><note>5 PHARMACOKINETICS/ADME/TOXICOKINETICS</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_421"><head></head><label></label><figDesc>ADME .......................................................................................................... 9</figDesc><table><row><cell>5.1 PK/BLA # 761062</cell><cell>Reviewer: Andrea L. Benedict, Ph.D.</cell><cell>. 9</cell></row><row><cell>3</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_422"><head>Table 1 :</head><label>1</label><figDesc>Comparison of AMG 785 drug product process material and formulation used in nonclinical and clinical studies ..................................................................................... 7Table 2: PK parameters (absolute and dose normalized) for FIH (Process 1) and CPD (Process 2) from a single-dose PK bridging study in male monkeys ............................. 14</figDesc><table><row><cell>BLA # 761062</cell><cell>Reviewer: Andrea L. Benedict, Ph.D.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_423"><head>Table of Figures</head><label>of</label><figDesc>Figure 1: Romosozumab (AMG 785) Structure ............................................................... 6 Figure 2: Mean (SD) AMG 785 Concentration-Time profiles following a single 3 mg/kg SC dose of AMG 785 given as 3 mg/kg FIH or 2.75 mg/kg CPD (semi-log scale) ........ 13 Figure 3: Mean (SD) AMG 785 Concentration-Time profiles following a single 3 mg/kg SC dose of AMG 785 given as 3 mg/kg FIH or 2.75 mg/kg CPD (linear scale) ............. 13</figDesc><table><row><cell cols="2">BLA # 761062</cell><cell>Reviewer: Andrea L. Benedict, Ph.D.</cell></row><row><cell>1</cell><cell>Executive Summary</cell></row><row><cell cols="2">1.1 Introduction</cell></row><row><cell></cell><cell>5</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_425"><head>Table 1 : Comparison of AMG 785 drug product process material and formulation used in nonclinical and clinical studies</head><label>1</label><figDesc></figDesc><table><row><cell>Reference ID: 4063752</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_426"><head>PK/ADME Study title: Pharmacokinetic Report for "A Single Subcutaneous Dose Pharmacokinetic Study of AMG 785 Manufactured by the FIH Process and CPD Process in Nave Male Cynomolgus Monkeys"</head><label></label><figDesc>The sponsor, Amgen, submitted the original IND (IND 100391) on October 27, 2006. There was no pre-IND meeting or communications prior to the original IND submission.Amgen submitted a new BLA submission on July 19, 2016, under BLA 761062. This is a non-GLP study submitted as a summary report, lacking certain specifics on methodology and did not contain information about drug formulation, certificates of analysis, or dosing solution analysis.</figDesc><table><row><cell>BLA # 761062 BLA # 761062</cell><cell cols="2">Reviewer: Andrea L. Benedict, Ph.D. Reviewer: Andrea L. Benedict, Ph.D.</cell></row><row><cell cols="2">5 Methods Pharmacokinetics/ADME/Toxicokinetics Doses: Target:</cell></row><row><cell cols="2">3 mg/kg AMG 785 FIH or 3 mg/kg AMG 785 CPD Actual: 3 mg/kg AMG 785 FIH or 2.75 mg/kg AMG 785 CPD* 5.1 Study no.: Frequency of dosing: Single-dose 113155 Route of administration: Subcutaneous injection Study report location: Electronic Document (eCTD 0001) Dose concentration: Target: Conducting laboratory and location: 70 mg/mL AMG 785 FIH or</cell><cell>(b) (4)</cell></row><row><cell></cell><cell>129 mg/mL AMG 785 CPD</cell></row><row><cell cols="3">3 3.1 Studies Reviewed Study 113155: Pharmacokinetic Report for "A Single Subcutaneous Dose Pharmacokinetic Study of AMG 785 Manufactured by the FIH Process and CPD Process in Nave Male Cynomolgus Monkeys" 3.3 Previous Reviews Referenced Product Quality Review of Dr. Michele K. Dougherty, IND 100391, dated December 5, 2012 Nonclinical review of Dr. Eric A. Andreasen, IND 103077, dated June 18, 2009 9 10 Reviewer comment: Reference ID: 4063752 Studies Submitted Actual: Date of study initiation: Not given; Report signed May 10, 2011 70 mg/mL AMG 785 FIH or GLP compliance: No 118 mg/mL AMG 785 CPD* QA statement: No Dose volume: Target: Drug, lot #, and % purity: AMG 785 FIH (Process 1): Lot # 42.9 L/kg AMG 785 FIH or 00089336 (used in 6-month rat and 23.3 L/kg AMG 785 CPD monkey studies) Formulation/Vehicle: Not given in study report AMG 785 CPD (Process 2): Lot # Species/Strain: Monkey/Cynomolgus 0010039243 Number/Sex/Group: 10 males/group</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_427"><head>Table 2 : PK parameters (absolute and dose normalized) for FIH (Process 1) and CPD (Process 2) from a single-dose PK bridging study in male monkeys</head><label>2</label><figDesc></figDesc><table><row><cell>Drug Product</cell><cell>Dose (mg/kg)</cell><cell>Animal No.</cell><cell>Tmax h</cell><cell cols="6">Absolute PK Values Cmax AUClast g/mL g*h/mL g*h/mL g/mL g*h/mL g*h/mL Dose Normalized PK Values AUCinf Cmax AUClast AUCinf</cell></row><row><cell></cell><cell></cell><cell>C38468*</cell><cell>--</cell><cell>--</cell><cell>--</cell><cell>--</cell><cell>--</cell><cell>--</cell><cell>--</cell></row><row><cell></cell><cell></cell><cell>C38912</cell><cell>24</cell><cell>26.8</cell><cell>2890</cell><cell>2890</cell><cell>8.9</cell><cell>963</cell><cell>964</cell></row><row><cell></cell><cell></cell><cell>C38927</cell><cell>24</cell><cell>25.5</cell><cell>2640</cell><cell>2650</cell><cell>8.5</cell><cell>881</cell><cell>882</cell></row><row><cell></cell><cell></cell><cell>C39107</cell><cell>24</cell><cell>28</cell><cell>3300</cell><cell>3310</cell><cell>9.3</cell><cell>1100</cell><cell>1100</cell></row><row><cell></cell><cell></cell><cell>C39125</cell><cell>24</cell><cell>30.6</cell><cell>3210</cell><cell>3220</cell><cell>10.2</cell><cell>1070</cell><cell>1070</cell></row><row><cell>FIH</cell><cell>3.0</cell><cell>C39337 C40313</cell><cell>48 48</cell><cell>31 25.7</cell><cell>4700 3290</cell><cell>4710 3290</cell><cell>10.3 8.6</cell><cell>1570 1100</cell><cell>1570 1100</cell></row><row><cell></cell><cell></cell><cell>C40314</cell><cell>48</cell><cell>28.3</cell><cell>3820</cell><cell>3830</cell><cell>9.4</cell><cell>1270</cell><cell>1280</cell></row><row><cell></cell><cell></cell><cell>C40323</cell><cell>72</cell><cell>23.7</cell><cell>3220</cell><cell>3230</cell><cell>7.9</cell><cell>1070</cell><cell>1080</cell></row><row><cell></cell><cell></cell><cell>C40330</cell><cell>72</cell><cell>18.3</cell><cell>2870</cell><cell>2870</cell><cell>6.1</cell><cell>957</cell><cell>958</cell></row><row><cell></cell><cell></cell><cell>Mean</cell><cell>43</cell><cell>26.4</cell><cell>3330</cell><cell>3330</cell><cell>8.8</cell><cell>1110</cell><cell>1110</cell></row><row><cell></cell><cell></cell><cell>SD</cell><cell>20</cell><cell>3.9</cell><cell>620</cell><cell>620</cell><cell>1.29</cell><cell>200</cell><cell>200</cell></row><row><cell></cell><cell></cell><cell>Mean</cell><cell>25</cell><cell>23.6</cell><cell>2760</cell><cell>2770</cell><cell>8.6</cell><cell>1000</cell><cell>1010</cell></row><row><cell></cell><cell></cell><cell>SD</cell><cell>10</cell><cell>3.5</cell><cell>280</cell><cell>280</cell><cell>1.26</cell><cell>110</cell><cell>100</cell></row><row><cell cols="2">CPD/FIH</cell><cell cols="2">Ratio % Difference -42% 0.58</cell><cell>0.89 -11%</cell><cell>0.83 -17%</cell><cell>0.83 -17%</cell><cell>0.98 -2.5%</cell><cell>0.90 -9.9%</cell><cell>0.91 -9.0%</cell></row><row><cell cols="10">*Animal No. C38468: Serum AMG 785 concentrations were below the LLOQ for all time points; Animal</cell></row><row><cell cols="3">was excluded from PK analysis</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="9">AUC values were rounded to 3 significant figures; calculations were performed by the sponsor using</cell><cell></cell></row><row><cell cols="2">unrounded numbers</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="9">CPD/FIH Ratio was calculated using mean absolute and mean dose normalized PK parameters and</cell><cell></cell></row><row><cell cols="4">expressed as a ratio of CPD/FIH values</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_428"><head></head><label></label><figDesc>Romosozumab (EVENITY  ) is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk of fracture. On July 19, 2016, Amgen submitted an original BLA, which included a 24-month phase 3 placebo-controlled fracture study(Study 337)   in women with postmenopausal osteoporosis. During the review cycle, the sponsor notified the FDA of preliminary results from two studies (Studies 142, and 174) intended for a future supplement. Study 142, an active-controlled study in women, identified a higher incidence of serious cardiovascular (CV) events in the romosozumab arm (2.5%) compared to the alendronate arm (active control) (1.9%). A similar trend was observed in Study 174, a placebo control study in men with osteoporosis.The key safety endpoints were major adverse cardiac events (MACE) and cardiovascular serious events (CV SAEs) adjudicated by Duke University Research Institute. The safety analysis included events observed during the double-blind 12-month period. The sponsor estimated the incidence and hazard ratio (HR) of MACE and CV SAE in each study. They conducted a meta-analysis, which compared romosozumab to alendronate and placebo combined. To distinguish the effect of alendronate on CV risk from the placebo effect, the reviewer conducted a network meta-analysis which compares multiple treatments simultaneously in a single analysis by combining direct and indirect evidence within a network of randomized controlled trials. The reviewer's analysis only included studies conducted in women with postmenopausal osteoporosis (Studies 337, and 142). The HR in Study 337 comparing romosozumab to placebo was approximately 1.0. In contrast, in Study 142 comparing romosozumab to alendronate, the HR was 1.87 [95% confidence interval (CI):1.11, 3.14], indicating an increased risk of MACE in the romosozumab arm compared to alendronate arm. The network meta-analysis resulted in a HR of 0.55 [95% CI: 0.27, 1.14] when comparing the risk of MACE in the alendronate arm to the placebo arm. This suggests that the large HR estimate in Study 142 might be because the incidence of MACE was low in the active control arm.It is difficult to discern whether the increased risk of MACE identified in the romosozumab arm in Study 142 is truly a drug effect, chance finding, or because of alendronate's potential protective effect on MACE. However, because a similar trend was noted in the study of osteoporosis in men (Study 174), this signal provides corroborate evidence and should not be ignored.Romosozumab (EVENITY  ) is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk of fracture. The proposed dose of romosozumab is 210 mg administered subcutaneously once every month for one year. 5%) arm. In contrast, the incidences of serious CV events in Study 337 were similar across arms (1.3% romosozumab and 1.3% placebo).OnJuly 13, 2017, the FDA issued a complete response letter stating that a complete analysis of Study 142, as well as an integrated assessment of cardiovascular risk from the above phase 3 studies (Studies 337, 142 and 174) would be needed to complete the benefit-risk assessment of romosozumab. In response, the sponsor submitted the Comprehensive Cardiovascular Report (CCR) on June 28, 2018, in the current submission.On August 17, 2018, the Division of Bone, Reproductive, and Urologic Products consulted the Division of Biometrics VII to evaluate the CV safety signal associated with romosozumab. This document is the statistical review of the CV safety of romosozumab.</figDesc><table><row><cell cols="3">1 EXECUTIVE SUMMARY 2 INTRODUCTION</cell><cell></cell><cell></cell></row><row><cell cols="2">2.1 Study Overview</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>-</cell><cell cols="2">On July 19, 2016, Amgen</cell></row><row><cell cols="5">submitted an original BLA, which included a 24-month phase 3, placebo-controlled fracture ANDREA BENEDICT 03/02/2017 study (Study 337) in women with postmenopausal osteoporosis.</cell></row><row><cell cols="5">During the review cycle, the sponsor notified the FDA of preliminary results from Study 142, a</cell></row><row><cell cols="5">phase 3 trial, intended for a future supplement. Study 142 compared romosozumab to an active KIMBERLY P HATFIELD control, alendronate, in women with postmenopausal osteoporosis. This study findings showed a 03/02/2017 higher incidence of serious cardiovascular (CV) events in the romosozumab arm (2.5%) On July 13, 2017, the FDA issued a complete response letter stating that a complete analysis of compared to the alendronate arm (1.9 %) during the 12-month double-blind period of the study. Studies 142 and 174, as well as an integrated assessment of cardiovascular risk from the above Study 174, a placebo-controlled, phase 3 bone mineral density study in men with osteoporosis, phase 3 studies (Studies 337, 142 and 174) would be needed to complete the benefit-risk also identified a higher incidence of serious CV events in the romosozumab (4.9%) arm assessment of romosozumab. In response, on June 28, 2018, the sponsor submitted the Comprehensive Cardiovascular Report that integrated assessment of cardiovascular risk from all pivotal studies (Studies 337, 142 and 174). compared to the placebo (2.Table 1. Studies included in the analysis</cell></row><row><cell>Study</cell><cell>Control</cell><cell>Treatment Period</cell><cell># of Subjects</cell><cell>Study Population</cell></row><row><cell>Number</cell><cell></cell><cell></cell><cell>per Arm</cell><cell></cell></row><row><cell>337</cell><cell>placebo</cell><cell>12 months double-blind</cell><cell>romosozumab:</cell><cell>Women with post-</cell></row><row><cell></cell><cell></cell><cell>period + 12 months open-</cell><cell>3589</cell><cell>menopausal</cell></row><row><cell></cell><cell></cell><cell>label denosumab treatment</cell><cell>placebo: 3591</cell><cell>osteoporosis</cell></row><row><cell></cell><cell></cell><cell>+ 12 months optional</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>extension period</cell><cell></cell><cell></cell></row><row><cell>142</cell><cell>alendronate</cell><cell>12 months double blind</cell><cell>romosozumab:</cell><cell>Women with post-</cell></row><row><cell></cell><cell></cell><cell>period + 12 months open-</cell><cell>2046</cell><cell>menopausal</cell></row><row><cell></cell><cell></cell><cell>label alendronate treatment</cell><cell>alendronate:</cell><cell>osteoporosis</cell></row><row><cell></cell><cell></cell><cell></cell><cell>2047</cell><cell></cell></row><row><cell>174</cell><cell>placebo</cell><cell>12 months double-blind</cell><cell>romosozumab:</cell><cell>Men with</cell></row><row><cell></cell><cell></cell><cell>period + 3 months follow-</cell><cell>163</cell><cell>osteoporosis</cell></row><row><cell></cell><cell></cell><cell>up</cell><cell>placebo: 82</cell><cell></cell></row><row><cell cols="2">Source: Reviewer's summary</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_429"><head></head><label></label><figDesc>or alendronate (N= 2047) for 12 months, followed by a 12-month open-label treatment period of alendronate. Compared to Study 337, Study 142 enrolled subjects at higher risk of fracture.</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_430"><head>Table 2 .</head><label>2</label><figDesc>Demographics and Baseline Characteristics (Studies 337, 142, 174)    </figDesc><table><row><cell></cell><cell>Study 337</cell><cell></cell><cell cols="2">Study 142</cell><cell cols="2">Study 174</cell></row><row><cell></cell><cell cols="5">Romosozumab Placebo Romosozumab Alendronate Romosozumab</cell><cell>Placebo</cell></row><row><cell>Number of subjects</cell><cell>3581</cell><cell>3576</cell><cell>2040</cell><cell>2014</cell><cell>163</cell><cell>81</cell></row><row><cell>Age</cell><cell>70.9</cell><cell>70.8</cell><cell>74.4</cell><cell>74.2</cell><cell>72.4</cell><cell>71.4</cell></row><row><cell>(Mean (SD))</cell><cell>(7.0)</cell><cell>(6.9)</cell><cell>(7.5)</cell><cell>(7.5)</cell><cell>(7.4)</cell><cell>(6.9)</cell></row><row><cell>Smoking,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Current/Former</cell><cell>982 (27.4)</cell><cell>1037 (29.0)</cell><cell>533 (26.1)</cell><cell>591 (29.3)</cell><cell>81 (49.7)</cell><cell>51 (63.0)</cell></row><row><cell>Never</cell><cell>2599 (72.6)</cell><cell>2539 (71.0)</cell><cell>1506 (73.8)</cell><cell>1423 (70.7)</cell><cell>82 (50.3)</cell><cell>30 (37.0)</cell></row><row><cell>Unknown</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell><cell>1 (&lt;0.1)</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell></row><row><cell>Creatine</cell><cell>0.83</cell><cell>0.82</cell><cell>0.84</cell><cell>0.82</cell><cell>1.00</cell><cell>1.03</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_431"><head>Table 3 .</head><label>3</label><figDesc>Number (%) and Hazard Ratios of MACE Composite and Individual Components through Month 12</figDesc><table><row><cell></cell><cell cols="2">Study 337</cell><cell cols="2">Study 142</cell><cell cols="2">Study 174</cell></row><row><cell></cell><cell>Romosozumab</cell><cell>Placebo</cell><cell>Romosozumab</cell><cell>Alendronate</cell><cell>Romosozumab</cell><cell>Placebo</cell></row><row><cell></cell><cell>N = 3581</cell><cell>N = 3576</cell><cell>N = 2040</cell><cell>N = 2014</cell><cell>N = 163</cell><cell>N = 81</cell></row><row><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>MACE</cell><cell>30 (0.8)</cell><cell>29 (0.8)</cell><cell>41 (2.0)</cell><cell>22 (1.1)</cell><cell>6 (3.7)</cell><cell>2 (2.5)</cell></row><row><cell>HR [95% CI]</cell><cell cols="2">1.03 [0.62, 1.72]</cell><cell cols="2">1.87 [1.11, 3.14]</cell><cell cols="2">1.55 [0.31, 7.69]</cell></row><row><cell>CV Death</cell><cell>17 (0.5)</cell><cell>15 (0.4)</cell><cell>17 (0.8)</cell><cell>12 (0.6)</cell><cell>2 (1.2)</cell><cell>1 (1.2)</cell></row><row><cell>HR [95% CI]</cell><cell cols="2">1.13 [0.56, 2.26]</cell><cell cols="2">1.42 [0.68, 2.97]</cell><cell cols="2">1.04 [0.09, 11.46]</cell></row><row><cell>MI</cell><cell>9 (0.3)</cell><cell>8 (0.2)</cell><cell>16 (0.8)</cell><cell>5 (0.2)</cell><cell>1 (0.6)</cell><cell>0 (0.0)</cell></row><row><cell>HR [95% CI]</cell><cell cols="2">1.12 [0.43, 2.91]</cell><cell cols="2">3.21 [1.18, 8.77]</cell><cell cols="2">Not Estimable</cell></row><row><cell>Stroke</cell><cell>8 (0.2)</cell><cell>10 (0.3)</cell><cell>13 (0.6)</cell><cell>7 (0.3)</cell><cell>3 (1.8)</cell><cell>1 (1.2)</cell></row><row><cell>HR [95% CI</cell><cell cols="2">0.80 [0.32, 2.02]</cell><cell cols="2">1.86 [0.74, 4.67]</cell><cell cols="2">1.54 [0.16, 14.83]</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_432"><head>.1.3 Network Meta-Analysis The</head><label></label><figDesc>The results of the meta-analysis of the two women studies were similar to that of all three studies because of the small number of events in Study 174. univariate network meta-analysis of Studies 337 and 142 yielded a HR [95% CI] of 1.03 [0.62, 1.72] when comparing hazard of romosozumab arm to placebo arm. The HR was the same as that of Study 337 because only this study compared romosozumab and placebo. In contrast the HR [95% CI] comparing alendronate arm to placebo arm was 0.55 [0.27, 1.14]; although the CI included one, the estimated risk of MACE in the alendronate arm was lower compared to the placebo arm. The results, adjusted by treatment group and age and stratified by countries did not differ from the univariate analysis</figDesc><table><row><cell>), the</cell></row><row><cell>number (%) of MACE events was 71 (1.3%) among the romosozumab subjects and 51 (0.9%)</cell></row><row><cell>among the control (placebo or alendronate) subjects. The HR [95% CI] of the meta-analysis was</cell></row><row><cell>1.38 [0.96, 1.99]. Figure 1. Time to first MACE through Month 12 (Studies 337, 142, and 174)</cell></row><row><cell>Source: Sponsor's CCR, page 24, Figure 2</cell></row><row><cell>3.5</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_433"><head>Table 4 .</head><label>4</label><figDesc>Network Meta-Analysis Results of MACE of Studies 337 and 142</figDesc><table><row><cell>Meta-analysis model</cell><cell>Treatment comparisons</cell><cell>HR [95% C.I]</cell></row><row><cell>Univariate</cell><cell>romosozumab vs. placebo</cell><cell>1.03 [0.62, 1.72]</cell></row><row><cell>Univariate</cell><cell>alendronate vs. placebo</cell><cell>0.55 [0.27, 1.14]</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_434"><head>Table 5 .</head><label>5</label><figDesc>Network Meta-Analysis of Components of MACE of Studies 337 and 142 190 events across the three trials were adjudicated as CV SAE in the 12-month doubleblind period; 104 CV SAE events in the romosozumab arm and 86 CV SAE events in the placebo or alendronate arms. In Study 337, the number (%) of CV SAE events was 46 (1.3%) and 46 (1.3%), in the romosozumab and placebo arm, respectively. The HR [95% CI] of CV SAE comparing romosozumab to placebo was 1.0 [0.66, 1.50], indicating no difference in risk. The HR of CV SAE comparing romosozumab to alendronate was 1.32 [0.87, 2.01] in Study 174, indicating a numerically higher risk in the romosozumab arm. The men study results also indicated a numerically higher risk of CV SAE in the romosozumab arm compared to placebo</figDesc><table><row><cell>Outcome</cell><cell>Comparison</cell><cell>Hazard Ratio [95% CI]</cell></row><row><cell>CV death</cell><cell>romosozumab vs. placebo</cell><cell>1.13 [0.56, 2.26]</cell></row><row><cell></cell><cell>alendronate vs. placebo</cell><cell>0.80 [0.29, 2.20]</cell></row><row><cell>MI</cell><cell>romosozumab vs. placebo</cell><cell>1.12 [0.43, 2.91]</cell></row><row><cell></cell><cell>alendronate vs. placebo</cell><cell>0.35 [0.09, 1.39]</cell></row><row><cell>Stroke</cell><cell>romosozumab vs. placebo</cell><cell>0.80 [0.32, 2.02]</cell></row><row><cell></cell><cell>alendronate vs. placebo</cell><cell>0.43 [0.12, 1.58]</cell></row><row><cell>Source: Reviewer's analysis</cell><cell></cell><cell></cell></row><row><cell>3.5.2 CV SAE</cell><cell></cell><cell></cell></row><row><cell cols="2">3.5.2.1 Incidence and Hazard Ratio</cell><cell></cell></row><row><cell>A total of</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_435"><head>Table 6 .</head><label>6</label><figDesc>Number (%) of CV SAE events through Month 12 CV SAE events in the romosozumab arm and 84 (1.5%) events in the control (placebo or alendronate) arm. The HR [95% CI] of the meta-analysis was 1.14 [0.85, 1.53].</figDesc><table><row><cell></cell><cell cols="2">Study 337</cell><cell cols="2">Study 142</cell><cell cols="2">Study 174</cell></row><row><cell></cell><cell>Romosozumab</cell><cell>Placebo</cell><cell>Romosozumab</cell><cell>Alendronate</cell><cell>Romosozumab</cell><cell>Placebo</cell></row><row><cell></cell><cell>N = 3581</cell><cell>N = 3576</cell><cell>N = 2040</cell><cell>N = 2014</cell><cell>N = 163</cell><cell>N = 81</cell></row><row><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell>CV SAE</cell><cell>46 (1.3)</cell><cell>46 (1.3)</cell><cell>50 (2.5)</cell><cell>38 (1.9)</cell><cell>8 (4.9)</cell><cell>2 (2.5)</cell></row><row><cell>HR [95% CI]</cell><cell cols="2">1.0 [0.66, 1.50]</cell><cell cols="2">1.32 [0.87, 2.01]</cell><cell cols="2">2.08 [0.44, 9.80]</cell></row><row><cell cols="3">Source: Sponsor's CCR, page 51, Table 7</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">3.5.2.2 Meta-Analysis</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="7">In the 12-month double blind period, across the three trials, the total number (%) of CV SAE</cell></row><row><cell cols="7">events was 104 (1.8%) in the romosozumab arm and 86 (1.5%) in the control (placebo or</cell></row><row><cell cols="7">alendronate) arms. The HR [95% CI] of the meta-analysis of the three trials was 1.17 [0.88, 1.56]</cell></row><row><cell>(Figure 2).</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="7">The reviewer's meta-analysis using the two studies in women (Studies 337 and 142) included 96</cell></row><row><cell>(1.7%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_436"><head></head><label></label><figDesc>univariate network meta-analysis of Studies 337 and 142 yielded a HR [95% CI] of 1.0 [0.66, 1.50] when comparing the hazard of the romosozumab arm to the placebo arm. The hazard ratio was the same as that of Study 337 because only this study compared romosozumab and placebo. In contrast, when comparing the hazard of the alendronate arm to the placebo arm, the HR [95% CI] was 0.76 [0.42, 1.36], which indicated a numerically lower risk in the alendronate arm compared to the placebo arm. The results, adjusted by treatment group and age and stratified by countries did not differ from the univariate analysis</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_437"><head>Table 7 .</head><label>7</label><figDesc>Network Meta-Analysis Results using CV SAE events of Studies 337 and 142</figDesc><table><row><cell>Meta-analysis model</cell><cell>Treatment comparisons</cell><cell>HR (95% C.I)</cell></row><row><cell>Univariate</cell><cell>romosozumab vs. placebo</cell><cell>1.00 [0.66, 1.50]</cell></row><row><cell>Univariate</cell><cell>alendronate vs. placebo</cell><cell>0.76 [0.42, 1.36]</cell></row><row><cell>Multivariate</cell><cell>romosozumab vs. placebo</cell><cell>1.00 [0.66, 1.50]</cell></row><row><cell>Multivariate</cell><cell>alendronate vs. placebo</cell><cell>0.77 [0.43, 1.40]</cell></row><row><cell>Source: Reviewer's analysis</cell><cell></cell><cell></cell></row><row><cell cols="2">4 SUMMARY AND CONCLUSIONS</cell><cell></cell></row><row><cell cols="3">Romosozumab (EVENITY  ) is a sclerostin inhibitor indicated for the treatment of osteoporosis</cell></row><row><cell cols="3">in postmenopausal women at high risk of fracture. Because the study findings showed a higher</cell></row><row><cell cols="3">incidence of serious cardiovascular (CV) events in the romosozumab arm compared to an active</cell></row><row><cell cols="3">control (Study 142), and placebo (Study 174), the FDA issued a complete response letter on July</cell></row><row><cell cols="3">13, 2017, stating that a complete analysis of Study 142 and 174, as well as an integrated</cell></row><row><cell cols="3">assessment of cardiovascular risk from the above phase 3 studies (Studies 337, 142 and 174)</cell></row><row><cell cols="3">would be needed to complete the benefit-risk assessment of romosozumab. In response, on June</cell></row><row><cell cols="3">28, 2018, the sponsor submitted the CCR that integrated assessment of cardiovascular risk from</cell></row><row><cell cols="2">all pivotal studies (Studies 337, 142 and 174).</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_438"><head></head><label></label><figDesc>in Study 142, indicating an increased risk of MACE in the romosozumab arm compared to alendronate arm. The network meta-analysis resulted in a HR of 0.55 [0.27, 1.14] when comparing the risk of MACE in the alendronate arm to the placebo arm. This suggests that the HR estimate in Study 142 might be because the incidence of MACE was low in the active control arm. However, the network meta-analysis had limitations because it only used two studies, which led to wide confidence interval. In addition, the HR comparing the alendronate arm to the placebo arm was estimated indirectly.It is difficult to discern whether the increased risk of MACE identified in the romosozumab arm in Study 142 is truly a drug effect, chance finding, or because of alendronate's potential protective effect on MACE. However, because a similar trend was noted in a study of osteoporosis in men (Study 174), this signal provides corroborate evidence of risk and should not be ignored.</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_440"><head></head><label></label><figDesc>OVERVIEW ....................................................................................................................................................................................... 5 2.2 DATA SOURCES ................................................................................................................................................................................ 5</figDesc><table><row><cell></cell><cell>. 5</cell></row><row><cell></cell><cell>2.1</cell></row><row><cell>3</cell><cell>STATISTICAL</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_441"><head></head><label></label><figDesc>DATA AND ANALYSIS QUALITY ........................................................................................................................................................ 6 3.2 EVALUATION OF EFFICACY ............................................................................................................................................................... 6 3.2.1 Study</figDesc><table><row><cell>. 6</cell></row><row><cell>3.1</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_442"><head></head><label></label><figDesc>.... 11 3.3 EVALUATION OF SAFETY ................................................................................................................................................................ 15</figDesc><table><row><cell>4</cell><cell>FINDINGS IN SPECIAL/SUBGROUP</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_443"><head></head><label></label><figDesc>AND GEOGRAPHIC REGION .......................................................................................................................................... 15 4.2 OTHER SPECIAL/SUBGROUP POPULATIONS...................................................................................................................................... 15</figDesc><table><row><cell></cell><cell>. 15</cell></row><row><cell>4.1</cell><cell>RACE, AGE,</cell></row></table><note>5 SUMMARY AND CONCLUSIONS...</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_444"><head></head><label></label><figDesc>STATISTICAL ISSUES ....................................................................................................................................................................... 16 5.2 COLLECTIVE EVIDENCE .................................................................................................................................................................. 16 5.3 CONCLUSIONS AND RECOMMENDATIONS ........................................................................................................................................ 17</figDesc><table><row><cell>..... 16</cell></row><row><cell>5.1</cell></row></table><note>APPENDIX ..</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_445"><head></head><label></label><figDesc>. 18 A1. DEMOGRAPHICS AND BASELINE CHARACTERISTICS .............................................................................................................................. 18 A2. SUBGROUP ANALYSIS RESULTS ............................................................................................................................................................. 23</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_446"><head>Table 1 :</head><label>1</label><figDesc>List of All Studies Included in the Statistical Review ........................................................................................................................ 5 Table 2: Study 20070337 -List of Secondary Efficacy Endpoints ................................................................................................................... 7Table 3: Study 20070337 -Summary of Patient Disposition .......................................................................................................................... 10 Table 4: Study 20120516 -Summary of Patient Disposition .......................................................................................................................... 11 Table 5: Study 20070337 -Incidence of New Vertebral Fracture .................................................................................................................. 11 Table 6: Study 20070337 -Incidence of Clinical Fracture and Nonvertebral Fracture ................................................................................... 12 Table 7: Study 20070337-Summary of BMD at Lumbar Spine at Month 12 and Month 24 ......................................................................... 13 Table 8: Study 20070337-Summary of BMD at Total Hip at Month 12 and Month 24 ................................................................................ 13 Table 9: Study 20070337-Summary of BMD at Femoral Neck at Month 12 and Month 24 ......................................................................... 13 Table 10: Study 20120156 -Summary of BMD at Lumbar Spine at Month 6 ............................................................................................... 14 Table 11: Study 20120156 -Summary of BMD at Total Hip at Month 6 ....................................................................................................... 14 Table 12: Study 20120156 -Summary of BMD at Femoral Neck at Month 6 ............................................................................................... 15 Table 13: Subgroup Categories ....................................................................................................................................................................... 15 Table 14: Study 20070337 Demographics and Baseline Characteristics ........................................................................................................ 18 Table 15: Study 20070337 -Key Baseline Disease Characteristics ................................................................................................................ 20 Table 16: Study 20120156 Demographics and Baseline Characteristics ....................................................................................................... 22 Subject Incidence of New Vertebral Fracture Through Month 12 by Demographics and Baseline Characteristics (20070337 Primary Analysis Set for Vertebral Fractures, LOCF Imputation) ................................................................................................................. 23 Figure 2 : Subject Incidence of New Vertebral Fracture Through Month 24 by Demographics and Baseline Characteristics (20070337 Primary Analysis Set for Vertebral Fractures, LOCF Imputation) ................................................................................................................. 24 Figure 3: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 by Subgroups (20070337 Primary Analysis Set for BMD, LOCF) ............................................................................................................................................................................................ 25 Figure 4. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24 by Subgroups (20070337 Primary Analysis Set for BMD, LOCF) ............................................................................................................................................................................................ 25 Figure 5. Total Hip Bone Mineral Density Percent Change From Baseline at Month 12 by Subgroups (20070337 Primary Analysis Set for BMD, LOCF) ................................................................................................................................................................................................. 26 Figure 6. Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 by Subgroups (20070337 Primary Analysis Set for BMD, LOCF) ................................................................................................................................................................................................. 26 Figure 7. Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12 by Subgroups (20070337 Primary Analysis Set for BMD, LOCF) ............................................................................................................................................................................................ 27 Figure 8. Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 by Subgroups (20070337 Primary Analysis Set for BMD, LOCF) ............................................................................................................................................................................................ 27</figDesc><table><row><cell>LIST OF FIGURES</cell></row><row><cell>Figure 1.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_447"><head>Table 1 : List of Studies Included in the Statistical Review Study Phase and Design</head><label>1</label><figDesc></figDesc><table><row><cell></cell><cell>Treatment</cell><cell># of Randomized Subjects</cell><cell>Study Population</cell></row><row><cell></cell><cell>Period</cell><cell>per Arm</cell><cell></cell></row><row><cell>20070337 Phase 3,</cell><cell>Year 1: Placebo or</cell><cell>Placebo:3591</cell><cell> Healthy ambulatory postmenopausal</cell></row><row><cell>Multicenter,</cell><cell>romosozumab 210 mg</cell><cell></cell><cell>women from 55 to 90 years of age</cell></row><row><cell>Randomized, Double-blind, Placebo-controlled</cell><cell>(70 mg/ml solution) SC QM Years 2 and 3: Open-label</cell><cell>Romosozumab: 3589</cell><cell>with osteoporosis.  Have a BMD T score -2.5 and &gt;-3.5 at the total hip (femoral neck)  No previous hip fracture or any</cell></row><row><cell></cell><cell>denosumab</cell><cell></cell><cell>severe or more than 2 moderate</cell></row><row><cell></cell><cell>60 mg SC Q6M</cell><cell></cell><cell>vertebral fractures</cell></row><row><cell>20120156 Phase 3</cell><cell>6 months</cell><cell>Placebo: 53</cell><cell> Healthy ambulatory postmenopausal</cell></row><row><cell>Multicenter,</cell><cell></cell><cell>Romosozumab 70mg/mL : 118</cell><cell>women from 55 to 90 years of age at</cell></row><row><cell>Randomized, Double-blind,</cell><cell></cell><cell>Romosozumab 90 mg/mL : 123</cell><cell>high risk for fracture.  DXA BMD T-score of  -2.50 at the</cell></row><row><cell>Non-inferiority</cell><cell></cell><cell></cell><cell>lumbar spine, total hip or femoral</cell></row><row><cell></cell><cell></cell><cell></cell><cell>neck.  Had a history of fragility fracture or</cell></row><row><cell></cell><cell></cell><cell></cell><cell>met at least 2 clinical risk factors for</cell></row><row><cell></cell><cell></cell><cell></cell><cell>fracture.</cell></row><row><cell>Source: Reviewer's summary.</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_448"><head>Table 2 : Study 20070337 -List of Secondary Efficacy Endpoints</head><label>2</label><figDesc></figDesc><table><row><cell>Endpoint</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_449"><head>Table 3 :</head><label>3</label><figDesc></figDesc><table><row><cell></cell><cell cols="3">Study 20070337 -Summary of Patient Disposition</cell><cell></cell></row><row><cell cols="2">Double-blind period study</cell><cell></cell><cell>Romo210 mg</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Placebo</cell><cell>(70 mg/ml)</cell><cell>All</cell></row><row><cell></cell><cell></cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row><row><cell cols="2">Randomized</cell><cell>3591 (100)</cell><cell>3589 (100)</cell><cell>7180 (100)</cell></row><row><cell cols="2">Completed double-blind period</cell><cell>3205 (89.3)</cell><cell>3185 (88.7)</cell><cell>6390 (89.0)</cell></row><row><cell cols="2">Discontinued study during double-blind</cell><cell>386 (10.7)</cell><cell>404 (11.3)</cell><cell>790 (11.0)</cell></row><row><cell>i d</cell><cell>Consent withdrawn</cell><cell>253 (7.0)</cell><cell>261 (7.3)</cell><cell>514 (7.2)</cell></row><row><cell></cell><cell>Adverse event</cell><cell>39 (1.1)</cell><cell>39 (1.1)</cell><cell>78 (1.1)</cell></row><row><cell></cell><cell>Other</cell><cell>24 (0.7)</cell><cell>34 (0.9)</cell><cell>58 (0.8)</cell></row><row><cell></cell><cell>Death</cell><cell>20 (0.6)</cell><cell>27 (0.8)</cell><cell>47 (0.7)</cell></row><row><cell></cell><cell>Lost to follow-up</cell><cell>21 (0.6)</cell><cell>22 (0.6)</cell><cell>43 (0.6)</cell></row><row><cell></cell><cell>Noncompliance</cell><cell>16 (0.4)</cell><cell>9 (0.3)</cell><cell>25 (0.3)</cell></row><row><cell></cell><cell>Ineligibility determined</cell><cell>6 (0.2)</cell><cell>7 (0.2)</cell><cell>13 (0.2)</cell></row><row><cell></cell><cell>Protocol deviation</cell><cell>3 (&lt;0.1)</cell><cell>2 (&lt;0.1)</cell><cell>5 (&lt;0.1)</cell></row><row><cell></cell><cell>Requirement for alternative therapy</cell><cell>2 (&lt;0.1)</cell><cell>2 (&lt;0.1)</cell><cell>4 (&lt;0.1)</cell></row><row><cell></cell><cell>Administrative decision</cell><cell>2 (&lt;0.1)</cell><cell>1 (&lt;0.1)</cell><cell>3 (&lt;0.1)</cell></row><row><cell cols="3">Percentages based on the number of patients randomized.</cell><cell></cell><cell></cell></row><row><cell cols="2">Source: Table 14-1.1 in Study 20070337 study report.</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_450"><head>Table 4 : Study 20120516 -Summary of Patient Disposition Placebo</head><label>4</label><figDesc></figDesc><table><row><cell></cell><cell>Romo</cell><cell>Romo</cell><cell></cell></row><row><cell></cell><cell>70 mg/ml</cell><cell>90 mg/ml</cell><cell>All</cell></row><row><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell><cell>n (%)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_451"><head>Table 5 : Study 20070337 -Incidence of New Vertebral Fracture Statistic Through Month 12 Through Month 24 Placebo</head><label>5</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Placebo/</cell><cell>Romo /</cell></row><row><cell></cell><cell></cell><cell>Romo</cell><cell>Denosumab</cell><cell>Denosumab</cell></row><row><cell></cell><cell>(N = 3591)</cell><cell>(N = 3589)</cell><cell>(N = 3591)</cell><cell>(N = 3589)</cell></row><row><cell>Incidence, n/N1 (%)</cell><cell>59/3322 (1.8)</cell><cell>16/3321 (0.5)</cell><cell>84/3327 (2.5)</cell><cell>21/3325 (0.6)</cell></row><row><cell></cell><cell cols="2">Risk Comparison Estimates</cell><cell></cell><cell></cell></row><row><cell>Absolute risk reduction (%)*</cell><cell>1.30</cell><cell></cell><cell>1.89</cell><cell></cell></row><row><cell>95% CI</cell><cell cols="2">(0.79, 1.80)</cell><cell cols="2">(1.30, 2.49)</cell></row><row><cell>Relative risk reduction *</cell><cell>73%</cell><cell></cell><cell>75%</cell><cell></cell></row><row><cell>95% CI</cell><cell cols="2">(53%, 84%)</cell><cell cols="2">(60%, 84%)</cell></row><row><cell>p-value  </cell><cell cols="2">&lt; 0.001</cell><cell cols="2">&lt; 0.001</cell></row><row><cell>Source: Table 10-1 in study report.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">N = Number of subjects randomized; N1 = Number of subjects in the primary analysis set for vertebral fractures</cell></row></table><note>*Based on the Mantel-Haenszel method adjusted for age and prevalent vertebral fracture stratification variables P-value is based on logistic regression</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_452"><head>Table 6 : Study 20070337 -Incidence of Clinical Fracture and Non-vertebral Fracture</head><label>6</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Absolute Risk</cell><cell>Relative Risk</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Fracture Category</cell><cell cols="2">Incidence (n/N1 [%])</cell><cell>Reduction</cell><cell>Reduction</cell><cell>Nominal</cell><cell></cell><cell>Statistically</cell></row><row><cell>/Time Point</cell><cell></cell><cell></cell><cell>% (95% CI)</cell><cell>% (95% CI)</cell><cell>p-value</cell><cell> level</cell><cell>Significant</cell></row><row><cell>Clinical</cell><cell>Placebo</cell><cell>Romo</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Month 12 Step 1</cell><cell>90/3591 (2.5)</cell><cell>58/3589 (1.6)</cell><cell>1.2% (0.4, 1.9)</cell><cell>36% (11, 54)</cell><cell>0.008</cell><cell>0.05</cell><cell>Yes</cell></row><row><cell>Month 24 Step 3</cell><cell>147/3591 (4.1)</cell><cell>99/3589 (2.8)</cell><cell>1.4% (0.5, 2.4)</cell><cell>33% (13, 48)</cell><cell>0.002</cell><cell>-</cell><cell>(stop testing)</cell></row><row><cell>Non-vertebral Step2</cell><cell>Placebo</cell><cell>Romo</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Month 12</cell><cell>75/3591 (2.1)</cell><cell>56/3589 (1.6)</cell><cell>0.8% (0.1, 1.4)</cell><cell>25% (-5, 47)</cell><cell>0.096</cell><cell>0.05</cell><cell>No</cell></row><row><cell>Month 24</cell><cell>129/3591 (3.6)</cell><cell>96/3589 (2.7)</cell><cell>1.0% (0.2, 1.9)</cell><cell>25% (3, 43)</cell><cell>0.029</cell><cell>0.025</cell><cell>No</cell></row><row><cell>Source:</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_453"><head>Table 7 : Study 20070337-Summary of BMD at Lumbar Spine at Month 12 and Month 24 Location Time</head><label>7</label><figDesc></figDesc><table><row><cell></cell><cell>Point</cell><cell>Statistic</cell><cell>Placebo/</cell><cell>Romo/</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Denosumab</cell><cell>Denosumab</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(N = 3591)</cell><cell>(N = 3589)</cell></row><row><cell>Lumbar spine</cell><cell>Baseline</cell><cell>Mean (SD)</cell><cell>0.8 (0.1)</cell><cell>0.8 (0.1)</cell></row><row><cell></cell><cell>Month 12</cell><cell>% Change from baseline (SE)</cell><cell>0.4 (0.1)</cell><cell>13.1 (0.1)</cell></row><row><cell></cell><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>12.7 (0.1)</cell></row><row><cell></cell><cell></cell><cell>95% CI</cell><cell></cell><cell>(12.4, 12.9)</cell></row><row><cell></cell><cell></cell><cell>P-value</cell><cell></cell><cell>&lt;0.001</cell></row><row><cell></cell><cell>Month 24</cell><cell>% Change from baseline (SE)</cell><cell>5.5 (0.1)</cell><cell>16.6 (0.1)</cell></row><row><cell></cell><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>11.1 (0.1)</cell></row><row><cell></cell><cell></cell><cell>95% CI</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>P-value</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_454"><head>Table 8 : Study 20070337-Summary of BMD at Total Hip at Month 12 and Month 24 Location</head><label>8</label><figDesc></figDesc><table><row><cell></cell><cell>Time Point</cell><cell>Statistic</cell><cell>Placebo/</cell><cell>Romo/</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Denosumab</cell><cell>Denosumab</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(N = 3591)</cell><cell>(N = 3589)</cell></row><row><cell>Total Hip</cell><cell>Baseline</cell><cell>Mean (SD)</cell><cell>0.7 (0.1)</cell><cell>0.7 (0.1)</cell></row><row><cell></cell><cell>Month 12</cell><cell>% Change from baseline (SE)</cell><cell>0.3 (0.1)</cell><cell>6.0 (0.1)</cell></row><row><cell></cell><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>5.8 (0.1)</cell></row><row><cell></cell><cell></cell><cell>95% CI</cell><cell></cell><cell>(5.6, 6.0)</cell></row><row><cell></cell><cell></cell><cell>P-value</cell><cell></cell><cell>&lt;0.001</cell></row><row><cell></cell><cell>Month 24</cell><cell>% Change from baseline (SE)</cell><cell>3.2 (0.1)</cell><cell>8.5 (0.1)</cell></row><row><cell></cell><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>5.3 (0.1)</cell></row><row><cell></cell><cell></cell><cell>95% CI</cell><cell></cell><cell>(5.1, 5.5)</cell></row><row><cell></cell><cell></cell><cell>P-value</cell><cell></cell><cell>&lt;0.001</cell></row><row><cell cols="2">Source: Reviewer's analysis,</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_455"><head>Table 9 : Study 20070337-Summary of BMD at Femoral Neck at Month 12 and Month 24 Location Time Point Statistic Placebo/ Denosumab (N = 3591) Romo/ Denosumab (N = 3589)</head><label>9</label><figDesc>Table 10-3 in study report. % change from baseline, LS means difference, 95% CI and P-value from ANCOVA model.</figDesc><table><row><cell>Femoral Neck</cell><cell>Baseline</cell><cell>Mean (SD)</cell><cell>0.6 (0.1)</cell><cell>0.6 (0.1)</cell></row><row><cell></cell><cell>Month 12</cell><cell>% Change from baseline (SE)</cell><cell>0.3 (0.1)</cell><cell>5.5 (0.1)</cell></row><row><cell></cell><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>5.2 (0.1)</cell></row><row><cell></cell><cell></cell><cell>95% CI</cell><cell></cell><cell>(4.9, 5.4)</cell></row><row><cell></cell><cell></cell><cell>P-value</cell><cell></cell><cell>&lt;0.001</cell></row><row><cell></cell><cell>Month 24</cell><cell>% Change from baseline (SE)</cell><cell>2.3 (0.1)</cell><cell>7.3 (0.1)</cell></row><row><cell></cell><cell></cell><cell>LS mean diff. (SE)</cell><cell></cell><cell>4.9 (0.1)</cell></row><row><cell></cell><cell></cell><cell>95% CI</cell><cell></cell><cell>(4.7, 5.2)</cell></row><row><cell></cell><cell></cell><cell>P-value</cell><cell></cell><cell>&lt;0.001</cell></row><row><cell cols="2">Source: Reviewer's analysis,</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_456"><head>Table 10 : Study 20120156 -Summary of BMD at Lumbar Spine at Month 6</head><label>10</label><figDesc>Table 10-1 in study report. %change from baseline, LS means difference, 95% CI and P-value from ANCOVA model.</figDesc><table><row><cell></cell><cell>Placebo</cell><cell>Romo</cell><cell>Romo</cell></row><row><cell>Statistic</cell><cell>(N = 46)</cell><cell>70 mg/mL</cell><cell>90 mg/mL</cell></row><row><cell></cell><cell></cell><cell>(N = 110)</cell><cell>(N = 117)</cell></row><row><cell>Baseline (SD)</cell><cell>0.8 (0.1)</cell><cell>0.8 (0.1)</cell><cell>0.8 (0.1)</cell></row><row><cell>% Change from baseline (SE)</cell><cell>0.8 (0.6)</cell><cell>9.6 (0.4)</cell><cell>9.2 (0.4)</cell></row><row><cell>LS mean diff vs. placebo (SE)</cell><cell></cell><cell>8.8 (0.8)</cell><cell>8.4 (0.7)</cell></row><row><cell>95% CI</cell><cell></cell><cell>(7.3, 10.3)</cell><cell>(6.9, 9.9)</cell></row><row><cell>P-value vs. placebo</cell><cell></cell><cell>&lt;0.0001</cell><cell>&lt;0.0001</cell></row><row><cell>LS mean diff vs. Romo 70 mg/ml(SE)</cell><cell></cell><cell></cell><cell>-0.4</cell></row><row><cell>95% CI</cell><cell></cell><cell></cell><cell>(-1.5, 0.7)</cell></row><row><cell>P-value</cell><cell></cell><cell></cell><cell>0.4739</cell></row><row><cell>Source: Reviewer's analysis,</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_457"><head>Table 11 : Study 20120156 -Summary of BMD at Total Hip at Month 6 Statistic Placebo (N = 46) Romo 70 mg/mL (N = 110) Romo 90 mg/mL (N = 117) Baseline</head><label>11</label><figDesc>Table 10-2 in study report. %change from baseline, LS means difference, 95% CI and P-value from ANCOVA model.</figDesc><table><row><cell>(SD)</cell><cell>0.7 (0.1)</cell><cell>0.7 (0.1)</cell><cell>0.7 (0.1)</cell></row><row><cell>% Change from baseline (SE)</cell><cell>-0.0 (0.4)</cell><cell>3.9 (0.3)</cell><cell>3.4 (0.3)</cell></row><row><cell>LS mean diff vs. placebo (SE)</cell><cell></cell><cell>3.9 (0.5)</cell><cell>3.5 (0.5)</cell></row><row><cell>95% CI</cell><cell></cell><cell>(3.0, 4.9)</cell><cell>(2.5, 4.4)</cell></row><row><cell>P-value vs. placebo</cell><cell></cell><cell>&lt;0.0001</cell><cell>&lt;0.0001</cell></row><row><cell>LS mean diff vs. Romo 70 mg/ml(SE)</cell><cell></cell><cell></cell><cell>-0.4 (0.4)</cell></row><row><cell>95% CI</cell><cell></cell><cell></cell><cell>(-1.2, 0.3)</cell></row><row><cell>P-value</cell><cell></cell><cell></cell><cell>0.2326</cell></row><row><cell>Source: Reviewer's analysis,</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_458"><head>Table 12 : Study 20120156 -Summary of BMD at Femoral Neck at Month 6</head><label>12</label><figDesc>Table 10-3 in study report. %change from baseline, LS means difference, 95% CI and P-value from ANCOVA model.</figDesc><table><row><cell></cell><cell></cell><cell>Romo</cell><cell>Romo</cell></row><row><cell>Statistic</cell><cell>Placebo</cell><cell>70 mg/mL</cell><cell>90 mg/mL</cell></row><row><cell></cell><cell>(N = 46)</cell><cell>(N = 110)</cell><cell>(N = 117)</cell></row><row><cell>Baseline (SD)</cell><cell>0.6 (0.1)</cell><cell>0.7 (0.1)</cell><cell>0.7 (0.1)</cell></row><row><cell>% Change from baseline (SE)</cell><cell>-0.5 (0.5)</cell><cell>3.1 (0.3)</cell><cell>2.6 (0.3)</cell></row><row><cell>LS mean diff vs. placebo (SE)</cell><cell></cell><cell>3.6 (0.6)</cell><cell>3.2 (0.6)</cell></row><row><cell>95% CI</cell><cell></cell><cell>(2.4, 4.8)</cell><cell>(2.0, 4.3)</cell></row><row><cell>P-value vs. placebo</cell><cell></cell><cell>&lt;0.0001</cell><cell>&lt;0.0001</cell></row><row><cell>LS mean diff vs. Romo 70 mg/ml(SE)</cell><cell></cell><cell></cell><cell>-0.5 (0.5)</cell></row><row><cell>95% CI</cell><cell></cell><cell></cell><cell>(-1.4, 0.4)</cell></row><row><cell>P-value</cell><cell></cell><cell></cell><cell>0.3014</cell></row><row><cell>Source: Reviewer's analysis,</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_459"><head>Table 13 : Subgroup Categories Grouping variable Subgroups</head><label>13</label><figDesc></figDesc><table><row><cell>Age group</cell><cell>&lt; 65 years,  65 years</cell></row><row><cell></cell><cell>&lt; 75 years,  75 years</cell></row><row><cell>Race</cell><cell>White, non-white</cell></row><row><cell>Geographic Region</cell><cell>Western Europe and Australia/New Zealand,</cell></row><row><cell></cell><cell>Central and Eastern Europe;</cell></row><row><cell></cell><cell>Asia Pacific;</cell></row><row><cell></cell><cell>North America;</cell></row><row><cell></cell><cell>Central/Latin America</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_461"><head>Table of Contents 1 SUMMARY</head><label></label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_462"><head></head><label></label><figDesc>ANALYSES ................................................................................................................................... 4 3.1.1Survival</figDesc><table><row><cell></cell><cell>3</cell></row><row><cell>3.1</cell><cell>SPONSOR'S</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_463"><head></head><label></label><figDesc>ANALYSES ................................................................................................................................. 5 3.2.1 Survival</figDesc><table><row><cell></cell><cell>.... 4</cell></row><row><cell>3.2</cell><cell>REVIEWER'S</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_464"><head>Table 1A :</head><label>1A</label><figDesc>Intercurrent Mortality Rate in Male Figure 1A: </figDesc><table /><note>5 REFERENCES ..</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_465"><head>Types with P-Values  0.05 for Dose Response Relationship or Pairwise Comparisons of Treated Groups and Vehicle Controls in Male and Female Rats</head><label></label><figDesc>The following table displays the tumor types showing p-values less than or equal to 0.05 either for dose response relationship or for pairwise comparisons of treated groups and vehicle control. YY (ZZ): X=number of tumor bearing animals; YY=unweighted total number of animals observed; ZZ=mortality weighted total number of animals; $ = Statistically significant at 0 05 level in rare tumor for test of dose response relationship /pairwise comparisons; @ = Not statistically significant at 0 01 level in common tumor for test of dose response relationship /pairwise comparisons; NC = Not calculable</figDesc><table><row><cell>Tumor Organ name</cell><cell>Tumor name</cell><cell>0 mg</cell><cell>3 mg</cell><cell>10 mg</cell><cell>50 mg</cell></row><row><cell></cell><cell></cell><cell>Vehicle (C)</cell><cell>Low (L)</cell><cell>Mid (M)</cell><cell>High (H)</cell></row><row><cell></cell><cell></cell><cell>P -Trend</cell><cell>P -C vs. L</cell><cell>P -C vs. M</cell><cell>P -C vs. H</cell></row><row><cell>Male-Adrenal</cell><cell>Adenoma: Cortical</cell><cell>0/60 (25)</cell><cell>2/60 (25)</cell><cell>6/60 (29)</cell><cell>2/54 (25)</cell></row><row><cell></cell><cell></cell><cell>0.4382</cell><cell>0.2449</cell><cell>0.0184 $</cell><cell>0.2449</cell></row><row><cell>Female-Adrenal</cell><cell>Benign Pheochromocytoma</cell><cell>2/60 (38)</cell><cell>8/60 (39)</cell><cell>2/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.9884</cell><cell>0.0473 @</cell><cell>0.6719</cell><cell>0.7250</cell></row><row><cell></cell><cell>Malignant Pheochromocytoma</cell><cell>0/60 (38)</cell><cell>2/60 (38)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.7308</cell><cell>0.2467</cell><cell>NC</cell><cell>NC</cell></row><row><cell></cell><cell>Benign Pheochromocytoma/</cell><cell>2/60 (38)</cell><cell>10/60 (40)</cell><cell>2/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell>Malignant Pheochromocytoma</cell><cell>0.9942</cell><cell>0.0159 @</cell><cell>0.6719</cell><cell>0.7250</cell></row><row><cell>Female-Kidney</cell><cell>Lipoma</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>3/60 (35)</cell></row><row><cell></cell><cell></cell><cell>0.0429 @</cell><cell>0.4933</cell><cell>0.4865</cell><cell>0.2766</cell></row><row><cell>Female-Pancreas</cell><cell>Adenoma: Islet Cell</cell><cell>0/60 (38)</cell><cell>0/60 (37)</cell><cell>3/60 (38)</cell><cell>3/60 (35)</cell></row><row><cell></cell><cell></cell><cell>0.0323 $</cell><cell>NC</cell><cell>0.1200</cell><cell>0.1052</cell></row><row><cell>&amp; X/</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_467"><head>Table 1A : Intercurrent Mortality Rate in Male Rats</head><label>1A</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">Vehicle Control</cell><cell>Low</cell><cell></cell><cell>Mid</cell><cell></cell><cell>High</cell><cell></cell></row><row><cell>Week /</cell><cell>No. of</cell><cell>Cum</cell><cell>No. of</cell><cell>Cum</cell><cell>No. of</cell><cell>Cum</cell><cell>No. of</cell><cell>Cum</cell></row><row><cell>Type of Death</cell><cell>Death</cell><cell>%</cell><cell>Death</cell><cell>%</cell><cell>Death</cell><cell>%</cell><cell>Death</cell><cell>%</cell></row><row><cell>0 -52</cell><cell>8</cell><cell>13.33</cell><cell>12</cell><cell>20.00</cell><cell>5</cell><cell>8.33</cell><cell>4</cell><cell>7.41</cell></row><row><cell>53 -78</cell><cell>21</cell><cell>48.33</cell><cell>21</cell><cell>55.00</cell><cell>23</cell><cell>46.67</cell><cell>19</cell><cell>42.59</cell></row><row><cell>79 -91</cell><cell>11</cell><cell>66.67</cell><cell>6</cell><cell>65.00</cell><cell>12</cell><cell>66.67</cell><cell>15</cell><cell>70.37</cell></row><row><cell>Terminal sacrifice</cell><cell>20</cell><cell>33.33</cell><cell>21</cell><cell>35.00</cell><cell>20</cell><cell>33.33</cell><cell>16</cell><cell>29.63</cell></row><row><cell>Total</cell><cell>60</cell><cell></cell><cell>60</cell><cell></cell><cell>60</cell><cell></cell><cell>54</cell><cell></cell></row><row><cell>Test</cell><cell cols="2">All Dose Groups</cell><cell cols="2">Vehicle Control vs. Low</cell><cell cols="2">Vehicle Control vs. Mid</cell><cell cols="2">Vehicle Control vs. High</cell></row><row><cell>Dose-Response (Likelihood Ratio)</cell><cell cols="2">0.8131</cell><cell cols="2">0.8069</cell><cell cols="2">0.8764</cell><cell cols="2">0.8954</cell></row><row><cell>Homogeneity (Log-Rank)</cell><cell cols="2">0.9749</cell><cell cols="2">0.8051</cell><cell cols="2">0.8748</cell><cell cols="2">0.8937</cell></row><row><cell cols="5">#All Cum. % Cumulative Percentage except for Terminal sacrifice;</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_468"><head>Table 1B : Intercurrent Mortality Rate in Female Rats</head><label>1B</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">Vehicle Control</cell><cell>Low</cell><cell></cell><cell>Mid</cell><cell></cell><cell>High</cell><cell></cell></row><row><cell>Week /</cell><cell>No. of</cell><cell>Cum</cell><cell>No. of</cell><cell>Cum</cell><cell>No. of</cell><cell>Cum</cell><cell>No. of</cell><cell>Cum</cell></row><row><cell>Type of Death</cell><cell>Death</cell><cell>%</cell><cell>Death</cell><cell>%</cell><cell>Death</cell><cell>%</cell><cell>Death</cell><cell>%</cell></row><row><cell>0 -52</cell><cell>3</cell><cell>5.00</cell><cell>1</cell><cell>1.67</cell><cell>4</cell><cell>6.67</cell><cell>1</cell><cell>1.67</cell></row><row><cell>53 -78</cell><cell>11</cell><cell>23.33</cell><cell>11</cell><cell>20.00</cell><cell>15</cell><cell>31.67</cell><cell>19</cell><cell>33.33</cell></row><row><cell>79 -91</cell><cell>14</cell><cell>46.67</cell><cell>18</cell><cell>50.00</cell><cell>10</cell><cell>48.33</cell><cell>16</cell><cell>60.00</cell></row><row><cell>92 -100</cell><cell>12</cell><cell>20.00</cell><cell>9</cell><cell>15.00</cell><cell>7</cell><cell>11.67</cell><cell>7</cell><cell>11.67</cell></row><row><cell>Terminal sacrifice</cell><cell>20</cell><cell>33.33</cell><cell>21</cell><cell>35.00</cell><cell>24</cell><cell>40.00</cell><cell>17</cell><cell>28.33</cell></row><row><cell>Total</cell><cell>60</cell><cell></cell><cell>60</cell><cell></cell><cell>60</cell><cell></cell><cell>60</cell><cell></cell></row><row><cell>Test</cell><cell cols="2">All Dose Groups</cell><cell cols="2">Vehicle Control vs. Low</cell><cell cols="2">Vehicle Control vs. Mid</cell><cell cols="2">Vehicle Control vs. High</cell></row><row><cell>Dose-Response (Likelihood Ratio)</cell><cell cols="2">0.2189</cell><cell cols="2">0.9224</cell><cell cols="2">0.8225</cell><cell cols="2">0.2996</cell></row><row><cell>Homogeneity (Log-Rank)</cell><cell cols="2">0.6033</cell><cell cols="2">0.9211</cell><cell cols="2">0.8200</cell><cell cols="2">0.2899</cell></row></table><note>#All Cum. % Cumulative Percentage except for Terminal sacrifice;</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_469"><head>Table 3A : Tumor Rates and P-Values for Trends and Pairwise Comparisons -Male Rats</head><label>3A</label><figDesc></figDesc><table><row><cell>Organ name</cell><cell>Tumor name</cell><cell>0 mg</cell><cell>3 mg</cell><cell>10 mg</cell><cell>50 mg</cell></row><row><cell></cell><cell></cell><cell>Vehicle (C)</cell><cell>Low (L)</cell><cell>Mid (M)</cell><cell>High (H)</cell></row><row><cell></cell><cell></cell><cell>P -Trend</cell><cell>P -C vs. L</cell><cell>P -C vs. M</cell><cell>P -C vs. H</cell></row><row><cell>Adrenal</cell><cell>Adenoma: Cortical</cell><cell>0/60 (25)</cell><cell>2/60 (25)</cell><cell>6/60 (29)</cell><cell>2/54 (25)</cell></row><row><cell></cell><cell></cell><cell>0.4382</cell><cell>0.2449</cell><cell>0.0184 $</cell><cell>0.2449</cell></row><row><cell></cell><cell>Benign Pheochromocytoma</cell><cell>4/60 (27)</cell><cell>3/60 (25)</cell><cell>6/60 (28)</cell><cell>3/54 (25)</cell></row><row><cell></cell><cell></cell><cell>0.6042</cell><cell>0.4553</cell><cell>0.3886</cell><cell>0.4553</cell></row><row><cell></cell><cell>Malignant Pheochromocytoma</cell><cell>1/60 (26)</cell><cell>2/60 (25)</cell><cell>1/60 (27)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.8235</cell><cell>0.4850</cell><cell>0.2547</cell><cell>0.4800</cell></row><row><cell></cell><cell>Benign Pheochromocytoma/</cell><cell>5/60 (27)</cell><cell>5/60 (26)</cell><cell>7/60 (29)</cell><cell>3/54 (25)</cell></row><row><cell></cell><cell>Malignant Pheochromocytoma</cell><cell>0.7867</cell><cell>0.6110</cell><cell>0.4274</cell><cell>0.6028</cell></row><row><cell>Bone-Tibia</cell><cell>Osteosarcoma</cell><cell>0/60 (25)</cell><cell>0/60 (24)</cell><cell>0/59 (26)</cell><cell>1/54 (25)</cell></row><row><cell></cell><cell></cell><cell>0.2500</cell><cell>NC</cell><cell>NC</cell><cell>0.5000</cell></row><row><cell>Bone Miscellaneous</cell><cell>Osteosarcoma</cell><cell>0/12 (6)</cell><cell>0/3 (2)</cell><cell>0/9 (6)</cell><cell>1/10 (7)</cell></row><row><cell></cell><cell></cell><cell>0.3333</cell><cell>NC</cell><cell>NC</cell><cell>0.5385</cell></row><row><cell>Bone-Tibia/ Bone</cell><cell>Osteosarcoma</cell><cell>0/60 (25)</cell><cell>0/60 (24)</cell><cell>0/59 (26)</cell><cell>2/54 (25)</cell></row><row><cell>Miscellaneous</cell><cell></cell><cell>0.0606</cell><cell>NC</cell><cell>NC</cell><cell>0.2449</cell></row><row><cell>Hemolym. Tissue</cell><cell>Histiocytic Sarcoma</cell><cell>0/60 (25)</cell><cell>1/60 (25)</cell><cell>0/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.5000</cell><cell>0.5000</cell><cell>NC</cell><cell>NC</cell></row><row><cell></cell><cell>Malignant Lymphoma</cell><cell>3/60 (27)</cell><cell>1/60 (24)</cell><cell>5/60 (30)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.9262</cell><cell>0.6489</cell><cell>0.4152</cell><cell>0.8595</cell></row><row><cell>I.S. Interscapular</cell><cell>Fibroma</cell><cell>0/60 (25)</cell><cell>0/60 (24)</cell><cell>1/60 (27)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.2400</cell><cell>NC</cell><cell>0.5192</cell><cell>NC</cell></row><row><cell>I.S. Scapular, Lef</cell><cell>Fibroma</cell><cell>1/60 (26)</cell><cell>0/60 (24)</cell><cell>1/60 (27)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.6184</cell><cell>0.4800</cell><cell>0.2547</cell><cell>0.4800</cell></row><row><cell></cell><cell>Fibrosarcoma</cell><cell>1/60 (26)</cell><cell>0/60 (24)</cell><cell>0/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.7400</cell><cell>0.4800</cell><cell>0.5000</cell><cell>0.4800</cell></row><row><cell></cell><cell>Fibroma/Fibrosarcoma</cell><cell>2/60 (26)</cell><cell>0/60 (24)</cell><cell>1/60 (27)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.8297</cell><cell>0.7347</cell><cell>0.5144</cell><cell>0.7347</cell></row><row><cell></cell><cell>Lipoma</cell><cell>0/60 (25)</cell><cell>0/60 (24)</cell><cell>1/60 (27)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.2400</cell><cell>NC</cell><cell>0.5192</cell><cell>NC</cell></row><row><cell></cell><cell>Trichoepithelioma</cell><cell>0/60 (25)</cell><cell>0/60 (24)</cell><cell>1/60 (27)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.2400</cell><cell>NC</cell><cell>0.5192</cell><cell>NC</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_470"><head>Table 2A : Tumor Rates and P-Values for Trends and Pairwise Comparisons in Male Rats (Continued)</head><label>2A</label><figDesc></figDesc><table><row><cell>Organ name</cell><cell>Tumor name</cell><cell>0 mg</cell><cell>3 mg</cell><cell>10 mg</cell><cell>50 mg</cell></row><row><cell></cell><cell></cell><cell>Vehicle (C)</cell><cell>Low (L)</cell><cell>Mid (M)</cell><cell>High (H)</cell></row><row><cell></cell><cell></cell><cell>P -Trend</cell><cell>P -C vs. L</cell><cell>P -C vs. M</cell><cell>P -C vs. H</cell></row><row><cell>Kidney</cell><cell>Adenoma: Tubular Cell</cell><cell>0/60 (25)</cell><cell>1/60 (24)</cell><cell>0/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.5051</cell><cell>0.4898</cell><cell>NC</cell><cell>NC</cell></row><row><cell></cell><cell>Carcinoma: Transitional Cell</cell><cell>0/60 (25)</cell><cell>1/60 (25)</cell><cell>0/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.5000</cell><cell>0.5000</cell><cell>NC</cell><cell>NC</cell></row><row><cell></cell><cell>Adenoma: Tubular Cell/</cell><cell>1/60 (26)</cell><cell>1/60 (24)</cell><cell>0/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell>Carcinoma: Tubular Cell</cell><cell>0.8083</cell><cell>0.7347</cell><cell>0.5000</cell><cell>0.4800</cell></row><row><cell></cell><cell>Carcinoma: Tubular Cell</cell><cell>1/60 (26)</cell><cell>0/60 (24)</cell><cell>0/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.7400</cell><cell>0.4800</cell><cell>0.5000</cell><cell>0.4800</cell></row><row><cell></cell><cell>Lipoma</cell><cell>0/60 (25)</cell><cell>0/60 (24)</cell><cell>0/60 (26)</cell><cell>1/54 (25)</cell></row><row><cell></cell><cell></cell><cell>0.2500</cell><cell>NC</cell><cell>NC</cell><cell>0.5000</cell></row><row><cell>L. Node Mandibular</cell><cell>Hemangioma</cell><cell>0/60 (25)</cell><cell>0/60 (24)</cell><cell>0/59 (26)</cell><cell>1/52 (25)</cell></row><row><cell></cell><cell></cell><cell>0.2500</cell><cell>NC</cell><cell>NC</cell><cell>0.5000</cell></row><row><cell>L.Node Mesenteric</cell><cell>Hemangioma</cell><cell>0/60 (25)</cell><cell>2/60 (24)</cell><cell>0/60 (26)</cell><cell>1/54 (25)</cell></row><row><cell></cell><cell></cell><cell>0.4433</cell><cell>0.2347</cell><cell>NC</cell><cell>0.5000</cell></row><row><cell></cell><cell>Hemangiosarcoma</cell><cell>0/60 (25)</cell><cell>2/60 (24)</cell><cell>1/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.6876</cell><cell>0.2347</cell><cell>0.5098</cell><cell>NC</cell></row><row><cell></cell><cell>Hemangioma/Hemangiosarcoma</cell><cell>0/60 (25)</cell><cell>4/60 (25)</cell><cell>1/60 (26)</cell><cell>1/54 (25)</cell></row><row><cell></cell><cell></cell><cell>0.6528</cell><cell>0.0549</cell><cell>0.5098</cell><cell>0.5000</cell></row><row><cell></cell><cell>Lipoma</cell><cell>0/60 (25)</cell><cell>1/60 (24)</cell><cell>0/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.5051</cell><cell>0.4898</cell><cell>NC</cell><cell>NC</cell></row><row><cell>Liver</cell><cell>Adenoma: Hepatocellular</cell><cell>0/60 (25)</cell><cell>3/60 (26)</cell><cell>1/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.8062</cell><cell>0.1248</cell><cell>0.5098</cell><cell>NC</cell></row><row><cell></cell><cell>Carcinoma: Hepatocellular</cell><cell>2/60 (26)</cell><cell>2/60 (25)</cell><cell>1/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.9121</cell><cell>0.6801</cell><cell>0.5000</cell><cell>0.7347</cell></row><row><cell></cell><cell>Adenoma: Hepatocellular/</cell><cell>2/60 (26)</cell><cell>5/60 (27)</cell><cell>2/60 (27)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell>Carcinoma: Hepatocellular</cell><cell>0.9689</cell><cell>0.2259</cell><cell>0.3196</cell><cell>0.7347</cell></row><row><cell>Mammary Gland</cell><cell>Adenocarcinoma</cell><cell>1/49 (21)</cell><cell>0/55 (22)</cell><cell>0/51 (23)</cell><cell>0/47 (21)</cell></row><row><cell></cell><cell></cell><cell>0.7586</cell><cell>0.5116</cell><cell>0.5227</cell><cell>0.5000</cell></row><row><cell></cell><cell>Fibroadenoma</cell><cell>1/49 (21)</cell><cell>0/55 (22)</cell><cell>0/51 (23)</cell><cell>2/47 (22)</cell></row><row><cell></cell><cell></cell><cell>0.1530</cell><cell>0.5116</cell><cell>0.5227</cell><cell>0.5179</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_471"><head>Table 2A : Tumor Rates and P-Values for Trends and Pairwise Comparisons in Male Rats (Continued)</head><label>2A</label><figDesc></figDesc><table><row><cell>Organ name</cell><cell>Tumor name</cell><cell>0 mg</cell><cell>3 mg</cell><cell>10 mg</cell><cell>50 mg</cell></row><row><cell></cell><cell></cell><cell>Vehicle (C)</cell><cell>Low (L)</cell><cell>Mid (M)</cell><cell>High (H)</cell></row><row><cell></cell><cell></cell><cell>P -Trend</cell><cell>P -C vs. L</cell><cell>P -C vs. M</cell><cell>P -C vs. H</cell></row><row><cell>Pancreas</cell><cell>Adenoma: Acinar Cell</cell><cell>0/60 (25)</cell><cell>0/60 (24)</cell><cell>3/60 (27)</cell><cell>2/54 (25)</cell></row><row><cell></cell><cell></cell><cell>0.1066</cell><cell>NC</cell><cell>0.1324</cell><cell>0.2449</cell></row><row><cell></cell><cell>Adenoma: Islet Cell</cell><cell>1/60 (26)</cell><cell>1/60 (24)</cell><cell>3/60 (27)</cell><cell>4/54 (26)</cell></row><row><cell></cell><cell></cell><cell>0.0644</cell><cell>0.7347</cell><cell>0.3196</cell><cell>0.1749</cell></row><row><cell></cell><cell>Carcinoma: Islet Cell</cell><cell>0/60 (25)</cell><cell>0/60 (24)</cell><cell>3/60 (27)</cell><cell>2/54 (25)</cell></row><row><cell></cell><cell></cell><cell>0.1066</cell><cell>NC</cell><cell>0.1324</cell><cell>0.2449</cell></row><row><cell></cell><cell>Adenoma: Islet Cell/</cell><cell>1/60 (26)</cell><cell>1/60 (24)</cell><cell>6/60 (28)</cell><cell>5/54 (27)</cell></row><row><cell></cell><cell>Carcinoma: Islet Cell</cell><cell>0.0767</cell><cell>0.7347</cell><cell>0.0620</cell><cell>0.1043</cell></row><row><cell>Parathyroid Gland</cell><cell>Adenoma</cell><cell>0/56 (23)</cell><cell>0/54 (21)</cell><cell>0/58 (25)</cell><cell>1/51 (23)</cell></row><row><cell></cell><cell></cell><cell>0.2500</cell><cell>NC</cell><cell>NC</cell><cell>0.5000</cell></row><row><cell>Pituitary</cell><cell>Adenoma: Pars Distalis</cell><cell>27/60 (39)</cell><cell>16/60 (32)</cell><cell>25/60 (39)</cell><cell>23/54 (36)</cell></row><row><cell></cell><cell></cell><cell>0.4255</cell><cell>0.9201</cell><cell>0.5948</cell><cell>0.5971</cell></row><row><cell></cell><cell>Adenoma: Pars Intermedia</cell><cell>2/60 (26)</cell><cell>0/60 (24)</cell><cell>0/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.9343</cell><cell>0.7347</cell><cell>0.7549</cell><cell>0.7347</cell></row><row><cell></cell><cell>Carcinoma: Pars Distalis</cell><cell>0/60 (25)</cell><cell>0/60 (24)</cell><cell>0/60 (26)</cell><cell>1/54 (25)</cell></row><row><cell></cell><cell></cell><cell>0.2500</cell><cell>NC</cell><cell>NC</cell><cell>0.5000</cell></row><row><cell></cell><cell>Adenoma: Pars Distalis/</cell><cell>29/60 (40)</cell><cell>16/60 (32)</cell><cell>25/60 (39)</cell><cell>24/54 (37)</cell></row><row><cell></cell><cell>Adenoma: Pars Intermedia/</cell><cell>0.4559</cell><cell>0.9568</cell><cell>0.7122</cell><cell>0.6832</cell></row><row><cell></cell><cell>Carcinoma: Pars Distalis</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Skin Miscellaneous</cell><cell>Adenoma: Basal Cell</cell><cell>1/19 (11)</cell><cell>0/21 (9)</cell><cell>0/22 (13)</cell><cell>0/19 (9)</cell></row><row><cell></cell><cell></cell><cell>0.7381</cell><cell>0.4500</cell><cell>0.5417</cell><cell>0.4500</cell></row><row><cell></cell><cell>Adenoma: Sebaceous</cell><cell>0/19 (10)</cell><cell>1/21 (9)</cell><cell>1/22 (13)</cell><cell>0/19 (9)</cell></row><row><cell></cell><cell></cell><cell>0.4902</cell><cell>0.4737</cell><cell>0.5652</cell><cell>NC</cell></row><row><cell></cell><cell>Papilloma: Squamous Cell</cell><cell>0/19 (10)</cell><cell>2/21 (10)</cell><cell>1/22 (13)</cell><cell>1/19 (9)</cell></row><row><cell></cell><cell></cell><cell>0.3912</cell><cell>0.2368</cell><cell>0.5652</cell><cell>0.4737</cell></row><row><cell></cell><cell>Carcinoma: Squamous Cell</cell><cell>2/19 (11)</cell><cell>2/21 (10)</cell><cell>3/22 (14)</cell><cell>0/19 (9)</cell></row><row><cell></cell><cell></cell><cell>0.8865</cell><cell>0.6692</cell><cell>0.6217</cell><cell>0.7105</cell></row><row><cell></cell><cell>Keratoacanthoma</cell><cell>2/19 (11)</cell><cell>1/21 (10)</cell><cell>7/22 (15)</cell><cell>0/19 (9)</cell></row><row><cell></cell><cell></cell><cell>0.9134</cell><cell>0.4624</cell><cell>0.1375</cell><cell>0.7105</cell></row><row><cell></cell><cell>Carcinoma: Squamous Cell/</cell><cell>4/19 (13)</cell><cell>5/21 (12)</cell><cell>9/22 (16)</cell><cell>1/19 (9)</cell></row><row><cell></cell><cell>Papilloma: Squamous Cell/</cell><cell>0.9302</cell><cell>0.4400</cell><cell>0.1597</cell><cell>0.7068</cell></row><row><cell></cell><cell>Keratoacanthoma</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Spleen</cell><cell>Hemangiosarcoma</cell><cell>1/60 (26)</cell><cell>1/60 (24)</cell><cell>1/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.7262</cell><cell>0.7347</cell><cell>NC</cell><cell>0.4800</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_472"><head>Table 2A : Tumor Rates and P-Values for Trends and Pairwise Comparisons in Male Rats (Continued)</head><label>2A</label><figDesc></figDesc><table><row><cell>Organ name</cell><cell>Tumor name</cell><cell>0 mg</cell><cell>3 mg</cell><cell>10 mg</cell><cell>50 mg</cell></row><row><cell></cell><cell></cell><cell>Vehicle (C)</cell><cell>Low (L)</cell><cell>Mid (M)</cell><cell>High (H)</cell></row><row><cell></cell><cell></cell><cell>P -Trend</cell><cell>P -C vs. L</cell><cell>P -C vs. M</cell><cell>P -C vs. H</cell></row><row><cell>Testis</cell><cell>Adenoma: Interstitial Cell</cell><cell>0/60 (25)</cell><cell>0/60 (24)</cell><cell>0/60 (26)</cell><cell>1/53 (25)</cell></row><row><cell></cell><cell></cell><cell>0.2500</cell><cell>NC</cell><cell>NC</cell><cell>0.5000</cell></row><row><cell></cell><cell>Mesothelioma(M)</cell><cell>0/60 (25)</cell><cell>1/60 (24)</cell><cell>0/60 (26)</cell><cell>0/53 (24)</cell></row><row><cell></cell><cell></cell><cell>0.5051</cell><cell>0.4898</cell><cell>NC</cell><cell>NC</cell></row><row><cell>Thymus</cell><cell>Benign Thymoma</cell><cell>0/59 (25)</cell><cell>0/57 (22)</cell><cell>0/59 (25)</cell><cell>1/53 (25)</cell></row><row><cell></cell><cell></cell><cell>0.2577</cell><cell>NC</cell><cell>NC</cell><cell>0.5000</cell></row><row><cell></cell><cell>Malignant Schwannoma</cell><cell>0/59 (25)</cell><cell>0/57 (22)</cell><cell>0/59 (25)</cell><cell>1/53 (25)</cell></row><row><cell></cell><cell></cell><cell>0.2577</cell><cell>NC</cell><cell>NC</cell><cell>0.5000</cell></row><row><cell>Thyroid</cell><cell>Adenoma: C-Cell</cell><cell>8/60 (29)</cell><cell>10/60 (27)</cell><cell>4/60 (28)</cell><cell>6/54 (27)</cell></row><row><cell></cell><cell></cell><cell>0.7449</cell><cell>0.3191</cell><cell>0.8172</cell><cell>0.5604</cell></row><row><cell></cell><cell>Carcinoma: C-Cell</cell><cell>0/60 (25)</cell><cell>0/60 (24)</cell><cell>2/60 (27)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.4242</cell><cell>NC</cell><cell>0.2647</cell><cell>NC</cell></row><row><cell></cell><cell>Adenoma: C-Cell/</cell><cell>8/60 (29)</cell><cell>10/60 (27)</cell><cell>6/60 (29)</cell><cell>6/54 (27)</cell></row><row><cell></cell><cell>Carcinoma: C-Cell</cell><cell>0.7742</cell><cell>0.3191</cell><cell>0.6201</cell><cell>0.5604</cell></row><row><cell></cell><cell>Adenoma: Follicular Cell</cell><cell>6/60 (28)</cell><cell>4/60 (25)</cell><cell>0/60 (26)</cell><cell>0/54 (24)</cell></row><row><cell></cell><cell></cell><cell>0.9996</cell><cell>0.5586</cell><cell>0.9854</cell><cell>0.9815</cell></row><row><cell cols="2">File Name: BLA761062Carcin by Chen-Zhou-Lin_v3.doc</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_473"><head>Table 3B : Tumor Rates and P-Values for Trends and Pairwise Comparisons -Female Rats</head><label>3B</label><figDesc></figDesc><table><row><cell>Organ name</cell><cell>Tumor name</cell><cell>0 mg</cell><cell>3 mg</cell><cell>10 mg</cell><cell>50 mg</cell></row><row><cell></cell><cell></cell><cell>Vehicle (C)</cell><cell>Low (L)</cell><cell>Mid (M)</cell><cell>High (H)</cell></row><row><cell></cell><cell></cell><cell>P -Trend</cell><cell>P -L vs. C</cell><cell>P -M vs. C</cell><cell>P -H vs. C</cell></row><row><cell>Adrenal</cell><cell>Adenoma: Cortical</cell><cell>6/60 (39)</cell><cell>3/60 (38)</cell><cell>1/60 (36)</cell><cell>7/60 (37)</cell></row><row><cell></cell><cell></cell><cell>0.0936</cell><cell>0.7466</cell><cell>0.9331</cell><cell>0.4580</cell></row><row><cell></cell><cell>Carcinoma: Cortical</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.7379</cell><cell>0.4933</cell><cell>0.4865</cell><cell>0.4722</cell></row><row><cell></cell><cell>Adenoma: Cortical/</cell><cell>7/60 (39)</cell><cell>3/60 (38)</cell><cell>1/60 (36)</cell><cell>7/60 (37)</cell></row><row><cell></cell><cell>Carcinoma: Cortical</cell><cell>0.1313</cell><cell>0.8344</cell><cell>0.9635</cell><cell>0.5732</cell></row><row><cell></cell><cell>Benign Pheochromocytoma</cell><cell>2/60 (38)</cell><cell>8/60 (39)</cell><cell>2/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.9884</cell><cell>0.0473</cell><cell>0.6719</cell><cell>0.7250</cell></row><row><cell></cell><cell>Malignant Pheochromocytoma</cell><cell>0/60 (38)</cell><cell>2/60 (38)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.7308</cell><cell>0.2467</cell><cell>NC</cell><cell>NC</cell></row><row><cell></cell><cell>Benign Pheochromocytoma/</cell><cell>2/60 (38)</cell><cell>10/60 (40)</cell><cell>2/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell>Malignant Pheochromocytoma</cell><cell>0.9942</cell><cell>0.0159</cell><cell>0.6719</cell><cell>0.7250</cell></row><row><cell>Cecum</cell><cell>Leiomyoma</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.7379</cell><cell>0.4933</cell><cell>0.4865</cell><cell>0.4722</cell></row><row><cell>Cervix</cell><cell>Benign Schwannoma</cell><cell>0/60 (38)</cell><cell>1/60 (38)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.4795</cell><cell>0.5000</cell><cell>NC</cell><cell>NC</cell></row><row><cell></cell><cell>Malignant Schwannoma</cell><cell>0/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>1/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.2345</cell><cell>NC</cell><cell>NC</cell><cell>0.4722</cell></row><row><cell></cell><cell>Benign Schwannoma/</cell><cell>0/60 (38)</cell><cell>1/60 (38)</cell><cell>0/60 (36)</cell><cell>1/60 (34)</cell></row><row><cell></cell><cell>Malignant Schwannoma</cell><cell>0.2907</cell><cell>0.5000</cell><cell>NC</cell><cell>0.4722</cell></row><row><cell></cell><cell>Hemangioma</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.7379</cell><cell>0.4933</cell><cell>0.4865</cell><cell>0.4722</cell></row><row><cell></cell><cell>Leiomyoma</cell><cell>1/60 (38)</cell><cell>1/60 (37)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.7980</cell><cell>0.7467</cell><cell>0.4865</cell><cell>0.4722</cell></row><row><cell>Fat</cell><cell>Mesothelioma(M)</cell><cell>0/3 (1)</cell><cell>0/3 (2)</cell><cell>1/2 (2)</cell><cell>0/3 (2)</cell></row><row><cell></cell><cell></cell><cell>0.2857</cell><cell>NC</cell><cell>0.6667</cell><cell>NC</cell></row><row><cell>Hemolym. Tissue</cell><cell>Histiocytic Sarcoma</cell><cell>1/60 (38)</cell><cell>1/60 (38)</cell><cell>2/60 (37)</cell><cell>1/60 (35)</cell></row><row><cell></cell><cell></cell><cell>0.4095</cell><cell>NC</cell><cell>0.4899</cell><cell>0.7325</cell></row><row><cell></cell><cell>Malignant Lymphoma</cell><cell>2/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.9327</cell><cell>0.7467</cell><cell>0.7397</cell><cell>0.7250</cell></row><row><cell>I.S. Interscapular</cell><cell>Fibroma</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>1/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.6032</cell><cell>0.4933</cell><cell>0.7397</cell><cell>0.4722</cell></row><row><cell>Kidney</cell><cell>Lipoma</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>3/60 (35)</cell></row><row><cell></cell><cell></cell><cell>0.0429</cell><cell>0.4933</cell><cell>0.4865</cell><cell>0.2766</cell></row><row><cell cols="2">File Name: BLA761062Carcin by Chen-Zhou-Lin_v3.doc</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_474"><head>Table 2B : Tumor Rates and P-Values for Trend and Pairwise Comparisons in Female Rats (Continued)</head><label>2B</label><figDesc></figDesc><table><row><cell>Organ name</cell><cell>Tumor name</cell><cell>0 mg</cell><cell>3 mg</cell><cell>10 mg</cell><cell>50 mg</cell></row><row><cell></cell><cell></cell><cell>Vehicle (C)</cell><cell>Low (L)</cell><cell>Mid (M)</cell><cell>High (H)</cell></row><row><cell></cell><cell></cell><cell>P -Trend</cell><cell>P -L vs. C</cell><cell>P -M vs. C</cell><cell>P -H vs. C</cell></row><row><cell>Liver</cell><cell>Adenoma: Hepatocellular</cell><cell>1/60 (38)</cell><cell>1/60 (37)</cell><cell>0/60 (36)</cell><cell>1/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.5062</cell><cell>0.7467</cell><cell>0.4865</cell><cell>0.7250</cell></row><row><cell></cell><cell>Carcinoma: Hepatocellular</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.7379</cell><cell>0.4933</cell><cell>0.4865</cell><cell>0.4722</cell></row><row><cell></cell><cell>Adenoma: Hepatocellular/</cell><cell>2/60 (38)</cell><cell>1/60 (37)</cell><cell>0/60 (36)</cell><cell>1/60 (34)</cell></row><row><cell></cell><cell>Carcinoma: Hepatocellular</cell><cell>0.5947</cell><cell>0.4899</cell><cell>0.7397</cell><cell>0.4578</cell></row><row><cell>Lymph Node</cell><cell>Sarcoma (Not Otherwise</cell><cell>0/26 (17)</cell><cell>0/25 (16)</cell><cell>1/25 (17)</cell><cell>0/21 (12)</cell></row><row><cell></cell><cell>Specified)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>0.1935</cell><cell>NC</cell><cell>0.5000</cell><cell>NC</cell></row><row><cell>Mammary Gland</cell><cell>Adenocarcinoma</cell><cell>15/60 (42)</cell><cell>15/60 (43)</cell><cell>16/59 (42)</cell><cell>18/60 (43)</cell></row><row><cell></cell><cell></cell><cell>0.2446</cell><cell>0.4418</cell><cell>0.5000</cell><cell>0.3601</cell></row><row><cell></cell><cell>Adenoma</cell><cell>2/60 (38)</cell><cell>1/60 (38)</cell><cell>1/59 (37)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.8616</cell><cell>0.5000</cell><cell>0.4899</cell><cell>0.7250</cell></row><row><cell></cell><cell>Carcinoma: Squamous Cell</cell><cell>0/60 (38)</cell><cell>0/60 (37)</cell><cell>1/59 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.2345</cell><cell>NC</cell><cell>0.4865</cell><cell>NC</cell></row><row><cell></cell><cell>Fibroadenoma</cell><cell>41/60 (50)</cell><cell>44/60 (51)</cell><cell>36/59 (48)</cell><cell>35/60 (47)</cell></row><row><cell></cell><cell></cell><cell>0.8780</cell><cell>0.3763</cell><cell>0.7249</cell><cell>0.7432</cell></row><row><cell></cell><cell>Fibrosarcoma</cell><cell>0/60 (38)</cell><cell>0/60 (37)</cell><cell>1/59 (37)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.2329</cell><cell>NC</cell><cell>0.4933</cell><cell>NC</cell></row><row><cell>Ovary</cell><cell>Adenoma: Sertoliform Tubular</cell><cell>0/60 (38)</cell><cell>0/60 (37)</cell><cell>1/60 (37)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.2329</cell><cell>NC</cell><cell>0.4933</cell><cell>NC</cell></row><row><cell></cell><cell>Carcinoma: Tubulostromal</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.7379</cell><cell>0.4933</cell><cell>0.4865</cell><cell>0.4722</cell></row><row><cell>Pancreas</cell><cell>Adenoma: Acinar Cell</cell><cell>0/60 (38)</cell><cell>0/60 (37)</cell><cell>1/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.2345</cell><cell>NC</cell><cell>0.4865</cell><cell>NC</cell></row><row><cell></cell><cell>Adenoma: Islet Cell</cell><cell>0/60 (38)</cell><cell>0/60 (37)</cell><cell>3/60 (38)</cell><cell>3/60 (35)</cell></row><row><cell></cell><cell></cell><cell>0.0323</cell><cell>NC</cell><cell>0.1200</cell><cell>0.1052</cell></row><row><cell></cell><cell>Carcinoma: Islet Cell</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>1/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.6032</cell><cell>0.4933</cell><cell>0.7397</cell><cell>0.4722</cell></row><row><cell></cell><cell>Adenoma: Islet Cell/</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>4/60 (38)</cell><cell>3/60 (35)</cell></row><row><cell></cell><cell>Carcinoma: Islet Cell</cell><cell>0.0985</cell><cell>0.4933</cell><cell>0.1790</cell><cell>0.2766</cell></row><row><cell>Parathyroid Gland</cell><cell>Adenoma</cell><cell>0/57 (35)</cell><cell>0/55 (34)</cell><cell>1/59 (37)</cell><cell>1/58 (33)</cell></row><row><cell></cell><cell></cell><cell>0.1824</cell><cell>NC</cell><cell>0.5139</cell><cell>0.4853</cell></row><row><cell cols="2">File Name: BLA761062Carcin by Chen-Zhou-Lin_v3.doc</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_475"><head>Table 2B : Tumor Rates and P-Values for Trend and Pairwise Comparisons in Female Rats (Continued)</head><label>2B</label><figDesc></figDesc><table><row><cell>Organ name</cell><cell>Tumor name</cell><cell>0 mg</cell><cell>3 mg</cell><cell>10 mg</cell><cell>50 mg</cell></row><row><cell></cell><cell></cell><cell>Vehicle (C)</cell><cell>Low (L)</cell><cell>Mid (M)</cell><cell>High (H)</cell></row><row><cell></cell><cell></cell><cell>P -Trend</cell><cell>P -L vs. C</cell><cell>P -M vs. C</cell><cell>P -H vs. C</cell></row><row><cell>Pituitary</cell><cell>Adenoma: Pars Distalis</cell><cell>36/60 (51)</cell><cell>32/60 (49)</cell><cell>40/60 (52)</cell><cell>39/59 (51)</cell></row><row><cell></cell><cell></cell><cell>0.1840</cell><cell>0.6375</cell><cell>0.3063</cell><cell>0.3270</cell></row><row><cell></cell><cell>Carcinoma: Pars Distalis</cell><cell>1/60 (38)</cell><cell>3/60 (38)</cell><cell>0/60 (36)</cell><cell>1/59 (34)</cell></row><row><cell></cell><cell></cell><cell>0.6602</cell><cell>0.3074</cell><cell>0.4865</cell><cell>0.7250</cell></row><row><cell></cell><cell>Adenoma: Pars Distalis/</cell><cell>37/60 (51)</cell><cell>35/60 (50)</cell><cell>40/60 (52)</cell><cell>40/59 (51)</cell></row><row><cell></cell><cell>Carcinoma: Pars Distalis</cell><cell>0.2023</cell><cell>0.5253</cell><cell>0.3882</cell><cell>0.3229</cell></row><row><cell></cell><cell>Sarcoma (Not Otherwise</cell><cell>0/60 (38)</cell><cell>1/60 (38)</cell><cell>0/60 (36)</cell><cell>0/59 (34)</cell></row><row><cell></cell><cell>Specified)</cell><cell>0.4795</cell><cell>0.5000</cell><cell>NC</cell><cell>NC</cell></row><row><cell>Skin Miscellaneous</cell><cell>Carcinoma: Squamous Cell</cell><cell>2/29 (22)</cell><cell>2/33 (22)</cell><cell>1/30 (20)</cell><cell>1/34 (23)</cell></row><row><cell></cell><cell></cell><cell>0.7159</cell><cell>NC</cell><cell>0.4634</cell><cell>0.5171</cell></row><row><cell></cell><cell>Keratoacanthoma</cell><cell>0/29 (20)</cell><cell>1/33 (21)</cell><cell>0/30 (20)</cell><cell>1/34 (23)</cell></row><row><cell></cell><cell></cell><cell>0.3431</cell><cell>0.5122</cell><cell>NC</cell><cell>0.5349</cell></row><row><cell></cell><cell>Carcinoma: Squamous Cell/</cell><cell>2/29 (22)</cell><cell>3/33 (22)</cell><cell>1/30 (20)</cell><cell>2/34 (24)</cell></row><row><cell></cell><cell>Keratoacanthoma</cell><cell>0.5917</cell><cell>0.5000</cell><cell>0.4634</cell><cell>0.3380</cell></row><row><cell>Spleen</cell><cell>Hemangioma</cell><cell>0/59 (37)</cell><cell>0/60 (37)</cell><cell>1/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.2361</cell><cell>NC</cell><cell>0.4932</cell><cell>NC</cell></row><row><cell>Stomach</cell><cell>Leiomyosarcoma</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.7379</cell><cell>0.4933</cell><cell>0.4865</cell><cell>0.4722</cell></row><row><cell>Thymus</cell><cell>Benign Thymoma</cell><cell>1/58 (37)</cell><cell>2/57 (36)</cell><cell>0/59 (35)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.8822</cell><cell>0.4896</cell><cell>0.4861</cell><cell>0.4789</cell></row><row><cell></cell><cell>Malignant Thymoma</cell><cell>0/58 (37)</cell><cell>1/57 (36)</cell><cell>0/59 (35)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.4859</cell><cell>0.4932</cell><cell>NC</cell><cell>NC</cell></row><row><cell></cell><cell>Benign Thymoma/</cell><cell>1/58 (37)</cell><cell>3/57 (37)</cell><cell>0/59 (35)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell>Malignant Thymoma</cell><cell>0.9351</cell><cell>0.3073</cell><cell>0.4861</cell><cell>0.4789</cell></row><row><cell cols="2">File Name: BLA761062Carcin by Chen-Zhou-Lin_v3.doc</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_476"><head>Table 2B : Tumor Rates and P-Values for Trend and Pairwise Comparisons in Female Rats (Continued)</head><label>2B</label><figDesc></figDesc><table><row><cell cols="4">BLA 761062  Romosozumab (AMG-785)  Amgen Inc.  Carcinogenicity Study</cell><cell cols="2">Page 17 of 18</cell></row><row><cell>Organ name</cell><cell>Tumor name</cell><cell>0 mg</cell><cell>3 mg</cell><cell>10 mg</cell><cell>50 mg</cell></row><row><cell></cell><cell></cell><cell>Vehicle (C)</cell><cell>Low (L)</cell><cell>Mid (M)</cell><cell>High (H)</cell></row><row><cell></cell><cell></cell><cell>P -Trend</cell><cell>P -L vs. C</cell><cell>P -M vs. C</cell><cell>P -H vs. C</cell></row><row><cell>Thyroid</cell><cell>Adenoma: C-Cell</cell><cell>5/60 (39)</cell><cell>11/60 (40)</cell><cell>8/60 (38)</cell><cell>8/60 (37)</cell></row><row><cell></cell><cell></cell><cell>0.3958</cell><cell>0.0890</cell><cell>0.2552</cell><cell>0.2380</cell></row><row><cell></cell><cell>Carcinoma: C-Cell</cell><cell>1/60 (38)</cell><cell>1/60 (37)</cell><cell>1/60 (37)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.7135</cell><cell>0.7467</cell><cell>0.7467</cell><cell>0.4722</cell></row><row><cell></cell><cell>Adenoma: C-Cell/</cell><cell>6/60 (39)</cell><cell>12/60 (40)</cell><cell>9/60 (39)</cell><cell>8/60 (37)</cell></row><row><cell></cell><cell>Carcinoma: C-Cell</cell><cell>0.5165</cell><cell>0.0998</cell><cell>0.2834</cell><cell>0.3428</cell></row><row><cell></cell><cell>Adenoma: Follicular Cell</cell><cell>0/60 (38)</cell><cell>2/60 (38)</cell><cell>1/60 (36)</cell><cell>2/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.1701</cell><cell>0.2467</cell><cell>0.4865</cell><cell>0.2195</cell></row><row><cell></cell><cell>Carcinoma: Follicular Cell</cell><cell>0/60 (38)</cell><cell>0/60 (37)</cell><cell>1/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.2345</cell><cell>NC</cell><cell>0.4865</cell><cell>NC</cell></row><row><cell></cell><cell>Adenoma: Follicular Cell/</cell><cell>0/60 (38)</cell><cell>2/60 (38)</cell><cell>2/60 (36)</cell><cell>2/60 (34)</cell></row><row><cell></cell><cell>Carcinoma: Follicular Cel</cell><cell>0.1873</cell><cell>0.2467</cell><cell>0.2332</cell><cell>0.2195</cell></row><row><cell></cell><cell>Neuroendocrine Tumor</cell><cell>0/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>1/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.2345</cell><cell>NC</cell><cell>NC</cell><cell>0.4722</cell></row><row><cell>Tooth</cell><cell>Odontoma</cell><cell>4/60 (39)</cell><cell>6/60 (40)</cell><cell>6/60 (38)</cell><cell>3/60 (36)</cell></row><row><cell></cell><cell></cell><cell>0.7437</cell><cell>0.3850</cell><cell>0.3514</cell><cell>0.4544</cell></row><row><cell>Uterus</cell><cell>Adenocarcinoma: Endometrial</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>1/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.6032</cell><cell>0.4933</cell><cell>0.7397</cell><cell>0.4722</cell></row><row><cell></cell><cell>Polyp: Endometrial Stromal</cell><cell>3/60 (39)</cell><cell>4/60 (39)</cell><cell>4/60 (37)</cell><cell>5/60 (36)</cell></row><row><cell></cell><cell></cell><cell>0.2132</cell><cell>0.5000</cell><cell>0.4700</cell><cell>0.3109</cell></row><row><cell></cell><cell>Sarcoma: Endometrial Stromal</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>1/60 (37)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.6050</cell><cell>0.4933</cell><cell>0.7467</cell><cell>0.4722</cell></row><row><cell></cell><cell>Adenocarcinoma: Endometrial/</cell><cell>4/60 (39)</cell><cell>4/60 (39)</cell><cell>4/60 (37)</cell><cell>5/60 (36)</cell></row><row><cell></cell><cell>Polyp: Endometrial Stromal/</cell><cell>0.2826</cell><cell>NC</cell><cell>0.6141</cell><cell>0.4480</cell></row><row><cell></cell><cell>Sarcoma: Endometrial Stromal</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Hemangioma</cell><cell>1/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.7379</cell><cell>0.4933</cell><cell>0.4865</cell><cell>0.4722</cell></row><row><cell>Vagina</cell><cell>Benign Schwannoma</cell><cell>0/60 (38)</cell><cell>1/60 (38)</cell><cell>0/60 (36)</cell><cell>0/60 (34)</cell></row><row><cell></cell><cell></cell><cell>0.4795</cell><cell>0.5000</cell><cell>NC</cell><cell>NC</cell></row><row><cell></cell><cell>Malignant Schwannoma</cell><cell>0/60 (38)</cell><cell>0/60 (37)</cell><cell>0/60 (36)</cell><cell>1/60 (35)</cell></row><row><cell></cell><cell></cell><cell>0.2397</cell><cell>NC</cell><cell>NC</cell><cell>0.4795</cell></row><row><cell></cell><cell>Benign Schwannoma/</cell><cell>0/60 (38)</cell><cell>1/60 (38)</cell><cell>0/60 (36)</cell><cell>1/60 (35)</cell></row><row><cell></cell><cell>Malignant Schwannoma</cell><cell>0.2968</cell><cell>0.5000</cell><cell>NC</cell><cell>0.4795</cell></row><row><cell cols="2">File Name: BLA761062Carcin by Chen-Zhou-Lin_v3.doc</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_477"><head>Table 1 . Pharmacologic Therapies for Postmenopausal Osteoporosis (Source: Table 1 of module 2.5 Clinical overview) The Clinical Development Program</head><label>1</label><figDesc>BLA contained 9 Phase 1 studies, 2 Phase 2 sutdies, and 4 Phase 3 studies. Studies are listed below. Phase 1 (Except Study 20090153 and 201101253, more details about other Phase 1 Studies can be found in Section 4.4):</figDesc><table><row><cell>The Reference ID: 4076576</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_478"><head>Table 2 . Subject Incidence Rates of New Vertebral Fracture Through Month 12 and Through Month 24 (Primary Efficacy Analysis Set, LOCF Imputation) (20070337 24- Month Primary Analysis Period)</head><label>2</label><figDesc>LOCF = last observation carried forward; RRR = relative risk reduction; N = Number of subjects randomized; N1 = Number of subjects in the primary analysis set for vertebral fractures.</figDesc><table><row><cell>Source: Table 10-1 of 02-csr-2007-0337-rpt-body.pdf</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_479"><head>Table 3 . Lumbar Spine Density Percent Change from Baseline at Month 12 and Month 24 (ANCOVA Model) (Primary Efficacy Analysis Set for BMD, LOCF)(20070337 24-Month Primary Anslyis Period)</head><label>3</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_480"><head>Table 4 . DXA Lumbar Spine BMD Percent Change From Baseline to Month 12 -Linear Mixed Effect</head><label>4</label><figDesc></figDesc><table /><note>Model Showing Each of Romosozumab Groups (Primary Efficacy Subset) (20060326 12-Month Primary Analysis) (Source: Table 10-2 of 02-csr-20060326-rpt- body.pdf)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_481"><head>Table 5 . Impact of Body Weight and Renal Function on AUC for 210 mg QM Dosing Based on Population PK Predictions for Patients in Study 20070337 (n=434) or Simulations* days</head><label>5</label><figDesc>. These conditions were included in the accuracy and precision experiments, from which results the acceptance criteria were determined. Robustness of the procedure to run 3 plates simultaneously was tested during validation and study.Coated Plate StabilityPlate coating stability established at 2 to 8C for up to 72 hours.</figDesc><table><row><cell></cell><cell>Plate blocking stability established at 22 to 28C from 1 to 3</cell></row><row><cell></cell><cell>hour.</cell></row><row><cell>Freeze-Thaw Stability</cell><cell>5 cycles</cell></row><row><cell>Bench-Top Stability</cell><cell>Stability was demonstrated as follows:</cell></row><row><cell></cell><cell>1. At 2 to 8 C for up to 27 hour in 100% serum</cell></row><row><cell></cell><cell>2. At ambient room temperature (ART) for 6 hours in 100%</cell></row><row><cell></cell><cell>serum</cell></row><row><cell></cell><cell>3. At ART for 6 hours after pretreatment</cell></row><row><cell>Long Term Storage Stability</cell><cell>Long-term stability was demonstrated up to 539 days</cell></row><row><cell></cell><cell>at -60 to -80C (ongoing) and up to 190 days at -15t</cell></row><row><cell></cell><cell>o -25C.</cell></row><row><cell>Incurred Sample Reanalysis</cell><cell>Reproducibility of the method was demonstrated using 76</cell></row><row><cell></cell><cell>samples (complete profiles from 4 patients).</cell></row><row><cell>Parallelism</cell><cell>Tested in 4 pooled samples. Parallelism was demonstrated in all</cell></row><row><cell></cell><cell>pooled samples.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_482"><head>Table 4</head><label>4</label><figDesc></figDesc><table /><note>.1.2.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_483"><head>Table 4 .1.2. Bioanalytical Methods and Validation Reports for Quantification of Serum Romosuzumab (Source: Table 9 of Module 2.7.1) 4.1.2 Bone Turnover Marker (Serum CTX-I and P1NP) Assays On</head><label>4</label><figDesc>October 21, 2016, the Applicant submitted bioanalytical methods for all the BTM markers tested in the clinical development program (SN 0009), in response to FDA 06 October 2016 Information Request. The Applicant evaluated multiple bone turnover markers, including CTX-I, P1NP, Bone Specific Alkaline Phosphatase (BSAP), Osteocalcin, and Tartrate-Resistant Acid Phosphaotase-5b (TRACP-5b). Since CTX-I and P1NP are the more common ones than the others and language related to changes in CTX-I and P1NP from Study 20070337 and Study 20060326 were proposed in the labeling, our review focuses on the serum CTX-I and P1NP assays for Study 20060326 and 20070337. Validation reports for the four assays (Table 4.1.3) were requested in an Information Request (IR) sent to the applicant on 03/10/17.</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_484"><head>Table 4 .1.3. Bioanalytical Methods and Supported Contract Laboratories of CTX-I and P1NPs in Human Serum for Study 20070337 and 20060326 (Source: Table 2 of Response to FDA 06 October 2016 Information Request)</head><label>4</label><figDesc>Assays for Study 20060326 Validation reports for assays measuring CTX-I and P1NP in Human Serum for Study 20060326 are adequate. Determination of serum CTX-I concentration in samples from Study 20060326 used a kit called "Serum CrossLaps ELISA"</figDesc><table><row><cell>Serum</cell><cell>Method</cell><cell>Supported Contract Lab</cell><cell>Amgen Study</cell></row><row><cell>Marker</cell><cell></cell><cell></cell><cell>No.</cell></row><row><cell>CTX-1</cell><cell></cell><cell></cell><cell>20060326</cell></row><row><cell></cell><cell></cell><cell></cell><cell>20070337</cell></row><row><cell>P1NP</cell><cell></cell><cell></cell><cell>20060326</cell></row><row><cell></cell><cell></cell><cell></cell><cell>20070337</cell></row><row><cell>4.1.2.1</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_485"><head>Table 4 .1.4 Validation Summary Table for Serum CTX-1 Assay for Study 20060326 (Source: .pdf submitted on 03/15/17 in response to IR sent on 03/10/17)</head><label>4</label><figDesc>Curve FitThe calibration curve is obtained by plotting the mean absorbances of the 6 standards in ordinate against the corresponding CTX-I concentrations in abscissa. The fitting of the calibration curve is performed by the "MultiCalc" software using the "4 PL" mathematical model which calculates and fits a curve through all the experimental points.</figDesc><table><row><cell>Standard Assay Range (nominal)</cell><cell>0.05 to 2.45 ng/mL</cell></row><row><cell>LLOQ (nominal)</cell><cell>0.052 ng/mL</cell></row><row><cell>ULOQ (nominal)</cell><cell>2.45 ng/mL</cell></row><row><cell>% of recovery</cell><cell>%</cell></row><row><cell>With-assay precision</cell><cell>&lt; 6 %</cell></row><row><cell>Between-assay precision</cell><cell>&lt; 10 %</cell></row><row><cell>Stability</cell><cell>For a conservation of 1 week the serum will be stored at -20C.</cell></row><row><cell>Reference ID: 4076576</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_486"><head>Table 4 .1.5 Validation Summary Table for Serum P1NP Assay for Study 20060326</head><label>4</label><figDesc></figDesc><table><row><cell>(Source:</cell><cell>.pdf submitted on 03/15/17 in response to IR sent on 03/10/17)</cell></row><row><cell>Standard Curve Fit</cell><cell>The fitting of the calibration curve is performed by Riasmart TM</cell></row><row><cell></cell><cell>software using the "Logistic Four Parameters" mathematical</cell></row><row><cell></cell><cell>model.</cell></row><row><cell>Assay Range (nominal)</cell><cell>2.8 to 190 ng/mL</cell></row><row><cell>LLOQ (nominal)</cell><cell>2.8 ng/mL</cell></row><row><cell>ULOQ (nominal)</cell><cell>190 ng/mL</cell></row><row><cell>% of recovery</cell><cell>%</cell></row><row><cell>With-assay precision</cell><cell>&lt; 8 %</cell></row><row><cell>Between-assay precision</cell><cell>&lt; 7 %</cell></row><row><cell>Stability</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_487"><head>Table 4 .1.6 Validation Summary Table for Serum CTX-1 Assay for Study 20070337 (Source: .pdf submitted on 03/15/17 in response to IR sent on 03/10/17)</head><label>4</label><figDesc></figDesc><table><row><cell>Assay Range (nominal)</cell><cell>0.043 to 6 ng/mL</cell></row><row><cell>LLOQ (nominal)</cell><cell>0.043 ng/mL</cell></row><row><cell>ULOQ (nominal)</cell><cell>6 ng/mL</cell></row><row><cell>Intra-&amp; inter-assay accuracy for QCs</cell><cell>Within  10%</cell></row><row><cell>Intra-&amp; inter-assay precision for QCs</cell><cell>Within  10%</cell></row><row><cell cols="2">Intra-&amp; inter-assay precision for samples Within  10%</cell></row><row><cell>Hook effect</cell><cell>Not observed</cell></row><row><cell>Dilutional linearity</cell><cell>Linearity validation was considered acceptable up to a</cell></row><row><cell></cell><cell>dilution of 4X.</cell></row><row><cell>Stability</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_488"><head>Table 4 .1.7 Validation Summary Table for Serum P1NP Assay for Study 20070337 (Source: PINP Method Validation Report CCLS_24March2017 submitted on 03/24/17 in response to IR dated 03/10/17)</head><label>4</label><figDesc></figDesc><table><row><cell>Assay Range (nominal)</cell><cell>4.9 to 250 ng/mL</cell></row><row><cell>LLOQ (nominal)</cell><cell>4.9 ng/mL</cell></row><row><cell>ULOQ (nominal)</cell><cell>250 ng/mL, can measure up to 5000 ng/mL with 1:20 dilution</cell></row><row><cell>Accuracy/Recovery</cell><cell>Acceptable</cell></row><row><cell>With-assay precision</cell><cell>&lt; 4 %</cell></row><row><cell>Between-assay precision</cell><cell>&lt; 12 %</cell></row><row><cell>Stability</cell><cell>A maximum of 3 freeze and thaw cycles is acceptable.</cell></row><row><cell></cell><cell>Ambient (18-26C): 4 days</cell></row><row><cell></cell><cell>Refridgerated (2-8C): 7 days</cell></row><row><cell></cell><cell>-20 C Frozen: 7 years (kit manufacturer documentation)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_489"><head>Table 4</head><label>4</label><figDesc>.1.7).</figDesc><table><row><cell>Reference ID: 4076576</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_490"><head>Table 4 .1.8. Accuracy Summary for Serum P1NP Assay for Study 20070337 (Source: Table 5.6.1 in PINP Method Validation Report CCLS_24March2017 submitted on 03/24/17 in response to IR sent on 03/10/17)</head><label>4</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_491"><head>Table 4 .1.4. Summary of Assay Parameters: Binding Antibody Assay for Romosozuamb (Source: Table 2 of the Applicant's Integrated Immunogenicity Report)</head><label>4</label><figDesc></figDesc><table><row><cell>Assay Sensitivity</cell><cell cols="2">Drug Tolerance</cell></row><row><cell>(ng/mL)</cell><cell>Anti-romoaozumab Ab</cell><cell>Romosozumab</cell></row><row><cell></cell><cell>Concentration (mcg/mL)</cell><cell>Concentration (mcg/mL)</cell></row><row><cell>5</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_492"><head>Table 4 .1.5. Summary of Assay Parameters: Neutralizing Antibody Assay for Romosozuamb (Source: Table 3 of the Applicant's Integrated Immunogenicity Report)</head><label>4</label><figDesc></figDesc><table><row><cell>Assay Sensitivity</cell><cell cols="2">Drug Tolerance</cell></row><row><cell>(mcg/mL)</cell><cell>Anti-romoaozumab Ab</cell><cell>Romosozumab</cell></row><row><cell></cell><cell>Concentration (mcg/mL)</cell><cell>Concentration (mcg/mL)</cell></row><row><cell>0.75</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_493"><head>Table 4 .2.1. Romosozuamb Drug Substance and Drug Product used in the different stage of clinical development. (Source: Reviewer's filing memo for BLA 761062) Romosozumab Drug Substance and Drug Product Drug substance</head><label>4</label><figDesc></figDesc><table><row><cell></cell><cell>Process 1</cell><cell></cell><cell>Process 2</cell><cell></cell><cell cols="2">Process 2</cell></row><row><cell></cell><cell>ATO</cell><cell></cell><cell>ATO</cell><cell></cell><cell></cell><cell>ARI</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>#5</cell><cell></cell></row><row><cell>Drug product</cell><cell>#1</cell><cell>#2</cell><cell>#3</cell><cell>#4</cell><cell>(To be</cell><cell>#6</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>marketed)</cell><cell></cell></row><row><cell>Formulation Strength</cell><cell cols="2">70 mg/mL 70 mg/mL</cell><cell>90 mg/mL</cell><cell>120 mg/mL</cell><cell></cell><cell>90 mg/mL</cell></row><row><cell>Presentation</cell><cell>Glass vial</cell><cell>Glass PFS</cell><cell>PFS</cell><cell>Glass PFS</cell><cell>PFS</cell><cell>Autoinjector (AI)</cell></row><row><cell>Phase 1</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>PK/PD</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>studies</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_494"><head>Table 4 .</head><label>4</label><figDesc>2.1 contains study design information for Study 20120277 and Study 20150197.</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_495"><head>Table 4 .2.1. Summary of Study Design Infor for Comparative PK Studies 20120277 and 20150197 Study 20120277 Study 20150197</head><label>4</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_496"><head>Table 4 .2.2. Pharmacokinetic Parameters for BioequivalenceTesting and Statistical Summary. (Source of Data: Table 11-2 in CSR Study 20120277 and Table 11-2 in CSR Study 20150197) Study</head><label>4</label><figDesc></figDesc><table><row><cell></cell><cell>Comparison</cell><cell>Reference</cell><cell>Test</cell><cell>Geometric Mean</cell><cell>90% CI</cell></row><row><cell>number</cell><cell></cell><cell></cell><cell></cell><cell>Ratio of</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Test/Reference</cell><cell></cell></row><row><cell>20120277</cell><cell>N</cell><cell>82</cell><cell>84</cell><cell></cell><cell>--</cell></row><row><cell></cell><cell>C max (mcg/mL)</cell><cell>22753.645</cell><cell>22568.183</cell><cell>0.992</cell><cell>(0.909 to 1.082)</cell></row><row><cell></cell><cell>AUC last (mg*d/L)</cell><cell>405790.848</cell><cell>363935.655</cell><cell>0.897</cell><cell>(0.814 to 0.989)</cell></row><row><cell></cell><cell>AUC inf (mg*d/L)</cell><cell>407765.090</cell><cell>363935.405</cell><cell>0.896</cell><cell>(0.813 to 0.987)</cell></row><row><cell>20150197</cell><cell>N</cell><cell>96</cell><cell>90</cell><cell>--</cell><cell>--</cell></row><row><cell></cell><cell>C max (ng/mL)</cell><cell>23398.97</cell><cell>21442.74</cell><cell>0.92</cell><cell>(0.86 to 0.98)</cell></row><row><cell></cell><cell>AUC last (ng*d/L)</cell><cell>399643.23</cell><cell>364019.92</cell><cell>0.91</cell><cell>(0.84 to 0.99)</cell></row><row><cell></cell><cell>AUC inf (ng*d/L)</cell><cell>406243.05</cell><cell>367291.55</cell><cell>0.90</cell><cell>(0.83 to 0.98)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_498"><head>Table 4 .</head><label>4</label><figDesc></figDesc><table /><note>3.1. Mean (SD) Noncompartmental Parameter Estimates Following a Single SC Administration of Romosozumab to Healthy Postmenopausal Women and Healthy Men (Source:Table 10-1 of CSR Study 20060220)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_499"><head>Table 4 .3.2. Mean (SD) Noncompartmental Parameter Estimates Following a Single IV Administration of Romosozumab to Healthy Postmenopausal Women and Healthy Men (Source:</head><label>4</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_500"><head>Table 4 .3.3. Noncompartmental Parameter Estimates Following Subcutaneous Administration of Romosozumab to Healthy Postmenopausal Japanese and Non-Japanese Women (3 mg/kg only</head><label>4</label><figDesc></figDesc><table /><note>) (Source: Table 10-3 of CSR Study 20090378)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_501"><head>Table 4 .3.4. Subjects Randomization Scheme for Study 20060221 (Source: Section 2.2.1.2, Summary of Clinial Pharmacology Studies)</head><label>4</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_502"><head>Table 4 .3.5. Mean (SD) Noncompartmental Parameter Estimates Following SC Administration of 6 Q2W Doses of AMG 785 to Healthy Men and Postmenopausal Women with Low Bone Mass (Source: Table 10-1, CSR of Study 20060221)</head><label>4</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_503"><head>Table 4 .3.6. Mean (SD) Noncompartmental Parameter Estimates Following SC Administration of 3 Q4W Doses of AMG 785 to Healthy Men and Postmenopausal Women with Low Bone Mass (Source: Table 10-2, CSR of Study 20060221) 4.3.4. Study 20110227 (The Dedicated Renal Impairment Study)</head><label>4</label><figDesc>Study 20110227 was an open-label, single-dose, parallel group Phase 1 Study of romosozumab in healthy subjects and subjects with Stage 4 renal impairment (RI) or Stage 5 renal impairment (ESRD) requiring hemodialysis. A total of 24 subjects (8 subjects with stage 4 RI, 8 subjects with ESRD requiring hemodialysis, and 8 healthy subjects) were enrolled in parallel into 1 of 3 treatment groups and each received a single 210 mg SC romosozumab dose.</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_504"><head>Table 4</head><label>4</label><figDesc>.2.8) and 0.895 (0.638, 1.256) (Table 4.3.9), respectively.</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_505"><head>Table 4 .3.7. Descriptive Statistics of Romosozumab PK Parameter Estimates After SC Administration of 210 mg Romosozumab in Subjects with Stage 4 RI, Subjects with ESRD Requiring Hemodialysis, and Healthy Subjects. The data are presented as Mean (SD), [Min-Max]. (Source: Table 11-1 of CSR Study 20110227)</head><label>4</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_506"><head>Table 4 .3.8. Least Squares Geometric Means of Pharmacokinetic Parameter Estimates of Romosozumab After Subcutaneous Administration of Romosozumab -Comparison of Group 1 With Group</head><label>4</label><figDesc></figDesc><table /><note>3 (Source: Table 11-2 of CSR Study 20060227)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_507"><head>Table 4 .3.9. Least Squares Geometric Means of Pharmacokinetic Parameter Estimates of Romosozumab After Subcutaneous Administration of Romosozumab -Comparison of Group 2 With Group 3 (Source: Table 11-3 of CSR Study 20110227)</head><label>4</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_508"><head>Table 4 .3.10. Summary Statistics for Noncompartmental PK Estimates Following a Single SC Administration of 3 mg/kg Romosozumab to Postmenopausal Women with Low Bone Mass. Group B: Alendronate switch to Romosozuamb; Group C: Treatment-nave Subjects (Source: Table 10-3 of CSR Study 20060223)</head><label>4</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_509"><head>Table 4 .3.11. Descriptive Statistics of Peak and Trough Serum Romosozumab Concentration-Time Data (ng/mL) After Subcutaneous Administrations of Romosozumab 210 mg QM to Postmenopausal Women with Osteoporosis (Source: Table 11-3, CSR of Study 20070337)</head><label>4</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_510"><head>Table 4 Table 4 .4.1. Summary of Trough Concentrations at Steady-state After Administration of Romosozumab 210 mg QM SC to Postmenopausal Women With Low BMD or Osteoporosis (Studies 20060326, 20101291, and 20070337) Stratified by Binding Antibody Status (Source: Table 18 of Summary of Clinical Pharmacology Studies)</head><label>44</label><figDesc>.4.2).</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_511"><head>Table 4 .4.2. Summary of Trough Concentrations at Steady-state After Multiple QM SC Administrations of 210 mg Romosozumab to Postmenopausal Women With Low BMD or Osteoporosis (Studies 20060326, 20101291 , and 20070337) Stratified by Neutralizing Antibody Status (Source: Table 19 of Summary of Clinical Pharmacology Studies)</head><label>4</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_512"><head>Table 4</head><label>4</label><figDesc>.4.3).</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_513"><head>Table 4 .4.3 Summary of Year 4 Trough Concentrations at Steady-state After Multiple QM SC Administrations of 210 mg Romosozumab to Postmenopausal Women With Low BMD or Osteoporosis (Study 20060326) Stratified by Varying Antibody Statuses Across Year 1, 2, and 4 (Source: Table 20 of Summary of Clinical Pharmacology Studies) 4</head><label>4</label><figDesc>.4.2.2 Impact of ADA on PK based on signal-to-noise (S/N) ratio</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_515"><head>Table 4 .4.4. Lumbar Spine Bone Mineral Density Percent Change from Baseline by Visit by Maximum Observed Immunoassay Signal-to-Noise Through Month 15 (Descriptive Statistics, Observed Data) (Romosozumab Arm in Primary Analysis Set for BMD (20070337 M24 Analysis) (Source of Data: Table 4 of Applicant's Supplemental Integrated Immunogenicity Report submitted on 2/15/17)</head><label>4</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">Romosozumab 210mg QM</cell><cell></cell></row><row><cell></cell><cell>ADA Negative</cell><cell cols="2">ADA Positive</cell></row><row><cell>Lumbar spine BMD</cell><cell></cell><cell cols="2">S/N Ratio  10 S/N Ratio &gt; 10</cell></row><row><cell>at Month 12</cell><cell></cell><cell></cell><cell></cell></row><row><cell>N</cell><cell>2550</cell><cell>553</cell><cell>67</cell></row><row><cell>n</cell><cell>2525</cell><cell>549</cell><cell>67</cell></row><row><cell>MeanSD</cell><cell>13.16.0</cell><cell>13.15.8</cell><cell>13.16.9</cell></row><row><cell>Median</cell><cell>12.9</cell><cell>12.9</cell><cell>13.0</cell></row><row><cell>Q1, Q3</cell><cell>8.9, 16.9</cell><cell>9.2, 16.5</cell><cell>8.4, 18.1</cell></row><row><cell>Min, Max</cell><cell>-6.1, 44.9</cell><cell>-3.2, 32.9</cell><cell>-1.5, 29.7</cell></row><row><cell>Lumbar spine BMD</cell><cell></cell><cell></cell><cell></cell></row><row><cell>at Month 24</cell><cell></cell><cell></cell><cell></cell></row><row><cell>n</cell><cell>2282</cell><cell>509</cell><cell>64</cell></row><row><cell>MeanSD</cell><cell>5.54.6</cell><cell>5.74.6</cell><cell>5.65.3</cell></row><row><cell>Median</cell><cell>5.2</cell><cell>5.0</cell><cell>5.7</cell></row><row><cell>Q1, Q3</cell><cell>2.5, 8.2</cell><cell>2.</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_516"><head>Table 4 .4.5 Subject Incidence of Treatment-emergent Injection Site Reaction, Hypersensitivity, and Autoimmune Disorders in the 12-Month Double-blind Period by Maximum Observed Immunoassay Signal-to-Noise Antibody Status Through Month 15 (Safety Analysis Set) (20070337 M24 Analysis) (Source: Table 3 of Supplemental Integrated</head><label>4</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_517"><head>Table 2 Parameter Estimates for the Final Covariate Model</head><label>2</label><figDesc></figDesc><table><row><cell>Source: Applicant's population PK report, Table 12-14, Page 74.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_518"><head>Table 4 Descriptive Statistics of Romosozumab Pharmacokinetic Parameter Estimates After Subcutaneous Administration of 210 mg Romosozumab in Subjects With Stage 4 RI, Subjects With ESRD Requiring Hemodialysis, and Healthy Subjects</head><label>4</label><figDesc></figDesc><table><row><cell>Source: Applicant's dedicated renal impairment study (20110227) report, Table 11-1, Page 51.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_519"><head>Table 5 Impact</head><label>5</label><figDesc></figDesc><table /><note>of body weight and renal function based on Phase 3 study (n=434) or simulation from Reviewer's population PK model with a dose of 210 mg QM</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_520"><head>Table 12</head><label>12</label><figDesc></figDesc><table /><note>-1, Page 39.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_521"><head>Table 7 Summary Statistics of Race, Body Weight, Age, Years since Menopause, BMD Lumbar Spine and Total Hip, P1NP and sCTX-I by Clinical Study</head><label>7</label><figDesc></figDesc><table /><note>Source: Applicant's dose-BMD analysis report, Table 12-6, Page 45.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_522"><head>Table 9 Summary of Categorical Covariates by Study</head><label>9</label><figDesc></figDesc><table><row><cell>Source: Applicant's exposure-BMD analysis report, Table 1, Page 42</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_523"><head>Table 10 Summary of Continuous Covariates by Study</head><label>10</label><figDesc></figDesc><table><row><cell>.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_524"><head>Table 11 Parameter Estimates from Full Covariate Population PK-PD Model</head><label>11</label><figDesc></figDesc><table /><note>Source: Applicant's exposure-BMD analysis report, Table 4, Page 45</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_525"><head>Table 12 Summary of BMD %CFB at Lumbar Spine across body weight and renal functions based on Phase 3 study (n=3157)</head><label>12</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_526"><head>Table 13 Summary of New Vertebral Fracture rate across body weight and renal functions based on Phase 3 study (n=3326)</head><label>13</label><figDesc></figDesc><table><row><cell>Category/Quantile</cell><cell>New Vertebral fracture,</cell></row><row><cell></cell><cell>12 mon; n/N (%)</cell></row></table><note></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4416253</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4416253 NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab}</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4416253 (b)<ref type="bibr" target="#b86">(4)</ref> NDA/BLA Multi-disciplinary Review and Evaluation {BLA 761062} {Evenity, romosozumab}</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4327225</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4124009</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4124009 (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b)(4)</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1">Excluded pathologic fractures and fractures of the skull, face, mandible, spine, fingers, and toes; also excluded the fractures associated with severe trauma.<ref type="bibr" target="#b84">2</ref> Alpha controlled within this step for both timepoints.Reference ID: 4124009</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4124009 (b) (4) (b)(4)</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4123729Cross Discipline Team Leader Review</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4123729(b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b)(4)</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4123729(b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b)<ref type="bibr" target="#b86">(4)</ref> </note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4123729 (b) (4) (b) (4) (b) (4) (b)<ref type="bibr" target="#b86">(4)</ref> </note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4123729 (b)<ref type="bibr" target="#b86">(4)</ref> </note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4093382</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="12">APPENDICES..........................................................................................................95Reference ID: 4081796</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4081796</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4081796(b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)BLA #761062Reviewer: Gemma Kuijpers, Ph.D.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4081796(b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)BLA #761062Reviewer: Gemma Kuijpers, Ph.D.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">From:Delgado-Calle and Bellido, Curr Mol Biol Rep, 2015   </note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4076742</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4075258</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4063752</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4370582</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4077213</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4074652</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">&amp; X/ZZ (YY): X=number of tumor bearing animals; YY=mortality weighted total number of animals; ZZ=unweighted total number of animals observed; NC = Not calculable.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4124393 3 Pages have been Withheld in Full as B4(CCI/TS) Immediately Following this Page</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4076576</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Immunogenicity Report)Reference ID: 4076576</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1">Impact of creatinine clearance (eGFR) was presented as power function centralized by 80 mL/min/1.73m 2 , which is median eGFR value from final population PK data.</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0">  <p>for initial rollout (NME/original BLA reviews) Labeling can manage this risk.</p><p> Hypocalcemia: Inhibition of sclerostin by romosozumab leads to rapid bone mass accrual at initiation of treatment and an increased demand for bone-building substrates such as calcium. Based on the clinical trial data, hypocalcemia is considered an important identified risk. Mild and transitory decreases in albumin-corrected calcium and a compensatory increase in iPTH were observed after initiation of romosozumab Based on the totality of data, the risk of hypocalcemia is manageable with appropriate monitoring recommended for patients with stage 5 CKD. See sections <ref type="bibr">8.3.8</ref> Laboratory evaluations. Labeling can manage this risk.</p><p> Hyperostosis: The intended pharmacologic effect of romosozumab is an increase in BMD and bone strength; however, hyperostosis (excessive bone growth) may be a potential risk with romosozumab administration. The current data, including the audiology substudy, do not support a safety risk of hyperostosis with romosozumab use; however, given the mechanism of action for romosozumab, it is considered a potential risk. See section <ref type="bibr">8.4.4</ref> Hyperostosis. The data does not support a safety risk for hyperostosis with romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9">Advisory Committee Meeting and Other External Consultations</head><p>No Advisory Committee Meeting was held or is planned.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="10">Labeling Recommendations</head><p>Prescribing Information 10.1.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">INDICATIONS AND USAGE Sponsor Proposed Indication:</head><p>"EVENITY is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.</p><p>Recommended Modifications: Delete from the indication.   for initial rollout (NME/original BLA reviews) 2 DOSAGE AND ADMINISTRATION Sponsor Proposed:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommended Modification:</head><p> Two separate syringes (and injections) are needed to administer the total dose of 210 mg of EVENITY. Inject two 105 mg/1.17 mL prefilled syringes, one after the other.</p><p> EVENITY should be administered by a healthcare provider.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: A single monthly dose consists of two full syringes; both injected one</head><p>after the other. Each monthly dose will be injected by healthcare provider.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">CONTRAINDICATIONS</head><p>Reviewer Comments: Categories of hypocalcemia and hypersensitivity are acceptable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">WARNINGS AND PRECAUTIONS</head><p>Reviewer Comments: Warning categories of hypocalcemia, hypersensitivity, osteonecrosis of the jaw and atypical femur fractures are acceptable. Recommend additional language to match other osteoporosis medications with similar warnings and precautions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6">ADVERSE REACTIONS</head><p>Sponsor Proposed:  ADVERSE REACTIONS</p><p>The following adverse reactions are discussed in greater detail in other sections of the label:</p><p> Hypocalcemia [see Contraindications <ref type="bibr" target="#b86">(4)</ref> and <ref type="bibr">Warnings and Precautions (5.1)]</ref>  Hypersensitivity [see Contraindications <ref type="bibr" target="#b86">(4)</ref> and <ref type="bibr">Warnings and Precautions (5.</ref>2)]</p><p>Reference ID: 4093382 (b) <ref type="bibr" target="#b86">(4)</ref> (b) <ref type="bibr" target="#b86">(4)</ref> Clinical Review Debuene Chang MD BLA 761062 Evenity (Proposed) -romosozumab CDER Clinical Review Template 2015 Edition 170 Version date:  for initial rollout (NME/original BLA reviews) Recommended Modifications: Include the following adverse reactions:</p><p> Osteonecrosis of the Jaw [ see <ref type="bibr">Warnings and Precautions (5.</ref>3)]</p><p> Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see <ref type="bibr">Warmings and Precautions (5.4)</ref>  <ref type="bibr">(5.3)</ref>].</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Atypical Subtrochanteric and Diaphyseal Fractures</head><p>In the osteoporosis clinical trial program, atypical femoral fractures were reported in patients treated with EVENITY. The duration of EVENITY exposure to time of atypical femoral fracture diagnosis was as early as 3.5 months [see <ref type="bibr">Warnings and Precautions (5.4)</ref>].</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Both ONJ and AFF were found in the pivotal trial and should be noted in the section under adverse reactions. See section 8.3.6</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7">DRUG INTERACTIONS</head><p>Reviewer Comments: No drug interaction issues.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8">USE IN SPECIFIC POPULATIONS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: No significant modification recommendations.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="12">CLINICAL PHARMACOLOGY</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reviewer Comments: Recommended modifications by Clin Pharm reviewer to add information on bone turnover markers and add detail to clinical study information. This reviewer agrees with Clin Pharm recommendations. See Clin Pharm review.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>123</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author of Draft: Miyun Tsai-Turton</head><p>The following information reflects a brief summary of the Committee discussion and its recommendations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #: 761062</head><p>Drug Name: Romosozumab (AMG785) Sponsor: Amgen Background: Romosozumab (AMG785) is a humanized murine monoclonal IgG2 antibody against sclerostin, a glycoprotein that blocks bone formation by inhibiting the Wnt/-catenin pathway in the osteoblast. Romosozumab is expected to increase bone formation and bone mass. The sought indication for the BLA is the treatment of postmenopausal osteoporosis. Romosozumab was evaluated in Phase III studies in postmenopausal women at a dose of 210 mg by subcutaneous injection every month (QM). The intended treatment duration is 1 year. The sponsor submitted the data from a 2-year lifetime carcinogenicity study in rats to their BLA application.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Rat Carcinogenicity Study:</head><p>Romosozumab was given to Sprague Dawley rats at doses of 0 , 3, 10, 50 mg/kg/week (60/sex/group) weekly via sc injection for a minimum of 91 weeks in males and 98 weeks in females. Dose selection was based on the expected pharmacologic effect in bone, clinical exposure multiples, and the lack of significant toxicity in a completed 6-month rat toxicity study. ECAC concurred with the study design <ref type="bibr">(October 11, 2011)</ref>.</p><p>Findings: The survival at the end of study was between 25-40% and comparable across all groups. There were non-neoplastic changes associated with the Reference ID: 4081796</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA #761062</head><p>Reviewer: Gemma Kuijpers, Ph.D. 168 pharmacologic effect of romosozumab administration: hyperostosis, spleen and liver (secondary extramedullary hematopoiesis), and injection site mononuclear cells infiltrate. However, there were no neoplastic changes associated with romosozumab administration. FDA statistical review showed adrenal cortical adenoma in the 10 mg/kg group; pairwise comparison p = 0.0184, i.e. &lt; 0.05) however the incidence was within the historical control range provided by the sponsor.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Executive CAC Recommendations and Conclusions:</head><p>Rat:</p><p> The Committee concurred that the study was adequate, noting prior approval of the protocol.  The Committee agreed that there were no drug-related neoplasms in the 2-</p><p>year rat carcinogenicity study results in either males or females. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key Study Findings</head><p>Once weekly subcutaneous administration of AMG 785 to male and female Sprague Dawley rats before cohabitation, through mating and implantation at dose levels of 0, 10, 60, 300 mg/kg had no effect on mortality, clinical signs, body weight, food consumption or necropsy. No effects on mating, fertility, male reproductive parameters (sperm analyses or organ weights), ovarian or uterine parameters, embryo-fetal survival or fetal body weights were observed.</p><p>At 300 mg/kg, there were 3 fetuses from 3 litters that had reduced ventral processes (which develop into the carotid tubercles) on the 6th cervical vertebrae, slightly exceeding the historical range of the test facility, which was considered to represent a developmental delay (development of the ventral processes of the cervical vertebrae proceed in an anterior to posterior direction and the ventral processes on the 7th cervical vertebrae had not started to develop at gestation day 21). No other fetal effects were observed at any dose level. , blood samples were collected from all animals for determination of AMG 785 serum concentrations and anti-AMG 785 antibodies (ADA). These data were used to select animals that were suitable for further evaluation based on whether they were ADA negative or if ADA positive, had lowest signal-to-noise ratio (used to assess strength of ADA response) and/or highest AMG 785 serum concentration values. At DS 22, 37% of the females and 53% of the males had measurable anti-AMG 785 antibodies (and were eliminated), with signal-to-noise (S/N) ratio ranging from less than 10 to more than 1000. Mating was initiated at Day 41/42</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Observations and Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mortality/ Clinical Signs</head><p>No treatment related effects were observed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Body Weight/ Feed Consumption</head><p>No treatment related effects on body weight or food consumption were observed.</p><p>Reference ID: 4076742 </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dosing Solution Analysis</head><p>All study samples analyzed had mean concentrations within or equal to the acceptance criteria of  10% of their theoretical concentrations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Necropsy</head><p>No treatment related effects were observed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fertility Parameters:</head><p>No treatment related effects were observed on mating, fertility, male reproductive parameters (sperm analyses or organ weights), ovarian or uterine parameters, embryofetal survival or fetal body weights.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fetal alterations</head><p>a. Dose administration occurred once weekly from Day 1 of study through the week of euthanasia. b. Excludes values for rats that had positive ADA results, high signal-to-noise ratio, low AMG 785 exposure and/or were arbitrarily euthanized and not assigned to the main or toxicokinetic portion of the study. c. Excludes values for rat 6410; ADA results could not be confirmed for cohort male 6115. d. Dead fetus was excluded from summarization and statistical analyses. This conceptus appeared normal for its developmental age. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fetal ossification sites</head><p>No treatment related effects were observed. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9.2">Embryonic Fetal Development</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key Study Findings</head><p>AMG 785 was well-tolerated in pregnant rats at doses up to 300 mg/kg, administered twice during the gestation period (GDs 6 and 13). No treatment related effects were observed on maternal or fetal parameters at any dose tested. There were no dosedependent differences in the litter or fetal incidences of any gross external, soft tissue or skeletal alterations. Fetal ossification site averages were generally comparable among the four dose groups.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of Fetal Alterations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fetal Skeletal Alterations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fetal Ossification Sites</head><p>No treatment related effects were observed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="11">Integrated Summary and Safety Evaluation</head><p>Fertility study:</p><p>Once weekly subcutaneous administration of AMG 785 to male and female Sprague Dawley rats before cohabitation, through mating and implantation (fertility study) at dose levels of 0, 10, 60, 300 mg/kg had no effect on mortality, clinical signs, body weight, food consumption or necropsy. No effects on mating, fertility, male reproductive parameters (sperm analyses or organ weights), ovarian or uterine parameters, embryofetal survival or fetal body weights were observed.</p><p>At 300 mg/kg, there were 3 fetuses from 3 litters that had reduced ventral processes (which develop into the carotid tubercles) on the 6th cervical vertebrae, slightly exceeding the historical range of the test facility, which was considered to represent a </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PHARMACOLOGY/TOXICOLOGY NDA/BLA REVIEW AND EVALUATION</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BASIS FOR DOSES SELECTED:</head><p>Doses for this study were based on the expected pharmacologic effect in bone, clinical exposure multiples, and the lack of significant toxicity in a completed 6 month rat toxicity study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PRIOR FDA DOSE CONCURRENCE: Yes</head><p>RAT CARCINOGENICITY: Negative.</p><p>RAT TUMOR FINDINGS: There were no AMG785-related tumor findings.</p><p> Macroscopically, there were AMG785-related macroscopic findings in bones (miscellaneous, calvarium femur, lumbar vertebrae L5-L6, sternum and tibia) and spleen. There was also AMG785-related thickening of the bone in males and females, in a dose dependent manner, correlating with the increase in bone mineral content (BMC) by ex vivo peripheral quantitative computed tomography (pQCT) and hyperostosis, microscopically. This effect was systemic, usually affecting all routinely collected bones. An increased incidence of spleen enlargement was noted in females at  3 mg/kg and in males at 10 mg/kg/dose, correlating with increased extramedullary hematopoiesis microscopically.</p><p> Microscopically, there were no neoplastic changes associated with AMG785 administration. The sponsor identified two significant findings. Renal lipoma in 3/60 females at 50 mg/kg (p =0.0486 by trend test, when compared to 1/60 in concurrent control; marginally above historical control data range). Adrenal cortical adenoma in 6/60 males at 10 mg/kg (p = 0.0169 by pairwise comparisons, when compared to 0/60 in concurrent control; within historical control data Page 3 of 41 range). Since renal lipoma was a rare tumor, it would be considered significant when the p value was  0.05. However, due to absence of pre-neoplastic lesion findings, the increased incidence in the female HD group had no toxicological significance. On the other hand, adrenal cortical adenoma was not a rare tumor, it would be considered significant when the p value was  0.01. Therefore, the increased incidence in the male MD group had no toxicological significance.</p><p> Microscopically, there were two osteosarcomas noted in the males at 50 mg/kg, which were not statistically significant by trend test and pairwise comparison, but the incidence was 3.7%, marginally higher than the historical range of 3.33%. Long term use of PTH has been known to result in osteosarcomas, osteoma, and osteoblast hyperplasia. Due to lack of pre-neoplastic findings and other bone tumors, the sponsor considered these as spontaneous.</p><p> FDA statistical review: tumor analysis did not show any statistically significant dose-response relationship in tumor incidence in tumor types tested in male rats. The pairwise comparison did show a statistically significant increase in incidence of adenoma cortical in MD groups compared to the control in male rats (p=0.0184&lt;0.05) and a statistically significant positive dose response relationship in adenoma islet cell for pancreas in female rats (p=0.0323&lt;0.05), if these tumor were considered as a rare tumor. No other statistically significant findings were noted for female rats.</p><p> Microscopically, there were non-neoplastic changes associated with AMG785. Bones: increased incidence of hyperostosis was noted in all dose groups. Spleen: increased incidence of secondary extramedullary hematopoiesis was noted in all dose groups (male: 13/60, 38/60, 44/60, 40/54 and female: 37/60, 49/60, 57/60, 60/60 in Groups 1, 2, 3, and 4 respectively). Liver: increased incidence of secondary extramedullary hematopoiesis was noted in all dose groups (male: 5/60, 13/60, 13/60, 12/54 and female: 22/60, 25/60, 41/60, 39/60 in Groups 1, 2, 3, and 4 respectively). Injection sites: mononuclear cells infiltrate was noted in all dose groups. However, changes in bones, spleen, and liver were dose dependent, whereas changes in injection sites were not dose dependent.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RAT STUDY COMMENTS:</head><p>The 104 week rat study via sc injection was conducted to assess the carcinogenic potential of AMG785. The study was terminated at Week 91 for male groups and Week 98 for female groups. The survival at the end of study was between 25-40% and comparable across all groups. There were non-neoplastic changes associated with AMG785 administration in bones (hyperostosis), spleen and liver (secondary extramedullary hematopoiesis), and injection sites (mononuclear cells infiltrate), which were all expected pharmacological effect of AMG785. However, there were no neoplastic changes associated with AMG785 administration. The sponsor identified two tumor findings that were significant (i.e. renal lipoma in 50 mg/kg females; p = 0.0486 by trend test, adrenal cortical adenoma in 10 mg/kg males; p = 0.0169 by pairwise comparison). Since renal lipoma (rare tumor) and adrenal cortical adenoma (common tumor) had no pre-neoplastic lesion findings, and there was a lack of dose , there were between 36-43 rats/sex/group died or euthanized. AMG785 had no effects on the overall survival rate or mortality.  There were increased bone radiopacity in almost all males and females treated with AMG785 that correlated with thickening of the bone (macroscopically) and hyperostosis (microscopically). This was an expected pharmacological effect of AMG785.  Marked dose-related increases in bone mass and geometry were noted at the femur metaphysis and diaphysis. Trabecular bone mineral density (BMD) was 4-fold and 6fold higher in males and females, respectively, when compared to vehicle controls.  There were no AMG785-related neoplastic findings.  There were AMG785-related non-neoplastic findings. However, findings were limited to pharmacological effect of AMG785, including hyperostosis, secondary extramedullary hematopoiesis in spleen/liver, and mononuclear cell infiltrate at the injection sites.  There were no satellite TK groups included in this study. However, at <ref type="bibr">Week 13,</ref><ref type="bibr">there</ref> were minimal or no differences in mean AMG785 serum concentration among animals.  Anti-drug antibodies (ADAs) were found in 1 female and 10 males at 50 mg/kg, 3 males at 10 mg/kg, and 18 males at 3 mg/kg. These ADA-positive animals had reduced mean serum AMG785 concentration when compared to ADA-negative </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ADA and TK Parameters: Week 13</head><p>At week 13, 33%, 19%, and 25% of female rats developed anti-drug antibody (ADA), and 70%, 28% and 42% of male rats developed ADA at 3, 10, and 50 mg/kg, respectively.</p><p>The ADA positive samples determined by immunoassay from Groups 2 through 4 were then analyzed in the bioassay to detect the presence of neutralizing ADA (Nab). Rats in the 3, 10, and 50 mg/kg AMG 785 dosed groups with ADA positive and Nab positive were then removed from the study per the protocol amendments 7 and 8. This removal reduced the group size to: 60, 60, and 60 in females and 60, 60, and 54 in males at 3, 10, and 50 mg/kg dosed groups. Among remaining animals, all rats were negative for Nab. However, there was a total of 32 ADA positive rats retained (1 female and 31 males).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA761062 -ECAC Review</head><p>Reviewer: Miyun Tsai-Turton Page 14 of 41</p><p>In summary, Nab-positive rats were not retained in the study and there were minimal or no difference in mean AMG 785 serum concentrations among retained animals.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In Vivo and Ex Vivo Bone Measurements: At necropsy</head><p>An increased bone radiopacity was noted in almost all AMG785 treated males and females (73%, 88%, and 85% in males and 97%, 93%, and 92% in females at 3, 10, and 50 mg/kg, respectively). This was systemic affecting all bones and was considered an expected pharmacological effect of AMG 785, correlating with hyperostosis of bones observed microscopically. No other AMG 785-related effects were noted based on the distribution of radiological changes among all groups. Radiographic bone production, bone loss or mixed reaction was noted in a few rats at miscellaneous bone sites or in the femur and tibia, generally correlated with macroscopic and microscopic histological changes.</p><p>Page 15 of 41</p><p>With regard to femur metaphysis, there was a significant increase in femural bone mineral density (BMD) in all AMG785 treated animals, in a dose dependent manner (30%, 60%, and 79% in males and 33%, 79%, and 116% in females at 3, 10, and 50 mg/kg). There was also a significant increase in femural bone mineral content (BMC) in all AMG785 treated animals, in a dose dependent manner (2x, 3x, and 4x in males and 2x, 4x, and 6x in females at 3, 10, and 50 mg/kg).</p><p>With regard to femur diaphysis, there was a significant increase in femur diaphyseal parameters in both males and females at all doses. Cortical BMD was increased in animals by 3-4% at 50 mg/kg in both sexes. Cortical thickness increased at 3, 10, or 50 mg/kg by 43%, 80% and 113% in males and by 25%, 58% and 106% in females, respectively, attributed to increases in periosteal circumference at 10 and 50 mg/kg, and marked decreases in endosteal circumference at all dose levels. These geometric changes resulted in increases in cross-sectional moment of inertia (CSMI) of 61% and 116% in </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S T A T I S T I C A L R E V I E W A N D E VA L U A T I O N</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S T A T I S T I C A L R E V I E W A N D E VA L U A T I O N</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CLINICAL STUDIES</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA Serial Number: 761062</head><p>Drug Name: Romosozumab</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Indication:</head><p>Treatment of osteoporosis in postmenopausal women at increased risk of fracture  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S T A T I S T I C A L R E V I E W A N D E VA L U A T I O N</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CARCINOGENICITY STUDIES</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary Reviewer</head><p>Lin Zhou, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary Reviewer</head><p>Yow-Ming Wang, Ph.D.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OCP Division DCP III</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OND Division</head><p>OND/ODEIII/DBRUP</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">CONCLUSION</head><p>The bioanalytical portion of pivotal pharmacokinetic (PK) comparability study (Study 20120277) is acceptable from a clinical pharmacology perspective.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">BACKGROUND</head><p>After filing of BLA 761062 (Romosozuamb), we sent a consult to office of study integrity and surveillance (OSIS) requesting inspections on sites that analyzed PK samples for pivotal PK comparability studies 20120277 and 20150197.</p><p>During inspections conducted by scientists Mohsen Rajabi Abhari and Stanley Au, significant issues were observed for one of the analytical sites for Study 20120277 (One Amgen Center Driver, Thousand Oaks, CA) and Form FDA-483 containing inspectional findings (concern over freeze-thaw stability of samples) was issued on February 17, 2017.</p><p>Amgen sent OSIS their response to the FDA-483 on March 9, 2017.</p><p>After reviewing Amgen's initial response to FDA-483 dated March 9, 2017, both OSIS and we found that the response was not adequate to support the -freeze-thaw stability of the PK samples. We discussed the issue with the Applicant during the late-cycle meeting on April 5, 2017. In addition, IR letters related to how to resolve the issue were sent to the Applicant on April 7 and 18, 2017.</p><p>Amgen provided response to April 7 and 18, 2017 IR letters on April 26, 2017. After OSIS reviewed the data, another IR went to the Applicant on May 3, 2017 and Amgen responded on May 15, 2017.</p><p>Based on all the information submitted, OSIS concluded that the freeze-thaw stability of romosozumab PK samples was supported and we agree with their assessment.  <ref type="figure">-------------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.</p><p>- <ref type="figure">----------------------------------------------------------------------------------------------------</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Submission Type Standard</head><p>Brand Name EVENITY</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Generic Name Romosozumab</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dosage Form and Strength</head><p>Single-use prefilled syringe: 105 mg of romosozumab in 1.17 mL solution (90 mg/mL).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dosage and Administration</head><p>Administer 210 mg subcutaneously once every month for 12 doses in the abdomen, thigh, or upper arm.</p><p>A full dose of 210 mg EVENITY requires two singleuse prefilled syringes.</p><p>EVENITY should be administered by a healthcare provider.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Proposed Indication</head><p>For the treatment of osteoporosis in postmenopausal women at increased risk of fracture </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">EXECUTIVE SUMMARY</head><p>The Applicant is seeking the approval of EVENITY (romosozumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. Romosozumab is a humanized IgG2 monoclonal antibody that binds and inhibits sclerostin. By blocking sclerostin, romosozumab increases bone formation due to the activation of bone lining cells, increased bone matrix production by osteoblasts, and recruitment of osteoprogenitor cells. Additionally, romosozumab results in changes to expression of osteoclast mediators, thereby decreasing bone resorption.</p><p>Romosozumab is administered by subcutaneous injection. The proposed dosing regimen is 210 mg monthly for 12 months. EVENITY should be administered by a healthcare professional and a full dose of EVENITY requires two single-use prefilled syringes, each delivering 105 mg of romosozumab. The 210 mg monthly dosing for 12 months was selected for Phase 3 studies based on a Phase 2 dose ranging study. The Applicant additionally submitted results of 8 clinical pharmacology studies in healthy subjects, subjects with low bone mineral density, and postmenopausal women with osteoporosis (PMO) to support the pharmacokinetics (PK) and pharmacodynamics (PD) of romosozumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.1">Recommendations</head><p>The Divisions of Clinical Pharmacology 3 and Pharmacometrics have reviewed the information contained in BLA 761,062. The review team recommends approval of this BLA from a clinical pharmacology perspective if inspection results of the analytical and clinical sites of the two pivotal PK comparability studies (Study 20120277 and 20150197) are acceptable (The inspection results will become available on 04/19/17). The key review issues with specific recommendations and/or comments are summarized below:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review Issue Recommendations and Comments</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pivotal or supportive evidence of effectiveness</head><p>The pivotal Phase 3 study 20070337 (n = 7157) provides the primary evidence of effectiveness. Subjects treated with romosozumab (12 months) followed by denosumab (12 months) had a reduced risk of fracture at Month 12 and Month 24 compared to subjects treated with placebo (12 months) followed by denosumab <ref type="formula">(12 months</ref>). In addition, romosozumab/denosumab treatment is associated with an increased bone mineral density in lumbrar spine, total hip, and femoral neck compared to placebo/denosumab at Month 12 and Month 24.</p><p>The Phase 2 dose ranging Study 20060326 provides supportive evidence. <ref type="bibr" target="#b88">6</ref> was estimated to be 0.383 mL/hr/kg, following a single SC administration of 3 mg/kg. The mean effective t1/2 was 12.8 days after 3 SC doses of Q4W 3 mg/kg.</p><p>Development of ADA was associated with reduced serum romosozumab concentrations. One subject tested neutralizing antibody positive in the first in human single dose Phase 1 study had a rapid decline in romosozumab serum concentrations after retreatment. After a single dose of 1mg/kg, romosozumab serum concentration rose to 2010 ng/ml on Day 5 dropped below the lower limit of quantification (BQL = 50 ng/mL) on Day 7 and remained BQL through the PK sampling window up to 168 days, despite continued dosing once every two weeks. In the Phase 3 studies, the presence of binding ADAs appeared to decrease romosozumab exposure up to 25% at months 3, 6, and 9. The exposures became comparable (approximate 10% difference in mean values) at month 12 between ADA positive and ADA negative subjects.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Intrinsic Factors:</head><p>Based on a population pharmacokinetic analysis, no notable difference in pharmacokinetics with age (20-89 years), gender, race, or disease state (low bone mass or osteoporosis) was shown.</p><p>The exposure of romosozumab decreased with increasing body weight.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Specific Populations:</head><p>Renal Impairment: Following a single 210 mg dose of romosozumab in a clinical study of 16 patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m 2 ) or end-stage renal disease (ESRD) requiring hemodialysis, mean Cmax and AUC were 29% and 44% higher in patients with severe renal impairment as compared to healthy subjects. Mean romosozumab exposure was similar between patients with ESRD requiring hemodialysis and healthy subjects. PK of romosozumab was not evulated in ESRD patients without dialysis. A population pharmacokinetic analysis indicated an increase in romosozumab exposure with increasing severity of renal impairment.</p><p>Prior exposure to alendronate: The pharmacokinetics of romosozumab was similar in patients transitioning from alendronate therapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">Dosing and Therapeutic Individualization</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.1">General dosing</head><p>The proposed dosing regimen is 210 mg monthly for 12 months.</p><p>The dose-response relationship for efficacy from the Phase 2 dose-finding study and the efficacy data from the pivotal Phase 3 study, where only one dose level was studied, support a recommendation of the 210 mg monthly dosing. In the Phase 3 study only Ctrough were collected, therefore the AUC data in <ref type="table">Table 5</ref> were predicted for the PK substudy population using the population model parameters estimated for each individual. Furthermore, due to the small number of subjects with severe renal impairment study 20070337, the reviewer simulated exposures in severe renal impairment using the same covariate model to evaluate the effect of renal impairment. The covariate model was developed based on a total of 10 subjects with severe renal impairment (8 from the dedicated renal impairment study and 2 from the pivotal phase 3 study 20070337). Please note, Study 20070337 had 10 subjects with severe renal impairment but only 2 of them had PK data.</p><p>An increasing exposure was also predicted for decreasing eGFR. In particular, the predicted exposure for patients with severe renal impairment was ~60% higher than subjects with normal renal function; which is consistent with what observed in the dedicated renal impairment study (Study 20110227). In the dedicated renal impairment study, mean AUC were 44% higher in patients with severe renal impairment as compared to healthy subjects.</p><p>Dose adjustment based on renal function is not warranted for the following two reasons: 1) the fixed dosing regimen (210 mg) was given to all subjects, including 10 subjects with severe renal impairment in the Phase 3 study and had an acceptable safety profile (Section 4.6), and 2) data from the dedicated renal impairment study indicated that the incidence of hypocalcemia was associated with severity of renal impairment, but not with exposure of romosozumab.</p><p>An increasing exposure was predicted for decreasing body weight. In particular, the predicted exposure for subjects in the lowest quartile of body weight was ~50% than that in the highest quartile of body weight; which could have the potential to affect the safety profile. However, the fixed dosing regimen (210 mg) was given to all subjects in the pivotal Phase 3 study and had an acceptable safety profile. Therefore, dose adjustment based on body weight is not warranted (Section 4.6).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.4">Are there clinically relevant food-drug or drug-drug interactions and what is the appropriate management strategy?</head><p>Food-drug interactions are not applicable as romosozumab is administered by SC injection.</p><p>Disease-drug-drug interactions are not applicable because postmenopausal women with osteoporosis do have not much elevated proinflammatory cytokins based on the current understanding.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">APPENDICES</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1">Summary of Bioanalytical Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.1">Romosozumab assay</head><p>The romosozumab serum concentrations were analyzed using an enzyme linked immunosorbent assay (ELISA) using specific anti-idiotype antibodies for capture and detection of romosozumab.</p><p>The method was developed and validated (validation number 108298) at Amgen Inc. (Thousand Oaks, CA) and was subsequently transferred where the method underwent partial method validations at each laboratory; validation number 108763 at and validation number 117101 at Briefly, microplate wells were coated with mouse anti-human-romosozumab antibody (Clone 2.59, Amgen Inc., Thousand Oaks, CA) to capture romosozumab. Unbound materials were removed by washing the wells. Horseradish peroxidase-labelled mouse anti-humanromosozumab antibody (Clone 2.5, Amgen Inc., Thousand Oaks, CA) was used for the detection of the captured romosozumab.</p><p>Validation reports for all three sites appear to be acceptable. Validated parameters from validation number 108298 is listed here as an example (   <ref type="bibr" target="#b84">2,</ref><ref type="bibr">3,</ref><ref type="bibr" target="#b86">4,</ref><ref type="bibr" target="#b88">6,</ref><ref type="bibr" target="#b41">8,</ref><ref type="bibr" target="#b50">11,</ref><ref type="bibr">15,</ref><ref type="bibr">18,</ref><ref type="bibr">22,</ref><ref type="bibr">29,</ref><ref type="bibr">36,</ref><ref type="bibr">43,</ref><ref type="bibr">57,</ref><ref type="bibr">85</ref>.</p><p>Day 1 (pre-dose), <ref type="bibr" target="#b84">2,</ref><ref type="bibr">3,</ref><ref type="bibr" target="#b86">4,</ref><ref type="bibr" target="#b88">6,</ref><ref type="bibr" target="#b41">8,</ref><ref type="bibr" target="#b50">11,</ref><ref type="bibr">15,</ref><ref type="bibr">18,</ref><ref type="bibr">22,</ref><ref type="bibr">29,</ref><ref type="bibr">36,</ref><ref type="bibr">43,</ref><ref type="bibr">57,</ref><ref type="bibr">85</ref>. Severe (15-30)* -* 837. <ref type="bibr">4 (707.0-967.9</ref>)* Note: The AUC data were summarized from the predicted AUC value for each individual subject in the PK substudy of Phase 3 study 20070337. The AUC prediction was based on the individual estimated PopPK model parameters which were obtained based on modeling the trough concentration data . *Simulation with 2910 number of patients, which represents demorgraphic of the phase 3 population based on Reviewer's updated population PK model with a dose of 210 mg QM. There were only two subjects with severe renal function in the Phase 3 study 20070337.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study sites</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Source: Reviewer's independent analysis.</head><p>The results elucidate that the exposures were relatively higher in low body weight patients and lower in high body weight patients, but the magnitude of difference between 1 st and 4 th quantile will be less than 1.5-fold. The difference in exposure across body weight is considered as relatively small and not clinically significant. Thus, no dose adjustment is necessary based on body weight.</p><p>The results indicate that the BMD is comparable across renal function categories. The similar conclusion can be drawn based on the primary efficacy endpoint, new vertebral fracture. There is no trend that the BMD %CFB and/or new vertebral fracture rate would be increased in more severe renal impairment patients. On the other side, BMD %CFB was decreased around 37% and 34% for 12 and 24 month in highest body weight group compared to that in lowest body weight group. However, this difference did not result in any clinically significant differences in incident rates of new vertebral fracture across body weight range. All these results demonstrate that no dose adjustment is necessary based on body weight and renal function from efficacy perspective.</p><p>From safety perspective, only one subject with hypocalcemia was identified in the Phase 3 study. In the dedicated renal impairment study <ref type="bibr">(Study 20110227)</ref>, hypocalcemia were reported to 5 subjects, 1 severe renal impairment subject and 4 ESRD subjects with hemodialysis. Based on <ref type="table">Table 4</ref> in section 4.5, the exposure in ESRD subjects with hemodialysis was comparable to that in normal renal function subject. Thus, the higher event rate of hypocalcemia is not driven by the exposure, which further support that no dose adjustment is necessary based on renal function.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Progressively increasing fracture risk with advancing age after initial incident fragility fracture: the Troms study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Center</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bjrnerem</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2214" to="2221" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">High risk of second fracture within 1, 2, 5 years after prior fracture among women 65 years or older</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Balasubramanian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Abstract presented at The American Society for Bone and Mineral Research Annual Meeting</title>
		<meeting><address><addrLine>Atlanta, Ga</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The impact of nonhip nonvertebral fractures in elderly women and men</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Bliuc</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">V</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Eisman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Center</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="415" to="423" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Bliuc</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">D</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">E</forename><surname>Milch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">V</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Eisman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Center</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="513" to="521" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Use of Nursing Home After Stroke and Dependence on Stroke Severity: A Population-Based Analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Ransom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Hass</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="924" to="929" />
			<date type="published" when="1999" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Coln-Emeric</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kuchibhatla</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Pieper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoporos Int</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="879" to="883" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Wnt Signaling in Cardiac and Vascular Disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Foulquier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">P</forename><surname>Daskalopoulos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lluri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kcm</forename><surname>Hermans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Deb</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">W</forename><surname>Blankesteijn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Rev</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="68" to="141" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Vertebral fracture assessment using a semiquantitative technique</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">K</forename><surname>Genant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Van Kuijk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Nevitt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Bone and Mineral Research</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1137" to="1185" />
			<date type="published" when="1993" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Imminent risk of fracture after fracture</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Johansson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Siggeirsdottir</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">C</forename><surname>Harvey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoporos Int</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="775" to="780" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Mortality after osteoporotic fractures</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Johnell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Kanis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Oden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoporos Int</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="38" to="42" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">An estimate of the worldwide prevalence, mortality and disability associated with hip fracture</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Johnell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoporosis Int</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="897" to="902" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Vertebral fractures and mortality in older women. A prospective study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename><surname>Kado</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">S</forename><surname>Browner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Palermo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="1215" to="1220" />
			<date type="published" when="1999" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Long-term risk of osteoporotic fracture in Malmo</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Kanis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Johnell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Oden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoporos Int</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="669" to="674" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Surrogates for fracture endpoints in clinical trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Khosla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1146" to="1149" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Bisphosphonates and risk of cardiovascular events: a meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename><surname>Fulchino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PloS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">4</biblScope>
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kranenburg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Bartstra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Weijmans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">252</biblScope>
			<biblScope unit="page" from="106" to="115" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
				<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Krishna</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Seto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Jose</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jiaze</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">K</forename><surname>Morton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Biros</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Nsengiyumva</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jhn</forename><surname>Lindeman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">G</forename><surname>Loots</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Rush</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Craig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Golledgeet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II-Induced Aortic Aneurysm and Atherosclerosis</title>
		<imprint>
			<date type="published" when="2017" />
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="553" to="566" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Risk of new vertebral fracture in the year following a fracture</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Lindsay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Silverman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Cooper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">285</biblScope>
			<biblScope unit="page" from="320" to="323" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">National Osteoporosis Foundation (NOF). What is osteoporosis and what causes it?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Morin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Lix</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Azimaee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Metge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Caetano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">D</forename><surname>Leslie</surname></persName>
		</author>
		<ptr target="https://www.nof.org/patients/what-is-osteoporosis/" />
	</analytic>
	<monogr>
		<title level="j">Osteoporosis Int</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2439" to="2448" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>Mortality rates after incident nontraumatic fractures in older men and women</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The 1-year mortality of patients treated in a hip fracture program for elders</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Schnell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">A</forename><surname>Mendelson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">W</forename><surname>Bingham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Kates</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Geriatr Orthop Surg Rehabil</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="6" to="14" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Association of Alendronate and Risk of Cardiovascular Events in Patients with Hip Fracture</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">W</forename><surname>Sing</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">Y</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">P</forename><surname>Kiel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1422" to="1434" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Death, debility, and destitution following hip fracture</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">S</forename><surname>Tajeu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Delzell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gerontol A Biol Sci Med Sci</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="346" to="353" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Population-wide impact of non-hip non-vertebral fractures on mortality</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Bliuc</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Van Geel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1802" to="1810" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Does a fracture at one site predict later fractures at other sites: a British Cohort Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">P</forename><surname>Van Staa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hgm</forename><surname>Leufkens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Cooper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoporos Int</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="624" to="629" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Coronary Artery Plaque Characteristics Associated with Adverse Outcomes in the SCOT-HEART Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Dweck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JACC</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="291" to="301" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main">World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level</title>
		<imprint>
			<date type="published" when="2004-05" />
			<biblScope unit="page" from="5" to="7" />
			<pubPlace>Brussels, Belgium</pubPlace>
		</imprint>
	</monogr>
	<note>Summary Meeting Report</note>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization</title>
		<imprint>
			<date type="published" when="1994" />
			<publisher>WHO Press</publisher>
			<biblScope unit="page" from="1" to="129" />
			<pubPlace>Geneva, Switzerland; Geneva, Switzerland</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">References</forename><surname>Keech</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Current Medical Research and Opinions</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="135" to="140" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Design and Methods of the Raloxifene Use for The Heart (RUTH) Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Mosca</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American Journal of Cardiology</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="392" to="395" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Clinical Review Debuene Chang MD BLA</title>
		<imprint>
			<biblScope unit="page">761062</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m" type="main">Proposed) -romosozumab CDER Clinical Review Template 2015 Edition 3 Version date</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Evenity</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015-11-05" />
		</imprint>
	</monogr>
	<note>for initial rollout (NME/original BLA reviews</note>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . .</forename><surname>Study Design</surname></persName>
			<affiliation>
				<orgName type="collaboration">.................................................................................................... 37</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . .</forename><surname>Study Results</surname></persName>
			<affiliation>
				<orgName type="collaboration">.................................................................................................... 46</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
				<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">)</forename><forename type="middle">. .</forename></persName>
			<affiliation>
				<orgName type="collaboration">................................................................ 65 Study 20060326 ...................................................................................................... 65 6.2.1. Study 20101291 ...................................................................................................... 82 6.2.2. Study 2012156 ........................................................................................................ 86 6.2.3. Study 20080289 Active-Comparator Controlled-Teriparatide ............................... 90</orgName>
			</affiliation>
		</author>
		<title level="m">Supportive Placebo-Controlled Studies</title>
		<editor>6.2. Active-Comparator Controlled Study</editor>
		<imprint>
			<date type="published" when="20060326" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . .</forename><surname>Primary Endpoints</surname></persName>
			<affiliation>
				<orgName type="collaboration">............................................................................................. 90</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Other</forename><surname>Secondary</surname></persName>
			<affiliation>
				<orgName type="collaboration">......................................................................... 91</orgName>
			</affiliation>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. .</forename><surname>Endpoints</surname></persName>
			<affiliation>
				<orgName type="collaboration">......................................................................... 91</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . . .</forename><surname>Subpopulations</surname></persName>
			<affiliation>
				<orgName type="collaboration">............................................................................................... 93</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Dose</surname></persName>
			<affiliation>
				<orgName type="collaboration">.................................................................................... 95</orgName>
			</affiliation>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. .</forename><surname>Dose-Response</surname></persName>
			<affiliation>
				<orgName type="collaboration">.................................................................................... 95</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<title level="m" type="main">Durability of Efficacy Effects</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
				<title level="m">Considerations on Benefit in the Postmarket Setting</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Other Relevant</surname></persName>
			<affiliation>
				<orgName type="collaboration">............................................................................. 102 7.2.2. Integrated Assessment of Effectiveness ...................................................................... 102</orgName>
			</affiliation>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . . . .</forename><surname>Benefits</surname></persName>
			<affiliation>
				<orgName type="collaboration">............................................................................. 102 7.2.2. Integrated Assessment of Effectiveness ...................................................................... 102</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . .</forename><surname>Review Of Safety</surname></persName>
			<affiliation>
				<orgName type="collaboration">............................................................................................................ 104</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<monogr>
		<title level="m" type="main">2.3. Adequacy of Applicant&apos;s Clinical Safety Assessments</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">...................... .</forename><surname>Overall Exposure</surname></persName>
			<affiliation>
				<orgName type="collaboration">......................................................................... 105 8. ; ............................................... 106 8. ; ........................................................................ 106 8. ; .................................................. 106</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
	<note>2.1. Relevant characteristics of the safety population:</note>
</biblStruct>

<biblStruct xml:id="b43">
	<monogr>
		<title level="m" type="main">Issues Regarding Data Integrity and Submission Quality</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . . .</forename><surname>Deaths</surname></persName>
			<affiliation>
				<orgName type="collaboration">.......................................................................................................... 110</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. .</forename><surname>Serious Adverse Events</surname></persName>
			<affiliation>
				<orgName type="collaboration">..................................................................................... 112</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<monogr>
		<title level="m" type="main">Proposed) -romosozumab CDER Clinical Review Template 2015 Edition 5 Version date</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Evenity</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015-11-05" />
		</imprint>
	</monogr>
	<note>for initial rollout (NME/original BLA reviews</note>
</biblStruct>

<biblStruct xml:id="b47">
	<monogr>
		<title level="m" type="main">Advisory Committee Meeting and Other External Consultations</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . .</forename><surname>Labeling Recommendations</surname></persName>
			<affiliation>
				<orgName type="collaboration">.......................................................................................... 168</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">........... .</forename><surname>Patient Labeling</surname></persName>
			<affiliation>
				<orgName type="collaboration">......................................................................................... 172 10.2. Nonprescription Labeling ......................................................................................... 172</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. .</forename><surname>Rems)</surname></persName>
			<affiliation>
				<orgName type="collaboration">.......................................................... 172</orgName>
			</affiliation>
		</author>
	</analytic>
	<monogr>
		<title level="j">Risk Evaluation and Mitigation Strategies</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<monogr>
		<title level="m" type="main">173 11.1. Conditions of Use to Address Safety Issue(s)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">....................................... .</forename><surname>Rems</surname></persName>
			<affiliation>
				<orgName type="collaboration">........................................................... 173 11.2. Recommendations on REMS .................................................................................... 173</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
	<note>Safety Issue(s) that Warrant Consideration of a</note>
</biblStruct>

<biblStruct xml:id="b52">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Postmarketing</forename><surname>Requirements</surname></persName>
			<affiliation>
				<orgName type="collaboration">........................................................... 173</orgName>
			</affiliation>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. .</forename><surname>Commitments</surname></persName>
			<affiliation>
				<orgName type="collaboration">........................................................... 173</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . . . .</forename><surname>Appendices</surname></persName>
			<affiliation>
				<orgName type="collaboration">................................................................................................................ 173</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . . .</forename><surname>References</surname></persName>
			<affiliation>
				<orgName type="collaboration">....................................................................................................... 173</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . .</forename><surname>Financial Disclosure</surname></persName>
			<affiliation>
				<orgName type="collaboration">........................................................................................... 175 13.2</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<monogr>
		<title level="m" type="main">All Clinical Studies in Romosozumab Clinical Development</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<title level="m" type="main">Supportive Study</title>
		<imprint>
			<date type="published" when="20060326" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fda</forename><surname>Key Regulatory</surname></persName>
			<affiliation>
				<orgName type="collaboration">..................................................................... 186 13.5. Study 20070337 Substudy Details ............................................................................ 187</orgName>
			</affiliation>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . . .</forename><surname>Interactions</surname></persName>
			<affiliation>
				<orgName type="collaboration">..................................................................... 186 13.5. Study 20070337 Substudy Details ............................................................................ 187</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<monogr>
		<title level="m" type="main">6.1. Forearm and Total Body Dual-energy X-ray Absorptiometry and Hi Resolution 13.6.2. Peripheral Quantitative Computed Tomography Sub-study (Imaging Sub-study I)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Biomarker</forename><surname>Bone Turnover Marker</surname></persName>
			<affiliation>
				<orgName type="collaboration">.................................... 187 13.</orgName>
			</affiliation>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">.</forename><forename type="middle">.</forename><surname>Sub-Study</surname></persName>
			<affiliation>
				<orgName type="collaboration">.................................... 187 13.</orgName>
			</affiliation>
		</author>
		<ptr target=".......190" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<monogr>
				<title level="m">Lumbar Spine and Proximal Femur Dual energy X-ray Absorptiometry Sub-13.6.3. study (Imaging Sub-study II)</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Calcium</forename><surname>Sub-Study</surname></persName>
			<affiliation>
				<orgName type="collaboration">..................................................................................... 199</orgName>
			</affiliation>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">.</forename><forename type="middle">.</forename></persName>
			<affiliation>
				<orgName type="collaboration">..................................................................................... 199</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Audiology</forename><surname>Sub-Study</surname></persName>
			<affiliation>
				<orgName type="collaboration">.................................................................................. 201</orgName>
			</affiliation>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">.</forename><forename type="middle">.</forename></persName>
			<affiliation>
				<orgName type="collaboration">.................................................................................. 201</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">.</forename><forename type="middle">.</forename><surname>Osteoarthritis Sub-Study</surname></persName>
			<affiliation>
				<orgName type="collaboration">............................................................................ 204</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Declining rates of osteoporosis management following fragility fractures in the U.S</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Balasubramanian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">L</forename><surname>Tosi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Lane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bone Joint Surg Am</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page">52</biblScope>
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">M</forename><surname>Bonafede</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">G</forename><surname>Bower</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoporos Int</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1203" to="1212" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<monogr>
		<title level="m" type="main">Incidence and economic burden of osteoporosis-related fractures in the United States</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Burge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Dawson-Hughes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">H</forename><surname>Solomon</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="465" to="475" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Coln-Emeric</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kuchibhatla</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Pieper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoporos Int</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="879" to="883" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Clinical Review Debuene Chang MD BLA</title>
		<imprint>
			<biblScope unit="page">761062</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<monogr>
		<title level="m" type="main">Proposed) -romosozumab CDER Clinical Review Template 2015 Edition 175 Version date</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Evenity</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015-11-05" />
		</imprint>
	</monogr>
	<note>for initial rollout (NME/original BLA reviews</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Estimating prevalence of osteoporosis: examples from industrialized countries</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Wade</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Strader</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename><surname>Fitzpatrick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Osteoporos</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">182</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Sex-and age-specific incidence of nontraumatic fractures in selected industrialized countries</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Wade</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Strader</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename><surname>Fitzpatrick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Anthony</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Osteoporos</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="219" to="227" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level</title>
	</analytic>
	<monogr>
		<title level="m">Summary Meeting Report</title>
		<meeting><address><addrLine>Brussels, Belgium; Geneva, Switzerland</addrLine></address></meeting>
		<imprint>
			<publisher>WHO Press</publisher>
			<date type="published" when="2004-05" />
			<biblScope unit="page" from="5" to="7" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">C</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">C</forename><surname>Looker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">G</forename><surname>Saag</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="2520" to="2526" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Bla761062 -Ecac Review</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Reviewer</surname></persName>
		</author>
		<editor>Miyun Tsai-Turton</editor>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<monogr>
				<title level="m">41%, 69%, and 86% in females and by 10%, 43%, and 53% in males at 3, 10, 50 mg/kg, respectively)</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<monogr>
		<title level="m" type="main">Expected pharmacological effects of AMG785 (hyperostosis in bones, secondary extramedullary hematopoiesis in spleen and liver, and mononuclear cells infiltrate at injection sites) were</title>
		<imprint/>
		<respStmt>
			<orgName> All in all</orgName>
		</respStmt>
	</monogr>
	<note>AMG785 was not carcinogenic in Sprague-Dawley rats at doses up to 50 mg/kg/week for 91 weeks in males and 98 weeks in females. observed in AMG-785 treated animals</note>
</biblStruct>

<biblStruct xml:id="b78">
	<monogr>
		<title level="m" type="main">Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Translational Sciences Office of Biostatistics</title>
		<idno>ID: 4063752 U.S</idno>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<monogr>
		<title level="m" type="main">After 6 months of treatment, mean lumbar spine BMD increased 0.8%, 9.6%, and 9.2% in the placebo, romo 70 mg/mL, and romo 90 mg/mL groups, respectively (Table 10). The mean differences from placebo were 8.8% and 8.4% for the romo 70 mg/mL and romo 90 mg/mL groups</title>
		<imprint/>
	</monogr>
	<note>respectively (Table 10</note>
</biblStruct>

<biblStruct xml:id="b80">
	<monogr>
		<title level="m" type="main">At lumber spine, the mean treatment difference between the romo 90 mg/mL and romo 70 mg/mL was -0</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<monogr>
		<title level="m" type="main">Because the lower bound of the 1-sided 97.5% CI of the mean difference between the two romo groups was -1.5%</title>
		<idno>5%, 0.7%</idno>
		<imprint/>
	</monogr>
	<note>which was greater than the pre-specified limit of -2.0%, the data supports the claim of noninferiority</note>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Translational Sciences Office of</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><forename type="middle">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biostatistics Reference ID</title>
		<imprint>
			<biblScope unit="issue">b</biblScope>
			<biblScope unit="page">4074652</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Bailer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Portier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrics</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="417" to="431" />
			<date type="published" when="1988" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">S</forename><surname>Bieler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrics</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="793" to="801" />
			<date type="published" when="1993" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Overall false positive rates in tests for linear trend in tumor incidence in animal carcinogenicity studies of new drugs</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">K</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Rahman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Biopharmaceutical Statistics</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="1998" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Test for trend in life table analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Tarone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biometrika</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="679" to="82" />
			<date type="published" when="1975" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Guidelines for Simple, Sensitive Significance Tests for Carcinogenic Effects in Long-Term Animal Experiments</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Peto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Pike</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">E</forename><surname>Day</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">G</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">N</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Parish</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Peto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Wahrendorf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">IARC Monographs</title>
		<imprint>
			<biblScope unit="page" from="311" to="426" />
			<date type="published" when="1980" />
			<publisher>Lyon</publisher>
		</imprint>
	</monogr>
	<note>Long-term and short-term screening assays for carcinogens: a critical appraisal. Supplement 2, IARC</note>
</biblStruct>

<biblStruct xml:id="b88">
	<monogr>
		<title level="m" type="main">Guidance for industry: Statistical aspects of the design, analysis, and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals. Draft guidelines</title>
		<imprint>
			<date type="published" when="2001-05" />
			<publisher>CDER</publisher>
			<pubPlace>Rockville (MD</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Center for Drug Evaluation and Research</orgName>
		</respStmt>
	</monogr>
	<note>US Department of Health and Human Services, Food and Drug Administration</note>
</biblStruct>

<biblStruct xml:id="b89">
	<monogr>
		<title level="m" type="main">2 Post-Marketing Requirements and Commitments</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">........................ .</forename><surname>Executive Summary</surname></persName>
			<affiliation>
				<orgName type="collaboration">..................................................................................................3 1.1 Recommendations..............................................................................................................................3 1. ; .............................................................................5</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<monogr>
		<title level="m" type="main">1 Overview of the Product and Regulatory Background</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Comprehensive</surname></persName>
			<affiliation>
				<orgName type="collaboration">.............................................................9 3. ; .......................................................................9 3.2 General Pharmacology and Pharmacokinetic Characteristics ..........................................................11</orgName>
			</affiliation>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">........... .</forename><surname>Pharmacology Review</surname></persName>
			<affiliation>
				<orgName type="collaboration">.............................................................9 3. ; .......................................................................9 3.2 General Pharmacology and Pharmacokinetic Characteristics ..........................................................11</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">15 3.3.1 To what extent does the available clinical pharmacology information provide pivotal or supportive evidence of effectiveness?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">.................................................................................... .</forename><surname>Questions</surname></persName>
			<affiliation>
				<orgName type="collaboration">...............................................................................................15 3. ; .................................................................................................................18 3. ; ..................................................................................................................22 3. ; .......................................................................................................................23</orgName>
			</affiliation>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical Pharmacology Review</title>
		<imprint/>
	</monogr>
	<note>3.4 Are there clinically relevant food-drug or drug-drug interactions and what is the appropriate management strategy?</note>
</biblStruct>

<biblStruct xml:id="b92">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">.</forename><forename type="middle">.</forename><surname>Summary Of Bioanalytical Methods</surname></persName>
			<affiliation>
				<orgName type="collaboration">..............................................................................................24</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">.</forename><forename type="middle">.</forename><surname>Biopharmaceutics: Comparative Pk Studies</surname></persName>
			<affiliation>
				<orgName type="collaboration">.................................................................................33</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">. . . . .</forename><surname>Immunogenicity</surname></persName>
			<affiliation>
				<orgName type="collaboration">.....................................................................................................................53</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="middle">....................... .</forename><surname>Exposure-Response Analyses</surname></persName>
			<affiliation>
				<orgName type="collaboration">.................................................................................73 4.6.1 Dose-BMD analysis ....................................................................................................................73 4.6.2 Exposure-BMD analysis..............................................................................................................77</orgName>
			</affiliation>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">D</forename><surname>Reference</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">4076576</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<monogr>
		<title level="m" type="main">(b) (4) Parameter Category/Quantile n AUC 330-360 (gday/mL) (mean</title>
		<idno>ID: 4076576</idno>
		<imprint>
			<biblScope unit="page">95</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Ai = Autoinjector</surname></persName>
		</author>
		<imprint>
			<pubPlace>ARI = Amgen Rhode Island</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Ato = Amgen Thousand</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Oaks</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">compared the pharmacokinetic profile after administration of a single 210-mg SC romosozumab dose, delivered as either three 1.0-mL PFS injections of 70-mg/mL concentration (Process 2 ATO), or two 1.17-mL PFS injections of 90-mg/mL concentration (Process 2 ATO)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Cz = Crystal</surname></persName>
		</author>
		<idno>product #2 vs.#3</idno>
	</analytic>
	<monogr>
		<title level="m">Zenith; the to-be-marketed product:  Study</title>
		<imprint>
			<date type="published" when="20120277" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">D</forename><surname>Reference</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">4076576</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<monogr>
				<title level="m">Pruducts compared Reference: Product #2 (70 mg/mL) Test: Product #3 (90 mg/mL)</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">D</forename><surname>Reference</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">4076576</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<monogr>
		<title level="m" type="main">Source: Applicant&apos;s population PK report</title>
		<idno>ID: 4076576</idno>
		<imprint>
			<biblScope unit="page">124</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">D</forename><surname>Reference</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">4076576</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Category/Quantile No</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Sub</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N BMD %CFB</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
		</imprint>
	</monogr>
	<note>min-max</note>
</biblStruct>

<biblStruct xml:id="b107">
	<monogr>
				<title level="m">Sub, 24 mon; N BMD %CFB</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
		</imprint>
	</monogr>
	<note>min-max</note>
</biblStruct>

<biblStruct xml:id="b108">
	<monogr>
		<title level="m" type="main">ESRD (&lt;15) ----Source: Reviewer&apos;s independent analysis. New Vertebral fracture</title>
		<imprint/>
	</monogr>
	<note>24 mon; n/N (%)</note>
</biblStruct>

<biblStruct xml:id="b109">
	<monogr>
		<title level="m" type="main">ESRD (&lt;15) --Source: Reviewer&apos;s independent analysis</title>
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
